{"doc_id": "10048291_2", "wnd_id": "10048291_2_1", "text": "Unaccountable severe hypercalcemia in a patient treated for hypoparathyroidism with dihydrotachysterol .", "tokens": ["Unaccountable", "severe", "hypercalcemia", "in", "a", "patient", "treated", "for", "hypoparathyroidism", "with", "dihydrotachysterol", "."], "event_mentions": [{"id": "10048291_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 6, "end": 7}, "arguments": [{"entity_id": "10048291_2_Ent1", "role": "Effect", "text": "Unaccountable severe hypercalcemia", "start": 0, "end": 3}, {"entity_id": "10048291_2_Ent0", "role": "Subject", "text": "patient", "start": 5, "end": 6}, {"entity_id": "10048291_2_Ent3", "role": "Treatment_Disorder", "text": "hypoparathyroidism", "start": 8, "end": 9}, {"entity_id": "10048291_2_Ent2", "role": "Treatment", "text": "dihydrotachysterol", "start": 10, "end": 11}, {"entity_id": "10048291_2_Ent4", "role": "Treatment_Drug", "text": "dihydrotachysterol", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "10048291_2_Ent1", "text": "Unaccountable severe hypercalcemia", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "10048291_2_Ent0", "text": "patient", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10048291_2_Ent3", "text": "hypoparathyroidism", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10048291_2_Ent2", "text": "dihydrotachysterol", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10048291_2_Ent4", "text": "dihydrotachysterol", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "10082597_2", "wnd_id": "10082597_2_1", "text": "Naproxen , the most common offender , has been associated with a dimorphic clinical pattern : a PCT - like presentation and one simulating erythropoietic protoporphyria in the pediatric population .", "tokens": ["Naproxen", ",", "the", "most", "common", "offender", ",", "has", "been", "associated", "with", "a", "dimorphic", "clinical", "pattern", ":", "a", "PCT", "-", "like", "presentation", "and", "one", "simulating", "erythropoietic", "protoporphyria", "in", "the", "pediatric", "population", "."], "event_mentions": [{"id": "10082597_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "10082597_2_Ent3", "role": "Treatment", "text": "Naproxen", "start": 0, "end": 1}, {"entity_id": "10082597_2_Ent4", "role": "Treatment_Drug", "text": "Naproxen", "start": 0, "end": 1}, {"entity_id": "10082597_2_Ent2", "role": "Effect", "text": "erythropoietic protoporphyria", "start": 24, "end": 26}, {"entity_id": "10082597_2_Ent1", "role": "Subject_Age", "text": "pediatric", "start": 28, "end": 29}, {"entity_id": "10082597_2_Ent0", "role": "Subject", "text": "pediatric population", "start": 28, "end": 30}]}], "entity_mentions": [{"id": "10082597_2_Ent3", "text": "Naproxen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10082597_2_Ent4", "text": "Naproxen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10082597_2_Ent2", "text": "erythropoietic protoporphyria", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "10082597_2_Ent1", "text": "pediatric", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "10082597_2_Ent0", "text": "pediatric population", "entity_type": "Entity", "start": 28, "end": 30}], "lang": "en"}
{"doc_id": "10203437_1", "wnd_id": "10203437_1_1", "text": "Lupus - like syndrome caused by 5 - aminosalicylic acid in patients with inflammatory bowel disease .", "tokens": ["Lupus", "-", "like", "syndrome", "caused", "by", "5", "-", "aminosalicylic", "acid", "in", "patients", "with", "inflammatory", "bowel", "disease", "."], "event_mentions": [{"id": "10203437_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 4, "end": 5}, "arguments": [{"entity_id": "10203437_1_Ent1", "role": "Effect", "text": "Lupus - like syndrome", "start": 0, "end": 4}, {"entity_id": "10203437_1_Ent2", "role": "Treatment", "text": "5 - aminosalicylic acid", "start": 6, "end": 10}, {"entity_id": "10203437_1_Ent4", "role": "Treatment_Drug", "text": "5 - aminosalicylic acid", "start": 6, "end": 10}, {"entity_id": "10203437_1_Ent0", "role": "Subject", "text": "patients with inflammatory bowel disease", "start": 11, "end": 16}, {"entity_id": "10203437_1_Ent3", "role": "Treatment_Disorder", "text": "inflammatory bowel disease", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "10203437_1_Ent1", "text": "Lupus - like syndrome", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10203437_1_Ent2", "text": "5 - aminosalicylic acid", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "10203437_1_Ent4", "text": "5 - aminosalicylic acid", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "10203437_1_Ent0", "text": "patients with inflammatory bowel disease", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "10203437_1_Ent3", "text": "inflammatory bowel disease", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "10332990_1", "wnd_id": "10332990_1_1", "text": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma .", "tokens": ["Pulmonary", "edema", "during", "acute", "infusion", "of", "epoprostenol", "in", "a", "patient", "with", "pulmonary", "hypertension", "and", "limited", "scleroderma", "."], "event_mentions": [{"id": "10332990_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 2, "end": 3}, "arguments": [{"entity_id": "10332990_1_Ent3", "role": "Treatment_Route", "text": "acute infusion", "start": 3, "end": 5}, {"entity_id": "10332990_1_Ent1", "role": "Treatment", "text": "acute infusion of epoprostenol", "start": 3, "end": 7}, {"entity_id": "10332990_1_Ent2", "role": "Treatment_Drug", "text": "epoprostenol", "start": 6, "end": 7}, {"entity_id": "10332990_1_Ent0", "role": "Subject", "text": "a patient with pulmonary hypertension and limited scleroderma", "start": 8, "end": 16}, {"entity_id": "10332990_1_Ent4", "role": "Treatment_Disorder", "text": "pulmonary hypertension and limited scleroderma", "start": 11, "end": 16}]}], "entity_mentions": [{"id": "10332990_1_Ent3", "text": "acute infusion", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "10332990_1_Ent1", "text": "acute infusion of epoprostenol", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "10332990_1_Ent2", "text": "epoprostenol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10332990_1_Ent0", "text": "a patient with pulmonary hypertension and limited scleroderma", "entity_type": "Entity", "start": 8, "end": 16}, {"id": "10332990_1_Ent4", "text": "pulmonary hypertension and limited scleroderma", "entity_type": "Entity", "start": 11, "end": 16}], "lang": "en"}
{"doc_id": "10357715_1", "wnd_id": "10357715_1_1", "text": "Allergic and irritant contact dermatitis to calcipotriol .", "tokens": ["Allergic", "and", "irritant", "contact", "dermatitis", "to", "calcipotriol", "."], "event_mentions": [{"id": "10357715_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 5, "end": 6}, "arguments": [{"entity_id": "10357715_1_Ent0", "role": "Effect", "text": "contact dermatitis", "start": 3, "end": 5}, {"entity_id": "10357715_1_Ent1", "role": "Treatment", "text": "calcipotriol", "start": 6, "end": 7}, {"entity_id": "10357715_1_Ent2", "role": "Treatment_Drug", "text": "calcipotriol", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "10357715_1_Ent0", "text": "contact dermatitis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "10357715_1_Ent1", "text": "calcipotriol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10357715_1_Ent2", "text": "calcipotriol", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "10367184_3", "wnd_id": "10367184_3_1", "text": "This case suggests that sarcoidosis and pravastatin , two entities not frequently associated with myotonia , may interact in a synergistic manner to produce severe clinical myotonia in humans .", "tokens": ["This", "case", "suggests", "that", "sarcoidosis", "and", "pravastatin", ",", "two", "entities", "not", "frequently", "associated", "with", "myotonia", ",", "may", "interact", "in", "a", "synergistic", "manner", "to", "produce", "severe", "clinical", "myotonia", "in", "humans", "."], "event_mentions": [{"id": "10367184_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "interact", "start": 17, "end": 18}, "arguments": [{"entity_id": "10367184_3_Ent2", "role": "Treatment", "text": "pravastatin", "start": 6, "end": 7}, {"entity_id": "10367184_3_Ent3", "role": "Treatment_Drug", "text": "pravastatin", "start": 6, "end": 7}, {"entity_id": "10367184_3_Ent1", "role": "Effect", "text": "severe clinical myotonia", "start": 24, "end": 27}, {"entity_id": "10367184_3_Ent0", "role": "Subject", "text": "humans .", "start": 28, "end": 30}]}], "entity_mentions": [{"id": "10367184_3_Ent2", "text": "pravastatin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10367184_3_Ent3", "text": "pravastatin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10367184_3_Ent1", "text": "severe clinical myotonia", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "10367184_3_Ent0", "text": "humans .", "entity_type": "Entity", "start": 28, "end": 30}], "lang": "en"}
{"doc_id": "10393393_1", "wnd_id": "10393393_1_1", "text": "Hypersensitivity to aspirin can be manifested as acute asthma , urticaria and/or angioedema , or a systemic anaphylactoid reaction .", "tokens": ["Hypersensitivity", "to", "aspirin", "can", "be", "manifested", "as", "acute", "asthma", ",", "urticaria", "and/or", "angioedema", ",", "or", "a", "systemic", "anaphylactoid", "reaction", "."], "event_mentions": [{"id": "10393393_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "manifested", "start": 5, "end": 6}, "arguments": [{"entity_id": "10393393_1_Ent4", "role": "Effect", "text": "Hypersensitivity", "start": 0, "end": 1}, {"entity_id": "10393393_1_Ent5", "role": "Treatment", "text": "aspirin", "start": 2, "end": 3}, {"entity_id": "10393393_1_Ent6", "role": "Treatment_Drug", "text": "aspirin", "start": 2, "end": 3}, {"entity_id": "10393393_1_Ent0", "role": "Effect", "text": "acute asthma", "start": 7, "end": 9}, {"entity_id": "10393393_1_Ent1", "role": "Effect", "text": "urticaria", "start": 10, "end": 11}, {"entity_id": "10393393_1_Ent2", "role": "Effect", "text": "angioedema", "start": 12, "end": 13}, {"entity_id": "10393393_1_Ent3", "role": "Effect", "text": "systemic anaphylactoid reaction", "start": 16, "end": 19}]}], "entity_mentions": [{"id": "10393393_1_Ent4", "text": "Hypersensitivity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10393393_1_Ent5", "text": "aspirin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10393393_1_Ent6", "text": "aspirin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10393393_1_Ent0", "text": "acute asthma", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "10393393_1_Ent1", "text": "urticaria", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10393393_1_Ent2", "text": "angioedema", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10393393_1_Ent3", "text": "systemic anaphylactoid reaction", "entity_type": "Entity", "start": 16, "end": 19}], "lang": "en"}
{"doc_id": "10395123_1", "wnd_id": "10395123_1_1", "text": "CONCLUSION : Fixed drug eruption is associated with many drugs but this is the first such report with omeprazole .", "tokens": ["CONCLUSION", ":", "Fixed", "drug", "eruption", "is", "associated", "with", "many", "drugs", "but", "this", "is", "the", "first", "such", "report", "with", "omeprazole", "."], "event_mentions": [{"id": "10395123_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "10395123_1_Ent0", "role": "Effect", "text": "Fixed drug eruption", "start": 2, "end": 5}, {"entity_id": "10395123_1_Ent1", "role": "Treatment", "text": "omeprazole", "start": 18, "end": 19}, {"entity_id": "10395123_1_Ent2", "role": "Treatment_Drug", "text": "omeprazole", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "10395123_1_Ent0", "text": "Fixed drug eruption", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "10395123_1_Ent1", "text": "omeprazole", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "10395123_1_Ent2", "text": "omeprazole", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "10405480_2", "wnd_id": "10405480_2_1", "text": "Acute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis .", "tokens": ["Acute", "generalized", "exanthematous", "pustulosis", "induced", "by", "salazosulfapyridine", "in", "a", "patient", "with", "ulcerative", "colitis", "."], "event_mentions": [{"id": "10405480_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "10405480_2_Ent1", "role": "Effect", "text": "Acute generalized exanthematous pustulosis", "start": 0, "end": 4}, {"entity_id": "10405480_2_Ent2", "role": "Treatment", "text": "salazosulfapyridine", "start": 6, "end": 7}, {"entity_id": "10405480_2_Ent3", "role": "Treatment_Drug", "text": "salazosulfapyridine", "start": 6, "end": 7}, {"entity_id": "10405480_2_Ent0", "role": "Subject", "text": "a patient with ulcerative colitis", "start": 8, "end": 13}, {"entity_id": "10405480_2_Ent4", "role": "Treatment_Disorder", "text": "ulcerative colitis", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "10405480_2_Ent1", "text": "Acute generalized exanthematous pustulosis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10405480_2_Ent2", "text": "salazosulfapyridine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10405480_2_Ent3", "text": "salazosulfapyridine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10405480_2_Ent0", "text": "a patient with ulcerative colitis", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "10405480_2_Ent4", "text": "ulcerative colitis", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "10410183_3", "wnd_id": "10410183_3_1", "text": "CASE SUMMARY : A 39 - year - old white Jewish schizophrenic man treated with olanzapine developed an elevated serum CK concentration with a peak concentration of 4000 IU / L ( normal < 230 ) .", "tokens": ["CASE", "SUMMARY", ":", "A", "39", "-", "year", "-", "old", "white", "Jewish", "schizophrenic", "man", "treated", "with", "olanzapine", "developed", "an", "elevated", "serum", "CK", "concentration", "with", "a", "peak", "concentration", "of", "4000", "IU", "/", "L", "(", "normal", "<", "230", ")", "."], "event_mentions": [{"id": "10410183_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 16, "end": 17}, "arguments": [{"entity_id": "10410183_3_Ent0", "role": "Subject", "text": "A 39 - year - old white Jewish schizophrenic man", "start": 3, "end": 13}, {"entity_id": "10410183_3_Ent1", "role": "Subject_Age", "text": "39 - year - old", "start": 4, "end": 9}, {"entity_id": "10410183_3_Ent2", "role": "Subject_Race", "text": "white Jewish", "start": 9, "end": 11}, {"entity_id": "10410183_3_Ent6", "role": "Treatment_Disorder", "text": "schizophrenic", "start": 11, "end": 12}, {"entity_id": "10410183_3_Ent3", "role": "Subject_Gender", "text": "man", "start": 12, "end": 13}, {"entity_id": "10410183_3_Ent5", "role": "Treatment", "text": "olanzapine", "start": 15, "end": 16}, {"entity_id": "10410183_3_Ent7", "role": "Treatment_Drug", "text": "olanzapine", "start": 15, "end": 16}, {"entity_id": "10410183_3_Ent4", "role": "Effect", "text": "an elevated serum CK concentration", "start": 17, "end": 22}]}], "entity_mentions": [{"id": "10410183_3_Ent0", "text": "A 39 - year - old white Jewish schizophrenic man", "entity_type": "Entity", "start": 3, "end": 13}, {"id": "10410183_3_Ent1", "text": "39 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "10410183_3_Ent2", "text": "white Jewish", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "10410183_3_Ent6", "text": "schizophrenic", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10410183_3_Ent3", "text": "man", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10410183_3_Ent5", "text": "olanzapine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10410183_3_Ent7", "text": "olanzapine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10410183_3_Ent4", "text": "an elevated serum CK concentration", "entity_type": "Entity", "start": 17, "end": 22}], "lang": "en"}
{"doc_id": "10439378_1", "wnd_id": "10439378_1_1", "text": "Acute neutrophilic dermatosis induced by all - trans - retinoic acid treatment for acute promyelocytic leukemia .", "tokens": ["Acute", "neutrophilic", "dermatosis", "induced", "by", "all", "-", "trans", "-", "retinoic", "acid", "treatment", "for", "acute", "promyelocytic", "leukemia", "."], "event_mentions": [{"id": "10439378_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced by", "start": 3, "end": 5}, "arguments": [{"entity_id": "10439378_1_Ent0", "role": "Effect", "text": "Acute neutrophilic dermatosis", "start": 0, "end": 3}, {"entity_id": "10439378_1_Ent1", "role": "Treatment", "text": "all - trans - retinoic acid", "start": 5, "end": 11}, {"entity_id": "10439378_1_Ent3", "role": "Treatment_Drug", "text": "all - trans - retinoic acid", "start": 5, "end": 11}, {"entity_id": "10439378_1_Ent2", "role": "Treatment_Disorder", "text": "acute promyelocytic leukemia", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "10439378_1_Ent0", "text": "Acute neutrophilic dermatosis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "10439378_1_Ent1", "text": "all - trans - retinoic acid", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "10439378_1_Ent3", "text": "all - trans - retinoic acid", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "10439378_1_Ent2", "text": "acute promyelocytic leukemia", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "10452772_1", "wnd_id": "10452772_1_1", "text": "CONCLUSION : Patients with insulin allergy may not have complete resolution of their symptoms after standard desensitization , particularly those patients with concomitant protamine allergy .", "tokens": ["CONCLUSION", ":", "Patients", "with", "insulin", "allergy", "may", "not", "have", "complete", "resolution", "of", "their", "symptoms", "after", "standard", "desensitization", ",", "particularly", "those", "patients", "with", "concomitant", "protamine", "allergy", "."], "event_mentions": [{"id": "10452772_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolution", "start": 10, "end": 11}, "arguments": [{"entity_id": "10452772_1_Ent0", "role": "Subject", "text": "Patients with insulin allergy", "start": 2, "end": 6}, {"entity_id": "10452772_1_Ent2", "role": "Subject_Disorder", "text": "insulin allergy", "start": 4, "end": 6}, {"entity_id": "10452772_1_Ent4", "role": "Treatment", "text": "standard desensitization", "start": 15, "end": 17}, {"entity_id": "10452772_1_Ent1", "role": "Subject", "text": "concomitant protamine allergy", "start": 22, "end": 25}, {"entity_id": "10452772_1_Ent3", "role": "Subject_Disorder", "text": "protamine allergy", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "10452772_1_Ent0", "text": "Patients with insulin allergy", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "10452772_1_Ent2", "text": "insulin allergy", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "10452772_1_Ent4", "text": "standard desensitization", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "10452772_1_Ent1", "text": "concomitant protamine allergy", "entity_type": "Entity", "start": 22, "end": 25}, {"id": "10452772_1_Ent3", "text": "protamine allergy", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "10452772_4", "wnd_id": "10452772_4_1", "text": "Patients receiving neutral protamine Hagedorn ( NPH ) insulin are at increased risk for the development of protamine hypersensitivity .", "tokens": ["Patients", "receiving", "neutral", "protamine", "Hagedorn", "(", "NPH", ")", "insulin", "are", "at", "increased", "risk", "for", "the", "development", "of", "protamine", "hypersensitivity", "."], "event_mentions": [{"id": "10452772_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 15, "end": 16}, "arguments": [{"entity_id": "10452772_4_Ent0", "role": "Subject", "text": "Patients", "start": 0, "end": 1}, {"entity_id": "10452772_4_Ent2", "role": "Treatment", "text": "neutral protamine Hagedorn ( NPH ) insulin", "start": 2, "end": 9}, {"entity_id": "10452772_4_Ent3", "role": "Treatment_Drug", "text": "neutral protamine Hagedorn ( NPH ) insulin", "start": 2, "end": 9}, {"entity_id": "10452772_4_Ent1", "role": "Effect", "text": "protamine hypersensitivity", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "10452772_4_Ent0", "text": "Patients", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10452772_4_Ent2", "text": "neutral protamine Hagedorn ( NPH ) insulin", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "10452772_4_Ent3", "text": "neutral protamine Hagedorn ( NPH ) insulin", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "10452772_4_Ent1", "text": "protamine hypersensitivity", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "10458196_2", "wnd_id": "10458196_2_1", "text": "An 11 - day - old infant became lethargic and apneic after a single drop of brimonidine .", "tokens": ["An", "11", "-", "day", "-", "old", "infant", "became", "lethargic", "and", "apneic", "after", "a", "single", "drop", "of", "brimonidine", "."], "event_mentions": [{"id": "10458196_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "became", "start": 7, "end": 8}, "arguments": [{"entity_id": "10458196_2_Ent0", "role": "Subject", "text": "An 11 - day - old infant", "start": 0, "end": 7}, {"entity_id": "10458196_2_Ent1", "role": "Subject_Age", "text": "11 - day - old", "start": 1, "end": 6}, {"entity_id": "10458196_2_Ent2", "role": "Subject_Age", "text": "infant", "start": 6, "end": 7}, {"entity_id": "10458196_2_Ent3", "role": "Effect", "text": "lethargic and apneic", "start": 8, "end": 11}, {"entity_id": "10458196_2_Ent4", "role": "Treatment", "text": "a single drop of brimonidine", "start": 12, "end": 17}, {"entity_id": "10458196_2_Ent5", "role": "Treatment_Dosage", "text": "single drop", "start": 13, "end": 15}, {"entity_id": "10458196_2_Ent6", "role": "Treatment_Drug", "text": "brimonidine", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "10458196_2_Ent0", "text": "An 11 - day - old infant", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "10458196_2_Ent1", "text": "11 - day - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "10458196_2_Ent2", "text": "infant", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10458196_2_Ent3", "text": "lethargic and apneic", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "10458196_2_Ent4", "text": "a single drop of brimonidine", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "10458196_2_Ent5", "text": "single drop", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "10458196_2_Ent6", "text": "brimonidine", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "10465148_6", "wnd_id": "10465148_6_1", "text": "The clinical data suggest that anterior lumbosacral radiculopathy is also a type of neurologic complication associated with intrathecal methotrexate treatment .", "tokens": ["The", "clinical", "data", "suggest", "that", "anterior", "lumbosacral", "radiculopathy", "is", "also", "a", "type", "of", "neurologic", "complication", "associated", "with", "intrathecal", "methotrexate", "treatment", "."], "event_mentions": [{"id": "10465148_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 15, "end": 16}, "arguments": [{"entity_id": "10465148_6_Ent0", "role": "Effect", "text": "anterior lumbosacral radiculopathy", "start": 5, "end": 8}, {"entity_id": "10465148_6_Ent2", "role": "Treatment_Route", "text": "intrathecal", "start": 17, "end": 18}, {"entity_id": "10465148_6_Ent1", "role": "Treatment", "text": "intrathecal methotrexate", "start": 17, "end": 19}, {"entity_id": "10465148_6_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "10465148_6_Ent0", "text": "anterior lumbosacral radiculopathy", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "10465148_6_Ent2", "text": "intrathecal", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "10465148_6_Ent1", "text": "intrathecal methotrexate", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "10465148_6_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "10466445_2", "wnd_id": "10466445_2_1", "text": "Arsenic trioxide has recently been introduced as a promising new agent to treat refractory acute promyelocytic leukemia ( APL ) .", "tokens": ["Arsenic", "trioxide", "has", "recently", "been", "introduced", "as", "a", "promising", "new", "agent", "to", "treat", "refractory", "acute", "promyelocytic", "leukemia", "(", "APL", ")", "."], "event_mentions": [{"id": "10466445_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treat", "start": 12, "end": 13}, "arguments": [{"entity_id": "10466445_2_Ent0", "role": "Treatment", "text": "Arsenic trioxide", "start": 0, "end": 2}, {"entity_id": "10466445_2_Ent1", "role": "Treatment_Drug", "text": "Arsenic trioxide", "start": 0, "end": 2}, {"entity_id": "10466445_2_Ent2", "role": "Treatment_Disorder", "text": "refractory acute promyelocytic leukemia", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "10466445_2_Ent0", "text": "Arsenic trioxide", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10466445_2_Ent1", "text": "Arsenic trioxide", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10466445_2_Ent2", "text": "refractory acute promyelocytic leukemia", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "10467499_1", "wnd_id": "10467499_1_1", "text": "A 22 - year - old black man developed fever , chills , fatigue , night sweats , tender lymphadenopathy , and a generalized , pruritic , macular eruption 3 weeks after starting minocycline therapy for acne .", "tokens": ["A", "22", "-", "year", "-", "old", "black", "man", "developed", "fever", ",", "chills", ",", "fatigue", ",", "night", "sweats", ",", "tender", "lymphadenopathy", ",", "and", "a", "generalized", ",", "pruritic", ",", "macular", "eruption", "3", "weeks", "after", "starting", "minocycline", "therapy", "for", "acne", "."], "event_mentions": [{"id": "10467499_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "10467499_1_Ent0", "role": "Subject", "text": "A 22 - year - old black man", "start": 0, "end": 8}, {"entity_id": "10467499_1_Ent1", "role": "Subject_Age", "text": "22 - year - old", "start": 1, "end": 6}, {"entity_id": "10467499_1_Ent2", "role": "Subject_Race", "text": "black", "start": 6, "end": 7}, {"entity_id": "10467499_1_Ent3", "role": "Subject_Gender", "text": "man", "start": 7, "end": 8}, {"entity_id": "10467499_1_Ent4", "role": "Effect", "text": "fever , chills , fatigue , night sweats , tender lymphadenopathy , and a generalized , pruritic , macular eruption", "start": 9, "end": 29}, {"entity_id": "10467499_1_Ent8", "role": "Treatment_Time_elapsed", "text": "3 weeks", "start": 29, "end": 31}, {"entity_id": "10467499_1_Ent7", "role": "Treatment_Drug", "text": "minocycline", "start": 33, "end": 34}, {"entity_id": "10467499_1_Ent5", "role": "Treatment", "text": "minocycline therapy", "start": 33, "end": 35}, {"entity_id": "10467499_1_Ent6", "role": "Treatment_Disorder", "text": "acne", "start": 36, "end": 37}]}], "entity_mentions": [{"id": "10467499_1_Ent0", "text": "A 22 - year - old black man", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "10467499_1_Ent1", "text": "22 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "10467499_1_Ent2", "text": "black", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10467499_1_Ent3", "text": "man", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10467499_1_Ent4", "text": "fever , chills , fatigue , night sweats , tender lymphadenopathy , and a generalized , pruritic , macular eruption", "entity_type": "Entity", "start": 9, "end": 29}, {"id": "10467499_1_Ent8", "text": "3 weeks", "entity_type": "Entity", "start": 29, "end": 31}, {"id": "10467499_1_Ent7", "text": "minocycline", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "10467499_1_Ent5", "text": "minocycline therapy", "entity_type": "Entity", "start": 33, "end": 35}, {"id": "10467499_1_Ent6", "text": "acne", "entity_type": "Entity", "start": 36, "end": 37}], "lang": "en"}
{"doc_id": "10473079_2", "wnd_id": "10473079_2_1", "text": "We now report the first known cancer patient who developed life - threatening complications after treatment with topical 5 - FU and was shown subsequently to have profound DPD deficiency .", "tokens": ["We", "now", "report", "the", "first", "known", "cancer", "patient", "who", "developed", "life", "-", "threatening", "complications", "after", "treatment", "with", "topical", "5", "-", "FU", "and", "was", "shown", "subsequently", "to", "have", "profound", "DPD", "deficiency", "."], "event_mentions": [{"id": "10473079_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "10473079_2_Ent4", "role": "Treatment_Disorder", "text": "cancer", "start": 6, "end": 7}, {"entity_id": "10473079_2_Ent0", "role": "Subject", "text": "cancer patient", "start": 6, "end": 8}, {"entity_id": "10473079_2_Ent1", "role": "Effect", "text": "life - threatening complications", "start": 10, "end": 14}, {"entity_id": "10473079_2_Ent6", "role": "Treatment_Route", "text": "topical", "start": 17, "end": 18}, {"entity_id": "10473079_2_Ent3", "role": "Treatment", "text": "topical 5 - FU", "start": 17, "end": 21}, {"entity_id": "10473079_2_Ent5", "role": "Treatment_Drug", "text": "5 - FU", "start": 18, "end": 21}, {"entity_id": "10473079_2_Ent2", "role": "Effect", "text": "have profound DPD deficiency", "start": 26, "end": 30}]}], "entity_mentions": [{"id": "10473079_2_Ent4", "text": "cancer", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10473079_2_Ent0", "text": "cancer patient", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "10473079_2_Ent1", "text": "life - threatening complications", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "10473079_2_Ent6", "text": "topical", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "10473079_2_Ent3", "text": "topical 5 - FU", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "10473079_2_Ent5", "text": "5 - FU", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "10473079_2_Ent2", "text": "have profound DPD deficiency", "entity_type": "Entity", "start": 26, "end": 30}], "lang": "en"}
{"doc_id": "10475726_2", "wnd_id": "10475726_2_1", "text": "The association of venlafaxine treatment with ischaemic events could be explained by its unique pharmacological and haemodynamic properties .", "tokens": ["The", "association", "of", "venlafaxine", "treatment", "with", "ischaemic", "events", "could", "be", "explained", "by", "its", "unique", "pharmacological", "and", "haemodynamic", "properties", "."], "event_mentions": [{"id": "10475726_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 1, "end": 2}, "arguments": [{"entity_id": "10475726_2_Ent2", "role": "Treatment_Drug", "text": "venlafaxine", "start": 3, "end": 4}, {"entity_id": "10475726_2_Ent1", "role": "Treatment", "text": "venlafaxine treatment", "start": 3, "end": 5}, {"entity_id": "10475726_2_Ent0", "role": "Effect", "text": "ischaemic events", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "10475726_2_Ent2", "text": "venlafaxine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10475726_2_Ent1", "text": "venlafaxine treatment", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "10475726_2_Ent0", "text": "ischaemic events", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "10485779_2", "wnd_id": "10485779_2_1", "text": "The human immunodeficiency virus protease inhibitor ritonavir is a potent inhibitor of the cytochrome P450 3A4 enzyme , and ritonavir 's concomitant administration with the substrates of this enzyme may lead to dangerous drug interactions .", "tokens": ["The", "human", "immunodeficiency", "virus", "protease", "inhibitor", "ritonavir", "is", "a", "potent", "inhibitor", "of", "the", "cytochrome", "P450", "3A4", "enzyme", ",", "and", "ritonavir", "'s", "concomitant", "administration", "with", "the", "substrates", "of", "this", "enzyme", "may", "lead", "to", "dangerous", "drug", "interactions", "."], "event_mentions": [{"id": "10485779_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "lead", "start": 30, "end": 31}, "arguments": [{"entity_id": "10485779_2_Ent2", "role": "Treatment_Drug", "text": "ritonavir", "start": 19, "end": 20}, {"entity_id": "10485779_2_Ent5", "role": "Combination_Drug", "text": "ritonavir", "start": 19, "end": 20}, {"entity_id": "10485779_2_Ent1", "role": "Treatment", "text": "ritonavir 's concomitant administration with the substrates of this enzyme", "start": 19, "end": 29}, {"entity_id": "10485779_2_Ent3", "role": "Treatment_Drug", "text": "substrates of this enzyme", "start": 25, "end": 29}, {"entity_id": "10485779_2_Ent4", "role": "Combination_Drug", "text": "substrates of this enzyme", "start": 25, "end": 29}, {"entity_id": "10485779_2_Ent0", "role": "Effect", "text": "drug interactions", "start": 33, "end": 35}]}], "entity_mentions": [{"id": "10485779_2_Ent2", "text": "ritonavir", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "10485779_2_Ent5", "text": "ritonavir", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "10485779_2_Ent1", "text": "ritonavir 's concomitant administration with the substrates of this enzyme", "entity_type": "Entity", "start": 19, "end": 29}, {"id": "10485779_2_Ent3", "text": "substrates of this enzyme", "entity_type": "Entity", "start": 25, "end": 29}, {"id": "10485779_2_Ent4", "text": "substrates of this enzyme", "entity_type": "Entity", "start": 25, "end": 29}, {"id": "10485779_2_Ent0", "text": "drug interactions", "entity_type": "Entity", "start": 33, "end": 35}], "lang": "en"}
{"doc_id": "10492493_4", "wnd_id": "10492493_4_1", "text": "The incidence of angioedema secondary to losartan , an angiotensin II receptor antagonist , is unknown .", "tokens": ["The", "incidence", "of", "angioedema", "secondary", "to", "losartan", ",", "an", "angiotensin", "II", "receptor", "antagonist", ",", "is", "unknown", "."], "event_mentions": [{"id": "10492493_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 4, "end": 5}, "arguments": [{"entity_id": "10492493_4_Ent0", "role": "Effect", "text": "angioedema", "start": 3, "end": 4}, {"entity_id": "10492493_4_Ent2", "role": "Treatment_Drug", "text": "losartan", "start": 6, "end": 7}, {"entity_id": "10492493_4_Ent1", "role": "Treatment", "text": "losartan , an angiotensin II receptor antagonist", "start": 6, "end": 13}]}], "entity_mentions": [{"id": "10492493_4_Ent0", "text": "angioedema", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10492493_4_Ent2", "text": "losartan", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10492493_4_Ent1", "text": "losartan , an angiotensin II receptor antagonist", "entity_type": "Entity", "start": 6, "end": 13}], "lang": "en"}
{"doc_id": "10510017_1", "wnd_id": "10510017_1_1", "text": "Heparin - induced thrombocytopenia is a rare and serious complication of anticoagulation therapy .", "tokens": ["Heparin", "-", "induced", "thrombocytopenia", "is", "a", "rare", "and", "serious", "complication", "of", "anticoagulation", "therapy", "."], "event_mentions": [{"id": "10510017_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 9, "end": 10}, "arguments": [{"entity_id": "10510017_1_Ent2", "role": "Treatment_Drug", "text": "Heparin", "start": 0, "end": 1}, {"entity_id": "10510017_1_Ent0", "role": "Effect", "text": "thrombocytopenia", "start": 3, "end": 4}, {"entity_id": "10510017_1_Ent1", "role": "Treatment", "text": "anticoagulation therapy", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "10510017_1_Ent2", "text": "Heparin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10510017_1_Ent0", "text": "thrombocytopenia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10510017_1_Ent1", "text": "anticoagulation therapy", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "10513720_1", "wnd_id": "10513720_1_1", "text": "Taxane - induced glaucoma .", "tokens": ["Taxane", "-", "induced", "glaucoma", "."], "event_mentions": [{"id": "10513720_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "10513720_1_Ent1", "role": "Treatment", "text": "Taxane", "start": 0, "end": 1}, {"entity_id": "10513720_1_Ent2", "role": "Treatment_Drug", "text": "Taxane", "start": 0, "end": 1}, {"entity_id": "10513720_1_Ent0", "role": "Effect", "text": "glaucoma", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "10513720_1_Ent1", "text": "Taxane", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10513720_1_Ent2", "text": "Taxane", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10513720_1_Ent0", "text": "glaucoma", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "10555917_3", "wnd_id": "10555917_3_1", "text": "In vitro inhibition of hematopoiesis in a patient with systemic sclerosis treated with D - penicillamine .", "tokens": ["In", "vitro", "inhibition", "of", "hematopoiesis", "in", "a", "patient", "with", "systemic", "sclerosis", "treated", "with", "D", "-", "penicillamine", "."], "event_mentions": [{"id": "10555917_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "inhibition", "start": 2, "end": 3}, "arguments": [{"entity_id": "10555917_3_Ent1", "role": "Effect", "text": "vitro inhibition of hematopoiesis", "start": 1, "end": 5}, {"entity_id": "10555917_3_Ent0", "role": "Subject", "text": "a patient with systemic sclerosis", "start": 6, "end": 11}, {"entity_id": "10555917_3_Ent3", "role": "Treatment_Disorder", "text": "systemic sclerosis", "start": 9, "end": 11}, {"entity_id": "10555917_3_Ent2", "role": "Treatment", "text": "D - penicillamine", "start": 13, "end": 16}, {"entity_id": "10555917_3_Ent4", "role": "Treatment_Drug", "text": "D - penicillamine", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "10555917_3_Ent1", "text": "vitro inhibition of hematopoiesis", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "10555917_3_Ent0", "text": "a patient with systemic sclerosis", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "10555917_3_Ent3", "text": "systemic sclerosis", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "10555917_3_Ent2", "text": "D - penicillamine", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "10555917_3_Ent4", "text": "D - penicillamine", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "10560960_1", "wnd_id": "10560960_1_1", "text": "A 48 - year - old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis .", "tokens": ["A", "48", "-", "year", "-", "old", "woman", "who", "was", "treated", "for", "thyrotoxicosis", "with", "methimazole", "developed", "agranulocytosis", "."], "event_mentions": [{"id": "10560960_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "10560960_1_Ent0", "role": "Subject", "text": "A 48 - year - old woman", "start": 0, "end": 7}, {"entity_id": "10560960_1_Ent1", "role": "Subject_Age", "text": "48 - year - old", "start": 1, "end": 6}, {"entity_id": "10560960_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "10560960_1_Ent5", "role": "Treatment_Disorder", "text": "thyrotoxicosis", "start": 11, "end": 12}, {"entity_id": "10560960_1_Ent4", "role": "Treatment", "text": "methimazole", "start": 13, "end": 14}, {"entity_id": "10560960_1_Ent6", "role": "Treatment_Drug", "text": "methimazole", "start": 13, "end": 14}, {"entity_id": "10560960_1_Ent3", "role": "Effect", "text": "agranulocytosis", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "10560960_1_Ent0", "text": "A 48 - year - old woman", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "10560960_1_Ent1", "text": "48 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "10560960_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10560960_1_Ent5", "text": "thyrotoxicosis", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10560960_1_Ent4", "text": "methimazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "10560960_1_Ent6", "text": "methimazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "10560960_1_Ent3", "text": "agranulocytosis", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "10573314_3", "wnd_id": "10573314_3_1", "text": "Two patients , each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation , developed adverse effects after the initiation of tolterodine for urinary disorders .", "tokens": ["Two", "patients", ",", "each", "receiving", "warfarin", "for", "stroke", "prophylaxis", "in", "association", "with", "chronic", "atrial", "fibrillation", ",", "developed", "adverse", "effects", "after", "the", "initiation", "of", "tolterodine", "for", "urinary", "disorders", "."], "event_mentions": [{"id": "10573314_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 16, "end": 17}, "arguments": [{"entity_id": "10573314_3_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "10573314_3_Ent0", "role": "Subject", "text": "Two patients", "start": 0, "end": 2}, {"entity_id": "10573314_3_Ent4", "role": "Treatment", "text": "receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation", "start": 4, "end": 15}, {"entity_id": "10573314_3_Ent9", "role": "Treatment_Drug", "text": "warfarin", "start": 5, "end": 6}, {"entity_id": "10573314_3_Ent11", "role": "Combination_Drug", "text": "warfarin", "start": 5, "end": 6}, {"entity_id": "10573314_3_Ent6", "role": "Treatment_Disorder", "text": "stroke", "start": 7, "end": 8}, {"entity_id": "10573314_3_Ent2", "role": "Subject_Disorder", "text": "chronic atrial fibrillation", "start": 12, "end": 15}, {"entity_id": "10573314_3_Ent3", "role": "Effect", "text": "adverse effects", "start": 17, "end": 19}, {"entity_id": "10573314_3_Ent5", "role": "Treatment", "text": "after the initiation of tolterodine for urinary disorders", "start": 19, "end": 27}, {"entity_id": "10573314_3_Ent8", "role": "Treatment_Drug", "text": "tolterodine", "start": 23, "end": 24}, {"entity_id": "10573314_3_Ent10", "role": "Combination_Drug", "text": "tolterodine", "start": 23, "end": 24}, {"entity_id": "10573314_3_Ent7", "role": "Treatment_Disorder", "text": "urinary disorders", "start": 25, "end": 27}]}], "entity_mentions": [{"id": "10573314_3_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10573314_3_Ent0", "text": "Two patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10573314_3_Ent4", "text": "receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation", "entity_type": "Entity", "start": 4, "end": 15}, {"id": "10573314_3_Ent9", "text": "warfarin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10573314_3_Ent11", "text": "warfarin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10573314_3_Ent6", "text": "stroke", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10573314_3_Ent2", "text": "chronic atrial fibrillation", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "10573314_3_Ent3", "text": "adverse effects", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "10573314_3_Ent5", "text": "after the initiation of tolterodine for urinary disorders", "entity_type": "Entity", "start": 19, "end": 27}, {"id": "10573314_3_Ent8", "text": "tolterodine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "10573314_3_Ent10", "text": "tolterodine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "10573314_3_Ent7", "text": "urinary disorders", "entity_type": "Entity", "start": 25, "end": 27}], "lang": "en"}
{"doc_id": "10579985_1", "wnd_id": "10579985_1_1", "text": "The first patient was a 61 - year - old man with a 30 - year history of fistulizing CD in whom B - cell non - Hodgkin 's lymphoma was diagnosed 9 months after treatment with infliximab .", "tokens": ["The", "first", "patient", "was", "a", "61", "-", "year", "-", "old", "man", "with", "a", "30", "-", "year", "history", "of", "fistulizing", "CD", "in", "whom", "B", "-", "cell", "non", "-", "Hodgkin", "'s", "lymphoma", "was", "diagnosed", "9", "months", "after", "treatment", "with", "infliximab", "."], "event_mentions": [{"id": "10579985_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "diagnosed", "start": 31, "end": 32}, "arguments": [{"entity_id": "10579985_1_Ent0", "role": "Subject", "text": "The first patient was a 61 - year - old man with a 30 - year history of fistulizing CD", "start": 0, "end": 20}, {"entity_id": "10579985_1_Ent1", "role": "Subject_Age", "text": "61 - year - old", "start": 5, "end": 10}, {"entity_id": "10579985_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 10, "end": 11}, {"entity_id": "10579985_1_Ent5", "role": "Treatment_Disorder", "text": "fistulizing CD", "start": 18, "end": 20}, {"entity_id": "10579985_1_Ent3", "role": "Effect", "text": "B - cell non - Hodgkin 's lymphoma", "start": 22, "end": 30}, {"entity_id": "10579985_1_Ent6", "role": "Treatment_Time_elapsed", "text": "9 months", "start": 32, "end": 34}, {"entity_id": "10579985_1_Ent4", "role": "Treatment", "text": "9 months after treatment with infliximab", "start": 32, "end": 38}, {"entity_id": "10579985_1_Ent7", "role": "Treatment_Drug", "text": "infliximab", "start": 37, "end": 38}]}], "entity_mentions": [{"id": "10579985_1_Ent0", "text": "The first patient was a 61 - year - old man with a 30 - year history of fistulizing CD", "entity_type": "Entity", "start": 0, "end": 20}, {"id": "10579985_1_Ent1", "text": "61 - year - old", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "10579985_1_Ent2", "text": "man", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10579985_1_Ent5", "text": "fistulizing CD", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "10579985_1_Ent3", "text": "B - cell non - Hodgkin 's lymphoma", "entity_type": "Entity", "start": 22, "end": 30}, {"id": "10579985_1_Ent6", "text": "9 months", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "10579985_1_Ent4", "text": "9 months after treatment with infliximab", "entity_type": "Entity", "start": 32, "end": 38}, {"id": "10579985_1_Ent7", "text": "infliximab", "entity_type": "Entity", "start": 37, "end": 38}], "lang": "en"}
{"doc_id": "10579985_3", "wnd_id": "10579985_3_1", "text": "The second is a 29 - year - old man with CD in whom nodular sclerosing Hodgkin 's lymphoma was diagnosed 3 weeks after infusion with infliximab .", "tokens": ["The", "second", "is", "a", "29", "-", "year", "-", "old", "man", "with", "CD", "in", "whom", "nodular", "sclerosing", "Hodgkin", "'s", "lymphoma", "was", "diagnosed", "3", "weeks", "after", "infusion", "with", "infliximab", "."], "event_mentions": [{"id": "10579985_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "diagnosed", "start": 20, "end": 21}, "arguments": [{"entity_id": "10579985_3_Ent0", "role": "Subject", "text": "a 29 - year - old man with CD", "start": 3, "end": 12}, {"entity_id": "10579985_3_Ent1", "role": "Subject_Age", "text": "29 - year - old", "start": 4, "end": 9}, {"entity_id": "10579985_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 9, "end": 10}, {"entity_id": "10579985_3_Ent5", "role": "Treatment_Disorder", "text": "CD", "start": 11, "end": 12}, {"entity_id": "10579985_3_Ent3", "role": "Effect", "text": "nodular sclerosing Hodgkin 's lymphoma", "start": 14, "end": 19}, {"entity_id": "10579985_3_Ent6", "role": "Treatment_Time_elapsed", "text": "3 weeks", "start": 21, "end": 23}, {"entity_id": "10579985_3_Ent4", "role": "Treatment", "text": "3 weeks after infusion with infliximab", "start": 21, "end": 27}, {"entity_id": "10579985_3_Ent7", "role": "Treatment_Route", "text": "infusion", "start": 24, "end": 25}, {"entity_id": "10579985_3_Ent8", "role": "Treatment_Drug", "text": "infliximab", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "10579985_3_Ent0", "text": "a 29 - year - old man with CD", "entity_type": "Entity", "start": 3, "end": 12}, {"id": "10579985_3_Ent1", "text": "29 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "10579985_3_Ent2", "text": "man", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10579985_3_Ent5", "text": "CD", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10579985_3_Ent3", "text": "nodular sclerosing Hodgkin 's lymphoma", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "10579985_3_Ent6", "text": "3 weeks", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "10579985_3_Ent4", "text": "3 weeks after infusion with infliximab", "entity_type": "Entity", "start": 21, "end": 27}, {"id": "10579985_3_Ent7", "text": "infusion", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "10579985_3_Ent8", "text": "infliximab", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "10589077_5", "wnd_id": "10589077_5_1", "text": "We conclude that low - dose HU therapy in patients with thalassemia intermedia may increase total Hb levels sufficiently to eliminate the need for transfusions .", "tokens": ["We", "conclude", "that", "low", "-", "dose", "HU", "therapy", "in", "patients", "with", "thalassemia", "intermedia", "may", "increase", "total", "Hb", "levels", "sufficiently", "to", "eliminate", "the", "need", "for", "transfusions", "."], "event_mentions": [{"id": "10589077_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "therapy", "start": 7, "end": 8}, "arguments": [{"entity_id": "10589077_5_Ent5", "role": "Treatment_Dosage", "text": "low - dose", "start": 3, "end": 6}, {"entity_id": "10589077_5_Ent2", "role": "Treatment", "text": "low - dose HU therapy", "start": 3, "end": 8}, {"entity_id": "10589077_5_Ent4", "role": "Treatment_Drug", "text": "HU", "start": 6, "end": 7}, {"entity_id": "10589077_5_Ent0", "role": "Subject", "text": "in patients with thalassemia intermedia", "start": 8, "end": 13}, {"entity_id": "10589077_5_Ent3", "role": "Treatment_Disorder", "text": "thalassemia intermedia", "start": 11, "end": 13}, {"entity_id": "10589077_5_Ent1", "role": "Effect", "text": "increase total Hb levels", "start": 14, "end": 18}]}], "entity_mentions": [{"id": "10589077_5_Ent5", "text": "low - dose", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "10589077_5_Ent2", "text": "low - dose HU therapy", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "10589077_5_Ent4", "text": "HU", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10589077_5_Ent0", "text": "in patients with thalassemia intermedia", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "10589077_5_Ent3", "text": "thalassemia intermedia", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "10589077_5_Ent1", "text": "increase total Hb levels", "entity_type": "Entity", "start": 14, "end": 18}], "lang": "en"}
{"doc_id": "10592946_2", "wnd_id": "10592946_2_1", "text": "After abstinence from oolong tea his delirium resolved .", "tokens": ["After", "abstinence", "from", "oolong", "tea", "his", "delirium", "resolved", "."], "event_mentions": [{"id": "10592946_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "After", "start": 0, "end": 1}, "arguments": [{"entity_id": "10592946_2_Ent0", "role": "Treatment", "text": "oolong tea", "start": 3, "end": 5}, {"entity_id": "10592946_2_Ent1", "role": "Treatment_Disorder", "text": "delirium", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "10592946_2_Ent0", "text": "oolong tea", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "10592946_2_Ent1", "text": "delirium", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "10592946_3", "wnd_id": "10592946_3_1", "text": "Severe rhabdomyolysis following massive ingestion of oolong tea : caffeine intoxication with coexisting hyponatremia .", "tokens": ["Severe", "rhabdomyolysis", "following", "massive", "ingestion", "of", "oolong", "tea", ":", "caffeine", "intoxication", "with", "coexisting", "hyponatremia", "."], "event_mentions": [{"id": "10592946_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "10592946_3_Ent4", "role": "Treatment_Dosage", "text": "massive", "start": 3, "end": 4}, {"entity_id": "10592946_3_Ent1", "role": "Treatment", "text": "massive ingestion of oolong tea", "start": 3, "end": 8}, {"entity_id": "10592946_3_Ent5", "role": "Treatment_Route", "text": "ingestion", "start": 4, "end": 5}, {"entity_id": "10592946_3_Ent2", "role": "Treatment_Drug", "text": "oolong tea", "start": 6, "end": 8}, {"entity_id": "10592946_3_Ent3", "role": "Treatment_Drug", "text": "caffeine", "start": 9, "end": 10}, {"entity_id": "10592946_3_Ent0", "role": "Effect", "text": "caffeine intoxication with coexisting hyponatremia", "start": 9, "end": 14}]}], "entity_mentions": [{"id": "10592946_3_Ent4", "text": "massive", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10592946_3_Ent1", "text": "massive ingestion of oolong tea", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "10592946_3_Ent5", "text": "ingestion", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "10592946_3_Ent2", "text": "oolong tea", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "10592946_3_Ent3", "text": "caffeine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10592946_3_Ent0", "text": "caffeine intoxication with coexisting hyponatremia", "entity_type": "Entity", "start": 9, "end": 14}], "lang": "en"}
{"doc_id": "10592946_4", "wnd_id": "10592946_4_1", "text": "The clinical course suggests that caffeine , which is present in oolong tea , was mainly responsible for the rhabdomyolysis as well as the delirium , although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions .", "tokens": ["The", "clinical", "course", "suggests", "that", "caffeine", ",", "which", "is", "present", "in", "oolong", "tea", ",", "was", "mainly", "responsible", "for", "the", "rhabdomyolysis", "as", "well", "as", "the", "delirium", ",", "although", "severe", "hyponatremia", "has", "been", "reported", "to", "cause", "rhabdomyolysis", "on", "rare", "occasions", "."], "event_mentions": [{"id": "10592946_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "responsible", "start": 16, "end": 17}, "arguments": [{"entity_id": "10592946_4_Ent2", "role": "Treatment_Drug", "text": "caffeine", "start": 5, "end": 6}, {"entity_id": "10592946_4_Ent1", "role": "Treatment", "text": "caffeine , which is present in oolong tea", "start": 5, "end": 13}, {"entity_id": "10592946_4_Ent0", "role": "Effect", "text": "rhabdomyolysis as well as the delirium", "start": 19, "end": 25}]}], "entity_mentions": [{"id": "10592946_4_Ent2", "text": "caffeine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10592946_4_Ent1", "text": "caffeine , which is present in oolong tea", "entity_type": "Entity", "start": 5, "end": 13}, {"id": "10592946_4_Ent0", "text": "rhabdomyolysis as well as the delirium", "entity_type": "Entity", "start": 19, "end": 25}], "lang": "en"}
{"doc_id": "10646879_1", "wnd_id": "10646879_1_1", "text": "Methylene blue in the treatment and prevention of ifosfamide - induced encephalopathy : report of 12 cases and a review of the literature .", "tokens": ["Methylene", "blue", "in", "the", "treatment", "and", "prevention", "of", "ifosfamide", "-", "induced", "encephalopathy", ":", "report", "of", "12", "cases", "and", "a", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "10646879_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "10646879_1_Ent1", "role": "Treatment", "text": "ifosfamide", "start": 8, "end": 9}, {"entity_id": "10646879_1_Ent2", "role": "Treatment_Drug", "text": "ifosfamide", "start": 8, "end": 9}, {"entity_id": "10646879_1_Ent0", "role": "Effect", "text": "encephalopathy", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "10646879_1_Ent1", "text": "ifosfamide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10646879_1_Ent2", "text": "ifosfamide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10646879_1_Ent0", "text": "encephalopathy", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "10660641_9", "wnd_id": "10660641_9_1", "text": "The symptoms did not recur during the 36 months of itraconazole treatment after discharge , and it was concluded that ITCZ was effective for A. flavus hypertrophic pachymeningitis .", "tokens": ["The", "symptoms", "did", "not", "recur", "during", "the", "36", "months", "of", "itraconazole", "treatment", "after", "discharge", ",", "and", "it", "was", "concluded", "that", "ITCZ", "was", "effective", "for", "A.", "flavus", "hypertrophic", "pachymeningitis", "."], "event_mentions": [{"id": "10660641_9_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "effective", "start": 22, "end": 23}, "arguments": [{"entity_id": "10660641_9_Ent0", "role": "Effect", "text": "The symptoms did not recur", "start": 0, "end": 5}, {"entity_id": "10660641_9_Ent1", "role": "Treatment", "text": "the 36 months of itraconazole treatment after discharge", "start": 6, "end": 14}, {"entity_id": "10660641_9_Ent3", "role": "Treatment_Duration", "text": "36 months", "start": 7, "end": 9}, {"entity_id": "10660641_9_Ent4", "role": "Treatment_Drug", "text": "itraconazole", "start": 10, "end": 11}, {"entity_id": "10660641_9_Ent2", "role": "Treatment_Disorder", "text": "A. flavus hypertrophic pachymeningitis", "start": 24, "end": 28}]}], "entity_mentions": [{"id": "10660641_9_Ent0", "text": "The symptoms did not recur", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "10660641_9_Ent1", "text": "the 36 months of itraconazole treatment after discharge", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "10660641_9_Ent3", "text": "36 months", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "10660641_9_Ent4", "text": "itraconazole", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10660641_9_Ent2", "text": "A. flavus hypertrophic pachymeningitis", "entity_type": "Entity", "start": 24, "end": 28}], "lang": "en"}
{"doc_id": "10679548_5", "wnd_id": "10679548_5_1", "text": "The spectrum of nitrofurantoin lung injury continues to widen .", "tokens": ["The", "spectrum", "of", "nitrofurantoin", "lung", "injury", "continues", "to", "widen", "."], "event_mentions": [{"id": "10679548_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "widen", "start": 8, "end": 9}, "arguments": [{"entity_id": "10679548_5_Ent1", "role": "Treatment", "text": "nitrofurantoin", "start": 3, "end": 4}, {"entity_id": "10679548_5_Ent2", "role": "Treatment_Drug", "text": "nitrofurantoin", "start": 3, "end": 4}, {"entity_id": "10679548_5_Ent0", "role": "Effect", "text": "lung injury", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "10679548_5_Ent1", "text": "nitrofurantoin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10679548_5_Ent2", "text": "nitrofurantoin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10679548_5_Ent0", "text": "lung injury", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "10682234_1", "wnd_id": "10682234_1_1", "text": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon - alpha .", "tokens": ["Intravenous", "administration", "of", "levodopa", "ameliorated", "a", "refractory", "akathisia", "case", "induced", "by", "interferon", "-", "alpha", "."], "event_mentions": [{"id": "10682234_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "ameliorated", "start": 4, "end": 5}, "arguments": [{"entity_id": "10682234_1_Ent2", "role": "Treatment_Route", "text": "Intravenous", "start": 0, "end": 1}, {"entity_id": "10682234_1_Ent0", "role": "Treatment", "text": "Intravenous administration of levodopa", "start": 0, "end": 4}, {"entity_id": "10682234_1_Ent3", "role": "Treatment_Drug", "text": "levodopa", "start": 3, "end": 4}, {"entity_id": "10682234_1_Ent1", "role": "Treatment_Disorder", "text": "a refractory akathisia case induced by interferon - alpha", "start": 5, "end": 14}]}, {"id": "10682234_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "10682234_1_Ent4", "role": "Effect", "text": "refractory akathisia", "start": 6, "end": 8}, {"entity_id": "10682234_1_Ent6", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 11, "end": 14}, {"entity_id": "10682234_1_Ent5", "role": "Treatment", "text": "interferon - alpha .", "start": 11, "end": 15}]}], "entity_mentions": [{"id": "10682234_1_Ent2", "text": "Intravenous", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10682234_1_Ent0", "text": "Intravenous administration of levodopa", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10682234_1_Ent3", "text": "levodopa", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10682234_1_Ent1", "text": "a refractory akathisia case induced by interferon - alpha", "entity_type": "Entity", "start": 5, "end": 14}, {"id": "10682234_1_Ent4", "text": "refractory akathisia", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "10682234_1_Ent6", "text": "interferon - alpha", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "10682234_1_Ent5", "text": "interferon - alpha .", "entity_type": "Entity", "start": 11, "end": 15}], "lang": "en"}
{"doc_id": "10688731_2", "wnd_id": "10688731_2_1", "text": "This is the first report of UFT - induced scleroderma - like reaction .", "tokens": ["This", "is", "the", "first", "report", "of", "UFT", "-", "induced", "scleroderma", "-", "like", "reaction", "."], "event_mentions": [{"id": "10688731_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "10688731_2_Ent1", "role": "Treatment", "text": "UFT", "start": 6, "end": 7}, {"entity_id": "10688731_2_Ent2", "role": "Treatment_Drug", "text": "UFT", "start": 6, "end": 7}, {"entity_id": "10688731_2_Ent0", "role": "Effect", "text": "scleroderma - like reaction", "start": 9, "end": 13}]}], "entity_mentions": [{"id": "10688731_2_Ent1", "text": "UFT", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10688731_2_Ent2", "text": "UFT", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10688731_2_Ent0", "text": "scleroderma - like reaction", "entity_type": "Entity", "start": 9, "end": 13}], "lang": "en"}
{"doc_id": "10707759_2", "wnd_id": "10707759_2_1", "text": "Flecainide is a rare cause of hypersensitivity pneumonitis , and few cases have been reported .", "tokens": ["Flecainide", "is", "a", "rare", "cause", "of", "hypersensitivity", "pneumonitis", ",", "and", "few", "cases", "have", "been", "reported", "."], "event_mentions": [{"id": "10707759_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 4, "end": 5}, "arguments": [{"entity_id": "10707759_2_Ent1", "role": "Treatment", "text": "Flecainide", "start": 0, "end": 1}, {"entity_id": "10707759_2_Ent2", "role": "Treatment_Drug", "text": "Flecainide", "start": 0, "end": 1}, {"entity_id": "10707759_2_Ent0", "role": "Effect", "text": "hypersensitivity pneumonitis", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "10707759_2_Ent1", "text": "Flecainide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10707759_2_Ent2", "text": "Flecainide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10707759_2_Ent0", "text": "hypersensitivity pneumonitis", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "10715308_1", "wnd_id": "10715308_1_1", "text": "Tirapazamine plus cisplatin versus cisplatin in advanced non - small - cell lung cancer : A report of the international CATAPULT I study group .", "tokens": ["Tirapazamine", "plus", "cisplatin", "versus", "cisplatin", "in", "advanced", "non", "-", "small", "-", "cell", "lung", "cancer", ":", "A", "report", "of", "the", "international", "CATAPULT", "I", "study", "group", "."], "event_mentions": [{"id": "10715308_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "in", "start": 5, "end": 6}, "arguments": [{"entity_id": "10715308_1_Ent3", "role": "Treatment_Drug", "text": "Tirapazamine", "start": 0, "end": 1}, {"entity_id": "10715308_1_Ent5", "role": "Combination_Drug", "text": "Tirapazamine", "start": 0, "end": 1}, {"entity_id": "10715308_1_Ent0", "role": "Treatment", "text": "Tirapazamine plus cisplatin", "start": 0, "end": 3}, {"entity_id": "10715308_1_Ent2", "role": "Treatment_Drug", "text": "cisplatin", "start": 2, "end": 3}, {"entity_id": "10715308_1_Ent4", "role": "Combination_Drug", "text": "cisplatin", "start": 2, "end": 3}, {"entity_id": "10715308_1_Ent1", "role": "Treatment_Disorder", "text": "advanced non - small - cell lung cancer", "start": 6, "end": 14}]}], "entity_mentions": [{"id": "10715308_1_Ent3", "text": "Tirapazamine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10715308_1_Ent5", "text": "Tirapazamine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10715308_1_Ent0", "text": "Tirapazamine plus cisplatin", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "10715308_1_Ent2", "text": "cisplatin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10715308_1_Ent4", "text": "cisplatin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10715308_1_Ent1", "text": "advanced non - small - cell lung cancer", "entity_type": "Entity", "start": 6, "end": 14}], "lang": "en"}
{"doc_id": "10715308_11", "wnd_id": "10715308_11_1", "text": "There were no incremental increases in myelosuppression , peripheral neuropathy , or renal , hepatic , or cardiac toxicity and no deaths related to tirapazamine .", "tokens": ["There", "were", "no", "incremental", "increases", "in", "myelosuppression", ",", "peripheral", "neuropathy", ",", "or", "renal", ",", "hepatic", ",", "or", "cardiac", "toxicity", "and", "no", "deaths", "related", "to", "tirapazamine", "."], "event_mentions": [{"id": "10715308_11_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "related", "start": 22, "end": 23}, "arguments": [{"entity_id": "10715308_11_Ent0", "role": "Effect", "text": "no incremental increases in myelosuppression , peripheral neuropathy , or renal , hepatic , or cardiac toxicity and no deaths", "start": 2, "end": 22}, {"entity_id": "10715308_11_Ent1", "role": "Treatment", "text": "tirapazamine", "start": 24, "end": 25}, {"entity_id": "10715308_11_Ent2", "role": "Treatment_Drug", "text": "tirapazamine", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "10715308_11_Ent0", "text": "no incremental increases in myelosuppression , peripheral neuropathy , or renal , hepatic , or cardiac toxicity and no deaths", "entity_type": "Entity", "start": 2, "end": 22}, {"id": "10715308_11_Ent1", "text": "tirapazamine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "10715308_11_Ent2", "text": "tirapazamine", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "10723699_1", "wnd_id": "10723699_1_1", "text": "Tetracycline - induced benign intracranial hypertension .", "tokens": ["Tetracycline", "-", "induced", "benign", "intracranial", "hypertension", "."], "event_mentions": [{"id": "10723699_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "10723699_1_Ent1", "role": "Treatment", "text": "Tetracycline", "start": 0, "end": 1}, {"entity_id": "10723699_1_Ent2", "role": "Treatment_Drug", "text": "Tetracycline", "start": 0, "end": 1}, {"entity_id": "10723699_1_Ent0", "role": "Effect", "text": "benign intracranial hypertension", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "10723699_1_Ent1", "text": "Tetracycline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10723699_1_Ent2", "text": "Tetracycline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10723699_1_Ent0", "text": "benign intracranial hypertension", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "10749332_4", "wnd_id": "10749332_4_1", "text": "The three reported cases demonstrate that troglitazone is an idiosyncratic hepatotoxin that can lead to irreversible liver injury .", "tokens": ["The", "three", "reported", "cases", "demonstrate", "that", "troglitazone", "is", "an", "idiosyncratic", "hepatotoxin", "that", "can", "lead", "to", "irreversible", "liver", "injury", "."], "event_mentions": [{"id": "10749332_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "lead", "start": 13, "end": 14}, "arguments": [{"entity_id": "10749332_4_Ent1", "role": "Subject_Population", "text": "three", "start": 1, "end": 2}, {"entity_id": "10749332_4_Ent0", "role": "Subject", "text": "three reported cases", "start": 1, "end": 4}, {"entity_id": "10749332_4_Ent3", "role": "Treatment", "text": "troglitazone", "start": 6, "end": 7}, {"entity_id": "10749332_4_Ent4", "role": "Treatment_Drug", "text": "troglitazone", "start": 6, "end": 7}, {"entity_id": "10749332_4_Ent2", "role": "Effect", "text": "irreversible liver injury", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "10749332_4_Ent1", "text": "three", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "10749332_4_Ent0", "text": "three reported cases", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "10749332_4_Ent3", "text": "troglitazone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10749332_4_Ent4", "text": "troglitazone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10749332_4_Ent2", "text": "irreversible liver injury", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "10759907_3", "wnd_id": "10759907_3_1", "text": "The temporal relationship suggests that the spinal cord infarction may be related to the use of zolmitriptan .", "tokens": ["The", "temporal", "relationship", "suggests", "that", "the", "spinal", "cord", "infarction", "may", "be", "related", "to", "the", "use", "of", "zolmitriptan", "."], "event_mentions": [{"id": "10759907_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 11, "end": 12}, "arguments": [{"entity_id": "10759907_3_Ent0", "role": "Effect", "text": "spinal cord infarction", "start": 6, "end": 9}, {"entity_id": "10759907_3_Ent1", "role": "Treatment", "text": "zolmitriptan", "start": 16, "end": 17}, {"entity_id": "10759907_3_Ent2", "role": "Treatment_Drug", "text": "zolmitriptan", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "10759907_3_Ent0", "text": "spinal cord infarction", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "10759907_3_Ent1", "text": "zolmitriptan", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "10759907_3_Ent2", "text": "zolmitriptan", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "10772434_2", "wnd_id": "10772434_2_1", "text": "This regimen could prove useful for other patients who develop hypersensitivity reactions to carboplatin and allow therapy to continue .", "tokens": ["This", "regimen", "could", "prove", "useful", "for", "other", "patients", "who", "develop", "hypersensitivity", "reactions", "to", "carboplatin", "and", "allow", "therapy", "to", "continue", "."], "event_mentions": [{"id": "10772434_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 9, "end": 10}, "arguments": [{"entity_id": "10772434_2_Ent0", "role": "Subject", "text": "patients", "start": 7, "end": 8}, {"entity_id": "10772434_2_Ent1", "role": "Effect", "text": "hypersensitivity reactions", "start": 10, "end": 12}, {"entity_id": "10772434_2_Ent2", "role": "Treatment", "text": "carboplatin", "start": 13, "end": 14}, {"entity_id": "10772434_2_Ent3", "role": "Treatment_Drug", "text": "carboplatin", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "10772434_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10772434_2_Ent1", "text": "hypersensitivity reactions", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "10772434_2_Ent2", "text": "carboplatin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "10772434_2_Ent3", "text": "carboplatin", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "10774758_1", "wnd_id": "10774758_1_1", "text": "Perinatal vasoconstrictive renal insufficiency associated with maternal nimesulide use .", "tokens": ["Perinatal", "vasoconstrictive", "renal", "insufficiency", "associated", "with", "maternal", "nimesulide", "use", "."], "event_mentions": [{"id": "10774758_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "10774758_1_Ent0", "role": "Effect", "text": "Perinatal vasoconstrictive renal insufficiency", "start": 0, "end": 4}, {"entity_id": "10774758_1_Ent1", "role": "Treatment", "text": "maternal nimesulide use", "start": 6, "end": 9}, {"entity_id": "10774758_1_Ent2", "role": "Treatment_Drug", "text": "nimesulide", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "10774758_1_Ent0", "text": "Perinatal vasoconstrictive renal insufficiency", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10774758_1_Ent1", "text": "maternal nimesulide use", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "10774758_1_Ent2", "text": "nimesulide", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "10803790_5", "wnd_id": "10803790_5_1", "text": "CONCLUSION : In some abstainers who take cyanamide for several years , thin septum - like liver fibrosis progresses along with the emergence of ground - glass hepatocytes .", "tokens": ["CONCLUSION", ":", "In", "some", "abstainers", "who", "take", "cyanamide", "for", "several", "years", ",", "thin", "septum", "-", "like", "liver", "fibrosis", "progresses", "along", "with", "the", "emergence", "of", "ground", "-", "glass", "hepatocytes", "."], "event_mentions": [{"id": "10803790_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "In", "start": 2, "end": 3}, "arguments": [{"entity_id": "10803790_5_Ent0", "role": "Subject", "text": "some abstainers", "start": 3, "end": 5}, {"entity_id": "10803790_5_Ent2", "role": "Treatment", "text": "take cyanamide for several years", "start": 6, "end": 11}, {"entity_id": "10803790_5_Ent3", "role": "Treatment_Drug", "text": "cyanamide", "start": 7, "end": 8}, {"entity_id": "10803790_5_Ent4", "role": "Treatment_Freq", "text": "several years", "start": 9, "end": 11}, {"entity_id": "10803790_5_Ent1", "role": "Effect", "text": "thin septum - like liver fibrosis progresses along with the emergence of ground - glass hepatocytes", "start": 12, "end": 28}]}], "entity_mentions": [{"id": "10803790_5_Ent0", "text": "some abstainers", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "10803790_5_Ent2", "text": "take cyanamide for several years", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "10803790_5_Ent3", "text": "cyanamide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10803790_5_Ent4", "text": "several years", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "10803790_5_Ent1", "text": "thin septum - like liver fibrosis progresses along with the emergence of ground - glass hepatocytes", "entity_type": "Entity", "start": 12, "end": 28}], "lang": "en"}
{"doc_id": "10803790_6", "wnd_id": "10803790_6_1", "text": "Cyanamide - induced liver dysfunction after abstinence in alcoholics : a long - term follow - up study on four cases .", "tokens": ["Cyanamide", "-", "induced", "liver", "dysfunction", "after", "abstinence", "in", "alcoholics", ":", "a", "long", "-", "term", "follow", "-", "up", "study", "on", "four", "cases", "."], "event_mentions": [{"id": "10803790_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "10803790_6_Ent2", "role": "Treatment", "text": "Cyanamide", "start": 0, "end": 1}, {"entity_id": "10803790_6_Ent3", "role": "Treatment_Drug", "text": "Cyanamide", "start": 0, "end": 1}, {"entity_id": "10803790_6_Ent1", "role": "Effect", "text": "liver dysfunction", "start": 3, "end": 5}, {"entity_id": "10803790_6_Ent0", "role": "Subject", "text": "abstinence in alcoholics", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "10803790_6_Ent2", "text": "Cyanamide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10803790_6_Ent3", "text": "Cyanamide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10803790_6_Ent1", "text": "liver dysfunction", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "10803790_6_Ent0", "text": "abstinence in alcoholics", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "10870485_1", "wnd_id": "10870485_1_1", "text": "Three months following splenectomy , multiple abscesses occurred in the muscles of both thighs while the patient was receiving the third course of the CHOP regimen .", "tokens": ["Three", "months", "following", "splenectomy", ",", "multiple", "abscesses", "occurred", "in", "the", "muscles", "of", "both", "thighs", "while", "the", "patient", "was", "receiving", "the", "third", "course", "of", "the", "CHOP", "regimen", "."], "event_mentions": [{"id": "10870485_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "while", "start": 14, "end": 15}, "arguments": [{"entity_id": "10870485_1_Ent4", "role": "Treatment_Duration", "text": "Three months", "start": 0, "end": 2}, {"entity_id": "10870485_1_Ent2", "role": "Treatment", "text": "Three months following splenectomy", "start": 0, "end": 4}, {"entity_id": "10870485_1_Ent5", "role": "Treatment_Drug", "text": "splenectomy", "start": 3, "end": 4}, {"entity_id": "10870485_1_Ent9", "role": "Combination_Drug", "text": "splenectomy", "start": 3, "end": 4}, {"entity_id": "10870485_1_Ent1", "role": "Effect", "text": "multiple abscesses occurred in the muscles of both thighs", "start": 5, "end": 14}, {"entity_id": "10870485_1_Ent0", "role": "Subject", "text": "the patient", "start": 15, "end": 17}, {"entity_id": "10870485_1_Ent7", "role": "Treatment_Dosage", "text": "third course", "start": 20, "end": 22}, {"entity_id": "10870485_1_Ent3", "role": "Treatment", "text": "third course of the CHOP regimen", "start": 20, "end": 26}, {"entity_id": "10870485_1_Ent6", "role": "Treatment_Drug", "text": "CHOP", "start": 24, "end": 25}, {"entity_id": "10870485_1_Ent8", "role": "Combination_Drug", "text": "CHOP", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "10870485_1_Ent4", "text": "Three months", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10870485_1_Ent2", "text": "Three months following splenectomy", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10870485_1_Ent5", "text": "splenectomy", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10870485_1_Ent9", "text": "splenectomy", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10870485_1_Ent1", "text": "multiple abscesses occurred in the muscles of both thighs", "entity_type": "Entity", "start": 5, "end": 14}, {"id": "10870485_1_Ent0", "text": "the patient", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "10870485_1_Ent7", "text": "third course", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "10870485_1_Ent3", "text": "third course of the CHOP regimen", "entity_type": "Entity", "start": 20, "end": 26}, {"id": "10870485_1_Ent6", "text": "CHOP", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "10870485_1_Ent8", "text": "CHOP", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "10891991_2", "wnd_id": "10891991_2_1", "text": "BACKGROUND : Reproductive endocrine disorders characterized by menstrual disorders , polycystic ovaries , and hyperandrogenism seem to be common among women treated with sodium valproate for epilepsy .", "tokens": ["BACKGROUND", ":", "Reproductive", "endocrine", "disorders", "characterized", "by", "menstrual", "disorders", ",", "polycystic", "ovaries", ",", "and", "hyperandrogenism", "seem", "to", "be", "common", "among", "women", "treated", "with", "sodium", "valproate", "for", "epilepsy", "."], "event_mentions": [{"id": "10891991_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 21, "end": 22}, "arguments": [{"entity_id": "10891991_2_Ent2", "role": "Effect", "text": "Reproductive endocrine disorders characterized by menstrual disorders , polycystic ovaries , and hyperandrogenism", "start": 2, "end": 15}, {"entity_id": "10891991_2_Ent0", "role": "Subject", "text": "women", "start": 20, "end": 21}, {"entity_id": "10891991_2_Ent1", "role": "Subject_Gender", "text": "women", "start": 20, "end": 21}, {"entity_id": "10891991_2_Ent4", "role": "Treatment_Drug", "text": "sodium valproate", "start": 23, "end": 25}, {"entity_id": "10891991_2_Ent3", "role": "Treatment", "text": "sodium valproate for epilepsy", "start": 23, "end": 27}, {"entity_id": "10891991_2_Ent5", "role": "Treatment_Disorder", "text": "epilepsy", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "10891991_2_Ent2", "text": "Reproductive endocrine disorders characterized by menstrual disorders , polycystic ovaries , and hyperandrogenism", "entity_type": "Entity", "start": 2, "end": 15}, {"id": "10891991_2_Ent0", "text": "women", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "10891991_2_Ent1", "text": "women", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "10891991_2_Ent4", "text": "sodium valproate", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "10891991_2_Ent3", "text": "sodium valproate for epilepsy", "entity_type": "Entity", "start": 23, "end": 27}, {"id": "10891991_2_Ent5", "text": "epilepsy", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "10891991_3", "wnd_id": "10891991_3_1", "text": "CONCLUSIONS : The 3 cases presented here illustrate the development of reproductive endocrine disorders after the initiation of valproate therapy in women with epilepsy .", "tokens": ["CONCLUSIONS", ":", "The", "3", "cases", "presented", "here", "illustrate", "the", "development", "of", "reproductive", "endocrine", "disorders", "after", "the", "initiation", "of", "valproate", "therapy", "in", "women", "with", "epilepsy", "."], "event_mentions": [{"id": "10891991_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 9, "end": 10}, "arguments": [{"entity_id": "10891991_3_Ent0", "role": "Subject", "text": "The 3 cases", "start": 2, "end": 5}, {"entity_id": "10891991_3_Ent2", "role": "Subject_Population", "text": "3", "start": 3, "end": 4}, {"entity_id": "10891991_3_Ent4", "role": "Effect", "text": "reproductive endocrine disorders", "start": 11, "end": 14}, {"entity_id": "10891991_3_Ent5", "role": "Treatment", "text": "after the initiation of valproate therapy", "start": 14, "end": 20}, {"entity_id": "10891991_3_Ent6", "role": "Treatment_Drug", "text": "valproate", "start": 18, "end": 19}, {"entity_id": "10891991_3_Ent3", "role": "Subject_Gender", "text": "women", "start": 21, "end": 22}, {"entity_id": "10891991_3_Ent1", "role": "Subject", "text": "women with epilepsy", "start": 21, "end": 24}, {"entity_id": "10891991_3_Ent7", "role": "Treatment_Disorder", "text": "epilepsy", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "10891991_3_Ent0", "text": "The 3 cases", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "10891991_3_Ent2", "text": "3", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10891991_3_Ent4", "text": "reproductive endocrine disorders", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "10891991_3_Ent5", "text": "after the initiation of valproate therapy", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "10891991_3_Ent6", "text": "valproate", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "10891991_3_Ent3", "text": "women", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "10891991_3_Ent1", "text": "women with epilepsy", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "10891991_3_Ent7", "text": "epilepsy", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "10891991_4", "wnd_id": "10891991_4_1", "text": "OBJECTIVE : To describe the development of valproate - related reproductive endocrine disorders in women with epilepsy .", "tokens": ["OBJECTIVE", ":", "To", "describe", "the", "development", "of", "valproate", "-", "related", "reproductive", "endocrine", "disorders", "in", "women", "with", "epilepsy", "."], "event_mentions": [{"id": "10891991_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 9, "end": 10}, "arguments": [{"entity_id": "10891991_4_Ent3", "role": "Treatment", "text": "valproate", "start": 7, "end": 8}, {"entity_id": "10891991_4_Ent4", "role": "Treatment_Drug", "text": "valproate", "start": 7, "end": 8}, {"entity_id": "10891991_4_Ent2", "role": "Effect", "text": "reproductive endocrine disorders", "start": 10, "end": 13}, {"entity_id": "10891991_4_Ent1", "role": "Subject_Gender", "text": "women", "start": 14, "end": 15}, {"entity_id": "10891991_4_Ent0", "role": "Subject", "text": "women with epilepsy", "start": 14, "end": 17}, {"entity_id": "10891991_4_Ent5", "role": "Treatment_Disorder", "text": "epilepsy", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "10891991_4_Ent3", "text": "valproate", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10891991_4_Ent4", "text": "valproate", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10891991_4_Ent2", "text": "reproductive endocrine disorders", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "10891991_4_Ent1", "text": "women", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "10891991_4_Ent0", "text": "women with epilepsy", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "10891991_4_Ent5", "text": "epilepsy", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "10891991_6", "wnd_id": "10891991_6_1", "text": "RESULTS : Replacing valproate with lamotrigine resulted in a decrease in serum testosterone concentrations in all 3 women .", "tokens": ["RESULTS", ":", "Replacing", "valproate", "with", "lamotrigine", "resulted", "in", "a", "decrease", "in", "serum", "testosterone", "concentrations", "in", "all", "3", "women", "."], "event_mentions": [{"id": "10891991_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 6, "end": 7}, "arguments": [{"entity_id": "10891991_6_Ent4", "role": "Treatment", "text": "Replacing valproate with lamotrigine", "start": 2, "end": 6}, {"entity_id": "10891991_6_Ent5", "role": "Treatment_Drug", "text": "lamotrigine", "start": 5, "end": 6}, {"entity_id": "10891991_6_Ent3", "role": "Effect", "text": "a decrease in serum testosterone concentrations", "start": 8, "end": 14}, {"entity_id": "10891991_6_Ent0", "role": "Subject", "text": "all 3 women", "start": 15, "end": 18}, {"entity_id": "10891991_6_Ent1", "role": "Subject_Population", "text": "3", "start": 16, "end": 17}, {"entity_id": "10891991_6_Ent2", "role": "Subject_Gender", "text": "women", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "10891991_6_Ent4", "text": "Replacing valproate with lamotrigine", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "10891991_6_Ent5", "text": "lamotrigine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10891991_6_Ent3", "text": "a decrease in serum testosterone concentrations", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "10891991_6_Ent0", "text": "all 3 women", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "10891991_6_Ent1", "text": "3", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "10891991_6_Ent2", "text": "women", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "10904571_2", "wnd_id": "10904571_2_1", "text": "Colchicine - induced myopathy in renal failure .", "tokens": ["Colchicine", "-", "induced", "myopathy", "in", "renal", "failure", "."], "event_mentions": [{"id": "10904571_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "10904571_2_Ent1", "role": "Treatment", "text": "Colchicine", "start": 0, "end": 1}, {"entity_id": "10904571_2_Ent2", "role": "Treatment_Drug", "text": "Colchicine", "start": 0, "end": 1}, {"entity_id": "10904571_2_Ent0", "role": "Effect", "text": "myopathy", "start": 3, "end": 4}, {"entity_id": "10904571_2_Ent3", "role": "Treatment_Disorder", "text": "renal failure", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "10904571_2_Ent1", "text": "Colchicine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10904571_2_Ent2", "text": "Colchicine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10904571_2_Ent0", "text": "myopathy", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10904571_2_Ent3", "text": "renal failure", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "10963515_2", "wnd_id": "10963515_2_1", "text": "We describe a case of EGE manifested as an allergy to gemfibrozil .", "tokens": ["We", "describe", "a", "case", "of", "EGE", "manifested", "as", "an", "allergy", "to", "gemfibrozil", "."], "event_mentions": [{"id": "10963515_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "manifested", "start": 6, "end": 7}, "arguments": [{"entity_id": "10963515_2_Ent0", "role": "Subject", "text": "a case of EGE", "start": 2, "end": 6}, {"entity_id": "10963515_2_Ent1", "role": "Subject_Disorder", "text": "EGE", "start": 5, "end": 6}, {"entity_id": "10963515_2_Ent2", "role": "Effect", "text": "allergy", "start": 9, "end": 10}, {"entity_id": "10963515_2_Ent3", "role": "Treatment", "text": "gemfibrozil", "start": 11, "end": 12}, {"entity_id": "10963515_2_Ent4", "role": "Treatment_Drug", "text": "gemfibrozil", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "10963515_2_Ent0", "text": "a case of EGE", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "10963515_2_Ent1", "text": "EGE", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10963515_2_Ent2", "text": "allergy", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10963515_2_Ent3", "text": "gemfibrozil", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10963515_2_Ent4", "text": "gemfibrozil", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "10987357_2", "wnd_id": "10987357_2_1", "text": "A 74 - year - old man received oral administration of pilsicainide , a pure sodium channel blocker with slow recovery kinetics , to convert paroxysmal atrial fibrillation to sinus rhythm and developed loss of consciousness two days later .", "tokens": ["A", "74", "-", "year", "-", "old", "man", "received", "oral", "administration", "of", "pilsicainide", ",", "a", "pure", "sodium", "channel", "blocker", "with", "slow", "recovery", "kinetics", ",", "to", "convert", "paroxysmal", "atrial", "fibrillation", "to", "sinus", "rhythm", "and", "developed", "loss", "of", "consciousness", "two", "days", "later", "."], "event_mentions": [{"id": "10987357_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 32, "end": 33}, "arguments": [{"entity_id": "10987357_2_Ent0", "role": "Subject", "text": "A 74 - year - old man", "start": 0, "end": 7}, {"entity_id": "10987357_2_Ent1", "role": "Subject_Age", "text": "74 - year - old", "start": 1, "end": 6}, {"entity_id": "10987357_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "10987357_2_Ent6", "role": "Treatment_Route", "text": "oral", "start": 8, "end": 9}, {"entity_id": "10987357_2_Ent4", "role": "Treatment", "text": "oral administration of pilsicainide", "start": 8, "end": 12}, {"entity_id": "10987357_2_Ent7", "role": "Treatment_Drug", "text": "pilsicainide", "start": 11, "end": 12}, {"entity_id": "10987357_2_Ent8", "role": "Treatment_Disorder", "text": "paroxysmal atrial fibrillation", "start": 25, "end": 28}, {"entity_id": "10987357_2_Ent3", "role": "Effect", "text": "loss of consciousness", "start": 33, "end": 36}, {"entity_id": "10987357_2_Ent5", "role": "Treatment", "text": "two days later", "start": 36, "end": 39}, {"entity_id": "10987357_2_Ent9", "role": "Treatment_Time_elapsed", "text": "two days later", "start": 36, "end": 39}]}], "entity_mentions": [{"id": "10987357_2_Ent0", "text": "A 74 - year - old man", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "10987357_2_Ent1", "text": "74 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "10987357_2_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10987357_2_Ent6", "text": "oral", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10987357_2_Ent4", "text": "oral administration of pilsicainide", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "10987357_2_Ent7", "text": "pilsicainide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10987357_2_Ent8", "text": "paroxysmal atrial fibrillation", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "10987357_2_Ent3", "text": "loss of consciousness", "entity_type": "Entity", "start": 33, "end": 36}, {"id": "10987357_2_Ent5", "text": "two days later", "entity_type": "Entity", "start": 36, "end": 39}, {"id": "10987357_2_Ent9", "text": "two days later", "entity_type": "Entity", "start": 36, "end": 39}], "lang": "en"}
{"doc_id": "11008259_2", "wnd_id": "11008259_2_1", "text": "The events of non - convulsive status epilepticus subsided following reduction in tiagabine dosages .", "tokens": ["The", "events", "of", "non", "-", "convulsive", "status", "epilepticus", "subsided", "following", "reduction", "in", "tiagabine", "dosages", "."], "event_mentions": [{"id": "11008259_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 9, "end": 10}, "arguments": [{"entity_id": "11008259_2_Ent0", "role": "Effect", "text": "non - convulsive status epilepticus subsided", "start": 3, "end": 9}, {"entity_id": "11008259_2_Ent1", "role": "Treatment", "text": "reduction in tiagabine dosages", "start": 10, "end": 14}, {"entity_id": "11008259_2_Ent2", "role": "Treatment_Drug", "text": "tiagabine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "11008259_2_Ent0", "text": "non - convulsive status epilepticus subsided", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "11008259_2_Ent1", "text": "reduction in tiagabine dosages", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "11008259_2_Ent2", "text": "tiagabine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "11020127_2", "wnd_id": "11020127_2_1", "text": "Protease inhibitors ( ritonavir and saquinavir ) were added to the treatment and the patient developed progressive ataxia related to carbamazepine toxicity .", "tokens": ["Protease", "inhibitors", "(", "ritonavir", "and", "saquinavir", ")", "were", "added", "to", "the", "treatment", "and", "the", "patient", "developed", "progressive", "ataxia", "related", "to", "carbamazepine", "toxicity", "."], "event_mentions": [{"id": "11020127_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 15, "end": 16}, "arguments": [{"entity_id": "11020127_2_Ent5", "role": "Treatment_Drug", "text": "Protease inhibitors", "start": 0, "end": 2}, {"entity_id": "11020127_2_Ent6", "role": "Combination_Drug", "text": "Protease inhibitors", "start": 0, "end": 2}, {"entity_id": "11020127_2_Ent2", "role": "Treatment", "text": "Protease inhibitors ( ritonavir and saquinavir ) were added to the treatment", "start": 0, "end": 12}, {"entity_id": "11020127_2_Ent0", "role": "Subject", "text": "the patient", "start": 13, "end": 15}, {"entity_id": "11020127_2_Ent1", "role": "Effect", "text": "progressive ataxia related to carbamazepine toxicity", "start": 16, "end": 22}, {"entity_id": "11020127_2_Ent3", "role": "Treatment", "text": "carbamazepine", "start": 20, "end": 21}, {"entity_id": "11020127_2_Ent4", "role": "Treatment_Drug", "text": "carbamazepine", "start": 20, "end": 21}, {"entity_id": "11020127_2_Ent7", "role": "Combination_Drug", "text": "carbamazepine", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "11020127_2_Ent5", "text": "Protease inhibitors", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11020127_2_Ent6", "text": "Protease inhibitors", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11020127_2_Ent2", "text": "Protease inhibitors ( ritonavir and saquinavir ) were added to the treatment", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "11020127_2_Ent0", "text": "the patient", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "11020127_2_Ent1", "text": "progressive ataxia related to carbamazepine toxicity", "entity_type": "Entity", "start": 16, "end": 22}, {"id": "11020127_2_Ent3", "text": "carbamazepine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "11020127_2_Ent4", "text": "carbamazepine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "11020127_2_Ent7", "text": "carbamazepine", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "11022272_4", "wnd_id": "11022272_4_1", "text": "We introduce a case of a sixty years old woman with several previous episodes of rhinitis , conjunctivitis and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration ( Calsynar ) .", "tokens": ["We", "introduce", "a", "case", "of", "a", "sixty", "years", "old", "woman", "with", "several", "previous", "episodes", "of", "rhinitis", ",", "conjunctivitis", "and", "perspiration", "immediately", "after", "the", "administration", "of", "salmon", "calcitonin", "with", "nasal", "spray", "or", "intramuscular", "administration", "(", "Calsynar", ")", "."], "event_mentions": [{"id": "11022272_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 21, "end": 22}, "arguments": [{"entity_id": "11022272_4_Ent0", "role": "Subject", "text": "a sixty years old woman", "start": 5, "end": 10}, {"entity_id": "11022272_4_Ent1", "role": "Subject_Age", "text": "sixty years old", "start": 6, "end": 9}, {"entity_id": "11022272_4_Ent2", "role": "Subject_Gender", "text": "woman", "start": 9, "end": 10}, {"entity_id": "11022272_4_Ent3", "role": "Effect", "text": "several previous episodes of rhinitis , conjunctivitis and perspiration immediately", "start": 11, "end": 21}, {"entity_id": "11022272_4_Ent7", "role": "Treatment_Drug", "text": "salmon calcitonin", "start": 25, "end": 27}, {"entity_id": "11022272_4_Ent4", "role": "Treatment", "text": "salmon calcitonin with nasal spray or intramuscular administration ( Calsynar )", "start": 25, "end": 36}, {"entity_id": "11022272_4_Ent5", "role": "Treatment_Route", "text": "nasal spray", "start": 28, "end": 30}, {"entity_id": "11022272_4_Ent6", "role": "Treatment_Route", "text": "intramuscular", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "11022272_4_Ent0", "text": "a sixty years old woman", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "11022272_4_Ent1", "text": "sixty years old", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "11022272_4_Ent2", "text": "woman", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11022272_4_Ent3", "text": "several previous episodes of rhinitis , conjunctivitis and perspiration immediately", "entity_type": "Entity", "start": 11, "end": 21}, {"id": "11022272_4_Ent7", "text": "salmon calcitonin", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "11022272_4_Ent4", "text": "salmon calcitonin with nasal spray or intramuscular administration ( Calsynar )", "entity_type": "Entity", "start": 25, "end": 36}, {"id": "11022272_4_Ent5", "text": "nasal spray", "entity_type": "Entity", "start": 28, "end": 30}, {"id": "11022272_4_Ent6", "text": "intramuscular", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "11033734_2", "wnd_id": "11033734_2_1", "text": "Incidence of seizures in pediatric cancer patients treated with imipenem / cilastatin .", "tokens": ["Incidence", "of", "seizures", "in", "pediatric", "cancer", "patients", "treated", "with", "imipenem", "/", "cilastatin", "."], "event_mentions": [{"id": "11033734_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 7, "end": 8}, "arguments": [{"entity_id": "11033734_2_Ent3", "role": "Effect", "text": "seizures", "start": 2, "end": 3}, {"entity_id": "11033734_2_Ent1", "role": "Subject_Age", "text": "pediatric", "start": 4, "end": 5}, {"entity_id": "11033734_2_Ent0", "role": "Subject", "text": "pediatric cancer patients", "start": 4, "end": 7}, {"entity_id": "11033734_2_Ent2", "role": "Subject_Disorder", "text": "cancer", "start": 5, "end": 6}, {"entity_id": "11033734_2_Ent5", "role": "Treatment_Drug", "text": "imipenem", "start": 9, "end": 10}, {"entity_id": "11033734_2_Ent7", "role": "Combination_Drug", "text": "imipenem", "start": 9, "end": 10}, {"entity_id": "11033734_2_Ent4", "role": "Treatment", "text": "imipenem / cilastatin", "start": 9, "end": 12}, {"entity_id": "11033734_2_Ent6", "role": "Treatment_Drug", "text": "cilastatin", "start": 11, "end": 12}, {"entity_id": "11033734_2_Ent8", "role": "Combination_Drug", "text": "cilastatin", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "11033734_2_Ent3", "text": "seizures", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11033734_2_Ent1", "text": "pediatric", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11033734_2_Ent0", "text": "pediatric cancer patients", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "11033734_2_Ent2", "text": "cancer", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11033734_2_Ent5", "text": "imipenem", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11033734_2_Ent7", "text": "imipenem", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11033734_2_Ent4", "text": "imipenem / cilastatin", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "11033734_2_Ent6", "text": "cilastatin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11033734_2_Ent8", "text": "cilastatin", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "11049910_11", "wnd_id": "11049910_11_1", "text": "Implications : Clinicians should be aware of the possibility of increased toxicity of ropivacaine when used together with inhibitors of CYP1A2 .", "tokens": ["Implications", ":", "Clinicians", "should", "be", "aware", "of", "the", "possibility", "of", "increased", "toxicity", "of", "ropivacaine", "when", "used", "together", "with", "inhibitors", "of", "CYP1A2", "."], "event_mentions": [{"id": "11049910_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increased", "start": 10, "end": 11}, "arguments": [{"entity_id": "11049910_11_Ent0", "role": "Effect", "text": "toxicity", "start": 11, "end": 12}, {"entity_id": "11049910_11_Ent1", "role": "Treatment", "text": "ropivacaine", "start": 13, "end": 14}, {"entity_id": "11049910_11_Ent3", "role": "Treatment_Drug", "text": "ropivacaine", "start": 13, "end": 14}, {"entity_id": "11049910_11_Ent6", "role": "Combination_Drug", "text": "ropivacaine", "start": 13, "end": 14}, {"entity_id": "11049910_11_Ent2", "role": "Treatment", "text": "inhibitors of CYP1A2", "start": 18, "end": 21}, {"entity_id": "11049910_11_Ent4", "role": "Treatment_Drug", "text": "inhibitors of CYP1A2", "start": 18, "end": 21}, {"entity_id": "11049910_11_Ent5", "role": "Combination_Drug", "text": "inhibitors of CYP1A2", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "11049910_11_Ent0", "text": "toxicity", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11049910_11_Ent1", "text": "ropivacaine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11049910_11_Ent3", "text": "ropivacaine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11049910_11_Ent6", "text": "ropivacaine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11049910_11_Ent2", "text": "inhibitors of CYP1A2", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "11049910_11_Ent4", "text": "inhibitors of CYP1A2", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "11049910_11_Ent5", "text": "inhibitors of CYP1A2", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "11059196_2", "wnd_id": "11059196_2_1", "text": "We describe a 10 - year - old boy with ulcerative colitis who developed acute pancreatitis while on long - term treatment with 5 - aminosalicylic acid .", "tokens": ["We", "describe", "a", "10", "-", "year", "-", "old", "boy", "with", "ulcerative", "colitis", "who", "developed", "acute", "pancreatitis", "while", "on", "long", "-", "term", "treatment", "with", "5", "-", "aminosalicylic", "acid", "."], "event_mentions": [{"id": "11059196_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "11059196_2_Ent0", "role": "Subject", "text": "a 10 - year - old boy with ulcerative colitis", "start": 2, "end": 12}, {"entity_id": "11059196_2_Ent1", "role": "Subject_Age", "text": "10 - year - old", "start": 3, "end": 8}, {"entity_id": "11059196_2_Ent2", "role": "Subject_Gender", "text": "boy", "start": 8, "end": 9}, {"entity_id": "11059196_2_Ent7", "role": "Treatment_Disorder", "text": "ulcerative colitis", "start": 10, "end": 12}, {"entity_id": "11059196_2_Ent3", "role": "Effect", "text": "acute pancreatitis", "start": 14, "end": 16}, {"entity_id": "11059196_2_Ent5", "role": "Treatment_Freq", "text": "long - term treatment", "start": 18, "end": 22}, {"entity_id": "11059196_2_Ent4", "role": "Treatment", "text": "long - term treatment with 5 - aminosalicylic acid", "start": 18, "end": 27}, {"entity_id": "11059196_2_Ent6", "role": "Treatment_Drug", "text": "5 - aminosalicylic acid", "start": 23, "end": 27}]}], "entity_mentions": [{"id": "11059196_2_Ent0", "text": "a 10 - year - old boy with ulcerative colitis", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "11059196_2_Ent1", "text": "10 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "11059196_2_Ent2", "text": "boy", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11059196_2_Ent7", "text": "ulcerative colitis", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "11059196_2_Ent3", "text": "acute pancreatitis", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "11059196_2_Ent5", "text": "long - term treatment", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "11059196_2_Ent4", "text": "long - term treatment with 5 - aminosalicylic acid", "entity_type": "Entity", "start": 18, "end": 27}, {"id": "11059196_2_Ent6", "text": "5 - aminosalicylic acid", "entity_type": "Entity", "start": 23, "end": 27}], "lang": "en"}
{"doc_id": "1109248_9", "wnd_id": "1109248_9_1", "text": "It is concluded that chloral hydrate and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy .", "tokens": ["It", "is", "concluded", "that", "chloral", "hydrate", "and", "methaqualone", "may", "be", "administered", "safely", "without", "additional", "caution", "in", "prothrombin", "test", "monitoring", "during", "oral", "anticoagulant", "therapy", "."], "event_mentions": [{"id": "1109248_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caution", "start": 14, "end": 15}, "arguments": [{"entity_id": "1109248_9_Ent2", "role": "Treatment_Drug", "text": "chloral hydrate", "start": 4, "end": 6}, {"entity_id": "1109248_9_Ent6", "role": "Combination_Drug", "text": "chloral hydrate", "start": 4, "end": 6}, {"entity_id": "1109248_9_Ent0", "role": "Treatment", "text": "chloral hydrate and methaqualone", "start": 4, "end": 8}, {"entity_id": "1109248_9_Ent3", "role": "Treatment_Drug", "text": "methaqualone", "start": 7, "end": 8}, {"entity_id": "1109248_9_Ent7", "role": "Combination_Drug", "text": "methaqualone", "start": 7, "end": 8}, {"entity_id": "1109248_9_Ent1", "role": "Treatment", "text": "during oral anticoagulant therapy", "start": 19, "end": 23}, {"entity_id": "1109248_9_Ent5", "role": "Treatment_Route", "text": "oral", "start": 20, "end": 21}, {"entity_id": "1109248_9_Ent4", "role": "Treatment_Drug", "text": "anticoagulant", "start": 21, "end": 22}, {"entity_id": "1109248_9_Ent8", "role": "Combination_Drug", "text": "anticoagulant", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "1109248_9_Ent2", "text": "chloral hydrate", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "1109248_9_Ent6", "text": "chloral hydrate", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "1109248_9_Ent0", "text": "chloral hydrate and methaqualone", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "1109248_9_Ent3", "text": "methaqualone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1109248_9_Ent7", "text": "methaqualone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1109248_9_Ent1", "text": "during oral anticoagulant therapy", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "1109248_9_Ent5", "text": "oral", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "1109248_9_Ent4", "text": "anticoagulant", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "1109248_9_Ent8", "text": "anticoagulant", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "11099623_1", "wnd_id": "11099623_1_1", "text": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen .", "tokens": ["We", "describe", "2", "children", "with", "cerebral", "palsy", "who", "suffered", "significant", "morbidity", "immediately", "after", "treatment", "with", "hyperbaric", "oxygen", "."], "event_mentions": [{"id": "11099623_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suffered", "start": 8, "end": 9}, "arguments": [{"entity_id": "11099623_1_Ent1", "role": "Subject_Population", "text": "2", "start": 2, "end": 3}, {"entity_id": "11099623_1_Ent0", "role": "Subject", "text": "2 children with cerebral palsy", "start": 2, "end": 7}, {"entity_id": "11099623_1_Ent2", "role": "Subject_Age", "text": "children", "start": 3, "end": 4}, {"entity_id": "11099623_1_Ent5", "role": "Treatment_Disorder", "text": "cerebral palsy", "start": 5, "end": 7}, {"entity_id": "11099623_1_Ent3", "role": "Effect", "text": "significant morbidity immediately", "start": 9, "end": 12}, {"entity_id": "11099623_1_Ent4", "role": "Treatment", "text": "treatment with hyperbaric oxygen", "start": 13, "end": 17}, {"entity_id": "11099623_1_Ent6", "role": "Treatment_Drug", "text": "hyperbaric oxygen", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "11099623_1_Ent1", "text": "2", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11099623_1_Ent0", "text": "2 children with cerebral palsy", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "11099623_1_Ent2", "text": "children", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11099623_1_Ent5", "text": "cerebral palsy", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11099623_1_Ent3", "text": "significant morbidity immediately", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "11099623_1_Ent4", "text": "treatment with hyperbaric oxygen", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "11099623_1_Ent6", "text": "hyperbaric oxygen", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "11105373_1", "wnd_id": "11105373_1_1", "text": "A 33 - year - old male presented with brown discolouration of the fingernails following the application of 4 % hydroquinone in sorbolene cream and 0.1 % tretinoin cream to the face intermittently for 9 months .", "tokens": ["A", "33", "-", "year", "-", "old", "male", "presented", "with", "brown", "discolouration", "of", "the", "fingernails", "following", "the", "application", "of", "4", "%", "hydroquinone", "in", "sorbolene", "cream", "and", "0.1", "%", "tretinoin", "cream", "to", "the", "face", "intermittently", "for", "9", "months", "."], "event_mentions": [{"id": "11105373_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "application", "start": 16, "end": 17}, "arguments": [{"entity_id": "11105373_1_Ent0", "role": "Subject", "text": "A 33 - year - old male", "start": 0, "end": 7}, {"entity_id": "11105373_1_Ent1", "role": "Subject_Age", "text": "33 - year - old", "start": 1, "end": 6}, {"entity_id": "11105373_1_Ent2", "role": "Subject_Gender", "text": "male", "start": 6, "end": 7}, {"entity_id": "11105373_1_Ent3", "role": "Effect", "text": "brown discolouration of the fingernails", "start": 9, "end": 14}, {"entity_id": "11105373_1_Ent7", "role": "Treatment_Dosage", "text": "4 %", "start": 18, "end": 20}, {"entity_id": "11105373_1_Ent4", "role": "Treatment", "text": "4 % hydroquinone in sorbolene cream and 0.1 % tretinoin cream to the face intermittently for 9 months", "start": 18, "end": 36}, {"entity_id": "11105373_1_Ent5", "role": "Treatment_Drug", "text": "hydroquinone", "start": 20, "end": 21}, {"entity_id": "11105373_1_Ent9", "role": "Treatment_Route", "text": "cream", "start": 23, "end": 24}, {"entity_id": "11105373_1_Ent8", "role": "Treatment_Dosage", "text": "0.1 %", "start": 25, "end": 27}, {"entity_id": "11105373_1_Ent6", "role": "Treatment_Drug", "text": "tretinoin", "start": 27, "end": 28}, {"entity_id": "11105373_1_Ent10", "role": "Treatment_Route", "text": "cream", "start": 28, "end": 29}, {"entity_id": "11105373_1_Ent11", "role": "Treatment_Route", "text": "face", "start": 31, "end": 32}, {"entity_id": "11105373_1_Ent12", "role": "Treatment_Freq", "text": "intermittently", "start": 32, "end": 33}, {"entity_id": "11105373_1_Ent13", "role": "Treatment_Duration", "text": "9 months", "start": 34, "end": 36}]}], "entity_mentions": [{"id": "11105373_1_Ent0", "text": "A 33 - year - old male", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "11105373_1_Ent1", "text": "33 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "11105373_1_Ent2", "text": "male", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11105373_1_Ent3", "text": "brown discolouration of the fingernails", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "11105373_1_Ent7", "text": "4 %", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "11105373_1_Ent4", "text": "4 % hydroquinone in sorbolene cream and 0.1 % tretinoin cream to the face intermittently for 9 months", "entity_type": "Entity", "start": 18, "end": 36}, {"id": "11105373_1_Ent5", "text": "hydroquinone", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "11105373_1_Ent9", "text": "cream", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "11105373_1_Ent8", "text": "0.1 %", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "11105373_1_Ent6", "text": "tretinoin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "11105373_1_Ent10", "text": "cream", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "11105373_1_Ent11", "text": "face", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "11105373_1_Ent12", "text": "intermittently", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "11105373_1_Ent13", "text": "9 months", "entity_type": "Entity", "start": 34, "end": 36}], "lang": "en"}
{"doc_id": "11126885_2", "wnd_id": "11126885_2_1", "text": "Quinine is universally used for the very common symptom of night leg cramps .", "tokens": ["Quinine", "is", "universally", "used", "for", "the", "very", "common", "symptom", "of", "night", "leg", "cramps", "."], "event_mentions": [{"id": "11126885_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "used", "start": 3, "end": 4}, "arguments": [{"entity_id": "11126885_2_Ent0", "role": "Treatment", "text": "Quinine", "start": 0, "end": 1}, {"entity_id": "11126885_2_Ent1", "role": "Treatment_Drug", "text": "Quinine", "start": 0, "end": 1}, {"entity_id": "11126885_2_Ent2", "role": "Treatment_Disorder", "text": "night leg cramps", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "11126885_2_Ent0", "text": "Quinine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11126885_2_Ent1", "text": "Quinine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11126885_2_Ent2", "text": "night leg cramps", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "11131346_4", "wnd_id": "11131346_4_1", "text": "CONCLUSION : To the best of our knowledge , this is the first time colchicine intoxication in this age group has been described in the English literature .", "tokens": ["CONCLUSION", ":", "To", "the", "best", "of", "our", "knowledge", ",", "this", "is", "the", "first", "time", "colchicine", "intoxication", "in", "this", "age", "group", "has", "been", "described", "in", "the", "English", "literature", "."], "event_mentions": [{"id": "11131346_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "intoxication", "start": 15, "end": 16}, "arguments": [{"entity_id": "11131346_4_Ent1", "role": "Treatment", "text": "colchicine", "start": 14, "end": 15}, {"entity_id": "11131346_4_Ent2", "role": "Treatment_Drug", "text": "colchicine", "start": 14, "end": 15}, {"entity_id": "11131346_4_Ent0", "role": "Effect", "text": "colchicine intoxication", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "11131346_4_Ent1", "text": "colchicine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11131346_4_Ent2", "text": "colchicine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11131346_4_Ent0", "text": "colchicine intoxication", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "11144696_10", "wnd_id": "11144696_10_1", "text": "Venlafaxine - associated seizures at therapeutic doses have not been reported in the literature .", "tokens": ["Venlafaxine", "-", "associated", "seizures", "at", "therapeutic", "doses", "have", "not", "been", "reported", "in", "the", "literature", "."], "event_mentions": [{"id": "11144696_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "11144696_10_Ent1", "role": "Treatment", "text": "Venlafaxine", "start": 0, "end": 1}, {"entity_id": "11144696_10_Ent2", "role": "Treatment_Drug", "text": "Venlafaxine", "start": 0, "end": 1}, {"entity_id": "11144696_10_Ent0", "role": "Effect", "text": "seizures", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "11144696_10_Ent1", "text": "Venlafaxine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11144696_10_Ent2", "text": "Venlafaxine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11144696_10_Ent0", "text": "seizures", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "11147747_1", "wnd_id": "11147747_1_1", "text": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta - blockers , both of which could have contributed to the incontinence .", "tokens": ["In", "2", "of", "the", "3", "cases", "the", "patients", "were", "also", "taking", "lithium", "carbonate", "and", "beta", "-", "blockers", ",", "both", "of", "which", "could", "have", "contributed", "to", "the", "incontinence", "."], "event_mentions": [{"id": "11147747_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "contributed", "start": 23, "end": 24}, "arguments": [{"entity_id": "11147747_1_Ent0", "role": "Subject", "text": "the patients", "start": 6, "end": 8}, {"entity_id": "11147747_1_Ent3", "role": "Treatment_Drug", "text": "lithium carbonate", "start": 11, "end": 13}, {"entity_id": "11147747_1_Ent6", "role": "Combination_Drug", "text": "lithium carbonate", "start": 11, "end": 13}, {"entity_id": "11147747_1_Ent2", "role": "Treatment", "text": "lithium carbonate and beta - blockers", "start": 11, "end": 17}, {"entity_id": "11147747_1_Ent4", "role": "Treatment_Drug", "text": "beta - blockers", "start": 14, "end": 17}, {"entity_id": "11147747_1_Ent5", "role": "Combination_Drug", "text": "beta - blockers", "start": 14, "end": 17}, {"entity_id": "11147747_1_Ent1", "role": "Effect", "text": "incontinence", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "11147747_1_Ent0", "text": "the patients", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "11147747_1_Ent3", "text": "lithium carbonate", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "11147747_1_Ent6", "text": "lithium carbonate", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "11147747_1_Ent2", "text": "lithium carbonate and beta - blockers", "entity_type": "Entity", "start": 11, "end": 17}, {"id": "11147747_1_Ent4", "text": "beta - blockers", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "11147747_1_Ent5", "text": "beta - blockers", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "11147747_1_Ent1", "text": "incontinence", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "11147747_3", "wnd_id": "11147747_3_1", "text": "This concerns 2 male patients who experienced incontinence while taking venlafaxine .", "tokens": ["This", "concerns", "2", "male", "patients", "who", "experienced", "incontinence", "while", "taking", "venlafaxine", "."], "event_mentions": [{"id": "11147747_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 6, "end": 7}, "arguments": [{"entity_id": "11147747_3_Ent1", "role": "Subject_Population", "text": "2", "start": 2, "end": 3}, {"entity_id": "11147747_3_Ent0", "role": "Subject", "text": "2 male patients", "start": 2, "end": 5}, {"entity_id": "11147747_3_Ent2", "role": "Subject_Gender", "text": "male", "start": 3, "end": 4}, {"entity_id": "11147747_3_Ent3", "role": "Effect", "text": "incontinence", "start": 7, "end": 8}, {"entity_id": "11147747_3_Ent4", "role": "Treatment", "text": "venlafaxine", "start": 10, "end": 11}, {"entity_id": "11147747_3_Ent5", "role": "Treatment_Drug", "text": "venlafaxine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "11147747_3_Ent1", "text": "2", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11147747_3_Ent0", "text": "2 male patients", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "11147747_3_Ent2", "text": "male", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11147747_3_Ent3", "text": "incontinence", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11147747_3_Ent4", "text": "venlafaxine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11147747_3_Ent5", "text": "venlafaxine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "11171531_2", "wnd_id": "11171531_2_1", "text": "It also highlights a current major etiologic question , that is , whether and to what degree lead exposure contributes to the development of hypertension , and raises the issue of whether lead - induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium .", "tokens": ["It", "also", "highlights", "a", "current", "major", "etiologic", "question", ",", "that", "is", ",", "whether", "and", "to", "what", "degree", "lead", "exposure", "contributes", "to", "the", "development", "of", "hypertension", ",", "and", "raises", "the", "issue", "of", "whether", "lead", "-", "induced", "hypertension", "constitutes", "a", "subset", "of", "hypertension", "that", "is", "especially", "amenable", "to", "therapy", "with", "dietary", "calcium", "."], "event_mentions": [{"id": "11171531_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "contributes", "start": 19, "end": 20}, "arguments": [{"entity_id": "11171531_2_Ent2", "role": "Treatment_Drug", "text": "lead", "start": 17, "end": 18}, {"entity_id": "11171531_2_Ent1", "role": "Treatment", "text": "lead exposure", "start": 17, "end": 19}, {"entity_id": "11171531_2_Ent3", "role": "Treatment_Route", "text": "exposure", "start": 18, "end": 19}, {"entity_id": "11171531_2_Ent0", "role": "Effect", "text": "hypertension", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "11171531_2_Ent2", "text": "lead", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "11171531_2_Ent1", "text": "lead exposure", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "11171531_2_Ent3", "text": "exposure", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "11171531_2_Ent0", "text": "hypertension", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "11206417_2", "wnd_id": "11206417_2_1", "text": "AIMS / HYPOTHESIS : There is evidence that insulin and glucose cause renal and ocular vasodilation .", "tokens": ["AIMS", "/", "HYPOTHESIS", ":", "There", "is", "evidence", "that", "insulin", "and", "glucose", "cause", "renal", "and", "ocular", "vasodilation", "."], "event_mentions": [{"id": "11206417_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 11, "end": 12}, "arguments": [{"entity_id": "11206417_2_Ent3", "role": "Treatment_Drug", "text": "insulin", "start": 8, "end": 9}, {"entity_id": "11206417_2_Ent4", "role": "Combination_Drug", "text": "insulin", "start": 8, "end": 9}, {"entity_id": "11206417_2_Ent1", "role": "Treatment", "text": "insulin and glucose", "start": 8, "end": 11}, {"entity_id": "11206417_2_Ent2", "role": "Treatment_Drug", "text": "glucose", "start": 10, "end": 11}, {"entity_id": "11206417_2_Ent5", "role": "Combination_Drug", "text": "glucose", "start": 10, "end": 11}, {"entity_id": "11206417_2_Ent0", "role": "Effect", "text": "renal and ocular vasodilation", "start": 12, "end": 16}]}], "entity_mentions": [{"id": "11206417_2_Ent3", "text": "insulin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11206417_2_Ent4", "text": "insulin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11206417_2_Ent1", "text": "insulin and glucose", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "11206417_2_Ent2", "text": "glucose", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11206417_2_Ent5", "text": "glucose", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11206417_2_Ent0", "text": "renal and ocular vasodilation", "entity_type": "Entity", "start": 12, "end": 16}], "lang": "en"}
{"doc_id": "11225532_1", "wnd_id": "11225532_1_1", "text": "Quinine induced coagulopathy -- a near fatal experience .", "tokens": ["Quinine", "induced", "coagulopathy", "--", "a", "near", "fatal", "experience", "."], "event_mentions": [{"id": "11225532_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "11225532_1_Ent1", "role": "Treatment", "text": "Quinine", "start": 0, "end": 1}, {"entity_id": "11225532_1_Ent2", "role": "Treatment_Drug", "text": "Quinine", "start": 0, "end": 1}, {"entity_id": "11225532_1_Ent0", "role": "Effect", "text": "coagulopathy -- a near fatal experience", "start": 2, "end": 8}]}], "entity_mentions": [{"id": "11225532_1_Ent1", "text": "Quinine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11225532_1_Ent2", "text": "Quinine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11225532_1_Ent0", "text": "coagulopathy -- a near fatal experience", "entity_type": "Entity", "start": 2, "end": 8}], "lang": "en"}
{"doc_id": "1124417_2", "wnd_id": "1124417_2_1", "text": "Renal failure associated with acetazolamide therapy for glaucoma .", "tokens": ["Renal", "failure", "associated", "with", "acetazolamide", "therapy", "for", "glaucoma", "."], "event_mentions": [{"id": "1124417_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "1124417_2_Ent0", "role": "Effect", "text": "Renal failure", "start": 0, "end": 2}, {"entity_id": "1124417_2_Ent2", "role": "Treatment_Drug", "text": "acetazolamide", "start": 4, "end": 5}, {"entity_id": "1124417_2_Ent1", "role": "Treatment", "text": "acetazolamide therapy", "start": 4, "end": 6}, {"entity_id": "1124417_2_Ent3", "role": "Treatment_Disorder", "text": "glaucoma", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "1124417_2_Ent0", "text": "Renal failure", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1124417_2_Ent2", "text": "acetazolamide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "1124417_2_Ent1", "text": "acetazolamide therapy", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "1124417_2_Ent3", "text": "glaucoma", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "1124417_3", "wnd_id": "1124417_3_1", "text": "This sulfonamide like nephropathy should be differentiated from acetazolamide - related calcium phosphate nephrolithiasis .", "tokens": ["This", "sulfonamide", "like", "nephropathy", "should", "be", "differentiated", "from", "acetazolamide", "-", "related", "calcium", "phosphate", "nephrolithiasis", "."], "event_mentions": [{"id": "1124417_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 10, "end": 11}, "arguments": [{"entity_id": "1124417_3_Ent1", "role": "Treatment", "text": "acetazolamide", "start": 8, "end": 9}, {"entity_id": "1124417_3_Ent2", "role": "Treatment_Drug", "text": "acetazolamide", "start": 8, "end": 9}, {"entity_id": "1124417_3_Ent0", "role": "Effect", "text": "calcium phosphate nephrolithiasis .", "start": 11, "end": 15}]}], "entity_mentions": [{"id": "1124417_3_Ent1", "text": "acetazolamide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1124417_3_Ent2", "text": "acetazolamide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1124417_3_Ent0", "text": "calcium phosphate nephrolithiasis .", "entity_type": "Entity", "start": 11, "end": 15}], "lang": "en"}
{"doc_id": "11247558_2", "wnd_id": "11247558_2_1", "text": "Symptoms and endoscopic lesions quickly regressed within 1 week of meloxicam withdrawal .", "tokens": ["Symptoms", "and", "endoscopic", "lesions", "quickly", "regressed", "within", "1", "week", "of", "meloxicam", "withdrawal", "."], "event_mentions": [{"id": "11247558_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "regressed", "start": 5, "end": 6}, "arguments": [{"entity_id": "11247558_2_Ent1", "role": "Treatment_Disorder", "text": "Symptoms and endoscopic lesions", "start": 0, "end": 4}, {"entity_id": "11247558_2_Ent0", "role": "Treatment", "text": "within 1 week of meloxicam withdrawal", "start": 6, "end": 12}, {"entity_id": "11247558_2_Ent2", "role": "Treatment_Time_elapsed", "text": "1 week", "start": 7, "end": 9}, {"entity_id": "11247558_2_Ent3", "role": "Treatment_Drug", "text": "meloxicam", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "11247558_2_Ent1", "text": "Symptoms and endoscopic lesions", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "11247558_2_Ent0", "text": "within 1 week of meloxicam withdrawal", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "11247558_2_Ent2", "text": "1 week", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "11247558_2_Ent3", "text": "meloxicam", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "11250985_4", "wnd_id": "11250985_4_1", "text": "Serious adverse events experienced by patients with chronic heart failure taking spironolactone .", "tokens": ["Serious", "adverse", "events", "experienced", "by", "patients", "with", "chronic", "heart", "failure", "taking", "spironolactone", "."], "event_mentions": [{"id": "11250985_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 3, "end": 4}, "arguments": [{"entity_id": "11250985_4_Ent2", "role": "Effect", "text": "Serious adverse events", "start": 0, "end": 3}, {"entity_id": "11250985_4_Ent0", "role": "Subject", "text": "patients with chronic heart failure", "start": 5, "end": 10}, {"entity_id": "11250985_4_Ent1", "role": "Subject_Disorder", "text": "chronic heart failure", "start": 7, "end": 10}, {"entity_id": "11250985_4_Ent3", "role": "Treatment", "text": "spironolactone", "start": 11, "end": 12}, {"entity_id": "11250985_4_Ent4", "role": "Treatment_Drug", "text": "spironolactone", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "11250985_4_Ent2", "text": "Serious adverse events", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11250985_4_Ent0", "text": "patients with chronic heart failure", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "11250985_4_Ent1", "text": "chronic heart failure", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "11250985_4_Ent3", "text": "spironolactone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11250985_4_Ent4", "text": "spironolactone", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "11283125_1", "wnd_id": "11283125_1_1", "text": "Value of high - dose cytarabine during interval therapy of a Berlin - Frankfurt - Munster - based protocol in increased - risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma : results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial .", "tokens": ["Value", "of", "high", "-", "dose", "cytarabine", "during", "interval", "therapy", "of", "a", "Berlin", "-", "Frankfurt", "-", "Munster", "-", "based", "protocol", "in", "increased", "-", "risk", "children", "with", "acute", "lymphoblastic", "leukemia", "and", "lymphoblastic", "lymphoma", ":", "results", "of", "the", "European", "Organization", "for", "Research", "and", "Treatment", "of", "Cancer", "58881", "randomized", "phase", "III", "trial", "."], "event_mentions": [{"id": "11283125_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Value", "start": 0, "end": 1}, "arguments": [{"entity_id": "11283125_1_Ent6", "role": "Treatment_Dosage", "text": "high - dose", "start": 2, "end": 5}, {"entity_id": "11283125_1_Ent2", "role": "Treatment", "text": "high - dose cytarabine during interval therapy of a Berlin - Frankfurt - Munster - based protocol", "start": 2, "end": 19}, {"entity_id": "11283125_1_Ent5", "role": "Treatment_Drug", "text": "cytarabine", "start": 5, "end": 6}, {"entity_id": "11283125_1_Ent0", "role": "Subject", "text": "increased - risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma", "start": 20, "end": 31}, {"entity_id": "11283125_1_Ent1", "role": "Subject_Age", "text": "children", "start": 23, "end": 24}, {"entity_id": "11283125_1_Ent3", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukemia", "start": 25, "end": 28}, {"entity_id": "11283125_1_Ent4", "role": "Treatment_Disorder", "text": "lymphoblastic lymphoma", "start": 29, "end": 31}]}], "entity_mentions": [{"id": "11283125_1_Ent6", "text": "high - dose", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "11283125_1_Ent2", "text": "high - dose cytarabine during interval therapy of a Berlin - Frankfurt - Munster - based protocol", "entity_type": "Entity", "start": 2, "end": 19}, {"id": "11283125_1_Ent5", "text": "cytarabine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11283125_1_Ent0", "text": "increased - risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma", "entity_type": "Entity", "start": 20, "end": 31}, {"id": "11283125_1_Ent1", "text": "children", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "11283125_1_Ent3", "text": "acute lymphoblastic leukemia", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "11283125_1_Ent4", "text": "lymphoblastic lymphoma", "entity_type": "Entity", "start": 29, "end": 31}], "lang": "en"}
{"doc_id": "11310527_2", "wnd_id": "11310527_2_1", "text": "A patient was treated with warfarin for atrial fibrillation .", "tokens": ["A", "patient", "was", "treated", "with", "warfarin", "for", "atrial", "fibrillation", "."], "event_mentions": [{"id": "11310527_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 3, "end": 4}, "arguments": [{"entity_id": "11310527_2_Ent0", "role": "Subject", "text": "A patient", "start": 0, "end": 2}, {"entity_id": "11310527_2_Ent1", "role": "Treatment", "text": "warfarin", "start": 5, "end": 6}, {"entity_id": "11310527_2_Ent3", "role": "Treatment_Drug", "text": "warfarin", "start": 5, "end": 6}, {"entity_id": "11310527_2_Ent2", "role": "Treatment_Disorder", "text": "atrial fibrillation", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "11310527_2_Ent0", "text": "A patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11310527_2_Ent1", "text": "warfarin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11310527_2_Ent3", "text": "warfarin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11310527_2_Ent2", "text": "atrial fibrillation", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "11319599_2", "wnd_id": "11319599_2_1", "text": "We describe two patients with aspergillus arthritis of the knee joint following fludarabine - based non - myeloablative stem cell transplantation .", "tokens": ["We", "describe", "two", "patients", "with", "aspergillus", "arthritis", "of", "the", "knee", "joint", "following", "fludarabine", "-", "based", "non", "-", "myeloablative", "stem", "cell", "transplantation", "."], "event_mentions": [{"id": "11319599_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 11, "end": 12}, "arguments": [{"entity_id": "11319599_2_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "11319599_2_Ent0", "role": "Subject", "text": "two patients", "start": 2, "end": 4}, {"entity_id": "11319599_2_Ent2", "role": "Effect", "text": "aspergillus arthritis of the knee joint", "start": 5, "end": 11}, {"entity_id": "11319599_2_Ent4", "role": "Treatment_Drug", "text": "fludarabine", "start": 12, "end": 13}, {"entity_id": "11319599_2_Ent3", "role": "Treatment", "text": "fludarabine - based non - myeloablative stem cell transplantation", "start": 12, "end": 21}]}], "entity_mentions": [{"id": "11319599_2_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11319599_2_Ent0", "text": "two patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "11319599_2_Ent2", "text": "aspergillus arthritis of the knee joint", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "11319599_2_Ent4", "text": "fludarabine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11319599_2_Ent3", "text": "fludarabine - based non - myeloablative stem cell transplantation", "entity_type": "Entity", "start": 12, "end": 21}], "lang": "en"}
{"doc_id": "11328247_5", "wnd_id": "11328247_5_1", "text": "The increased libido disappeared after fluvoxamine was discontinued .", "tokens": ["The", "increased", "libido", "disappeared", "after", "fluvoxamine", "was", "discontinued", "."], "event_mentions": [{"id": "11328247_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 4, "end": 5}, "arguments": [{"entity_id": "11328247_5_Ent0", "role": "Effect", "text": "increased libido", "start": 1, "end": 3}, {"entity_id": "11328247_5_Ent1", "role": "Treatment", "text": "fluvoxamine", "start": 5, "end": 6}, {"entity_id": "11328247_5_Ent2", "role": "Treatment_Drug", "text": "fluvoxamine", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "11328247_5_Ent0", "text": "increased libido", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "11328247_5_Ent1", "text": "fluvoxamine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11328247_5_Ent2", "text": "fluvoxamine", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "11335880_4", "wnd_id": "11335880_4_1", "text": "OBJECTIVES : The authors described a case of Hashimoto 's disease during interferon - alpha ( IFN - alpha ) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease .", "tokens": ["OBJECTIVES", ":", "The", "authors", "described", "a", "case", "of", "Hashimoto", "'s", "disease", "during", "interferon", "-", "alpha", "(", "IFN", "-", "alpha", ")", "treatment", "for", "chronic", "viral", "C", "hepatitis", "in", "a", "patient", "with", "the", "specific", "genetic", "susceptibility", "associated", "with", "the", "thyroid", "disease", "."], "event_mentions": [{"id": "11335880_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 11, "end": 12}, "arguments": [{"entity_id": "11335880_4_Ent2", "role": "Effect", "text": "Hashimoto 's disease", "start": 8, "end": 11}, {"entity_id": "11335880_4_Ent4", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 12, "end": 15}, {"entity_id": "11335880_4_Ent3", "role": "Treatment", "text": "interferon - alpha ( IFN - alpha ) treatment", "start": 12, "end": 21}, {"entity_id": "11335880_4_Ent5", "role": "Treatment_Disorder", "text": "chronic viral C hepatitis", "start": 22, "end": 26}, {"entity_id": "11335880_4_Ent0", "role": "Subject", "text": "a patient with the specific genetic susceptibility associated with the thyroid disease", "start": 27, "end": 39}, {"entity_id": "11335880_4_Ent1", "role": "Subject_Disorder", "text": "specific genetic susceptibility", "start": 31, "end": 34}]}], "entity_mentions": [{"id": "11335880_4_Ent2", "text": "Hashimoto 's disease", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "11335880_4_Ent4", "text": "interferon - alpha", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "11335880_4_Ent3", "text": "interferon - alpha ( IFN - alpha ) treatment", "entity_type": "Entity", "start": 12, "end": 21}, {"id": "11335880_4_Ent5", "text": "chronic viral C hepatitis", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "11335880_4_Ent0", "text": "a patient with the specific genetic susceptibility associated with the thyroid disease", "entity_type": "Entity", "start": 27, "end": 39}, {"id": "11335880_4_Ent1", "text": "specific genetic susceptibility", "entity_type": "Entity", "start": 31, "end": 34}], "lang": "en"}
{"doc_id": "11341670_2", "wnd_id": "11341670_2_1", "text": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole , lansoprazole , or pantoprazole for 7 - 15 days for peptic acid diseases in recommended standard doses .", "tokens": ["Pheripheral", "edema", "was", "observed", "in", "five", "female", "patients", "after", "taking", "proton", "pump", "inhibitors", "omeprazole", ",", "lansoprazole", ",", "or", "pantoprazole", "for", "7", "-", "15", "days", "for", "peptic", "acid", "diseases", "in", "recommended", "standard", "doses", "."], "event_mentions": [{"id": "11341670_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 9, "end": 10}, "arguments": [{"entity_id": "11341670_2_Ent3", "role": "Effect", "text": "Pheripheral edema", "start": 0, "end": 2}, {"entity_id": "11341670_2_Ent1", "role": "Subject_Population", "text": "five", "start": 5, "end": 6}, {"entity_id": "11341670_2_Ent0", "role": "Subject", "text": "five female patients", "start": 5, "end": 8}, {"entity_id": "11341670_2_Ent2", "role": "Subject_Gender", "text": "female", "start": 6, "end": 7}, {"entity_id": "11341670_2_Ent5", "role": "Treatment_Drug", "text": "omeprazole", "start": 13, "end": 14}, {"entity_id": "11341670_2_Ent4", "role": "Treatment", "text": "omeprazole , lansoprazole , or pantoprazole", "start": 13, "end": 19}, {"entity_id": "11341670_2_Ent6", "role": "Treatment_Drug", "text": "lansoprazole", "start": 15, "end": 16}, {"entity_id": "11341670_2_Ent7", "role": "Treatment_Drug", "text": "pantoprazole", "start": 18, "end": 19}, {"entity_id": "11341670_2_Ent8", "role": "Treatment_Freq", "text": "7 - 15 days", "start": 20, "end": 24}, {"entity_id": "11341670_2_Ent9", "role": "Treatment_Disorder", "text": "peptic acid diseases", "start": 25, "end": 28}, {"entity_id": "11341670_2_Ent10", "role": "Treatment_Dosage", "text": "standard doses .", "start": 30, "end": 33}]}], "entity_mentions": [{"id": "11341670_2_Ent3", "text": "Pheripheral edema", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11341670_2_Ent1", "text": "five", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11341670_2_Ent0", "text": "five female patients", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "11341670_2_Ent2", "text": "female", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11341670_2_Ent5", "text": "omeprazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11341670_2_Ent4", "text": "omeprazole , lansoprazole , or pantoprazole", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "11341670_2_Ent6", "text": "lansoprazole", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "11341670_2_Ent7", "text": "pantoprazole", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "11341670_2_Ent8", "text": "7 - 15 days", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "11341670_2_Ent9", "text": "peptic acid diseases", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "11341670_2_Ent10", "text": "standard doses .", "entity_type": "Entity", "start": 30, "end": 33}], "lang": "en"}
{"doc_id": "11373877_1", "wnd_id": "11373877_1_1", "text": "Avascular necrosis of the femoral head in patients with prostate cancer treated with cyproterone acetate and radiotherapy .", "tokens": ["Avascular", "necrosis", "of", "the", "femoral", "head", "in", "patients", "with", "prostate", "cancer", "treated", "with", "cyproterone", "acetate", "and", "radiotherapy", "."], "event_mentions": [{"id": "11373877_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 6, "end": 7}, "arguments": [{"entity_id": "11373877_1_Ent1", "role": "Effect", "text": "Avascular necrosis of the femoral head", "start": 0, "end": 6}, {"entity_id": "11373877_1_Ent0", "role": "Subject", "text": "patients with prostate cancer", "start": 7, "end": 11}, {"entity_id": "11373877_1_Ent3", "role": "Treatment_Disorder", "text": "prostate cancer", "start": 9, "end": 11}, {"entity_id": "11373877_1_Ent4", "role": "Treatment_Drug", "text": "cyproterone acetate", "start": 13, "end": 15}, {"entity_id": "11373877_1_Ent2", "role": "Treatment", "text": "cyproterone acetate and radiotherapy", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "11373877_1_Ent1", "text": "Avascular necrosis of the femoral head", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "11373877_1_Ent0", "text": "patients with prostate cancer", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "11373877_1_Ent3", "text": "prostate cancer", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "11373877_1_Ent4", "text": "cyproterone acetate", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "11373877_1_Ent2", "text": "cyproterone acetate and radiotherapy", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "11399735_1", "wnd_id": "11399735_1_1", "text": "So far , few cases of pulmonary side effects caused by ticlopidine have been reported .", "tokens": ["So", "far", ",", "few", "cases", "of", "pulmonary", "side", "effects", "caused", "by", "ticlopidine", "have", "been", "reported", "."], "event_mentions": [{"id": "11399735_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 9, "end": 10}, "arguments": [{"entity_id": "11399735_1_Ent0", "role": "Effect", "text": "pulmonary side effects", "start": 6, "end": 9}, {"entity_id": "11399735_1_Ent1", "role": "Treatment", "text": "ticlopidine", "start": 11, "end": 12}, {"entity_id": "11399735_1_Ent2", "role": "Treatment_Drug", "text": "ticlopidine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "11399735_1_Ent0", "text": "pulmonary side effects", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "11399735_1_Ent1", "text": "ticlopidine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11399735_1_Ent2", "text": "ticlopidine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "11399735_2", "wnd_id": "11399735_2_1", "text": "Special care should be taken when pulmonary symptoms appear in association with ticlopidine treatment .", "tokens": ["Special", "care", "should", "be", "taken", "when", "pulmonary", "symptoms", "appear", "in", "association", "with", "ticlopidine", "treatment", "."], "event_mentions": [{"id": "11399735_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "appear", "start": 8, "end": 9}, "arguments": [{"entity_id": "11399735_2_Ent0", "role": "Effect", "text": "pulmonary symptoms", "start": 6, "end": 8}, {"entity_id": "11399735_2_Ent2", "role": "Treatment_Drug", "text": "ticlopidine", "start": 12, "end": 13}, {"entity_id": "11399735_2_Ent1", "role": "Treatment", "text": "ticlopidine treatment", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "11399735_2_Ent0", "text": "pulmonary symptoms", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "11399735_2_Ent2", "text": "ticlopidine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11399735_2_Ent1", "text": "ticlopidine treatment", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "11399735_4", "wnd_id": "11399735_4_1", "text": "We report a case of interstitial pulmonary disease that occurred together with lymphocytic colitis during treatment with ticlopidine .", "tokens": ["We", "report", "a", "case", "of", "interstitial", "pulmonary", "disease", "that", "occurred", "together", "with", "lymphocytic", "colitis", "during", "treatment", "with", "ticlopidine", "."], "event_mentions": [{"id": "11399735_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 14, "end": 15}, "arguments": [{"entity_id": "11399735_4_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "11399735_4_Ent1", "role": "Effect", "text": "interstitial pulmonary disease", "start": 5, "end": 8}, {"entity_id": "11399735_4_Ent2", "role": "Effect", "text": "lymphocytic colitis", "start": 12, "end": 14}, {"entity_id": "11399735_4_Ent3", "role": "Treatment", "text": "ticlopidine", "start": 17, "end": 18}, {"entity_id": "11399735_4_Ent4", "role": "Treatment_Drug", "text": "ticlopidine", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "11399735_4_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "11399735_4_Ent1", "text": "interstitial pulmonary disease", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "11399735_4_Ent2", "text": "lymphocytic colitis", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "11399735_4_Ent3", "text": "ticlopidine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "11399735_4_Ent4", "text": "ticlopidine", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "11406880_1", "wnd_id": "11406880_1_1", "text": "Methadone - induced myoclonus in advanced cancer .", "tokens": ["Methadone", "-", "induced", "myoclonus", "in", "advanced", "cancer", "."], "event_mentions": [{"id": "11406880_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "11406880_1_Ent1", "role": "Treatment", "text": "Methadone", "start": 0, "end": 1}, {"entity_id": "11406880_1_Ent3", "role": "Treatment_Drug", "text": "Methadone", "start": 0, "end": 1}, {"entity_id": "11406880_1_Ent0", "role": "Effect", "text": "myoclonus", "start": 3, "end": 4}, {"entity_id": "11406880_1_Ent2", "role": "Treatment_Disorder", "text": "advanced cancer", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "11406880_1_Ent1", "text": "Methadone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11406880_1_Ent3", "text": "Methadone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11406880_1_Ent0", "text": "myoclonus", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11406880_1_Ent2", "text": "advanced cancer", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "11414270_2", "wnd_id": "11414270_2_1", "text": "OBJECTIVE : To report a case of fatal hyperkalemia owing to succinylcholine administration in a patient with mucositis secondary to chemotherapy .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "fatal", "hyperkalemia", "owing", "to", "succinylcholine", "administration", "in", "a", "patient", "with", "mucositis", "secondary", "to", "chemotherapy", "."], "event_mentions": [{"id": "11414270_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "owing", "start": 9, "end": 10}, "arguments": [{"entity_id": "11414270_2_Ent1", "role": "Effect", "text": "hyperkalemia", "start": 8, "end": 9}, {"entity_id": "11414270_2_Ent4", "role": "Treatment_Drug", "text": "succinylcholine", "start": 11, "end": 12}, {"entity_id": "11414270_2_Ent2", "role": "Treatment", "text": "succinylcholine administration", "start": 11, "end": 13}, {"entity_id": "11414270_2_Ent0", "role": "Subject", "text": "a patient with mucositis secondary to chemotherapy", "start": 14, "end": 21}, {"entity_id": "11414270_2_Ent3", "role": "Treatment_Disorder", "text": "mucositis", "start": 17, "end": 18}]}, {"id": "11414270_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 18, "end": 19}, "arguments": [{"entity_id": "11414270_2_Ent5", "role": "Subject", "text": "a patient", "start": 14, "end": 16}, {"entity_id": "11414270_2_Ent6", "role": "Effect", "text": "mucositis", "start": 17, "end": 18}, {"entity_id": "11414270_2_Ent7", "role": "Treatment", "text": "chemotherapy", "start": 20, "end": 21}, {"entity_id": "11414270_2_Ent8", "role": "Treatment_Drug", "text": "chemotherapy", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "11414270_2_Ent1", "text": "hyperkalemia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11414270_2_Ent4", "text": "succinylcholine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11414270_2_Ent2", "text": "succinylcholine administration", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "11414270_2_Ent5", "text": "a patient", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "11414270_2_Ent0", "text": "a patient with mucositis secondary to chemotherapy", "entity_type": "Entity", "start": 14, "end": 21}, {"id": "11414270_2_Ent3", "text": "mucositis", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "11414270_2_Ent6", "text": "mucositis", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "11414270_2_Ent7", "text": "chemotherapy", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "11414270_2_Ent8", "text": "chemotherapy", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "11424102_3", "wnd_id": "11424102_3_1", "text": "We describe a case of needle - track cutaneous seeding of hepatocellular carcinoma ( HCC ) after sonographically guided percutaneous ethanol injection ( PEI ) .", "tokens": ["We", "describe", "a", "case", "of", "needle", "-", "track", "cutaneous", "seeding", "of", "hepatocellular", "carcinoma", "(", "HCC", ")", "after", "sonographically", "guided", "percutaneous", "ethanol", "injection", "(", "PEI", ")", "."], "event_mentions": [{"id": "11424102_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 16, "end": 17}, "arguments": [{"entity_id": "11424102_3_Ent0", "role": "Effect", "text": "needle - track cutaneous seeding of hepatocellular carcinoma", "start": 5, "end": 13}, {"entity_id": "11424102_3_Ent1", "role": "Treatment", "text": "sonographically guided percutaneous ethanol injection", "start": 17, "end": 22}, {"entity_id": "11424102_3_Ent3", "role": "Treatment_Drug", "text": "ethanol", "start": 20, "end": 21}, {"entity_id": "11424102_3_Ent2", "role": "Treatment_Route", "text": "injection", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "11424102_3_Ent0", "text": "needle - track cutaneous seeding of hepatocellular carcinoma", "entity_type": "Entity", "start": 5, "end": 13}, {"id": "11424102_3_Ent1", "text": "sonographically guided percutaneous ethanol injection", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "11424102_3_Ent3", "text": "ethanol", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "11424102_3_Ent2", "text": "injection", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "11483161_3", "wnd_id": "11483161_3_1", "text": "We report the occurrence of spontaneous intracranial bleeding in an human immunodeficiency virus ( HIV) - infected adolescent with hemophilia A who was receiving amprenavir ( APV ) .", "tokens": ["We", "report", "the", "occurrence", "of", "spontaneous", "intracranial", "bleeding", "in", "an", "human", "immunodeficiency", "virus", "(", "HIV)", "-", "infected", "adolescent", "with", "hemophilia", "A", "who", "was", "receiving", "amprenavir", "(", "APV", ")", "."], "event_mentions": [{"id": "11483161_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurrence", "start": 3, "end": 4}, "arguments": [{"entity_id": "11483161_3_Ent1", "role": "Effect", "text": "spontaneous intracranial bleeding", "start": 5, "end": 8}, {"entity_id": "11483161_3_Ent0", "role": "Subject", "text": "an human immunodeficiency virus ( HIV) - infected adolescent with hemophilia A", "start": 9, "end": 21}, {"entity_id": "11483161_3_Ent3", "role": "Treatment_Disorder", "text": "immunodeficiency virus ( HIV) - infected adolescent with hemophilia A", "start": 11, "end": 21}, {"entity_id": "11483161_3_Ent2", "role": "Treatment", "text": "amprenavir ( APV )", "start": 24, "end": 28}, {"entity_id": "11483161_3_Ent4", "role": "Treatment_Drug", "text": "amprenavir ( APV )", "start": 24, "end": 28}]}], "entity_mentions": [{"id": "11483161_3_Ent1", "text": "spontaneous intracranial bleeding", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "11483161_3_Ent0", "text": "an human immunodeficiency virus ( HIV) - infected adolescent with hemophilia A", "entity_type": "Entity", "start": 9, "end": 21}, {"id": "11483161_3_Ent3", "text": "immunodeficiency virus ( HIV) - infected adolescent with hemophilia A", "entity_type": "Entity", "start": 11, "end": 21}, {"id": "11483161_3_Ent2", "text": "amprenavir ( APV )", "entity_type": "Entity", "start": 24, "end": 28}, {"id": "11483161_3_Ent4", "text": "amprenavir ( APV )", "entity_type": "Entity", "start": 24, "end": 28}], "lang": "en"}
{"doc_id": "11485141_1", "wnd_id": "11485141_1_1", "text": "According to the Naranjo probability scale , the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible .", "tokens": ["According", "to", "the", "Naranjo", "probability", "scale", ",", "the", "relationship", "of", "gemcitabine", "treatment", "with", "cutaneous", "eruption", "in", "our", "patient", "is", "possible", "."], "event_mentions": [{"id": "11485141_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 12, "end": 13}, "arguments": [{"entity_id": "11485141_1_Ent3", "role": "Treatment_Drug", "text": "gemcitabine", "start": 10, "end": 11}, {"entity_id": "11485141_1_Ent2", "role": "Treatment", "text": "gemcitabine treatment", "start": 10, "end": 12}, {"entity_id": "11485141_1_Ent1", "role": "Effect", "text": "cutaneous eruption", "start": 13, "end": 15}, {"entity_id": "11485141_1_Ent0", "role": "Subject", "text": "our patient", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "11485141_1_Ent3", "text": "gemcitabine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11485141_1_Ent2", "text": "gemcitabine treatment", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "11485141_1_Ent1", "text": "cutaneous eruption", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "11485141_1_Ent0", "text": "our patient", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "11487721_2", "wnd_id": "11487721_2_1", "text": "A rare case of advanced ovarian carcinoma who developed difficulty walking 25 days after treatment with weekly paclitaxel .", "tokens": ["A", "rare", "case", "of", "advanced", "ovarian", "carcinoma", "who", "developed", "difficulty", "walking", "25", "days", "after", "treatment", "with", "weekly", "paclitaxel", "."], "event_mentions": [{"id": "11487721_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "11487721_2_Ent0", "role": "Subject", "text": "A rare case of advanced ovarian carcinoma", "start": 0, "end": 7}, {"entity_id": "11487721_2_Ent3", "role": "Treatment_Disorder", "text": "advanced ovarian carcinoma", "start": 4, "end": 7}, {"entity_id": "11487721_2_Ent1", "role": "Effect", "text": "difficulty walking", "start": 9, "end": 11}, {"entity_id": "11487721_2_Ent4", "role": "Treatment_Time_elapsed", "text": "25 days", "start": 11, "end": 13}, {"entity_id": "11487721_2_Ent2", "role": "Treatment", "text": "25 days after treatment with weekly paclitaxel", "start": 11, "end": 18}, {"entity_id": "11487721_2_Ent5", "role": "Treatment_Freq", "text": "weekly", "start": 16, "end": 17}, {"entity_id": "11487721_2_Ent6", "role": "Treatment_Drug", "text": "paclitaxel", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "11487721_2_Ent0", "text": "A rare case of advanced ovarian carcinoma", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "11487721_2_Ent3", "text": "advanced ovarian carcinoma", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "11487721_2_Ent1", "text": "difficulty walking", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "11487721_2_Ent4", "text": "25 days", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "11487721_2_Ent2", "text": "25 days after treatment with weekly paclitaxel", "entity_type": "Entity", "start": 11, "end": 18}, {"id": "11487721_2_Ent5", "text": "weekly", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11487721_2_Ent6", "text": "paclitaxel", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "115078_1", "wnd_id": "115078_1_1", "text": "A patient with rheumatoid arthritis developed an acute intrahepatic cholestasis after 100 mg of sodium aurothiomalate .", "tokens": ["A", "patient", "with", "rheumatoid", "arthritis", "developed", "an", "acute", "intrahepatic", "cholestasis", "after", "100", "mg", "of", "sodium", "aurothiomalate", "."], "event_mentions": [{"id": "115078_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "115078_1_Ent0", "role": "Subject", "text": "A patient with rheumatoid arthritis", "start": 0, "end": 5}, {"entity_id": "115078_1_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 3, "end": 5}, {"entity_id": "115078_1_Ent1", "role": "Effect", "text": "acute intrahepatic cholestasis", "start": 7, "end": 10}, {"entity_id": "115078_1_Ent4", "role": "Treatment_Dosage", "text": "100 mg", "start": 11, "end": 13}, {"entity_id": "115078_1_Ent2", "role": "Treatment", "text": "100 mg of sodium aurothiomalate", "start": 11, "end": 16}, {"entity_id": "115078_1_Ent5", "role": "Treatment_Drug", "text": "sodium aurothiomalate", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "115078_1_Ent0", "text": "A patient with rheumatoid arthritis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "115078_1_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "115078_1_Ent1", "text": "acute intrahepatic cholestasis", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "115078_1_Ent4", "text": "100 mg", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "115078_1_Ent2", "text": "100 mg of sodium aurothiomalate", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "115078_1_Ent5", "text": "sodium aurothiomalate", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "11510798_1", "wnd_id": "11510798_1_1", "text": "Acute lung injury associated with 5 - fluorouracil and oxaliplatinum combined chemotherapy .", "tokens": ["Acute", "lung", "injury", "associated", "with", "5", "-", "fluorouracil", "and", "oxaliplatinum", "combined", "chemotherapy", "."], "event_mentions": [{"id": "11510798_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "11510798_1_Ent0", "role": "Effect", "text": "Acute lung injury", "start": 0, "end": 3}, {"entity_id": "11510798_1_Ent3", "role": "Treatment_Drug", "text": "5 - fluorouracil", "start": 5, "end": 8}, {"entity_id": "11510798_1_Ent5", "role": "Combination_Drug", "text": "5 - fluorouracil", "start": 5, "end": 8}, {"entity_id": "11510798_1_Ent1", "role": "Treatment", "text": "5 - fluorouracil and oxaliplatinum combined chemotherapy", "start": 5, "end": 12}, {"entity_id": "11510798_1_Ent2", "role": "Treatment_Drug", "text": "oxaliplatinum", "start": 9, "end": 10}, {"entity_id": "11510798_1_Ent6", "role": "Combination_Drug", "text": "oxaliplatinum", "start": 9, "end": 10}, {"entity_id": "11510798_1_Ent4", "role": "Treatment_Route", "text": "chemotherapy", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "11510798_1_Ent0", "text": "Acute lung injury", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11510798_1_Ent3", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "11510798_1_Ent5", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "11510798_1_Ent1", "text": "5 - fluorouracil and oxaliplatinum combined chemotherapy", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "11510798_1_Ent2", "text": "oxaliplatinum", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11510798_1_Ent6", "text": "oxaliplatinum", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11510798_1_Ent4", "text": "chemotherapy", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "11554897_3", "wnd_id": "11554897_3_1", "text": "METHODS : A 55 - year - old woman became stuporous after overdose with lamotrigine ( LTG ) and valproic acid ( VPA ) tablets .", "tokens": ["METHODS", ":", "A", "55", "-", "year", "-", "old", "woman", "became", "stuporous", "after", "overdose", "with", "lamotrigine", "(", "LTG", ")", "and", "valproic", "acid", "(", "VPA", ")", "tablets", "."], "event_mentions": [{"id": "11554897_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "became", "start": 9, "end": 10}, "arguments": [{"entity_id": "11554897_3_Ent0", "role": "Subject", "text": "A 55 - year - old woman", "start": 2, "end": 9}, {"entity_id": "11554897_3_Ent1", "role": "Subject_Age", "text": "55 - year - old", "start": 3, "end": 8}, {"entity_id": "11554897_3_Ent2", "role": "Subject_Gender", "text": "woman", "start": 8, "end": 9}, {"entity_id": "11554897_3_Ent3", "role": "Effect", "text": "stuporous", "start": 10, "end": 11}, {"entity_id": "11554897_3_Ent5", "role": "Treatment_Dosage", "text": "overdose", "start": 12, "end": 13}, {"entity_id": "11554897_3_Ent4", "role": "Treatment", "text": "overdose with lamotrigine ( LTG ) and valproic acid ( VPA ) tablets", "start": 12, "end": 25}, {"entity_id": "11554897_3_Ent6", "role": "Treatment_Drug", "text": "lamotrigine", "start": 14, "end": 15}, {"entity_id": "11554897_3_Ent9", "role": "Combination_Drug", "text": "lamotrigine", "start": 14, "end": 15}, {"entity_id": "11554897_3_Ent7", "role": "Treatment_Drug", "text": "valproic acid", "start": 19, "end": 21}, {"entity_id": "11554897_3_Ent10", "role": "Combination_Drug", "text": "valproic acid", "start": 19, "end": 21}, {"entity_id": "11554897_3_Ent8", "role": "Treatment_Route", "text": "tablets", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "11554897_3_Ent0", "text": "A 55 - year - old woman", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "11554897_3_Ent1", "text": "55 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "11554897_3_Ent2", "text": "woman", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11554897_3_Ent3", "text": "stuporous", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11554897_3_Ent5", "text": "overdose", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11554897_3_Ent4", "text": "overdose with lamotrigine ( LTG ) and valproic acid ( VPA ) tablets", "entity_type": "Entity", "start": 12, "end": 25}, {"id": "11554897_3_Ent6", "text": "lamotrigine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11554897_3_Ent9", "text": "lamotrigine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11554897_3_Ent7", "text": "valproic acid", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "11554897_3_Ent10", "text": "valproic acid", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "11554897_3_Ent8", "text": "tablets", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "11563738_1", "wnd_id": "11563738_1_1", "text": "The cause of death was determined to be acute intoxication by olanzapine , and the manner of death was accidental .", "tokens": ["The", "cause", "of", "death", "was", "determined", "to", "be", "acute", "intoxication", "by", "olanzapine", ",", "and", "the", "manner", "of", "death", "was", "accidental", "."], "event_mentions": [{"id": "11563738_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "by", "start": 10, "end": 11}, "arguments": [{"entity_id": "11563738_1_Ent0", "role": "Effect", "text": "death", "start": 3, "end": 4}, {"entity_id": "11563738_1_Ent1", "role": "Effect", "text": "acute intoxication", "start": 8, "end": 10}, {"entity_id": "11563738_1_Ent2", "role": "Treatment", "text": "olanzapine", "start": 11, "end": 12}, {"entity_id": "11563738_1_Ent3", "role": "Treatment_Drug", "text": "olanzapine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "11563738_1_Ent0", "text": "death", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11563738_1_Ent1", "text": "acute intoxication", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "11563738_1_Ent2", "text": "olanzapine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11563738_1_Ent3", "text": "olanzapine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "11568758_2", "wnd_id": "11568758_2_1", "text": "This eruption emerged after 1 month of therapy with salsalate , persisted for as long as salsalate was administered , and cleared within 3 weeks of discontinuing the medication .", "tokens": ["This", "eruption", "emerged", "after", "1", "month", "of", "therapy", "with", "salsalate", ",", "persisted", "for", "as", "long", "as", "salsalate", "was", "administered", ",", "and", "cleared", "within", "3", "weeks", "of", "discontinuing", "the", "medication", "."], "event_mentions": [{"id": "11568758_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "emerged", "start": 2, "end": 3}, "arguments": [{"entity_id": "11568758_2_Ent0", "role": "Effect", "text": "eruption", "start": 1, "end": 2}, {"entity_id": "11568758_2_Ent1", "role": "Treatment", "text": "after 1 month of therapy with salsalate", "start": 3, "end": 10}, {"entity_id": "11568758_2_Ent2", "role": "Treatment_Time_elapsed", "text": "1 month", "start": 4, "end": 6}, {"entity_id": "11568758_2_Ent3", "role": "Treatment_Drug", "text": "salsalate", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "11568758_2_Ent0", "text": "eruption", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11568758_2_Ent1", "text": "after 1 month of therapy with salsalate", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "11568758_2_Ent2", "text": "1 month", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "11568758_2_Ent3", "text": "salsalate", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "11573852_1", "wnd_id": "11573852_1_1", "text": "Amphotericin B - induced seizures in a patient with AIDS .", "tokens": ["Amphotericin", "B", "-", "induced", "seizures", "in", "a", "patient", "with", "AIDS", "."], "event_mentions": [{"id": "11573852_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "11573852_1_Ent3", "role": "Treatment", "text": "Amphotericin B", "start": 0, "end": 2}, {"entity_id": "11573852_1_Ent4", "role": "Treatment_Drug", "text": "Amphotericin B", "start": 0, "end": 2}, {"entity_id": "11573852_1_Ent2", "role": "Effect", "text": "seizures", "start": 4, "end": 5}, {"entity_id": "11573852_1_Ent0", "role": "Subject", "text": "a patient with AIDS", "start": 6, "end": 10}, {"entity_id": "11573852_1_Ent1", "role": "Subject_Disorder", "text": "AIDS", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "11573852_1_Ent3", "text": "Amphotericin B", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11573852_1_Ent4", "text": "Amphotericin B", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11573852_1_Ent2", "text": "seizures", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11573852_1_Ent0", "text": "a patient with AIDS", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "11573852_1_Ent1", "text": "AIDS", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "11573852_4", "wnd_id": "11573852_4_1", "text": "Despite administration of phenytoin and lorazepam , the seizures persisted and occurred only during amphotercin B administration .", "tokens": ["Despite", "administration", "of", "phenytoin", "and", "lorazepam", ",", "the", "seizures", "persisted", "and", "occurred", "only", "during", "amphotercin", "B", "administration", "."], "event_mentions": [{"id": "11573852_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 13, "end": 14}, "arguments": [{"entity_id": "11573852_4_Ent0", "role": "Effect", "text": "seizures", "start": 8, "end": 9}, {"entity_id": "11573852_4_Ent1", "role": "Treatment", "text": "amphotercin B", "start": 14, "end": 16}, {"entity_id": "11573852_4_Ent2", "role": "Treatment_Drug", "text": "amphotercin B", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "11573852_4_Ent0", "text": "seizures", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11573852_4_Ent1", "text": "amphotercin B", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "11573852_4_Ent2", "text": "amphotercin B", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "11576059_1", "wnd_id": "11576059_1_1", "text": "Vocal cord paralysis as a consequence of peritonsillar infiltration with bupivacaine .", "tokens": ["Vocal", "cord", "paralysis", "as", "a", "consequence", "of", "peritonsillar", "infiltration", "with", "bupivacaine", "."], "event_mentions": [{"id": "11576059_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "consequence", "start": 5, "end": 6}, "arguments": [{"entity_id": "11576059_1_Ent0", "role": "Effect", "text": "Vocal cord paralysis", "start": 0, "end": 3}, {"entity_id": "11576059_1_Ent2", "role": "Treatment_Route", "text": "peritonsillar infiltration", "start": 7, "end": 9}, {"entity_id": "11576059_1_Ent1", "role": "Treatment", "text": "peritonsillar infiltration with bupivacaine", "start": 7, "end": 11}, {"entity_id": "11576059_1_Ent3", "role": "Treatment_Drug", "text": "bupivacaine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "11576059_1_Ent0", "text": "Vocal cord paralysis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11576059_1_Ent2", "text": "peritonsillar infiltration", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "11576059_1_Ent1", "text": "peritonsillar infiltration with bupivacaine", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "11576059_1_Ent3", "text": "bupivacaine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "11672959_1", "wnd_id": "11672959_1_1", "text": "A 34 - year - old lady developed a constellation of dermatitis , fever , lymphadenopathy and hepatitis , beginning on the 17th day of a course of oral sulphasalazine for sero - negative rheumatoid arthritis .", "tokens": ["A", "34", "-", "year", "-", "old", "lady", "developed", "a", "constellation", "of", "dermatitis", ",", "fever", ",", "lymphadenopathy", "and", "hepatitis", ",", "beginning", "on", "the", "17th", "day", "of", "a", "course", "of", "oral", "sulphasalazine", "for", "sero", "-", "negative", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "11672959_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "11672959_1_Ent0", "role": "Subject", "text": "A 34 - year - old lady", "start": 0, "end": 7}, {"entity_id": "11672959_1_Ent1", "role": "Subject_Age", "text": "34 - year - old", "start": 1, "end": 6}, {"entity_id": "11672959_1_Ent2", "role": "Subject_Gender", "text": "lady", "start": 6, "end": 7}, {"entity_id": "11672959_1_Ent3", "role": "Effect", "text": "a constellation of dermatitis , fever , lymphadenopathy and hepatitis", "start": 8, "end": 18}, {"entity_id": "11672959_1_Ent8", "role": "Treatment_Duration", "text": "17th day", "start": 22, "end": 24}, {"entity_id": "11672959_1_Ent4", "role": "Treatment", "text": "a course of oral sulphasalazine", "start": 25, "end": 30}, {"entity_id": "11672959_1_Ent5", "role": "Treatment_Route", "text": "oral", "start": 28, "end": 29}, {"entity_id": "11672959_1_Ent6", "role": "Treatment_Drug", "text": "sulphasalazine", "start": 29, "end": 30}, {"entity_id": "11672959_1_Ent7", "role": "Treatment_Disorder", "text": "sero - negative rheumatoid arthritis", "start": 31, "end": 36}]}], "entity_mentions": [{"id": "11672959_1_Ent0", "text": "A 34 - year - old lady", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "11672959_1_Ent1", "text": "34 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "11672959_1_Ent2", "text": "lady", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11672959_1_Ent3", "text": "a constellation of dermatitis , fever , lymphadenopathy and hepatitis", "entity_type": "Entity", "start": 8, "end": 18}, {"id": "11672959_1_Ent8", "text": "17th day", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "11672959_1_Ent4", "text": "a course of oral sulphasalazine", "entity_type": "Entity", "start": 25, "end": 30}, {"id": "11672959_1_Ent5", "text": "oral", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "11672959_1_Ent6", "text": "sulphasalazine", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "11672959_1_Ent7", "text": "sero - negative rheumatoid arthritis", "entity_type": "Entity", "start": 31, "end": 36}], "lang": "en"}
{"doc_id": "11696132_2", "wnd_id": "11696132_2_1", "text": "Anisocoria from transdermal scopolamine .", "tokens": ["Anisocoria", "from", "transdermal", "scopolamine", "."], "event_mentions": [{"id": "11696132_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 1, "end": 2}, "arguments": [{"entity_id": "11696132_2_Ent0", "role": "Effect", "text": "Anisocoria", "start": 0, "end": 1}, {"entity_id": "11696132_2_Ent1", "role": "Treatment", "text": "transdermal scopolamine", "start": 2, "end": 4}, {"entity_id": "11696132_2_Ent2", "role": "Treatment_Drug", "text": "transdermal scopolamine", "start": 2, "end": 4}]}], "entity_mentions": [{"id": "11696132_2_Ent0", "text": "Anisocoria", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11696132_2_Ent1", "text": "transdermal scopolamine", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "11696132_2_Ent2", "text": "transdermal scopolamine", "entity_type": "Entity", "start": 2, "end": 4}], "lang": "en"}
{"doc_id": "11720625_3", "wnd_id": "11720625_3_1", "text": "Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval have been known to cause TdP. However , clarithromycin is thought to be less frequently associated with drug induced TdP , because it inactivates hepatic cytochrome P - 450 to a lesser extent than erythromycin .", "tokens": ["Drug", "interactions", "between", "macrolide", "antibiotics", "such", "as", "erythomycin", "and", "pharmacologic", "agents", "that", "prolong", "the", "QT", "interval", "have", "been", "known", "to", "cause", "TdP.", "However", ",", "clarithromycin", "is", "thought", "to", "be", "less", "frequently", "associated", "with", "drug", "induced", "TdP", ",", "because", "it", "inactivates", "hepatic", "cytochrome", "P", "-", "450", "to", "a", "lesser", "extent", "than", "erythromycin", "."], "event_mentions": [{"id": "11720625_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 20, "end": 21}, "arguments": [{"entity_id": "11720625_3_Ent1", "role": "Treatment", "text": "Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval", "start": 0, "end": 16}, {"entity_id": "11720625_3_Ent4", "role": "Treatment_Drug", "text": "macrolide antibiotics", "start": 3, "end": 5}, {"entity_id": "11720625_3_Ent2", "role": "Treatment_Drug", "text": "erythomycin", "start": 7, "end": 8}, {"entity_id": "11720625_3_Ent5", "role": "Combination_Drug", "text": "erythomycin", "start": 7, "end": 8}, {"entity_id": "11720625_3_Ent3", "role": "Treatment_Drug", "text": "pharmacologic agents", "start": 9, "end": 11}, {"entity_id": "11720625_3_Ent6", "role": "Combination_Drug", "text": "pharmacologic agents", "start": 9, "end": 11}, {"entity_id": "11720625_3_Ent0", "role": "Effect", "text": "TdP.", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "11720625_3_Ent1", "text": "Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval", "entity_type": "Entity", "start": 0, "end": 16}, {"id": "11720625_3_Ent4", "text": "macrolide antibiotics", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11720625_3_Ent2", "text": "erythomycin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11720625_3_Ent5", "text": "erythomycin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11720625_3_Ent3", "text": "pharmacologic agents", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "11720625_3_Ent6", "text": "pharmacologic agents", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "11720625_3_Ent0", "text": "TdP.", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "11724089_1", "wnd_id": "11724089_1_1", "text": "CONCLUSIONS : There is very little published information regarding ofloxacin - induced toxic epidermal necrolysis .", "tokens": ["CONCLUSIONS", ":", "There", "is", "very", "little", "published", "information", "regarding", "ofloxacin", "-", "induced", "toxic", "epidermal", "necrolysis", "."], "event_mentions": [{"id": "11724089_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 11, "end": 12}, "arguments": [{"entity_id": "11724089_1_Ent1", "role": "Treatment", "text": "ofloxacin", "start": 9, "end": 10}, {"entity_id": "11724089_1_Ent2", "role": "Treatment_Drug", "text": "ofloxacin", "start": 9, "end": 10}, {"entity_id": "11724089_1_Ent0", "role": "Effect", "text": "toxic epidermal necrolysis", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "11724089_1_Ent1", "text": "ofloxacin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11724089_1_Ent2", "text": "ofloxacin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11724089_1_Ent0", "text": "toxic epidermal necrolysis", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "11737689_3", "wnd_id": "11737689_3_1", "text": "Neutrophilic dermatoses in two children with idiopathic neutropenia : association with granulocyte colony - stimulating factor ( G - CSF ) therapy .", "tokens": ["Neutrophilic", "dermatoses", "in", "two", "children", "with", "idiopathic", "neutropenia", ":", "association", "with", "granulocyte", "colony", "-", "stimulating", "factor", "(", "G", "-", "CSF", ")", "therapy", "."], "event_mentions": [{"id": "11737689_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 9, "end": 10}, "arguments": [{"entity_id": "11737689_3_Ent3", "role": "Effect", "text": "Neutrophilic dermatoses", "start": 0, "end": 2}, {"entity_id": "11737689_3_Ent1", "role": "Subject_Population", "text": "two", "start": 3, "end": 4}, {"entity_id": "11737689_3_Ent0", "role": "Subject", "text": "two children with idiopathic neutropenia", "start": 3, "end": 8}, {"entity_id": "11737689_3_Ent2", "role": "Subject_Age", "text": "children", "start": 4, "end": 5}, {"entity_id": "11737689_3_Ent5", "role": "Treatment_Disorder", "text": "idiopathic neutropenia", "start": 6, "end": 8}, {"entity_id": "11737689_3_Ent6", "role": "Treatment_Drug", "text": "granulocyte colony - stimulating factor", "start": 11, "end": 16}, {"entity_id": "11737689_3_Ent4", "role": "Treatment", "text": "granulocyte colony - stimulating factor ( G - CSF ) therapy", "start": 11, "end": 22}]}], "entity_mentions": [{"id": "11737689_3_Ent3", "text": "Neutrophilic dermatoses", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11737689_3_Ent1", "text": "two", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11737689_3_Ent0", "text": "two children with idiopathic neutropenia", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "11737689_3_Ent2", "text": "children", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11737689_3_Ent5", "text": "idiopathic neutropenia", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "11737689_3_Ent6", "text": "granulocyte colony - stimulating factor", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "11737689_3_Ent4", "text": "granulocyte colony - stimulating factor ( G - CSF ) therapy", "entity_type": "Entity", "start": 11, "end": 22}], "lang": "en"}
{"doc_id": "11757641_1", "wnd_id": "11757641_1_1", "text": "Pulmonary toxicity with mefloquine .", "tokens": ["Pulmonary", "toxicity", "with", "mefloquine", "."], "event_mentions": [{"id": "11757641_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 2, "end": 3}, "arguments": [{"entity_id": "11757641_1_Ent0", "role": "Effect", "text": "Pulmonary toxicity", "start": 0, "end": 2}, {"entity_id": "11757641_1_Ent1", "role": "Treatment", "text": "mefloquine", "start": 3, "end": 4}, {"entity_id": "11757641_1_Ent2", "role": "Treatment_Drug", "text": "mefloquine", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "11757641_1_Ent0", "text": "Pulmonary toxicity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11757641_1_Ent1", "text": "mefloquine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11757641_1_Ent2", "text": "mefloquine", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "11788010_2", "wnd_id": "11788010_2_1", "text": "Gallstones and bile sludge are common side effects of octreotide therapy but rarely become symptomatic or require treatment .", "tokens": ["Gallstones", "and", "bile", "sludge", "are", "common", "side", "effects", "of", "octreotide", "therapy", "but", "rarely", "become", "symptomatic", "or", "require", "treatment", "."], "event_mentions": [{"id": "11788010_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effects of", "start": 6, "end": 9}, "arguments": [{"entity_id": "11788010_2_Ent0", "role": "Effect", "text": "Gallstones and bile sludge", "start": 0, "end": 4}, {"entity_id": "11788010_2_Ent2", "role": "Treatment_Drug", "text": "octreotide", "start": 9, "end": 10}, {"entity_id": "11788010_2_Ent1", "role": "Treatment", "text": "octreotide therapy", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "11788010_2_Ent0", "text": "Gallstones and bile sludge", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "11788010_2_Ent2", "text": "octreotide", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11788010_2_Ent1", "text": "octreotide therapy", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "11795358_1", "wnd_id": "11795358_1_1", "text": "However , in the mid - to - late 1980s , a series of letters to the editor and case reports announced an association between tamoxifen therapy in women with breast cancer and the development of endometrial carcinoma .", "tokens": ["However", ",", "in", "the", "mid", "-", "to", "-", "late", "1980s", ",", "a", "series", "of", "letters", "to", "the", "editor", "and", "case", "reports", "announced", "an", "association", "between", "tamoxifen", "therapy", "in", "women", "with", "breast", "cancer", "and", "the", "development", "of", "endometrial", "carcinoma", "."], "event_mentions": [{"id": "11795358_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 34, "end": 35}, "arguments": [{"entity_id": "11795358_1_Ent3", "role": "Treatment", "text": "tamoxifen", "start": 25, "end": 26}, {"entity_id": "11795358_1_Ent4", "role": "Treatment_Drug", "text": "tamoxifen", "start": 25, "end": 26}, {"entity_id": "11795358_1_Ent1", "role": "Subject_Gender", "text": "women", "start": 28, "end": 29}, {"entity_id": "11795358_1_Ent0", "role": "Subject", "text": "women with breast cancer", "start": 28, "end": 32}, {"entity_id": "11795358_1_Ent5", "role": "Treatment_Disorder", "text": "breast cancer", "start": 30, "end": 32}, {"entity_id": "11795358_1_Ent2", "role": "Effect", "text": "endometrial carcinoma", "start": 36, "end": 38}]}], "entity_mentions": [{"id": "11795358_1_Ent3", "text": "tamoxifen", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "11795358_1_Ent4", "text": "tamoxifen", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "11795358_1_Ent1", "text": "women", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "11795358_1_Ent0", "text": "women with breast cancer", "entity_type": "Entity", "start": 28, "end": 32}, {"id": "11795358_1_Ent5", "text": "breast cancer", "entity_type": "Entity", "start": 30, "end": 32}, {"id": "11795358_1_Ent2", "text": "endometrial carcinoma", "entity_type": "Entity", "start": 36, "end": 38}], "lang": "en"}
{"doc_id": "11795358_2", "wnd_id": "11795358_2_1", "text": "In this healthy population , the relative risk of developing endometrial carcinoma in the tamoxifen arm was 2.54 , although when stratified by age , in women over 50 , the risk grew to 4.01 .", "tokens": ["In", "this", "healthy", "population", ",", "the", "relative", "risk", "of", "developing", "endometrial", "carcinoma", "in", "the", "tamoxifen", "arm", "was", "2.54", ",", "although", "when", "stratified", "by", "age", ",", "in", "women", "over", "50", ",", "the", "risk", "grew", "to", "4.01", "."], "event_mentions": [{"id": "11795358_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developing", "start": 9, "end": 10}, "arguments": [{"entity_id": "11795358_2_Ent0", "role": "Subject", "text": "healthy population", "start": 2, "end": 4}, {"entity_id": "11795358_2_Ent1", "role": "Effect", "text": "endometrial carcinoma", "start": 10, "end": 12}, {"entity_id": "11795358_2_Ent2", "role": "Treatment", "text": "tamoxifen", "start": 14, "end": 15}, {"entity_id": "11795358_2_Ent3", "role": "Treatment_Drug", "text": "tamoxifen", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "11795358_2_Ent0", "text": "healthy population", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "11795358_2_Ent1", "text": "endometrial carcinoma", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "11795358_2_Ent2", "text": "tamoxifen", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11795358_2_Ent3", "text": "tamoxifen", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "11807466_2", "wnd_id": "11807466_2_1", "text": "We report a patient who experienced LABD shortly after starting carbamazepine therapy .", "tokens": ["We", "report", "a", "patient", "who", "experienced", "LABD", "shortly", "after", "starting", "carbamazepine", "therapy", "."], "event_mentions": [{"id": "11807466_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 8, "end": 9}, "arguments": [{"entity_id": "11807466_2_Ent0", "role": "Subject", "text": "a patient", "start": 2, "end": 4}, {"entity_id": "11807466_2_Ent1", "role": "Effect", "text": "experienced LABD shortly", "start": 5, "end": 8}, {"entity_id": "11807466_2_Ent4", "role": "Treatment_Route", "text": "starting", "start": 9, "end": 10}, {"entity_id": "11807466_2_Ent2", "role": "Treatment", "text": "starting carbamazepine therapy", "start": 9, "end": 12}, {"entity_id": "11807466_2_Ent3", "role": "Treatment_Drug", "text": "carbamazepine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "11807466_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "11807466_2_Ent1", "text": "experienced LABD shortly", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "11807466_2_Ent4", "text": "starting", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11807466_2_Ent2", "text": "starting carbamazepine therapy", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "11807466_2_Ent3", "text": "carbamazepine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "11834188_4", "wnd_id": "11834188_4_1", "text": "We presented the case of a patient who developed a cutaneous reaction induced by captopril with positive patch test .", "tokens": ["We", "presented", "the", "case", "of", "a", "patient", "who", "developed", "a", "cutaneous", "reaction", "induced", "by", "captopril", "with", "positive", "patch", "test", "."], "event_mentions": [{"id": "11834188_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 12, "end": 13}, "arguments": [{"entity_id": "11834188_4_Ent0", "role": "Subject", "text": "a patient", "start": 5, "end": 7}, {"entity_id": "11834188_4_Ent1", "role": "Effect", "text": "cutaneous reaction", "start": 10, "end": 12}, {"entity_id": "11834188_4_Ent2", "role": "Treatment", "text": "captopril", "start": 14, "end": 15}, {"entity_id": "11834188_4_Ent3", "role": "Treatment_Drug", "text": "captopril", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "11834188_4_Ent0", "text": "a patient", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11834188_4_Ent1", "text": "cutaneous reaction", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "11834188_4_Ent2", "text": "captopril", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11834188_4_Ent3", "text": "captopril", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "11850606_3", "wnd_id": "11850606_3_1", "text": "Polymyositis is a rare complication of interferon alpha treatment as a result of immune - modulating role of the drug itself .", "tokens": ["Polymyositis", "is", "a", "rare", "complication", "of", "interferon", "alpha", "treatment", "as", "a", "result", "of", "immune", "-", "modulating", "role", "of", "the", "drug", "itself", "."], "event_mentions": [{"id": "11850606_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication of", "start": 4, "end": 6}, "arguments": [{"entity_id": "11850606_3_Ent0", "role": "Effect", "text": "Polymyositis", "start": 0, "end": 1}, {"entity_id": "11850606_3_Ent2", "role": "Treatment_Drug", "text": "interferon alpha", "start": 6, "end": 8}, {"entity_id": "11850606_3_Ent1", "role": "Treatment", "text": "interferon alpha treatment", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "11850606_3_Ent0", "text": "Polymyositis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11850606_3_Ent2", "text": "interferon alpha", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "11850606_3_Ent1", "text": "interferon alpha treatment", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "11876387_1", "wnd_id": "11876387_1_1", "text": "Aggressive endometrial carcinoma in a breast cancer patient treated with tamoxifen with normal transvaginal ultrasonography .", "tokens": ["Aggressive", "endometrial", "carcinoma", "in", "a", "breast", "cancer", "patient", "treated", "with", "tamoxifen", "with", "normal", "transvaginal", "ultrasonography", "."], "event_mentions": [{"id": "11876387_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 8, "end": 9}, "arguments": [{"entity_id": "11876387_1_Ent2", "role": "Effect", "text": "Aggressive endometrial carcinoma", "start": 0, "end": 3}, {"entity_id": "11876387_1_Ent4", "role": "Treatment_Disorder", "text": "breast cancer", "start": 5, "end": 7}, {"entity_id": "11876387_1_Ent0", "role": "Subject", "text": "breast cancer patient", "start": 5, "end": 8}, {"entity_id": "11876387_1_Ent3", "role": "Treatment", "text": "tamoxifen", "start": 10, "end": 11}, {"entity_id": "11876387_1_Ent5", "role": "Treatment_Drug", "text": "tamoxifen", "start": 10, "end": 11}, {"entity_id": "11876387_1_Ent1", "role": "Subject", "text": "with normal transvaginal ultrasonography", "start": 11, "end": 15}]}], "entity_mentions": [{"id": "11876387_1_Ent2", "text": "Aggressive endometrial carcinoma", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11876387_1_Ent4", "text": "breast cancer", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11876387_1_Ent0", "text": "breast cancer patient", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "11876387_1_Ent3", "text": "tamoxifen", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11876387_1_Ent5", "text": "tamoxifen", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11876387_1_Ent1", "text": "with normal transvaginal ultrasonography", "entity_type": "Entity", "start": 11, "end": 15}], "lang": "en"}
{"doc_id": "11876387_2", "wnd_id": "11876387_2_1", "text": "Since tamoxifen therapy can induce endometrial disorders , surveillance schemes of women taking tamoxifen have been recommended .", "tokens": ["Since", "tamoxifen", "therapy", "can", "induce", "endometrial", "disorders", ",", "surveillance", "schemes", "of", "women", "taking", "tamoxifen", "have", "been", "recommended", "."], "event_mentions": [{"id": "11876387_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 4, "end": 5}, "arguments": [{"entity_id": "11876387_2_Ent4", "role": "Treatment_Drug", "text": "tamoxifen", "start": 1, "end": 2}, {"entity_id": "11876387_2_Ent3", "role": "Treatment", "text": "tamoxifen therapy", "start": 1, "end": 3}, {"entity_id": "11876387_2_Ent2", "role": "Effect", "text": "endometrial disorders", "start": 5, "end": 7}, {"entity_id": "11876387_2_Ent0", "role": "Subject", "text": "women", "start": 11, "end": 12}, {"entity_id": "11876387_2_Ent1", "role": "Subject_Gender", "text": "women", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "11876387_2_Ent4", "text": "tamoxifen", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11876387_2_Ent3", "text": "tamoxifen therapy", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "11876387_2_Ent2", "text": "endometrial disorders", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11876387_2_Ent0", "text": "women", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11876387_2_Ent1", "text": "women", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "11881322_1", "wnd_id": "11881322_1_1", "text": "Beginning ductopenia was present in two , suggesting that itraconazole might be responsible for the occurrence of prolonged drug - induced cholangiopathy .", "tokens": ["Beginning", "ductopenia", "was", "present", "in", "two", ",", "suggesting", "that", "itraconazole", "might", "be", "responsible", "for", "the", "occurrence", "of", "prolonged", "drug", "-", "induced", "cholangiopathy", "."], "event_mentions": [{"id": "11881322_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "responsible", "start": 12, "end": 13}, "arguments": [{"entity_id": "11881322_1_Ent1", "role": "Effect", "text": "ductopenia", "start": 1, "end": 2}, {"entity_id": "11881322_1_Ent0", "role": "Subject", "text": "two", "start": 5, "end": 6}, {"entity_id": "11881322_1_Ent2", "role": "Treatment", "text": "itraconazole", "start": 9, "end": 10}, {"entity_id": "11881322_1_Ent4", "role": "Treatment_Drug", "text": "itraconazole", "start": 9, "end": 10}, {"entity_id": "11881322_1_Ent3", "role": "Treatment_Disorder", "text": "prolonged drug - induced cholangiopathy", "start": 17, "end": 22}]}], "entity_mentions": [{"id": "11881322_1_Ent1", "text": "ductopenia", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11881322_1_Ent0", "text": "two", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11881322_1_Ent2", "text": "itraconazole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11881322_1_Ent4", "text": "itraconazole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11881322_1_Ent3", "text": "prolonged drug - induced cholangiopathy", "entity_type": "Entity", "start": 17, "end": 22}], "lang": "en"}
{"doc_id": "11881322_2", "wnd_id": "11881322_2_1", "text": "CONCLUSIONS : Itraconazole - induced liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts , possibly leading to ductopenia .", "tokens": ["CONCLUSIONS", ":", "Itraconazole", "-", "induced", "liver", "injury", "presents", "with", "a", "cholestatic", "pattern", "of", "injury", "with", "damage", "to", "the", "interlobular", "bile", "ducts", ",", "possibly", "leading", "to", "ductopenia", "."], "event_mentions": [{"id": "11881322_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "11881322_2_Ent1", "role": "Treatment", "text": "Itraconazole", "start": 2, "end": 3}, {"entity_id": "11881322_2_Ent2", "role": "Treatment_Drug", "text": "Itraconazole", "start": 2, "end": 3}, {"entity_id": "11881322_2_Ent0", "role": "Effect", "text": "liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts , possibly leading to ductopenia", "start": 5, "end": 26}]}], "entity_mentions": [{"id": "11881322_2_Ent1", "text": "Itraconazole", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11881322_2_Ent2", "text": "Itraconazole", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11881322_2_Ent0", "text": "liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts , possibly leading to ductopenia", "entity_type": "Entity", "start": 5, "end": 26}], "lang": "en"}
{"doc_id": "11881322_3", "wnd_id": "11881322_3_1", "text": "Hepatotoxicity related to itraconazole : report of three cases .", "tokens": ["Hepatotoxicity", "related", "to", "itraconazole", ":", "report", "of", "three", "cases", "."], "event_mentions": [{"id": "11881322_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 1, "end": 2}, "arguments": [{"entity_id": "11881322_3_Ent2", "role": "Effect", "text": "Hepatotoxicity", "start": 0, "end": 1}, {"entity_id": "11881322_3_Ent3", "role": "Treatment", "text": "itraconazole", "start": 3, "end": 4}, {"entity_id": "11881322_3_Ent4", "role": "Treatment_Drug", "text": "itraconazole", "start": 3, "end": 4}, {"entity_id": "11881322_3_Ent1", "role": "Subject_Population", "text": "three", "start": 7, "end": 8}, {"entity_id": "11881322_3_Ent0", "role": "Subject", "text": "three cases", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "11881322_3_Ent2", "text": "Hepatotoxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11881322_3_Ent3", "text": "itraconazole", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11881322_3_Ent4", "text": "itraconazole", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11881322_3_Ent1", "text": "three", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11881322_3_Ent0", "text": "three cases", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "11881322_5", "wnd_id": "11881322_5_1", "text": "The occurrence of acute hepatitis is best known for ketoconazole .", "tokens": ["The", "occurrence", "of", "acute", "hepatitis", "is", "best", "known", "for", "ketoconazole", "."], "event_mentions": [{"id": "11881322_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "for", "start": 8, "end": 9}, "arguments": [{"entity_id": "11881322_5_Ent0", "role": "Effect", "text": "acute hepatitis", "start": 3, "end": 5}, {"entity_id": "11881322_5_Ent1", "role": "Treatment", "text": "ketoconazole", "start": 9, "end": 10}, {"entity_id": "11881322_5_Ent2", "role": "Treatment_Drug", "text": "ketoconazole", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "11881322_5_Ent0", "text": "acute hepatitis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11881322_5_Ent1", "text": "ketoconazole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11881322_5_Ent2", "text": "ketoconazole", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "11881322_7", "wnd_id": "11881322_7_1", "text": "We suggest that itraconazole should be added to the list of drugs that may be responsible for a drug - induced vanishing bile duct syndrome .", "tokens": ["We", "suggest", "that", "itraconazole", "should", "be", "added", "to", "the", "list", "of", "drugs", "that", "may", "be", "responsible", "for", "a", "drug", "-", "induced", "vanishing", "bile", "duct", "syndrome", "."], "event_mentions": [{"id": "11881322_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "responsible", "start": 15, "end": 16}, "arguments": [{"entity_id": "11881322_7_Ent1", "role": "Treatment", "text": "itraconazole", "start": 3, "end": 4}, {"entity_id": "11881322_7_Ent2", "role": "Treatment_Drug", "text": "itraconazole", "start": 3, "end": 4}, {"entity_id": "11881322_7_Ent0", "role": "Effect", "text": "drug - induced vanishing bile duct syndrome", "start": 18, "end": 25}]}], "entity_mentions": [{"id": "11881322_7_Ent1", "text": "itraconazole", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11881322_7_Ent2", "text": "itraconazole", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11881322_7_Ent0", "text": "drug - induced vanishing bile duct syndrome", "entity_type": "Entity", "start": 18, "end": 25}], "lang": "en"}
{"doc_id": "11886466_1", "wnd_id": "11886466_1_1", "text": "Thrombotic stroke associated with the use of porcine factor VIII in a patient with acquired haemophilia .", "tokens": ["Thrombotic", "stroke", "associated", "with", "the", "use", "of", "porcine", "factor", "VIII", "in", "a", "patient", "with", "acquired", "haemophilia", "."], "event_mentions": [{"id": "11886466_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "11886466_1_Ent1", "role": "Effect", "text": "Thrombotic stroke", "start": 0, "end": 2}, {"entity_id": "11886466_1_Ent2", "role": "Treatment", "text": "porcine factor VIII", "start": 7, "end": 10}, {"entity_id": "11886466_1_Ent3", "role": "Treatment_Drug", "text": "porcine factor VIII", "start": 7, "end": 10}, {"entity_id": "11886466_1_Ent0", "role": "Subject", "text": "patient with acquired haemophilia", "start": 12, "end": 16}, {"entity_id": "11886466_1_Ent4", "role": "Treatment_Disorder", "text": "acquired haemophilia", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "11886466_1_Ent1", "text": "Thrombotic stroke", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11886466_1_Ent2", "text": "porcine factor VIII", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "11886466_1_Ent3", "text": "porcine factor VIII", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "11886466_1_Ent0", "text": "patient with acquired haemophilia", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "11886466_1_Ent4", "text": "acquired haemophilia", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "11889149_3", "wnd_id": "11889149_3_1", "text": "This phase 3 , randomized , double - blind 1 - yr study assessed the effects of combined RLX and ALN in 331 postmenopausal women with osteoporosis ( femoral neck BMD T - score , less than -2 ) .", "tokens": ["This", "phase", "3", ",", "randomized", ",", "double", "-", "blind", "1", "-", "yr", "study", "assessed", "the", "effects", "of", "combined", "RLX", "and", "ALN", "in", "331", "postmenopausal", "women", "with", "osteoporosis", "(", "femoral", "neck", "BMD", "T", "-", "score", ",", "less", "than", "-2", ")", "."], "event_mentions": [{"id": "11889149_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "effects", "start": 15, "end": 16}, "arguments": [{"entity_id": "11889149_3_Ent4", "role": "Treatment", "text": "combined RLX and ALN", "start": 17, "end": 21}, {"entity_id": "11889149_3_Ent6", "role": "Treatment_Drug", "text": "RLX", "start": 18, "end": 19}, {"entity_id": "11889149_3_Ent8", "role": "Combination_Drug", "text": "RLX", "start": 18, "end": 19}, {"entity_id": "11889149_3_Ent7", "role": "Treatment_Drug", "text": "ALN", "start": 20, "end": 21}, {"entity_id": "11889149_3_Ent9", "role": "Combination_Drug", "text": "ALN", "start": 20, "end": 21}, {"entity_id": "11889149_3_Ent1", "role": "Subject_Population", "text": "331", "start": 22, "end": 23}, {"entity_id": "11889149_3_Ent0", "role": "Subject", "text": "331 postmenopausal women with osteoporosis ( femoral neck BMD T - score , less than -2 )", "start": 22, "end": 39}, {"entity_id": "11889149_3_Ent3", "role": "Subject_Age", "text": "postmenopausal", "start": 23, "end": 24}, {"entity_id": "11889149_3_Ent2", "role": "Subject_Gender", "text": "women", "start": 24, "end": 25}, {"entity_id": "11889149_3_Ent5", "role": "Treatment_Disorder", "text": "osteoporosis", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "11889149_3_Ent4", "text": "combined RLX and ALN", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "11889149_3_Ent6", "text": "RLX", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "11889149_3_Ent8", "text": "RLX", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "11889149_3_Ent7", "text": "ALN", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "11889149_3_Ent9", "text": "ALN", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "11889149_3_Ent1", "text": "331", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "11889149_3_Ent0", "text": "331 postmenopausal women with osteoporosis ( femoral neck BMD T - score , less than -2 )", "entity_type": "Entity", "start": 22, "end": 39}, {"id": "11889149_3_Ent3", "text": "postmenopausal", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "11889149_3_Ent2", "text": "women", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "11889149_3_Ent5", "text": "osteoporosis", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "11889149_4", "wnd_id": "11889149_4_1", "text": "Women ( aged < or = 75 yr ; > or = 2 yr since their last menstrual period ) received placebo , RLX 60 mg / d , ALN 10 mg / d , or RLX 60 mg / d and ALN 10 mg / d combined .", "tokens": ["Women", "(", "aged", "<", "or", "=", "75", "yr", ";", ">", "or", "=", "2", "yr", "since", "their", "last", "menstrual", "period", ")", "received", "placebo", ",", "RLX", "60", "mg", "/", "d", ",", "ALN", "10", "mg", "/", "d", ",", "or", "RLX", "60", "mg", "/", "d", "and", "ALN", "10", "mg", "/", "d", "combined", "."], "event_mentions": [{"id": "11889149_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "received", "start": 20, "end": 21}, "arguments": [{"entity_id": "11889149_4_Ent1", "role": "Subject_Gender", "text": "Women", "start": 0, "end": 1}, {"entity_id": "11889149_4_Ent0", "role": "Subject", "text": "Women ( aged < or = 75 yr ; > or = 2 yr since their last menstrual period )", "start": 0, "end": 20}, {"entity_id": "11889149_4_Ent2", "role": "Subject_Age", "text": "aged < or = 75 yr ; > or = 2 yr", "start": 2, "end": 14}, {"entity_id": "11889149_4_Ent8", "role": "Treatment_Drug", "text": "RLX", "start": 23, "end": 24}, {"entity_id": "11889149_4_Ent3", "role": "Treatment", "text": "RLX 60 mg / d , ALN 10 mg / d , or RLX 60 mg / d and ALN 10 mg / d combined", "start": 23, "end": 48}, {"entity_id": "11889149_4_Ent4", "role": "Treatment_Dosage", "text": "60 mg / d", "start": 24, "end": 28}, {"entity_id": "11889149_4_Ent9", "role": "Treatment_Drug", "text": "ALN", "start": 29, "end": 30}, {"entity_id": "11889149_4_Ent5", "role": "Treatment_Dosage", "text": "10 mg / d", "start": 30, "end": 34}, {"entity_id": "11889149_4_Ent10", "role": "Treatment_Drug", "text": "RLX", "start": 36, "end": 37}, {"entity_id": "11889149_4_Ent13", "role": "Combination_Drug", "text": "RLX", "start": 36, "end": 37}, {"entity_id": "11889149_4_Ent6", "role": "Treatment_Dosage", "text": "60 mg / d", "start": 37, "end": 41}, {"entity_id": "11889149_4_Ent11", "role": "Treatment_Drug", "text": "ALN", "start": 42, "end": 43}, {"entity_id": "11889149_4_Ent12", "role": "Combination_Drug", "text": "ALN", "start": 42, "end": 43}, {"entity_id": "11889149_4_Ent7", "role": "Treatment_Dosage", "text": "10 mg / d", "start": 43, "end": 47}]}], "entity_mentions": [{"id": "11889149_4_Ent1", "text": "Women", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11889149_4_Ent0", "text": "Women ( aged < or = 75 yr ; > or = 2 yr since their last menstrual period )", "entity_type": "Entity", "start": 0, "end": 20}, {"id": "11889149_4_Ent2", "text": "aged < or = 75 yr ; > or = 2 yr", "entity_type": "Entity", "start": 2, "end": 14}, {"id": "11889149_4_Ent8", "text": "RLX", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "11889149_4_Ent3", "text": "RLX 60 mg / d , ALN 10 mg / d , or RLX 60 mg / d and ALN 10 mg / d combined", "entity_type": "Entity", "start": 23, "end": 48}, {"id": "11889149_4_Ent4", "text": "60 mg / d", "entity_type": "Entity", "start": 24, "end": 28}, {"id": "11889149_4_Ent9", "text": "ALN", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "11889149_4_Ent5", "text": "10 mg / d", "entity_type": "Entity", "start": 30, "end": 34}, {"id": "11889149_4_Ent10", "text": "RLX", "entity_type": "Entity", "start": 36, "end": 37}, {"id": "11889149_4_Ent13", "text": "RLX", "entity_type": "Entity", "start": 36, "end": 37}, {"id": "11889149_4_Ent6", "text": "60 mg / d", "entity_type": "Entity", "start": 37, "end": 41}, {"id": "11889149_4_Ent11", "text": "ALN", "entity_type": "Entity", "start": 42, "end": 43}, {"id": "11889149_4_Ent12", "text": "ALN", "entity_type": "Entity", "start": 42, "end": 43}, {"id": "11889149_4_Ent7", "text": "10 mg / d", "entity_type": "Entity", "start": 43, "end": 47}], "lang": "en"}
{"doc_id": "11903249_3", "wnd_id": "11903249_3_1", "text": "We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin .", "tokens": ["We", "report", "two", "new", "cases", "of", "sarcoidosis", "in", "two", "patients", "with", "hepatitis", "C", "virus", "infection", "treated", "with", "interferon", "alfa", "and", "ribavirin", "."], "event_mentions": [{"id": "11903249_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 7, "end": 8}, "arguments": [{"entity_id": "11903249_3_Ent2", "role": "Effect", "text": "sarcoidosis", "start": 6, "end": 7}, {"entity_id": "11903249_3_Ent1", "role": "Subject_Population", "text": "two", "start": 8, "end": 9}, {"entity_id": "11903249_3_Ent0", "role": "Subject", "text": "two patients with hepatitis C virus infection", "start": 8, "end": 15}, {"entity_id": "11903249_3_Ent4", "role": "Treatment_Disorder", "text": "hepatitis C virus infection", "start": 11, "end": 15}, {"entity_id": "11903249_3_Ent5", "role": "Treatment_Drug", "text": "interferon alfa", "start": 17, "end": 19}, {"entity_id": "11903249_3_Ent7", "role": "Combination_Drug", "text": "interferon alfa", "start": 17, "end": 19}, {"entity_id": "11903249_3_Ent3", "role": "Treatment", "text": "interferon alfa and ribavirin", "start": 17, "end": 21}, {"entity_id": "11903249_3_Ent6", "role": "Treatment_Drug", "text": "ribavirin", "start": 20, "end": 21}, {"entity_id": "11903249_3_Ent8", "role": "Combination_Drug", "text": "ribavirin", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "11903249_3_Ent2", "text": "sarcoidosis", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11903249_3_Ent1", "text": "two", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11903249_3_Ent0", "text": "two patients with hepatitis C virus infection", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "11903249_3_Ent4", "text": "hepatitis C virus infection", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "11903249_3_Ent5", "text": "interferon alfa", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "11903249_3_Ent7", "text": "interferon alfa", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "11903249_3_Ent3", "text": "interferon alfa and ribavirin", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "11903249_3_Ent6", "text": "ribavirin", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "11903249_3_Ent8", "text": "ribavirin", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "11918514_1", "wnd_id": "11918514_1_1", "text": "CONCLUSIONS : Although mirtazapine offers clinicians a combination of strong efficacy and good safety , we suggest bearing SS in mind when prescribing this drug , especially in frail , elderly patients with underlying chronic conditions .", "tokens": ["CONCLUSIONS", ":", "Although", "mirtazapine", "offers", "clinicians", "a", "combination", "of", "strong", "efficacy", "and", "good", "safety", ",", "we", "suggest", "bearing", "SS", "in", "mind", "when", "prescribing", "this", "drug", ",", "especially", "in", "frail", ",", "elderly", "patients", "with", "underlying", "chronic", "conditions", "."], "event_mentions": [{"id": "11918514_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "bearing", "start": 17, "end": 18}, "arguments": [{"entity_id": "11918514_1_Ent4", "role": "Treatment", "text": "mirtazapine", "start": 3, "end": 4}, {"entity_id": "11918514_1_Ent5", "role": "Treatment_Drug", "text": "mirtazapine", "start": 3, "end": 4}, {"entity_id": "11918514_1_Ent3", "role": "Effect", "text": "SS", "start": 18, "end": 19}, {"entity_id": "11918514_1_Ent0", "role": "Subject", "text": "frail , elderly patients with underlying chronic conditions", "start": 28, "end": 36}, {"entity_id": "11918514_1_Ent1", "role": "Subject_Age", "text": "elderly", "start": 30, "end": 31}, {"entity_id": "11918514_1_Ent2", "role": "Subject_Disorder", "text": "underlying chronic conditions", "start": 33, "end": 36}]}], "entity_mentions": [{"id": "11918514_1_Ent4", "text": "mirtazapine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11918514_1_Ent5", "text": "mirtazapine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11918514_1_Ent3", "text": "SS", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "11918514_1_Ent0", "text": "frail , elderly patients with underlying chronic conditions", "entity_type": "Entity", "start": 28, "end": 36}, {"id": "11918514_1_Ent1", "text": "elderly", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "11918514_1_Ent2", "text": "underlying chronic conditions", "entity_type": "Entity", "start": 33, "end": 36}], "lang": "en"}
{"doc_id": "11978156_4", "wnd_id": "11978156_4_1", "text": "Lansoprazole - induced thrombocytopenia .", "tokens": ["Lansoprazole", "-", "induced", "thrombocytopenia", "."], "event_mentions": [{"id": "11978156_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "11978156_4_Ent1", "role": "Treatment", "text": "Lansoprazole", "start": 0, "end": 1}, {"entity_id": "11978156_4_Ent2", "role": "Treatment_Drug", "text": "Lansoprazole", "start": 0, "end": 1}, {"entity_id": "11978156_4_Ent0", "role": "Effect", "text": "thrombocytopenia", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "11978156_4_Ent1", "text": "Lansoprazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11978156_4_Ent2", "text": "Lansoprazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11978156_4_Ent0", "text": "thrombocytopenia", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "11984077_1", "wnd_id": "11984077_1_1", "text": "Life - threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis : a case report with literature review .", "tokens": ["Life", "-", "threatening", "anaphylactoid", "reaction", "to", "amifostine", "used", "with", "concurrent", "chemoradiotherapy", "for", "nasopharyngeal", "cancer", "in", "a", "patient", "with", "dermatomyositis", ":", "a", "case", "report", "with", "literature", "review", "."], "event_mentions": [{"id": "11984077_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 5, "end": 6}, "arguments": [{"entity_id": "11984077_1_Ent2", "role": "Effect", "text": "Life - threatening anaphylactoid reaction", "start": 0, "end": 5}, {"entity_id": "11984077_1_Ent5", "role": "Treatment_Drug", "text": "amifostine", "start": 6, "end": 7}, {"entity_id": "11984077_1_Ent7", "role": "Combination_Drug", "text": "amifostine", "start": 6, "end": 7}, {"entity_id": "11984077_1_Ent3", "role": "Treatment", "text": "amifostine used with concurrent chemoradiotherapy", "start": 6, "end": 11}, {"entity_id": "11984077_1_Ent6", "role": "Treatment_Drug", "text": "chemoradiotherapy", "start": 10, "end": 11}, {"entity_id": "11984077_1_Ent8", "role": "Combination_Drug", "text": "chemoradiotherapy", "start": 10, "end": 11}, {"entity_id": "11984077_1_Ent4", "role": "Treatment_Disorder", "text": "nasopharyngeal cancer", "start": 12, "end": 14}, {"entity_id": "11984077_1_Ent0", "role": "Subject", "text": "a patient with dermatomyositis", "start": 15, "end": 19}, {"entity_id": "11984077_1_Ent1", "role": "Subject_Disorder", "text": "dermatomyositis", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "11984077_1_Ent2", "text": "Life - threatening anaphylactoid reaction", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "11984077_1_Ent5", "text": "amifostine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11984077_1_Ent7", "text": "amifostine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11984077_1_Ent3", "text": "amifostine used with concurrent chemoradiotherapy", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "11984077_1_Ent6", "text": "chemoradiotherapy", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11984077_1_Ent8", "text": "chemoradiotherapy", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11984077_1_Ent4", "text": "nasopharyngeal cancer", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "11984077_1_Ent0", "text": "a patient with dermatomyositis", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "11984077_1_Ent1", "text": "dermatomyositis", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "11984077_3", "wnd_id": "11984077_3_1", "text": "The patient suffered a life - threatening anaphylactoid reaction to amifostine .", "tokens": ["The", "patient", "suffered", "a", "life", "-", "threatening", "anaphylactoid", "reaction", "to", "amifostine", "."], "event_mentions": [{"id": "11984077_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suffered", "start": 2, "end": 3}, "arguments": [{"entity_id": "11984077_3_Ent0", "role": "Subject", "text": "patient", "start": 1, "end": 2}, {"entity_id": "11984077_3_Ent1", "role": "Effect", "text": "life - threatening anaphylactoid reaction", "start": 4, "end": 9}, {"entity_id": "11984077_3_Ent2", "role": "Treatment", "text": "amifostine", "start": 10, "end": 11}, {"entity_id": "11984077_3_Ent3", "role": "Treatment_Drug", "text": "amifostine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "11984077_3_Ent0", "text": "patient", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11984077_3_Ent1", "text": "life - threatening anaphylactoid reaction", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "11984077_3_Ent2", "text": "amifostine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11984077_3_Ent3", "text": "amifostine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "11999915_1", "wnd_id": "11999915_1_1", "text": "Agranulocytosis during clozapine therapy .", "tokens": ["Agranulocytosis", "during", "clozapine", "therapy", "."], "event_mentions": [{"id": "11999915_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 1, "end": 2}, "arguments": [{"entity_id": "11999915_1_Ent0", "role": "Effect", "text": "Agranulocytosis", "start": 0, "end": 1}, {"entity_id": "11999915_1_Ent2", "role": "Treatment_Drug", "text": "clozapine", "start": 2, "end": 3}, {"entity_id": "11999915_1_Ent1", "role": "Treatment", "text": "clozapine therapy", "start": 2, "end": 4}]}], "entity_mentions": [{"id": "11999915_1_Ent0", "text": "Agranulocytosis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11999915_1_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11999915_1_Ent1", "text": "clozapine therapy", "entity_type": "Entity", "start": 2, "end": 4}], "lang": "en"}
{"doc_id": "12013364_1", "wnd_id": "12013364_1_1", "text": "A 53 - year - old man developed NMS without rigidity while taking olanzapine .", "tokens": ["A", "53", "-", "year", "-", "old", "man", "developed", "NMS", "without", "rigidity", "while", "taking", "olanzapine", "."], "event_mentions": [{"id": "12013364_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "12013364_1_Ent0", "role": "Subject", "text": "A 53 - year - old man", "start": 0, "end": 7}, {"entity_id": "12013364_1_Ent1", "role": "Subject_Age", "text": "53 - year - old", "start": 1, "end": 6}, {"entity_id": "12013364_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "12013364_1_Ent3", "role": "Effect", "text": "NMS without rigidity", "start": 8, "end": 11}, {"entity_id": "12013364_1_Ent4", "role": "Treatment", "text": "olanzapine", "start": 13, "end": 14}, {"entity_id": "12013364_1_Ent5", "role": "Treatment_Drug", "text": "olanzapine", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "12013364_1_Ent0", "text": "A 53 - year - old man", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12013364_1_Ent1", "text": "53 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "12013364_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12013364_1_Ent3", "text": "NMS without rigidity", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "12013364_1_Ent4", "text": "olanzapine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12013364_1_Ent5", "text": "olanzapine", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "12022905_2", "wnd_id": "12022905_2_1", "text": "CONCLUSIONS : Priapism is an uncommon but potentially serious adverse effect of zuclopenthixol that practitioners , as with many other antipsychotics , should be aware of .", "tokens": ["CONCLUSIONS", ":", "Priapism", "is", "an", "uncommon", "but", "potentially", "serious", "adverse", "effect", "of", "zuclopenthixol", "that", "practitioners", ",", "as", "with", "many", "other", "antipsychotics", ",", "should", "be", "aware", "of", "."], "event_mentions": [{"id": "12022905_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "serious adverse effect", "start": 8, "end": 11}, "arguments": [{"entity_id": "12022905_2_Ent0", "role": "Effect", "text": "Priapism", "start": 2, "end": 3}, {"entity_id": "12022905_2_Ent1", "role": "Treatment", "text": "zuclopenthixol", "start": 12, "end": 13}, {"entity_id": "12022905_2_Ent2", "role": "Treatment_Drug", "text": "zuclopenthixol", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "12022905_2_Ent0", "text": "Priapism", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12022905_2_Ent1", "text": "zuclopenthixol", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12022905_2_Ent2", "text": "zuclopenthixol", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "12066972_1", "wnd_id": "12066972_1_1", "text": "Levofloxacin - induced toxic epidermal necrolysis in an elderly patient .", "tokens": ["Levofloxacin", "-", "induced", "toxic", "epidermal", "necrolysis", "in", "an", "elderly", "patient", "."], "event_mentions": [{"id": "12066972_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "12066972_1_Ent3", "role": "Treatment", "text": "Levofloxacin", "start": 0, "end": 1}, {"entity_id": "12066972_1_Ent4", "role": "Treatment_Drug", "text": "Levofloxacin", "start": 0, "end": 1}, {"entity_id": "12066972_1_Ent2", "role": "Effect", "text": "toxic epidermal necrolysis", "start": 3, "end": 6}, {"entity_id": "12066972_1_Ent0", "role": "Subject", "text": "an elderly patient .", "start": 7, "end": 11}, {"entity_id": "12066972_1_Ent1", "role": "Subject_Age", "text": "elderly", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "12066972_1_Ent3", "text": "Levofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12066972_1_Ent4", "text": "Levofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12066972_1_Ent2", "text": "toxic epidermal necrolysis", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "12066972_1_Ent0", "text": "an elderly patient .", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "12066972_1_Ent1", "text": "elderly", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "12092878_2", "wnd_id": "12092878_2_1", "text": "A case of anaphylactoid reaction due solely to the use of Gelofusine in a patient with non - haemorrhagic hypovolaemia is presented , with a discussion on the management and the use of allergy identification jewellery .", "tokens": ["A", "case", "of", "anaphylactoid", "reaction", "due", "solely", "to", "the", "use", "of", "Gelofusine", "in", "a", "patient", "with", "non", "-", "haemorrhagic", "hypovolaemia", "is", "presented", ",", "with", "a", "discussion", "on", "the", "management", "and", "the", "use", "of", "allergy", "identification", "jewellery", "."], "event_mentions": [{"id": "12092878_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reaction", "start": 4, "end": 5}, "arguments": [{"entity_id": "12092878_2_Ent1", "role": "Effect", "text": "anaphylactoid", "start": 3, "end": 4}, {"entity_id": "12092878_2_Ent2", "role": "Treatment", "text": "Gelofusine", "start": 11, "end": 12}, {"entity_id": "12092878_2_Ent4", "role": "Treatment_Drug", "text": "Gelofusine", "start": 11, "end": 12}, {"entity_id": "12092878_2_Ent0", "role": "Subject", "text": "patient with non - haemorrhagic hypovolaemia", "start": 14, "end": 20}, {"entity_id": "12092878_2_Ent3", "role": "Treatment_Disorder", "text": "non - haemorrhagic hypovolaemia", "start": 16, "end": 20}]}], "entity_mentions": [{"id": "12092878_2_Ent1", "text": "anaphylactoid", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12092878_2_Ent2", "text": "Gelofusine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12092878_2_Ent4", "text": "Gelofusine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12092878_2_Ent0", "text": "patient with non - haemorrhagic hypovolaemia", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "12092878_2_Ent3", "text": "non - haemorrhagic hypovolaemia", "entity_type": "Entity", "start": 16, "end": 20}], "lang": "en"}
{"doc_id": "12095907_1", "wnd_id": "12095907_1_1", "text": "The authors describe valproate - induced hyperammonemia and mental status changes in an 88 - year - old man , the first known reported case in an elderly patient .", "tokens": ["The", "authors", "describe", "valproate", "-", "induced", "hyperammonemia", "and", "mental", "status", "changes", "in", "an", "88", "-", "year", "-", "old", "man", ",", "the", "first", "known", "reported", "case", "in", "an", "elderly", "patient", "."], "event_mentions": [{"id": "12095907_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "12095907_1_Ent4", "role": "Treatment", "text": "valproate", "start": 3, "end": 4}, {"entity_id": "12095907_1_Ent5", "role": "Treatment_Drug", "text": "valproate", "start": 3, "end": 4}, {"entity_id": "12095907_1_Ent3", "role": "Effect", "text": "hyperammonemia and mental status changes", "start": 6, "end": 11}, {"entity_id": "12095907_1_Ent0", "role": "Subject", "text": "an 88 - year - old man", "start": 12, "end": 19}, {"entity_id": "12095907_1_Ent1", "role": "Subject_Age", "text": "88 - year - old", "start": 13, "end": 18}, {"entity_id": "12095907_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "12095907_1_Ent4", "text": "valproate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12095907_1_Ent5", "text": "valproate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12095907_1_Ent3", "text": "hyperammonemia and mental status changes", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "12095907_1_Ent0", "text": "an 88 - year - old man", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "12095907_1_Ent1", "text": "88 - year - old", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "12095907_1_Ent2", "text": "man", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "12095907_2", "wnd_id": "12095907_2_1", "text": "Valproate - induced hyperammonemia as a cause of altered mental status .", "tokens": ["Valproate", "-", "induced", "hyperammonemia", "as", "a", "cause", "of", "altered", "mental", "status", "."], "event_mentions": [{"id": "12095907_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "12095907_2_Ent2", "role": "Treatment", "text": "Valproate", "start": 0, "end": 1}, {"entity_id": "12095907_2_Ent3", "role": "Treatment_Drug", "text": "Valproate", "start": 0, "end": 1}, {"entity_id": "12095907_2_Ent1", "role": "Effect", "text": "hyperammonemia", "start": 3, "end": 4}, {"entity_id": "12095907_2_Ent0", "role": "Effect", "text": "altered mental status", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "12095907_2_Ent2", "text": "Valproate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12095907_2_Ent3", "text": "Valproate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12095907_2_Ent1", "text": "hyperammonemia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12095907_2_Ent0", "text": "altered mental status", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "12111771_1", "wnd_id": "12111771_1_1", "text": "A 73 - year - old woman presented with fever and cough 2 weeks after completing the third cycle of fludarabine for chronic lymphocytic leukemia ( CLL ) .", "tokens": ["A", "73", "-", "year", "-", "old", "woman", "presented", "with", "fever", "and", "cough", "2", "weeks", "after", "completing", "the", "third", "cycle", "of", "fludarabine", "for", "chronic", "lymphocytic", "leukemia", "(", "CLL", ")", "."], "event_mentions": [{"id": "12111771_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 7, "end": 8}, "arguments": [{"entity_id": "12111771_1_Ent0", "role": "Subject", "text": "A 73 - year - old woman", "start": 0, "end": 7}, {"entity_id": "12111771_1_Ent1", "role": "Subject_Age", "text": "73 - year - old", "start": 1, "end": 6}, {"entity_id": "12111771_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "12111771_1_Ent3", "role": "Effect", "text": "fever and cough", "start": 9, "end": 12}, {"entity_id": "12111771_1_Ent6", "role": "Treatment_Time_elapsed", "text": "2 weeks", "start": 12, "end": 14}, {"entity_id": "12111771_1_Ent4", "role": "Treatment", "text": "2 weeks after completing the third cycle of fludarabine for chronic lymphocytic leukemia ( CLL )", "start": 12, "end": 28}, {"entity_id": "12111771_1_Ent7", "role": "Treatment_Drug", "text": "fludarabine", "start": 20, "end": 21}, {"entity_id": "12111771_1_Ent5", "role": "Treatment_Disorder", "text": "chronic lymphocytic leukemia ( CLL )", "start": 22, "end": 28}]}], "entity_mentions": [{"id": "12111771_1_Ent0", "text": "A 73 - year - old woman", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12111771_1_Ent1", "text": "73 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "12111771_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12111771_1_Ent3", "text": "fever and cough", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "12111771_1_Ent6", "text": "2 weeks", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "12111771_1_Ent4", "text": "2 weeks after completing the third cycle of fludarabine for chronic lymphocytic leukemia ( CLL )", "entity_type": "Entity", "start": 12, "end": 28}, {"id": "12111771_1_Ent7", "text": "fludarabine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "12111771_1_Ent5", "text": "chronic lymphocytic leukemia ( CLL )", "entity_type": "Entity", "start": 22, "end": 28}], "lang": "en"}
{"doc_id": "12111771_3", "wnd_id": "12111771_3_1", "text": "Multiple pulmonary nodules : an unusual presentation of fludarabine pulmonary toxicity : case report and review of literature .", "tokens": ["Multiple", "pulmonary", "nodules", ":", "an", "unusual", "presentation", "of", "fludarabine", "pulmonary", "toxicity", ":", "case", "report", "and", "review", "of", "literature", "."], "event_mentions": [{"id": "12111771_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presentation", "start": 6, "end": 7}, "arguments": [{"entity_id": "12111771_3_Ent0", "role": "Effect", "text": "Multiple pulmonary nodules", "start": 0, "end": 3}, {"entity_id": "12111771_3_Ent1", "role": "Treatment", "text": "fludarabine", "start": 8, "end": 9}, {"entity_id": "12111771_3_Ent2", "role": "Treatment_Drug", "text": "fludarabine", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "12111771_3_Ent0", "text": "Multiple pulmonary nodules", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12111771_3_Ent1", "text": "fludarabine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12111771_3_Ent2", "text": "fludarabine", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "12114387_3", "wnd_id": "12114387_3_1", "text": "We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who , after 2 months of treatment with epoprostenol , presented with rapidly progressive erythema , scaling , nausea and vomiting , and fever .", "tokens": ["We", "report", "a", "case", "of", "a", "patient", "with", "pulmonary", "hypertension", "and", "undifferentiated", "connective", "tissue", "disease", "who", ",", "after", "2", "months", "of", "treatment", "with", "epoprostenol", ",", "presented", "with", "rapidly", "progressive", "erythema", ",", "scaling", ",", "nausea", "and", "vomiting", ",", "and", "fever", "."], "event_mentions": [{"id": "12114387_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 25, "end": 26}, "arguments": [{"entity_id": "12114387_3_Ent0", "role": "Subject", "text": "a patient with pulmonary hypertension and undifferentiated connective tissue disease", "start": 5, "end": 15}, {"entity_id": "12114387_3_Ent5", "role": "Treatment_Disorder", "text": "pulmonary hypertension", "start": 8, "end": 10}, {"entity_id": "12114387_3_Ent6", "role": "Treatment_Disorder", "text": "undifferentiated connective tissue disease", "start": 11, "end": 15}, {"entity_id": "12114387_3_Ent4", "role": "Treatment_Time_elapsed", "text": "after 2 months", "start": 17, "end": 20}, {"entity_id": "12114387_3_Ent2", "role": "Treatment", "text": "2 months of treatment with epoprostenol", "start": 18, "end": 24}, {"entity_id": "12114387_3_Ent3", "role": "Treatment_Drug", "text": "epoprostenol", "start": 23, "end": 24}, {"entity_id": "12114387_3_Ent1", "role": "Effect", "text": "rapidly progressive erythema , scaling , nausea and vomiting , and fever", "start": 27, "end": 39}]}], "entity_mentions": [{"id": "12114387_3_Ent0", "text": "a patient with pulmonary hypertension and undifferentiated connective tissue disease", "entity_type": "Entity", "start": 5, "end": 15}, {"id": "12114387_3_Ent5", "text": "pulmonary hypertension", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "12114387_3_Ent6", "text": "undifferentiated connective tissue disease", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "12114387_3_Ent4", "text": "after 2 months", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "12114387_3_Ent2", "text": "2 months of treatment with epoprostenol", "entity_type": "Entity", "start": 18, "end": 24}, {"id": "12114387_3_Ent3", "text": "epoprostenol", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "12114387_3_Ent1", "text": "rapidly progressive erythema , scaling , nausea and vomiting , and fever", "entity_type": "Entity", "start": 27, "end": 39}], "lang": "en"}
{"doc_id": "12121061_6", "wnd_id": "12121061_6_1", "text": "Alone or in combination with corticosteroids , cyclosporine is an effective drug of choice for the resistant patients .", "tokens": ["Alone", "or", "in", "combination", "with", "corticosteroids", ",", "cyclosporine", "is", "an", "effective", "drug", "of", "choice", "for", "the", "resistant", "patients", "."], "event_mentions": [{"id": "12121061_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "is", "start": 8, "end": 9}, "arguments": [{"entity_id": "12121061_6_Ent1", "role": "Treatment", "text": "Alone or in combination with corticosteroids , cyclosporine", "start": 0, "end": 8}, {"entity_id": "12121061_6_Ent2", "role": "Treatment_Drug", "text": "corticosteroids", "start": 5, "end": 6}, {"entity_id": "12121061_6_Ent4", "role": "Combination_Drug", "text": "corticosteroids", "start": 5, "end": 6}, {"entity_id": "12121061_6_Ent3", "role": "Treatment_Drug", "text": "cyclosporine", "start": 7, "end": 8}, {"entity_id": "12121061_6_Ent5", "role": "Combination_Drug", "text": "cyclosporine", "start": 7, "end": 8}, {"entity_id": "12121061_6_Ent0", "role": "Subject", "text": "resistant patients", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "12121061_6_Ent1", "text": "Alone or in combination with corticosteroids , cyclosporine", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "12121061_6_Ent2", "text": "corticosteroids", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12121061_6_Ent4", "text": "corticosteroids", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12121061_6_Ent3", "text": "cyclosporine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12121061_6_Ent5", "text": "cyclosporine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12121061_6_Ent0", "text": "resistant patients", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "12149193_2", "wnd_id": "12149193_2_1", "text": "Ten percent of newly diagnosed myeloma patients treated with any type of chemotherapy develop deep venous thrombosis ( DVT ) .", "tokens": ["Ten", "percent", "of", "newly", "diagnosed", "myeloma", "patients", "treated", "with", "any", "type", "of", "chemotherapy", "develop", "deep", "venous", "thrombosis", "(", "DVT", ")", "."], "event_mentions": [{"id": "12149193_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 13, "end": 14}, "arguments": [{"entity_id": "12149193_2_Ent3", "role": "Treatment_Disorder", "text": "myeloma", "start": 5, "end": 6}, {"entity_id": "12149193_2_Ent0", "role": "Subject", "text": "myeloma patients", "start": 5, "end": 7}, {"entity_id": "12149193_2_Ent2", "role": "Treatment", "text": "any type of chemotherapy", "start": 9, "end": 13}, {"entity_id": "12149193_2_Ent4", "role": "Treatment_Route", "text": "chemotherapy", "start": 12, "end": 13}, {"entity_id": "12149193_2_Ent1", "role": "Effect", "text": "deep venous thrombosis ( DVT )", "start": 14, "end": 20}]}], "entity_mentions": [{"id": "12149193_2_Ent3", "text": "myeloma", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12149193_2_Ent0", "text": "myeloma patients", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "12149193_2_Ent2", "text": "any type of chemotherapy", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "12149193_2_Ent4", "text": "chemotherapy", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12149193_2_Ent1", "text": "deep venous thrombosis ( DVT )", "entity_type": "Entity", "start": 14, "end": 20}], "lang": "en"}
{"doc_id": "12149193_8", "wnd_id": "12149193_8_1", "text": "A statistical association between the incidence of DVT and combination chemotherapy including doxorubicin ( P = .02 ) was observed ; this association was confirmed on multivariate analysis .", "tokens": ["A", "statistical", "association", "between", "the", "incidence", "of", "DVT", "and", "combination", "chemotherapy", "including", "doxorubicin", "(", "P", "=", ".02", ")", "was", "observed", ";", "this", "association", "was", "confirmed", "on", "multivariate", "analysis", "."], "event_mentions": [{"id": "12149193_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 2, "end": 3}, "arguments": [{"entity_id": "12149193_8_Ent0", "role": "Effect", "text": "DVT", "start": 7, "end": 8}, {"entity_id": "12149193_8_Ent1", "role": "Treatment", "text": "combination chemotherapy including doxorubicin ( P = .02 )", "start": 9, "end": 18}, {"entity_id": "12149193_8_Ent2", "role": "Treatment_Drug", "text": "chemotherapy", "start": 10, "end": 11}, {"entity_id": "12149193_8_Ent4", "role": "Combination_Drug", "text": "chemotherapy", "start": 10, "end": 11}, {"entity_id": "12149193_8_Ent3", "role": "Treatment_Drug", "text": "doxorubicin", "start": 12, "end": 13}, {"entity_id": "12149193_8_Ent5", "role": "Combination_Drug", "text": "doxorubicin", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "12149193_8_Ent0", "text": "DVT", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12149193_8_Ent1", "text": "combination chemotherapy including doxorubicin ( P = .02 )", "entity_type": "Entity", "start": 9, "end": 18}, {"id": "12149193_8_Ent2", "text": "chemotherapy", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12149193_8_Ent4", "text": "chemotherapy", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12149193_8_Ent3", "text": "doxorubicin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12149193_8_Ent5", "text": "doxorubicin", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "12150593_1", "wnd_id": "12150593_1_1", "text": "Neonatal mydriasis : intravenous lidocaine adverse reaction .", "tokens": ["Neonatal", "mydriasis", ":", "intravenous", "lidocaine", "adverse", "reaction", "."], "event_mentions": [{"id": "12150593_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse reaction", "start": 5, "end": 7}, "arguments": [{"entity_id": "12150593_1_Ent0", "role": "Subject", "text": "Neonatal", "start": 0, "end": 1}, {"entity_id": "12150593_1_Ent1", "role": "Subject_Age", "text": "Neonatal", "start": 0, "end": 1}, {"entity_id": "12150593_1_Ent2", "role": "Effect", "text": "Neonatal mydriasis", "start": 0, "end": 2}, {"entity_id": "12150593_1_Ent3", "role": "Treatment", "text": "lidocaine", "start": 4, "end": 5}, {"entity_id": "12150593_1_Ent4", "role": "Treatment_Drug", "text": "lidocaine", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "12150593_1_Ent0", "text": "Neonatal", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12150593_1_Ent1", "text": "Neonatal", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12150593_1_Ent2", "text": "Neonatal mydriasis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12150593_1_Ent3", "text": "lidocaine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12150593_1_Ent4", "text": "lidocaine", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "12163813_2", "wnd_id": "12163813_2_1", "text": "OBJECTIVE : To describe a case of severe skin necrosis resulting from peripheral intravenous administration of low - dose vasopressin in a patient with catecholamine - resistant septic shock .", "tokens": ["OBJECTIVE", ":", "To", "describe", "a", "case", "of", "severe", "skin", "necrosis", "resulting", "from", "peripheral", "intravenous", "administration", "of", "low", "-", "dose", "vasopressin", "in", "a", "patient", "with", "catecholamine", "-", "resistant", "septic", "shock", "."], "event_mentions": [{"id": "12163813_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 10, "end": 11}, "arguments": [{"entity_id": "12163813_2_Ent1", "role": "Effect", "text": "skin necrosis", "start": 8, "end": 10}, {"entity_id": "12163813_2_Ent3", "role": "Treatment_Route", "text": "peripheral intravenous administration", "start": 12, "end": 15}, {"entity_id": "12163813_2_Ent2", "role": "Treatment", "text": "peripheral intravenous administration of low - dose vasopressin", "start": 12, "end": 20}, {"entity_id": "12163813_2_Ent4", "role": "Treatment_Dosage", "text": "low - dose", "start": 16, "end": 19}, {"entity_id": "12163813_2_Ent5", "role": "Treatment_Drug", "text": "vasopressin", "start": 19, "end": 20}, {"entity_id": "12163813_2_Ent0", "role": "Subject", "text": "a patient with catecholamine - resistant septic shock", "start": 21, "end": 29}, {"entity_id": "12163813_2_Ent6", "role": "Treatment_Disorder", "text": "catecholamine - resistant septic shock", "start": 24, "end": 29}]}], "entity_mentions": [{"id": "12163813_2_Ent1", "text": "skin necrosis", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "12163813_2_Ent3", "text": "peripheral intravenous administration", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "12163813_2_Ent2", "text": "peripheral intravenous administration of low - dose vasopressin", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "12163813_2_Ent4", "text": "low - dose", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "12163813_2_Ent5", "text": "vasopressin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "12163813_2_Ent0", "text": "a patient with catecholamine - resistant septic shock", "entity_type": "Entity", "start": 21, "end": 29}, {"id": "12163813_2_Ent6", "text": "catecholamine - resistant septic shock", "entity_type": "Entity", "start": 24, "end": 29}], "lang": "en"}
{"doc_id": "12187348_6", "wnd_id": "12187348_6_1", "text": "She had been on a combined treatment of steroid and lobenzarit disodium for the first 3 years , and then continued with a combined treatment of steroid and bucillamine for the following years until she was found to have pulmonary tuberculosis , at which time the steroid was suspended 10 months before she visited the authors ' clinic .", "tokens": ["She", "had", "been", "on", "a", "combined", "treatment", "of", "steroid", "and", "lobenzarit", "disodium", "for", "the", "first", "3", "years", ",", "and", "then", "continued", "with", "a", "combined", "treatment", "of", "steroid", "and", "bucillamine", "for", "the", "following", "years", "until", "she", "was", "found", "to", "have", "pulmonary", "tuberculosis", ",", "at", "which", "time", "the", "steroid", "was", "suspended", "10", "months", "before", "she", "visited", "the", "authors", "'", "clinic", "."], "event_mentions": [{"id": "12187348_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 6, "end": 7}, "arguments": [{"entity_id": "12187348_6_Ent5", "role": "Treatment_Drug", "text": "steroid", "start": 8, "end": 9}, {"entity_id": "12187348_6_Ent11", "role": "Combination_Drug", "text": "steroid", "start": 8, "end": 9}, {"entity_id": "12187348_6_Ent1", "role": "Treatment", "text": "steroid and lobenzarit disodium for the first 3 years , and then continued with a combined treatment of steroid and bucillamine for the following years", "start": 8, "end": 33}, {"entity_id": "12187348_6_Ent4", "role": "Treatment_Drug", "text": "lobenzarit disodium", "start": 10, "end": 12}, {"entity_id": "12187348_6_Ent10", "role": "Combination_Drug", "text": "lobenzarit disodium", "start": 10, "end": 12}, {"entity_id": "12187348_6_Ent6", "role": "Treatment_Time_elapsed", "text": "3 years", "start": 15, "end": 17}, {"entity_id": "12187348_6_Ent2", "role": "Treatment_Drug", "text": "steroid", "start": 26, "end": 27}, {"entity_id": "12187348_6_Ent8", "role": "Combination_Drug", "text": "steroid", "start": 26, "end": 27}, {"entity_id": "12187348_6_Ent3", "role": "Treatment_Drug", "text": "bucillamine", "start": 28, "end": 29}, {"entity_id": "12187348_6_Ent9", "role": "Combination_Drug", "text": "bucillamine", "start": 28, "end": 29}, {"entity_id": "12187348_6_Ent7", "role": "Treatment_Duration", "text": "for the following years", "start": 29, "end": 33}, {"entity_id": "12187348_6_Ent0", "role": "Effect", "text": "pulmonary tuberculosis", "start": 39, "end": 41}]}], "entity_mentions": [{"id": "12187348_6_Ent5", "text": "steroid", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12187348_6_Ent11", "text": "steroid", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12187348_6_Ent1", "text": "steroid and lobenzarit disodium for the first 3 years , and then continued with a combined treatment of steroid and bucillamine for the following years", "entity_type": "Entity", "start": 8, "end": 33}, {"id": "12187348_6_Ent4", "text": "lobenzarit disodium", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "12187348_6_Ent10", "text": "lobenzarit disodium", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "12187348_6_Ent6", "text": "3 years", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "12187348_6_Ent2", "text": "steroid", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "12187348_6_Ent8", "text": "steroid", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "12187348_6_Ent3", "text": "bucillamine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "12187348_6_Ent9", "text": "bucillamine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "12187348_6_Ent7", "text": "for the following years", "entity_type": "Entity", "start": 29, "end": 33}, {"id": "12187348_6_Ent0", "text": "pulmonary tuberculosis", "entity_type": "Entity", "start": 39, "end": 41}], "lang": "en"}
{"doc_id": "12221670_1", "wnd_id": "12221670_1_1", "text": "The first case concerns a 70 - year - old man who developed severe aplastic anemia 7 weeks after treatment with 500 mg of ticlopidine daily .", "tokens": ["The", "first", "case", "concerns", "a", "70", "-", "year", "-", "old", "man", "who", "developed", "severe", "aplastic", "anemia", "7", "weeks", "after", "treatment", "with", "500", "mg", "of", "ticlopidine", "daily", "."], "event_mentions": [{"id": "12221670_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "12221670_1_Ent1", "role": "Subject_Age", "text": "70 - year - old", "start": 5, "end": 10}, {"entity_id": "12221670_1_Ent0", "role": "Subject", "text": "70 - year - old man", "start": 5, "end": 11}, {"entity_id": "12221670_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 10, "end": 11}, {"entity_id": "12221670_1_Ent3", "role": "Effect", "text": "severe aplastic anemia", "start": 13, "end": 16}, {"entity_id": "12221670_1_Ent5", "role": "Treatment_Time_elapsed", "text": "7 weeks", "start": 16, "end": 18}, {"entity_id": "12221670_1_Ent4", "role": "Treatment", "text": "7 weeks after treatment with 500 mg of ticlopidine daily", "start": 16, "end": 26}, {"entity_id": "12221670_1_Ent6", "role": "Treatment_Dosage", "text": "500 mg", "start": 21, "end": 23}, {"entity_id": "12221670_1_Ent7", "role": "Treatment_Drug", "text": "ticlopidine", "start": 24, "end": 25}, {"entity_id": "12221670_1_Ent8", "role": "Treatment_Freq", "text": "daily", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "12221670_1_Ent1", "text": "70 - year - old", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "12221670_1_Ent0", "text": "70 - year - old man", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "12221670_1_Ent2", "text": "man", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12221670_1_Ent3", "text": "severe aplastic anemia", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "12221670_1_Ent5", "text": "7 weeks", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "12221670_1_Ent4", "text": "7 weeks after treatment with 500 mg of ticlopidine daily", "entity_type": "Entity", "start": 16, "end": 26}, {"id": "12221670_1_Ent6", "text": "500 mg", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "12221670_1_Ent7", "text": "ticlopidine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "12221670_1_Ent8", "text": "daily", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "12234159_1", "wnd_id": "12234159_1_1", "text": "Fixed drug eruption to rofecoxib .", "tokens": ["Fixed", "drug", "eruption", "to", "rofecoxib", "."], "event_mentions": [{"id": "12234159_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 3, "end": 4}, "arguments": [{"entity_id": "12234159_1_Ent0", "role": "Effect", "text": "Fixed drug eruption", "start": 0, "end": 3}, {"entity_id": "12234159_1_Ent1", "role": "Treatment", "text": "rofecoxib", "start": 4, "end": 5}, {"entity_id": "12234159_1_Ent2", "role": "Treatment_Drug", "text": "rofecoxib", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "12234159_1_Ent0", "text": "Fixed drug eruption", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12234159_1_Ent1", "text": "rofecoxib", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12234159_1_Ent2", "text": "rofecoxib", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "122410_1", "wnd_id": "122410_1_1", "text": "A patient who had been treated with large doses of thyroid hormone for several years developed features of secondary hypothyroidism after thyroid hormone withdrawal .", "tokens": ["A", "patient", "who", "had", "been", "treated", "with", "large", "doses", "of", "thyroid", "hormone", "for", "several", "years", "developed", "features", "of", "secondary", "hypothyroidism", "after", "thyroid", "hormone", "withdrawal", "."], "event_mentions": [{"id": "122410_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 15, "end": 16}, "arguments": [{"entity_id": "122410_1_Ent0", "role": "Subject", "text": "A patient", "start": 0, "end": 2}, {"entity_id": "122410_1_Ent1", "role": "Effect", "text": "secondary hypothyroidism", "start": 18, "end": 20}, {"entity_id": "122410_1_Ent3", "role": "Treatment_Drug", "text": "thyroid hormone", "start": 21, "end": 23}, {"entity_id": "122410_1_Ent2", "role": "Treatment", "text": "thyroid hormone withdrawal", "start": 21, "end": 24}]}], "entity_mentions": [{"id": "122410_1_Ent0", "text": "A patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "122410_1_Ent1", "text": "secondary hypothyroidism", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "122410_1_Ent3", "text": "thyroid hormone", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "122410_1_Ent2", "text": "thyroid hormone withdrawal", "entity_type": "Entity", "start": 21, "end": 24}], "lang": "en"}
{"doc_id": "12243603_7", "wnd_id": "12243603_7_1", "text": "Atorvastatin is the most potent of this class of agents currently available and is commonly used in the treatment of hyperlipidemia .", "tokens": ["Atorvastatin", "is", "the", "most", "potent", "of", "this", "class", "of", "agents", "currently", "available", "and", "is", "commonly", "used", "in", "the", "treatment", "of", "hyperlipidemia", "."], "event_mentions": [{"id": "12243603_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 18, "end": 19}, "arguments": [{"entity_id": "12243603_7_Ent1", "role": "Treatment", "text": "Atorvastatin", "start": 0, "end": 1}, {"entity_id": "12243603_7_Ent3", "role": "Treatment_Drug", "text": "Atorvastatin", "start": 0, "end": 1}, {"entity_id": "12243603_7_Ent0", "role": "Effect", "text": "most potent", "start": 3, "end": 5}, {"entity_id": "12243603_7_Ent2", "role": "Treatment_Disorder", "text": "hyperlipidemia", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "12243603_7_Ent1", "text": "Atorvastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12243603_7_Ent3", "text": "Atorvastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12243603_7_Ent0", "text": "most potent", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "12243603_7_Ent2", "text": "hyperlipidemia", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "12243603_8", "wnd_id": "12243603_8_1", "text": "Rhabdomyolysis resulting from the drug interaction between diltiazem and other HMG - CoA reductase inhibitors has been described in the literature .", "tokens": ["Rhabdomyolysis", "resulting", "from", "the", "drug", "interaction", "between", "diltiazem", "and", "other", "HMG", "-", "CoA", "reductase", "inhibitors", "has", "been", "described", "in", "the", "literature", "."], "event_mentions": [{"id": "12243603_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 1, "end": 2}, "arguments": [{"entity_id": "12243603_8_Ent0", "role": "Effect", "text": "Rhabdomyolysis", "start": 0, "end": 1}, {"entity_id": "12243603_8_Ent2", "role": "Treatment_Drug", "text": "diltiazem", "start": 7, "end": 8}, {"entity_id": "12243603_8_Ent4", "role": "Combination_Drug", "text": "diltiazem", "start": 7, "end": 8}, {"entity_id": "12243603_8_Ent1", "role": "Treatment", "text": "diltiazem and other HMG - CoA reductase inhibitors", "start": 7, "end": 15}, {"entity_id": "12243603_8_Ent3", "role": "Treatment_Drug", "text": "HMG - CoA reductase inhibitors", "start": 10, "end": 15}, {"entity_id": "12243603_8_Ent5", "role": "Combination_Drug", "text": "HMG - CoA reductase inhibitors", "start": 10, "end": 15}]}], "entity_mentions": [{"id": "12243603_8_Ent0", "text": "Rhabdomyolysis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12243603_8_Ent2", "text": "diltiazem", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12243603_8_Ent4", "text": "diltiazem", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12243603_8_Ent1", "text": "diltiazem and other HMG - CoA reductase inhibitors", "entity_type": "Entity", "start": 7, "end": 15}, {"id": "12243603_8_Ent3", "text": "HMG - CoA reductase inhibitors", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "12243603_8_Ent5", "text": "HMG - CoA reductase inhibitors", "entity_type": "Entity", "start": 10, "end": 15}], "lang": "en"}
{"doc_id": "12390172_3", "wnd_id": "12390172_3_1", "text": "Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin .", "tokens": ["Retinal", "dysfunction", "and", "anterior", "segment", "deposits", "in", "a", "patient", "treated", "with", "rifabutin", "."], "event_mentions": [{"id": "12390172_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 9, "end": 10}, "arguments": [{"entity_id": "12390172_3_Ent1", "role": "Effect", "text": "Retinal dysfunction and anterior segment deposits", "start": 0, "end": 6}, {"entity_id": "12390172_3_Ent0", "role": "Subject", "text": "patient", "start": 8, "end": 9}, {"entity_id": "12390172_3_Ent2", "role": "Treatment", "text": "rifabutin", "start": 11, "end": 12}, {"entity_id": "12390172_3_Ent3", "role": "Treatment_Drug", "text": "rifabutin", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "12390172_3_Ent1", "text": "Retinal dysfunction and anterior segment deposits", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "12390172_3_Ent0", "text": "patient", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12390172_3_Ent2", "text": "rifabutin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12390172_3_Ent3", "text": "rifabutin", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "12397859_1", "wnd_id": "12397859_1_1", "text": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone , an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme .", "tokens": ["A", "case", "is", "presented", "of", "a", "patient", "who", "experienced", "benzodiazepine", "withdrawal", "symptoms", "on", "discontinuation", "of", "nefazodone", ",", "an", "antidepressant", "that", "inhibits", "the", "cytochrome", "P450", "3A4", "isoenzyme", "."], "event_mentions": [{"id": "12397859_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "discontinuation", "start": 13, "end": 14}, "arguments": [{"entity_id": "12397859_1_Ent0", "role": "Subject", "text": "a patient", "start": 5, "end": 7}, {"entity_id": "12397859_1_Ent1", "role": "Effect", "text": "benzodiazepine withdrawal symptoms", "start": 9, "end": 12}, {"entity_id": "12397859_1_Ent2", "role": "Treatment", "text": "nefazodone", "start": 15, "end": 16}, {"entity_id": "12397859_1_Ent3", "role": "Treatment_Drug", "text": "nefazodone", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "12397859_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "12397859_1_Ent1", "text": "benzodiazepine withdrawal symptoms", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "12397859_1_Ent2", "text": "nefazodone", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12397859_1_Ent3", "text": "nefazodone", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "12399645_2", "wnd_id": "12399645_2_1", "text": "ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal , suggesting that bredinin might adversely induce SIADH .", "tokens": ["ADH", "hypersecretion", "in", "relation", "to", "plasma", "osmolality", "was", "reversed", "by", "mizoribin", "withdrawal", ",", "suggesting", "that", "bredinin", "might", "adversely", "induce", "SIADH", "."], "event_mentions": [{"id": "12399645_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "reversed", "start": 8, "end": 9}, "arguments": [{"entity_id": "12399645_2_Ent3", "role": "Treatment_Disorder", "text": "ADH hypersecretion", "start": 0, "end": 2}, {"entity_id": "12399645_2_Ent0", "role": "Subject", "text": "plasma osmolality", "start": 5, "end": 7}, {"entity_id": "12399645_2_Ent1", "role": "Subject_Disorder", "text": "plasma osmolality", "start": 5, "end": 7}, {"entity_id": "12399645_2_Ent4", "role": "Treatment_Drug", "text": "mizoribin", "start": 10, "end": 11}, {"entity_id": "12399645_2_Ent2", "role": "Treatment", "text": "mizoribin withdrawal", "start": 10, "end": 12}]}, {"id": "12399645_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 18, "end": 19}, "arguments": [{"entity_id": "12399645_2_Ent6", "role": "Treatment", "text": "bredinin", "start": 15, "end": 16}, {"entity_id": "12399645_2_Ent7", "role": "Treatment_Drug", "text": "bredinin", "start": 15, "end": 16}, {"entity_id": "12399645_2_Ent5", "role": "Effect", "text": "adversely induce SIADH", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "12399645_2_Ent3", "text": "ADH hypersecretion", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12399645_2_Ent0", "text": "plasma osmolality", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "12399645_2_Ent1", "text": "plasma osmolality", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "12399645_2_Ent4", "text": "mizoribin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12399645_2_Ent2", "text": "mizoribin withdrawal", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "12399645_2_Ent6", "text": "bredinin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12399645_2_Ent7", "text": "bredinin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12399645_2_Ent5", "text": "adversely induce SIADH", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "12452753_1", "wnd_id": "12452753_1_1", "text": "Capecitabine was discontinued and the allergic reactions resolved after the woman took diphenhydramine for 1 week .", "tokens": ["Capecitabine", "was", "discontinued", "and", "the", "allergic", "reactions", "resolved", "after", "the", "woman", "took", "diphenhydramine", "for", "1", "week", "."], "event_mentions": [{"id": "12452753_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "took", "start": 11, "end": 12}, "arguments": [{"entity_id": "12452753_1_Ent2", "role": "Effect", "text": "Capecitabine was discontinued and the allergic reactions resolved", "start": 0, "end": 8}, {"entity_id": "12452753_1_Ent0", "role": "Subject", "text": "woman", "start": 10, "end": 11}, {"entity_id": "12452753_1_Ent1", "role": "Subject_Gender", "text": "woman", "start": 10, "end": 11}, {"entity_id": "12452753_1_Ent4", "role": "Treatment_Drug", "text": "diphenhydramine", "start": 12, "end": 13}, {"entity_id": "12452753_1_Ent3", "role": "Treatment", "text": "diphenhydramine for 1 week", "start": 12, "end": 16}, {"entity_id": "12452753_1_Ent5", "role": "Treatment_Time_elapsed", "text": "1 week", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "12452753_1_Ent2", "text": "Capecitabine was discontinued and the allergic reactions resolved", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "12452753_1_Ent0", "text": "woman", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12452753_1_Ent1", "text": "woman", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12452753_1_Ent4", "text": "diphenhydramine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12452753_1_Ent3", "text": "diphenhydramine for 1 week", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "12452753_1_Ent5", "text": "1 week", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "12455453_1", "wnd_id": "12455453_1_1", "text": "After five and six weeks of continuous oral administration of methylprednisolone , the boys developed steroid diabetes .", "tokens": ["After", "five", "and", "six", "weeks", "of", "continuous", "oral", "administration", "of", "methylprednisolone", ",", "the", "boys", "developed", "steroid", "diabetes", "."], "event_mentions": [{"id": "12455453_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "12455453_1_Ent4", "role": "Treatment_Duration", "text": "After five and six weeks", "start": 0, "end": 5}, {"entity_id": "12455453_1_Ent3", "role": "Treatment", "text": "After five and six weeks of continuous oral administration of methylprednisolone", "start": 0, "end": 11}, {"entity_id": "12455453_1_Ent5", "role": "Treatment_Route", "text": "oral", "start": 7, "end": 8}, {"entity_id": "12455453_1_Ent6", "role": "Treatment_Drug", "text": "methylprednisolone", "start": 10, "end": 11}, {"entity_id": "12455453_1_Ent0", "role": "Subject", "text": "boys", "start": 13, "end": 14}, {"entity_id": "12455453_1_Ent1", "role": "Subject_Gender", "text": "boys", "start": 13, "end": 14}, {"entity_id": "12455453_1_Ent2", "role": "Effect", "text": "steroid diabetes", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "12455453_1_Ent4", "text": "After five and six weeks", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "12455453_1_Ent3", "text": "After five and six weeks of continuous oral administration of methylprednisolone", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "12455453_1_Ent5", "text": "oral", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12455453_1_Ent6", "text": "methylprednisolone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12455453_1_Ent0", "text": "boys", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12455453_1_Ent1", "text": "boys", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12455453_1_Ent2", "text": "steroid diabetes", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "12460237_2", "wnd_id": "12460237_2_1", "text": "Palmar - plantar erythrodysaesthesia ( PPE ) is an uncommon cutaneous complication of cytotoxic chemotherapy which generally presents as a painful erythema involving the palms and soles .", "tokens": ["Palmar", "-", "plantar", "erythrodysaesthesia", "(", "PPE", ")", "is", "an", "uncommon", "cutaneous", "complication", "of", "cytotoxic", "chemotherapy", "which", "generally", "presents", "as", "a", "painful", "erythema", "involving", "the", "palms", "and", "soles", "."], "event_mentions": [{"id": "12460237_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 11, "end": 12}, "arguments": [{"entity_id": "12460237_2_Ent0", "role": "Effect", "text": "Palmar - plantar erythrodysaesthesia ( PPE )", "start": 0, "end": 7}, {"entity_id": "12460237_2_Ent1", "role": "Effect", "text": "an uncommon cutaneous complication", "start": 8, "end": 12}, {"entity_id": "12460237_2_Ent4", "role": "Treatment_Drug", "text": "cytotoxic", "start": 13, "end": 14}, {"entity_id": "12460237_2_Ent3", "role": "Treatment", "text": "cytotoxic chemotherapy", "start": 13, "end": 15}, {"entity_id": "12460237_2_Ent5", "role": "Treatment_Route", "text": "chemotherapy", "start": 14, "end": 15}, {"entity_id": "12460237_2_Ent2", "role": "Effect", "text": "a painful erythema involving the palms and soles", "start": 19, "end": 27}]}], "entity_mentions": [{"id": "12460237_2_Ent0", "text": "Palmar - plantar erythrodysaesthesia ( PPE )", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12460237_2_Ent1", "text": "an uncommon cutaneous complication", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "12460237_2_Ent4", "text": "cytotoxic", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12460237_2_Ent3", "text": "cytotoxic chemotherapy", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "12460237_2_Ent5", "text": "chemotherapy", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "12460237_2_Ent2", "text": "a painful erythema involving the palms and soles", "entity_type": "Entity", "start": 19, "end": 27}], "lang": "en"}
{"doc_id": "12460237_5", "wnd_id": "12460237_5_1", "text": "Contrary to previous recommendations , our experience cautions against the further use of high - dose cytarabine in patients who develop PPE , and is a timely reminder of the potential toxicity of this agent , which is now increasingly being used as first - line treatment in the management of haematologic malignancies .", "tokens": ["Contrary", "to", "previous", "recommendations", ",", "our", "experience", "cautions", "against", "the", "further", "use", "of", "high", "-", "dose", "cytarabine", "in", "patients", "who", "develop", "PPE", ",", "and", "is", "a", "timely", "reminder", "of", "the", "potential", "toxicity", "of", "this", "agent", ",", "which", "is", "now", "increasingly", "being", "used", "as", "first", "-", "line", "treatment", "in", "the", "management", "of", "haematologic", "malignancies", "."], "event_mentions": [{"id": "12460237_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 31, "end": 32}, "arguments": [{"entity_id": "12460237_5_Ent2", "role": "Treatment_Dosage", "text": "high - dose", "start": 13, "end": 16}, {"entity_id": "12460237_5_Ent1", "role": "Treatment", "text": "high - dose cytarabine", "start": 13, "end": 17}, {"entity_id": "12460237_5_Ent3", "role": "Treatment_Drug", "text": "cytarabine", "start": 16, "end": 17}, {"entity_id": "12460237_5_Ent0", "role": "Effect", "text": "PPE", "start": 21, "end": 22}, {"entity_id": "12460237_5_Ent4", "role": "Treatment_Disorder", "text": "haematologic malignancies", "start": 51, "end": 53}]}], "entity_mentions": [{"id": "12460237_5_Ent2", "text": "high - dose", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "12460237_5_Ent1", "text": "high - dose cytarabine", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "12460237_5_Ent3", "text": "cytarabine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "12460237_5_Ent0", "text": "PPE", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "12460237_5_Ent4", "text": "haematologic malignancies", "entity_type": "Entity", "start": 51, "end": 53}], "lang": "en"}
{"doc_id": "12477460_4", "wnd_id": "12477460_4_1", "text": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer : a case report .", "tokens": ["Ovarian", "endometrioid", "adenocarcinoma", "arising", "from", "an", "endometriotic", "cyst", "in", "a", "postmenopausal", "woman", "under", "tamoxifen", "therapy", "for", "breast", "cancer", ":", "a", "case", "report", "."], "event_mentions": [{"id": "12477460_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "under", "start": 12, "end": 13}, "arguments": [{"entity_id": "12477460_4_Ent3", "role": "Effect", "text": "Ovarian endometrioid adenocarcinoma", "start": 0, "end": 3}, {"entity_id": "12477460_4_Ent0", "role": "Subject", "text": "a postmenopausal woman", "start": 9, "end": 12}, {"entity_id": "12477460_4_Ent1", "role": "Subject_Age", "text": "postmenopausal", "start": 10, "end": 11}, {"entity_id": "12477460_4_Ent2", "role": "Subject_Gender", "text": "woman", "start": 11, "end": 12}, {"entity_id": "12477460_4_Ent5", "role": "Treatment_Drug", "text": "tamoxifen", "start": 13, "end": 14}, {"entity_id": "12477460_4_Ent4", "role": "Treatment", "text": "tamoxifen therapy", "start": 13, "end": 15}, {"entity_id": "12477460_4_Ent6", "role": "Treatment_Disorder", "text": "breast cancer", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "12477460_4_Ent3", "text": "Ovarian endometrioid adenocarcinoma", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12477460_4_Ent0", "text": "a postmenopausal woman", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "12477460_4_Ent1", "text": "postmenopausal", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12477460_4_Ent2", "text": "woman", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12477460_4_Ent5", "text": "tamoxifen", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12477460_4_Ent4", "text": "tamoxifen therapy", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "12477460_4_Ent6", "text": "breast cancer", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "12503933_6", "wnd_id": "12503933_6_1", "text": "OBJECTIVE : To report a patient developing fulminant liver failure while being treated with clarithromycin for pneumonia .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "patient", "developing", "fulminant", "liver", "failure", "while", "being", "treated", "with", "clarithromycin", "for", "pneumonia", "."], "event_mentions": [{"id": "12503933_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 12, "end": 13}, "arguments": [{"entity_id": "12503933_6_Ent0", "role": "Subject", "text": "a patient", "start": 4, "end": 6}, {"entity_id": "12503933_6_Ent1", "role": "Effect", "text": "fulminant liver failure", "start": 7, "end": 10}, {"entity_id": "12503933_6_Ent2", "role": "Treatment", "text": "clarithromycin", "start": 14, "end": 15}, {"entity_id": "12503933_6_Ent3", "role": "Treatment_Drug", "text": "clarithromycin", "start": 14, "end": 15}, {"entity_id": "12503933_6_Ent4", "role": "Treatment_Disorder", "text": "pneumonia", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "12503933_6_Ent0", "text": "a patient", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "12503933_6_Ent1", "text": "fulminant liver failure", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "12503933_6_Ent2", "text": "clarithromycin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "12503933_6_Ent3", "text": "clarithromycin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "12503933_6_Ent4", "text": "pneumonia", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "12504711_2", "wnd_id": "12504711_2_1", "text": "CONCLUSION : Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow - up of patients on topical brimonidine .", "tokens": ["CONCLUSION", ":", "Under", "certain", "circumstances", "topical", "brimonidine", "can", "cause", "paradoxical", "raised", "IOP", "necessitating", "vigilance", "in", "follow", "-", "up", "of", "patients", "on", "topical", "brimonidine", "."], "event_mentions": [{"id": "12504711_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 8, "end": 9}, "arguments": [{"entity_id": "12504711_2_Ent3", "role": "Treatment_Route", "text": "topical", "start": 5, "end": 6}, {"entity_id": "12504711_2_Ent2", "role": "Treatment", "text": "topical brimonidine", "start": 5, "end": 7}, {"entity_id": "12504711_2_Ent4", "role": "Treatment_Drug", "text": "brimonidine", "start": 6, "end": 7}, {"entity_id": "12504711_2_Ent1", "role": "Effect", "text": "raised IOP", "start": 10, "end": 12}, {"entity_id": "12504711_2_Ent0", "role": "Subject", "text": "patients on topical brimonidine", "start": 19, "end": 23}]}], "entity_mentions": [{"id": "12504711_2_Ent3", "text": "topical", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12504711_2_Ent2", "text": "topical brimonidine", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "12504711_2_Ent4", "text": "brimonidine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12504711_2_Ent1", "text": "raised IOP", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "12504711_2_Ent0", "text": "patients on topical brimonidine", "entity_type": "Entity", "start": 19, "end": 23}], "lang": "en"}
{"doc_id": "12523465_1", "wnd_id": "12523465_1_1", "text": "Although visual hallucinations have not been reported as an adverse effect of this agent , we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased .", "tokens": ["Although", "visual", "hallucinations", "have", "not", "been", "reported", "as", "an", "adverse", "effect", "of", "this", "agent", ",", "we", "describe", "three", "patients", "who", "experienced", "complex", "visual", "hallucinations", "and", "altered", "mental", "status", "after", "zonisamide", "treatment", "was", "begun", "or", "its", "dosage", "increased", "."], "event_mentions": [{"id": "12523465_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 28, "end": 29}, "arguments": [{"entity_id": "12523465_1_Ent0", "role": "Effect", "text": "complex visual hallucinations and altered mental status", "start": 21, "end": 28}, {"entity_id": "12523465_1_Ent1", "role": "Treatment", "text": "zonisamide", "start": 29, "end": 30}, {"entity_id": "12523465_1_Ent2", "role": "Treatment_Drug", "text": "zonisamide", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "12523465_1_Ent0", "text": "complex visual hallucinations and altered mental status", "entity_type": "Entity", "start": 21, "end": 28}, {"id": "12523465_1_Ent1", "text": "zonisamide", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "12523465_1_Ent2", "text": "zonisamide", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "12581772_3", "wnd_id": "12581772_3_1", "text": "Rapamycin / sirolimus ( SR ) , trade named Rapammune ( Wyeth - Ayerst , Sydney , Australia ) , is a potent immunosuppressive drug associated with myelosuppression , hypertension , hyperlipidemia , and infection .", "tokens": ["Rapamycin", "/", "sirolimus", "(", "SR", ")", ",", "trade", "named", "Rapammune", "(", "Wyeth", "-", "Ayerst", ",", "Sydney", ",", "Australia", ")", ",", "is", "a", "potent", "immunosuppressive", "drug", "associated", "with", "myelosuppression", ",", "hypertension", ",", "hyperlipidemia", ",", "and", "infection", "."], "event_mentions": [{"id": "12581772_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 25, "end": 26}, "arguments": [{"entity_id": "12581772_3_Ent2", "role": "Treatment_Drug", "text": "Rapamycin / sirolimus", "start": 0, "end": 3}, {"entity_id": "12581772_3_Ent1", "role": "Treatment", "text": "Rapamycin / sirolimus ( SR ) , trade named Rapammune ( Wyeth - Ayerst , Sydney , Australia )", "start": 0, "end": 19}, {"entity_id": "12581772_3_Ent0", "role": "Effect", "text": "myelosuppression , hypertension , hyperlipidemia , and infection", "start": 27, "end": 35}]}], "entity_mentions": [{"id": "12581772_3_Ent2", "text": "Rapamycin / sirolimus", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12581772_3_Ent1", "text": "Rapamycin / sirolimus ( SR ) , trade named Rapammune ( Wyeth - Ayerst , Sydney , Australia )", "entity_type": "Entity", "start": 0, "end": 19}, {"id": "12581772_3_Ent0", "text": "myelosuppression , hypertension , hyperlipidemia , and infection", "entity_type": "Entity", "start": 27, "end": 35}], "lang": "en"}
{"doc_id": "12587815_1", "wnd_id": "12587815_1_1", "text": "A 16 - year - old boy developed fever , generalized rigidity , leukocytosis , and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and lithium .", "tokens": ["A", "16", "-", "year", "-", "old", "boy", "developed", "fever", ",", "generalized", "rigidity", ",", "leukocytosis", ",", "and", "increased", "serum", "transaminase", "and", "creatine", "kinase", "levels", "while", "receiving", "treatment", "with", "olanzapine", "and", "lithium", "."], "event_mentions": [{"id": "12587815_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "while", "start": 23, "end": 24}, "arguments": [{"entity_id": "12587815_1_Ent0", "role": "Subject", "text": "A 16 - year - old boy", "start": 0, "end": 7}, {"entity_id": "12587815_1_Ent1", "role": "Subject_Age", "text": "16 - year - old", "start": 1, "end": 6}, {"entity_id": "12587815_1_Ent2", "role": "Subject_Gender", "text": "boy", "start": 6, "end": 7}, {"entity_id": "12587815_1_Ent3", "role": "Effect", "text": "fever , generalized rigidity , leukocytosis , and increased serum transaminase and creatine kinase levels", "start": 8, "end": 23}, {"entity_id": "12587815_1_Ent5", "role": "Treatment_Drug", "text": "olanzapine", "start": 27, "end": 28}, {"entity_id": "12587815_1_Ent7", "role": "Combination_Drug", "text": "olanzapine", "start": 27, "end": 28}, {"entity_id": "12587815_1_Ent4", "role": "Treatment", "text": "olanzapine and lithium", "start": 27, "end": 30}, {"entity_id": "12587815_1_Ent6", "role": "Treatment_Drug", "text": "lithium", "start": 29, "end": 30}, {"entity_id": "12587815_1_Ent8", "role": "Combination_Drug", "text": "lithium", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "12587815_1_Ent0", "text": "A 16 - year - old boy", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12587815_1_Ent1", "text": "16 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "12587815_1_Ent2", "text": "boy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12587815_1_Ent3", "text": "fever , generalized rigidity , leukocytosis , and increased serum transaminase and creatine kinase levels", "entity_type": "Entity", "start": 8, "end": 23}, {"id": "12587815_1_Ent5", "text": "olanzapine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "12587815_1_Ent7", "text": "olanzapine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "12587815_1_Ent4", "text": "olanzapine and lithium", "entity_type": "Entity", "start": 27, "end": 30}, {"id": "12587815_1_Ent6", "text": "lithium", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "12587815_1_Ent8", "text": "lithium", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "12590235_1", "wnd_id": "12590235_1_1", "text": "Both 6 - MP and AZA are widely used and are known to cause hepatotoxicity in a proportion of patients .", "tokens": ["Both", "6", "-", "MP", "and", "AZA", "are", "widely", "used", "and", "are", "known", "to", "cause", "hepatotoxicity", "in", "a", "proportion", "of", "patients", "."], "event_mentions": [{"id": "12590235_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "used", "start": 8, "end": 9}, "arguments": [{"entity_id": "12590235_1_Ent4", "role": "Treatment_Drug", "text": "6 - MP", "start": 1, "end": 4}, {"entity_id": "12590235_1_Ent5", "role": "Combination_Drug", "text": "6 - MP", "start": 1, "end": 4}, {"entity_id": "12590235_1_Ent2", "role": "Treatment", "text": "6 - MP and AZA", "start": 1, "end": 6}, {"entity_id": "12590235_1_Ent3", "role": "Treatment_Drug", "text": "AZA", "start": 5, "end": 6}, {"entity_id": "12590235_1_Ent6", "role": "Combination_Drug", "text": "AZA", "start": 5, "end": 6}, {"entity_id": "12590235_1_Ent1", "role": "Effect", "text": "hepatotoxicity", "start": 14, "end": 15}, {"entity_id": "12590235_1_Ent0", "role": "Subject", "text": "a proportion of patients", "start": 16, "end": 20}]}], "entity_mentions": [{"id": "12590235_1_Ent4", "text": "6 - MP", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "12590235_1_Ent5", "text": "6 - MP", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "12590235_1_Ent2", "text": "6 - MP and AZA", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "12590235_1_Ent3", "text": "AZA", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12590235_1_Ent6", "text": "AZA", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12590235_1_Ent1", "text": "hepatotoxicity", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "12590235_1_Ent0", "text": "a proportion of patients", "entity_type": "Entity", "start": 16, "end": 20}], "lang": "en"}
{"doc_id": "12621956_1", "wnd_id": "12621956_1_1", "text": "The diagnosis of hypothermia was delayed until it was apparent for several days but resolved with the discontinuation of risperidone and continuation of clozapine .", "tokens": ["The", "diagnosis", "of", "hypothermia", "was", "delayed", "until", "it", "was", "apparent", "for", "several", "days", "but", "resolved", "with", "the", "discontinuation", "of", "risperidone", "and", "continuation", "of", "clozapine", "."], "event_mentions": [{"id": "12621956_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 14, "end": 15}, "arguments": [{"entity_id": "12621956_1_Ent3", "role": "Treatment_Disorder", "text": "hypothermia", "start": 3, "end": 4}, {"entity_id": "12621956_1_Ent0", "role": "Treatment", "text": "discontinuation of risperidone and continuation of clozapine", "start": 17, "end": 24}, {"entity_id": "12621956_1_Ent2", "role": "Treatment_Drug", "text": "risperidone", "start": 19, "end": 20}, {"entity_id": "12621956_1_Ent1", "role": "Treatment_Drug", "text": "clozapine", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "12621956_1_Ent3", "text": "hypothermia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12621956_1_Ent0", "text": "discontinuation of risperidone and continuation of clozapine", "entity_type": "Entity", "start": 17, "end": 24}, {"id": "12621956_1_Ent2", "text": "risperidone", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "12621956_1_Ent1", "text": "clozapine", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "12625995_2", "wnd_id": "12625995_2_1", "text": "Clozapine - induced akathisia in children with schizophrenia .", "tokens": ["Clozapine", "-", "induced", "akathisia", "in", "children", "with", "schizophrenia", "."], "event_mentions": [{"id": "12625995_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "12625995_2_Ent3", "role": "Treatment", "text": "Clozapine", "start": 0, "end": 1}, {"entity_id": "12625995_2_Ent4", "role": "Treatment_Drug", "text": "Clozapine", "start": 0, "end": 1}, {"entity_id": "12625995_2_Ent2", "role": "Effect", "text": "akathisia", "start": 3, "end": 4}, {"entity_id": "12625995_2_Ent1", "role": "Subject_Age", "text": "children", "start": 5, "end": 6}, {"entity_id": "12625995_2_Ent0", "role": "Subject", "text": "children with schizophrenia", "start": 5, "end": 8}, {"entity_id": "12625995_2_Ent5", "role": "Treatment_Disorder", "text": "schizophrenia", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "12625995_2_Ent3", "text": "Clozapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12625995_2_Ent4", "text": "Clozapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12625995_2_Ent2", "text": "akathisia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12625995_2_Ent1", "text": "children", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12625995_2_Ent0", "text": "children with schizophrenia", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "12625995_2_Ent5", "text": "schizophrenia", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "12635752_2", "wnd_id": "12635752_2_1", "text": "Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration : a case report .", "tokens": ["Successful", "treatment", "with", "carbimazole", "of", "a", "hyperthyroid", "pregnancy", "with", "hepatic", "impairment", "after", "propylthiouracil", "administration", ":", "a", "case", "report", "."], "event_mentions": [{"id": "12635752_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Successful treatment", "start": 0, "end": 2}, "arguments": [{"entity_id": "12635752_2_Ent0", "role": "Treatment", "text": "carbimazole", "start": 3, "end": 4}, {"entity_id": "12635752_2_Ent2", "role": "Treatment_Drug", "text": "carbimazole", "start": 3, "end": 4}, {"entity_id": "12635752_2_Ent1", "role": "Treatment_Disorder", "text": "a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration", "start": 5, "end": 14}]}, {"id": "12635752_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 11, "end": 12}, "arguments": [{"entity_id": "12635752_2_Ent3", "role": "Effect", "text": "a hyperthyroid pregnancy with hepatic impairment", "start": 5, "end": 11}, {"entity_id": "12635752_2_Ent4", "role": "Treatment", "text": "propylthiouracil", "start": 12, "end": 13}, {"entity_id": "12635752_2_Ent5", "role": "Treatment_Drug", "text": "propylthiouracil", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "12635752_2_Ent0", "text": "carbimazole", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12635752_2_Ent2", "text": "carbimazole", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12635752_2_Ent3", "text": "a hyperthyroid pregnancy with hepatic impairment", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "12635752_2_Ent1", "text": "a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration", "entity_type": "Entity", "start": 5, "end": 14}, {"id": "12635752_2_Ent4", "text": "propylthiouracil", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12635752_2_Ent5", "text": "propylthiouracil", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "12659609_9", "wnd_id": "12659609_9_1", "text": "Pharmacokinetic modeling suggested that the patient 's initial over - treatment was as reported and that the predicted maximum serum concentration of chloroquine ( 902 micro g / L ) was within the range seen in fatal chloroquine overdose .", "tokens": ["Pharmacokinetic", "modeling", "suggested", "that", "the", "patient", "'s", "initial", "over", "-", "treatment", "was", "as", "reported", "and", "that", "the", "predicted", "maximum", "serum", "concentration", "of", "chloroquine", "(", "902", "micro", "g", "/", "L", ")", "was", "within", "the", "range", "seen", "in", "fatal", "chloroquine", "overdose", "."], "event_mentions": [{"id": "12659609_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "over - treatment", "start": 8, "end": 11}, "arguments": [{"entity_id": "12659609_9_Ent0", "role": "Subject", "text": "the patient 's", "start": 4, "end": 7}, {"entity_id": "12659609_9_Ent3", "role": "Treatment_Drug", "text": "chloroquine", "start": 22, "end": 23}, {"entity_id": "12659609_9_Ent2", "role": "Treatment", "text": "chloroquine ( 902 micro g / L )", "start": 22, "end": 30}, {"entity_id": "12659609_9_Ent4", "role": "Treatment_Dosage", "text": "902 micro g / L", "start": 24, "end": 29}, {"entity_id": "12659609_9_Ent1", "role": "Effect", "text": "fatal", "start": 36, "end": 37}]}], "entity_mentions": [{"id": "12659609_9_Ent0", "text": "the patient 's", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "12659609_9_Ent3", "text": "chloroquine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "12659609_9_Ent2", "text": "chloroquine ( 902 micro g / L )", "entity_type": "Entity", "start": 22, "end": 30}, {"id": "12659609_9_Ent4", "text": "902 micro g / L", "entity_type": "Entity", "start": 24, "end": 29}, {"id": "12659609_9_Ent1", "text": "fatal", "entity_type": "Entity", "start": 36, "end": 37}], "lang": "en"}
{"doc_id": "12661801_2", "wnd_id": "12661801_2_1", "text": "Treatment of carbimazole - induced agranulocytosis and sepsis with granulocyte colony stimulating factor .", "tokens": ["Treatment", "of", "carbimazole", "-", "induced", "agranulocytosis", "and", "sepsis", "with", "granulocyte", "colony", "stimulating", "factor", "."], "event_mentions": [{"id": "12661801_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Treatment", "start": 0, "end": 1}, "arguments": [{"entity_id": "12661801_2_Ent1", "role": "Treatment_Disorder", "text": "carbimazole - induced agranulocytosis and sepsis", "start": 2, "end": 8}, {"entity_id": "12661801_2_Ent0", "role": "Treatment", "text": "granulocyte colony stimulating factor", "start": 9, "end": 13}, {"entity_id": "12661801_2_Ent2", "role": "Treatment_Drug", "text": "granulocyte colony stimulating factor", "start": 9, "end": 13}]}], "entity_mentions": [{"id": "12661801_2_Ent1", "text": "carbimazole - induced agranulocytosis and sepsis", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "12661801_2_Ent0", "text": "granulocyte colony stimulating factor", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "12661801_2_Ent2", "text": "granulocyte colony stimulating factor", "entity_type": "Entity", "start": 9, "end": 13}], "lang": "en"}
{"doc_id": "12699871_4", "wnd_id": "12699871_4_1", "text": "Tacrolimus ( FK506) - induced mutism after liver transplant .", "tokens": ["Tacrolimus", "(", "FK506)", "-", "induced", "mutism", "after", "liver", "transplant", "."], "event_mentions": [{"id": "12699871_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "12699871_4_Ent2", "role": "Treatment_Drug", "text": "Tacrolimus", "start": 0, "end": 1}, {"entity_id": "12699871_4_Ent1", "role": "Treatment", "text": "Tacrolimus ( FK506)", "start": 0, "end": 3}, {"entity_id": "12699871_4_Ent0", "role": "Effect", "text": "mutism", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "12699871_4_Ent2", "text": "Tacrolimus", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12699871_4_Ent1", "text": "Tacrolimus ( FK506)", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12699871_4_Ent0", "text": "mutism", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "12702914_1", "wnd_id": "12702914_1_1", "text": "Does the use of insulin in a patient with liver dysfunction increase water retention in the body , i.e. cause insulin oedema ?", "tokens": ["Does", "the", "use", "of", "insulin", "in", "a", "patient", "with", "liver", "dysfunction", "increase", "water", "retention", "in", "the", "body", ",", "i.e.", "cause", "insulin", "oedema", "?"], "event_mentions": [{"id": "12702914_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "use", "start": 2, "end": 3}, "arguments": [{"entity_id": "12702914_1_Ent2", "role": "Treatment", "text": "insulin", "start": 4, "end": 5}, {"entity_id": "12702914_1_Ent3", "role": "Treatment_Drug", "text": "insulin", "start": 4, "end": 5}, {"entity_id": "12702914_1_Ent0", "role": "Subject", "text": "a patient with liver dysfunction", "start": 6, "end": 11}, {"entity_id": "12702914_1_Ent4", "role": "Treatment_Disorder", "text": "liver dysfunction", "start": 9, "end": 11}, {"entity_id": "12702914_1_Ent1", "role": "Effect", "text": "increase water retention in the body , i.e. cause insulin oedema ?", "start": 11, "end": 23}]}], "entity_mentions": [{"id": "12702914_1_Ent2", "text": "insulin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12702914_1_Ent3", "text": "insulin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12702914_1_Ent0", "text": "a patient with liver dysfunction", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "12702914_1_Ent4", "text": "liver dysfunction", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "12702914_1_Ent1", "text": "increase water retention in the body , i.e. cause insulin oedema ?", "entity_type": "Entity", "start": 11, "end": 23}], "lang": "en"}
{"doc_id": "12707728_1", "wnd_id": "12707728_1_1", "text": "Intrathecal methotrexate - induced acute cerebellar syndrome .", "tokens": ["Intrathecal", "methotrexate", "-", "induced", "acute", "cerebellar", "syndrome", "."], "event_mentions": [{"id": "12707728_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "12707728_1_Ent1", "role": "Treatment", "text": "methotrexate", "start": 1, "end": 2}, {"entity_id": "12707728_1_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 1, "end": 2}, {"entity_id": "12707728_1_Ent0", "role": "Effect", "text": "acute cerebellar syndrome", "start": 4, "end": 7}]}], "entity_mentions": [{"id": "12707728_1_Ent1", "text": "methotrexate", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "12707728_1_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "12707728_1_Ent0", "text": "acute cerebellar syndrome", "entity_type": "Entity", "start": 4, "end": 7}], "lang": "en"}
{"doc_id": "12729371_2", "wnd_id": "12729371_2_1", "text": "We report a case of AILD in an 80 - year - old male who presented with a generalized pruritic maculopapular eruption and fever following doxycycline administration .", "tokens": ["We", "report", "a", "case", "of", "AILD", "in", "an", "80", "-", "year", "-", "old", "male", "who", "presented", "with", "a", "generalized", "pruritic", "maculopapular", "eruption", "and", "fever", "following", "doxycycline", "administration", "."], "event_mentions": [{"id": "12729371_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 15, "end": 16}, "arguments": [{"entity_id": "12729371_2_Ent0", "role": "Subject", "text": "a case of AILD in an 80 - year - old male", "start": 2, "end": 14}, {"entity_id": "12729371_2_Ent1", "role": "Subject_Disorder", "text": "AILD", "start": 5, "end": 6}, {"entity_id": "12729371_2_Ent2", "role": "Subject_Age", "text": "80 - year - old", "start": 8, "end": 13}, {"entity_id": "12729371_2_Ent3", "role": "Subject_Gender", "text": "male", "start": 13, "end": 14}, {"entity_id": "12729371_2_Ent4", "role": "Effect", "text": "generalized pruritic maculopapular eruption and fever", "start": 18, "end": 24}, {"entity_id": "12729371_2_Ent6", "role": "Treatment_Drug", "text": "doxycycline", "start": 25, "end": 26}, {"entity_id": "12729371_2_Ent5", "role": "Treatment", "text": "doxycycline administration", "start": 25, "end": 27}]}], "entity_mentions": [{"id": "12729371_2_Ent0", "text": "a case of AILD in an 80 - year - old male", "entity_type": "Entity", "start": 2, "end": 14}, {"id": "12729371_2_Ent1", "text": "AILD", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12729371_2_Ent2", "text": "80 - year - old", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "12729371_2_Ent3", "text": "male", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12729371_2_Ent4", "text": "generalized pruritic maculopapular eruption and fever", "entity_type": "Entity", "start": 18, "end": 24}, {"id": "12729371_2_Ent6", "text": "doxycycline", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "12729371_2_Ent5", "text": "doxycycline administration", "entity_type": "Entity", "start": 25, "end": 27}], "lang": "en"}
{"doc_id": "12757344_1", "wnd_id": "12757344_1_1", "text": "Carbamazepine - related hyponatremia following cardiopulmonary bypass .", "tokens": ["Carbamazepine", "-", "related", "hyponatremia", "following", "cardiopulmonary", "bypass", "."], "event_mentions": [{"id": "12757344_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 2, "end": 3}, "arguments": [{"entity_id": "12757344_1_Ent1", "role": "Treatment", "text": "Carbamazepine", "start": 0, "end": 1}, {"entity_id": "12757344_1_Ent2", "role": "Treatment_Drug", "text": "Carbamazepine", "start": 0, "end": 1}, {"entity_id": "12757344_1_Ent0", "role": "Effect", "text": "hyponatremia", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "12757344_1_Ent1", "text": "Carbamazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12757344_1_Ent2", "text": "Carbamazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12757344_1_Ent0", "text": "hyponatremia", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "12792223_3", "wnd_id": "12792223_3_1", "text": "Infliximab therapy may cause a lupus - like syndrome that is reversible upon discontinuing this agent .", "tokens": ["Infliximab", "therapy", "may", "cause", "a", "lupus", "-", "like", "syndrome", "that", "is", "reversible", "upon", "discontinuing", "this", "agent", "."], "event_mentions": [{"id": "12792223_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 3, "end": 4}, "arguments": [{"entity_id": "12792223_3_Ent2", "role": "Treatment_Drug", "text": "Infliximab", "start": 0, "end": 1}, {"entity_id": "12792223_3_Ent1", "role": "Treatment", "text": "Infliximab therapy", "start": 0, "end": 2}, {"entity_id": "12792223_3_Ent0", "role": "Effect", "text": "lupus - like syndrome", "start": 5, "end": 9}]}], "entity_mentions": [{"id": "12792223_3_Ent2", "text": "Infliximab", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12792223_3_Ent1", "text": "Infliximab therapy", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12792223_3_Ent0", "text": "lupus - like syndrome", "entity_type": "Entity", "start": 5, "end": 9}], "lang": "en"}
{"doc_id": "12792223_4", "wnd_id": "12792223_4_1", "text": "We report in detail an unusual adverse reaction to infliximab therapy , a drug - induced lupus - like clinical syndrome .", "tokens": ["We", "report", "in", "detail", "an", "unusual", "adverse", "reaction", "to", "infliximab", "therapy", ",", "a", "drug", "-", "induced", "lupus", "-", "like", "clinical", "syndrome", "."], "event_mentions": [{"id": "12792223_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 15, "end": 16}, "arguments": [{"entity_id": "12792223_4_Ent1", "role": "Treatment", "text": "infliximab", "start": 9, "end": 10}, {"entity_id": "12792223_4_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 9, "end": 10}, {"entity_id": "12792223_4_Ent0", "role": "Effect", "text": "lupus - like clinical syndrome", "start": 16, "end": 21}]}], "entity_mentions": [{"id": "12792223_4_Ent1", "text": "infliximab", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12792223_4_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12792223_4_Ent0", "text": "lupus - like clinical syndrome", "entity_type": "Entity", "start": 16, "end": 21}], "lang": "en"}
{"doc_id": "12796597_1", "wnd_id": "12796597_1_1", "text": "Chronic myelogenous leukemia ( CML ) , hepatitis C , and interferon alpha ( IFNalpha ) have all been associated with renal dysfunction .", "tokens": ["Chronic", "myelogenous", "leukemia", "(", "CML", ")", ",", "hepatitis", "C", ",", "and", "interferon", "alpha", "(", "IFNalpha", ")", "have", "all", "been", "associated", "with", "renal", "dysfunction", "."], "event_mentions": [{"id": "12796597_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 19, "end": 20}, "arguments": [{"entity_id": "12796597_1_Ent2", "role": "Treatment_Drug", "text": "interferon alpha", "start": 11, "end": 13}, {"entity_id": "12796597_1_Ent1", "role": "Treatment", "text": "interferon alpha ( IFNalpha )", "start": 11, "end": 16}, {"entity_id": "12796597_1_Ent0", "role": "Effect", "text": "renal dysfunction", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "12796597_1_Ent2", "text": "interferon alpha", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "12796597_1_Ent1", "text": "interferon alpha ( IFNalpha )", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "12796597_1_Ent0", "text": "renal dysfunction", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "12802933_3", "wnd_id": "12802933_3_1", "text": "We report the first case , to our knowledge , of rituximab - related autoimmune hemolytic anemia .", "tokens": ["We", "report", "the", "first", "case", ",", "to", "our", "knowledge", ",", "of", "rituximab", "-", "related", "autoimmune", "hemolytic", "anemia", "."], "event_mentions": [{"id": "12802933_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 13, "end": 14}, "arguments": [{"entity_id": "12802933_3_Ent1", "role": "Treatment", "text": "rituximab", "start": 11, "end": 12}, {"entity_id": "12802933_3_Ent2", "role": "Treatment_Drug", "text": "rituximab", "start": 11, "end": 12}, {"entity_id": "12802933_3_Ent0", "role": "Effect", "text": "autoimmune hemolytic anemia", "start": 14, "end": 17}]}], "entity_mentions": [{"id": "12802933_3_Ent1", "text": "rituximab", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12802933_3_Ent2", "text": "rituximab", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12802933_3_Ent0", "text": "autoimmune hemolytic anemia", "entity_type": "Entity", "start": 14, "end": 17}], "lang": "en"}
{"doc_id": "12811715_1", "wnd_id": "12811715_1_1", "text": "Although it would be expected that , like other type IA toxicities , diphenhydramine - induced cardiotoxicity could be responsive to hypertonic sodium bicarbonate , this finding is largely unappreciated .", "tokens": ["Although", "it", "would", "be", "expected", "that", ",", "like", "other", "type", "IA", "toxicities", ",", "diphenhydramine", "-", "induced", "cardiotoxicity", "could", "be", "responsive", "to", "hypertonic", "sodium", "bicarbonate", ",", "this", "finding", "is", "largely", "unappreciated", "."], "event_mentions": [{"id": "12811715_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 15, "end": 16}, "arguments": [{"entity_id": "12811715_1_Ent1", "role": "Treatment", "text": "diphenhydramine", "start": 13, "end": 14}, {"entity_id": "12811715_1_Ent2", "role": "Treatment_Drug", "text": "diphenhydramine", "start": 13, "end": 14}, {"entity_id": "12811715_1_Ent0", "role": "Effect", "text": "cardiotoxicity", "start": 16, "end": 17}]}, {"id": "12811715_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "responsive", "start": 19, "end": 20}, "arguments": [{"entity_id": "12811715_1_Ent4", "role": "Treatment_Disorder", "text": "diphenhydramine - induced cardiotoxicity", "start": 13, "end": 17}, {"entity_id": "12811715_1_Ent3", "role": "Treatment", "text": "hypertonic sodium bicarbonate", "start": 21, "end": 24}, {"entity_id": "12811715_1_Ent5", "role": "Treatment_Drug", "text": "hypertonic sodium bicarbonate", "start": 21, "end": 24}]}], "entity_mentions": [{"id": "12811715_1_Ent1", "text": "diphenhydramine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12811715_1_Ent2", "text": "diphenhydramine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12811715_1_Ent4", "text": "diphenhydramine - induced cardiotoxicity", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "12811715_1_Ent0", "text": "cardiotoxicity", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "12811715_1_Ent3", "text": "hypertonic sodium bicarbonate", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "12811715_1_Ent5", "text": "hypertonic sodium bicarbonate", "entity_type": "Entity", "start": 21, "end": 24}], "lang": "en"}
{"doc_id": "12823045_1", "wnd_id": "12823045_1_1", "text": "We describe a patient with extranodal non - Hodgkin lymphoma who developed systemic candidiasis after treatment with a cyclophosphamide - based chemotherapy regimen .", "tokens": ["We", "describe", "a", "patient", "with", "extranodal", "non", "-", "Hodgkin", "lymphoma", "who", "developed", "systemic", "candidiasis", "after", "treatment", "with", "a", "cyclophosphamide", "-", "based", "chemotherapy", "regimen", "."], "event_mentions": [{"id": "12823045_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treatment", "start": 15, "end": 16}, "arguments": [{"entity_id": "12823045_1_Ent0", "role": "Subject", "text": "a patient with extranodal non - Hodgkin lymphoma", "start": 2, "end": 10}, {"entity_id": "12823045_1_Ent3", "role": "Treatment_Disorder", "text": "extranodal non - Hodgkin lymphoma", "start": 5, "end": 10}, {"entity_id": "12823045_1_Ent1", "role": "Effect", "text": "systemic candidiasis", "start": 12, "end": 14}, {"entity_id": "12823045_1_Ent2", "role": "Treatment", "text": "a cyclophosphamide - based chemotherapy regimen .", "start": 17, "end": 24}, {"entity_id": "12823045_1_Ent4", "role": "Treatment_Drug", "text": "cyclophosphamide - based chemotherapy", "start": 18, "end": 22}]}], "entity_mentions": [{"id": "12823045_1_Ent0", "text": "a patient with extranodal non - Hodgkin lymphoma", "entity_type": "Entity", "start": 2, "end": 10}, {"id": "12823045_1_Ent3", "text": "extranodal non - Hodgkin lymphoma", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "12823045_1_Ent1", "text": "systemic candidiasis", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "12823045_1_Ent2", "text": "a cyclophosphamide - based chemotherapy regimen .", "entity_type": "Entity", "start": 17, "end": 24}, {"id": "12823045_1_Ent4", "text": "cyclophosphamide - based chemotherapy", "entity_type": "Entity", "start": 18, "end": 22}], "lang": "en"}
{"doc_id": "12847760_1", "wnd_id": "12847760_1_1", "text": "A 25 - year - old man with a history of mid - borderline ( BB ) Hansen 's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented .", "tokens": ["A", "25", "-", "year", "-", "old", "man", "with", "a", "history", "of", "mid", "-", "borderline", "(", "BB", ")", "Hansen", "'s", "disease", "developing", "a", "reversal", "reaction", "after", "starting", "dapsone", "and", "rifampin", "therapy", "is", "presented", "."], "event_mentions": [{"id": "12847760_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 24, "end": 25}, "arguments": [{"entity_id": "12847760_1_Ent0", "role": "Subject", "text": "A 25 - year - old man with a history of mid - borderline ( BB ) Hansen 's disease", "start": 0, "end": 20}, {"entity_id": "12847760_1_Ent1", "role": "Subject_Age", "text": "25 - year - old", "start": 1, "end": 6}, {"entity_id": "12847760_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "12847760_1_Ent3", "role": "Subject_Disorder", "text": "mid - borderline ( BB ) Hansen 's disease", "start": 11, "end": 20}, {"entity_id": "12847760_1_Ent4", "role": "Effect", "text": "a reversal reaction", "start": 21, "end": 24}, {"entity_id": "12847760_1_Ent6", "role": "Treatment_Drug", "text": "dapsone", "start": 26, "end": 27}, {"entity_id": "12847760_1_Ent8", "role": "Combination_Drug", "text": "dapsone", "start": 26, "end": 27}, {"entity_id": "12847760_1_Ent5", "role": "Treatment", "text": "dapsone and rifampin therapy", "start": 26, "end": 30}, {"entity_id": "12847760_1_Ent7", "role": "Treatment_Drug", "text": "rifampin", "start": 28, "end": 29}, {"entity_id": "12847760_1_Ent9", "role": "Combination_Drug", "text": "rifampin", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "12847760_1_Ent0", "text": "A 25 - year - old man with a history of mid - borderline ( BB ) Hansen 's disease", "entity_type": "Entity", "start": 0, "end": 20}, {"id": "12847760_1_Ent1", "text": "25 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "12847760_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12847760_1_Ent3", "text": "mid - borderline ( BB ) Hansen 's disease", "entity_type": "Entity", "start": 11, "end": 20}, {"id": "12847760_1_Ent4", "text": "a reversal reaction", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "12847760_1_Ent6", "text": "dapsone", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "12847760_1_Ent8", "text": "dapsone", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "12847760_1_Ent5", "text": "dapsone and rifampin therapy", "entity_type": "Entity", "start": 26, "end": 30}, {"id": "12847760_1_Ent7", "text": "rifampin", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "12847760_1_Ent9", "text": "rifampin", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "12854039_1", "wnd_id": "12854039_1_1", "text": "After a two - month interruption of interferon administration , natural interferon alpha was given but followed by another episode of the same neurological manifestations .", "tokens": ["After", "a", "two", "-", "month", "interruption", "of", "interferon", "administration", ",", "natural", "interferon", "alpha", "was", "given", "but", "followed", "by", "another", "episode", "of", "the", "same", "neurological", "manifestations", "."], "event_mentions": [{"id": "12854039_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "followed by", "start": 16, "end": 18}, "arguments": [{"entity_id": "12854039_1_Ent1", "role": "Treatment", "text": "interferon alpha", "start": 11, "end": 13}, {"entity_id": "12854039_1_Ent2", "role": "Treatment_Drug", "text": "interferon alpha", "start": 11, "end": 13}, {"entity_id": "12854039_1_Ent0", "role": "Effect", "text": "neurological manifestations", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "12854039_1_Ent1", "text": "interferon alpha", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "12854039_1_Ent2", "text": "interferon alpha", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "12854039_1_Ent0", "text": "neurological manifestations", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "12854039_5", "wnd_id": "12854039_5_1", "text": "Multiple sclerosis - like disease secondary to alpha interferon .", "tokens": ["Multiple", "sclerosis", "-", "like", "disease", "secondary", "to", "alpha", "interferon", "."], "event_mentions": [{"id": "12854039_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 5, "end": 6}, "arguments": [{"entity_id": "12854039_5_Ent0", "role": "Effect", "text": "Multiple sclerosis - like disease", "start": 0, "end": 5}, {"entity_id": "12854039_5_Ent1", "role": "Treatment", "text": "alpha interferon", "start": 7, "end": 9}, {"entity_id": "12854039_5_Ent2", "role": "Treatment_Drug", "text": "alpha interferon", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "12854039_5_Ent0", "text": "Multiple sclerosis - like disease", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "12854039_5_Ent1", "text": "alpha interferon", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "12854039_5_Ent2", "text": "alpha interferon", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "12875956_1", "wnd_id": "12875956_1_1", "text": "Acute psychosis associated with levetiracetam .", "tokens": ["Acute", "psychosis", "associated", "with", "levetiracetam", "."], "event_mentions": [{"id": "12875956_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "12875956_1_Ent0", "role": "Effect", "text": "Acute psychosis", "start": 0, "end": 2}, {"entity_id": "12875956_1_Ent1", "role": "Treatment", "text": "levetiracetam", "start": 4, "end": 5}, {"entity_id": "12875956_1_Ent2", "role": "Treatment_Drug", "text": "levetiracetam", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "12875956_1_Ent0", "text": "Acute psychosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12875956_1_Ent1", "text": "levetiracetam", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12875956_1_Ent2", "text": "levetiracetam", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "12885108_1", "wnd_id": "12885108_1_1", "text": "Possible heart failure exacerbation associated with rosiglitazone : case report and literature review .", "tokens": ["Possible", "heart", "failure", "exacerbation", "associated", "with", "rosiglitazone", ":", "case", "report", "and", "literature", "review", "."], "event_mentions": [{"id": "12885108_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "12885108_1_Ent0", "role": "Effect", "text": "heart failure exacerbation", "start": 1, "end": 4}, {"entity_id": "12885108_1_Ent1", "role": "Treatment", "text": "rosiglitazone", "start": 6, "end": 7}, {"entity_id": "12885108_1_Ent2", "role": "Treatment_Drug", "text": "rosiglitazone", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "12885108_1_Ent0", "text": "heart failure exacerbation", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "12885108_1_Ent1", "text": "rosiglitazone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12885108_1_Ent2", "text": "rosiglitazone", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "12889716_2", "wnd_id": "12889716_2_1", "text": "Only one case of a generalized maculopapular rash with enoxaparin has been reported in Europe .", "tokens": ["Only", "one", "case", "of", "a", "generalized", "maculopapular", "rash", "with", "enoxaparin", "has", "been", "reported", "in", "Europe", "."], "event_mentions": [{"id": "12889716_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 8, "end": 9}, "arguments": [{"entity_id": "12889716_2_Ent1", "role": "Subject_Population", "text": "one", "start": 1, "end": 2}, {"entity_id": "12889716_2_Ent0", "role": "Subject", "text": "one case", "start": 1, "end": 3}, {"entity_id": "12889716_2_Ent2", "role": "Effect", "text": "generalized maculopapular rash", "start": 5, "end": 8}, {"entity_id": "12889716_2_Ent3", "role": "Treatment", "text": "enoxaparin", "start": 9, "end": 10}, {"entity_id": "12889716_2_Ent4", "role": "Treatment_Drug", "text": "enoxaparin", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "12889716_2_Ent1", "text": "one", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "12889716_2_Ent0", "text": "one case", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "12889716_2_Ent2", "text": "generalized maculopapular rash", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "12889716_2_Ent3", "text": "enoxaparin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12889716_2_Ent4", "text": "enoxaparin", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "12921505_4", "wnd_id": "12921505_4_1", "text": "OBJECTIVE : To report a case of significant hepatic and renal failure with the use of argatroban in a patient with heparin - induced thrombocytopenia ( HIT ) requiring continuous veno - veno hemodialysis ( CVVHD ) .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "significant", "hepatic", "and", "renal", "failure", "with", "the", "use", "of", "argatroban", "in", "a", "patient", "with", "heparin", "-", "induced", "thrombocytopenia", "(", "HIT", ")", "requiring", "continuous", "veno", "-", "veno", "hemodialysis", "(", "CVVHD", ")", "."], "event_mentions": [{"id": "12921505_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "use", "start": 14, "end": 15}, "arguments": [{"entity_id": "12921505_4_Ent2", "role": "Effect", "text": "significant hepatic and renal failure", "start": 7, "end": 12}, {"entity_id": "12921505_4_Ent3", "role": "Treatment", "text": "argatroban", "start": 16, "end": 17}, {"entity_id": "12921505_4_Ent4", "role": "Treatment_Drug", "text": "argatroban", "start": 16, "end": 17}, {"entity_id": "12921505_4_Ent0", "role": "Subject", "text": "a patient with heparin - induced thrombocytopenia ( HIT ) requiring continuous veno - veno hemodialysis ( CVVHD )", "start": 18, "end": 37}, {"entity_id": "12921505_4_Ent1", "role": "Subject_Disorder", "text": "heparin - induced thrombocytopenia ( HIT )", "start": 21, "end": 28}]}, {"id": "12921505_4_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 23, "end": 24}, "arguments": [{"entity_id": "12921505_4_Ent6", "role": "Treatment", "text": "heparin", "start": 21, "end": 22}, {"entity_id": "12921505_4_Ent7", "role": "Treatment_Drug", "text": "heparin", "start": 21, "end": 22}, {"entity_id": "12921505_4_Ent5", "role": "Effect", "text": "thrombocytopenia", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "12921505_4_Ent2", "text": "significant hepatic and renal failure", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "12921505_4_Ent3", "text": "argatroban", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "12921505_4_Ent4", "text": "argatroban", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "12921505_4_Ent0", "text": "a patient with heparin - induced thrombocytopenia ( HIT ) requiring continuous veno - veno hemodialysis ( CVVHD )", "entity_type": "Entity", "start": 18, "end": 37}, {"id": "12921505_4_Ent6", "text": "heparin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "12921505_4_Ent7", "text": "heparin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "12921505_4_Ent1", "text": "heparin - induced thrombocytopenia ( HIT )", "entity_type": "Entity", "start": 21, "end": 28}, {"id": "12921505_4_Ent5", "text": "thrombocytopenia", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "12923827_3", "wnd_id": "12923827_3_1", "text": "This communication describes a patient who developed Schneiderian first - rank symptoms in the course of treatment with fluvoxamine .", "tokens": ["This", "communication", "describes", "a", "patient", "who", "developed", "Schneiderian", "first", "-", "rank", "symptoms", "in", "the", "course", "of", "treatment", "with", "fluvoxamine", "."], "event_mentions": [{"id": "12923827_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "12923827_3_Ent0", "role": "Subject", "text": "a patient", "start": 3, "end": 5}, {"entity_id": "12923827_3_Ent1", "role": "Effect", "text": "Schneiderian first - rank symptoms", "start": 7, "end": 12}, {"entity_id": "12923827_3_Ent2", "role": "Treatment", "text": "fluvoxamine", "start": 18, "end": 19}, {"entity_id": "12923827_3_Ent3", "role": "Treatment_Drug", "text": "fluvoxamine", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "12923827_3_Ent0", "text": "a patient", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "12923827_3_Ent1", "text": "Schneiderian first - rank symptoms", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "12923827_3_Ent2", "text": "fluvoxamine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "12923827_3_Ent3", "text": "fluvoxamine", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "12923827_4", "wnd_id": "12923827_4_1", "text": "This finding suggests that fluvoxamine can precipitate Schneiderian first - rank symptoms in some susceptible patients .", "tokens": ["This", "finding", "suggests", "that", "fluvoxamine", "can", "precipitate", "Schneiderian", "first", "-", "rank", "symptoms", "in", "some", "susceptible", "patients", "."], "event_mentions": [{"id": "12923827_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "precipitate", "start": 6, "end": 7}, "arguments": [{"entity_id": "12923827_4_Ent2", "role": "Treatment", "text": "fluvoxamine", "start": 4, "end": 5}, {"entity_id": "12923827_4_Ent3", "role": "Treatment_Drug", "text": "fluvoxamine", "start": 4, "end": 5}, {"entity_id": "12923827_4_Ent1", "role": "Effect", "text": "Schneiderian first - rank symptoms", "start": 7, "end": 12}, {"entity_id": "12923827_4_Ent0", "role": "Subject", "text": "some susceptible patients", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "12923827_4_Ent2", "text": "fluvoxamine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12923827_4_Ent3", "text": "fluvoxamine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12923827_4_Ent1", "text": "Schneiderian first - rank symptoms", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "12923827_4_Ent0", "text": "some susceptible patients", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "12944250_1", "wnd_id": "12944250_1_1", "text": "It is concluded that simultaneous administration of ciprofloxacin and tazobactam / piperacillin may cause marked thrombocytosis .", "tokens": ["It", "is", "concluded", "that", "simultaneous", "administration", "of", "ciprofloxacin", "and", "tazobactam", "/", "piperacillin", "may", "cause", "marked", "thrombocytosis", "."], "event_mentions": [{"id": "12944250_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 13, "end": 14}, "arguments": [{"entity_id": "12944250_1_Ent1", "role": "Treatment", "text": "simultaneous administration of ciprofloxacin and tazobactam / piperacillin", "start": 4, "end": 12}, {"entity_id": "12944250_1_Ent2", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 7, "end": 8}, {"entity_id": "12944250_1_Ent4", "role": "Combination_Drug", "text": "ciprofloxacin", "start": 7, "end": 8}, {"entity_id": "12944250_1_Ent3", "role": "Treatment_Drug", "text": "tazobactam / piperacillin", "start": 9, "end": 12}, {"entity_id": "12944250_1_Ent5", "role": "Combination_Drug", "text": "tazobactam / piperacillin", "start": 9, "end": 12}, {"entity_id": "12944250_1_Ent0", "role": "Effect", "text": "marked thrombocytosis", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "12944250_1_Ent1", "text": "simultaneous administration of ciprofloxacin and tazobactam / piperacillin", "entity_type": "Entity", "start": 4, "end": 12}, {"id": "12944250_1_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12944250_1_Ent4", "text": "ciprofloxacin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12944250_1_Ent3", "text": "tazobactam / piperacillin", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "12944250_1_Ent5", "text": "tazobactam / piperacillin", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "12944250_1_Ent0", "text": "marked thrombocytosis", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "12951892_1", "wnd_id": "12951892_1_1", "text": "Lethargy in a newborn : lithium toxicity or lab error ?", "tokens": ["Lethargy", "in", "a", "newborn", ":", "lithium", "toxicity", "or", "lab", "error", "?"], "event_mentions": [{"id": "12951892_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 6, "end": 7}, "arguments": [{"entity_id": "12951892_1_Ent2", "role": "Effect", "text": "Lethargy", "start": 0, "end": 1}, {"entity_id": "12951892_1_Ent0", "role": "Subject", "text": "a newborn", "start": 2, "end": 4}, {"entity_id": "12951892_1_Ent1", "role": "Subject_Age", "text": "newborn", "start": 3, "end": 4}, {"entity_id": "12951892_1_Ent3", "role": "Treatment", "text": "lithium", "start": 5, "end": 6}, {"entity_id": "12951892_1_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "12951892_1_Ent2", "text": "Lethargy", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12951892_1_Ent0", "text": "a newborn", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "12951892_1_Ent1", "text": "newborn", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12951892_1_Ent3", "text": "lithium", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12951892_1_Ent4", "text": "lithium", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "12951892_2", "wnd_id": "12951892_2_1", "text": "The newborn manifested a four day course of lethargy with unexplained high lithium levels in the adult toxic range .", "tokens": ["The", "newborn", "manifested", "a", "four", "day", "course", "of", "lethargy", "with", "unexplained", "high", "lithium", "levels", "in", "the", "adult", "toxic", "range", "."], "event_mentions": [{"id": "12951892_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "manifested", "start": 2, "end": 3}, "arguments": [{"entity_id": "12951892_2_Ent0", "role": "Subject", "text": "newborn", "start": 1, "end": 2}, {"entity_id": "12951892_2_Ent1", "role": "Subject_Age", "text": "newborn", "start": 1, "end": 2}, {"entity_id": "12951892_2_Ent2", "role": "Effect", "text": "four day course of lethargy with unexplained high lithium levels", "start": 4, "end": 14}, {"entity_id": "12951892_2_Ent3", "role": "Treatment", "text": "lithium", "start": 12, "end": 13}, {"entity_id": "12951892_2_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "12951892_2_Ent0", "text": "newborn", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "12951892_2_Ent1", "text": "newborn", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "12951892_2_Ent2", "text": "four day course of lethargy with unexplained high lithium levels", "entity_type": "Entity", "start": 4, "end": 14}, {"id": "12951892_2_Ent3", "text": "lithium", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12951892_2_Ent4", "text": "lithium", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "1295628_3", "wnd_id": "1295628_3_1", "text": "Clinical symptoms and leukopenia normalized after discontinuation of CBZ and administration of prednisolone at 40 mg .", "tokens": ["Clinical", "symptoms", "and", "leukopenia", "normalized", "after", "discontinuation", "of", "CBZ", "and", "administration", "of", "prednisolone", "at", "40", "mg", "."], "event_mentions": [{"id": "1295628_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "normalized", "start": 4, "end": 5}, "arguments": [{"entity_id": "1295628_3_Ent0", "role": "Effect", "text": "Clinical symptoms and leukopenia normalized", "start": 0, "end": 5}, {"entity_id": "1295628_3_Ent1", "role": "Treatment", "text": "discontinuation of CBZ and administration of prednisolone at 40 mg", "start": 6, "end": 16}, {"entity_id": "1295628_3_Ent2", "role": "Treatment_Drug", "text": "CBZ", "start": 8, "end": 9}, {"entity_id": "1295628_3_Ent5", "role": "Combination_Drug", "text": "CBZ", "start": 8, "end": 9}, {"entity_id": "1295628_3_Ent3", "role": "Treatment_Drug", "text": "prednisolone", "start": 12, "end": 13}, {"entity_id": "1295628_3_Ent6", "role": "Combination_Drug", "text": "prednisolone", "start": 12, "end": 13}, {"entity_id": "1295628_3_Ent4", "role": "Treatment_Dosage", "text": "40 mg", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "1295628_3_Ent0", "text": "Clinical symptoms and leukopenia normalized", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "1295628_3_Ent1", "text": "discontinuation of CBZ and administration of prednisolone at 40 mg", "entity_type": "Entity", "start": 6, "end": 16}, {"id": "1295628_3_Ent2", "text": "CBZ", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1295628_3_Ent5", "text": "CBZ", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1295628_3_Ent3", "text": "prednisolone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1295628_3_Ent6", "text": "prednisolone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1295628_3_Ent4", "text": "40 mg", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "1348483_2", "wnd_id": "1348483_2_1", "text": "Pleuropulmonary changes during treatment of Parkinson 's disease with a long - acting ergot derivative , cabergoline .", "tokens": ["Pleuropulmonary", "changes", "during", "treatment", "of", "Parkinson", "'s", "disease", "with", "a", "long", "-", "acting", "ergot", "derivative", ",", "cabergoline", "."], "event_mentions": [{"id": "1348483_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 2, "end": 3}, "arguments": [{"entity_id": "1348483_2_Ent0", "role": "Effect", "text": "Pleuropulmonary changes", "start": 0, "end": 2}, {"entity_id": "1348483_2_Ent2", "role": "Treatment_Disorder", "text": "Parkinson 's disease", "start": 5, "end": 8}, {"entity_id": "1348483_2_Ent1", "role": "Treatment", "text": "cabergoline", "start": 16, "end": 17}, {"entity_id": "1348483_2_Ent3", "role": "Treatment_Drug", "text": "cabergoline", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "1348483_2_Ent0", "text": "Pleuropulmonary changes", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1348483_2_Ent2", "text": "Parkinson 's disease", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "1348483_2_Ent1", "text": "cabergoline", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "1348483_2_Ent3", "text": "cabergoline", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "1356045_2", "wnd_id": "1356045_2_1", "text": "Flaccid quadriparesis was noted after discontinuation of vecuronium .", "tokens": ["Flaccid", "quadriparesis", "was", "noted", "after", "discontinuation", "of", "vecuronium", "."], "event_mentions": [{"id": "1356045_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "noted", "start": 3, "end": 4}, "arguments": [{"entity_id": "1356045_2_Ent0", "role": "Effect", "text": "Flaccid quadriparesis", "start": 0, "end": 2}, {"entity_id": "1356045_2_Ent1", "role": "Treatment", "text": "vecuronium", "start": 7, "end": 8}, {"entity_id": "1356045_2_Ent2", "role": "Treatment_Drug", "text": "vecuronium", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "1356045_2_Ent0", "text": "Flaccid quadriparesis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1356045_2_Ent1", "text": "vecuronium", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1356045_2_Ent2", "text": "vecuronium", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "1359782_1", "wnd_id": "1359782_1_1", "text": "A patient with ulcerative colitis developed skin pigmentation and diffuse pulmonary shadowing without respiratory symptomatology , while taking sulfasalazine .", "tokens": ["A", "patient", "with", "ulcerative", "colitis", "developed", "skin", "pigmentation", "and", "diffuse", "pulmonary", "shadowing", "without", "respiratory", "symptomatology", ",", "while", "taking", "sulfasalazine", "."], "event_mentions": [{"id": "1359782_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "1359782_1_Ent0", "role": "Subject", "text": "A patient with ulcerative colitis", "start": 0, "end": 5}, {"entity_id": "1359782_1_Ent4", "role": "Treatment_Disorder", "text": "ulcerative colitis", "start": 3, "end": 5}, {"entity_id": "1359782_1_Ent1", "role": "Effect", "text": "skin pigmentation and diffuse pulmonary shadowing without respiratory symptomatology", "start": 6, "end": 15}, {"entity_id": "1359782_1_Ent2", "role": "Treatment", "text": "sulfasalazine", "start": 18, "end": 19}, {"entity_id": "1359782_1_Ent3", "role": "Treatment_Drug", "text": "sulfasalazine", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "1359782_1_Ent0", "text": "A patient with ulcerative colitis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "1359782_1_Ent4", "text": "ulcerative colitis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "1359782_1_Ent1", "text": "skin pigmentation and diffuse pulmonary shadowing without respiratory symptomatology", "entity_type": "Entity", "start": 6, "end": 15}, {"id": "1359782_1_Ent2", "text": "sulfasalazine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "1359782_1_Ent3", "text": "sulfasalazine", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "13680140_1", "wnd_id": "13680140_1_1", "text": "Reversible sclerotic changes of lumbar spine and femur due to long - term oral isotretinoin therapy .", "tokens": ["Reversible", "sclerotic", "changes", "of", "lumbar", "spine", "and", "femur", "due", "to", "long", "-", "term", "oral", "isotretinoin", "therapy", "."], "event_mentions": [{"id": "13680140_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 8, "end": 9}, "arguments": [{"entity_id": "13680140_1_Ent0", "role": "Effect", "text": "Reversible sclerotic changes of lumbar spine and femur", "start": 0, "end": 8}, {"entity_id": "13680140_1_Ent4", "role": "Treatment_Duration", "text": "long - term", "start": 10, "end": 13}, {"entity_id": "13680140_1_Ent1", "role": "Treatment", "text": "long - term oral isotretinoin", "start": 10, "end": 15}, {"entity_id": "13680140_1_Ent3", "role": "Treatment_Route", "text": "oral", "start": 13, "end": 14}, {"entity_id": "13680140_1_Ent2", "role": "Treatment_Drug", "text": "isotretinoin", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "13680140_1_Ent0", "text": "Reversible sclerotic changes of lumbar spine and femur", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "13680140_1_Ent4", "text": "long - term", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "13680140_1_Ent1", "text": "long - term oral isotretinoin", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "13680140_1_Ent3", "text": "oral", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "13680140_1_Ent2", "text": "isotretinoin", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "1389744_1", "wnd_id": "1389744_1_1", "text": "A patient presented with dilated cardiomyopathy after many years of overusing an adrenaline inhaler .", "tokens": ["A", "patient", "presented", "with", "dilated", "cardiomyopathy", "after", "many", "years", "of", "overusing", "an", "adrenaline", "inhaler", "."], "event_mentions": [{"id": "1389744_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 6, "end": 7}, "arguments": [{"entity_id": "1389744_1_Ent0", "role": "Subject", "text": "A patient", "start": 0, "end": 2}, {"entity_id": "1389744_1_Ent1", "role": "Effect", "text": "dilated cardiomyopathy", "start": 4, "end": 6}, {"entity_id": "1389744_1_Ent2", "role": "Treatment", "text": "many years of overusing an adrenaline inhaler", "start": 7, "end": 14}, {"entity_id": "1389744_1_Ent3", "role": "Treatment_Dosage", "text": "overusing", "start": 10, "end": 11}, {"entity_id": "1389744_1_Ent4", "role": "Treatment_Drug", "text": "adrenaline", "start": 12, "end": 13}, {"entity_id": "1389744_1_Ent5", "role": "Treatment_Route", "text": "inhaler", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "1389744_1_Ent0", "text": "A patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1389744_1_Ent1", "text": "dilated cardiomyopathy", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "1389744_1_Ent2", "text": "many years of overusing an adrenaline inhaler", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "1389744_1_Ent3", "text": "overusing", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1389744_1_Ent4", "text": "adrenaline", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1389744_1_Ent5", "text": "inhaler", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "1393348_1", "wnd_id": "1393348_1_1", "text": "A 21 - year - old woman suffering from bipolar affective disorder developed systemic lupus erythematosus ( SLE ) with characteristic laboratory findings , 18 months after starting carbamazepine maintenance treatment .", "tokens": ["A", "21", "-", "year", "-", "old", "woman", "suffering", "from", "bipolar", "affective", "disorder", "developed", "systemic", "lupus", "erythematosus", "(", "SLE", ")", "with", "characteristic", "laboratory", "findings", ",", "18", "months", "after", "starting", "carbamazepine", "maintenance", "treatment", "."], "event_mentions": [{"id": "1393348_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "1393348_1_Ent0", "role": "Subject", "text": "A 21 - year - old woman suffering from bipolar affective disorder", "start": 0, "end": 12}, {"entity_id": "1393348_1_Ent1", "role": "Subject_Age", "text": "21 - year - old", "start": 1, "end": 6}, {"entity_id": "1393348_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "1393348_1_Ent5", "role": "Treatment_Disorder", "text": "bipolar affective disorder", "start": 9, "end": 12}, {"entity_id": "1393348_1_Ent3", "role": "Effect", "text": "systemic lupus erythematosus ( SLE )", "start": 13, "end": 19}, {"entity_id": "1393348_1_Ent6", "role": "Treatment_Time_elapsed", "text": "18 months", "start": 24, "end": 26}, {"entity_id": "1393348_1_Ent4", "role": "Treatment", "text": "18 months after starting carbamazepine maintenance treatment", "start": 24, "end": 31}, {"entity_id": "1393348_1_Ent7", "role": "Treatment_Drug", "text": "carbamazepine", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "1393348_1_Ent0", "text": "A 21 - year - old woman suffering from bipolar affective disorder", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "1393348_1_Ent1", "text": "21 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "1393348_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1393348_1_Ent5", "text": "bipolar affective disorder", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "1393348_1_Ent3", "text": "systemic lupus erythematosus ( SLE )", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "1393348_1_Ent6", "text": "18 months", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "1393348_1_Ent4", "text": "18 months after starting carbamazepine maintenance treatment", "entity_type": "Entity", "start": 24, "end": 31}, {"id": "1393348_1_Ent7", "text": "carbamazepine", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "1420650_3", "wnd_id": "1420650_3_1", "text": "We consider asterixis to be an easily overlooked sign of neurotoxicity , which may occur even at low or moderate dosage levels , if certain drugs as lithium or clozapine are used in combination with CBZ .", "tokens": ["We", "consider", "asterixis", "to", "be", "an", "easily", "overlooked", "sign", "of", "neurotoxicity", ",", "which", "may", "occur", "even", "at", "low", "or", "moderate", "dosage", "levels", ",", "if", "certain", "drugs", "as", "lithium", "or", "clozapine", "are", "used", "in", "combination", "with", "CBZ", "."], "event_mentions": [{"id": "1420650_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 14, "end": 15}, "arguments": [{"entity_id": "1420650_3_Ent0", "role": "Effect", "text": "asterixis", "start": 2, "end": 3}, {"entity_id": "1420650_3_Ent1", "role": "Treatment", "text": "even at low or moderate dosage levels", "start": 15, "end": 22}, {"entity_id": "1420650_3_Ent6", "role": "Treatment_Dosage", "text": "low or moderate dosage", "start": 17, "end": 21}, {"entity_id": "1420650_3_Ent2", "role": "Treatment", "text": "certain drugs as lithium or clozapine are used in combination with CBZ", "start": 24, "end": 36}, {"entity_id": "1420650_3_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 27, "end": 28}, {"entity_id": "1420650_3_Ent8", "role": "Combination_Drug", "text": "lithium", "start": 27, "end": 28}, {"entity_id": "1420650_3_Ent5", "role": "Treatment_Drug", "text": "clozapine", "start": 29, "end": 30}, {"entity_id": "1420650_3_Ent10", "role": "Combination_Drug", "text": "clozapine", "start": 29, "end": 30}, {"entity_id": "1420650_3_Ent3", "role": "Treatment_Drug", "text": "CBZ", "start": 35, "end": 36}, {"entity_id": "1420650_3_Ent7", "role": "Combination_Drug", "text": "CBZ", "start": 35, "end": 36}, {"entity_id": "1420650_3_Ent9", "role": "Combination_Drug", "text": "CBZ", "start": 35, "end": 36}]}], "entity_mentions": [{"id": "1420650_3_Ent0", "text": "asterixis", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "1420650_3_Ent1", "text": "even at low or moderate dosage levels", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "1420650_3_Ent6", "text": "low or moderate dosage", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "1420650_3_Ent2", "text": "certain drugs as lithium or clozapine are used in combination with CBZ", "entity_type": "Entity", "start": 24, "end": 36}, {"id": "1420650_3_Ent4", "text": "lithium", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "1420650_3_Ent8", "text": "lithium", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "1420650_3_Ent5", "text": "clozapine", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "1420650_3_Ent10", "text": "clozapine", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "1420650_3_Ent3", "text": "CBZ", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "1420650_3_Ent7", "text": "CBZ", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "1420650_3_Ent9", "text": "CBZ", "entity_type": "Entity", "start": 35, "end": 36}], "lang": "en"}
{"doc_id": "1445134_3", "wnd_id": "1445134_3_1", "text": "In a single practice during the 21 years 1971 - 1991 , the incidence of gestational diabetes in pregnancies in which norethisterone was prescribed was 32.4 % ( 22 of 69 ) in comparison with 7.1 % in pregnancies in which the women did not take norethisterone ( 137 of 1,684 ) ( p < 0.001 ) .", "tokens": ["In", "a", "single", "practice", "during", "the", "21", "years", "1971", "-", "1991", ",", "the", "incidence", "of", "gestational", "diabetes", "in", "pregnancies", "in", "which", "norethisterone", "was", "prescribed", "was", "32.4", "%", "(", "22", "of", "69", ")", "in", "comparison", "with", "7.1", "%", "in", "pregnancies", "in", "which", "the", "women", "did", "not", "take", "norethisterone", "(", "137", "of", "1,684", ")", "(", "p", "<", "0.001", ")", "."], "event_mentions": [{"id": "1445134_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "incidence", "start": 13, "end": 14}, "arguments": [{"entity_id": "1445134_3_Ent1", "role": "Effect", "text": "gestational diabetes", "start": 15, "end": 17}, {"entity_id": "1445134_3_Ent0", "role": "Subject", "text": "pregnancies", "start": 18, "end": 19}, {"entity_id": "1445134_3_Ent2", "role": "Treatment", "text": "norethisterone", "start": 21, "end": 22}, {"entity_id": "1445134_3_Ent3", "role": "Treatment_Drug", "text": "norethisterone", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "1445134_3_Ent1", "text": "gestational diabetes", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "1445134_3_Ent0", "text": "pregnancies", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "1445134_3_Ent2", "text": "norethisterone", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "1445134_3_Ent3", "text": "norethisterone", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "1445134_5", "wnd_id": "1445134_5_1", "text": "Norethisterone in these 69 pregnancies accounted for 33.3 % ( 5 of 15 ) cases of clitoral hypertrophy diagnosed in 100,756 consecutive births .", "tokens": ["Norethisterone", "in", "these", "69", "pregnancies", "accounted", "for", "33.3", "%", "(", "5", "of", "15", ")", "cases", "of", "clitoral", "hypertrophy", "diagnosed", "in", "100,756", "consecutive", "births", "."], "event_mentions": [{"id": "1445134_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "accounted", "start": 5, "end": 6}, "arguments": [{"entity_id": "1445134_5_Ent3", "role": "Treatment", "text": "Norethisterone", "start": 0, "end": 1}, {"entity_id": "1445134_5_Ent4", "role": "Treatment_Drug", "text": "Norethisterone", "start": 0, "end": 1}, {"entity_id": "1445134_5_Ent1", "role": "Subject_Population", "text": "69", "start": 3, "end": 4}, {"entity_id": "1445134_5_Ent0", "role": "Subject", "text": "69 pregnancies", "start": 3, "end": 5}, {"entity_id": "1445134_5_Ent2", "role": "Effect", "text": "clitoral hypertrophy", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "1445134_5_Ent3", "text": "Norethisterone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1445134_5_Ent4", "text": "Norethisterone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1445134_5_Ent1", "text": "69", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1445134_5_Ent0", "text": "69 pregnancies", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "1445134_5_Ent2", "text": "clitoral hypertrophy", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "14514135_1", "wnd_id": "14514135_1_1", "text": "Neutrophilic eccrine hidradenitis mimicking cutaneous vasculitis in a lupus patient : a complication of cyclophosphamide .", "tokens": ["Neutrophilic", "eccrine", "hidradenitis", "mimicking", "cutaneous", "vasculitis", "in", "a", "lupus", "patient", ":", "a", "complication", "of", "cyclophosphamide", "."], "event_mentions": [{"id": "14514135_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 12, "end": 13}, "arguments": [{"entity_id": "14514135_1_Ent1", "role": "Effect", "text": "Neutrophilic eccrine hidradenitis", "start": 0, "end": 3}, {"entity_id": "14514135_1_Ent0", "role": "Subject", "text": "a lupus patient", "start": 7, "end": 10}, {"entity_id": "14514135_1_Ent3", "role": "Treatment_Disorder", "text": "lupus", "start": 8, "end": 9}, {"entity_id": "14514135_1_Ent2", "role": "Treatment", "text": "cyclophosphamide", "start": 14, "end": 15}, {"entity_id": "14514135_1_Ent4", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "14514135_1_Ent1", "text": "Neutrophilic eccrine hidradenitis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "14514135_1_Ent0", "text": "a lupus patient", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "14514135_1_Ent3", "text": "lupus", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "14514135_1_Ent2", "text": "cyclophosphamide", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "14514135_1_Ent4", "text": "cyclophosphamide", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "14514135_2", "wnd_id": "14514135_2_1", "text": "We report a case of NEH masquerading as cutaneous vasculitis in a woman receiving cyclophosphamide for lupus nephritis .", "tokens": ["We", "report", "a", "case", "of", "NEH", "masquerading", "as", "cutaneous", "vasculitis", "in", "a", "woman", "receiving", "cyclophosphamide", "for", "lupus", "nephritis", "."], "event_mentions": [{"id": "14514135_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 10, "end": 11}, "arguments": [{"entity_id": "14514135_2_Ent3", "role": "Effect", "text": "NEH masquerading as cutaneous vasculitis", "start": 5, "end": 10}, {"entity_id": "14514135_2_Ent0", "role": "Subject", "text": "a woman", "start": 11, "end": 13}, {"entity_id": "14514135_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 12, "end": 13}, {"entity_id": "14514135_2_Ent4", "role": "Treatment", "text": "cyclophosphamide", "start": 14, "end": 15}, {"entity_id": "14514135_2_Ent5", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 14, "end": 15}, {"entity_id": "14514135_2_Ent1", "role": "Subject", "text": "for lupus nephritis", "start": 15, "end": 18}, {"entity_id": "14514135_2_Ent6", "role": "Treatment_Disorder", "text": "lupus nephritis .", "start": 16, "end": 19}]}], "entity_mentions": [{"id": "14514135_2_Ent3", "text": "NEH masquerading as cutaneous vasculitis", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "14514135_2_Ent0", "text": "a woman", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "14514135_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "14514135_2_Ent4", "text": "cyclophosphamide", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "14514135_2_Ent5", "text": "cyclophosphamide", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "14514135_2_Ent1", "text": "for lupus nephritis", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "14514135_2_Ent6", "text": "lupus nephritis .", "entity_type": "Entity", "start": 16, "end": 19}], "lang": "en"}
{"doc_id": "14522628_2", "wnd_id": "14522628_2_1", "text": "Skin rash and splinter hemorrhages from ganciclovir .", "tokens": ["Skin", "rash", "and", "splinter", "hemorrhages", "from", "ganciclovir", "."], "event_mentions": [{"id": "14522628_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 5, "end": 6}, "arguments": [{"entity_id": "14522628_2_Ent0", "role": "Effect", "text": "Skin rash and splinter hemorrhages", "start": 0, "end": 5}, {"entity_id": "14522628_2_Ent1", "role": "Treatment", "text": "ganciclovir", "start": 6, "end": 7}, {"entity_id": "14522628_2_Ent2", "role": "Treatment_Drug", "text": "ganciclovir", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "14522628_2_Ent0", "text": "Skin rash and splinter hemorrhages", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "14522628_2_Ent1", "text": "ganciclovir", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14522628_2_Ent2", "text": "ganciclovir", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "14557583_1", "wnd_id": "14557583_1_1", "text": "A 74 - year - old patient with idiopathic Parkinson 's disease was evaluated for unintended sleep episodes that occurred after long - term treatment with 400 mg / day of L - dopa .", "tokens": ["A", "74", "-", "year", "-", "old", "patient", "with", "idiopathic", "Parkinson", "'s", "disease", "was", "evaluated", "for", "unintended", "sleep", "episodes", "that", "occurred", "after", "long", "-", "term", "treatment", "with", "400", "mg", "/", "day", "of", "L", "-", "dopa", "."], "event_mentions": [{"id": "14557583_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 20, "end": 21}, "arguments": [{"entity_id": "14557583_1_Ent0", "role": "Subject", "text": "A 74 - year - old patient with idiopathic Parkinson 's disease", "start": 0, "end": 12}, {"entity_id": "14557583_1_Ent1", "role": "Subject_Age", "text": "74 - year - old", "start": 1, "end": 6}, {"entity_id": "14557583_1_Ent4", "role": "Treatment_Disorder", "text": "idiopathic Parkinson 's disease", "start": 8, "end": 12}, {"entity_id": "14557583_1_Ent2", "role": "Effect", "text": "unintended sleep episodes", "start": 15, "end": 18}, {"entity_id": "14557583_1_Ent7", "role": "Treatment_Duration", "text": "long - term treatment", "start": 21, "end": 25}, {"entity_id": "14557583_1_Ent3", "role": "Treatment", "text": "long - term treatment with 400 mg / day of L - dopa", "start": 21, "end": 34}, {"entity_id": "14557583_1_Ent5", "role": "Treatment_Dosage", "text": "400 mg / day", "start": 26, "end": 30}, {"entity_id": "14557583_1_Ent6", "role": "Treatment_Drug", "text": "L - dopa", "start": 31, "end": 34}]}], "entity_mentions": [{"id": "14557583_1_Ent0", "text": "A 74 - year - old patient with idiopathic Parkinson 's disease", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "14557583_1_Ent1", "text": "74 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "14557583_1_Ent4", "text": "idiopathic Parkinson 's disease", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "14557583_1_Ent2", "text": "unintended sleep episodes", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "14557583_1_Ent7", "text": "long - term treatment", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "14557583_1_Ent3", "text": "long - term treatment with 400 mg / day of L - dopa", "entity_type": "Entity", "start": 21, "end": 34}, {"id": "14557583_1_Ent5", "text": "400 mg / day", "entity_type": "Entity", "start": 26, "end": 30}, {"id": "14557583_1_Ent6", "text": "L - dopa", "entity_type": "Entity", "start": 31, "end": 34}], "lang": "en"}
{"doc_id": "14557583_2", "wnd_id": "14557583_2_1", "text": "L - DOPA - induced excessive daytime sleepiness in PD : a placebo - controlled case with MSLT assessment .", "tokens": ["L", "-", "DOPA", "-", "induced", "excessive", "daytime", "sleepiness", "in", "PD", ":", "a", "placebo", "-", "controlled", "case", "with", "MSLT", "assessment", "."], "event_mentions": [{"id": "14557583_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "14557583_2_Ent1", "role": "Treatment", "text": "L - DOPA", "start": 0, "end": 3}, {"entity_id": "14557583_2_Ent2", "role": "Treatment_Drug", "text": "DOPA", "start": 2, "end": 3}, {"entity_id": "14557583_2_Ent0", "role": "Effect", "text": "daytime sleepiness", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "14557583_2_Ent1", "text": "L - DOPA", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "14557583_2_Ent2", "text": "DOPA", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "14557583_2_Ent0", "text": "daytime sleepiness", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "14557583_3", "wnd_id": "14557583_3_1", "text": "The authors ' results suggest that L - dopa may cause daytime somnolence in some patients with Parkinson 's disease .", "tokens": ["The", "authors", "'", "results", "suggest", "that", "L", "-", "dopa", "may", "cause", "daytime", "somnolence", "in", "some", "patients", "with", "Parkinson", "'s", "disease", "."], "event_mentions": [{"id": "14557583_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 10, "end": 11}, "arguments": [{"entity_id": "14557583_3_Ent2", "role": "Treatment", "text": "L - dopa", "start": 6, "end": 9}, {"entity_id": "14557583_3_Ent3", "role": "Treatment_Drug", "text": "L - dopa", "start": 6, "end": 9}, {"entity_id": "14557583_3_Ent1", "role": "Effect", "text": "daytime somnolence", "start": 11, "end": 13}, {"entity_id": "14557583_3_Ent0", "role": "Subject", "text": "some patients with Parkinson 's disease", "start": 14, "end": 20}, {"entity_id": "14557583_3_Ent4", "role": "Treatment_Disorder", "text": "Parkinson 's disease", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "14557583_3_Ent2", "text": "L - dopa", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "14557583_3_Ent3", "text": "L - dopa", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "14557583_3_Ent1", "text": "daytime somnolence", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "14557583_3_Ent0", "text": "some patients with Parkinson 's disease", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "14557583_3_Ent4", "text": "Parkinson 's disease", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "14641354_2", "wnd_id": "14641354_2_1", "text": "We report a 43 - year - old woman who developed sore throat , swelling of the lips and oral cavity and dysphagia , 2 weeks after the use of budesonide spray ( Budefat ) for treatment of bronchial asthma .", "tokens": ["We", "report", "a", "43", "-", "year", "-", "old", "woman", "who", "developed", "sore", "throat", ",", "swelling", "of", "the", "lips", "and", "oral", "cavity", "and", "dysphagia", ",", "2", "weeks", "after", "the", "use", "of", "budesonide", "spray", "(", "Budefat", ")", "for", "treatment", "of", "bronchial", "asthma", "."], "event_mentions": [{"id": "14641354_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "14641354_2_Ent0", "role": "Subject", "text": "a 43 - year - old woman", "start": 2, "end": 9}, {"entity_id": "14641354_2_Ent1", "role": "Subject_Age", "text": "43 - year - old", "start": 3, "end": 8}, {"entity_id": "14641354_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 8, "end": 9}, {"entity_id": "14641354_2_Ent3", "role": "Effect", "text": "sore throat , swelling of the lips and oral cavity and dysphagia", "start": 11, "end": 23}, {"entity_id": "14641354_2_Ent5", "role": "Treatment_Time_elapsed", "text": "2 weeks after", "start": 24, "end": 27}, {"entity_id": "14641354_2_Ent4", "role": "Treatment", "text": "2 weeks after the use of budesonide spray ( Budefat )", "start": 24, "end": 35}, {"entity_id": "14641354_2_Ent6", "role": "Treatment_Drug", "text": "budesonide", "start": 30, "end": 31}, {"entity_id": "14641354_2_Ent9", "role": "Treatment_Route", "text": "spray", "start": 31, "end": 32}, {"entity_id": "14641354_2_Ent7", "role": "Treatment_Drug", "text": "Budefat", "start": 33, "end": 34}, {"entity_id": "14641354_2_Ent8", "role": "Treatment_Disorder", "text": "bronchial asthma .", "start": 38, "end": 41}]}], "entity_mentions": [{"id": "14641354_2_Ent0", "text": "a 43 - year - old woman", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "14641354_2_Ent1", "text": "43 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "14641354_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "14641354_2_Ent3", "text": "sore throat , swelling of the lips and oral cavity and dysphagia", "entity_type": "Entity", "start": 11, "end": 23}, {"id": "14641354_2_Ent5", "text": "2 weeks after", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "14641354_2_Ent4", "text": "2 weeks after the use of budesonide spray ( Budefat )", "entity_type": "Entity", "start": 24, "end": 35}, {"id": "14641354_2_Ent6", "text": "budesonide", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "14641354_2_Ent9", "text": "spray", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "14641354_2_Ent7", "text": "Budefat", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "14641354_2_Ent8", "text": "bronchial asthma .", "entity_type": "Entity", "start": 38, "end": 41}], "lang": "en"}
{"doc_id": "1467295_1", "wnd_id": "1467295_1_1", "text": "We describe a patient who developed NEH on three separate occasions provoked by two different chemotherapeutic agents -- cytarabine and mitoxantrone .", "tokens": ["We", "describe", "a", "patient", "who", "developed", "NEH", "on", "three", "separate", "occasions", "provoked", "by", "two", "different", "chemotherapeutic", "agents", "--", "cytarabine", "and", "mitoxantrone", "."], "event_mentions": [{"id": "1467295_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "provoked", "start": 11, "end": 12}, "arguments": [{"entity_id": "1467295_1_Ent0", "role": "Subject", "text": "a patient", "start": 2, "end": 4}, {"entity_id": "1467295_1_Ent1", "role": "Effect", "text": "NEH", "start": 6, "end": 7}, {"entity_id": "1467295_1_Ent3", "role": "Treatment_Drug", "text": "cytarabine", "start": 18, "end": 19}, {"entity_id": "1467295_1_Ent5", "role": "Combination_Drug", "text": "cytarabine", "start": 18, "end": 19}, {"entity_id": "1467295_1_Ent2", "role": "Treatment", "text": "cytarabine and mitoxantrone", "start": 18, "end": 21}, {"entity_id": "1467295_1_Ent4", "role": "Treatment_Drug", "text": "mitoxantrone", "start": 20, "end": 21}, {"entity_id": "1467295_1_Ent6", "role": "Combination_Drug", "text": "mitoxantrone", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "1467295_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "1467295_1_Ent1", "text": "NEH", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1467295_1_Ent3", "text": "cytarabine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "1467295_1_Ent5", "text": "cytarabine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "1467295_1_Ent2", "text": "cytarabine and mitoxantrone", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "1467295_1_Ent4", "text": "mitoxantrone", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "1467295_1_Ent6", "text": "mitoxantrone", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "14684937_1", "wnd_id": "14684937_1_1", "text": "After initiation of topical vitamin D3 ointment ( 20 micro g / g of tacalcitol ) 10 g / day for the skin lesions , both the serum level of calcium and urinary excretion of calcium increased gradually .", "tokens": ["After", "initiation", "of", "topical", "vitamin", "D3", "ointment", "(", "20", "micro", "g", "/", "g", "of", "tacalcitol", ")", "10", "g", "/", "day", "for", "the", "skin", "lesions", ",", "both", "the", "serum", "level", "of", "calcium", "and", "urinary", "excretion", "of", "calcium", "increased", "gradually", "."], "event_mentions": [{"id": "14684937_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increased", "start": 36, "end": 37}, "arguments": [{"entity_id": "14684937_1_Ent1", "role": "Treatment", "text": "After initiation of topical vitamin D3 ointment ( 20 micro g / g of tacalcitol ) 10 g / day", "start": 0, "end": 20}, {"entity_id": "14684937_1_Ent4", "role": "Treatment_Route", "text": "topical", "start": 3, "end": 4}, {"entity_id": "14684937_1_Ent3", "role": "Treatment_Drug", "text": "vitamin D3", "start": 4, "end": 6}, {"entity_id": "14684937_1_Ent5", "role": "Treatment_Dosage", "text": "20 micro g / g", "start": 8, "end": 13}, {"entity_id": "14684937_1_Ent6", "role": "Treatment_Dosage", "text": "10 g", "start": 16, "end": 18}, {"entity_id": "14684937_1_Ent7", "role": "Treatment_Freq", "text": "10 g / day", "start": 16, "end": 20}, {"entity_id": "14684937_1_Ent2", "role": "Treatment_Disorder", "text": "skin lesions ,", "start": 22, "end": 25}, {"entity_id": "14684937_1_Ent0", "role": "Effect", "text": "serum level of calcium and urinary excretion of calcium increased", "start": 27, "end": 37}]}], "entity_mentions": [{"id": "14684937_1_Ent1", "text": "After initiation of topical vitamin D3 ointment ( 20 micro g / g of tacalcitol ) 10 g / day", "entity_type": "Entity", "start": 0, "end": 20}, {"id": "14684937_1_Ent4", "text": "topical", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14684937_1_Ent3", "text": "vitamin D3", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "14684937_1_Ent5", "text": "20 micro g / g", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "14684937_1_Ent6", "text": "10 g", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "14684937_1_Ent7", "text": "10 g / day", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "14684937_1_Ent2", "text": "skin lesions ,", "entity_type": "Entity", "start": 22, "end": 25}, {"id": "14684937_1_Ent0", "text": "serum level of calcium and urinary excretion of calcium increased", "entity_type": "Entity", "start": 27, "end": 37}], "lang": "en"}
{"doc_id": "14684937_2", "wnd_id": "14684937_2_1", "text": "Iatrogenic hypercalcemia due to vitamin D3 ointment ( 1,24(OH)2D3 ) combined with thiazide diuretics in a case of psoriasis .", "tokens": ["Iatrogenic", "hypercalcemia", "due", "to", "vitamin", "D3", "ointment", "(", "1,24(OH)2D3", ")", "combined", "with", "thiazide", "diuretics", "in", "a", "case", "of", "psoriasis", "."], "event_mentions": [{"id": "14684937_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 2, "end": 3}, "arguments": [{"entity_id": "14684937_2_Ent0", "role": "Effect", "text": "Iatrogenic hypercalcemia", "start": 0, "end": 2}, {"entity_id": "14684937_2_Ent3", "role": "Treatment_Drug", "text": "vitamin D3", "start": 4, "end": 6}, {"entity_id": "14684937_2_Ent6", "role": "Combination_Drug", "text": "vitamin D3", "start": 4, "end": 6}, {"entity_id": "14684937_2_Ent1", "role": "Treatment", "text": "vitamin D3 ointment ( 1,24(OH)2D3 ) combined with thiazide diuretics", "start": 4, "end": 14}, {"entity_id": "14684937_2_Ent5", "role": "Treatment_Route", "text": "ointment", "start": 6, "end": 7}, {"entity_id": "14684937_2_Ent4", "role": "Treatment_Drug", "text": "thiazide diuretics", "start": 12, "end": 14}, {"entity_id": "14684937_2_Ent7", "role": "Combination_Drug", "text": "thiazide diuretics", "start": 12, "end": 14}, {"entity_id": "14684937_2_Ent2", "role": "Treatment_Disorder", "text": "psoriasis", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "14684937_2_Ent0", "text": "Iatrogenic hypercalcemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "14684937_2_Ent3", "text": "vitamin D3", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "14684937_2_Ent6", "text": "vitamin D3", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "14684937_2_Ent1", "text": "vitamin D3 ointment ( 1,24(OH)2D3 ) combined with thiazide diuretics", "entity_type": "Entity", "start": 4, "end": 14}, {"id": "14684937_2_Ent5", "text": "ointment", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14684937_2_Ent4", "text": "thiazide diuretics", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "14684937_2_Ent7", "text": "thiazide diuretics", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "14684937_2_Ent2", "text": "psoriasis", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "14684937_4", "wnd_id": "14684937_4_1", "text": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide , respectively , resulting in hypercalciuria and hypercalcemia .", "tokens": ["We", "experienced", "a", "male", "patient", "with", "psoriasis", "and", "hypertension", "whose", "conditions", "were", "treated", "with", "tacalcitol", "ointment", "and", "thiazide", ",", "respectively", ",", "resulting", "in", "hypercalciuria", "and", "hypercalcemia", "."], "event_mentions": [{"id": "14684937_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 21, "end": 22}, "arguments": [{"entity_id": "14684937_4_Ent0", "role": "Subject", "text": "a male patient with psoriasis and hypertension", "start": 2, "end": 9}, {"entity_id": "14684937_4_Ent1", "role": "Subject_Gender", "text": "male", "start": 3, "end": 4}, {"entity_id": "14684937_4_Ent4", "role": "Treatment_Disorder", "text": "psoriasis", "start": 6, "end": 7}, {"entity_id": "14684937_4_Ent5", "role": "Treatment_Disorder", "text": "hypertension", "start": 8, "end": 9}, {"entity_id": "14684937_4_Ent6", "role": "Treatment_Drug", "text": "tacalcitol", "start": 14, "end": 15}, {"entity_id": "14684937_4_Ent9", "role": "Combination_Drug", "text": "tacalcitol", "start": 14, "end": 15}, {"entity_id": "14684937_4_Ent3", "role": "Treatment", "text": "tacalcitol ointment and thiazide", "start": 14, "end": 18}, {"entity_id": "14684937_4_Ent8", "role": "Treatment_Route", "text": "ointment", "start": 15, "end": 16}, {"entity_id": "14684937_4_Ent7", "role": "Treatment_Drug", "text": "thiazide", "start": 17, "end": 18}, {"entity_id": "14684937_4_Ent10", "role": "Combination_Drug", "text": "thiazide", "start": 17, "end": 18}, {"entity_id": "14684937_4_Ent2", "role": "Effect", "text": "hypercalciuria and hypercalcemia", "start": 23, "end": 26}]}], "entity_mentions": [{"id": "14684937_4_Ent0", "text": "a male patient with psoriasis and hypertension", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "14684937_4_Ent1", "text": "male", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14684937_4_Ent4", "text": "psoriasis", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14684937_4_Ent5", "text": "hypertension", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "14684937_4_Ent6", "text": "tacalcitol", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "14684937_4_Ent9", "text": "tacalcitol", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "14684937_4_Ent3", "text": "tacalcitol ointment and thiazide", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "14684937_4_Ent8", "text": "ointment", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "14684937_4_Ent7", "text": "thiazide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "14684937_4_Ent10", "text": "thiazide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "14684937_4_Ent2", "text": "hypercalciuria and hypercalcemia", "entity_type": "Entity", "start": 23, "end": 26}], "lang": "en"}
{"doc_id": "14690166_2", "wnd_id": "14690166_2_1", "text": "There is currently no consensus on the best treatment for unresectable hyaline - vascular variant or for multicentric Castleman 's disease ( MCD ) , because none of the reported regimens have consistently produced complete response or durable remission in the majority of patients In the present study , we report on the use of 2 - CdA ( 2 - chloro - deoxyadenosine ) in three patients , two of them with MCD and one with unresectable hyaline - vascular type disease .", "tokens": ["There", "is", "currently", "no", "consensus", "on", "the", "best", "treatment", "for", "unresectable", "hyaline", "-", "vascular", "variant", "or", "for", "multicentric", "Castleman", "'s", "disease", "(", "MCD", ")", ",", "because", "none", "of", "the", "reported", "regimens", "have", "consistently", "produced", "complete", "response", "or", "durable", "remission", "in", "the", "majority", "of", "patients", "In", "the", "present", "study", ",", "we", "report", "on", "the", "use", "of", "2", "-", "CdA", "(", "2", "-", "chloro", "-", "deoxyadenosine", ")", "in", "three", "patients", ",", "two", "of", "them", "with", "MCD", "and", "one", "with", "unresectable", "hyaline", "-", "vascular", "type", "disease", "."], "event_mentions": [{"id": "14690166_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "use", "start": 53, "end": 54}, "arguments": [{"entity_id": "14690166_2_Ent0", "role": "Subject", "text": "one", "start": 75, "end": 76}, {"entity_id": "14690166_2_Ent1", "role": "Subject_Population", "text": "one", "start": 75, "end": 76}]}, {"id": "14690166_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "use", "start": 53, "end": 54}, "arguments": [{"entity_id": "14690166_2_Ent6", "role": "Treatment_Drug", "text": "2 - CdA", "start": 55, "end": 58}, {"entity_id": "14690166_2_Ent7", "role": "Treatment_Drug", "text": "2 - CdA", "start": 55, "end": 58}, {"entity_id": "14690166_2_Ent4", "role": "Treatment", "text": "2 - CdA ( 2 - chloro - deoxyadenosine )", "start": 55, "end": 65}, {"entity_id": "14690166_2_Ent5", "role": "Treatment", "text": "2 - CdA ( 2 - chloro - deoxyadenosine )", "start": 55, "end": 65}, {"entity_id": "14690166_2_Ent2", "role": "Subject", "text": "two", "start": 69, "end": 70}, {"entity_id": "14690166_2_Ent3", "role": "Subject_Population", "text": "two", "start": 69, "end": 70}, {"entity_id": "14690166_2_Ent8", "role": "Treatment_Disorder", "text": "MCD", "start": 73, "end": 74}, {"entity_id": "14690166_2_Ent9", "role": "Treatment_Disorder", "text": "unresectable hyaline - vascular type disease", "start": 77, "end": 83}]}], "entity_mentions": [{"id": "14690166_2_Ent6", "text": "2 - CdA", "entity_type": "Entity", "start": 55, "end": 58}, {"id": "14690166_2_Ent7", "text": "2 - CdA", "entity_type": "Entity", "start": 55, "end": 58}, {"id": "14690166_2_Ent4", "text": "2 - CdA ( 2 - chloro - deoxyadenosine )", "entity_type": "Entity", "start": 55, "end": 65}, {"id": "14690166_2_Ent5", "text": "2 - CdA ( 2 - chloro - deoxyadenosine )", "entity_type": "Entity", "start": 55, "end": 65}, {"id": "14690166_2_Ent2", "text": "two", "entity_type": "Entity", "start": 69, "end": 70}, {"id": "14690166_2_Ent3", "text": "two", "entity_type": "Entity", "start": 69, "end": 70}, {"id": "14690166_2_Ent8", "text": "MCD", "entity_type": "Entity", "start": 73, "end": 74}, {"id": "14690166_2_Ent0", "text": "one", "entity_type": "Entity", "start": 75, "end": 76}, {"id": "14690166_2_Ent1", "text": "one", "entity_type": "Entity", "start": 75, "end": 76}, {"id": "14690166_2_Ent9", "text": "unresectable hyaline - vascular type disease", "entity_type": "Entity", "start": 77, "end": 83}], "lang": "en"}
{"doc_id": "14690166_5", "wnd_id": "14690166_5_1", "text": "2 - CdA typically causes a long - lasting state of immunodeficiency and the profound influence of this drug on the immune system has raised questions concerning the emergence of secondary neoplasms after its use .", "tokens": ["2", "-", "CdA", "typically", "causes", "a", "long", "-", "lasting", "state", "of", "immunodeficiency", "and", "the", "profound", "influence", "of", "this", "drug", "on", "the", "immune", "system", "has", "raised", "questions", "concerning", "the", "emergence", "of", "secondary", "neoplasms", "after", "its", "use", "."], "event_mentions": [{"id": "14690166_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causes", "start": 4, "end": 5}, "arguments": [{"entity_id": "14690166_5_Ent2", "role": "Treatment", "text": "2 - CdA", "start": 0, "end": 3}, {"entity_id": "14690166_5_Ent3", "role": "Treatment_Drug", "text": "2 - CdA", "start": 0, "end": 3}, {"entity_id": "14690166_5_Ent0", "role": "Effect", "text": "a long - lasting state of immunodeficiency", "start": 5, "end": 12}, {"entity_id": "14690166_5_Ent1", "role": "Effect", "text": "emergence of secondary neoplasms after its use", "start": 28, "end": 35}]}], "entity_mentions": [{"id": "14690166_5_Ent2", "text": "2 - CdA", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "14690166_5_Ent3", "text": "2 - CdA", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "14690166_5_Ent0", "text": "a long - lasting state of immunodeficiency", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "14690166_5_Ent1", "text": "emergence of secondary neoplasms after its use", "entity_type": "Entity", "start": 28, "end": 35}], "lang": "en"}
{"doc_id": "14690166_6", "wnd_id": "14690166_6_1", "text": "Therefore , it is reasonable to conclude that : 1 ) 2 - CdA can induce durable complete remission in MCD patients but unfortunately it can not cure the disease ; 2 ) the possibility that 2 - CdA may accelerate the transformation of MCD to NHL can not be ruled out .", "tokens": ["Therefore", ",", "it", "is", "reasonable", "to", "conclude", "that", ":", "1", ")", "2", "-", "CdA", "can", "induce", "durable", "complete", "remission", "in", "MCD", "patients", "but", "unfortunately", "it", "can", "not", "cure", "the", "disease", ";", "2", ")", "the", "possibility", "that", "2", "-", "CdA", "may", "accelerate", "the", "transformation", "of", "MCD", "to", "NHL", "can", "not", "be", "ruled", "out", "."], "event_mentions": [{"id": "14690166_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "induce", "start": 15, "end": 16}, "arguments": [{"entity_id": "14690166_6_Ent1", "role": "Treatment", "text": "2 - CdA", "start": 11, "end": 14}, {"entity_id": "14690166_6_Ent3", "role": "Treatment_Drug", "text": "2 - CdA", "start": 11, "end": 14}, {"entity_id": "14690166_6_Ent0", "role": "Effect", "text": "durable complete remission", "start": 16, "end": 19}, {"entity_id": "14690166_6_Ent2", "role": "Treatment_Disorder", "text": "MCD", "start": 20, "end": 21}]}, {"id": "14690166_6_Evt1", "event_type": "Adverse_event", "trigger": {"text": "accelerate", "start": 40, "end": 41}, "arguments": [{"entity_id": "14690166_6_Ent5", "role": "Treatment", "text": "2 - CdA", "start": 36, "end": 39}, {"entity_id": "14690166_6_Ent6", "role": "Treatment_Drug", "text": "2 - CdA", "start": 36, "end": 39}, {"entity_id": "14690166_6_Ent4", "role": "Effect", "text": "the transformation of MCD to NHL", "start": 41, "end": 47}]}], "entity_mentions": [{"id": "14690166_6_Ent1", "text": "2 - CdA", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "14690166_6_Ent3", "text": "2 - CdA", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "14690166_6_Ent0", "text": "durable complete remission", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "14690166_6_Ent2", "text": "MCD", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "14690166_6_Ent5", "text": "2 - CdA", "entity_type": "Entity", "start": 36, "end": 39}, {"id": "14690166_6_Ent6", "text": "2 - CdA", "entity_type": "Entity", "start": 36, "end": 39}, {"id": "14690166_6_Ent4", "text": "the transformation of MCD to NHL", "entity_type": "Entity", "start": 41, "end": 47}], "lang": "en"}
{"doc_id": "1469187_1", "wnd_id": "1469187_1_1", "text": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti - digitalis antibodies .", "tokens": ["Treatment", "of", "a", "patient", "with", "severe", "digitoxin", "intoxication", "by", "Fab", "fragments", "of", "anti", "-", "digitalis", "antibodies", "."], "event_mentions": [{"id": "1469187_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Treatment", "start": 0, "end": 1}, "arguments": [{"entity_id": "1469187_1_Ent0", "role": "Subject", "text": "a patient with severe digitoxin intoxication", "start": 2, "end": 8}, {"entity_id": "1469187_1_Ent2", "role": "Treatment_Disorder", "text": "digitoxin intoxication", "start": 6, "end": 8}, {"entity_id": "1469187_1_Ent1", "role": "Treatment", "text": "Fab fragments of anti - digitalis antibodies", "start": 9, "end": 16}, {"entity_id": "1469187_1_Ent3", "role": "Treatment_Drug", "text": "Fab fragments of anti - digitalis antibodies", "start": 9, "end": 16}]}], "entity_mentions": [{"id": "1469187_1_Ent0", "text": "a patient with severe digitoxin intoxication", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "1469187_1_Ent2", "text": "digitoxin intoxication", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "1469187_1_Ent1", "text": "Fab fragments of anti - digitalis antibodies", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "1469187_1_Ent3", "text": "Fab fragments of anti - digitalis antibodies", "entity_type": "Entity", "start": 9, "end": 16}], "lang": "en"}
{"doc_id": "14697943_2", "wnd_id": "14697943_2_1", "text": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus .", "tokens": ["Reflex", "sympathetic", "dystrophy", "syndrome", "in", "renal", "transplanted", "patients", "under", "immunosuppression", "with", "tacrolimus", "."], "event_mentions": [{"id": "14697943_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 10, "end": 11}, "arguments": [{"entity_id": "14697943_2_Ent2", "role": "Effect", "text": "Reflex sympathetic dystrophy syndrome", "start": 0, "end": 4}, {"entity_id": "14697943_2_Ent1", "role": "Subject_Disorder", "text": "renal transplanted", "start": 5, "end": 7}, {"entity_id": "14697943_2_Ent0", "role": "Subject", "text": "renal transplanted patients", "start": 5, "end": 8}, {"entity_id": "14697943_2_Ent3", "role": "Treatment", "text": "tacrolimus", "start": 11, "end": 12}, {"entity_id": "14697943_2_Ent4", "role": "Treatment_Drug", "text": "tacrolimus", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "14697943_2_Ent2", "text": "Reflex sympathetic dystrophy syndrome", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "14697943_2_Ent1", "text": "renal transplanted", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "14697943_2_Ent0", "text": "renal transplanted patients", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "14697943_2_Ent3", "text": "tacrolimus", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "14697943_2_Ent4", "text": "tacrolimus", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "14712320_7", "wnd_id": "14712320_7_1", "text": "In this report , we describe a case of rhabdomyolysis and acute renal failure secondary to the interaction between danazol and simvastatin .", "tokens": ["In", "this", "report", ",", "we", "describe", "a", "case", "of", "rhabdomyolysis", "and", "acute", "renal", "failure", "secondary", "to", "the", "interaction", "between", "danazol", "and", "simvastatin", "."], "event_mentions": [{"id": "14712320_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 14, "end": 15}, "arguments": [{"entity_id": "14712320_7_Ent0", "role": "Effect", "text": "rhabdomyolysis and acute renal failure", "start": 9, "end": 14}, {"entity_id": "14712320_7_Ent1", "role": "Treatment", "text": "interaction between danazol and simvastatin", "start": 17, "end": 22}, {"entity_id": "14712320_7_Ent2", "role": "Treatment_Drug", "text": "danazol", "start": 19, "end": 20}, {"entity_id": "14712320_7_Ent4", "role": "Combination_Drug", "text": "danazol", "start": 19, "end": 20}, {"entity_id": "14712320_7_Ent3", "role": "Treatment_Drug", "text": "simvastatin", "start": 21, "end": 22}, {"entity_id": "14712320_7_Ent5", "role": "Combination_Drug", "text": "simvastatin", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "14712320_7_Ent0", "text": "rhabdomyolysis and acute renal failure", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "14712320_7_Ent1", "text": "interaction between danazol and simvastatin", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "14712320_7_Ent2", "text": "danazol", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "14712320_7_Ent4", "text": "danazol", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "14712320_7_Ent3", "text": "simvastatin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "14712320_7_Ent5", "text": "simvastatin", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "14723711_1", "wnd_id": "14723711_1_1", "text": "A new type of minocycline - induced cutaneous hyperpigmentation .", "tokens": ["A", "new", "type", "of", "minocycline", "-", "induced", "cutaneous", "hyperpigmentation", "."], "event_mentions": [{"id": "14723711_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "14723711_1_Ent1", "role": "Treatment", "text": "minocycline", "start": 4, "end": 5}, {"entity_id": "14723711_1_Ent2", "role": "Treatment_Drug", "text": "minocycline", "start": 4, "end": 5}, {"entity_id": "14723711_1_Ent0", "role": "Effect", "text": "cutaneous hyperpigmentation", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "14723711_1_Ent1", "text": "minocycline", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "14723711_1_Ent2", "text": "minocycline", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "14723711_1_Ent0", "text": "cutaneous hyperpigmentation", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "14723711_3", "wnd_id": "14723711_3_1", "text": "Three distinct types of minocycline - induced cutaneous pigmentation have been described .", "tokens": ["Three", "distinct", "types", "of", "minocycline", "-", "induced", "cutaneous", "pigmentation", "have", "been", "described", "."], "event_mentions": [{"id": "14723711_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "14723711_3_Ent1", "role": "Treatment", "text": "minocycline", "start": 4, "end": 5}, {"entity_id": "14723711_3_Ent2", "role": "Treatment_Drug", "text": "minocycline", "start": 4, "end": 5}, {"entity_id": "14723711_3_Ent0", "role": "Effect", "text": "cutaneous pigmentation", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "14723711_3_Ent1", "text": "minocycline", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "14723711_3_Ent2", "text": "minocycline", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "14723711_3_Ent0", "text": "cutaneous pigmentation", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "14740795_1", "wnd_id": "14740795_1_1", "text": "A 56 - year - old Caucasian man who received concomitant chemotherapy and radiation for head and neck cancer developed fever concurrent with the administration of amifostine .", "tokens": ["A", "56", "-", "year", "-", "old", "Caucasian", "man", "who", "received", "concomitant", "chemotherapy", "and", "radiation", "for", "head", "and", "neck", "cancer", "developed", "fever", "concurrent", "with", "the", "administration", "of", "amifostine", "."], "event_mentions": [{"id": "14740795_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 19, "end": 20}, "arguments": [{"entity_id": "14740795_1_Ent0", "role": "Subject", "text": "A 56 - year - old Caucasian man", "start": 0, "end": 8}, {"entity_id": "14740795_1_Ent1", "role": "Subject_Age", "text": "56 - year - old", "start": 1, "end": 6}, {"entity_id": "14740795_1_Ent2", "role": "Subject_Race", "text": "Caucasian", "start": 6, "end": 7}, {"entity_id": "14740795_1_Ent3", "role": "Subject_Gender", "text": "man", "start": 7, "end": 8}, {"entity_id": "14740795_1_Ent5", "role": "Treatment", "text": "concomitant chemotherapy and radiation for head and neck cancer", "start": 10, "end": 19}, {"entity_id": "14740795_1_Ent10", "role": "Treatment_Drug", "text": "chemotherapy", "start": 11, "end": 12}, {"entity_id": "14740795_1_Ent13", "role": "Combination_Drug", "text": "chemotherapy", "start": 11, "end": 12}, {"entity_id": "14740795_1_Ent9", "role": "Treatment_Drug", "text": "radiation", "start": 13, "end": 14}, {"entity_id": "14740795_1_Ent12", "role": "Combination_Drug", "text": "radiation", "start": 13, "end": 14}, {"entity_id": "14740795_1_Ent7", "role": "Treatment_Disorder", "text": "head and neck cancer", "start": 15, "end": 19}, {"entity_id": "14740795_1_Ent4", "role": "Effect", "text": "fever", "start": 20, "end": 21}, {"entity_id": "14740795_1_Ent6", "role": "Treatment", "text": "concurrent with the administration of amifostine", "start": 21, "end": 27}, {"entity_id": "14740795_1_Ent8", "role": "Treatment_Drug", "text": "amifostine", "start": 26, "end": 27}, {"entity_id": "14740795_1_Ent11", "role": "Combination_Drug", "text": "amifostine", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "14740795_1_Ent0", "text": "A 56 - year - old Caucasian man", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "14740795_1_Ent1", "text": "56 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "14740795_1_Ent2", "text": "Caucasian", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14740795_1_Ent3", "text": "man", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "14740795_1_Ent5", "text": "concomitant chemotherapy and radiation for head and neck cancer", "entity_type": "Entity", "start": 10, "end": 19}, {"id": "14740795_1_Ent10", "text": "chemotherapy", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "14740795_1_Ent13", "text": "chemotherapy", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "14740795_1_Ent9", "text": "radiation", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "14740795_1_Ent12", "text": "radiation", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "14740795_1_Ent7", "text": "head and neck cancer", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "14740795_1_Ent4", "text": "fever", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "14740795_1_Ent6", "text": "concurrent with the administration of amifostine", "entity_type": "Entity", "start": 21, "end": 27}, {"id": "14740795_1_Ent8", "text": "amifostine", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "14740795_1_Ent11", "text": "amifostine", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "14740795_3", "wnd_id": "14740795_3_1", "text": "Patients receiving amifostine who develop only fever should be evaluated for an adverse drug reaction , as well as for sepsis and fevers of neutropenia , and it may be necessary to discontinue the drug .", "tokens": ["Patients", "receiving", "amifostine", "who", "develop", "only", "fever", "should", "be", "evaluated", "for", "an", "adverse", "drug", "reaction", ",", "as", "well", "as", "for", "sepsis", "and", "fevers", "of", "neutropenia", ",", "and", "it", "may", "be", "necessary", "to", "discontinue", "the", "drug", "."], "event_mentions": [{"id": "14740795_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 4, "end": 5}, "arguments": [{"entity_id": "14740795_3_Ent2", "role": "Treatment", "text": "amifostine", "start": 2, "end": 3}, {"entity_id": "14740795_3_Ent3", "role": "Treatment_Drug", "text": "amifostine", "start": 2, "end": 3}, {"entity_id": "14740795_3_Ent0", "role": "Effect", "text": "fever", "start": 6, "end": 7}, {"entity_id": "14740795_3_Ent1", "role": "Effect", "text": "sepsis and fevers of neutropenia", "start": 20, "end": 25}]}], "entity_mentions": [{"id": "14740795_3_Ent2", "text": "amifostine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "14740795_3_Ent3", "text": "amifostine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "14740795_3_Ent0", "text": "fever", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14740795_3_Ent1", "text": "sepsis and fevers of neutropenia", "entity_type": "Entity", "start": 20, "end": 25}], "lang": "en"}
{"doc_id": "14742791_3", "wnd_id": "14742791_3_1", "text": "OBJECTIVE : To describe what is believed , as of November 4 , 2003 , to be the first case published in the literature of acute interstitial nephritis ( AIN ) due to pantoprazole .", "tokens": ["OBJECTIVE", ":", "To", "describe", "what", "is", "believed", ",", "as", "of", "November", "4", ",", "2003", ",", "to", "be", "the", "first", "case", "published", "in", "the", "literature", "of", "acute", "interstitial", "nephritis", "(", "AIN", ")", "due", "to", "pantoprazole", "."], "event_mentions": [{"id": "14742791_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 31, "end": 32}, "arguments": [{"entity_id": "14742791_3_Ent0", "role": "Effect", "text": "acute interstitial nephritis ( AIN )", "start": 25, "end": 31}, {"entity_id": "14742791_3_Ent1", "role": "Treatment", "text": "pantoprazole", "start": 33, "end": 34}, {"entity_id": "14742791_3_Ent2", "role": "Treatment_Drug", "text": "pantoprazole", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "14742791_3_Ent0", "text": "acute interstitial nephritis ( AIN )", "entity_type": "Entity", "start": 25, "end": 31}, {"id": "14742791_3_Ent1", "text": "pantoprazole", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "14742791_3_Ent2", "text": "pantoprazole", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "14746605_1", "wnd_id": "14746605_1_1", "text": "It was highly suspected that finasteride was associated with the anterior subcapsular opacity on the lens , and the patient therefore discontinued use of finasteride .", "tokens": ["It", "was", "highly", "suspected", "that", "finasteride", "was", "associated", "with", "the", "anterior", "subcapsular", "opacity", "on", "the", "lens", ",", "and", "the", "patient", "therefore", "discontinued", "use", "of", "finasteride", "."], "event_mentions": [{"id": "14746605_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "14746605_1_Ent2", "role": "Treatment", "text": "finasteride", "start": 5, "end": 6}, {"entity_id": "14746605_1_Ent3", "role": "Treatment_Drug", "text": "finasteride", "start": 5, "end": 6}, {"entity_id": "14746605_1_Ent1", "role": "Effect", "text": "anterior subcapsular opacity on the lens", "start": 10, "end": 16}, {"entity_id": "14746605_1_Ent0", "role": "Subject", "text": "the patient", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "14746605_1_Ent2", "text": "finasteride", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "14746605_1_Ent3", "text": "finasteride", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "14746605_1_Ent1", "text": "anterior subcapsular opacity on the lens", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "14746605_1_Ent0", "text": "the patient", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "14746605_2", "wnd_id": "14746605_2_1", "text": "Propecia - associated bilateral cataract .", "tokens": ["Propecia", "-", "associated", "bilateral", "cataract", "."], "event_mentions": [{"id": "14746605_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "14746605_2_Ent1", "role": "Treatment", "text": "Propecia", "start": 0, "end": 1}, {"entity_id": "14746605_2_Ent2", "role": "Treatment_Drug", "text": "Propecia", "start": 0, "end": 1}, {"entity_id": "14746605_2_Ent0", "role": "Effect", "text": "bilateral cataract", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "14746605_2_Ent1", "text": "Propecia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14746605_2_Ent2", "text": "Propecia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14746605_2_Ent0", "text": "bilateral cataract", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "1477441_3", "wnd_id": "1477441_3_1", "text": "Fixed drug eruption of the scrotum due to methylphenidate .", "tokens": ["Fixed", "drug", "eruption", "of", "the", "scrotum", "due", "to", "methylphenidate", "."], "event_mentions": [{"id": "1477441_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 6, "end": 7}, "arguments": [{"entity_id": "1477441_3_Ent0", "role": "Effect", "text": "Fixed drug eruption of the scrotum", "start": 0, "end": 6}, {"entity_id": "1477441_3_Ent1", "role": "Treatment", "text": "methylphenidate", "start": 8, "end": 9}, {"entity_id": "1477441_3_Ent2", "role": "Treatment_Drug", "text": "methylphenidate", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "1477441_3_Ent0", "text": "Fixed drug eruption of the scrotum", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "1477441_3_Ent1", "text": "methylphenidate", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1477441_3_Ent2", "text": "methylphenidate", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "14960440_1", "wnd_id": "14960440_1_1", "text": "BACKGROUND : The risk / benefit ratio of warfarin therapy changes in the over 75s , when haemorrhagic side - effects become more common .", "tokens": ["BACKGROUND", ":", "The", "risk", "/", "benefit", "ratio", "of", "warfarin", "therapy", "changes", "in", "the", "over", "75s", ",", "when", "haemorrhagic", "side", "-", "effects", "become", "more", "common", "."], "event_mentions": [{"id": "14960440_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "become", "start": 21, "end": 22}, "arguments": [{"entity_id": "14960440_1_Ent4", "role": "Treatment_Drug", "text": "warfarin", "start": 8, "end": 9}, {"entity_id": "14960440_1_Ent3", "role": "Treatment", "text": "warfarin therapy", "start": 8, "end": 10}, {"entity_id": "14960440_1_Ent0", "role": "Subject", "text": "over 75s", "start": 13, "end": 15}, {"entity_id": "14960440_1_Ent1", "role": "Subject_Age", "text": "over 75s", "start": 13, "end": 15}, {"entity_id": "14960440_1_Ent2", "role": "Effect", "text": "haemorrhagic side - effects", "start": 17, "end": 21}]}], "entity_mentions": [{"id": "14960440_1_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "14960440_1_Ent3", "text": "warfarin therapy", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "14960440_1_Ent0", "text": "over 75s", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "14960440_1_Ent1", "text": "over 75s", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "14960440_1_Ent2", "text": "haemorrhagic side - effects", "entity_type": "Entity", "start": 17, "end": 21}], "lang": "en"}
{"doc_id": "14960440_2", "wnd_id": "14960440_2_1", "text": "CASE REPORT : A woman of 80 years , on long - term warfarin therapy presented with an acute dissecting thoracic aortic aneurysm ; on investigation the only precipitating factor found was an international normalised ratio of 4.8 .", "tokens": ["CASE", "REPORT", ":", "A", "woman", "of", "80", "years", ",", "on", "long", "-", "term", "warfarin", "therapy", "presented", "with", "an", "acute", "dissecting", "thoracic", "aortic", "aneurysm", ";", "on", "investigation", "the", "only", "precipitating", "factor", "found", "was", "an", "international", "normalised", "ratio", "of", "4.8", "."], "event_mentions": [{"id": "14960440_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 15, "end": 16}, "arguments": [{"entity_id": "14960440_2_Ent0", "role": "Subject", "text": "A woman of 80 years", "start": 3, "end": 8}, {"entity_id": "14960440_2_Ent1", "role": "Subject_Gender", "text": "woman", "start": 4, "end": 5}, {"entity_id": "14960440_2_Ent2", "role": "Subject_Age", "text": "80 years", "start": 6, "end": 8}, {"entity_id": "14960440_2_Ent4", "role": "Treatment", "text": "on long - term warfarin", "start": 9, "end": 14}, {"entity_id": "14960440_2_Ent5", "role": "Treatment_Duration", "text": "long - term", "start": 10, "end": 13}, {"entity_id": "14960440_2_Ent6", "role": "Treatment_Drug", "text": "warfarin", "start": 13, "end": 14}, {"entity_id": "14960440_2_Ent3", "role": "Effect", "text": "acute dissecting thoracic aortic aneurysm", "start": 18, "end": 23}]}], "entity_mentions": [{"id": "14960440_2_Ent0", "text": "A woman of 80 years", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "14960440_2_Ent1", "text": "woman", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "14960440_2_Ent2", "text": "80 years", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "14960440_2_Ent4", "text": "on long - term warfarin", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "14960440_2_Ent5", "text": "long - term", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "14960440_2_Ent6", "text": "warfarin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "14960440_2_Ent3", "text": "acute dissecting thoracic aortic aneurysm", "entity_type": "Entity", "start": 18, "end": 23}], "lang": "en"}
{"doc_id": "14964753_1", "wnd_id": "14964753_1_1", "text": "Cutaneous vasculitis secondary to ramipril .", "tokens": ["Cutaneous", "vasculitis", "secondary", "to", "ramipril", "."], "event_mentions": [{"id": "14964753_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 2, "end": 3}, "arguments": [{"entity_id": "14964753_1_Ent0", "role": "Effect", "text": "Cutaneous vasculitis", "start": 0, "end": 2}, {"entity_id": "14964753_1_Ent1", "role": "Treatment", "text": "ramipril", "start": 4, "end": 5}, {"entity_id": "14964753_1_Ent2", "role": "Treatment_Drug", "text": "ramipril", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "14964753_1_Ent0", "text": "Cutaneous vasculitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "14964753_1_Ent1", "text": "ramipril", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "14964753_1_Ent2", "text": "ramipril", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "14964753_2", "wnd_id": "14964753_2_1", "text": "A 61 - year - old patient who had been treated with lisinopril in the past without any problems was commenced on ramipril for left ventricular dysfunction .", "tokens": ["A", "61", "-", "year", "-", "old", "patient", "who", "had", "been", "treated", "with", "lisinopril", "in", "the", "past", "without", "any", "problems", "was", "commenced", "on", "ramipril", "for", "left", "ventricular", "dysfunction", "."], "event_mentions": [{"id": "14964753_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "commenced", "start": 20, "end": 21}, "arguments": [{"entity_id": "14964753_2_Ent0", "role": "Subject", "text": "A 61 - year - old patient who had been treated with lisinopril in the past without any problems", "start": 0, "end": 19}, {"entity_id": "14964753_2_Ent1", "role": "Subject_Age", "text": "61 - year - old", "start": 1, "end": 6}, {"entity_id": "14964753_2_Ent2", "role": "Treatment", "text": "ramipril", "start": 22, "end": 23}, {"entity_id": "14964753_2_Ent3", "role": "Treatment_Drug", "text": "ramipril", "start": 22, "end": 23}, {"entity_id": "14964753_2_Ent4", "role": "Treatment_Disorder", "text": "left ventricular dysfunction", "start": 24, "end": 27}]}], "entity_mentions": [{"id": "14964753_2_Ent0", "text": "A 61 - year - old patient who had been treated with lisinopril in the past without any problems", "entity_type": "Entity", "start": 0, "end": 19}, {"id": "14964753_2_Ent1", "text": "61 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "14964753_2_Ent2", "text": "ramipril", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "14964753_2_Ent3", "text": "ramipril", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "14964753_2_Ent4", "text": "left ventricular dysfunction", "entity_type": "Entity", "start": 24, "end": 27}], "lang": "en"}
{"doc_id": "14964753_5", "wnd_id": "14964753_5_1", "text": "Ramipril was stopped and he required a course of steroids after which the rash improved slowly .", "tokens": ["Ramipril", "was", "stopped", "and", "he", "required", "a", "course", "of", "steroids", "after", "which", "the", "rash", "improved", "slowly", "."], "event_mentions": [{"id": "14964753_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "improved", "start": 14, "end": 15}, "arguments": [{"entity_id": "14964753_5_Ent0", "role": "Subject", "text": "he", "start": 4, "end": 5}, {"entity_id": "14964753_5_Ent1", "role": "Subject_Gender", "text": "he", "start": 4, "end": 5}, {"entity_id": "14964753_5_Ent5", "role": "Treatment_Dosage", "text": "a course", "start": 6, "end": 8}, {"entity_id": "14964753_5_Ent3", "role": "Treatment", "text": "a course of steroids", "start": 6, "end": 10}, {"entity_id": "14964753_5_Ent6", "role": "Treatment_Drug", "text": "steroids", "start": 9, "end": 10}, {"entity_id": "14964753_5_Ent2", "role": "Effect", "text": "the rash improved slowly", "start": 12, "end": 16}, {"entity_id": "14964753_5_Ent4", "role": "Treatment_Disorder", "text": "rash", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "14964753_5_Ent0", "text": "he", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "14964753_5_Ent1", "text": "he", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "14964753_5_Ent5", "text": "a course", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "14964753_5_Ent3", "text": "a course of steroids", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "14964753_5_Ent6", "text": "steroids", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "14964753_5_Ent2", "text": "the rash improved slowly", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "14964753_5_Ent4", "text": "rash", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "14968106_1", "wnd_id": "14968106_1_1", "text": "CONCLUSION : This is , to our knowledge , the first report of severe myelopathy following accidental intrathecal administration of doxorubicin .", "tokens": ["CONCLUSION", ":", "This", "is", ",", "to", "our", "knowledge", ",", "the", "first", "report", "of", "severe", "myelopathy", "following", "accidental", "intrathecal", "administration", "of", "doxorubicin", "."], "event_mentions": [{"id": "14968106_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 15, "end": 16}, "arguments": [{"entity_id": "14968106_1_Ent0", "role": "Effect", "text": "severe myelopathy", "start": 13, "end": 15}, {"entity_id": "14968106_1_Ent3", "role": "Treatment_Route", "text": "intrathecal administration", "start": 17, "end": 19}, {"entity_id": "14968106_1_Ent1", "role": "Treatment", "text": "intrathecal administration of doxorubicin", "start": 17, "end": 21}, {"entity_id": "14968106_1_Ent2", "role": "Treatment_Drug", "text": "doxorubicin", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "14968106_1_Ent0", "text": "severe myelopathy", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "14968106_1_Ent3", "text": "intrathecal administration", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "14968106_1_Ent1", "text": "intrathecal administration of doxorubicin", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "14968106_1_Ent2", "text": "doxorubicin", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "14971874_1", "wnd_id": "14971874_1_1", "text": "After infliximab treatment , additional sleep studies revealed an increase in the number of apneic events and SaO2 dips suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea .", "tokens": ["After", "infliximab", "treatment", ",", "additional", "sleep", "studies", "revealed", "an", "increase", "in", "the", "number", "of", "apneic", "events", "and", "SaO2", "dips", "suggesting", "that", "TNFalpha", "plays", "an", "important", "role", "in", "the", "pathophysiology", "of", "sleep", "apnea", "."], "event_mentions": [{"id": "14971874_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increase", "start": 9, "end": 10}, "arguments": [{"entity_id": "14971874_1_Ent1", "role": "Treatment", "text": "infliximab", "start": 1, "end": 2}, {"entity_id": "14971874_1_Ent3", "role": "Treatment_Drug", "text": "infliximab", "start": 1, "end": 2}, {"entity_id": "14971874_1_Ent0", "role": "Effect", "text": "increase in the number of apneic events and SaO2 dips", "start": 9, "end": 19}, {"entity_id": "14971874_1_Ent2", "role": "Treatment_Disorder", "text": "pathophysiology of sleep apnea", "start": 28, "end": 32}]}], "entity_mentions": [{"id": "14971874_1_Ent1", "text": "infliximab", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "14971874_1_Ent3", "text": "infliximab", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "14971874_1_Ent0", "text": "increase in the number of apneic events and SaO2 dips", "entity_type": "Entity", "start": 9, "end": 19}, {"id": "14971874_1_Ent2", "text": "pathophysiology of sleep apnea", "entity_type": "Entity", "start": 28, "end": 32}], "lang": "en"}
{"doc_id": "14996269_2", "wnd_id": "14996269_2_1", "text": "We describe two ELBW infants affected by hyperkalaemia , treated with Kayexalate , who developed serious hypernatraemia , that has never been reported before in preterm infants .", "tokens": ["We", "describe", "two", "ELBW", "infants", "affected", "by", "hyperkalaemia", ",", "treated", "with", "Kayexalate", ",", "who", "developed", "serious", "hypernatraemia", ",", "that", "has", "never", "been", "reported", "before", "in", "preterm", "infants", "."], "event_mentions": [{"id": "14996269_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "14996269_2_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "14996269_2_Ent0", "role": "Subject", "text": "two ELBW infants affected by hyperkalaemia", "start": 2, "end": 8}, {"entity_id": "14996269_2_Ent3", "role": "Subject_Disorder", "text": "ELBW", "start": 3, "end": 4}, {"entity_id": "14996269_2_Ent2", "role": "Subject_Age", "text": "infants", "start": 4, "end": 5}, {"entity_id": "14996269_2_Ent6", "role": "Treatment_Disorder", "text": "hyperkalaemia", "start": 7, "end": 8}, {"entity_id": "14996269_2_Ent5", "role": "Treatment", "text": "Kayexalate", "start": 11, "end": 12}, {"entity_id": "14996269_2_Ent7", "role": "Treatment_Drug", "text": "Kayexalate", "start": 11, "end": 12}, {"entity_id": "14996269_2_Ent4", "role": "Effect", "text": "serious hypernatraemia", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "14996269_2_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "14996269_2_Ent0", "text": "two ELBW infants affected by hyperkalaemia", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "14996269_2_Ent3", "text": "ELBW", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14996269_2_Ent2", "text": "infants", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "14996269_2_Ent6", "text": "hyperkalaemia", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "14996269_2_Ent5", "text": "Kayexalate", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "14996269_2_Ent7", "text": "Kayexalate", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "14996269_2_Ent4", "text": "serious hypernatraemia", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "14998226_2", "wnd_id": "14998226_2_1", "text": "A 67 - year - old man receiving a stable maintenance dosage of warfarin experienced an increased international normalized ratio ( INR ) without bleeding when his atorvastatin therapy was switched to fluvastatin .", "tokens": ["A", "67", "-", "year", "-", "old", "man", "receiving", "a", "stable", "maintenance", "dosage", "of", "warfarin", "experienced", "an", "increased", "international", "normalized", "ratio", "(", "INR", ")", "without", "bleeding", "when", "his", "atorvastatin", "therapy", "was", "switched", "to", "fluvastatin", "."], "event_mentions": [{"id": "14998226_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 14, "end": 15}, "arguments": [{"entity_id": "14998226_2_Ent0", "role": "Subject", "text": "A 67 - year - old man", "start": 0, "end": 7}, {"entity_id": "14998226_2_Ent1", "role": "Subject_Age", "text": "67 - year - old", "start": 1, "end": 6}, {"entity_id": "14998226_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "14998226_2_Ent4", "role": "Treatment", "text": "warfarin", "start": 13, "end": 14}, {"entity_id": "14998226_2_Ent5", "role": "Treatment_Drug", "text": "warfarin", "start": 13, "end": 14}, {"entity_id": "14998226_2_Ent3", "role": "Effect", "text": "increased international normalized ratio ( INR )", "start": 16, "end": 23}]}, {"id": "14998226_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "switched", "start": 30, "end": 31}, "arguments": [{"entity_id": "14998226_2_Ent9", "role": "Treatment_Disorder", "text": "bleeding", "start": 24, "end": 25}, {"entity_id": "14998226_2_Ent8", "role": "Treatment_Drug", "text": "atorvastatin", "start": 27, "end": 28}, {"entity_id": "14998226_2_Ent6", "role": "Treatment", "text": "atorvastatin therapy was switched to fluvastatin", "start": 27, "end": 33}, {"entity_id": "14998226_2_Ent7", "role": "Treatment_Drug", "text": "fluvastatin", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "14998226_2_Ent0", "text": "A 67 - year - old man", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "14998226_2_Ent1", "text": "67 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "14998226_2_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14998226_2_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "14998226_2_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "14998226_2_Ent3", "text": "increased international normalized ratio ( INR )", "entity_type": "Entity", "start": 16, "end": 23}, {"id": "14998226_2_Ent9", "text": "bleeding", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "14998226_2_Ent8", "text": "atorvastatin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "14998226_2_Ent6", "text": "atorvastatin therapy was switched to fluvastatin", "entity_type": "Entity", "start": 27, "end": 33}, {"id": "14998226_2_Ent7", "text": "fluvastatin", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "15013892_1", "wnd_id": "15013892_1_1", "text": "Bull's - eye maculopathy associated with quinacrine therapy for malaria .", "tokens": ["Bull's", "-", "eye", "maculopathy", "associated", "with", "quinacrine", "therapy", "for", "malaria", "."], "event_mentions": [{"id": "15013892_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "15013892_1_Ent0", "role": "Effect", "text": "Bull's - eye maculopathy", "start": 0, "end": 4}, {"entity_id": "15013892_1_Ent1", "role": "Treatment", "text": "quinacrine", "start": 6, "end": 7}, {"entity_id": "15013892_1_Ent2", "role": "Treatment_Drug", "text": "quinacrine", "start": 6, "end": 7}, {"entity_id": "15013892_1_Ent3", "role": "Treatment_Disorder", "text": "malaria", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "15013892_1_Ent0", "text": "Bull's - eye maculopathy", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "15013892_1_Ent1", "text": "quinacrine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15013892_1_Ent2", "text": "quinacrine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15013892_1_Ent3", "text": "malaria", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "15013892_3", "wnd_id": "15013892_3_1", "text": "RESULTS : A patient developed a bilaterally symmetric bull's - eye maculopathy 45 years after taking quinacrine for 18 months as prophylaxis against malaria .", "tokens": ["RESULTS", ":", "A", "patient", "developed", "a", "bilaterally", "symmetric", "bull's", "-", "eye", "maculopathy", "45", "years", "after", "taking", "quinacrine", "for", "18", "months", "as", "prophylaxis", "against", "malaria", "."], "event_mentions": [{"id": "15013892_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 4, "end": 5}, "arguments": [{"entity_id": "15013892_3_Ent0", "role": "Effect", "text": "A patient", "start": 2, "end": 4}, {"entity_id": "15013892_3_Ent1", "role": "Effect", "text": "bilaterally symmetric bull's - eye maculopathy", "start": 6, "end": 12}, {"entity_id": "15013892_3_Ent3", "role": "Treatment_Time_elapsed", "text": "45 years after", "start": 12, "end": 15}, {"entity_id": "15013892_3_Ent2", "role": "Treatment", "text": "45 years after taking quinacrine for 18 months", "start": 12, "end": 20}, {"entity_id": "15013892_3_Ent5", "role": "Treatment_Drug", "text": "quinacrine", "start": 16, "end": 17}, {"entity_id": "15013892_3_Ent4", "role": "Treatment_Time_elapsed", "text": "18 months", "start": 18, "end": 20}, {"entity_id": "15013892_3_Ent6", "role": "Treatment_Disorder", "text": "malaria", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "15013892_3_Ent0", "text": "A patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "15013892_3_Ent1", "text": "bilaterally symmetric bull's - eye maculopathy", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "15013892_3_Ent3", "text": "45 years after", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "15013892_3_Ent2", "text": "45 years after taking quinacrine for 18 months", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "15013892_3_Ent5", "text": "quinacrine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15013892_3_Ent4", "text": "18 months", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "15013892_3_Ent6", "text": "malaria", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "15028964_7", "wnd_id": "15028964_7_1", "text": "Given that significant thyroid disorders may be only mildly symptomatic and thus may escape clinical detection , we suggest that thyroid function should be tested in any patient with otherwise unexplained changes in warfarin dose requirements , particularly if concomitantly treated with amiodarone .", "tokens": ["Given", "that", "significant", "thyroid", "disorders", "may", "be", "only", "mildly", "symptomatic", "and", "thus", "may", "escape", "clinical", "detection", ",", "we", "suggest", "that", "thyroid", "function", "should", "be", "tested", "in", "any", "patient", "with", "otherwise", "unexplained", "changes", "in", "warfarin", "dose", "requirements", ",", "particularly", "if", "concomitantly", "treated", "with", "amiodarone", "."], "event_mentions": [{"id": "15028964_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "changes", "start": 31, "end": 32}, "arguments": [{"entity_id": "15028964_7_Ent0", "role": "Effect", "text": "significant thyroid disorders", "start": 2, "end": 5}, {"entity_id": "15028964_7_Ent1", "role": "Treatment", "text": "warfarin", "start": 33, "end": 34}, {"entity_id": "15028964_7_Ent3", "role": "Treatment_Drug", "text": "warfarin", "start": 33, "end": 34}, {"entity_id": "15028964_7_Ent6", "role": "Combination_Drug", "text": "warfarin", "start": 33, "end": 34}, {"entity_id": "15028964_7_Ent2", "role": "Treatment", "text": "with amiodarone", "start": 41, "end": 43}, {"entity_id": "15028964_7_Ent4", "role": "Treatment_Drug", "text": "amiodarone", "start": 42, "end": 43}, {"entity_id": "15028964_7_Ent5", "role": "Combination_Drug", "text": "amiodarone", "start": 42, "end": 43}]}], "entity_mentions": [{"id": "15028964_7_Ent0", "text": "significant thyroid disorders", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "15028964_7_Ent1", "text": "warfarin", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "15028964_7_Ent3", "text": "warfarin", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "15028964_7_Ent6", "text": "warfarin", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "15028964_7_Ent2", "text": "with amiodarone", "entity_type": "Entity", "start": 41, "end": 43}, {"id": "15028964_7_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 42, "end": 43}, {"id": "15028964_7_Ent5", "text": "amiodarone", "entity_type": "Entity", "start": 42, "end": 43}], "lang": "en"}
{"doc_id": "1504404_2", "wnd_id": "1504404_2_1", "text": "Ciprofloxacin - induced psychosis .", "tokens": ["Ciprofloxacin", "-", "induced", "psychosis", "."], "event_mentions": [{"id": "1504404_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "1504404_2_Ent1", "role": "Treatment", "text": "Ciprofloxacin", "start": 0, "end": 1}, {"entity_id": "1504404_2_Ent2", "role": "Treatment_Drug", "text": "Ciprofloxacin", "start": 0, "end": 1}, {"entity_id": "1504404_2_Ent0", "role": "Effect", "text": "psychosis", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "1504404_2_Ent1", "text": "Ciprofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1504404_2_Ent2", "text": "Ciprofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1504404_2_Ent0", "text": "psychosis", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "15072497_2", "wnd_id": "15072497_2_1", "text": "However here we reported two patients , presenting with PD during high dose colchicine treatment for familiar mediterranean fever ( FMF ) .", "tokens": ["However", "here", "we", "reported", "two", "patients", ",", "presenting", "with", "PD", "during", "high", "dose", "colchicine", "treatment", "for", "familiar", "mediterranean", "fever", "(", "FMF", ")", "."], "event_mentions": [{"id": "15072497_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 10, "end": 11}, "arguments": [{"entity_id": "15072497_2_Ent1", "role": "Subject_Population", "text": "two", "start": 4, "end": 5}, {"entity_id": "15072497_2_Ent0", "role": "Subject", "text": "two patients ,", "start": 4, "end": 7}, {"entity_id": "15072497_2_Ent2", "role": "Effect", "text": "PD", "start": 9, "end": 10}, {"entity_id": "15072497_2_Ent4", "role": "Treatment_Dosage", "text": "high dose", "start": 11, "end": 13}, {"entity_id": "15072497_2_Ent3", "role": "Treatment", "text": "high dose colchicine treatment", "start": 11, "end": 15}, {"entity_id": "15072497_2_Ent5", "role": "Treatment_Drug", "text": "colchicine", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "15072497_2_Ent1", "text": "two", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15072497_2_Ent0", "text": "two patients ,", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "15072497_2_Ent2", "text": "PD", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15072497_2_Ent4", "text": "high dose", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "15072497_2_Ent3", "text": "high dose colchicine treatment", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "15072497_2_Ent5", "text": "colchicine", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "1509179_1", "wnd_id": "1509179_1_1", "text": "A case of phenobarbital exacerbation of a preexisting maladaptive behavior partially suppressed by chlorpromazine and misinterpreted as chlorpromazine efficacy .", "tokens": ["A", "case", "of", "phenobarbital", "exacerbation", "of", "a", "preexisting", "maladaptive", "behavior", "partially", "suppressed", "by", "chlorpromazine", "and", "misinterpreted", "as", "chlorpromazine", "efficacy", "."], "event_mentions": [{"id": "1509179_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exacerbation", "start": 4, "end": 5}, "arguments": [{"entity_id": "1509179_1_Ent3", "role": "Treatment", "text": "phenobarbital", "start": 3, "end": 4}, {"entity_id": "1509179_1_Ent5", "role": "Treatment_Drug", "text": "phenobarbital", "start": 3, "end": 4}, {"entity_id": "1509179_1_Ent7", "role": "Combination_Drug", "text": "phenobarbital", "start": 3, "end": 4}, {"entity_id": "1509179_1_Ent2", "role": "Effect", "text": "exacerbation of a preexisting maladaptive behavior", "start": 4, "end": 10}, {"entity_id": "1509179_1_Ent0", "role": "Subject", "text": "preexisting maladaptive behavior", "start": 7, "end": 10}, {"entity_id": "1509179_1_Ent1", "role": "Subject_Disorder", "text": "preexisting maladaptive behavior", "start": 7, "end": 10}, {"entity_id": "1509179_1_Ent4", "role": "Treatment", "text": "partially suppressed by chlorpromazine", "start": 10, "end": 14}, {"entity_id": "1509179_1_Ent6", "role": "Treatment_Drug", "text": "chlorpromazine", "start": 13, "end": 14}, {"entity_id": "1509179_1_Ent8", "role": "Combination_Drug", "text": "chlorpromazine", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "1509179_1_Ent3", "text": "phenobarbital", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1509179_1_Ent5", "text": "phenobarbital", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1509179_1_Ent7", "text": "phenobarbital", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1509179_1_Ent2", "text": "exacerbation of a preexisting maladaptive behavior", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "1509179_1_Ent0", "text": "preexisting maladaptive behavior", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "1509179_1_Ent1", "text": "preexisting maladaptive behavior", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "1509179_1_Ent4", "text": "partially suppressed by chlorpromazine", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "1509179_1_Ent6", "text": "chlorpromazine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "1509179_1_Ent8", "text": "chlorpromazine", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "1509179_2", "wnd_id": "1509179_2_1", "text": "Ten years of behavioral data are presented to support the hypothesis that phenobarbital was exacerbating maladaptive behaviors .", "tokens": ["Ten", "years", "of", "behavioral", "data", "are", "presented", "to", "support", "the", "hypothesis", "that", "phenobarbital", "was", "exacerbating", "maladaptive", "behaviors", "."], "event_mentions": [{"id": "1509179_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exacerbating", "start": 14, "end": 15}, "arguments": [{"entity_id": "1509179_2_Ent1", "role": "Treatment", "text": "phenobarbital", "start": 12, "end": 13}, {"entity_id": "1509179_2_Ent2", "role": "Treatment_Drug", "text": "phenobarbital", "start": 12, "end": 13}, {"entity_id": "1509179_2_Ent0", "role": "Effect", "text": "maladaptive behaviors", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "1509179_2_Ent1", "text": "phenobarbital", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1509179_2_Ent2", "text": "phenobarbital", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1509179_2_Ent0", "text": "maladaptive behaviors", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "1509179_3", "wnd_id": "1509179_3_1", "text": "This profile should trigger a \" red flag \" as to the possibility of phenobarbital behavioral side effects or exacerbation of preexisting maladaptive behaviors .", "tokens": ["This", "profile", "should", "trigger", "a", "\"", "red", "flag", "\"", "as", "to", "the", "possibility", "of", "phenobarbital", "behavioral", "side", "effects", "or", "exacerbation", "of", "preexisting", "maladaptive", "behaviors", "."], "event_mentions": [{"id": "1509179_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "trigger", "start": 3, "end": 4}, "arguments": [{"entity_id": "1509179_3_Ent1", "role": "Treatment", "text": "phenobarbital", "start": 14, "end": 15}, {"entity_id": "1509179_3_Ent2", "role": "Treatment_Drug", "text": "phenobarbital", "start": 14, "end": 15}, {"entity_id": "1509179_3_Ent0", "role": "Effect", "text": "behavioral side effects or exacerbation of preexisting maladaptive behaviors", "start": 15, "end": 24}]}], "entity_mentions": [{"id": "1509179_3_Ent1", "text": "phenobarbital", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "1509179_3_Ent2", "text": "phenobarbital", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "1509179_3_Ent0", "text": "behavioral side effects or exacerbation of preexisting maladaptive behaviors", "entity_type": "Entity", "start": 15, "end": 24}], "lang": "en"}
{"doc_id": "15107195_2", "wnd_id": "15107195_2_1", "text": "Heat stroke in schizophrenia during clozapine treatment : rapid recognition and management .", "tokens": ["Heat", "stroke", "in", "schizophrenia", "during", "clozapine", "treatment", ":", "rapid", "recognition", "and", "management", "."], "event_mentions": [{"id": "15107195_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 4, "end": 5}, "arguments": [{"entity_id": "15107195_2_Ent0", "role": "Effect", "text": "Heat stroke", "start": 0, "end": 2}, {"entity_id": "15107195_2_Ent2", "role": "Treatment_Disorder", "text": "schizophrenia", "start": 3, "end": 4}, {"entity_id": "15107195_2_Ent1", "role": "Treatment", "text": "clozapine", "start": 5, "end": 6}, {"entity_id": "15107195_2_Ent3", "role": "Treatment_Drug", "text": "clozapine", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "15107195_2_Ent0", "text": "Heat stroke", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15107195_2_Ent2", "text": "schizophrenia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15107195_2_Ent1", "text": "clozapine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15107195_2_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "15126179_1", "wnd_id": "15126179_1_1", "text": "Cystoid macular edema in a low - risk patient after switching from latanoprost to bimatoprost .", "tokens": ["Cystoid", "macular", "edema", "in", "a", "low", "-", "risk", "patient", "after", "switching", "from", "latanoprost", "to", "bimatoprost", "."], "event_mentions": [{"id": "15126179_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 3, "end": 4}, "arguments": [{"entity_id": "15126179_1_Ent1", "role": "Effect", "text": "Cystoid macular edema", "start": 0, "end": 3}, {"entity_id": "15126179_1_Ent0", "role": "Subject", "text": "low - risk patient", "start": 5, "end": 9}, {"entity_id": "15126179_1_Ent2", "role": "Treatment", "text": "switching from latanoprost to bimatoprost", "start": 10, "end": 15}, {"entity_id": "15126179_1_Ent4", "role": "Treatment_Drug", "text": "latanoprost", "start": 12, "end": 13}, {"entity_id": "15126179_1_Ent5", "role": "Combination_Drug", "text": "latanoprost", "start": 12, "end": 13}, {"entity_id": "15126179_1_Ent3", "role": "Treatment_Drug", "text": "bimatoprost", "start": 14, "end": 15}, {"entity_id": "15126179_1_Ent6", "role": "Combination_Drug", "text": "bimatoprost", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "15126179_1_Ent1", "text": "Cystoid macular edema", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15126179_1_Ent0", "text": "low - risk patient", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "15126179_1_Ent2", "text": "switching from latanoprost to bimatoprost", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "15126179_1_Ent4", "text": "latanoprost", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15126179_1_Ent5", "text": "latanoprost", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15126179_1_Ent3", "text": "bimatoprost", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "15126179_1_Ent6", "text": "bimatoprost", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "15162903_3", "wnd_id": "15162903_3_1", "text": "Fatal acute encephalomyelitis after a single dose of intrathecal methotrexate .", "tokens": ["Fatal", "acute", "encephalomyelitis", "after", "a", "single", "dose", "of", "intrathecal", "methotrexate", "."], "event_mentions": [{"id": "15162903_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "15162903_3_Ent0", "role": "Effect", "text": "Fatal acute encephalomyelitis", "start": 0, "end": 3}, {"entity_id": "15162903_3_Ent2", "role": "Treatment_Dosage", "text": "single dose", "start": 5, "end": 7}, {"entity_id": "15162903_3_Ent1", "role": "Treatment", "text": "single dose of intrathecal methotrexate", "start": 5, "end": 10}, {"entity_id": "15162903_3_Ent3", "role": "Treatment_Route", "text": "intrathecal", "start": 8, "end": 9}, {"entity_id": "15162903_3_Ent4", "role": "Treatment_Drug", "text": "methotrexate", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "15162903_3_Ent0", "text": "Fatal acute encephalomyelitis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15162903_3_Ent2", "text": "single dose", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "15162903_3_Ent1", "text": "single dose of intrathecal methotrexate", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "15162903_3_Ent3", "text": "intrathecal", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15162903_3_Ent4", "text": "methotrexate", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "15162903_4", "wnd_id": "15162903_4_1", "text": "The day after methotrexate administration , the patient complained of severe back pain and urinary retention .", "tokens": ["The", "day", "after", "methotrexate", "administration", ",", "the", "patient", "complained", "of", "severe", "back", "pain", "and", "urinary", "retention", "."], "event_mentions": [{"id": "15162903_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complained", "start": 8, "end": 9}, "arguments": [{"entity_id": "15162903_4_Ent3", "role": "Treatment_Time_elapsed", "text": "The day after", "start": 0, "end": 3}, {"entity_id": "15162903_4_Ent1", "role": "Treatment", "text": "The day after methotrexate administration", "start": 0, "end": 5}, {"entity_id": "15162903_4_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 3, "end": 4}, {"entity_id": "15162903_4_Ent0", "role": "Effect", "text": "severe back pain and urinary retention", "start": 10, "end": 16}]}], "entity_mentions": [{"id": "15162903_4_Ent3", "text": "The day after", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15162903_4_Ent1", "text": "The day after methotrexate administration", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "15162903_4_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15162903_4_Ent0", "text": "severe back pain and urinary retention", "entity_type": "Entity", "start": 10, "end": 16}], "lang": "en"}
{"doc_id": "1517501_4", "wnd_id": "1517501_4_1", "text": "We report a third case of a 6 - week - old infant with Escherichia coli sepsis who received ampicillin and other antibiotics and subsequently developed TEN .", "tokens": ["We", "report", "a", "third", "case", "of", "a", "6", "-", "week", "-", "old", "infant", "with", "Escherichia", "coli", "sepsis", "who", "received", "ampicillin", "and", "other", "antibiotics", "and", "subsequently", "developed", "TEN", "."], "event_mentions": [{"id": "1517501_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 25, "end": 26}, "arguments": [{"entity_id": "1517501_4_Ent1", "role": "Subject_Age", "text": "6 - week - old", "start": 7, "end": 12}, {"entity_id": "1517501_4_Ent0", "role": "Subject", "text": "6 - week - old infant with Escherichia coli sepsis", "start": 7, "end": 17}, {"entity_id": "1517501_4_Ent2", "role": "Subject_Age", "text": "infant", "start": 12, "end": 13}, {"entity_id": "1517501_4_Ent7", "role": "Treatment_Disorder", "text": "Escherichia coli sepsis", "start": 14, "end": 17}, {"entity_id": "1517501_4_Ent4", "role": "Treatment", "text": "received ampicillin and other antibiotics", "start": 18, "end": 23}, {"entity_id": "1517501_4_Ent5", "role": "Treatment_Drug", "text": "ampicillin", "start": 19, "end": 20}, {"entity_id": "1517501_4_Ent8", "role": "Combination_Drug", "text": "ampicillin", "start": 19, "end": 20}, {"entity_id": "1517501_4_Ent6", "role": "Treatment_Drug", "text": "other antibiotics", "start": 21, "end": 23}, {"entity_id": "1517501_4_Ent9", "role": "Combination_Drug", "text": "other antibiotics", "start": 21, "end": 23}, {"entity_id": "1517501_4_Ent3", "role": "Effect", "text": "TEN", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "1517501_4_Ent1", "text": "6 - week - old", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "1517501_4_Ent0", "text": "6 - week - old infant with Escherichia coli sepsis", "entity_type": "Entity", "start": 7, "end": 17}, {"id": "1517501_4_Ent2", "text": "infant", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1517501_4_Ent7", "text": "Escherichia coli sepsis", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "1517501_4_Ent4", "text": "received ampicillin and other antibiotics", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "1517501_4_Ent5", "text": "ampicillin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "1517501_4_Ent8", "text": "ampicillin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "1517501_4_Ent6", "text": "other antibiotics", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "1517501_4_Ent9", "text": "other antibiotics", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "1517501_4_Ent3", "text": "TEN", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "15197722_2", "wnd_id": "15197722_2_1", "text": "Restless legs syndrome due to interferon - alpha .", "tokens": ["Restless", "legs", "syndrome", "due", "to", "interferon", "-", "alpha", "."], "event_mentions": [{"id": "15197722_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 3, "end": 4}, "arguments": [{"entity_id": "15197722_2_Ent0", "role": "Effect", "text": "Restless legs syndrome", "start": 0, "end": 3}, {"entity_id": "15197722_2_Ent1", "role": "Treatment", "text": "interferon - alpha", "start": 5, "end": 8}, {"entity_id": "15197722_2_Ent2", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 5, "end": 8}]}], "entity_mentions": [{"id": "15197722_2_Ent0", "text": "Restless legs syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15197722_2_Ent1", "text": "interferon - alpha", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "15197722_2_Ent2", "text": "interferon - alpha", "entity_type": "Entity", "start": 5, "end": 8}], "lang": "en"}
{"doc_id": "15197722_3", "wnd_id": "15197722_3_1", "text": "Restless legs syndrome may thus be an adverse effect of IFN alpha treatment .", "tokens": ["Restless", "legs", "syndrome", "may", "thus", "be", "an", "adverse", "effect", "of", "IFN", "alpha", "treatment", "."], "event_mentions": [{"id": "15197722_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse effect", "start": 7, "end": 9}, "arguments": [{"entity_id": "15197722_3_Ent0", "role": "Effect", "text": "Restless legs syndrome", "start": 0, "end": 3}, {"entity_id": "15197722_3_Ent2", "role": "Treatment_Drug", "text": "IFN alpha", "start": 10, "end": 12}, {"entity_id": "15197722_3_Ent1", "role": "Treatment", "text": "IFN alpha treatment .", "start": 10, "end": 14}]}], "entity_mentions": [{"id": "15197722_3_Ent0", "text": "Restless legs syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15197722_3_Ent2", "text": "IFN alpha", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "15197722_3_Ent1", "text": "IFN alpha treatment .", "entity_type": "Entity", "start": 10, "end": 14}], "lang": "en"}
{"doc_id": "15279668_1", "wnd_id": "15279668_1_1", "text": "Fatal peripheral neuropathy following FLA chemotherapy .", "tokens": ["Fatal", "peripheral", "neuropathy", "following", "FLA", "chemotherapy", "."], "event_mentions": [{"id": "15279668_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "15279668_1_Ent0", "role": "Effect", "text": "Fatal peripheral neuropathy", "start": 0, "end": 3}, {"entity_id": "15279668_1_Ent2", "role": "Treatment_Drug", "text": "FLA", "start": 4, "end": 5}, {"entity_id": "15279668_1_Ent1", "role": "Treatment", "text": "FLA chemotherapy", "start": 4, "end": 6}, {"entity_id": "15279668_1_Ent3", "role": "Treatment_Route", "text": "chemotherapy", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "15279668_1_Ent0", "text": "Fatal peripheral neuropathy", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15279668_1_Ent2", "text": "FLA", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15279668_1_Ent1", "text": "FLA chemotherapy", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "15279668_1_Ent3", "text": "chemotherapy", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "15316423_2", "wnd_id": "15316423_2_1", "text": "Here we describe a patient with Crohn 's disease who developed a severe infliximab infusion reaction ( IIR ) , complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of infliximab infusion .", "tokens": ["Here", "we", "describe", "a", "patient", "with", "Crohn", "'s", "disease", "who", "developed", "a", "severe", "infliximab", "infusion", "reaction", "(", "IIR", ")", ",", "complicated", "1", "day", "later", "by", "severe", "swelling", "of", "the", "forearm", "and", "hand", "ipsilateral", "to", "the", "site", "of", "infliximab", "infusion", "."], "event_mentions": [{"id": "15316423_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "15316423_2_Ent0", "role": "Subject", "text": "a patient with Crohn 's disease", "start": 3, "end": 9}, {"entity_id": "15316423_2_Ent5", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 6, "end": 9}, {"entity_id": "15316423_2_Ent1", "role": "Effect", "text": "severe infliximab infusion reaction ( IIR ) , complicated 1 day later by severe swelling of the forearm and hand ipsilateral", "start": 12, "end": 33}, {"entity_id": "15316423_2_Ent3", "role": "Treatment_Drug", "text": "infliximab", "start": 37, "end": 38}, {"entity_id": "15316423_2_Ent2", "role": "Treatment", "text": "infliximab infusion", "start": 37, "end": 39}, {"entity_id": "15316423_2_Ent4", "role": "Treatment_Route", "text": "infusion", "start": 38, "end": 39}]}], "entity_mentions": [{"id": "15316423_2_Ent0", "text": "a patient with Crohn 's disease", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "15316423_2_Ent5", "text": "Crohn 's disease", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "15316423_2_Ent1", "text": "severe infliximab infusion reaction ( IIR ) , complicated 1 day later by severe swelling of the forearm and hand ipsilateral", "entity_type": "Entity", "start": 12, "end": 33}, {"id": "15316423_2_Ent3", "text": "infliximab", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "15316423_2_Ent2", "text": "infliximab infusion", "entity_type": "Entity", "start": 37, "end": 39}, {"id": "15316423_2_Ent4", "text": "infusion", "entity_type": "Entity", "start": 38, "end": 39}], "lang": "en"}
{"doc_id": "15316423_3", "wnd_id": "15316423_3_1", "text": "The site of thrombosis and the chronological relationship with the IIR implicates a hypersensitivity to infliximab in the causation of the venous thrombosis in this case .", "tokens": ["The", "site", "of", "thrombosis", "and", "the", "chronological", "relationship", "with", "the", "IIR", "implicates", "a", "hypersensitivity", "to", "infliximab", "in", "the", "causation", "of", "the", "venous", "thrombosis", "in", "this", "case", "."], "event_mentions": [{"id": "15316423_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causation", "start": 18, "end": 19}, "arguments": [{"entity_id": "15316423_3_Ent1", "role": "Treatment", "text": "infliximab", "start": 15, "end": 16}, {"entity_id": "15316423_3_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 15, "end": 16}, {"entity_id": "15316423_3_Ent0", "role": "Effect", "text": "venous thrombosis", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "15316423_3_Ent1", "text": "infliximab", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15316423_3_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15316423_3_Ent0", "text": "venous thrombosis", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "15331204_1", "wnd_id": "15331204_1_1", "text": "Possible induction of diabetes by treatment of hypertension with indapamide ( with four case reports ) .", "tokens": ["Possible", "induction", "of", "diabetes", "by", "treatment", "of", "hypertension", "with", "indapamide", "(", "with", "four", "case", "reports", ")", "."], "event_mentions": [{"id": "15331204_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induction", "start": 1, "end": 2}, "arguments": [{"entity_id": "15331204_1_Ent0", "role": "Effect", "text": "diabetes", "start": 3, "end": 4}, {"entity_id": "15331204_1_Ent2", "role": "Treatment_Disorder", "text": "hypertension", "start": 7, "end": 8}, {"entity_id": "15331204_1_Ent1", "role": "Treatment", "text": "indapamide", "start": 9, "end": 10}, {"entity_id": "15331204_1_Ent3", "role": "Treatment_Drug", "text": "indapamide", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "15331204_1_Ent0", "text": "diabetes", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15331204_1_Ent2", "text": "hypertension", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15331204_1_Ent1", "text": "indapamide", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15331204_1_Ent3", "text": "indapamide", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "15331204_2", "wnd_id": "15331204_2_1", "text": "OBJECTIVE : To study therapy with indapamide impairing carbohydrate metabolism in essential hypertension patients and achieve earlier prevention , diagnoses and treatment of diabetes induced by indapamide .", "tokens": ["OBJECTIVE", ":", "To", "study", "therapy", "with", "indapamide", "impairing", "carbohydrate", "metabolism", "in", "essential", "hypertension", "patients", "and", "achieve", "earlier", "prevention", ",", "diagnoses", "and", "treatment", "of", "diabetes", "induced", "by", "indapamide", "."], "event_mentions": [{"id": "15331204_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "therapy", "start": 4, "end": 5}, "arguments": [{"entity_id": "15331204_2_Ent1", "role": "Treatment", "text": "indapamide", "start": 6, "end": 7}, {"entity_id": "15331204_2_Ent4", "role": "Treatment_Drug", "text": "indapamide", "start": 6, "end": 7}, {"entity_id": "15331204_2_Ent2", "role": "Treatment_Disorder", "text": "carbohydrate metabolism", "start": 8, "end": 10}, {"entity_id": "15331204_2_Ent0", "role": "Subject", "text": "essential hypertension patients", "start": 11, "end": 14}, {"entity_id": "15331204_2_Ent3", "role": "Treatment_Disorder", "text": "hypertension", "start": 12, "end": 13}]}, {"id": "15331204_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 24, "end": 25}, "arguments": [{"entity_id": "15331204_2_Ent5", "role": "Effect", "text": "diabetes", "start": 23, "end": 24}, {"entity_id": "15331204_2_Ent6", "role": "Treatment", "text": "indapamide", "start": 26, "end": 27}, {"entity_id": "15331204_2_Ent7", "role": "Treatment_Drug", "text": "indapamide", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "15331204_2_Ent1", "text": "indapamide", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15331204_2_Ent4", "text": "indapamide", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15331204_2_Ent2", "text": "carbohydrate metabolism", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "15331204_2_Ent0", "text": "essential hypertension patients", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "15331204_2_Ent3", "text": "hypertension", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15331204_2_Ent5", "text": "diabetes", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "15331204_2_Ent6", "text": "indapamide", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "15331204_2_Ent7", "text": "indapamide", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "15331204_8", "wnd_id": "15331204_8_1", "text": "After stopping indapamide , glucose tolerance impairing may be reversed .", "tokens": ["After", "stopping", "indapamide", ",", "glucose", "tolerance", "impairing", "may", "be", "reversed", "."], "event_mentions": [{"id": "15331204_8_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "stopping", "start": 1, "end": 2}, "arguments": [{"entity_id": "15331204_8_Ent2", "role": "Treatment_Drug", "text": "indapamide", "start": 2, "end": 3}, {"entity_id": "15331204_8_Ent0", "role": "Treatment", "text": "indapamide , glucose tolerance impairing", "start": 2, "end": 7}, {"entity_id": "15331204_8_Ent1", "role": "Treatment_Disorder", "text": "glucose tolerance impairing", "start": 4, "end": 7}]}], "entity_mentions": [{"id": "15331204_8_Ent2", "text": "indapamide", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "15331204_8_Ent0", "text": "indapamide , glucose tolerance impairing", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "15331204_8_Ent1", "text": "glucose tolerance impairing", "entity_type": "Entity", "start": 4, "end": 7}], "lang": "en"}
{"doc_id": "15338554_5", "wnd_id": "15338554_5_1", "text": "Our findings suggest that significant progression of marrow reticulin fibrosis during imatinib therapy can be an indicator for a return or progression of CML and , in some patients with CML , imatinib may promote cytogenetic clonal evolution , resulting in a poor response to treatment .", "tokens": ["Our", "findings", "suggest", "that", "significant", "progression", "of", "marrow", "reticulin", "fibrosis", "during", "imatinib", "therapy", "can", "be", "an", "indicator", "for", "a", "return", "or", "progression", "of", "CML", "and", ",", "in", "some", "patients", "with", "CML", ",", "imatinib", "may", "promote", "cytogenetic", "clonal", "evolution", ",", "resulting", "in", "a", "poor", "response", "to", "treatment", "."], "event_mentions": [{"id": "15338554_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 10, "end": 11}, "arguments": [{"entity_id": "15338554_5_Ent0", "role": "Effect", "text": "significant progression of marrow reticulin fibrosis", "start": 4, "end": 10}, {"entity_id": "15338554_5_Ent1", "role": "Treatment", "text": "imatinib", "start": 11, "end": 12}, {"entity_id": "15338554_5_Ent2", "role": "Treatment_Drug", "text": "imatinib", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "15338554_5_Ent0", "text": "significant progression of marrow reticulin fibrosis", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "15338554_5_Ent1", "text": "imatinib", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15338554_5_Ent2", "text": "imatinib", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "15338554_6", "wnd_id": "15338554_6_1", "text": "Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate .", "tokens": ["Progression", "of", "chronic", "myeloid", "leukemia", "to", "blast", "crisis", "during", "treatment", "with", "imatinib", "mesylate", "."], "event_mentions": [{"id": "15338554_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 8, "end": 9}, "arguments": [{"entity_id": "15338554_6_Ent0", "role": "Effect", "text": "Progression of chronic myeloid leukemia to blast crisis", "start": 0, "end": 8}, {"entity_id": "15338554_6_Ent1", "role": "Treatment", "text": "imatinib mesylate", "start": 11, "end": 13}, {"entity_id": "15338554_6_Ent2", "role": "Treatment_Drug", "text": "imatinib mesylate", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "15338554_6_Ent0", "text": "Progression of chronic myeloid leukemia to blast crisis", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "15338554_6_Ent1", "text": "imatinib mesylate", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "15338554_6_Ent2", "text": "imatinib mesylate", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "15362597_2", "wnd_id": "15362597_2_1", "text": "We present a case of a diabetic patient taking glyburide who was prescribed ciprofloxacin and developed prolonged hypoglycemia , which persisted for over 24 hours .", "tokens": ["We", "present", "a", "case", "of", "a", "diabetic", "patient", "taking", "glyburide", "who", "was", "prescribed", "ciprofloxacin", "and", "developed", "prolonged", "hypoglycemia", ",", "which", "persisted", "for", "over", "24", "hours", "."], "event_mentions": [{"id": "15362597_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 15, "end": 16}, "arguments": [{"entity_id": "15362597_2_Ent0", "role": "Subject", "text": "a case of a diabetic patient taking glyburide", "start": 2, "end": 10}, {"entity_id": "15362597_2_Ent5", "role": "Treatment_Disorder", "text": "diabetic", "start": 6, "end": 7}, {"entity_id": "15362597_2_Ent3", "role": "Treatment_Drug", "text": "glyburide", "start": 9, "end": 10}, {"entity_id": "15362597_2_Ent6", "role": "Combination_Drug", "text": "glyburide", "start": 9, "end": 10}, {"entity_id": "15362597_2_Ent2", "role": "Treatment", "text": "ciprofloxacin", "start": 13, "end": 14}, {"entity_id": "15362597_2_Ent4", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 13, "end": 14}, {"entity_id": "15362597_2_Ent7", "role": "Combination_Drug", "text": "ciprofloxacin", "start": 13, "end": 14}, {"entity_id": "15362597_2_Ent1", "role": "Effect", "text": "prolonged hypoglycemia , which persisted for over 24 hours", "start": 16, "end": 25}]}], "entity_mentions": [{"id": "15362597_2_Ent0", "text": "a case of a diabetic patient taking glyburide", "entity_type": "Entity", "start": 2, "end": 10}, {"id": "15362597_2_Ent5", "text": "diabetic", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15362597_2_Ent3", "text": "glyburide", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15362597_2_Ent6", "text": "glyburide", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15362597_2_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15362597_2_Ent4", "text": "ciprofloxacin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15362597_2_Ent7", "text": "ciprofloxacin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15362597_2_Ent1", "text": "prolonged hypoglycemia , which persisted for over 24 hours", "entity_type": "Entity", "start": 16, "end": 25}], "lang": "en"}
{"doc_id": "15368548_5", "wnd_id": "15368548_5_1", "text": "We present a pediatric patient with leukemia and a severe , L - asparaginase - induced necrotizing pancreatitis , treated successfully with percutaneous drainage used to flush the infected necrotic parts .", "tokens": ["We", "present", "a", "pediatric", "patient", "with", "leukemia", "and", "a", "severe", ",", "L", "-", "asparaginase", "-", "induced", "necrotizing", "pancreatitis", ",", "treated", "successfully", "with", "percutaneous", "drainage", "used", "to", "flush", "the", "infected", "necrotic", "parts", "."], "event_mentions": [{"id": "15368548_5_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 15, "end": 16}, "arguments": [{"entity_id": "15368548_5_Ent7", "role": "Treatment", "text": "L - asparaginase", "start": 11, "end": 14}, {"entity_id": "15368548_5_Ent8", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 11, "end": 14}, {"entity_id": "15368548_5_Ent6", "role": "Effect", "text": "necrotizing pancreatitis", "start": 16, "end": 18}]}, {"id": "15368548_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "used to", "start": 24, "end": 26}, "arguments": [{"entity_id": "15368548_5_Ent1", "role": "Subject_Age", "text": "pediatric", "start": 3, "end": 4}, {"entity_id": "15368548_5_Ent0", "role": "Subject", "text": "pediatric patient with leukemia and a severe , L - asparaginase - induced necrotizing pancreatitis", "start": 3, "end": 18}, {"entity_id": "15368548_5_Ent2", "role": "Subject_Disorder", "text": "leukemia", "start": 6, "end": 7}, {"entity_id": "15368548_5_Ent5", "role": "Treatment_Disorder", "text": "L - asparaginase - induced necrotizing pancreatitis", "start": 11, "end": 18}, {"entity_id": "15368548_5_Ent4", "role": "Treatment", "text": "percutaneous drainage", "start": 22, "end": 24}, {"entity_id": "15368548_5_Ent3", "role": "Effect", "text": "flush the infected necrotic parts .", "start": 26, "end": 32}]}], "entity_mentions": [{"id": "15368548_5_Ent1", "text": "pediatric", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15368548_5_Ent0", "text": "pediatric patient with leukemia and a severe , L - asparaginase - induced necrotizing pancreatitis", "entity_type": "Entity", "start": 3, "end": 18}, {"id": "15368548_5_Ent2", "text": "leukemia", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15368548_5_Ent7", "text": "L - asparaginase", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "15368548_5_Ent8", "text": "L - asparaginase", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "15368548_5_Ent5", "text": "L - asparaginase - induced necrotizing pancreatitis", "entity_type": "Entity", "start": 11, "end": 18}, {"id": "15368548_5_Ent6", "text": "necrotizing pancreatitis", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "15368548_5_Ent4", "text": "percutaneous drainage", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "15368548_5_Ent3", "text": "flush the infected necrotic parts .", "entity_type": "Entity", "start": 26, "end": 32}], "lang": "en"}
{"doc_id": "15373932_2", "wnd_id": "15373932_2_1", "text": "Fungal infection is a significant comorbidity in patients with diabetes mellitus , and ketoconazole , an antifungal agent , causes a number of drug interactions with coadministered drugs .", "tokens": ["Fungal", "infection", "is", "a", "significant", "comorbidity", "in", "patients", "with", "diabetes", "mellitus", ",", "and", "ketoconazole", ",", "an", "antifungal", "agent", ",", "causes", "a", "number", "of", "drug", "interactions", "with", "coadministered", "drugs", "."], "event_mentions": [{"id": "15373932_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causes", "start": 19, "end": 20}, "arguments": [{"entity_id": "15373932_2_Ent5", "role": "Treatment_Disorder", "text": "Fungal infection", "start": 0, "end": 2}, {"entity_id": "15373932_2_Ent0", "role": "Subject", "text": "patients with diabetes mellitus", "start": 7, "end": 11}, {"entity_id": "15373932_2_Ent1", "role": "Subject_Disorder", "text": "diabetes mellitus", "start": 9, "end": 11}, {"entity_id": "15373932_2_Ent3", "role": "Treatment", "text": "ketoconazole", "start": 13, "end": 14}, {"entity_id": "15373932_2_Ent4", "role": "Treatment_Drug", "text": "ketoconazole", "start": 13, "end": 14}, {"entity_id": "15373932_2_Ent2", "role": "Effect", "text": "a number of drug interactions with coadministered drugs", "start": 20, "end": 28}]}], "entity_mentions": [{"id": "15373932_2_Ent5", "text": "Fungal infection", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15373932_2_Ent0", "text": "patients with diabetes mellitus", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "15373932_2_Ent1", "text": "diabetes mellitus", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "15373932_2_Ent3", "text": "ketoconazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15373932_2_Ent4", "text": "ketoconazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15373932_2_Ent2", "text": "a number of drug interactions with coadministered drugs", "entity_type": "Entity", "start": 20, "end": 28}], "lang": "en"}
{"doc_id": "15379082_2", "wnd_id": "15379082_2_1", "text": "Fulminant hepatic failure is a rare complication of disulfiram treatment for alcoholism .", "tokens": ["Fulminant", "hepatic", "failure", "is", "a", "rare", "complication", "of", "disulfiram", "treatment", "for", "alcoholism", "."], "event_mentions": [{"id": "15379082_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 6, "end": 7}, "arguments": [{"entity_id": "15379082_2_Ent0", "role": "Effect", "text": "Fulminant hepatic failure", "start": 0, "end": 3}, {"entity_id": "15379082_2_Ent1", "role": "Treatment", "text": "disulfiram", "start": 8, "end": 9}, {"entity_id": "15379082_2_Ent3", "role": "Treatment_Drug", "text": "disulfiram", "start": 8, "end": 9}, {"entity_id": "15379082_2_Ent2", "role": "Treatment_Disorder", "text": "alcoholism", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "15379082_2_Ent0", "text": "Fulminant hepatic failure", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15379082_2_Ent1", "text": "disulfiram", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15379082_2_Ent3", "text": "disulfiram", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15379082_2_Ent2", "text": "alcoholism", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "15461766_1", "wnd_id": "15461766_1_1", "text": "In this report , two newborns with congenital heart anomalies demonstrated the harlequin color change , one whose skin findings showed a course related to the dose of systemic prostaglandin E1 , suggesting a possible association .", "tokens": ["In", "this", "report", ",", "two", "newborns", "with", "congenital", "heart", "anomalies", "demonstrated", "the", "harlequin", "color", "change", ",", "one", "whose", "skin", "findings", "showed", "a", "course", "related", "to", "the", "dose", "of", "systemic", "prostaglandin", "E1", ",", "suggesting", "a", "possible", "association", "."], "event_mentions": [{"id": "15461766_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 23, "end": 24}, "arguments": [{"entity_id": "15461766_1_Ent1", "role": "Subject_Population", "text": "two", "start": 4, "end": 5}, {"entity_id": "15461766_1_Ent0", "role": "Subject", "text": "two newborns with congenital heart anomalies", "start": 4, "end": 10}, {"entity_id": "15461766_1_Ent2", "role": "Subject_Age", "text": "newborns", "start": 5, "end": 6}, {"entity_id": "15461766_1_Ent5", "role": "Treatment_Disorder", "text": "congenital heart anomalies", "start": 7, "end": 10}, {"entity_id": "15461766_1_Ent3", "role": "Effect", "text": "harlequin color change", "start": 12, "end": 15}, {"entity_id": "15461766_1_Ent4", "role": "Treatment", "text": "prostaglandin E1", "start": 29, "end": 31}, {"entity_id": "15461766_1_Ent6", "role": "Treatment_Drug", "text": "prostaglandin E1", "start": 29, "end": 31}]}], "entity_mentions": [{"id": "15461766_1_Ent1", "text": "two", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15461766_1_Ent0", "text": "two newborns with congenital heart anomalies", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "15461766_1_Ent2", "text": "newborns", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15461766_1_Ent5", "text": "congenital heart anomalies", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "15461766_1_Ent3", "text": "harlequin color change", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "15461766_1_Ent4", "text": "prostaglandin E1", "entity_type": "Entity", "start": 29, "end": 31}, {"id": "15461766_1_Ent6", "text": "prostaglandin E1", "entity_type": "Entity", "start": 29, "end": 31}], "lang": "en"}
{"doc_id": "15479299_2", "wnd_id": "15479299_2_1", "text": "We report a case of severe anemia , which responded well to steroid therapy , in a patient receiving IL - 2 plus IFN - alpha for metastatic renal cell carcinoma .", "tokens": ["We", "report", "a", "case", "of", "severe", "anemia", ",", "which", "responded", "well", "to", "steroid", "therapy", ",", "in", "a", "patient", "receiving", "IL", "-", "2", "plus", "IFN", "-", "alpha", "for", "metastatic", "renal", "cell", "carcinoma", "."], "event_mentions": [{"id": "15479299_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "responded", "start": 9, "end": 10}, "arguments": [{"entity_id": "15479299_2_Ent9", "role": "Treatment_Disorder", "text": "severe anemia", "start": 5, "end": 7}, {"entity_id": "15479299_2_Ent8", "role": "Treatment", "text": "steroid", "start": 12, "end": 13}, {"entity_id": "15479299_2_Ent10", "role": "Treatment_Drug", "text": "steroid", "start": 12, "end": 13}]}, {"id": "15479299_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 18, "end": 19}, "arguments": [{"entity_id": "15479299_2_Ent1", "role": "Effect", "text": "severe anemia", "start": 5, "end": 7}, {"entity_id": "15479299_2_Ent0", "role": "Subject", "text": "a patient", "start": 16, "end": 18}, {"entity_id": "15479299_2_Ent4", "role": "Treatment_Drug", "text": "IL - 2", "start": 19, "end": 22}, {"entity_id": "15479299_2_Ent7", "role": "Combination_Drug", "text": "IL - 2", "start": 19, "end": 22}, {"entity_id": "15479299_2_Ent2", "role": "Treatment", "text": "IL - 2 plus IFN - alpha", "start": 19, "end": 26}, {"entity_id": "15479299_2_Ent5", "role": "Treatment_Drug", "text": "IFN - alpha", "start": 23, "end": 26}, {"entity_id": "15479299_2_Ent6", "role": "Combination_Drug", "text": "IFN - alpha", "start": 23, "end": 26}, {"entity_id": "15479299_2_Ent3", "role": "Treatment_Disorder", "text": "metastatic renal cell carcinoma", "start": 27, "end": 31}]}], "entity_mentions": [{"id": "15479299_2_Ent1", "text": "severe anemia", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "15479299_2_Ent9", "text": "severe anemia", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "15479299_2_Ent8", "text": "steroid", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15479299_2_Ent10", "text": "steroid", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15479299_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "15479299_2_Ent4", "text": "IL - 2", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "15479299_2_Ent7", "text": "IL - 2", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "15479299_2_Ent2", "text": "IL - 2 plus IFN - alpha", "entity_type": "Entity", "start": 19, "end": 26}, {"id": "15479299_2_Ent5", "text": "IFN - alpha", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "15479299_2_Ent6", "text": "IFN - alpha", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "15479299_2_Ent3", "text": "metastatic renal cell carcinoma", "entity_type": "Entity", "start": 27, "end": 31}], "lang": "en"}
{"doc_id": "15482394_1", "wnd_id": "15482394_1_1", "text": "An objective causality assessment indicated a probable relationship between clotting abnormality and warfarin administration , although the degree of elevation of the INR was unusual in the light of the daily warfarin dose and duration of its exposure .", "tokens": ["An", "objective", "causality", "assessment", "indicated", "a", "probable", "relationship", "between", "clotting", "abnormality", "and", "warfarin", "administration", ",", "although", "the", "degree", "of", "elevation", "of", "the", "INR", "was", "unusual", "in", "the", "light", "of", "the", "daily", "warfarin", "dose", "and", "duration", "of", "its", "exposure", "."], "event_mentions": [{"id": "15482394_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "relationship", "start": 7, "end": 8}, "arguments": [{"entity_id": "15482394_1_Ent0", "role": "Effect", "text": "clotting abnormality", "start": 9, "end": 11}, {"entity_id": "15482394_1_Ent1", "role": "Treatment", "text": "warfarin", "start": 12, "end": 13}, {"entity_id": "15482394_1_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "15482394_1_Ent0", "text": "clotting abnormality", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "15482394_1_Ent1", "text": "warfarin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15482394_1_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "15482394_2", "wnd_id": "15482394_2_1", "text": "Based on the clinical status of the patient , it was suspected that several conditions contributed to the abnormal hypersensitivity to warfarin .", "tokens": ["Based", "on", "the", "clinical", "status", "of", "the", "patient", ",", "it", "was", "suspected", "that", "several", "conditions", "contributed", "to", "the", "abnormal", "hypersensitivity", "to", "warfarin", "."], "event_mentions": [{"id": "15482394_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 20, "end": 21}, "arguments": [{"entity_id": "15482394_2_Ent0", "role": "Subject", "text": "the patient", "start": 6, "end": 8}, {"entity_id": "15482394_2_Ent1", "role": "Effect", "text": "abnormal hypersensitivity", "start": 18, "end": 20}, {"entity_id": "15482394_2_Ent2", "role": "Treatment", "text": "warfarin", "start": 21, "end": 22}, {"entity_id": "15482394_2_Ent3", "role": "Treatment_Drug", "text": "warfarin", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "15482394_2_Ent0", "text": "the patient", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "15482394_2_Ent1", "text": "abnormal hypersensitivity", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "15482394_2_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "15482394_2_Ent3", "text": "warfarin", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "15482394_4", "wnd_id": "15482394_4_1", "text": "In view of our experience in the present case , it should be stressed that close monitoring of coagulation capacity is necessary in critically ill patients in order to avoid fatal haemorrhage after initiating warfarin therapy regardless of the dosage .", "tokens": ["In", "view", "of", "our", "experience", "in", "the", "present", "case", ",", "it", "should", "be", "stressed", "that", "close", "monitoring", "of", "coagulation", "capacity", "is", "necessary", "in", "critically", "ill", "patients", "in", "order", "to", "avoid", "fatal", "haemorrhage", "after", "initiating", "warfarin", "therapy", "regardless", "of", "the", "dosage", "."], "event_mentions": [{"id": "15482394_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 32, "end": 33}, "arguments": [{"entity_id": "15482394_4_Ent0", "role": "Effect", "text": "haemorrhage", "start": 31, "end": 32}, {"entity_id": "15482394_4_Ent1", "role": "Treatment", "text": "initiating warfarin therapy regardless of the dosage", "start": 33, "end": 40}, {"entity_id": "15482394_4_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 34, "end": 35}]}], "entity_mentions": [{"id": "15482394_4_Ent0", "text": "haemorrhage", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "15482394_4_Ent1", "text": "initiating warfarin therapy regardless of the dosage", "entity_type": "Entity", "start": 33, "end": 40}, {"id": "15482394_4_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 34, "end": 35}], "lang": "en"}
{"doc_id": "15494638_7", "wnd_id": "15494638_7_1", "text": "Patient A reported right leg weakness ( foot drop ) during week 4 of CAP - XRT ( 1600 mg / m2 ) .", "tokens": ["Patient", "A", "reported", "right", "leg", "weakness", "(", "foot", "drop", ")", "during", "week", "4", "of", "CAP", "-", "XRT", "(", "1600", "mg", "/", "m2", ")", "."], "event_mentions": [{"id": "15494638_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 10, "end": 11}, "arguments": [{"entity_id": "15494638_7_Ent0", "role": "Subject", "text": "Patient A", "start": 0, "end": 2}, {"entity_id": "15494638_7_Ent1", "role": "Effect", "text": "right leg weakness", "start": 3, "end": 6}, {"entity_id": "15494638_7_Ent3", "role": "Treatment_Duration", "text": "week 4", "start": 11, "end": 13}, {"entity_id": "15494638_7_Ent2", "role": "Treatment", "text": "week 4 of CAP - XRT ( 1600 mg / m2 )", "start": 11, "end": 23}, {"entity_id": "15494638_7_Ent4", "role": "Treatment_Drug", "text": "CAP - XRT", "start": 14, "end": 17}, {"entity_id": "15494638_7_Ent5", "role": "Treatment_Dosage", "text": "1600 mg / m2", "start": 18, "end": 22}]}], "entity_mentions": [{"id": "15494638_7_Ent0", "text": "Patient A", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15494638_7_Ent1", "text": "right leg weakness", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "15494638_7_Ent3", "text": "week 4", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "15494638_7_Ent2", "text": "week 4 of CAP - XRT ( 1600 mg / m2 )", "entity_type": "Entity", "start": 11, "end": 23}, {"id": "15494638_7_Ent4", "text": "CAP - XRT", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "15494638_7_Ent5", "text": "1600 mg / m2", "entity_type": "Entity", "start": 18, "end": 22}], "lang": "en"}
{"doc_id": "15504988_2", "wnd_id": "15504988_2_1", "text": "We report three patients , all of whom had preexisting diabetic dyslipidemia , who showed a profound reduction in plasma HDL cholesterol and apolipoprotein AI levels soon after the initiation of rosiglitazone therapy .", "tokens": ["We", "report", "three", "patients", ",", "all", "of", "whom", "had", "preexisting", "diabetic", "dyslipidemia", ",", "who", "showed", "a", "profound", "reduction", "in", "plasma", "HDL", "cholesterol", "and", "apolipoprotein", "AI", "levels", "soon", "after", "the", "initiation", "of", "rosiglitazone", "therapy", "."], "event_mentions": [{"id": "15504988_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "initiation", "start": 29, "end": 30}, "arguments": [{"entity_id": "15504988_2_Ent1", "role": "Subject_Population", "text": "three", "start": 2, "end": 3}, {"entity_id": "15504988_2_Ent0", "role": "Subject", "text": "three patients", "start": 2, "end": 4}, {"entity_id": "15504988_2_Ent6", "role": "Treatment_Disorder", "text": "preexisting diabetic dyslipidemia", "start": 9, "end": 12}, {"entity_id": "15504988_2_Ent2", "role": "Effect", "text": "profound reduction in plasma HDL cholesterol and apolipoprotein AI levels", "start": 16, "end": 26}, {"entity_id": "15504988_2_Ent5", "role": "Treatment_Time_elapsed", "text": "soon after", "start": 26, "end": 28}, {"entity_id": "15504988_2_Ent4", "role": "Treatment_Drug", "text": "rosiglitazone", "start": 31, "end": 32}, {"entity_id": "15504988_2_Ent3", "role": "Treatment", "text": "rosiglitazone therapy", "start": 31, "end": 33}]}], "entity_mentions": [{"id": "15504988_2_Ent1", "text": "three", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "15504988_2_Ent0", "text": "three patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "15504988_2_Ent6", "text": "preexisting diabetic dyslipidemia", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "15504988_2_Ent2", "text": "profound reduction in plasma HDL cholesterol and apolipoprotein AI levels", "entity_type": "Entity", "start": 16, "end": 26}, {"id": "15504988_2_Ent5", "text": "soon after", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "15504988_2_Ent4", "text": "rosiglitazone", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "15504988_2_Ent3", "text": "rosiglitazone therapy", "entity_type": "Entity", "start": 31, "end": 33}], "lang": "en"}
{"doc_id": "15507779_2", "wnd_id": "15507779_2_1", "text": "Nevirapine is a non - nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus ( HIV) - infected patients and in post - exposure prophylaxis .", "tokens": ["Nevirapine", "is", "a", "non", "-", "nucleoside", "reverse", "transcriptase", "inhibitor", "used", "in", "the", "treatment", "of", "human", "immunodeficiency", "virus", "(", "HIV)", "-", "infected", "patients", "and", "in", "post", "-", "exposure", "prophylaxis", "."], "event_mentions": [{"id": "15507779_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 12, "end": 13}, "arguments": [{"entity_id": "15507779_2_Ent1", "role": "Treatment", "text": "Nevirapine", "start": 0, "end": 1}, {"entity_id": "15507779_2_Ent2", "role": "Treatment_Drug", "text": "Nevirapine", "start": 0, "end": 1}, {"entity_id": "15507779_2_Ent0", "role": "Subject", "text": "human immunodeficiency virus ( HIV) - infected patients", "start": 14, "end": 22}, {"entity_id": "15507779_2_Ent3", "role": "Treatment_Disorder", "text": "immunodeficiency virus", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "15507779_2_Ent1", "text": "Nevirapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15507779_2_Ent2", "text": "Nevirapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15507779_2_Ent0", "text": "human immunodeficiency virus ( HIV) - infected patients", "entity_type": "Entity", "start": 14, "end": 22}, {"id": "15507779_2_Ent3", "text": "immunodeficiency virus", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "15516308_1", "wnd_id": "15516308_1_1", "text": "Fatal overdoses associated with quetiapine .", "tokens": ["Fatal", "overdoses", "associated", "with", "quetiapine", "."], "event_mentions": [{"id": "15516308_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "15516308_1_Ent0", "role": "Effect", "text": "Fatal overdoses", "start": 0, "end": 2}, {"entity_id": "15516308_1_Ent1", "role": "Treatment", "text": "quetiapine", "start": 4, "end": 5}, {"entity_id": "15516308_1_Ent2", "role": "Treatment_Drug", "text": "quetiapine", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "15516308_1_Ent0", "text": "Fatal overdoses", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15516308_1_Ent1", "text": "quetiapine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15516308_1_Ent2", "text": "quetiapine", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "15516308_15", "wnd_id": "15516308_15_1", "text": "In all cases , drugs in addition to quetiapine were detected , but in cases # 1 and # 2 , the cause of death was considered to be a quetiapine overdose and the other drugs were not considered to be contributory .", "tokens": ["In", "all", "cases", ",", "drugs", "in", "addition", "to", "quetiapine", "were", "detected", ",", "but", "in", "cases", "#", "1", "and", "#", "2", ",", "the", "cause", "of", "death", "was", "considered", "to", "be", "a", "quetiapine", "overdose", "and", "the", "other", "drugs", "were", "not", "considered", "to", "be", "contributory", "."], "event_mentions": [{"id": "15516308_15_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 22, "end": 23}, "arguments": [{"entity_id": "15516308_15_Ent4", "role": "Treatment_Drug", "text": "quetiapine", "start": 8, "end": 9}, {"entity_id": "15516308_15_Ent0", "role": "Subject", "text": "cases # 1 and # 2", "start": 14, "end": 20}, {"entity_id": "15516308_15_Ent1", "role": "Effect", "text": "death", "start": 24, "end": 25}, {"entity_id": "15516308_15_Ent3", "role": "Treatment_Drug", "text": "quetiapine", "start": 30, "end": 31}, {"entity_id": "15516308_15_Ent2", "role": "Treatment", "text": "quetiapine overdose", "start": 30, "end": 32}, {"entity_id": "15516308_15_Ent5", "role": "Treatment_Dosage", "text": "overdose", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "15516308_15_Ent4", "text": "quetiapine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15516308_15_Ent0", "text": "cases # 1 and # 2", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "15516308_15_Ent1", "text": "death", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "15516308_15_Ent3", "text": "quetiapine", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "15516308_15_Ent2", "text": "quetiapine overdose", "entity_type": "Entity", "start": 30, "end": 32}, {"id": "15516308_15_Ent5", "text": "overdose", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "15522120_13", "wnd_id": "15522120_13_1", "text": "The itch spread to the arms , abdomen and legs and the patient treated himself with clemastine and the itch disappeared .", "tokens": ["The", "itch", "spread", "to", "the", "arms", ",", "abdomen", "and", "legs", "and", "the", "patient", "treated", "himself", "with", "clemastine", "and", "the", "itch", "disappeared", "."], "event_mentions": [{"id": "15522120_13_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "disappeared", "start": 20, "end": 21}, "arguments": [{"entity_id": "15522120_13_Ent0", "role": "Subject", "text": "The itch spread to the arms , abdomen and legs and the patient", "start": 0, "end": 13}, {"entity_id": "15522120_13_Ent6", "role": "Treatment_Disorder", "text": "itch", "start": 1, "end": 2}, {"entity_id": "15522120_13_Ent1", "role": "Subject", "text": "himself", "start": 14, "end": 15}, {"entity_id": "15522120_13_Ent2", "role": "Subject_Gender", "text": "himself", "start": 14, "end": 15}, {"entity_id": "15522120_13_Ent4", "role": "Treatment", "text": "clemastine", "start": 16, "end": 17}, {"entity_id": "15522120_13_Ent5", "role": "Treatment_Drug", "text": "clemastine", "start": 16, "end": 17}, {"entity_id": "15522120_13_Ent3", "role": "Effect", "text": "itch disappeared", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "15522120_13_Ent0", "text": "The itch spread to the arms , abdomen and legs and the patient", "entity_type": "Entity", "start": 0, "end": 13}, {"id": "15522120_13_Ent6", "text": "itch", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "15522120_13_Ent1", "text": "himself", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "15522120_13_Ent2", "text": "himself", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "15522120_13_Ent4", "text": "clemastine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15522120_13_Ent5", "text": "clemastine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15522120_13_Ent3", "text": "itch disappeared", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "15522120_9", "wnd_id": "15522120_9_1", "text": "An adverse drug reaction ( ADR ) induced by fluoxetine was suspected and fluoxetine treatment was discontinued .", "tokens": ["An", "adverse", "drug", "reaction", "(", "ADR", ")", "induced", "by", "fluoxetine", "was", "suspected", "and", "fluoxetine", "treatment", "was", "discontinued", "."], "event_mentions": [{"id": "15522120_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "15522120_9_Ent0", "role": "Effect", "text": "An adverse drug reaction ( ADR )", "start": 0, "end": 7}, {"entity_id": "15522120_9_Ent1", "role": "Treatment", "text": "fluoxetine", "start": 9, "end": 10}, {"entity_id": "15522120_9_Ent2", "role": "Treatment_Drug", "text": "fluoxetine", "start": 9, "end": 10}, {"entity_id": "15522120_9_Ent3", "role": "Treatment_Drug", "text": "fluoxetine", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "15522120_9_Ent0", "text": "An adverse drug reaction ( ADR )", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "15522120_9_Ent1", "text": "fluoxetine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15522120_9_Ent2", "text": "fluoxetine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15522120_9_Ent3", "text": "fluoxetine", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "15529178_2", "wnd_id": "15529178_2_1", "text": "This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis , who developed new onset of pulmonary signs and symptoms with alveolar infiltrates temporally related to the institution of etanercept therapy .", "tokens": ["This", "report", "details", "the", "pulmonary", "pathologic", "findings", "in", "four", "patients", "with", "rheumatoid", "arthritis", ",", "who", "developed", "new", "onset", "of", "pulmonary", "signs", "and", "symptoms", "with", "alveolar", "infiltrates", "temporally", "related", "to", "the", "institution", "of", "etanercept", "therapy", "."], "event_mentions": [{"id": "15529178_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related to", "start": 27, "end": 29}, "arguments": [{"entity_id": "15529178_2_Ent1", "role": "Subject_Population", "text": "four", "start": 8, "end": 9}, {"entity_id": "15529178_2_Ent0", "role": "Subject", "text": "four patients with rheumatoid arthritis", "start": 8, "end": 13}, {"entity_id": "15529178_2_Ent5", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 11, "end": 13}, {"entity_id": "15529178_2_Ent2", "role": "Effect", "text": "developed new onset of pulmonary signs and symptoms with alveolar infiltrates", "start": 15, "end": 26}, {"entity_id": "15529178_2_Ent3", "role": "Treatment", "text": "institution of etanercept therapy", "start": 30, "end": 34}, {"entity_id": "15529178_2_Ent4", "role": "Treatment_Drug", "text": "etanercept", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "15529178_2_Ent1", "text": "four", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15529178_2_Ent0", "text": "four patients with rheumatoid arthritis", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "15529178_2_Ent5", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "15529178_2_Ent2", "text": "developed new onset of pulmonary signs and symptoms with alveolar infiltrates", "entity_type": "Entity", "start": 15, "end": 26}, {"id": "15529178_2_Ent3", "text": "institution of etanercept therapy", "entity_type": "Entity", "start": 30, "end": 34}, {"id": "15529178_2_Ent4", "text": "etanercept", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "15533031_1", "wnd_id": "15533031_1_1", "text": "Paradoxical cerebral cortical hyperexcitability following flupirtine overdose .", "tokens": ["Paradoxical", "cerebral", "cortical", "hyperexcitability", "following", "flupirtine", "overdose", "."], "event_mentions": [{"id": "15533031_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 4, "end": 5}, "arguments": [{"entity_id": "15533031_1_Ent0", "role": "Effect", "text": "Paradoxical cerebral cortical hyperexcitability", "start": 0, "end": 4}, {"entity_id": "15533031_1_Ent2", "role": "Treatment_Drug", "text": "flupirtine", "start": 5, "end": 6}, {"entity_id": "15533031_1_Ent1", "role": "Treatment", "text": "flupirtine overdose", "start": 5, "end": 7}, {"entity_id": "15533031_1_Ent3", "role": "Treatment_Dosage", "text": "overdose", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "15533031_1_Ent0", "text": "Paradoxical cerebral cortical hyperexcitability", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "15533031_1_Ent2", "text": "flupirtine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15533031_1_Ent1", "text": "flupirtine overdose", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "15533031_1_Ent3", "text": "overdose", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "1557089_1", "wnd_id": "1557089_1_1", "text": "In a postoperative patient with pre - existent myasthenia gravis , oral verapamil caused a marked exacerbation in myasthenic weakness .", "tokens": ["In", "a", "postoperative", "patient", "with", "pre", "-", "existent", "myasthenia", "gravis", ",", "oral", "verapamil", "caused", "a", "marked", "exacerbation", "in", "myasthenic", "weakness", "."], "event_mentions": [{"id": "1557089_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 13, "end": 14}, "arguments": [{"entity_id": "1557089_1_Ent0", "role": "Subject", "text": "a postoperative patient with pre - existent myasthenia gravis", "start": 1, "end": 10}, {"entity_id": "1557089_1_Ent1", "role": "Subject_Disorder", "text": "pre - existent myasthenia gravis", "start": 5, "end": 10}, {"entity_id": "1557089_1_Ent4", "role": "Treatment_Route", "text": "oral", "start": 11, "end": 12}, {"entity_id": "1557089_1_Ent3", "role": "Treatment", "text": "oral verapamil", "start": 11, "end": 13}, {"entity_id": "1557089_1_Ent5", "role": "Treatment_Drug", "text": "verapamil", "start": 12, "end": 13}, {"entity_id": "1557089_1_Ent2", "role": "Effect", "text": "marked exacerbation in myasthenic weakness", "start": 15, "end": 20}]}], "entity_mentions": [{"id": "1557089_1_Ent0", "text": "a postoperative patient with pre - existent myasthenia gravis", "entity_type": "Entity", "start": 1, "end": 10}, {"id": "1557089_1_Ent1", "text": "pre - existent myasthenia gravis", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "1557089_1_Ent4", "text": "oral", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "1557089_1_Ent3", "text": "oral verapamil", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "1557089_1_Ent5", "text": "verapamil", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1557089_1_Ent2", "text": "marked exacerbation in myasthenic weakness", "entity_type": "Entity", "start": 15, "end": 20}], "lang": "en"}
{"doc_id": "15588385_1", "wnd_id": "15588385_1_1", "text": "Acute hepatic failure is a rare and potentially lethal complication of propylthiouracil ( PTU ) use for hyperthyroidism .", "tokens": ["Acute", "hepatic", "failure", "is", "a", "rare", "and", "potentially", "lethal", "complication", "of", "propylthiouracil", "(", "PTU", ")", "use", "for", "hyperthyroidism", "."], "event_mentions": [{"id": "15588385_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 9, "end": 10}, "arguments": [{"entity_id": "15588385_1_Ent0", "role": "Effect", "text": "Acute hepatic failure", "start": 0, "end": 3}, {"entity_id": "15588385_1_Ent3", "role": "Treatment_Drug", "text": "propylthiouracil", "start": 11, "end": 12}, {"entity_id": "15588385_1_Ent1", "role": "Treatment", "text": "propylthiouracil ( PTU )", "start": 11, "end": 15}, {"entity_id": "15588385_1_Ent2", "role": "Treatment_Disorder", "text": "hyperthyroidism", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "15588385_1_Ent0", "text": "Acute hepatic failure", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15588385_1_Ent3", "text": "propylthiouracil", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15588385_1_Ent1", "text": "propylthiouracil ( PTU )", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "15588385_1_Ent2", "text": "hyperthyroidism", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "15588385_4", "wnd_id": "15588385_4_1", "text": "We present a 20 - year - old woman with Basedow - Graves ' disease who developed PTU - induced fulminant hepatitis , which progressed to acute hepatic failure with grade III hepatic encephalopathy .", "tokens": ["We", "present", "a", "20", "-", "year", "-", "old", "woman", "with", "Basedow", "-", "Graves", "'", "disease", "who", "developed", "PTU", "-", "induced", "fulminant", "hepatitis", ",", "which", "progressed", "to", "acute", "hepatic", "failure", "with", "grade", "III", "hepatic", "encephalopathy", "."], "event_mentions": [{"id": "15588385_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 19, "end": 20}, "arguments": [{"entity_id": "15588385_4_Ent0", "role": "Subject", "text": "a 20 - year - old woman with Basedow - Graves ' disease", "start": 2, "end": 15}, {"entity_id": "15588385_4_Ent1", "role": "Subject_Age", "text": "20 - year - old", "start": 3, "end": 8}, {"entity_id": "15588385_4_Ent2", "role": "Subject_Gender", "text": "woman", "start": 8, "end": 9}, {"entity_id": "15588385_4_Ent5", "role": "Treatment_Disorder", "text": "Basedow - Graves ' disease", "start": 10, "end": 15}, {"entity_id": "15588385_4_Ent4", "role": "Treatment", "text": "PTU", "start": 17, "end": 18}, {"entity_id": "15588385_4_Ent6", "role": "Treatment_Drug", "text": "PTU", "start": 17, "end": 18}, {"entity_id": "15588385_4_Ent3", "role": "Effect", "text": "fulminant hepatitis , which progressed to acute hepatic failure with grade III hepatic encephalopathy", "start": 20, "end": 34}]}], "entity_mentions": [{"id": "15588385_4_Ent0", "text": "a 20 - year - old woman with Basedow - Graves ' disease", "entity_type": "Entity", "start": 2, "end": 15}, {"id": "15588385_4_Ent1", "text": "20 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "15588385_4_Ent2", "text": "woman", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15588385_4_Ent5", "text": "Basedow - Graves ' disease", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "15588385_4_Ent4", "text": "PTU", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15588385_4_Ent6", "text": "PTU", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15588385_4_Ent3", "text": "fulminant hepatitis , which progressed to acute hepatic failure with grade III hepatic encephalopathy", "entity_type": "Entity", "start": 20, "end": 34}], "lang": "en"}
{"doc_id": "15606443_2", "wnd_id": "15606443_2_1", "text": "Rosiglitazone , a thiazolidinedione antidiabetic medication used in the treatment of Type 2 diabetes mellitus , is predominantly metabolized by the cytochrome P450 ( CYP ) enzyme CYP2C8 .", "tokens": ["Rosiglitazone", ",", "a", "thiazolidinedione", "antidiabetic", "medication", "used", "in", "the", "treatment", "of", "Type", "2", "diabetes", "mellitus", ",", "is", "predominantly", "metabolized", "by", "the", "cytochrome", "P450", "(", "CYP", ")", "enzyme", "CYP2C8", "."], "event_mentions": [{"id": "15606443_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "used", "start": 6, "end": 7}, "arguments": [{"entity_id": "15606443_2_Ent0", "role": "Treatment", "text": "Rosiglitazone", "start": 0, "end": 1}, {"entity_id": "15606443_2_Ent2", "role": "Treatment_Drug", "text": "Rosiglitazone", "start": 0, "end": 1}, {"entity_id": "15606443_2_Ent1", "role": "Treatment", "text": "a thiazolidinedione antidiabetic medication", "start": 2, "end": 6}, {"entity_id": "15606443_2_Ent3", "role": "Treatment_Drug", "text": "thiazolidinedione antidiabetic medication", "start": 3, "end": 6}, {"entity_id": "15606443_2_Ent4", "role": "Treatment_Disorder", "text": "Type 2 diabetes mellitus", "start": 11, "end": 15}]}], "entity_mentions": [{"id": "15606443_2_Ent0", "text": "Rosiglitazone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15606443_2_Ent2", "text": "Rosiglitazone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15606443_2_Ent1", "text": "a thiazolidinedione antidiabetic medication", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "15606443_2_Ent3", "text": "thiazolidinedione antidiabetic medication", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "15606443_2_Ent4", "text": "Type 2 diabetes mellitus", "entity_type": "Entity", "start": 11, "end": 15}], "lang": "en"}
{"doc_id": "15623719_1", "wnd_id": "15623719_1_1", "text": "Vision declined after treatment with methylprednisolone , after which fundus examination became consistent with progressive outer retinal necrosis .", "tokens": ["Vision", "declined", "after", "treatment", "with", "methylprednisolone", ",", "after", "which", "fundus", "examination", "became", "consistent", "with", "progressive", "outer", "retinal", "necrosis", "."], "event_mentions": [{"id": "15623719_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "15623719_1_Ent0", "role": "Effect", "text": "Vision declined", "start": 0, "end": 2}, {"entity_id": "15623719_1_Ent1", "role": "Treatment", "text": "methylprednisolone", "start": 5, "end": 6}, {"entity_id": "15623719_1_Ent2", "role": "Treatment_Drug", "text": "methylprednisolone", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "15623719_1_Ent0", "text": "Vision declined", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15623719_1_Ent1", "text": "methylprednisolone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15623719_1_Ent2", "text": "methylprednisolone", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "15628319_3", "wnd_id": "15628319_3_1", "text": "Drug eruption caused by azathioprine : value of using the drug - induced lymphocytes stimulation test for diagnosis .", "tokens": ["Drug", "eruption", "caused", "by", "azathioprine", ":", "value", "of", "using", "the", "drug", "-", "induced", "lymphocytes", "stimulation", "test", "for", "diagnosis", "."], "event_mentions": [{"id": "15628319_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 2, "end": 3}, "arguments": [{"entity_id": "15628319_3_Ent0", "role": "Effect", "text": "Drug eruption", "start": 0, "end": 2}, {"entity_id": "15628319_3_Ent1", "role": "Treatment", "text": "azathioprine", "start": 4, "end": 5}, {"entity_id": "15628319_3_Ent2", "role": "Treatment_Drug", "text": "azathioprine", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "15628319_3_Ent0", "text": "Drug eruption", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15628319_3_Ent1", "text": "azathioprine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15628319_3_Ent2", "text": "azathioprine", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "15644988_3", "wnd_id": "15644988_3_1", "text": "Ziprasidone is an atypical antipsychotic drug that is believed to have a low propensity for inducing extrapyramidal symptoms , including tardive dyskinesia ( TD ) .", "tokens": ["Ziprasidone", "is", "an", "atypical", "antipsychotic", "drug", "that", "is", "believed", "to", "have", "a", "low", "propensity", "for", "inducing", "extrapyramidal", "symptoms", ",", "including", "tardive", "dyskinesia", "(", "TD", ")", "."], "event_mentions": [{"id": "15644988_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "inducing", "start": 15, "end": 16}, "arguments": [{"entity_id": "15644988_3_Ent1", "role": "Treatment", "text": "Ziprasidone", "start": 0, "end": 1}, {"entity_id": "15644988_3_Ent2", "role": "Treatment_Drug", "text": "Ziprasidone", "start": 0, "end": 1}, {"entity_id": "15644988_3_Ent3", "role": "Treatment_Disorder", "text": "antipsychotic", "start": 4, "end": 5}, {"entity_id": "15644988_3_Ent0", "role": "Effect", "text": "extrapyramidal symptoms , including tardive dyskinesia ( TD )", "start": 16, "end": 25}]}], "entity_mentions": [{"id": "15644988_3_Ent1", "text": "Ziprasidone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15644988_3_Ent2", "text": "Ziprasidone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15644988_3_Ent3", "text": "antipsychotic", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15644988_3_Ent0", "text": "extrapyramidal symptoms , including tardive dyskinesia ( TD )", "entity_type": "Entity", "start": 16, "end": 25}], "lang": "en"}
{"doc_id": "15685264_11", "wnd_id": "15685264_11_1", "text": "CONCLUSION : A possible pharmacokinetic interaction between Dantrolene and Oxybutynin should be borne in mind when considering Carbamazepine medication for a patient with a spinal cord lesion .", "tokens": ["CONCLUSION", ":", "A", "possible", "pharmacokinetic", "interaction", "between", "Dantrolene", "and", "Oxybutynin", "should", "be", "borne", "in", "mind", "when", "considering", "Carbamazepine", "medication", "for", "a", "patient", "with", "a", "spinal", "cord", "lesion", "."], "event_mentions": [{"id": "15685264_11_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "medication", "start": 18, "end": 19}, "arguments": [{"entity_id": "15685264_11_Ent3", "role": "Treatment_Drug", "text": "Dantrolene", "start": 7, "end": 8}, {"entity_id": "15685264_11_Ent6", "role": "Combination_Drug", "text": "Dantrolene", "start": 7, "end": 8}, {"entity_id": "15685264_11_Ent4", "role": "Treatment_Drug", "text": "Oxybutynin", "start": 9, "end": 10}, {"entity_id": "15685264_11_Ent7", "role": "Combination_Drug", "text": "Oxybutynin", "start": 9, "end": 10}, {"entity_id": "15685264_11_Ent5", "role": "Treatment_Drug", "text": "Carbamazepine", "start": 17, "end": 18}, {"entity_id": "15685264_11_Ent1", "role": "Treatment", "text": "Carbamazepine medication", "start": 17, "end": 19}, {"entity_id": "15685264_11_Ent0", "role": "Subject", "text": "a patient", "start": 20, "end": 22}, {"entity_id": "15685264_11_Ent2", "role": "Treatment_Disorder", "text": "a spinal cord lesion", "start": 23, "end": 27}]}], "entity_mentions": [{"id": "15685264_11_Ent3", "text": "Dantrolene", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15685264_11_Ent6", "text": "Dantrolene", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15685264_11_Ent4", "text": "Oxybutynin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15685264_11_Ent7", "text": "Oxybutynin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15685264_11_Ent5", "text": "Carbamazepine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15685264_11_Ent1", "text": "Carbamazepine medication", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "15685264_11_Ent0", "text": "a patient", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "15685264_11_Ent2", "text": "a spinal cord lesion", "entity_type": "Entity", "start": 23, "end": 27}], "lang": "en"}
{"doc_id": "15685264_2", "wnd_id": "15685264_2_1", "text": "OBJECTIVE : To report a case of Carbamazepine toxicity following the administration of Oxybutynin and Dantrolene .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "Carbamazepine", "toxicity", "following", "the", "administration", "of", "Oxybutynin", "and", "Dantrolene", "."], "event_mentions": [{"id": "15685264_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 9, "end": 10}, "arguments": [{"entity_id": "15685264_2_Ent1", "role": "Treatment", "text": "Carbamazepine", "start": 7, "end": 8}, {"entity_id": "15685264_2_Ent5", "role": "Treatment_Drug", "text": "Carbamazepine", "start": 7, "end": 8}, {"entity_id": "15685264_2_Ent6", "role": "Combination_Drug", "text": "Carbamazepine", "start": 7, "end": 8}, {"entity_id": "15685264_2_Ent0", "role": "Effect", "text": "Carbamazepine toxicity", "start": 7, "end": 9}, {"entity_id": "15685264_2_Ent3", "role": "Treatment_Drug", "text": "Oxybutynin", "start": 13, "end": 14}, {"entity_id": "15685264_2_Ent7", "role": "Combination_Drug", "text": "Oxybutynin", "start": 13, "end": 14}, {"entity_id": "15685264_2_Ent2", "role": "Treatment", "text": "Oxybutynin and Dantrolene", "start": 13, "end": 16}, {"entity_id": "15685264_2_Ent4", "role": "Treatment_Drug", "text": "Dantrolene", "start": 15, "end": 16}, {"entity_id": "15685264_2_Ent8", "role": "Combination_Drug", "text": "Dantrolene", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "15685264_2_Ent1", "text": "Carbamazepine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15685264_2_Ent5", "text": "Carbamazepine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15685264_2_Ent6", "text": "Carbamazepine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15685264_2_Ent0", "text": "Carbamazepine toxicity", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "15685264_2_Ent3", "text": "Oxybutynin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15685264_2_Ent7", "text": "Oxybutynin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15685264_2_Ent2", "text": "Oxybutynin and Dantrolene", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "15685264_2_Ent4", "text": "Dantrolene", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15685264_2_Ent8", "text": "Dantrolene", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "15694139_2", "wnd_id": "15694139_2_1", "text": "Thalidomide was withdrawn from world markets in 1961 following recognition of its teratogenic effects .", "tokens": ["Thalidomide", "was", "withdrawn", "from", "world", "markets", "in", "1961", "following", "recognition", "of", "its", "teratogenic", "effects", "."], "event_mentions": [{"id": "15694139_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 8, "end": 9}, "arguments": [{"entity_id": "15694139_2_Ent1", "role": "Treatment", "text": "Thalidomide", "start": 0, "end": 1}, {"entity_id": "15694139_2_Ent2", "role": "Treatment_Drug", "text": "Thalidomide", "start": 0, "end": 1}, {"entity_id": "15694139_2_Ent0", "role": "Effect", "text": "teratogenic effects", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "15694139_2_Ent1", "text": "Thalidomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15694139_2_Ent2", "text": "Thalidomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15694139_2_Ent0", "text": "teratogenic effects", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "15729090_2", "wnd_id": "15729090_2_1", "text": "We report a case of myoclonus induced by quetiapine .", "tokens": ["We", "report", "a", "case", "of", "myoclonus", "induced", "by", "quetiapine", "."], "event_mentions": [{"id": "15729090_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "15729090_2_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "15729090_2_Ent1", "role": "Effect", "text": "myoclonus", "start": 5, "end": 6}, {"entity_id": "15729090_2_Ent2", "role": "Treatment", "text": "quetiapine", "start": 8, "end": 9}, {"entity_id": "15729090_2_Ent3", "role": "Treatment_Drug", "text": "quetiapine", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "15729090_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "15729090_2_Ent1", "text": "myoclonus", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15729090_2_Ent2", "text": "quetiapine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15729090_2_Ent3", "text": "quetiapine", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "15735923_5", "wnd_id": "15735923_5_1", "text": "MDS was diagnosed 8.4 months after beginning TMZ .", "tokens": ["MDS", "was", "diagnosed", "8.4", "months", "after", "beginning", "TMZ", "."], "event_mentions": [{"id": "15735923_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "diagnosed", "start": 2, "end": 3}, "arguments": [{"entity_id": "15735923_5_Ent0", "role": "Effect", "text": "MDS", "start": 0, "end": 1}, {"entity_id": "15735923_5_Ent3", "role": "Treatment_Time_elapsed", "text": "8.4 months", "start": 3, "end": 5}, {"entity_id": "15735923_5_Ent1", "role": "Treatment", "text": "8.4 months after beginning TMZ", "start": 3, "end": 8}, {"entity_id": "15735923_5_Ent2", "role": "Treatment_Drug", "text": "TMZ", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "15735923_5_Ent0", "text": "MDS", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15735923_5_Ent3", "text": "8.4 months", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "15735923_5_Ent1", "text": "8.4 months after beginning TMZ", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "15735923_5_Ent2", "text": "TMZ", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "15773973_3", "wnd_id": "15773973_3_1", "text": "We report the case of a 40 - year - old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin .", "tokens": ["We", "report", "the", "case", "of", "a", "40", "-", "year", "-", "old", "woman", "who", "developed", "fulminant", "hepatic", "failure", "and", "aplastic", "anaemia", "following", "a", "course", "of", "oral", "flucloxacillin", "."], "event_mentions": [{"id": "15773973_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "15773973_3_Ent0", "role": "Subject", "text": "a 40 - year - old woman", "start": 5, "end": 12}, {"entity_id": "15773973_3_Ent1", "role": "Subject_Age", "text": "40 - year - old", "start": 6, "end": 11}, {"entity_id": "15773973_3_Ent2", "role": "Subject_Gender", "text": "woman", "start": 11, "end": 12}, {"entity_id": "15773973_3_Ent3", "role": "Effect", "text": "fulminant hepatic failure and aplastic anaemia", "start": 14, "end": 20}, {"entity_id": "15773973_3_Ent7", "role": "Treatment_Duration", "text": "a course", "start": 21, "end": 23}, {"entity_id": "15773973_3_Ent4", "role": "Treatment", "text": "a course of oral flucloxacillin", "start": 21, "end": 26}, {"entity_id": "15773973_3_Ent5", "role": "Treatment_Route", "text": "oral", "start": 24, "end": 25}, {"entity_id": "15773973_3_Ent6", "role": "Treatment_Drug", "text": "flucloxacillin", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "15773973_3_Ent0", "text": "a 40 - year - old woman", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "15773973_3_Ent1", "text": "40 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "15773973_3_Ent2", "text": "woman", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15773973_3_Ent3", "text": "fulminant hepatic failure and aplastic anaemia", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "15773973_3_Ent7", "text": "a course", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "15773973_3_Ent4", "text": "a course of oral flucloxacillin", "entity_type": "Entity", "start": 21, "end": 26}, {"id": "15773973_3_Ent5", "text": "oral", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "15773973_3_Ent6", "text": "flucloxacillin", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "15779196_2", "wnd_id": "15779196_2_1", "text": "Zoledronic acid - induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases .", "tokens": ["Zoledronic", "acid", "-", "induced", "severe", "hypocalcaemia", "in", "a", "prostate", "cancer", "patient", "with", "extensive", "osteoblastic", "bone", "metastases", "."], "event_mentions": [{"id": "15779196_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "15779196_2_Ent2", "role": "Treatment", "text": "Zoledronic acid", "start": 0, "end": 2}, {"entity_id": "15779196_2_Ent3", "role": "Treatment_Drug", "text": "Zoledronic acid", "start": 0, "end": 2}, {"entity_id": "15779196_2_Ent1", "role": "Effect", "text": "severe hypocalcaemia", "start": 4, "end": 6}, {"entity_id": "15779196_2_Ent4", "role": "Treatment_Disorder", "text": "prostate cancer", "start": 8, "end": 10}, {"entity_id": "15779196_2_Ent0", "role": "Subject", "text": "prostate cancer patient with extensive osteoblastic bone metastases", "start": 8, "end": 16}, {"entity_id": "15779196_2_Ent5", "role": "Treatment_Disorder", "text": "extensive osteoblastic bone metastases", "start": 12, "end": 16}]}], "entity_mentions": [{"id": "15779196_2_Ent2", "text": "Zoledronic acid", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15779196_2_Ent3", "text": "Zoledronic acid", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15779196_2_Ent1", "text": "severe hypocalcaemia", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "15779196_2_Ent4", "text": "prostate cancer", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "15779196_2_Ent0", "text": "prostate cancer patient with extensive osteoblastic bone metastases", "entity_type": "Entity", "start": 8, "end": 16}, {"id": "15779196_2_Ent5", "text": "extensive osteoblastic bone metastases", "entity_type": "Entity", "start": 12, "end": 16}], "lang": "en"}
{"doc_id": "15785053_1", "wnd_id": "15785053_1_1", "text": "Mucosal pigmentation after oral lichen planus treatment with topical tacrolimus .", "tokens": ["Mucosal", "pigmentation", "after", "oral", "lichen", "planus", "treatment", "with", "topical", "tacrolimus", "."], "event_mentions": [{"id": "15785053_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treatment", "start": 6, "end": 7}, "arguments": [{"entity_id": "15785053_1_Ent0", "role": "Effect", "text": "Mucosal pigmentation", "start": 0, "end": 2}, {"entity_id": "15785053_1_Ent2", "role": "Treatment_Disorder", "text": "oral lichen planus", "start": 3, "end": 6}, {"entity_id": "15785053_1_Ent4", "role": "Treatment_Route", "text": "topical", "start": 8, "end": 9}, {"entity_id": "15785053_1_Ent1", "role": "Treatment", "text": "topical tacrolimus", "start": 8, "end": 10}, {"entity_id": "15785053_1_Ent3", "role": "Treatment_Drug", "text": "tacrolimus", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "15785053_1_Ent0", "text": "Mucosal pigmentation", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15785053_1_Ent2", "text": "oral lichen planus", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "15785053_1_Ent4", "text": "topical", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15785053_1_Ent1", "text": "topical tacrolimus", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "15785053_1_Ent3", "text": "tacrolimus", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "15806568_1", "wnd_id": "15806568_1_1", "text": "In this study , we report on three individual patients who received BTX - B and who subsequently developed parasympathetic dysfunction of the visual system after injections of BTX - B at remote sites .", "tokens": ["In", "this", "study", ",", "we", "report", "on", "three", "individual", "patients", "who", "received", "BTX", "-", "B", "and", "who", "subsequently", "developed", "parasympathetic", "dysfunction", "of", "the", "visual", "system", "after", "injections", "of", "BTX", "-", "B", "at", "remote", "sites", "."], "event_mentions": [{"id": "15806568_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 18, "end": 19}, "arguments": [{"entity_id": "15806568_1_Ent1", "role": "Subject_Population", "text": "three", "start": 7, "end": 8}, {"entity_id": "15806568_1_Ent0", "role": "Subject", "text": "three individual patients", "start": 7, "end": 10}, {"entity_id": "15806568_1_Ent3", "role": "Treatment", "text": "BTX - B", "start": 12, "end": 15}, {"entity_id": "15806568_1_Ent5", "role": "Treatment_Drug", "text": "BTX - B", "start": 12, "end": 15}, {"entity_id": "15806568_1_Ent2", "role": "Effect", "text": "parasympathetic dysfunction of the visual system", "start": 19, "end": 25}, {"entity_id": "15806568_1_Ent4", "role": "Treatment", "text": "BTX - B", "start": 28, "end": 31}, {"entity_id": "15806568_1_Ent6", "role": "Treatment_Drug", "text": "BTX - B", "start": 28, "end": 31}]}], "entity_mentions": [{"id": "15806568_1_Ent1", "text": "three", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15806568_1_Ent0", "text": "three individual patients", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "15806568_1_Ent3", "text": "BTX - B", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "15806568_1_Ent5", "text": "BTX - B", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "15806568_1_Ent2", "text": "parasympathetic dysfunction of the visual system", "entity_type": "Entity", "start": 19, "end": 25}, {"id": "15806568_1_Ent4", "text": "BTX - B", "entity_type": "Entity", "start": 28, "end": 31}, {"id": "15806568_1_Ent6", "text": "BTX - B", "entity_type": "Entity", "start": 28, "end": 31}], "lang": "en"}
{"doc_id": "15806568_3", "wnd_id": "15806568_3_1", "text": "Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections .", "tokens": ["Visual", "system", "side", "effects", "caused", "by", "parasympathetic", "dysfunction", "after", "botulinum", "toxin", "type", "B", "injections", "."], "event_mentions": [{"id": "15806568_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 8, "end": 9}, "arguments": [{"entity_id": "15806568_3_Ent0", "role": "Effect", "text": "Visual system side effects caused by parasympathetic dysfunction", "start": 0, "end": 8}, {"entity_id": "15806568_3_Ent2", "role": "Treatment_Drug", "text": "botulinum toxin type B", "start": 9, "end": 13}, {"entity_id": "15806568_3_Ent1", "role": "Treatment", "text": "botulinum toxin type B injections", "start": 9, "end": 14}, {"entity_id": "15806568_3_Ent3", "role": "Treatment_Route", "text": "injections", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "15806568_3_Ent0", "text": "Visual system side effects caused by parasympathetic dysfunction", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "15806568_3_Ent2", "text": "botulinum toxin type B", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "15806568_3_Ent1", "text": "botulinum toxin type B injections", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "15806568_3_Ent3", "text": "injections", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "1580986_1", "wnd_id": "1580986_1_1", "text": "Enalapril - induced anemia in two kidney transplant recipients .", "tokens": ["Enalapril", "-", "induced", "anemia", "in", "two", "kidney", "transplant", "recipients", "."], "event_mentions": [{"id": "1580986_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "1580986_1_Ent2", "role": "Treatment", "text": "Enalapril", "start": 0, "end": 1}, {"entity_id": "1580986_1_Ent3", "role": "Treatment_Drug", "text": "Enalapril", "start": 0, "end": 1}, {"entity_id": "1580986_1_Ent1", "role": "Effect", "text": "anemia", "start": 3, "end": 4}, {"entity_id": "1580986_1_Ent0", "role": "Subject", "text": "two kidney transplant recipients", "start": 5, "end": 9}, {"entity_id": "1580986_1_Ent4", "role": "Treatment_Disorder", "text": "kidney transplant", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "1580986_1_Ent2", "text": "Enalapril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1580986_1_Ent3", "text": "Enalapril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1580986_1_Ent1", "text": "anemia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1580986_1_Ent0", "text": "two kidney transplant recipients", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "1580986_1_Ent4", "text": "kidney transplant", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "1580986_2", "wnd_id": "1580986_2_1", "text": "Two renal transplant patients developed anemia during treatment of hypertension with enalapril medication .", "tokens": ["Two", "renal", "transplant", "patients", "developed", "anemia", "during", "treatment", "of", "hypertension", "with", "enalapril", "medication", "."], "event_mentions": [{"id": "1580986_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 4, "end": 5}, "arguments": [{"entity_id": "1580986_2_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "1580986_2_Ent0", "role": "Subject", "text": "Two renal transplant patients", "start": 0, "end": 4}, {"entity_id": "1580986_2_Ent2", "role": "Subject_Disorder", "text": "renal transplant", "start": 1, "end": 3}, {"entity_id": "1580986_2_Ent3", "role": "Effect", "text": "anemia", "start": 5, "end": 6}, {"entity_id": "1580986_2_Ent5", "role": "Treatment_Disorder", "text": "hypertension", "start": 9, "end": 10}, {"entity_id": "1580986_2_Ent6", "role": "Treatment_Drug", "text": "enalapril", "start": 11, "end": 12}, {"entity_id": "1580986_2_Ent4", "role": "Treatment", "text": "enalapril medication", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "1580986_2_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1580986_2_Ent0", "text": "Two renal transplant patients", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "1580986_2_Ent2", "text": "renal transplant", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "1580986_2_Ent3", "text": "anemia", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1580986_2_Ent5", "text": "hypertension", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "1580986_2_Ent6", "text": "enalapril", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "1580986_2_Ent4", "text": "enalapril medication", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "15823103_2", "wnd_id": "15823103_2_1", "text": "However , one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea , and another four patients developed eruptions , hypotension , and tachycardia soon after administration of CBDCA .", "tokens": ["However", ",", "one", "patient", "exhibited", "severe", "hypersensitivity", "reactions", "including", "cardiac", "arrest", "and", "apnea", ",", "and", "another", "four", "patients", "developed", "eruptions", ",", "hypotension", ",", "and", "tachycardia", "soon", "after", "administration", "of", "CBDCA", "."], "event_mentions": [{"id": "15823103_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "administration", "start": 27, "end": 28}, "arguments": [{"entity_id": "15823103_2_Ent0", "role": "Subject", "text": "one patient", "start": 2, "end": 4}, {"entity_id": "15823103_2_Ent1", "role": "Effect", "text": "severe hypersensitivity reactions including cardiac arrest and apnea", "start": 5, "end": 13}, {"entity_id": "15823103_2_Ent2", "role": "Treatment", "text": "CBDCA", "start": 29, "end": 30}, {"entity_id": "15823103_2_Ent3", "role": "Treatment_Drug", "text": "CBDCA", "start": 29, "end": 30}]}, {"id": "15823103_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "administration", "start": 27, "end": 28}, "arguments": [{"entity_id": "15823103_2_Ent4", "role": "Subject", "text": "four patients", "start": 16, "end": 18}, {"entity_id": "15823103_2_Ent5", "role": "Effect", "text": "eruptions , hypotension , and tachycardia", "start": 19, "end": 25}, {"entity_id": "15823103_2_Ent6", "role": "Treatment", "text": "CBDCA", "start": 29, "end": 30}, {"entity_id": "15823103_2_Ent7", "role": "Treatment_Drug", "text": "CBDCA", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "15823103_2_Ent0", "text": "one patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "15823103_2_Ent1", "text": "severe hypersensitivity reactions including cardiac arrest and apnea", "entity_type": "Entity", "start": 5, "end": 13}, {"id": "15823103_2_Ent4", "text": "four patients", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "15823103_2_Ent5", "text": "eruptions , hypotension , and tachycardia", "entity_type": "Entity", "start": 19, "end": 25}, {"id": "15823103_2_Ent2", "text": "CBDCA", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "15823103_2_Ent3", "text": "CBDCA", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "15823103_2_Ent6", "text": "CBDCA", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "15823103_2_Ent7", "text": "CBDCA", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "15823103_4", "wnd_id": "15823103_4_1", "text": "We report five cases of carboplatin ( CBDCA ) hypersensitivity after weekly low - dose paclitaxel ( 60 mg / m2)/CBDCA ( area under the concentration curve = 2 ) therapy in patients with recurrent ovarian cancer receiving multiple platinum - based chemotherapy .", "tokens": ["We", "report", "five", "cases", "of", "carboplatin", "(", "CBDCA", ")", "hypersensitivity", "after", "weekly", "low", "-", "dose", "paclitaxel", "(", "60", "mg", "/", "m2)/CBDCA", "(", "area", "under", "the", "concentration", "curve", "=", "2", ")", "therapy", "in", "patients", "with", "recurrent", "ovarian", "cancer", "receiving", "multiple", "platinum", "-", "based", "chemotherapy", "."], "event_mentions": [{"id": "15823103_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 10, "end": 11}, "arguments": [{"entity_id": "15823103_4_Ent1", "role": "Subject_Population", "text": "five", "start": 2, "end": 3}, {"entity_id": "15823103_4_Ent7", "role": "Treatment_Drug", "text": "carboplatin", "start": 5, "end": 6}, {"entity_id": "15823103_4_Ent2", "role": "Effect", "text": "carboplatin ( CBDCA ) hypersensitivity", "start": 5, "end": 10}, {"entity_id": "15823103_4_Ent11", "role": "Treatment_Freq", "text": "weekly", "start": 11, "end": 12}, {"entity_id": "15823103_4_Ent3", "role": "Treatment", "text": "weekly low - dose paclitaxel ( 60 mg / m2)/CBDCA ( area under the concentration curve = 2 ) therapy", "start": 11, "end": 31}, {"entity_id": "15823103_4_Ent9", "role": "Treatment_Dosage", "text": "low - dose", "start": 12, "end": 15}, {"entity_id": "15823103_4_Ent5", "role": "Treatment_Drug", "text": "paclitaxel", "start": 15, "end": 16}, {"entity_id": "15823103_4_Ent14", "role": "Combination_Drug", "text": "paclitaxel", "start": 15, "end": 16}, {"entity_id": "15823103_4_Ent10", "role": "Treatment_Dosage", "text": "60 mg / m2)/CBDCA", "start": 17, "end": 21}, {"entity_id": "15823103_4_Ent6", "role": "Treatment_Drug", "text": "m2)/CBDCA", "start": 20, "end": 21}, {"entity_id": "15823103_4_Ent15", "role": "Combination_Drug", "text": "m2)/CBDCA", "start": 20, "end": 21}, {"entity_id": "15823103_4_Ent0", "role": "Subject", "text": "patients with recurrent ovarian cancer", "start": 32, "end": 37}, {"entity_id": "15823103_4_Ent12", "role": "Treatment_Disorder", "text": "recurrent ovarian cancer", "start": 34, "end": 37}, {"entity_id": "15823103_4_Ent4", "role": "Treatment", "text": "multiple platinum - based chemotherapy", "start": 38, "end": 43}, {"entity_id": "15823103_4_Ent8", "role": "Treatment_Drug", "text": "platinum", "start": 39, "end": 40}, {"entity_id": "15823103_4_Ent16", "role": "Combination_Drug", "text": "platinum", "start": 39, "end": 40}, {"entity_id": "15823103_4_Ent13", "role": "Treatment_Route", "text": "chemotherapy", "start": 42, "end": 43}]}], "entity_mentions": [{"id": "15823103_4_Ent1", "text": "five", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "15823103_4_Ent7", "text": "carboplatin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15823103_4_Ent2", "text": "carboplatin ( CBDCA ) hypersensitivity", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "15823103_4_Ent11", "text": "weekly", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15823103_4_Ent3", "text": "weekly low - dose paclitaxel ( 60 mg / m2)/CBDCA ( area under the concentration curve = 2 ) therapy", "entity_type": "Entity", "start": 11, "end": 31}, {"id": "15823103_4_Ent9", "text": "low - dose", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "15823103_4_Ent5", "text": "paclitaxel", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15823103_4_Ent14", "text": "paclitaxel", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15823103_4_Ent10", "text": "60 mg / m2)/CBDCA", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "15823103_4_Ent6", "text": "m2)/CBDCA", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "15823103_4_Ent15", "text": "m2)/CBDCA", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "15823103_4_Ent0", "text": "patients with recurrent ovarian cancer", "entity_type": "Entity", "start": 32, "end": 37}, {"id": "15823103_4_Ent12", "text": "recurrent ovarian cancer", "entity_type": "Entity", "start": 34, "end": 37}, {"id": "15823103_4_Ent4", "text": "multiple platinum - based chemotherapy", "entity_type": "Entity", "start": 38, "end": 43}, {"id": "15823103_4_Ent8", "text": "platinum", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "15823103_4_Ent16", "text": "platinum", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "15823103_4_Ent13", "text": "chemotherapy", "entity_type": "Entity", "start": 42, "end": 43}], "lang": "en"}
{"doc_id": "15827071_13", "wnd_id": "15827071_13_1", "text": "A review of published case reports showed a short time to onset of symptoms following the introduction of linezolid , generally within 1 - 3 days .", "tokens": ["A", "review", "of", "published", "case", "reports", "showed", "a", "short", "time", "to", "onset", "of", "symptoms", "following", "the", "introduction", "of", "linezolid", ",", "generally", "within", "1", "-", "3", "days", "."], "event_mentions": [{"id": "15827071_13_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 14, "end": 15}, "arguments": [{"entity_id": "15827071_13_Ent0", "role": "Effect", "text": "a short time to onset of symptoms", "start": 7, "end": 14}, {"entity_id": "15827071_13_Ent1", "role": "Treatment", "text": "introduction of linezolid , generally within 1 - 3 days", "start": 16, "end": 26}, {"entity_id": "15827071_13_Ent2", "role": "Treatment_Drug", "text": "linezolid", "start": 18, "end": 19}, {"entity_id": "15827071_13_Ent3", "role": "Treatment_Time_elapsed", "text": "within 1 - 3 days", "start": 21, "end": 26}]}], "entity_mentions": [{"id": "15827071_13_Ent0", "text": "a short time to onset of symptoms", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "15827071_13_Ent1", "text": "introduction of linezolid , generally within 1 - 3 days", "entity_type": "Entity", "start": 16, "end": 26}, {"id": "15827071_13_Ent2", "text": "linezolid", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "15827071_13_Ent3", "text": "within 1 - 3 days", "entity_type": "Entity", "start": 21, "end": 26}], "lang": "en"}
{"doc_id": "15827071_4", "wnd_id": "15827071_4_1", "text": "A 38 - year - old white female with cystic fibrosis treated with venlafaxine 300 mg / day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin - resistant Staphylococcus aureus ( MRSA ) pulmonary infection .", "tokens": ["A", "38", "-", "year", "-", "old", "white", "female", "with", "cystic", "fibrosis", "treated", "with", "venlafaxine", "300", "mg", "/", "day", "for", "one", "year", "was", "prescribed", "linezolid", "600", "mg", "intravenously", "every", "12", "hours", "for", "treatment", "of", "methicillin", "-", "resistant", "Staphylococcus", "aureus", "(", "MRSA", ")", "pulmonary", "infection", "."], "event_mentions": [{"id": "15827071_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 11, "end": 12}, "arguments": [{"entity_id": "15827071_4_Ent0", "role": "Subject", "text": "A 38 - year - old white female", "start": 0, "end": 8}, {"entity_id": "15827071_4_Ent1", "role": "Subject_Age", "text": "38 - year - old", "start": 1, "end": 6}, {"entity_id": "15827071_4_Ent2", "role": "Subject_Race", "text": "white", "start": 6, "end": 7}, {"entity_id": "15827071_4_Ent3", "role": "Subject_Gender", "text": "female", "start": 7, "end": 8}, {"entity_id": "15827071_4_Ent5", "role": "Treatment_Disorder", "text": "cystic fibrosis", "start": 9, "end": 11}, {"entity_id": "15827071_4_Ent7", "role": "Treatment_Drug", "text": "venlafaxine", "start": 13, "end": 14}, {"entity_id": "15827071_4_Ent4", "role": "Treatment", "text": "venlafaxine 300 mg / day for one year", "start": 13, "end": 21}, {"entity_id": "15827071_4_Ent6", "role": "Treatment_Dosage", "text": "300 mg / day", "start": 14, "end": 18}, {"entity_id": "15827071_4_Ent8", "role": "Treatment_Duration", "text": "one year", "start": 19, "end": 21}]}, {"id": "15827071_4_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 31, "end": 32}, "arguments": [{"entity_id": "15827071_4_Ent9", "role": "Subject", "text": "A 38 - year - old white female", "start": 0, "end": 8}, {"entity_id": "15827071_4_Ent10", "role": "Subject_Age", "text": "38 - year - old", "start": 1, "end": 6}, {"entity_id": "15827071_4_Ent11", "role": "Subject_Race", "text": "white", "start": 6, "end": 7}, {"entity_id": "15827071_4_Ent12", "role": "Subject_Gender", "text": "female", "start": 7, "end": 8}, {"entity_id": "15827071_4_Ent15", "role": "Treatment_Drug", "text": "linezolid", "start": 23, "end": 24}, {"entity_id": "15827071_4_Ent13", "role": "Treatment", "text": "linezolid 600 mg intravenously every 12 hours", "start": 23, "end": 30}, {"entity_id": "15827071_4_Ent16", "role": "Treatment_Dosage", "text": "600 mg", "start": 24, "end": 26}, {"entity_id": "15827071_4_Ent18", "role": "Treatment_Route", "text": "intravenously", "start": 26, "end": 27}, {"entity_id": "15827071_4_Ent17", "role": "Treatment_Freq", "text": "every 12 hours", "start": 27, "end": 30}, {"entity_id": "15827071_4_Ent14", "role": "Treatment_Disorder", "text": "methicillin - resistant Staphylococcus aureus ( MRSA ) pulmonary infection", "start": 33, "end": 43}]}], "entity_mentions": [{"id": "15827071_4_Ent0", "text": "A 38 - year - old white female", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "15827071_4_Ent9", "text": "A 38 - year - old white female", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "15827071_4_Ent1", "text": "38 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "15827071_4_Ent10", "text": "38 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "15827071_4_Ent2", "text": "white", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15827071_4_Ent11", "text": "white", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15827071_4_Ent3", "text": "female", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15827071_4_Ent12", "text": "female", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15827071_4_Ent5", "text": "cystic fibrosis", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "15827071_4_Ent7", "text": "venlafaxine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15827071_4_Ent4", "text": "venlafaxine 300 mg / day for one year", "entity_type": "Entity", "start": 13, "end": 21}, {"id": "15827071_4_Ent6", "text": "300 mg / day", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "15827071_4_Ent8", "text": "one year", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "15827071_4_Ent15", "text": "linezolid", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "15827071_4_Ent13", "text": "linezolid 600 mg intravenously every 12 hours", "entity_type": "Entity", "start": 23, "end": 30}, {"id": "15827071_4_Ent16", "text": "600 mg", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "15827071_4_Ent18", "text": "intravenously", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "15827071_4_Ent17", "text": "every 12 hours", "entity_type": "Entity", "start": 27, "end": 30}, {"id": "15827071_4_Ent14", "text": "methicillin - resistant Staphylococcus aureus ( MRSA ) pulmonary infection", "entity_type": "Entity", "start": 33, "end": 43}], "lang": "en"}
{"doc_id": "15840734_8", "wnd_id": "15840734_8_1", "text": "DISCUSSION : NMS is a rare but potentially fatal reaction associated with neuroleptic drugs .", "tokens": ["DISCUSSION", ":", "NMS", "is", "a", "rare", "but", "potentially", "fatal", "reaction", "associated", "with", "neuroleptic", "drugs", "."], "event_mentions": [{"id": "15840734_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 10, "end": 11}, "arguments": [{"entity_id": "15840734_8_Ent0", "role": "Effect", "text": "NMS", "start": 2, "end": 3}, {"entity_id": "15840734_8_Ent2", "role": "Treatment_Drug", "text": "neuroleptic", "start": 12, "end": 13}, {"entity_id": "15840734_8_Ent1", "role": "Treatment", "text": "neuroleptic drugs", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "15840734_8_Ent0", "text": "NMS", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "15840734_8_Ent2", "text": "neuroleptic", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15840734_8_Ent1", "text": "neuroleptic drugs", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "1584367_1", "wnd_id": "1584367_1_1", "text": "Intraventricular vancomycin - induced cerebrospinal fluid eosinophilia : report of two patients .", "tokens": ["Intraventricular", "vancomycin", "-", "induced", "cerebrospinal", "fluid", "eosinophilia", ":", "report", "of", "two", "patients", "."], "event_mentions": [{"id": "1584367_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "1584367_1_Ent4", "role": "Treatment_Route", "text": "Intraventricular", "start": 0, "end": 1}, {"entity_id": "1584367_1_Ent3", "role": "Treatment", "text": "Intraventricular vancomycin", "start": 0, "end": 2}, {"entity_id": "1584367_1_Ent5", "role": "Treatment_Drug", "text": "vancomycin", "start": 1, "end": 2}, {"entity_id": "1584367_1_Ent2", "role": "Effect", "text": "cerebrospinal fluid eosinophilia", "start": 4, "end": 7}, {"entity_id": "1584367_1_Ent1", "role": "Subject_Population", "text": "two", "start": 10, "end": 11}, {"entity_id": "1584367_1_Ent0", "role": "Subject", "text": "two patients .", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "1584367_1_Ent4", "text": "Intraventricular", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1584367_1_Ent3", "text": "Intraventricular vancomycin", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1584367_1_Ent5", "text": "vancomycin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "1584367_1_Ent2", "text": "cerebrospinal fluid eosinophilia", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "1584367_1_Ent1", "text": "two", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1584367_1_Ent0", "text": "two patients .", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "1584367_3", "wnd_id": "1584367_3_1", "text": "We report two cases of cerebrospinal fluid eosinophilia ( CSFE ) secondary to the intraventricular administration of vancomycin .", "tokens": ["We", "report", "two", "cases", "of", "cerebrospinal", "fluid", "eosinophilia", "(", "CSFE", ")", "secondary", "to", "the", "intraventricular", "administration", "of", "vancomycin", "."], "event_mentions": [{"id": "1584367_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 11, "end": 12}, "arguments": [{"entity_id": "1584367_3_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "1584367_3_Ent0", "role": "Subject", "text": "two cases", "start": 2, "end": 4}, {"entity_id": "1584367_3_Ent2", "role": "Effect", "text": "cerebrospinal fluid eosinophilia ( CSFE )", "start": 5, "end": 11}, {"entity_id": "1584367_3_Ent4", "role": "Treatment_Route", "text": "intraventricular", "start": 14, "end": 15}, {"entity_id": "1584367_3_Ent3", "role": "Treatment", "text": "intraventricular administration of vancomycin", "start": 14, "end": 18}, {"entity_id": "1584367_3_Ent5", "role": "Treatment_Drug", "text": "vancomycin", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "1584367_3_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "1584367_3_Ent0", "text": "two cases", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "1584367_3_Ent2", "text": "cerebrospinal fluid eosinophilia ( CSFE )", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "1584367_3_Ent4", "text": "intraventricular", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "1584367_3_Ent3", "text": "intraventricular administration of vancomycin", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "1584367_3_Ent5", "text": "vancomycin", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "15857283_1", "wnd_id": "15857283_1_1", "text": "CONCLUSIONS : In these 3 cases , the unique positive ocular finding was corneal endothelial deposits , which may be related to the use of rifabutin .", "tokens": ["CONCLUSIONS", ":", "In", "these", "3", "cases", ",", "the", "unique", "positive", "ocular", "finding", "was", "corneal", "endothelial", "deposits", ",", "which", "may", "be", "related", "to", "the", "use", "of", "rifabutin", "."], "event_mentions": [{"id": "15857283_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 20, "end": 21}, "arguments": [{"entity_id": "15857283_1_Ent0", "role": "Effect", "text": "corneal endothelial deposits", "start": 13, "end": 16}, {"entity_id": "15857283_1_Ent1", "role": "Treatment", "text": "rifabutin", "start": 25, "end": 26}, {"entity_id": "15857283_1_Ent2", "role": "Treatment_Drug", "text": "rifabutin", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "15857283_1_Ent0", "text": "corneal endothelial deposits", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "15857283_1_Ent1", "text": "rifabutin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "15857283_1_Ent2", "text": "rifabutin", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "15863610_4", "wnd_id": "15863610_4_1", "text": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene , which is also a selective estrogen receptor modulator .", "tokens": ["We", "report", "a", "case", "of", "a", "women", "in", "whom", "a", "malignant", "mixed", "mesodermal", "tumor", "was", "diagnosed", "while", "she", "was", "taking", "raloxifene", ",", "which", "is", "also", "a", "selective", "estrogen", "receptor", "modulator", "."], "event_mentions": [{"id": "15863610_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "diagnosed", "start": 15, "end": 16}, "arguments": [{"entity_id": "15863610_4_Ent0", "role": "Subject", "text": "a women", "start": 5, "end": 7}, {"entity_id": "15863610_4_Ent1", "role": "Subject_Gender", "text": "women", "start": 6, "end": 7}, {"entity_id": "15863610_4_Ent2", "role": "Effect", "text": "a malignant mixed mesodermal tumor", "start": 9, "end": 14}, {"entity_id": "15863610_4_Ent3", "role": "Treatment", "text": "while she was taking raloxifene", "start": 16, "end": 21}, {"entity_id": "15863610_4_Ent4", "role": "Treatment_Drug", "text": "raloxifene", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "15863610_4_Ent0", "text": "a women", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "15863610_4_Ent1", "text": "women", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15863610_4_Ent2", "text": "a malignant mixed mesodermal tumor", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "15863610_4_Ent3", "text": "while she was taking raloxifene", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "15863610_4_Ent4", "text": "raloxifene", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "15863610_5", "wnd_id": "15863610_5_1", "text": "CASE : A malignant mixed mesodermal tumor was diagnosed in a 64 - year - old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention .", "tokens": ["CASE", ":", "A", "malignant", "mixed", "mesodermal", "tumor", "was", "diagnosed", "in", "a", "64", "-", "year", "-", "old", "woman", "with", "a", "bicornuate", "uterus", "while", "she", "was", "taking", "raloxifene", "for", "osteoporosis", "prevention", "."], "event_mentions": [{"id": "15863610_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "diagnosed", "start": 8, "end": 9}, "arguments": [{"entity_id": "15863610_5_Ent4", "role": "Effect", "text": "A malignant mixed mesodermal tumor", "start": 2, "end": 7}, {"entity_id": "15863610_5_Ent0", "role": "Subject", "text": "a 64 - year - old woman with a bicornuate uterus", "start": 10, "end": 21}, {"entity_id": "15863610_5_Ent1", "role": "Subject_Age", "text": "64 - year - old", "start": 11, "end": 16}, {"entity_id": "15863610_5_Ent2", "role": "Subject_Gender", "text": "woman", "start": 16, "end": 17}, {"entity_id": "15863610_5_Ent3", "role": "Subject_Disorder", "text": "bicornuate uterus", "start": 19, "end": 21}, {"entity_id": "15863610_5_Ent5", "role": "Treatment", "text": "raloxifene", "start": 25, "end": 26}, {"entity_id": "15863610_5_Ent6", "role": "Treatment_Drug", "text": "raloxifene", "start": 25, "end": 26}, {"entity_id": "15863610_5_Ent7", "role": "Treatment_Disorder", "text": "osteoporosis", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "15863610_5_Ent4", "text": "A malignant mixed mesodermal tumor", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "15863610_5_Ent0", "text": "a 64 - year - old woman with a bicornuate uterus", "entity_type": "Entity", "start": 10, "end": 21}, {"id": "15863610_5_Ent1", "text": "64 - year - old", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "15863610_5_Ent2", "text": "woman", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15863610_5_Ent3", "text": "bicornuate uterus", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "15863610_5_Ent5", "text": "raloxifene", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "15863610_5_Ent6", "text": "raloxifene", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "15863610_5_Ent7", "text": "osteoporosis", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "15920338_1", "wnd_id": "15920338_1_1", "text": "A case of high - grade endometrial stromal sarcoma , confined into an intrauterine polypoid growth , in a woman with a history of breast cancer who was treated with adjuvant tamoxifen .", "tokens": ["A", "case", "of", "high", "-", "grade", "endometrial", "stromal", "sarcoma", ",", "confined", "into", "an", "intrauterine", "polypoid", "growth", ",", "in", "a", "woman", "with", "a", "history", "of", "breast", "cancer", "who", "was", "treated", "with", "adjuvant", "tamoxifen", "."], "event_mentions": [{"id": "15920338_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 28, "end": 29}, "arguments": [{"entity_id": "15920338_1_Ent3", "role": "Subject_Population", "text": "A", "start": 0, "end": 1}, {"entity_id": "15920338_1_Ent0", "role": "Subject", "text": "A case of high - grade endometrial stromal sarcoma , confined into an intrauterine polypoid growth , in a woman with a history of breast cancer", "start": 0, "end": 26}, {"entity_id": "15920338_1_Ent6", "role": "Treatment_Disorder", "text": "high - grade endometrial stromal sarcoma , confined into an intrauterine polypoid growth", "start": 3, "end": 16}, {"entity_id": "15920338_1_Ent1", "role": "Subject_Gender", "text": "woman", "start": 19, "end": 20}, {"entity_id": "15920338_1_Ent2", "role": "Subject_Disorder", "text": "breast cancer", "start": 24, "end": 26}, {"entity_id": "15920338_1_Ent4", "role": "Treatment", "text": "adjuvant tamoxifen", "start": 30, "end": 32}, {"entity_id": "15920338_1_Ent5", "role": "Treatment_Drug", "text": "tamoxifen", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "15920338_1_Ent3", "text": "A", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15920338_1_Ent0", "text": "A case of high - grade endometrial stromal sarcoma , confined into an intrauterine polypoid growth , in a woman with a history of breast cancer", "entity_type": "Entity", "start": 0, "end": 26}, {"id": "15920338_1_Ent6", "text": "high - grade endometrial stromal sarcoma , confined into an intrauterine polypoid growth", "entity_type": "Entity", "start": 3, "end": 16}, {"id": "15920338_1_Ent1", "text": "woman", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "15920338_1_Ent2", "text": "breast cancer", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "15920338_1_Ent4", "text": "adjuvant tamoxifen", "entity_type": "Entity", "start": 30, "end": 32}, {"id": "15920338_1_Ent5", "text": "tamoxifen", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "15920338_2", "wnd_id": "15920338_2_1", "text": "High - grade endometrial stromal sarcoma after tamoxifen therapy for breast cancer .", "tokens": ["High", "-", "grade", "endometrial", "stromal", "sarcoma", "after", "tamoxifen", "therapy", "for", "breast", "cancer", "."], "event_mentions": [{"id": "15920338_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 6, "end": 7}, "arguments": [{"entity_id": "15920338_2_Ent0", "role": "Effect", "text": "High - grade endometrial stromal sarcoma", "start": 0, "end": 6}, {"entity_id": "15920338_2_Ent1", "role": "Treatment", "text": "tamoxifen", "start": 7, "end": 8}, {"entity_id": "15920338_2_Ent2", "role": "Treatment_Drug", "text": "tamoxifen", "start": 7, "end": 8}, {"entity_id": "15920338_2_Ent3", "role": "Treatment_Disorder", "text": "breast cancer", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "15920338_2_Ent0", "text": "High - grade endometrial stromal sarcoma", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "15920338_2_Ent1", "text": "tamoxifen", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15920338_2_Ent2", "text": "tamoxifen", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15920338_2_Ent3", "text": "breast cancer", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "15927910_4", "wnd_id": "15927910_4_1", "text": "Early - onset pentamidine - associated second - degree heart block and sinus bradycardia : case report and review of the literature .", "tokens": ["Early", "-", "onset", "pentamidine", "-", "associated", "second", "-", "degree", "heart", "block", "and", "sinus", "bradycardia", ":", "case", "report", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "15927910_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "15927910_4_Ent1", "role": "Effect", "text": "Early - onset", "start": 0, "end": 3}, {"entity_id": "15927910_4_Ent3", "role": "Treatment", "text": "pentamidine", "start": 3, "end": 4}, {"entity_id": "15927910_4_Ent4", "role": "Treatment_Drug", "text": "pentamidine", "start": 3, "end": 4}, {"entity_id": "15927910_4_Ent2", "role": "Effect", "text": "second - degree heart block and sinus bradycardia", "start": 6, "end": 14}, {"entity_id": "15927910_4_Ent0", "role": "Subject", "text": "case", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "15927910_4_Ent1", "text": "Early - onset", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15927910_4_Ent3", "text": "pentamidine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15927910_4_Ent4", "text": "pentamidine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15927910_4_Ent2", "text": "second - degree heart block and sinus bradycardia", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "15927910_4_Ent0", "text": "case", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "1592841_2", "wnd_id": "1592841_2_1", "text": "RESULTS : Both patients experienced a previously unreported side effect -- falling backward -- associated with bupropion use .", "tokens": ["RESULTS", ":", "Both", "patients", "experienced", "a", "previously", "unreported", "side", "effect", "--", "falling", "backward", "--", "associated", "with", "bupropion", "use", "."], "event_mentions": [{"id": "1592841_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 14, "end": 15}, "arguments": [{"entity_id": "1592841_2_Ent1", "role": "Subject_Population", "text": "Both", "start": 2, "end": 3}, {"entity_id": "1592841_2_Ent0", "role": "Subject", "text": "Both patients", "start": 2, "end": 4}, {"entity_id": "1592841_2_Ent2", "role": "Effect", "text": "falling backward", "start": 11, "end": 13}, {"entity_id": "1592841_2_Ent3", "role": "Treatment", "text": "bupropion", "start": 16, "end": 17}, {"entity_id": "1592841_2_Ent4", "role": "Treatment_Drug", "text": "bupropion", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "1592841_2_Ent1", "text": "Both", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "1592841_2_Ent0", "text": "Both patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "1592841_2_Ent2", "text": "falling backward", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "1592841_2_Ent3", "text": "bupropion", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "1592841_2_Ent4", "text": "bupropion", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "15941649_2", "wnd_id": "15941649_2_1", "text": "The knowledge concerning VGB - associated visual dysfunction in pediatric patients , particularly in those who have been exposed to VGB in utero is limited .", "tokens": ["The", "knowledge", "concerning", "VGB", "-", "associated", "visual", "dysfunction", "in", "pediatric", "patients", ",", "particularly", "in", "those", "who", "have", "been", "exposed", "to", "VGB", "in", "utero", "is", "limited", "."], "event_mentions": [{"id": "15941649_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "15941649_2_Ent3", "role": "Treatment", "text": "VGB", "start": 3, "end": 4}, {"entity_id": "15941649_2_Ent4", "role": "Treatment_Drug", "text": "VGB", "start": 3, "end": 4}, {"entity_id": "15941649_2_Ent2", "role": "Effect", "text": "visual dysfunction", "start": 6, "end": 8}, {"entity_id": "15941649_2_Ent1", "role": "Subject_Age", "text": "pediatric", "start": 9, "end": 10}, {"entity_id": "15941649_2_Ent0", "role": "Subject", "text": "pediatric patients", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "15941649_2_Ent3", "text": "VGB", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15941649_2_Ent4", "text": "VGB", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15941649_2_Ent2", "text": "visual dysfunction", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "15941649_2_Ent1", "text": "pediatric", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15941649_2_Ent0", "text": "pediatric patients", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "15977922_1", "wnd_id": "15977922_1_1", "text": "Potential mechanisms involved in the occurrence of ischemic colitis in patients receiving tegaserod are also discussed .", "tokens": ["Potential", "mechanisms", "involved", "in", "the", "occurrence", "of", "ischemic", "colitis", "in", "patients", "receiving", "tegaserod", "are", "also", "discussed", "."], "event_mentions": [{"id": "15977922_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurrence", "start": 5, "end": 6}, "arguments": [{"entity_id": "15977922_1_Ent1", "role": "Effect", "text": "ischemic colitis", "start": 7, "end": 9}, {"entity_id": "15977922_1_Ent0", "role": "Subject", "text": "patients", "start": 10, "end": 11}, {"entity_id": "15977922_1_Ent2", "role": "Treatment", "text": "tegaserod", "start": 12, "end": 13}, {"entity_id": "15977922_1_Ent3", "role": "Treatment_Drug", "text": "tegaserod", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "15977922_1_Ent1", "text": "ischemic colitis", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "15977922_1_Ent0", "text": "patients", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "15977922_1_Ent2", "text": "tegaserod", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15977922_1_Ent3", "text": "tegaserod", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "15977922_2", "wnd_id": "15977922_2_1", "text": "Tegaserod - associated ischemic colitis .", "tokens": ["Tegaserod", "-", "associated", "ischemic", "colitis", "."], "event_mentions": [{"id": "15977922_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "15977922_2_Ent1", "role": "Treatment", "text": "Tegaserod", "start": 0, "end": 1}, {"entity_id": "15977922_2_Ent2", "role": "Treatment_Drug", "text": "Tegaserod", "start": 0, "end": 1}, {"entity_id": "15977922_2_Ent0", "role": "Effect", "text": "ischemic colitis", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "15977922_2_Ent1", "text": "Tegaserod", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15977922_2_Ent2", "text": "Tegaserod", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15977922_2_Ent0", "text": "ischemic colitis", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "15977922_3", "wnd_id": "15977922_3_1", "text": "We describe the development of ischemic colitis in a woman who was treated with tegaserod and review the relationship among ischemic colitis , tegaserod use , and irritable bowel syndrome .", "tokens": ["We", "describe", "the", "development", "of", "ischemic", "colitis", "in", "a", "woman", "who", "was", "treated", "with", "tegaserod", "and", "review", "the", "relationship", "among", "ischemic", "colitis", ",", "tegaserod", "use", ",", "and", "irritable", "bowel", "syndrome", "."], "event_mentions": [{"id": "15977922_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 3, "end": 4}, "arguments": [{"entity_id": "15977922_3_Ent2", "role": "Effect", "text": "ischemic colitis", "start": 5, "end": 7}, {"entity_id": "15977922_3_Ent0", "role": "Subject", "text": "woman", "start": 9, "end": 10}, {"entity_id": "15977922_3_Ent1", "role": "Subject_Gender", "text": "woman", "start": 9, "end": 10}, {"entity_id": "15977922_3_Ent3", "role": "Treatment", "text": "tegaserod", "start": 14, "end": 15}, {"entity_id": "15977922_3_Ent4", "role": "Treatment_Drug", "text": "tegaserod", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "15977922_3_Ent2", "text": "ischemic colitis", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "15977922_3_Ent0", "text": "woman", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15977922_3_Ent1", "text": "woman", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15977922_3_Ent3", "text": "tegaserod", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "15977922_3_Ent4", "text": "tegaserod", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "16001348_1", "wnd_id": "16001348_1_1", "text": "Lansoprazole - associated collagenous colitis : a case report .", "tokens": ["Lansoprazole", "-", "associated", "collagenous", "colitis", ":", "a", "case", "report", "."], "event_mentions": [{"id": "16001348_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "16001348_1_Ent1", "role": "Treatment", "text": "Lansoprazole", "start": 0, "end": 1}, {"entity_id": "16001348_1_Ent2", "role": "Treatment_Drug", "text": "Lansoprazole", "start": 0, "end": 1}, {"entity_id": "16001348_1_Ent0", "role": "Effect", "text": "collagenous colitis", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "16001348_1_Ent1", "text": "Lansoprazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16001348_1_Ent2", "text": "Lansoprazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16001348_1_Ent0", "text": "collagenous colitis", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "16001348_2", "wnd_id": "16001348_2_1", "text": "A 57 - year - old man developed chronic , watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease .", "tokens": ["A", "57", "-", "year", "-", "old", "man", "developed", "chronic", ",", "watery", "diarrhea", "four", "weeks", "after", "Helicobacter", "pylori", "eradication", "therapy", "including", "lansoprazole", "followed", "by", "lansoprazole", "monotherapy", "for", "gastroesophageal", "reflux", "disease", "."], "event_mentions": [{"id": "16001348_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "16001348_2_Ent1", "role": "Subject_Age", "text": "57 - year - old", "start": 1, "end": 6}, {"entity_id": "16001348_2_Ent0", "role": "Subject", "text": "57 - year - old man", "start": 1, "end": 7}, {"entity_id": "16001348_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "16001348_2_Ent3", "role": "Effect", "text": "chronic , watery diarrhea", "start": 8, "end": 12}, {"entity_id": "16001348_2_Ent8", "role": "Treatment_Time_elapsed", "text": "four weeks", "start": 12, "end": 14}, {"entity_id": "16001348_2_Ent4", "role": "Treatment", "text": "four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease", "start": 12, "end": 29}, {"entity_id": "16001348_2_Ent6", "role": "Treatment_Drug", "text": "lansoprazole", "start": 20, "end": 21}, {"entity_id": "16001348_2_Ent9", "role": "Combination_Drug", "text": "lansoprazole", "start": 20, "end": 21}, {"entity_id": "16001348_2_Ent7", "role": "Treatment_Drug", "text": "lansoprazole", "start": 23, "end": 24}, {"entity_id": "16001348_2_Ent10", "role": "Combination_Drug", "text": "lansoprazole", "start": 23, "end": 24}, {"entity_id": "16001348_2_Ent5", "role": "Treatment_Disorder", "text": "gastroesophageal reflux disease", "start": 26, "end": 29}]}], "entity_mentions": [{"id": "16001348_2_Ent1", "text": "57 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "16001348_2_Ent0", "text": "57 - year - old man", "entity_type": "Entity", "start": 1, "end": 7}, {"id": "16001348_2_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16001348_2_Ent3", "text": "chronic , watery diarrhea", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "16001348_2_Ent8", "text": "four weeks", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "16001348_2_Ent4", "text": "four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease", "entity_type": "Entity", "start": 12, "end": 29}, {"id": "16001348_2_Ent6", "text": "lansoprazole", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "16001348_2_Ent9", "text": "lansoprazole", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "16001348_2_Ent7", "text": "lansoprazole", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "16001348_2_Ent10", "text": "lansoprazole", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "16001348_2_Ent5", "text": "gastroesophageal reflux disease", "entity_type": "Entity", "start": 26, "end": 29}], "lang": "en"}
{"doc_id": "16001348_9", "wnd_id": "16001348_9_1", "text": "The reported case represents an unusual association between medication with the proton pump inhibitor lansoprazole and the development of collagenous colitis suggesting the importance of evaluation of drug use in patients with microscopic colitis .", "tokens": ["The", "reported", "case", "represents", "an", "unusual", "association", "between", "medication", "with", "the", "proton", "pump", "inhibitor", "lansoprazole", "and", "the", "development", "of", "collagenous", "colitis", "suggesting", "the", "importance", "of", "evaluation", "of", "drug", "use", "in", "patients", "with", "microscopic", "colitis", "."], "event_mentions": [{"id": "16001348_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 6, "end": 7}, "arguments": [{"entity_id": "16001348_9_Ent3", "role": "Treatment", "text": "proton pump inhibitor lansoprazole", "start": 11, "end": 15}, {"entity_id": "16001348_9_Ent4", "role": "Treatment_Drug", "text": "lansoprazole", "start": 14, "end": 15}, {"entity_id": "16001348_9_Ent2", "role": "Effect", "text": "collagenous colitis", "start": 19, "end": 21}, {"entity_id": "16001348_9_Ent0", "role": "Subject", "text": "patients with microscopic colitis", "start": 30, "end": 34}, {"entity_id": "16001348_9_Ent1", "role": "Subject_Disorder", "text": "microscopic colitis", "start": 32, "end": 34}]}], "entity_mentions": [{"id": "16001348_9_Ent3", "text": "proton pump inhibitor lansoprazole", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "16001348_9_Ent4", "text": "lansoprazole", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16001348_9_Ent2", "text": "collagenous colitis", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "16001348_9_Ent0", "text": "patients with microscopic colitis", "entity_type": "Entity", "start": 30, "end": 34}, {"id": "16001348_9_Ent1", "text": "microscopic colitis", "entity_type": "Entity", "start": 32, "end": 34}], "lang": "en"}
{"doc_id": "16012330_5", "wnd_id": "16012330_5_1", "text": "A 3 - year - old boy diagnosed with acute lymphoblastic leukemia received induction chemotherapy .", "tokens": ["A", "3", "-", "year", "-", "old", "boy", "diagnosed", "with", "acute", "lymphoblastic", "leukemia", "received", "induction", "chemotherapy", "."], "event_mentions": [{"id": "16012330_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "received", "start": 12, "end": 13}, "arguments": [{"entity_id": "16012330_5_Ent0", "role": "Subject", "text": "A 3 - year - old boy diagnosed with acute lymphoblastic leukemia", "start": 0, "end": 12}, {"entity_id": "16012330_5_Ent1", "role": "Subject_Age", "text": "3 - year - old", "start": 1, "end": 6}, {"entity_id": "16012330_5_Ent2", "role": "Subject_Gender", "text": "boy", "start": 6, "end": 7}, {"entity_id": "16012330_5_Ent4", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukemia", "start": 9, "end": 12}, {"entity_id": "16012330_5_Ent3", "role": "Treatment", "text": "induction chemotherapy", "start": 13, "end": 15}, {"entity_id": "16012330_5_Ent5", "role": "Treatment_Route", "text": "induction chemotherapy", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "16012330_5_Ent0", "text": "A 3 - year - old boy diagnosed with acute lymphoblastic leukemia", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "16012330_5_Ent1", "text": "3 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "16012330_5_Ent2", "text": "boy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16012330_5_Ent4", "text": "acute lymphoblastic leukemia", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "16012330_5_Ent3", "text": "induction chemotherapy", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "16012330_5_Ent5", "text": "induction chemotherapy", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "16012330_9", "wnd_id": "16012330_9_1", "text": "Nineteen cases of unusual enhanced vincristine neurotoxicity related to itraconazole have been reported in children .", "tokens": ["Nineteen", "cases", "of", "unusual", "enhanced", "vincristine", "neurotoxicity", "related", "to", "itraconazole", "have", "been", "reported", "in", "children", "."], "event_mentions": [{"id": "16012330_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 7, "end": 8}, "arguments": [{"entity_id": "16012330_9_Ent2", "role": "Subject_Population", "text": "Nineteen", "start": 0, "end": 1}, {"entity_id": "16012330_9_Ent0", "role": "Subject", "text": "Nineteen cases", "start": 0, "end": 2}, {"entity_id": "16012330_9_Ent4", "role": "Effect", "text": "unusual enhanced vincristine neurotoxicity", "start": 3, "end": 7}, {"entity_id": "16012330_9_Ent5", "role": "Treatment", "text": "itraconazole", "start": 9, "end": 10}, {"entity_id": "16012330_9_Ent6", "role": "Treatment_Drug", "text": "itraconazole", "start": 9, "end": 10}, {"entity_id": "16012330_9_Ent1", "role": "Subject", "text": "children", "start": 14, "end": 15}, {"entity_id": "16012330_9_Ent3", "role": "Subject_Age", "text": "children", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "16012330_9_Ent2", "text": "Nineteen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16012330_9_Ent0", "text": "Nineteen cases", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16012330_9_Ent4", "text": "unusual enhanced vincristine neurotoxicity", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "16012330_9_Ent5", "text": "itraconazole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16012330_9_Ent6", "text": "itraconazole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16012330_9_Ent1", "text": "children", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16012330_9_Ent3", "text": "children", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "16018164_2", "wnd_id": "16018164_2_1", "text": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM .", "tokens": ["Only", "one", "report", "links", "phenylpropanolamine", "consumption", "to", "an", "intracerebral", "hemorrhage", "in", "a", "patient", "with", "an", "AVM", "."], "event_mentions": [{"id": "16018164_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "links", "start": 3, "end": 4}, "arguments": [{"entity_id": "16018164_2_Ent3", "role": "Treatment", "text": "phenylpropanolamine", "start": 4, "end": 5}, {"entity_id": "16018164_2_Ent4", "role": "Treatment_Drug", "text": "phenylpropanolamine", "start": 4, "end": 5}, {"entity_id": "16018164_2_Ent2", "role": "Effect", "text": "intracerebral hemorrhage", "start": 8, "end": 10}, {"entity_id": "16018164_2_Ent0", "role": "Subject", "text": "a patient with an AVM", "start": 11, "end": 16}, {"entity_id": "16018164_2_Ent1", "role": "Subject_Disorder", "text": "AVM", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "16018164_2_Ent3", "text": "phenylpropanolamine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16018164_2_Ent4", "text": "phenylpropanolamine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16018164_2_Ent2", "text": "intracerebral hemorrhage", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "16018164_2_Ent0", "text": "a patient with an AVM", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "16018164_2_Ent1", "text": "AVM", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "16035204_1", "wnd_id": "16035204_1_1", "text": "We report an unusual case of massive fluoxetine ingestion resulting in neurological and cardiovascular toxicity resulting in death .", "tokens": ["We", "report", "an", "unusual", "case", "of", "massive", "fluoxetine", "ingestion", "resulting", "in", "neurological", "and", "cardiovascular", "toxicity", "resulting", "in", "death", "."], "event_mentions": [{"id": "16035204_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting in", "start": 9, "end": 11}, "arguments": [{"entity_id": "16035204_1_Ent0", "role": "Subject", "text": "an unusual case", "start": 2, "end": 5}, {"entity_id": "16035204_1_Ent4", "role": "Treatment_Dosage", "text": "massive", "start": 6, "end": 7}, {"entity_id": "16035204_1_Ent2", "role": "Treatment", "text": "massive fluoxetine ingestion", "start": 6, "end": 9}, {"entity_id": "16035204_1_Ent3", "role": "Treatment_Drug", "text": "fluoxetine", "start": 7, "end": 8}, {"entity_id": "16035204_1_Ent5", "role": "Treatment_Route", "text": "ingestion", "start": 8, "end": 9}, {"entity_id": "16035204_1_Ent1", "role": "Effect", "text": "neurological and cardiovascular toxicity resulting in death", "start": 11, "end": 18}]}], "entity_mentions": [{"id": "16035204_1_Ent0", "text": "an unusual case", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "16035204_1_Ent4", "text": "massive", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16035204_1_Ent2", "text": "massive fluoxetine ingestion", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "16035204_1_Ent3", "text": "fluoxetine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16035204_1_Ent5", "text": "ingestion", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16035204_1_Ent1", "text": "neurological and cardiovascular toxicity resulting in death", "entity_type": "Entity", "start": 11, "end": 18}], "lang": "en"}
{"doc_id": "16044093_1", "wnd_id": "16044093_1_1", "text": "Hepatocellular damage following therapeutic intravenous iron sucrose infusion in a child .", "tokens": ["Hepatocellular", "damage", "following", "therapeutic", "intravenous", "iron", "sucrose", "infusion", "in", "a", "child", "."], "event_mentions": [{"id": "16044093_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "16044093_1_Ent2", "role": "Effect", "text": "Hepatocellular damage", "start": 0, "end": 2}, {"entity_id": "16044093_1_Ent5", "role": "Treatment_Route", "text": "intravenous", "start": 4, "end": 5}, {"entity_id": "16044093_1_Ent3", "role": "Treatment", "text": "intravenous iron sucrose infusion", "start": 4, "end": 8}, {"entity_id": "16044093_1_Ent4", "role": "Treatment_Drug", "text": "iron sucrose", "start": 5, "end": 7}, {"entity_id": "16044093_1_Ent6", "role": "Treatment_Route", "text": "infusion", "start": 7, "end": 8}, {"entity_id": "16044093_1_Ent0", "role": "Subject", "text": "a child", "start": 9, "end": 11}, {"entity_id": "16044093_1_Ent1", "role": "Subject_Age", "text": "child", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "16044093_1_Ent2", "text": "Hepatocellular damage", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16044093_1_Ent5", "text": "intravenous", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16044093_1_Ent3", "text": "intravenous iron sucrose infusion", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "16044093_1_Ent4", "text": "iron sucrose", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "16044093_1_Ent6", "text": "infusion", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16044093_1_Ent0", "text": "a child", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "16044093_1_Ent1", "text": "child", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "16062101_1", "wnd_id": "16062101_1_1", "text": "Acute dystonia induced by lamivudine .", "tokens": ["Acute", "dystonia", "induced", "by", "lamivudine", "."], "event_mentions": [{"id": "16062101_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "16062101_1_Ent0", "role": "Effect", "text": "Acute dystonia", "start": 0, "end": 2}, {"entity_id": "16062101_1_Ent1", "role": "Treatment", "text": "lamivudine", "start": 4, "end": 5}, {"entity_id": "16062101_1_Ent2", "role": "Treatment_Drug", "text": "lamivudine", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "16062101_1_Ent0", "text": "Acute dystonia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16062101_1_Ent1", "text": "lamivudine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16062101_1_Ent2", "text": "lamivudine", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "16062101_2", "wnd_id": "16062101_2_1", "text": "ADR induced by drug treatment can be a side effect of treatment with antipsychotic drugs and other drugs ; however , there have been no reports of lamivudine - induced ADR in the English literature .", "tokens": ["ADR", "induced", "by", "drug", "treatment", "can", "be", "a", "side", "effect", "of", "treatment", "with", "antipsychotic", "drugs", "and", "other", "drugs", ";", "however", ",", "there", "have", "been", "no", "reports", "of", "lamivudine", "-", "induced", "ADR", "in", "the", "English", "literature", "."], "event_mentions": [{"id": "16062101_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 29, "end": 30}, "arguments": [{"entity_id": "16062101_2_Ent1", "role": "Treatment", "text": "lamivudine", "start": 27, "end": 28}, {"entity_id": "16062101_2_Ent2", "role": "Treatment_Drug", "text": "lamivudine", "start": 27, "end": 28}, {"entity_id": "16062101_2_Ent0", "role": "Effect", "text": "ADR", "start": 30, "end": 31}]}], "entity_mentions": [{"id": "16062101_2_Ent1", "text": "lamivudine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "16062101_2_Ent2", "text": "lamivudine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "16062101_2_Ent0", "text": "ADR", "entity_type": "Entity", "start": 30, "end": 31}], "lang": "en"}
{"doc_id": "16109609_1", "wnd_id": "16109609_1_1", "text": "Gemcitabine - induced pericardial effusion and tamponade after unblocked cardiac irradiation .", "tokens": ["Gemcitabine", "-", "induced", "pericardial", "effusion", "and", "tamponade", "after", "unblocked", "cardiac", "irradiation", "."], "event_mentions": [{"id": "16109609_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "16109609_1_Ent1", "role": "Treatment", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "16109609_1_Ent2", "role": "Treatment_Drug", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "16109609_1_Ent0", "role": "Effect", "text": "pericardial effusion and tamponade", "start": 3, "end": 7}, {"entity_id": "16109609_1_Ent3", "role": "Treatment_Disorder", "text": "unblocked cardiac irradiation", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "16109609_1_Ent1", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16109609_1_Ent2", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16109609_1_Ent0", "text": "pericardial effusion and tamponade", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "16109609_1_Ent3", "text": "unblocked cardiac irradiation", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "16132305_5", "wnd_id": "16132305_5_1", "text": "After discontinuing captopril and starting systemic steroids , her symptomatology rapidly improved , and her eosinophilia and radiographic abnormalities both resolved .", "tokens": ["After", "discontinuing", "captopril", "and", "starting", "systemic", "steroids", ",", "her", "symptomatology", "rapidly", "improved", ",", "and", "her", "eosinophilia", "and", "radiographic", "abnormalities", "both", "resolved", "."], "event_mentions": [{"id": "16132305_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 20, "end": 21}, "arguments": [{"entity_id": "16132305_5_Ent1", "role": "Treatment", "text": "discontinuing captopril and starting systemic steroids", "start": 1, "end": 7}, {"entity_id": "16132305_5_Ent2", "role": "Treatment_Drug", "text": "captopril", "start": 2, "end": 3}, {"entity_id": "16132305_5_Ent3", "role": "Treatment_Drug", "text": "steroids", "start": 6, "end": 7}, {"entity_id": "16132305_5_Ent0", "role": "Effect", "text": "her eosinophilia and radiographic abnormalities both resolved", "start": 14, "end": 21}, {"entity_id": "16132305_5_Ent4", "role": "Treatment_Disorder", "text": "eosinophilia", "start": 15, "end": 16}, {"entity_id": "16132305_5_Ent5", "role": "Treatment_Disorder", "text": "radiographic abnormalities", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "16132305_5_Ent1", "text": "discontinuing captopril and starting systemic steroids", "entity_type": "Entity", "start": 1, "end": 7}, {"id": "16132305_5_Ent2", "text": "captopril", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16132305_5_Ent3", "text": "steroids", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16132305_5_Ent0", "text": "her eosinophilia and radiographic abnormalities both resolved", "entity_type": "Entity", "start": 14, "end": 21}, {"id": "16132305_5_Ent4", "text": "eosinophilia", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "16132305_5_Ent5", "text": "radiographic abnormalities", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "16160485_2", "wnd_id": "16160485_2_1", "text": "Recently , CD20 - negative tumors have been described after Rituximab therapy .", "tokens": ["Recently", ",", "CD20", "-", "negative", "tumors", "have", "been", "described", "after", "Rituximab", "therapy", "."], "event_mentions": [{"id": "16160485_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 9, "end": 10}, "arguments": [{"entity_id": "16160485_2_Ent0", "role": "Effect", "text": "CD20 - negative tumors", "start": 2, "end": 6}, {"entity_id": "16160485_2_Ent1", "role": "Treatment", "text": "Rituximab", "start": 10, "end": 11}, {"entity_id": "16160485_2_Ent2", "role": "Treatment_Drug", "text": "Rituximab", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "16160485_2_Ent0", "text": "CD20 - negative tumors", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "16160485_2_Ent1", "text": "Rituximab", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16160485_2_Ent2", "text": "Rituximab", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "16164579_1", "wnd_id": "16164579_1_1", "text": "A 51 - year old physically fit woman experienced angio - oedema and hypotensive shock after irbesartan ingestion requiring noradrenaline infusion .", "tokens": ["A", "51", "-", "year", "old", "physically", "fit", "woman", "experienced", "angio", "-", "oedema", "and", "hypotensive", "shock", "after", "irbesartan", "ingestion", "requiring", "noradrenaline", "infusion", "."], "event_mentions": [{"id": "16164579_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 8, "end": 9}, "arguments": [{"entity_id": "16164579_1_Ent0", "role": "Subject", "text": "A 51 - year old physically fit woman", "start": 0, "end": 8}, {"entity_id": "16164579_1_Ent1", "role": "Subject_Age", "text": "51 - year old", "start": 1, "end": 5}, {"entity_id": "16164579_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 7, "end": 8}, {"entity_id": "16164579_1_Ent3", "role": "Effect", "text": "angio - oedema and hypotensive shock", "start": 9, "end": 15}, {"entity_id": "16164579_1_Ent5", "role": "Treatment_Drug", "text": "irbesartan", "start": 16, "end": 17}, {"entity_id": "16164579_1_Ent4", "role": "Treatment", "text": "irbesartan ingestion", "start": 16, "end": 18}, {"entity_id": "16164579_1_Ent6", "role": "Treatment_Route", "text": "ingestion", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "16164579_1_Ent0", "text": "A 51 - year old physically fit woman", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "16164579_1_Ent1", "text": "51 - year old", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "16164579_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16164579_1_Ent3", "text": "angio - oedema and hypotensive shock", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "16164579_1_Ent5", "text": "irbesartan", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16164579_1_Ent4", "text": "irbesartan ingestion", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "16164579_1_Ent6", "text": "ingestion", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "16167682_1", "wnd_id": "16167682_1_1", "text": "She died within six weeks of developing congestive heart failure coupled with liver failure due to haemosiderosis despite regular use of desferrioxamine .", "tokens": ["She", "died", "within", "six", "weeks", "of", "developing", "congestive", "heart", "failure", "coupled", "with", "liver", "failure", "due", "to", "haemosiderosis", "despite", "regular", "use", "of", "desferrioxamine", "."], "event_mentions": [{"id": "16167682_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "despite", "start": 17, "end": 18}, "arguments": [{"entity_id": "16167682_1_Ent0", "role": "Effect", "text": "died within six weeks of developing congestive heart failure coupled with liver failure", "start": 1, "end": 14}, {"entity_id": "16167682_1_Ent3", "role": "Treatment_Disorder", "text": "haemosiderosis", "start": 16, "end": 17}, {"entity_id": "16167682_1_Ent1", "role": "Treatment", "text": "regular use of desferrioxamine", "start": 18, "end": 22}, {"entity_id": "16167682_1_Ent2", "role": "Treatment_Drug", "text": "desferrioxamine", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "16167682_1_Ent0", "text": "died within six weeks of developing congestive heart failure coupled with liver failure", "entity_type": "Entity", "start": 1, "end": 14}, {"id": "16167682_1_Ent3", "text": "haemosiderosis", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16167682_1_Ent1", "text": "regular use of desferrioxamine", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "16167682_1_Ent2", "text": "desferrioxamine", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "16176119_2", "wnd_id": "16176119_2_1", "text": "Gefitinib ( IRESSA , ZD1839 ) , an epidermal growth factor receptor tyrosine kinase inhibitor , has been approved in several countries for the treatment of advanced non - small - cell lung cancer .", "tokens": ["Gefitinib", "(", "IRESSA", ",", "ZD1839", ")", ",", "an", "epidermal", "growth", "factor", "receptor", "tyrosine", "kinase", "inhibitor", ",", "has", "been", "approved", "in", "several", "countries", "for", "the", "treatment", "of", "advanced", "non", "-", "small", "-", "cell", "lung", "cancer", "."], "event_mentions": [{"id": "16176119_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 24, "end": 25}, "arguments": [{"entity_id": "16176119_2_Ent0", "role": "Treatment", "text": "Gefitinib", "start": 0, "end": 1}, {"entity_id": "16176119_2_Ent2", "role": "Treatment_Drug", "text": "Gefitinib", "start": 0, "end": 1}, {"entity_id": "16176119_2_Ent3", "role": "Treatment_Drug", "text": "IRESSA", "start": 2, "end": 3}, {"entity_id": "16176119_2_Ent4", "role": "Treatment_Drug", "text": "ZD1839", "start": 4, "end": 5}, {"entity_id": "16176119_2_Ent5", "role": "Treatment_Drug", "text": "epidermal growth factor receptor tyrosine kinase inhibitor", "start": 8, "end": 15}, {"entity_id": "16176119_2_Ent1", "role": "Treatment_Disorder", "text": "advanced non - small - cell lung cancer", "start": 26, "end": 34}]}], "entity_mentions": [{"id": "16176119_2_Ent0", "text": "Gefitinib", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16176119_2_Ent2", "text": "Gefitinib", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16176119_2_Ent3", "text": "IRESSA", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16176119_2_Ent4", "text": "ZD1839", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16176119_2_Ent5", "text": "epidermal growth factor receptor tyrosine kinase inhibitor", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "16176119_2_Ent1", "text": "advanced non - small - cell lung cancer", "entity_type": "Entity", "start": 26, "end": 34}], "lang": "en"}
{"doc_id": "16192734_2", "wnd_id": "16192734_2_1", "text": "Rhabdomyolysis has been recognized as a complication of tocolytic therapy with ritodrine hydrochloride .", "tokens": ["Rhabdomyolysis", "has", "been", "recognized", "as", "a", "complication", "of", "tocolytic", "therapy", "with", "ritodrine", "hydrochloride", "."], "event_mentions": [{"id": "16192734_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 6, "end": 7}, "arguments": [{"entity_id": "16192734_2_Ent0", "role": "Effect", "text": "Rhabdomyolysis", "start": 0, "end": 1}, {"entity_id": "16192734_2_Ent1", "role": "Treatment", "text": "ritodrine hydrochloride", "start": 11, "end": 13}, {"entity_id": "16192734_2_Ent2", "role": "Treatment_Drug", "text": "ritodrine hydrochloride .", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "16192734_2_Ent0", "text": "Rhabdomyolysis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16192734_2_Ent1", "text": "ritodrine hydrochloride", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "16192734_2_Ent2", "text": "ritodrine hydrochloride .", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "16200540_3", "wnd_id": "16200540_3_1", "text": "Videopolysomnographic and pharmacokinetic studies with monitoring of plasma levodopa levels demonstrated marked motor hyperactivity during augmentation , with anarchic discharges of motor unit potentials , tonic grouped discharges and flexor spasms , associated with painful dysesthesia .", "tokens": ["Videopolysomnographic", "and", "pharmacokinetic", "studies", "with", "monitoring", "of", "plasma", "levodopa", "levels", "demonstrated", "marked", "motor", "hyperactivity", "during", "augmentation", ",", "with", "anarchic", "discharges", "of", "motor", "unit", "potentials", ",", "tonic", "grouped", "discharges", "and", "flexor", "spasms", ",", "associated", "with", "painful", "dysesthesia", "."], "event_mentions": [{"id": "16200540_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "demonstrated", "start": 10, "end": 11}, "arguments": [{"entity_id": "16200540_3_Ent1", "role": "Treatment", "text": "levodopa", "start": 8, "end": 9}, {"entity_id": "16200540_3_Ent2", "role": "Treatment_Drug", "text": "levodopa", "start": 8, "end": 9}, {"entity_id": "16200540_3_Ent0", "role": "Effect", "text": "marked motor hyperactivity during augmentation , with anarchic discharges of motor unit potentials , tonic grouped discharges and flexor spasms , associated with painful dysesthesia", "start": 11, "end": 36}]}], "entity_mentions": [{"id": "16200540_3_Ent1", "text": "levodopa", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16200540_3_Ent2", "text": "levodopa", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16200540_3_Ent0", "text": "marked motor hyperactivity during augmentation , with anarchic discharges of motor unit potentials , tonic grouped discharges and flexor spasms , associated with painful dysesthesia", "entity_type": "Entity", "start": 11, "end": 36}], "lang": "en"}
{"doc_id": "16204273_2", "wnd_id": "16204273_2_1", "text": "This report describes a probable case of infliximab - induced membranous nephropathy .", "tokens": ["This", "report", "describes", "a", "probable", "case", "of", "infliximab", "-", "induced", "membranous", "nephropathy", "."], "event_mentions": [{"id": "16204273_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "16204273_2_Ent1", "role": "Treatment", "text": "infliximab", "start": 7, "end": 8}, {"entity_id": "16204273_2_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 7, "end": 8}, {"entity_id": "16204273_2_Ent0", "role": "Effect", "text": "membranous nephropathy", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "16204273_2_Ent1", "text": "infliximab", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16204273_2_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16204273_2_Ent0", "text": "membranous nephropathy", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "16211208_2", "wnd_id": "16211208_2_1", "text": "Marked QT prolongation and torsades de pointes secondary to acute ischemia in an elderly man taking dofetilide for atrial fibrillation : a cautionary tale .", "tokens": ["Marked", "QT", "prolongation", "and", "torsades", "de", "pointes", "secondary", "to", "acute", "ischemia", "in", "an", "elderly", "man", "taking", "dofetilide", "for", "atrial", "fibrillation", ":", "a", "cautionary", "tale", "."], "event_mentions": [{"id": "16211208_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 15, "end": 16}, "arguments": [{"entity_id": "16211208_2_Ent3", "role": "Effect", "text": "Marked QT prolongation and torsades de pointes secondary to acute ischemia", "start": 0, "end": 11}, {"entity_id": "16211208_2_Ent0", "role": "Subject", "text": "an elderly man", "start": 12, "end": 15}, {"entity_id": "16211208_2_Ent1", "role": "Subject_Age", "text": "elderly", "start": 13, "end": 14}, {"entity_id": "16211208_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 14, "end": 15}, {"entity_id": "16211208_2_Ent4", "role": "Treatment", "text": "dofetilide", "start": 16, "end": 17}, {"entity_id": "16211208_2_Ent5", "role": "Treatment_Drug", "text": "dofetilide", "start": 16, "end": 17}, {"entity_id": "16211208_2_Ent6", "role": "Treatment_Disorder", "text": "atrial fibrillation", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "16211208_2_Ent3", "text": "Marked QT prolongation and torsades de pointes secondary to acute ischemia", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "16211208_2_Ent0", "text": "an elderly man", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "16211208_2_Ent1", "text": "elderly", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16211208_2_Ent2", "text": "man", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16211208_2_Ent4", "text": "dofetilide", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16211208_2_Ent5", "text": "dofetilide", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16211208_2_Ent6", "text": "atrial fibrillation", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "16221163_1", "wnd_id": "16221163_1_1", "text": "Sirolimus - associated hepatotoxicity in the kidney graft recipient .", "tokens": ["Sirolimus", "-", "associated", "hepatotoxicity", "in", "the", "kidney", "graft", "recipient", "."], "event_mentions": [{"id": "16221163_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "16221163_1_Ent2", "role": "Treatment", "text": "Sirolimus", "start": 0, "end": 1}, {"entity_id": "16221163_1_Ent3", "role": "Treatment_Drug", "text": "Sirolimus", "start": 0, "end": 1}, {"entity_id": "16221163_1_Ent1", "role": "Effect", "text": "hepatotoxicity", "start": 3, "end": 4}, {"entity_id": "16221163_1_Ent4", "role": "Treatment_Disorder", "text": "kidney graft recipient", "start": 6, "end": 9}, {"entity_id": "16221163_1_Ent0", "role": "Subject", "text": "kidney graft recipient .", "start": 6, "end": 10}]}], "entity_mentions": [{"id": "16221163_1_Ent2", "text": "Sirolimus", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16221163_1_Ent3", "text": "Sirolimus", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16221163_1_Ent1", "text": "hepatotoxicity", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16221163_1_Ent4", "text": "kidney graft recipient", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "16221163_1_Ent0", "text": "kidney graft recipient .", "entity_type": "Entity", "start": 6, "end": 10}], "lang": "en"}
{"doc_id": "16221163_2", "wnd_id": "16221163_2_1", "text": "The aim of our paper was to describe hepatotoxicity of sirolimus ( SRL ) in a kidney graft recipient .", "tokens": ["The", "aim", "of", "our", "paper", "was", "to", "describe", "hepatotoxicity", "of", "sirolimus", "(", "SRL", ")", "in", "a", "kidney", "graft", "recipient", "."], "event_mentions": [{"id": "16221163_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 14, "end": 15}, "arguments": [{"entity_id": "16221163_2_Ent2", "role": "Effect", "text": "hepatotoxicity", "start": 8, "end": 9}, {"entity_id": "16221163_2_Ent4", "role": "Treatment_Drug", "text": "sirolimus", "start": 10, "end": 11}, {"entity_id": "16221163_2_Ent3", "role": "Treatment", "text": "sirolimus ( SRL )", "start": 10, "end": 14}, {"entity_id": "16221163_2_Ent0", "role": "Subject", "text": "a kidney graft recipient", "start": 15, "end": 19}, {"entity_id": "16221163_2_Ent1", "role": "Subject_Disorder", "text": "kidney graft", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "16221163_2_Ent2", "text": "hepatotoxicity", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16221163_2_Ent4", "text": "sirolimus", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16221163_2_Ent3", "text": "sirolimus ( SRL )", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "16221163_2_Ent0", "text": "a kidney graft recipient", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "16221163_2_Ent1", "text": "kidney graft", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "16221163_3", "wnd_id": "16221163_3_1", "text": "We report the case of a 30 - year - old male after kidney transplantation , treated with steroids , cyclosporin A and SRL , with steroid - resistant acute rejection in anamnesis .", "tokens": ["We", "report", "the", "case", "of", "a", "30", "-", "year", "-", "old", "male", "after", "kidney", "transplantation", ",", "treated", "with", "steroids", ",", "cyclosporin", "A", "and", "SRL", ",", "with", "steroid", "-", "resistant", "acute", "rejection", "in", "anamnesis", "."], "event_mentions": [{"id": "16221163_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 12, "end": 13}, "arguments": [{"entity_id": "16221163_3_Ent0", "role": "Subject", "text": "the case of a 30 - year - old male", "start": 2, "end": 12}, {"entity_id": "16221163_3_Ent1", "role": "Subject_Age", "text": "30 - year - old", "start": 6, "end": 11}, {"entity_id": "16221163_3_Ent2", "role": "Subject_Gender", "text": "male", "start": 11, "end": 12}, {"entity_id": "16221163_3_Ent4", "role": "Treatment", "text": "kidney transplantation , treated with steroids , cyclosporin A and SRL", "start": 13, "end": 24}, {"entity_id": "16221163_3_Ent5", "role": "Treatment_Drug", "text": "steroids", "start": 18, "end": 19}, {"entity_id": "16221163_3_Ent8", "role": "Combination_Drug", "text": "steroids", "start": 18, "end": 19}, {"entity_id": "16221163_3_Ent6", "role": "Treatment_Drug", "text": "cyclosporin A", "start": 20, "end": 22}, {"entity_id": "16221163_3_Ent9", "role": "Combination_Drug", "text": "cyclosporin A", "start": 20, "end": 22}, {"entity_id": "16221163_3_Ent7", "role": "Treatment_Drug", "text": "SRL", "start": 23, "end": 24}, {"entity_id": "16221163_3_Ent10", "role": "Combination_Drug", "text": "SRL", "start": 23, "end": 24}, {"entity_id": "16221163_3_Ent3", "role": "Effect", "text": "steroid - resistant acute rejection", "start": 26, "end": 31}]}], "entity_mentions": [{"id": "16221163_3_Ent0", "text": "the case of a 30 - year - old male", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "16221163_3_Ent1", "text": "30 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "16221163_3_Ent2", "text": "male", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16221163_3_Ent4", "text": "kidney transplantation , treated with steroids , cyclosporin A and SRL", "entity_type": "Entity", "start": 13, "end": 24}, {"id": "16221163_3_Ent5", "text": "steroids", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "16221163_3_Ent8", "text": "steroids", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "16221163_3_Ent6", "text": "cyclosporin A", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "16221163_3_Ent9", "text": "cyclosporin A", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "16221163_3_Ent7", "text": "SRL", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "16221163_3_Ent10", "text": "SRL", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "16221163_3_Ent3", "text": "steroid - resistant acute rejection", "entity_type": "Entity", "start": 26, "end": 31}], "lang": "en"}
{"doc_id": "16221163_8", "wnd_id": "16221163_8_1", "text": "Hepatoxicity is a rare complication of SRL therapy and may be connected with some diagnostic and/or therapeutic problems .", "tokens": ["Hepatoxicity", "is", "a", "rare", "complication", "of", "SRL", "therapy", "and", "may", "be", "connected", "with", "some", "diagnostic", "and/or", "therapeutic", "problems", "."], "event_mentions": [{"id": "16221163_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "is", "start": 1, "end": 2}, "arguments": [{"entity_id": "16221163_8_Ent0", "role": "Effect", "text": "Hepatoxicity", "start": 0, "end": 1}, {"entity_id": "16221163_8_Ent2", "role": "Treatment_Drug", "text": "SRL", "start": 6, "end": 7}, {"entity_id": "16221163_8_Ent1", "role": "Treatment", "text": "SRL therapy", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "16221163_8_Ent0", "text": "Hepatoxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16221163_8_Ent2", "text": "SRL", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16221163_8_Ent1", "text": "SRL therapy", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "16237130_1", "wnd_id": "16237130_1_1", "text": "Capecitabine - induced multifocal leukoencephalopathy : a report of five cases .", "tokens": ["Capecitabine", "-", "induced", "multifocal", "leukoencephalopathy", ":", "a", "report", "of", "five", "cases", "."], "event_mentions": [{"id": "16237130_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "16237130_1_Ent3", "role": "Treatment", "text": "Capecitabine", "start": 0, "end": 1}, {"entity_id": "16237130_1_Ent4", "role": "Treatment_Drug", "text": "Capecitabine", "start": 0, "end": 1}, {"entity_id": "16237130_1_Ent2", "role": "Effect", "text": "multifocal leukoencephalopathy", "start": 3, "end": 5}, {"entity_id": "16237130_1_Ent1", "role": "Subject_Population", "text": "five", "start": 9, "end": 10}, {"entity_id": "16237130_1_Ent0", "role": "Subject", "text": "five cases", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "16237130_1_Ent3", "text": "Capecitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16237130_1_Ent4", "text": "Capecitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16237130_1_Ent2", "text": "multifocal leukoencephalopathy", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16237130_1_Ent1", "text": "five", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16237130_1_Ent0", "text": "five cases", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "16239768_1", "wnd_id": "16239768_1_1", "text": "A 56 - year - old white woman with a diagnosis of reactive depression developed severe UI after a 30 days ' treatment with venlafaxine 75 mg / day .", "tokens": ["A", "56", "-", "year", "-", "old", "white", "woman", "with", "a", "diagnosis", "of", "reactive", "depression", "developed", "severe", "UI", "after", "a", "30", "days", "'", "treatment", "with", "venlafaxine", "75", "mg", "/", "day", "."], "event_mentions": [{"id": "16239768_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 17, "end": 18}, "arguments": [{"entity_id": "16239768_1_Ent0", "role": "Subject", "text": "A 56 - year - old white woman with a diagnosis of reactive depression", "start": 0, "end": 14}, {"entity_id": "16239768_1_Ent1", "role": "Subject_Age", "text": "56 - year - old", "start": 1, "end": 6}, {"entity_id": "16239768_1_Ent2", "role": "Subject_Race", "text": "white", "start": 6, "end": 7}, {"entity_id": "16239768_1_Ent3", "role": "Subject_Gender", "text": "woman", "start": 7, "end": 8}, {"entity_id": "16239768_1_Ent6", "role": "Treatment_Disorder", "text": "reactive depression", "start": 12, "end": 14}, {"entity_id": "16239768_1_Ent4", "role": "Effect", "text": "severe UI", "start": 15, "end": 17}, {"entity_id": "16239768_1_Ent7", "role": "Treatment_Time_elapsed", "text": "30 days", "start": 19, "end": 21}, {"entity_id": "16239768_1_Ent5", "role": "Treatment", "text": "30 days ' treatment with venlafaxine 75 mg / day .", "start": 19, "end": 30}, {"entity_id": "16239768_1_Ent8", "role": "Treatment_Drug", "text": "venlafaxine", "start": 24, "end": 25}, {"entity_id": "16239768_1_Ent9", "role": "Treatment_Dosage", "text": "75 mg / day", "start": 25, "end": 29}]}], "entity_mentions": [{"id": "16239768_1_Ent0", "text": "A 56 - year - old white woman with a diagnosis of reactive depression", "entity_type": "Entity", "start": 0, "end": 14}, {"id": "16239768_1_Ent1", "text": "56 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "16239768_1_Ent2", "text": "white", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16239768_1_Ent3", "text": "woman", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16239768_1_Ent6", "text": "reactive depression", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "16239768_1_Ent4", "text": "severe UI", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "16239768_1_Ent7", "text": "30 days", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "16239768_1_Ent5", "text": "30 days ' treatment with venlafaxine 75 mg / day .", "entity_type": "Entity", "start": 19, "end": 30}, {"id": "16239768_1_Ent8", "text": "venlafaxine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "16239768_1_Ent9", "text": "75 mg / day", "entity_type": "Entity", "start": 25, "end": 29}], "lang": "en"}
{"doc_id": "16239768_3", "wnd_id": "16239768_3_1", "text": "Venlafaxine - induced urinary incontinence resolved after switching to sertraline .", "tokens": ["Venlafaxine", "-", "induced", "urinary", "incontinence", "resolved", "after", "switching", "to", "sertraline", "."], "event_mentions": [{"id": "16239768_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "16239768_3_Ent1", "role": "Treatment", "text": "Venlafaxine", "start": 0, "end": 1}, {"entity_id": "16239768_3_Ent2", "role": "Treatment_Drug", "text": "Venlafaxine", "start": 0, "end": 1}, {"entity_id": "16239768_3_Ent0", "role": "Effect", "text": "urinary incontinence", "start": 3, "end": 5}]}, {"id": "16239768_3_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 5, "end": 6}, "arguments": [{"entity_id": "16239768_3_Ent4", "role": "Treatment_Disorder", "text": "Venlafaxine - induced urinary incontinence", "start": 0, "end": 5}, {"entity_id": "16239768_3_Ent3", "role": "Treatment", "text": "sertraline", "start": 9, "end": 10}, {"entity_id": "16239768_3_Ent5", "role": "Treatment_Drug", "text": "sertraline", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "16239768_3_Ent1", "text": "Venlafaxine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16239768_3_Ent2", "text": "Venlafaxine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16239768_3_Ent4", "text": "Venlafaxine - induced urinary incontinence", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "16239768_3_Ent0", "text": "urinary incontinence", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16239768_3_Ent3", "text": "sertraline", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16239768_3_Ent5", "text": "sertraline", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "1624172_3", "wnd_id": "1624172_3_1", "text": "Thyroid dysfunction has been reported in patients with malignant disease treated with recombinant alpha interferon .", "tokens": ["Thyroid", "dysfunction", "has", "been", "reported", "in", "patients", "with", "malignant", "disease", "treated", "with", "recombinant", "alpha", "interferon", "."], "event_mentions": [{"id": "1624172_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 4, "end": 5}, "arguments": [{"entity_id": "1624172_3_Ent1", "role": "Effect", "text": "Thyroid dysfunction", "start": 0, "end": 2}, {"entity_id": "1624172_3_Ent0", "role": "Subject", "text": "patients with malignant disease", "start": 6, "end": 10}, {"entity_id": "1624172_3_Ent3", "role": "Treatment_Disorder", "text": "malignant disease", "start": 8, "end": 10}, {"entity_id": "1624172_3_Ent2", "role": "Treatment", "text": "recombinant alpha interferon", "start": 12, "end": 15}, {"entity_id": "1624172_3_Ent4", "role": "Treatment_Drug", "text": "recombinant alpha interferon", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "1624172_3_Ent1", "text": "Thyroid dysfunction", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1624172_3_Ent0", "text": "patients with malignant disease", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "1624172_3_Ent3", "text": "malignant disease", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "1624172_3_Ent2", "text": "recombinant alpha interferon", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "1624172_3_Ent4", "text": "recombinant alpha interferon", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "1624172_4", "wnd_id": "1624172_4_1", "text": "Two cases of hypothyroidism in patients with chronic hepatitis C treated with recombinant alpha interferon are reported .", "tokens": ["Two", "cases", "of", "hypothyroidism", "in", "patients", "with", "chronic", "hepatitis", "C", "treated", "with", "recombinant", "alpha", "interferon", "are", "reported", "."], "event_mentions": [{"id": "1624172_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 10, "end": 11}, "arguments": [{"entity_id": "1624172_4_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "1624172_4_Ent0", "role": "Subject", "text": "Two cases", "start": 0, "end": 2}, {"entity_id": "1624172_4_Ent2", "role": "Effect", "text": "hypothyroidism", "start": 3, "end": 4}, {"entity_id": "1624172_4_Ent5", "role": "Treatment_Disorder", "text": "chronic hepatitis C", "start": 7, "end": 10}, {"entity_id": "1624172_4_Ent3", "role": "Treatment", "text": "recombinant alpha interferon", "start": 12, "end": 15}, {"entity_id": "1624172_4_Ent4", "role": "Treatment_Drug", "text": "recombinant alpha interferon", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "1624172_4_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1624172_4_Ent0", "text": "Two cases", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1624172_4_Ent2", "text": "hypothyroidism", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1624172_4_Ent5", "text": "chronic hepatitis C", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "1624172_4_Ent3", "text": "recombinant alpha interferon", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "1624172_4_Ent4", "text": "recombinant alpha interferon", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "16244351_1", "wnd_id": "16244351_1_1", "text": "Atrial fibrillation after vardenafil therapy .", "tokens": ["Atrial", "fibrillation", "after", "vardenafil", "therapy", "."], "event_mentions": [{"id": "16244351_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "16244351_1_Ent0", "role": "Effect", "text": "Atrial fibrillation", "start": 0, "end": 2}, {"entity_id": "16244351_1_Ent2", "role": "Treatment_Drug", "text": "vardenafil", "start": 3, "end": 4}, {"entity_id": "16244351_1_Ent1", "role": "Treatment", "text": "vardenafil therapy", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "16244351_1_Ent0", "text": "Atrial fibrillation", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16244351_1_Ent2", "text": "vardenafil", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16244351_1_Ent1", "text": "vardenafil therapy", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "16249064_1", "wnd_id": "16249064_1_1", "text": "We describe a case of infection with Mycobacterium abscessus in a 67 - year - old woman receiving infliximab as a component of her therapy for RA .", "tokens": ["We", "describe", "a", "case", "of", "infection", "with", "Mycobacterium", "abscessus", "in", "a", "67", "-", "year", "-", "old", "woman", "receiving", "infliximab", "as", "a", "component", "of", "her", "therapy", "for", "RA", "."], "event_mentions": [{"id": "16249064_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 17, "end": 18}, "arguments": [{"entity_id": "16249064_1_Ent4", "role": "Effect", "text": "infection with Mycobacterium abscessus", "start": 5, "end": 9}, {"entity_id": "16249064_1_Ent0", "role": "Subject", "text": "a 67 - year - old woman", "start": 10, "end": 17}, {"entity_id": "16249064_1_Ent2", "role": "Subject_Age", "text": "67 - year - old", "start": 11, "end": 16}, {"entity_id": "16249064_1_Ent3", "role": "Subject_Gender", "text": "woman", "start": 16, "end": 17}, {"entity_id": "16249064_1_Ent6", "role": "Treatment_Drug", "text": "infliximab", "start": 18, "end": 19}, {"entity_id": "16249064_1_Ent5", "role": "Treatment", "text": "infliximab as a component of her therapy", "start": 18, "end": 25}, {"entity_id": "16249064_1_Ent1", "role": "Subject", "text": "RA", "start": 26, "end": 27}, {"entity_id": "16249064_1_Ent7", "role": "Treatment_Disorder", "text": "RA", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "16249064_1_Ent4", "text": "infection with Mycobacterium abscessus", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "16249064_1_Ent0", "text": "a 67 - year - old woman", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "16249064_1_Ent2", "text": "67 - year - old", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "16249064_1_Ent3", "text": "woman", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16249064_1_Ent6", "text": "infliximab", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "16249064_1_Ent5", "text": "infliximab as a component of her therapy", "entity_type": "Entity", "start": 18, "end": 25}, {"id": "16249064_1_Ent1", "text": "RA", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "16249064_1_Ent7", "text": "RA", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "16265343_2", "wnd_id": "16265343_2_1", "text": "Reversible cardiomyopathy caused by administration of interferon alpha .", "tokens": ["Reversible", "cardiomyopathy", "caused", "by", "administration", "of", "interferon", "alpha", "."], "event_mentions": [{"id": "16265343_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused by", "start": 2, "end": 4}, "arguments": [{"entity_id": "16265343_2_Ent0", "role": "Effect", "text": "Reversible cardiomyopathy", "start": 0, "end": 2}, {"entity_id": "16265343_2_Ent1", "role": "Treatment", "text": "administration of interferon alpha", "start": 4, "end": 8}, {"entity_id": "16265343_2_Ent2", "role": "Treatment_Drug", "text": "interferon alpha", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "16265343_2_Ent0", "text": "Reversible cardiomyopathy", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16265343_2_Ent1", "text": "administration of interferon alpha", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "16265343_2_Ent2", "text": "interferon alpha", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "16284443_2", "wnd_id": "16284443_2_1", "text": "Insulin - induced lipohypertrophy : report of a case with histopathology .", "tokens": ["Insulin", "-", "induced", "lipohypertrophy", ":", "report", "of", "a", "case", "with", "histopathology", "."], "event_mentions": [{"id": "16284443_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "16284443_2_Ent1", "role": "Treatment", "text": "Insulin", "start": 0, "end": 1}, {"entity_id": "16284443_2_Ent2", "role": "Treatment_Drug", "text": "Insulin", "start": 0, "end": 1}, {"entity_id": "16284443_2_Ent0", "role": "Effect", "text": "lipohypertrophy", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "16284443_2_Ent1", "text": "Insulin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16284443_2_Ent2", "text": "Insulin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16284443_2_Ent0", "text": "lipohypertrophy", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "16284443_3", "wnd_id": "16284443_3_1", "text": "Thus , the possible in vivo effects of insulin on adipocytes were clearly observed in this case of insulin - induced lipohypertrophy .", "tokens": ["Thus", ",", "the", "possible", "in", "vivo", "effects", "of", "insulin", "on", "adipocytes", "were", "clearly", "observed", "in", "this", "case", "of", "insulin", "-", "induced", "lipohypertrophy", "."], "event_mentions": [{"id": "16284443_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 20, "end": 21}, "arguments": [{"entity_id": "16284443_3_Ent1", "role": "Treatment", "text": "insulin", "start": 18, "end": 19}, {"entity_id": "16284443_3_Ent2", "role": "Treatment_Drug", "text": "insulin", "start": 18, "end": 19}, {"entity_id": "16284443_3_Ent0", "role": "Effect", "text": "lipohypertrophy", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "16284443_3_Ent1", "text": "insulin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "16284443_3_Ent2", "text": "insulin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "16284443_3_Ent0", "text": "lipohypertrophy", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "1628669_1", "wnd_id": "1628669_1_1", "text": "A 7 - year - old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or prednisone for idiopathic auto - immune haemolytic anaemia .", "tokens": ["A", "7", "-", "year", "-", "old", "girl", "developed", "diabetes", "mellitus", "and", "exocrine", "pancreatic", "insufficiency", "after", "3.5", "years", "of", "almost", "continuous", "treatment", "with", "azathioprine", "and/or", "prednisone", "for", "idiopathic", "auto", "-", "immune", "haemolytic", "anaemia", "."], "event_mentions": [{"id": "1628669_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "1628669_1_Ent0", "role": "Subject", "text": "A 7 - year - old girl", "start": 0, "end": 7}, {"entity_id": "1628669_1_Ent1", "role": "Subject_Age", "text": "7 - year - old", "start": 1, "end": 6}, {"entity_id": "1628669_1_Ent2", "role": "Subject_Gender", "text": "girl", "start": 6, "end": 7}, {"entity_id": "1628669_1_Ent3", "role": "Effect", "text": "diabetes mellitus and exocrine pancreatic insufficiency", "start": 8, "end": 14}, {"entity_id": "1628669_1_Ent10", "role": "Treatment_Duration", "text": "3.5 years", "start": 15, "end": 17}, {"entity_id": "1628669_1_Ent4", "role": "Treatment", "text": "3.5 years of almost continuous treatment with azathioprine and/or prednisone", "start": 15, "end": 25}, {"entity_id": "1628669_1_Ent5", "role": "Treatment_Drug", "text": "azathioprine", "start": 22, "end": 23}, {"entity_id": "1628669_1_Ent7", "role": "Treatment_Drug", "text": "azathioprine", "start": 22, "end": 23}, {"entity_id": "1628669_1_Ent11", "role": "Combination_Drug", "text": "azathioprine", "start": 22, "end": 23}, {"entity_id": "1628669_1_Ent6", "role": "Treatment_Drug", "text": "prednisone", "start": 24, "end": 25}, {"entity_id": "1628669_1_Ent8", "role": "Treatment_Drug", "text": "prednisone", "start": 24, "end": 25}, {"entity_id": "1628669_1_Ent12", "role": "Combination_Drug", "text": "prednisone", "start": 24, "end": 25}, {"entity_id": "1628669_1_Ent9", "role": "Treatment_Disorder", "text": "idiopathic auto - immune haemolytic anaemia", "start": 26, "end": 32}]}], "entity_mentions": [{"id": "1628669_1_Ent0", "text": "A 7 - year - old girl", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "1628669_1_Ent1", "text": "7 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "1628669_1_Ent2", "text": "girl", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1628669_1_Ent3", "text": "diabetes mellitus and exocrine pancreatic insufficiency", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "1628669_1_Ent10", "text": "3.5 years", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "1628669_1_Ent4", "text": "3.5 years of almost continuous treatment with azathioprine and/or prednisone", "entity_type": "Entity", "start": 15, "end": 25}, {"id": "1628669_1_Ent5", "text": "azathioprine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "1628669_1_Ent7", "text": "azathioprine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "1628669_1_Ent11", "text": "azathioprine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "1628669_1_Ent6", "text": "prednisone", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "1628669_1_Ent8", "text": "prednisone", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "1628669_1_Ent12", "text": "prednisone", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "1628669_1_Ent9", "text": "idiopathic auto - immune haemolytic anaemia", "entity_type": "Entity", "start": 26, "end": 32}], "lang": "en"}
{"doc_id": "16288069_2", "wnd_id": "16288069_2_1", "text": "CASE SUMMARY : A 45 - year - old HIV - positive man ( CD4 + count 450 cells / mm(3 ) and history of AIDS - defining illness ) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis .", "tokens": ["CASE", "SUMMARY", ":", "A", "45", "-", "year", "-", "old", "HIV", "-", "positive", "man", "(", "CD4", "+", "count", "450", "cells", "/", "mm(3", ")", "and", "history", "of", "AIDS", "-", "defining", "illness", ")", "presented", "with", "JHR", "after", "an", "initial", "intravenous", "dose", "of", "penicillin", "G", "for", "presumed", "neurosyphilis", "."], "event_mentions": [{"id": "16288069_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 33, "end": 34}, "arguments": [{"entity_id": "16288069_2_Ent0", "role": "Subject", "text": "A 45 - year - old HIV - positive man ( CD4 + count 450 cells / mm(3 ) and history of AIDS - defining illness )", "start": 3, "end": 30}, {"entity_id": "16288069_2_Ent1", "role": "Subject_Age", "text": "45 - year - old", "start": 4, "end": 9}, {"entity_id": "16288069_2_Ent2", "role": "Subject_Disorder", "text": "HIV - positive", "start": 9, "end": 12}, {"entity_id": "16288069_2_Ent3", "role": "Effect", "text": "JHR", "start": 32, "end": 33}, {"entity_id": "16288069_2_Ent8", "role": "Treatment_Dosage", "text": "an initial intravenous dose", "start": 34, "end": 38}, {"entity_id": "16288069_2_Ent4", "role": "Treatment", "text": "an initial intravenous dose of penicillin G", "start": 34, "end": 41}, {"entity_id": "16288069_2_Ent7", "role": "Treatment_Route", "text": "intravenous", "start": 36, "end": 37}, {"entity_id": "16288069_2_Ent5", "role": "Treatment_Drug", "text": "penicillin G", "start": 39, "end": 41}, {"entity_id": "16288069_2_Ent6", "role": "Treatment_Disorder", "text": "neurosyphilis", "start": 43, "end": 44}]}], "entity_mentions": [{"id": "16288069_2_Ent0", "text": "A 45 - year - old HIV - positive man ( CD4 + count 450 cells / mm(3 ) and history of AIDS - defining illness )", "entity_type": "Entity", "start": 3, "end": 30}, {"id": "16288069_2_Ent1", "text": "45 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "16288069_2_Ent2", "text": "HIV - positive", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "16288069_2_Ent3", "text": "JHR", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "16288069_2_Ent8", "text": "an initial intravenous dose", "entity_type": "Entity", "start": 34, "end": 38}, {"id": "16288069_2_Ent4", "text": "an initial intravenous dose of penicillin G", "entity_type": "Entity", "start": 34, "end": 41}, {"id": "16288069_2_Ent7", "text": "intravenous", "entity_type": "Entity", "start": 36, "end": 37}, {"id": "16288069_2_Ent5", "text": "penicillin G", "entity_type": "Entity", "start": 39, "end": 41}, {"id": "16288069_2_Ent6", "text": "neurosyphilis", "entity_type": "Entity", "start": 43, "end": 44}], "lang": "en"}
{"doc_id": "16317298_1", "wnd_id": "16317298_1_1", "text": "Gemcitabine - related radiation recall in a patient with pancreatic cancer .", "tokens": ["Gemcitabine", "-", "related", "radiation", "recall", "in", "a", "patient", "with", "pancreatic", "cancer", "."], "event_mentions": [{"id": "16317298_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 2, "end": 3}, "arguments": [{"entity_id": "16317298_1_Ent2", "role": "Treatment", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "16317298_1_Ent3", "role": "Treatment_Drug", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "16317298_1_Ent1", "role": "Effect", "text": "radiation recall", "start": 3, "end": 5}, {"entity_id": "16317298_1_Ent0", "role": "Subject", "text": "a patient with pancreatic cancer", "start": 6, "end": 11}, {"entity_id": "16317298_1_Ent4", "role": "Treatment_Disorder", "text": "pancreatic cancer", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "16317298_1_Ent2", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16317298_1_Ent3", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16317298_1_Ent1", "text": "radiation recall", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16317298_1_Ent0", "text": "a patient with pancreatic cancer", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "16317298_1_Ent4", "text": "pancreatic cancer", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "16317298_4", "wnd_id": "16317298_4_1", "text": "Radiation recall related to gemcitabine has been reported in lung and breast cancer .", "tokens": ["Radiation", "recall", "related", "to", "gemcitabine", "has", "been", "reported", "in", "lung", "and", "breast", "cancer", "."], "event_mentions": [{"id": "16317298_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 2, "end": 3}, "arguments": [{"entity_id": "16317298_4_Ent0", "role": "Effect", "text": "Radiation recall", "start": 0, "end": 2}, {"entity_id": "16317298_4_Ent1", "role": "Treatment", "text": "gemcitabine", "start": 4, "end": 5}, {"entity_id": "16317298_4_Ent3", "role": "Treatment_Drug", "text": "gemcitabine", "start": 4, "end": 5}, {"entity_id": "16317298_4_Ent2", "role": "Treatment_Disorder", "text": "lung and breast cancer", "start": 9, "end": 13}]}], "entity_mentions": [{"id": "16317298_4_Ent0", "text": "Radiation recall", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16317298_4_Ent1", "text": "gemcitabine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16317298_4_Ent3", "text": "gemcitabine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16317298_4_Ent2", "text": "lung and breast cancer", "entity_type": "Entity", "start": 9, "end": 13}], "lang": "en"}
{"doc_id": "16326413_3", "wnd_id": "16326413_3_1", "text": "Methotrexate - associated nephropathy is a rare complication in pediatric oncology , and a review of the literature suggests that exposure to nephrotoxic agents may be a significant but perhaps underrecognized risk factor for its development .", "tokens": ["Methotrexate", "-", "associated", "nephropathy", "is", "a", "rare", "complication", "in", "pediatric", "oncology", ",", "and", "a", "review", "of", "the", "literature", "suggests", "that", "exposure", "to", "nephrotoxic", "agents", "may", "be", "a", "significant", "but", "perhaps", "underrecognized", "risk", "factor", "for", "its", "development", "."], "event_mentions": [{"id": "16326413_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "16326413_3_Ent1", "role": "Treatment", "text": "Methotrexate", "start": 0, "end": 1}, {"entity_id": "16326413_3_Ent2", "role": "Treatment_Drug", "text": "Methotrexate", "start": 0, "end": 1}, {"entity_id": "16326413_3_Ent0", "role": "Effect", "text": "nephropathy", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "16326413_3_Ent1", "text": "Methotrexate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16326413_3_Ent2", "text": "Methotrexate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16326413_3_Ent0", "text": "nephropathy", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "16357738_1", "wnd_id": "16357738_1_1", "text": "Moreover , treatment with immunosuppressive drugs such as cyclosporine , cisplatin , tacrolimus , and interferon - alpha can induce a condition resembling RPLS .", "tokens": ["Moreover", ",", "treatment", "with", "immunosuppressive", "drugs", "such", "as", "cyclosporine", ",", "cisplatin", ",", "tacrolimus", ",", "and", "interferon", "-", "alpha", "can", "induce", "a", "condition", "resembling", "RPLS", "."], "event_mentions": [{"id": "16357738_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 19, "end": 20}, "arguments": [{"entity_id": "16357738_1_Ent1", "role": "Treatment", "text": "immunosuppressive drugs such as cyclosporine , cisplatin , tacrolimus , and interferon - alpha", "start": 4, "end": 18}, {"entity_id": "16357738_1_Ent2", "role": "Treatment_Drug", "text": "cyclosporine", "start": 8, "end": 9}, {"entity_id": "16357738_1_Ent3", "role": "Treatment_Drug", "text": "cisplatin", "start": 10, "end": 11}, {"entity_id": "16357738_1_Ent4", "role": "Treatment_Drug", "text": "tacrolimus", "start": 12, "end": 13}, {"entity_id": "16357738_1_Ent5", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 15, "end": 18}, {"entity_id": "16357738_1_Ent0", "role": "Effect", "text": "RPLS", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "16357738_1_Ent1", "text": "immunosuppressive drugs such as cyclosporine , cisplatin , tacrolimus , and interferon - alpha", "entity_type": "Entity", "start": 4, "end": 18}, {"id": "16357738_1_Ent2", "text": "cyclosporine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16357738_1_Ent3", "text": "cisplatin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16357738_1_Ent4", "text": "tacrolimus", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16357738_1_Ent5", "text": "interferon - alpha", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "16357738_1_Ent0", "text": "RPLS", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "16357738_2", "wnd_id": "16357738_2_1", "text": "Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine .", "tokens": ["Reversible", "posterior", "leukoencephalopathy", "syndrome", "in", "systemic", "lupus", "erythematosus", "with", "thrombocytopenia", "treated", "with", "cyclosporine", "."], "event_mentions": [{"id": "16357738_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 10, "end": 11}, "arguments": [{"entity_id": "16357738_2_Ent2", "role": "Treatment_Disorder", "text": "systemic lupus erythematosus with thrombocytopenia", "start": 5, "end": 10}, {"entity_id": "16357738_2_Ent0", "role": "Treatment", "text": "cyclosporine", "start": 12, "end": 13}, {"entity_id": "16357738_2_Ent1", "role": "Treatment_Drug", "text": "cyclosporine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "16357738_2_Ent2", "text": "systemic lupus erythematosus with thrombocytopenia", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "16357738_2_Ent0", "text": "cyclosporine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16357738_2_Ent1", "text": "cyclosporine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "16357738_3", "wnd_id": "16357738_3_1", "text": "We report a case of a young woman with SLE and thrombocytopenia , who developed severe perspiration , headache , and seizure after receiving cyclosporine .", "tokens": ["We", "report", "a", "case", "of", "a", "young", "woman", "with", "SLE", "and", "thrombocytopenia", ",", "who", "developed", "severe", "perspiration", ",", "headache", ",", "and", "seizure", "after", "receiving", "cyclosporine", "."], "event_mentions": [{"id": "16357738_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 22, "end": 23}, "arguments": [{"entity_id": "16357738_3_Ent2", "role": "Subject_Age", "text": "young", "start": 6, "end": 7}, {"entity_id": "16357738_3_Ent0", "role": "Subject", "text": "young woman with SLE and thrombocytopenia", "start": 6, "end": 12}, {"entity_id": "16357738_3_Ent3", "role": "Subject_Gender", "text": "woman", "start": 7, "end": 8}, {"entity_id": "16357738_3_Ent7", "role": "Treatment_Disorder", "text": "SLE", "start": 9, "end": 10}, {"entity_id": "16357738_3_Ent1", "role": "Subject_Disorder", "text": "thrombocytopenia", "start": 11, "end": 12}, {"entity_id": "16357738_3_Ent4", "role": "Effect", "text": "severe perspiration , headache , and seizure", "start": 15, "end": 22}, {"entity_id": "16357738_3_Ent5", "role": "Treatment", "text": "cyclosporine", "start": 24, "end": 25}, {"entity_id": "16357738_3_Ent6", "role": "Treatment_Drug", "text": "cyclosporine", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "16357738_3_Ent2", "text": "young", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16357738_3_Ent0", "text": "young woman with SLE and thrombocytopenia", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "16357738_3_Ent3", "text": "woman", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16357738_3_Ent7", "text": "SLE", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16357738_3_Ent1", "text": "thrombocytopenia", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16357738_3_Ent4", "text": "severe perspiration , headache , and seizure", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "16357738_3_Ent5", "text": "cyclosporine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "16357738_3_Ent6", "text": "cyclosporine", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "16371793_11", "wnd_id": "16371793_11_1", "text": "CONCLUSIONS : Intravitreal injection of triamcinolone acetonide may be an additional tool in the treatment of therapy - resistant cystoid macular edema after penetrating keratoplasty .", "tokens": ["CONCLUSIONS", ":", "Intravitreal", "injection", "of", "triamcinolone", "acetonide", "may", "be", "an", "additional", "tool", "in", "the", "treatment", "of", "therapy", "-", "resistant", "cystoid", "macular", "edema", "after", "penetrating", "keratoplasty", "."], "event_mentions": [{"id": "16371793_11_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 14, "end": 15}, "arguments": [{"entity_id": "16371793_11_Ent1", "role": "Treatment_Route", "text": "Intravitreal injection", "start": 2, "end": 4}, {"entity_id": "16371793_11_Ent0", "role": "Treatment", "text": "Intravitreal injection of triamcinolone acetonide", "start": 2, "end": 7}, {"entity_id": "16371793_11_Ent2", "role": "Treatment_Drug", "text": "triamcinolone acetonide", "start": 5, "end": 7}, {"entity_id": "16371793_11_Ent3", "role": "Treatment_Disorder", "text": "therapy - resistant cystoid macular edema", "start": 16, "end": 22}]}], "entity_mentions": [{"id": "16371793_11_Ent1", "text": "Intravitreal injection", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "16371793_11_Ent0", "text": "Intravitreal injection of triamcinolone acetonide", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "16371793_11_Ent2", "text": "triamcinolone acetonide", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "16371793_11_Ent3", "text": "therapy - resistant cystoid macular edema", "entity_type": "Entity", "start": 16, "end": 22}], "lang": "en"}
{"doc_id": "16405935_3", "wnd_id": "16405935_3_1", "text": "This report describes a case of bilateral ptosis induced by chloroquine .", "tokens": ["This", "report", "describes", "a", "case", "of", "bilateral", "ptosis", "induced", "by", "chloroquine", "."], "event_mentions": [{"id": "16405935_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "16405935_3_Ent0", "role": "Subject", "text": "a case", "start": 3, "end": 5}, {"entity_id": "16405935_3_Ent1", "role": "Effect", "text": "bilateral ptosis", "start": 6, "end": 8}, {"entity_id": "16405935_3_Ent2", "role": "Treatment", "text": "chloroquine", "start": 10, "end": 11}, {"entity_id": "16405935_3_Ent3", "role": "Treatment_Drug", "text": "chloroquine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "16405935_3_Ent0", "text": "a case", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16405935_3_Ent1", "text": "bilateral ptosis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "16405935_3_Ent2", "text": "chloroquine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16405935_3_Ent3", "text": "chloroquine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "16411025_1", "wnd_id": "16411025_1_1", "text": "DESIGN : We reviewed the medical records of four patients , who were seen by us between July 2000 and February 2004 for sudden onset of a central neurological syndrome within days of intrathecal MTX .", "tokens": ["DESIGN", ":", "We", "reviewed", "the", "medical", "records", "of", "four", "patients", ",", "who", "were", "seen", "by", "us", "between", "July", "2000", "and", "February", "2004", "for", "sudden", "onset", "of", "a", "central", "neurological", "syndrome", "within", "days", "of", "intrathecal", "MTX", "."], "event_mentions": [{"id": "16411025_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "intrathecal", "start": 33, "end": 34}, "arguments": [{"entity_id": "16411025_1_Ent0", "role": "Subject", "text": "medical records of four patients", "start": 5, "end": 10}, {"entity_id": "16411025_1_Ent1", "role": "Subject_Population", "text": "four", "start": 8, "end": 9}, {"entity_id": "16411025_1_Ent2", "role": "Effect", "text": "a central neurological syndrome", "start": 26, "end": 30}, {"entity_id": "16411025_1_Ent5", "role": "Treatment_Time_elapsed", "text": "within days", "start": 30, "end": 32}, {"entity_id": "16411025_1_Ent3", "role": "Treatment", "text": "MTX", "start": 34, "end": 35}, {"entity_id": "16411025_1_Ent4", "role": "Treatment_Drug", "text": "MTX", "start": 34, "end": 35}]}], "entity_mentions": [{"id": "16411025_1_Ent0", "text": "medical records of four patients", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "16411025_1_Ent1", "text": "four", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16411025_1_Ent2", "text": "a central neurological syndrome", "entity_type": "Entity", "start": 26, "end": 30}, {"id": "16411025_1_Ent5", "text": "within days", "entity_type": "Entity", "start": 30, "end": 32}, {"id": "16411025_1_Ent3", "text": "MTX", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "16411025_1_Ent4", "text": "MTX", "entity_type": "Entity", "start": 34, "end": 35}], "lang": "en"}
{"doc_id": "16449538_4", "wnd_id": "16449538_4_1", "text": "NCSE , an epileptic disorder in which typical convulsive activity is absent , has previously been reported in only 4 patients receiving ifosfamide .", "tokens": ["NCSE", ",", "an", "epileptic", "disorder", "in", "which", "typical", "convulsive", "activity", "is", "absent", ",", "has", "previously", "been", "reported", "in", "only", "4", "patients", "receiving", "ifosfamide", "."], "event_mentions": [{"id": "16449538_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 21, "end": 22}, "arguments": [{"entity_id": "16449538_4_Ent2", "role": "Effect", "text": "NCSE", "start": 0, "end": 1}, {"entity_id": "16449538_4_Ent1", "role": "Subject_Population", "text": "4", "start": 19, "end": 20}, {"entity_id": "16449538_4_Ent0", "role": "Subject", "text": "4 patients", "start": 19, "end": 21}, {"entity_id": "16449538_4_Ent3", "role": "Treatment", "text": "ifosfamide", "start": 22, "end": 23}, {"entity_id": "16449538_4_Ent4", "role": "Treatment_Drug", "text": "ifosfamide", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "16449538_4_Ent2", "text": "NCSE", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16449538_4_Ent1", "text": "4", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16449538_4_Ent0", "text": "4 patients", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "16449538_4_Ent3", "text": "ifosfamide", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "16449538_4_Ent4", "text": "ifosfamide", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "16453964_1", "wnd_id": "16453964_1_1", "text": "We describe a case of intraoperative gelatine - induced anaphylaxis whose diagnosis was delayed as the use of gelatine during surgical procedures was omitted for two times in patient 's medical records .", "tokens": ["We", "describe", "a", "case", "of", "intraoperative", "gelatine", "-", "induced", "anaphylaxis", "whose", "diagnosis", "was", "delayed", "as", "the", "use", "of", "gelatine", "during", "surgical", "procedures", "was", "omitted", "for", "two", "times", "in", "patient", "'s", "medical", "records", "."], "event_mentions": [{"id": "16453964_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "16453964_1_Ent3", "role": "Treatment_Route", "text": "intraoperative", "start": 5, "end": 6}, {"entity_id": "16453964_1_Ent1", "role": "Treatment", "text": "intraoperative gelatine", "start": 5, "end": 7}, {"entity_id": "16453964_1_Ent2", "role": "Treatment_Drug", "text": "gelatine", "start": 6, "end": 7}, {"entity_id": "16453964_1_Ent0", "role": "Effect", "text": "anaphylaxis", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "16453964_1_Ent3", "text": "intraoperative", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16453964_1_Ent1", "text": "intraoperative gelatine", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "16453964_1_Ent2", "text": "gelatine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16453964_1_Ent0", "text": "anaphylaxis", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "16463436_1", "wnd_id": "16463436_1_1", "text": "Some patients develop hypersensitivity rash in response to HCQ .", "tokens": ["Some", "patients", "develop", "hypersensitivity", "rash", "in", "response", "to", "HCQ", "."], "event_mentions": [{"id": "16463436_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 2, "end": 3}, "arguments": [{"entity_id": "16463436_1_Ent1", "role": "Subject_Population", "text": "Some", "start": 0, "end": 1}, {"entity_id": "16463436_1_Ent0", "role": "Subject", "text": "Some patients", "start": 0, "end": 2}, {"entity_id": "16463436_1_Ent2", "role": "Effect", "text": "hypersensitivity rash", "start": 3, "end": 5}, {"entity_id": "16463436_1_Ent3", "role": "Treatment", "text": "HCQ", "start": 8, "end": 9}, {"entity_id": "16463436_1_Ent4", "role": "Treatment_Drug", "text": "HCQ", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "16463436_1_Ent1", "text": "Some", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16463436_1_Ent0", "text": "Some patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16463436_1_Ent2", "text": "hypersensitivity rash", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16463436_1_Ent3", "text": "HCQ", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16463436_1_Ent4", "text": "HCQ", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "16490518_1", "wnd_id": "16490518_1_1", "text": "PURPOSE : To report a case of severe corticosteroid - induced glaucoma after intravitreal injection of triamcinolone acetate in a 34 - year - old man without a history of glaucoma .", "tokens": ["PURPOSE", ":", "To", "report", "a", "case", "of", "severe", "corticosteroid", "-", "induced", "glaucoma", "after", "intravitreal", "injection", "of", "triamcinolone", "acetate", "in", "a", "34", "-", "year", "-", "old", "man", "without", "a", "history", "of", "glaucoma", "."], "event_mentions": [{"id": "16490518_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "16490518_1_Ent5", "role": "Treatment_Drug", "text": "corticosteroid", "start": 8, "end": 9}, {"entity_id": "16490518_1_Ent3", "role": "Effect", "text": "glaucoma", "start": 11, "end": 12}, {"entity_id": "16490518_1_Ent7", "role": "Treatment_Route", "text": "intravitreal injection", "start": 13, "end": 15}, {"entity_id": "16490518_1_Ent4", "role": "Treatment", "text": "intravitreal injection of triamcinolone acetate", "start": 13, "end": 18}, {"entity_id": "16490518_1_Ent6", "role": "Treatment_Drug", "text": "triamcinolone acetate", "start": 16, "end": 18}, {"entity_id": "16490518_1_Ent0", "role": "Subject", "text": "a 34 - year - old man without a history of glaucoma", "start": 19, "end": 31}, {"entity_id": "16490518_1_Ent1", "role": "Subject_Age", "text": "34 - year - old", "start": 20, "end": 25}, {"entity_id": "16490518_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "16490518_1_Ent5", "text": "corticosteroid", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16490518_1_Ent3", "text": "glaucoma", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16490518_1_Ent7", "text": "intravitreal injection", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "16490518_1_Ent4", "text": "intravitreal injection of triamcinolone acetate", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "16490518_1_Ent6", "text": "triamcinolone acetate", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "16490518_1_Ent0", "text": "a 34 - year - old man without a history of glaucoma", "entity_type": "Entity", "start": 19, "end": 31}, {"id": "16490518_1_Ent1", "text": "34 - year - old", "entity_type": "Entity", "start": 20, "end": 25}, {"id": "16490518_1_Ent2", "text": "man", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "16498048_1", "wnd_id": "16498048_1_1", "text": "Autoimmune thyroid disease is a common side - effect of interferon - alpha ( IFN - alpha ) treatment of viral hepatitis C.", "tokens": ["Autoimmune", "thyroid", "disease", "is", "a", "common", "side", "-", "effect", "of", "interferon", "-", "alpha", "(", "IFN", "-", "alpha", ")", "treatment", "of", "viral", "hepatitis", "C."], "event_mentions": [{"id": "16498048_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side - effect", "start": 6, "end": 9}, "arguments": [{"entity_id": "16498048_1_Ent0", "role": "Effect", "text": "Autoimmune thyroid disease", "start": 0, "end": 3}, {"entity_id": "16498048_1_Ent2", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 10, "end": 13}, {"entity_id": "16498048_1_Ent1", "role": "Treatment", "text": "interferon - alpha ( IFN - alpha )", "start": 10, "end": 18}, {"entity_id": "16498048_1_Ent3", "role": "Treatment_Disorder", "text": "viral hepatitis C.", "start": 20, "end": 23}]}], "entity_mentions": [{"id": "16498048_1_Ent0", "text": "Autoimmune thyroid disease", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16498048_1_Ent2", "text": "interferon - alpha", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "16498048_1_Ent1", "text": "interferon - alpha ( IFN - alpha )", "entity_type": "Entity", "start": 10, "end": 18}, {"id": "16498048_1_Ent3", "text": "viral hepatitis C.", "entity_type": "Entity", "start": 20, "end": 23}], "lang": "en"}
{"doc_id": "16498048_5", "wnd_id": "16498048_5_1", "text": "We have described three patients with hepatitis C for whom IFN - alpha and ribavirin were prescribed and who developed two successive phases of silent thyroiditis followed by hyperthryroidism relapse due to Graves ' disease .", "tokens": ["We", "have", "described", "three", "patients", "with", "hepatitis", "C", "for", "whom", "IFN", "-", "alpha", "and", "ribavirin", "were", "prescribed", "and", "who", "developed", "two", "successive", "phases", "of", "silent", "thyroiditis", "followed", "by", "hyperthryroidism", "relapse", "due", "to", "Graves", "'", "disease", "."], "event_mentions": [{"id": "16498048_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 19, "end": 20}, "arguments": [{"entity_id": "16498048_5_Ent1", "role": "Subject_Population", "text": "three", "start": 3, "end": 4}, {"entity_id": "16498048_5_Ent0", "role": "Subject", "text": "three patients with hepatitis C", "start": 3, "end": 8}, {"entity_id": "16498048_5_Ent5", "role": "Treatment_Disorder", "text": "hepatitis C", "start": 6, "end": 8}, {"entity_id": "16498048_5_Ent6", "role": "Treatment_Drug", "text": "IFN - alpha", "start": 10, "end": 13}, {"entity_id": "16498048_5_Ent4", "role": "Treatment", "text": "IFN - alpha and ribavirin", "start": 10, "end": 15}, {"entity_id": "16498048_5_Ent7", "role": "Treatment_Drug", "text": "ribavirin", "start": 14, "end": 15}, {"entity_id": "16498048_5_Ent3", "role": "Effect", "text": "two successive phases of silent thyroiditis followed by hyperthryroidism relapse due to Graves ' disease", "start": 20, "end": 35}, {"entity_id": "16498048_5_Ent2", "role": "Subject_Disorder", "text": "Graves ' disease", "start": 32, "end": 35}]}], "entity_mentions": [{"id": "16498048_5_Ent1", "text": "three", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16498048_5_Ent0", "text": "three patients with hepatitis C", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "16498048_5_Ent5", "text": "hepatitis C", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "16498048_5_Ent6", "text": "IFN - alpha", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "16498048_5_Ent4", "text": "IFN - alpha and ribavirin", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "16498048_5_Ent7", "text": "ribavirin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16498048_5_Ent3", "text": "two successive phases of silent thyroiditis followed by hyperthryroidism relapse due to Graves ' disease", "entity_type": "Entity", "start": 20, "end": 35}, {"id": "16498048_5_Ent2", "text": "Graves ' disease", "entity_type": "Entity", "start": 32, "end": 35}], "lang": "en"}
{"doc_id": "16503727_2", "wnd_id": "16503727_2_1", "text": "Dipyrone - induced granulocytopenia : a case for awareness .", "tokens": ["Dipyrone", "-", "induced", "granulocytopenia", ":", "a", "case", "for", "awareness", "."], "event_mentions": [{"id": "16503727_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "16503727_2_Ent2", "role": "Treatment", "text": "Dipyrone", "start": 0, "end": 1}, {"entity_id": "16503727_2_Ent3", "role": "Treatment_Drug", "text": "Dipyrone", "start": 0, "end": 1}, {"entity_id": "16503727_2_Ent1", "role": "Effect", "text": "granulocytopenia", "start": 3, "end": 4}, {"entity_id": "16503727_2_Ent0", "role": "Subject", "text": "a case", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "16503727_2_Ent2", "text": "Dipyrone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16503727_2_Ent3", "text": "Dipyrone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16503727_2_Ent1", "text": "granulocytopenia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16503727_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "16515630_3", "wnd_id": "16515630_3_1", "text": "Physicians should keep in mind that taxanes such as paclitaxel have the potential to cause pneumonitis and lung fibrosis .", "tokens": ["Physicians", "should", "keep", "in", "mind", "that", "taxanes", "such", "as", "paclitaxel", "have", "the", "potential", "to", "cause", "pneumonitis", "and", "lung", "fibrosis", "."], "event_mentions": [{"id": "16515630_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 14, "end": 15}, "arguments": [{"entity_id": "16515630_3_Ent2", "role": "Treatment_Drug", "text": "taxanes", "start": 6, "end": 7}, {"entity_id": "16515630_3_Ent1", "role": "Treatment", "text": "taxanes such as paclitaxel", "start": 6, "end": 10}, {"entity_id": "16515630_3_Ent0", "role": "Effect", "text": "pneumonitis and lung fibrosis", "start": 15, "end": 19}]}], "entity_mentions": [{"id": "16515630_3_Ent2", "text": "taxanes", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16515630_3_Ent1", "text": "taxanes such as paclitaxel", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "16515630_3_Ent0", "text": "pneumonitis and lung fibrosis", "entity_type": "Entity", "start": 15, "end": 19}], "lang": "en"}
{"doc_id": "16515630_4", "wnd_id": "16515630_4_1", "text": "Pulmonary fibrosis is a complication of paclitaxel therapy that may occur despite treatments with corticosteroids .", "tokens": ["Pulmonary", "fibrosis", "is", "a", "complication", "of", "paclitaxel", "therapy", "that", "may", "occur", "despite", "treatments", "with", "corticosteroids", "."], "event_mentions": [{"id": "16515630_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 4, "end": 5}, "arguments": [{"entity_id": "16515630_4_Ent0", "role": "Effect", "text": "Pulmonary fibrosis", "start": 0, "end": 2}, {"entity_id": "16515630_4_Ent2", "role": "Treatment_Drug", "text": "paclitaxel", "start": 6, "end": 7}, {"entity_id": "16515630_4_Ent1", "role": "Treatment", "text": "paclitaxel therapy", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "16515630_4_Ent0", "text": "Pulmonary fibrosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16515630_4_Ent2", "text": "paclitaxel", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16515630_4_Ent1", "text": "paclitaxel therapy", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "16521231_2", "wnd_id": "16521231_2_1", "text": "In this case report , we have described a patient with Crohn 's disease who developed subfulminant hepatitis B after the fourth infusion of infliximab due to an unrecognized HBs - antigen carrier state .", "tokens": ["In", "this", "case", "report", ",", "we", "have", "described", "a", "patient", "with", "Crohn", "'s", "disease", "who", "developed", "subfulminant", "hepatitis", "B", "after", "the", "fourth", "infusion", "of", "infliximab", "due", "to", "an", "unrecognized", "HBs", "-", "antigen", "carrier", "state", "."], "event_mentions": [{"id": "16521231_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 15, "end": 16}, "arguments": [{"entity_id": "16521231_2_Ent0", "role": "Subject", "text": "a patient with Crohn 's disease", "start": 8, "end": 14}, {"entity_id": "16521231_2_Ent3", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 11, "end": 14}, {"entity_id": "16521231_2_Ent1", "role": "Effect", "text": "subfulminant hepatitis B", "start": 16, "end": 19}, {"entity_id": "16521231_2_Ent4", "role": "Treatment_Time_elapsed", "text": "fourth", "start": 21, "end": 22}, {"entity_id": "16521231_2_Ent2", "role": "Treatment", "text": "fourth infusion of infliximab", "start": 21, "end": 25}, {"entity_id": "16521231_2_Ent6", "role": "Treatment_Route", "text": "infusion", "start": 22, "end": 23}, {"entity_id": "16521231_2_Ent5", "role": "Treatment_Drug", "text": "infliximab", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "16521231_2_Ent0", "text": "a patient with Crohn 's disease", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "16521231_2_Ent3", "text": "Crohn 's disease", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "16521231_2_Ent1", "text": "subfulminant hepatitis B", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "16521231_2_Ent4", "text": "fourth", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16521231_2_Ent2", "text": "fourth infusion of infliximab", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "16521231_2_Ent6", "text": "infusion", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "16521231_2_Ent5", "text": "infliximab", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "16521231_3", "wnd_id": "16521231_3_1", "text": "Subfulminant hepatitis B after infliximab in Crohn 's disease : need for HBV - screening ?", "tokens": ["Subfulminant", "hepatitis", "B", "after", "infliximab", "in", "Crohn", "'s", "disease", ":", "need", "for", "HBV", "-", "screening", "?"], "event_mentions": [{"id": "16521231_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "16521231_3_Ent0", "role": "Effect", "text": "Subfulminant hepatitis B", "start": 0, "end": 3}, {"entity_id": "16521231_3_Ent1", "role": "Treatment", "text": "infliximab", "start": 4, "end": 5}, {"entity_id": "16521231_3_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 4, "end": 5}, {"entity_id": "16521231_3_Ent3", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "16521231_3_Ent0", "text": "Subfulminant hepatitis B", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16521231_3_Ent1", "text": "infliximab", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16521231_3_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16521231_3_Ent3", "text": "Crohn 's disease", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "16531969_1", "wnd_id": "16531969_1_1", "text": "Drug induced liver injury secondary to interferon - beta ( IFN - beta ) in multiple sclerosis .", "tokens": ["Drug", "induced", "liver", "injury", "secondary", "to", "interferon", "-", "beta", "(", "IFN", "-", "beta", ")", "in", "multiple", "sclerosis", "."], "event_mentions": [{"id": "16531969_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 4, "end": 5}, "arguments": [{"entity_id": "16531969_1_Ent0", "role": "Effect", "text": "liver injury", "start": 2, "end": 4}, {"entity_id": "16531969_1_Ent2", "role": "Treatment_Drug", "text": "interferon - beta", "start": 6, "end": 9}, {"entity_id": "16531969_1_Ent1", "role": "Treatment", "text": "interferon - beta ( IFN - beta )", "start": 6, "end": 14}, {"entity_id": "16531969_1_Ent3", "role": "Treatment_Disorder", "text": "multiple sclerosis", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "16531969_1_Ent0", "text": "liver injury", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "16531969_1_Ent2", "text": "interferon - beta", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "16531969_1_Ent1", "text": "interferon - beta ( IFN - beta )", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "16531969_1_Ent3", "text": "multiple sclerosis", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "16531969_3", "wnd_id": "16531969_3_1", "text": "Post marketing studies of Interferon - beta ( IFN beta ) therapy in multiple sclerosis ( MS ) have demonstrated surprisingly high rates of hepatotoxicity .", "tokens": ["Post", "marketing", "studies", "of", "Interferon", "-", "beta", "(", "IFN", "beta", ")", "therapy", "in", "multiple", "sclerosis", "(", "MS", ")", "have", "demonstrated", "surprisingly", "high", "rates", "of", "hepatotoxicity", "."], "event_mentions": [{"id": "16531969_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "demonstrated", "start": 19, "end": 20}, "arguments": [{"entity_id": "16531969_3_Ent1", "role": "Treatment", "text": "Interferon - beta", "start": 4, "end": 7}, {"entity_id": "16531969_3_Ent2", "role": "Treatment_Drug", "text": "Interferon - beta ( IFN beta )", "start": 4, "end": 11}, {"entity_id": "16531969_3_Ent0", "role": "Effect", "text": "hepatotoxicity", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "16531969_3_Ent1", "text": "Interferon - beta", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "16531969_3_Ent2", "text": "Interferon - beta ( IFN beta )", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "16531969_3_Ent0", "text": "hepatotoxicity", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "16537817_1", "wnd_id": "16537817_1_1", "text": "Simvastatin - amiodarone interaction resulting in rhabdomyolysis , azotemia , and possible hepatotoxicity .", "tokens": ["Simvastatin", "-", "amiodarone", "interaction", "resulting", "in", "rhabdomyolysis", ",", "azotemia", ",", "and", "possible", "hepatotoxicity", "."], "event_mentions": [{"id": "16537817_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 4, "end": 5}, "arguments": [{"entity_id": "16537817_1_Ent3", "role": "Treatment_Drug", "text": "Simvastatin", "start": 0, "end": 1}, {"entity_id": "16537817_1_Ent5", "role": "Combination_Drug", "text": "Simvastatin", "start": 0, "end": 1}, {"entity_id": "16537817_1_Ent1", "role": "Treatment", "text": "Simvastatin - amiodarone interaction", "start": 0, "end": 4}, {"entity_id": "16537817_1_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 2, "end": 3}, {"entity_id": "16537817_1_Ent4", "role": "Combination_Drug", "text": "amiodarone", "start": 2, "end": 3}, {"entity_id": "16537817_1_Ent0", "role": "Effect", "text": "rhabdomyolysis , azotemia , and possible hepatotoxicity", "start": 6, "end": 13}]}], "entity_mentions": [{"id": "16537817_1_Ent3", "text": "Simvastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16537817_1_Ent5", "text": "Simvastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16537817_1_Ent1", "text": "Simvastatin - amiodarone interaction", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "16537817_1_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16537817_1_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16537817_1_Ent0", "text": "rhabdomyolysis , azotemia , and possible hepatotoxicity", "entity_type": "Entity", "start": 6, "end": 13}], "lang": "en"}
{"doc_id": "16537817_10", "wnd_id": "16537817_10_1", "text": "An objective causal assessment suggests that rhabdomyolysis , renal failure , and possibly hepatotoxicity were probably related to an amiodarone - simvastatin interaction .", "tokens": ["An", "objective", "causal", "assessment", "suggests", "that", "rhabdomyolysis", ",", "renal", "failure", ",", "and", "possibly", "hepatotoxicity", "were", "probably", "related", "to", "an", "amiodarone", "-", "simvastatin", "interaction", "."], "event_mentions": [{"id": "16537817_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 16, "end": 17}, "arguments": [{"entity_id": "16537817_10_Ent0", "role": "Effect", "text": "rhabdomyolysis , renal failure , and possibly hepatotoxicity", "start": 6, "end": 14}, {"entity_id": "16537817_10_Ent1", "role": "Treatment", "text": "an amiodarone - simvastatin interaction", "start": 18, "end": 23}, {"entity_id": "16537817_10_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 19, "end": 20}, {"entity_id": "16537817_10_Ent4", "role": "Combination_Drug", "text": "amiodarone", "start": 19, "end": 20}, {"entity_id": "16537817_10_Ent3", "role": "Treatment_Drug", "text": "simvastatin", "start": 21, "end": 22}, {"entity_id": "16537817_10_Ent5", "role": "Combination_Drug", "text": "simvastatin", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "16537817_10_Ent0", "text": "rhabdomyolysis , renal failure , and possibly hepatotoxicity", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "16537817_10_Ent1", "text": "an amiodarone - simvastatin interaction", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "16537817_10_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16537817_10_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16537817_10_Ent3", "text": "simvastatin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16537817_10_Ent5", "text": "simvastatin", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "16540070_2", "wnd_id": "16540070_2_1", "text": "Allergy to cloxacillin with normal tolerance to amoxicillin and cefuroxime .", "tokens": ["Allergy", "to", "cloxacillin", "with", "normal", "tolerance", "to", "amoxicillin", "and", "cefuroxime", "."], "event_mentions": [{"id": "16540070_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 1, "end": 2}, "arguments": [{"entity_id": "16540070_2_Ent0", "role": "Effect", "text": "Allergy", "start": 0, "end": 1}, {"entity_id": "16540070_2_Ent1", "role": "Treatment", "text": "cloxacillin", "start": 2, "end": 3}, {"entity_id": "16540070_2_Ent2", "role": "Treatment_Drug", "text": "cloxacillin", "start": 2, "end": 3}, {"entity_id": "16540070_2_Ent3", "role": "Treatment_Drug", "text": "amoxicillin", "start": 7, "end": 8}, {"entity_id": "16540070_2_Ent4", "role": "Treatment_Drug", "text": "cefuroxime", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "16540070_2_Ent0", "text": "Allergy", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16540070_2_Ent1", "text": "cloxacillin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16540070_2_Ent2", "text": "cloxacillin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16540070_2_Ent3", "text": "amoxicillin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16540070_2_Ent4", "text": "cefuroxime", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "1655228_1", "wnd_id": "1655228_1_1", "text": "Cardiac toxicity related to BCNU has not been described well .", "tokens": ["Cardiac", "toxicity", "related", "to", "BCNU", "has", "not", "been", "described", "well", "."], "event_mentions": [{"id": "1655228_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 2, "end": 3}, "arguments": [{"entity_id": "1655228_1_Ent0", "role": "Effect", "text": "Cardiac toxicity", "start": 0, "end": 2}, {"entity_id": "1655228_1_Ent1", "role": "Treatment", "text": "BCNU", "start": 4, "end": 5}, {"entity_id": "1655228_1_Ent2", "role": "Treatment_Drug", "text": "BCNU", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "1655228_1_Ent0", "text": "Cardiac toxicity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1655228_1_Ent1", "text": "BCNU", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "1655228_1_Ent2", "text": "BCNU", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "1655228_2", "wnd_id": "1655228_2_1", "text": "Myocardial ischemia associated with high - dose carmustine infusion .", "tokens": ["Myocardial", "ischemia", "associated", "with", "high", "-", "dose", "carmustine", "infusion", "."], "event_mentions": [{"id": "1655228_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "1655228_2_Ent0", "role": "Effect", "text": "Myocardial ischemia", "start": 0, "end": 2}, {"entity_id": "1655228_2_Ent2", "role": "Treatment_Dosage", "text": "high - dose", "start": 4, "end": 7}, {"entity_id": "1655228_2_Ent1", "role": "Treatment", "text": "high - dose carmustine infusion", "start": 4, "end": 9}, {"entity_id": "1655228_2_Ent3", "role": "Treatment_Drug", "text": "carmustine", "start": 7, "end": 8}, {"entity_id": "1655228_2_Ent4", "role": "Treatment_Route", "text": "infusion", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "1655228_2_Ent0", "text": "Myocardial ischemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1655228_2_Ent2", "text": "high - dose", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "1655228_2_Ent1", "text": "high - dose carmustine infusion", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "1655228_2_Ent3", "text": "carmustine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1655228_2_Ent4", "text": "infusion", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "16580907_2", "wnd_id": "16580907_2_1", "text": "A 72 - year - old woman with renal insufficiency who was taking oral pilsicainide ( 150 mg / d ) complained of feeling faint 3 days after she was prescribed oral cetirizine ( 20 mg / d ) .", "tokens": ["A", "72", "-", "year", "-", "old", "woman", "with", "renal", "insufficiency", "who", "was", "taking", "oral", "pilsicainide", "(", "150", "mg", "/", "d", ")", "complained", "of", "feeling", "faint", "3", "days", "after", "she", "was", "prescribed", "oral", "cetirizine", "(", "20", "mg", "/", "d", ")", "."], "event_mentions": [{"id": "16580907_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complained", "start": 21, "end": 22}, "arguments": [{"entity_id": "16580907_2_Ent0", "role": "Subject", "text": "A 72 - year - old woman with renal insufficiency", "start": 0, "end": 10}, {"entity_id": "16580907_2_Ent2", "role": "Subject_Age", "text": "72 - year - old", "start": 1, "end": 6}, {"entity_id": "16580907_2_Ent3", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "16580907_2_Ent1", "role": "Subject_Disorder", "text": "renal insufficiency", "start": 8, "end": 10}, {"entity_id": "16580907_2_Ent5", "role": "Treatment", "text": "taking oral pilsicainide ( 150 mg / d )", "start": 12, "end": 21}, {"entity_id": "16580907_2_Ent7", "role": "Treatment_Route", "text": "oral", "start": 13, "end": 14}, {"entity_id": "16580907_2_Ent9", "role": "Treatment_Drug", "text": "pilsicainide", "start": 14, "end": 15}, {"entity_id": "16580907_2_Ent15", "role": "Combination_Drug", "text": "pilsicainide", "start": 14, "end": 15}, {"entity_id": "16580907_2_Ent11", "role": "Treatment_Dosage", "text": "150 mg / d", "start": 16, "end": 20}, {"entity_id": "16580907_2_Ent4", "role": "Effect", "text": "feeling faint", "start": 23, "end": 25}, {"entity_id": "16580907_2_Ent13", "role": "Treatment_Time_elapsed", "text": "3 days", "start": 25, "end": 27}, {"entity_id": "16580907_2_Ent6", "role": "Treatment", "text": "3 days after she was prescribed oral cetirizine ( 20 mg / d )", "start": 25, "end": 39}, {"entity_id": "16580907_2_Ent8", "role": "Treatment_Route", "text": "oral", "start": 31, "end": 32}, {"entity_id": "16580907_2_Ent10", "role": "Treatment_Drug", "text": "cetirizine", "start": 32, "end": 33}, {"entity_id": "16580907_2_Ent14", "role": "Combination_Drug", "text": "cetirizine", "start": 32, "end": 33}, {"entity_id": "16580907_2_Ent12", "role": "Treatment_Dosage", "text": "20 mg / d", "start": 34, "end": 38}]}], "entity_mentions": [{"id": "16580907_2_Ent0", "text": "A 72 - year - old woman with renal insufficiency", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "16580907_2_Ent2", "text": "72 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "16580907_2_Ent3", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16580907_2_Ent1", "text": "renal insufficiency", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "16580907_2_Ent5", "text": "taking oral pilsicainide ( 150 mg / d )", "entity_type": "Entity", "start": 12, "end": 21}, {"id": "16580907_2_Ent7", "text": "oral", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16580907_2_Ent9", "text": "pilsicainide", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16580907_2_Ent15", "text": "pilsicainide", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16580907_2_Ent11", "text": "150 mg / d", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "16580907_2_Ent4", "text": "feeling faint", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "16580907_2_Ent13", "text": "3 days", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "16580907_2_Ent6", "text": "3 days after she was prescribed oral cetirizine ( 20 mg / d )", "entity_type": "Entity", "start": 25, "end": 39}, {"id": "16580907_2_Ent8", "text": "oral", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "16580907_2_Ent10", "text": "cetirizine", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "16580907_2_Ent14", "text": "cetirizine", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "16580907_2_Ent12", "text": "20 mg / d", "entity_type": "Entity", "start": 34, "end": 38}], "lang": "en"}
{"doc_id": "16599252_2", "wnd_id": "16599252_2_1", "text": "We present a case of hypereosinophilia related to zafirlukast therapy .", "tokens": ["We", "present", "a", "case", "of", "hypereosinophilia", "related", "to", "zafirlukast", "therapy", "."], "event_mentions": [{"id": "16599252_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 6, "end": 7}, "arguments": [{"entity_id": "16599252_2_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "16599252_2_Ent1", "role": "Effect", "text": "hypereosinophilia", "start": 5, "end": 6}, {"entity_id": "16599252_2_Ent3", "role": "Treatment_Drug", "text": "zafirlukast", "start": 8, "end": 9}, {"entity_id": "16599252_2_Ent2", "role": "Treatment", "text": "zafirlukast therapy .", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "16599252_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "16599252_2_Ent1", "text": "hypereosinophilia", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16599252_2_Ent3", "text": "zafirlukast", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16599252_2_Ent2", "text": "zafirlukast therapy .", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "16620273_1", "wnd_id": "16620273_1_1", "text": "CONCLUSIONS : The increasing prevalence of Type 2 diabetes and its treatment with metformin might result in more cases of lactic acidosis .", "tokens": ["CONCLUSIONS", ":", "The", "increasing", "prevalence", "of", "Type", "2", "diabetes", "and", "its", "treatment", "with", "metformin", "might", "result", "in", "more", "cases", "of", "lactic", "acidosis", "."], "event_mentions": [{"id": "16620273_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "result", "start": 15, "end": 16}, "arguments": [{"entity_id": "16620273_1_Ent3", "role": "Treatment_Disorder", "text": "Type 2 diabetes", "start": 6, "end": 9}, {"entity_id": "16620273_1_Ent1", "role": "Treatment", "text": "metformin", "start": 13, "end": 14}, {"entity_id": "16620273_1_Ent2", "role": "Treatment_Drug", "text": "metformin", "start": 13, "end": 14}, {"entity_id": "16620273_1_Ent0", "role": "Effect", "text": "lactic acidosis", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "16620273_1_Ent3", "text": "Type 2 diabetes", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "16620273_1_Ent1", "text": "metformin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16620273_1_Ent2", "text": "metformin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16620273_1_Ent0", "text": "lactic acidosis", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "16623611_2", "wnd_id": "16623611_2_1", "text": "The following is a case report analysis intended to draw attention to the need for better care coordination by describing the observed relationship of olanzapine to metabolic changes manifested as uncontrolled diabetes mellitus and weight gain .", "tokens": ["The", "following", "is", "a", "case", "report", "analysis", "intended", "to", "draw", "attention", "to", "the", "need", "for", "better", "care", "coordination", "by", "describing", "the", "observed", "relationship", "of", "olanzapine", "to", "metabolic", "changes", "manifested", "as", "uncontrolled", "diabetes", "mellitus", "and", "weight", "gain", "."], "event_mentions": [{"id": "16623611_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "relationship", "start": 22, "end": 23}, "arguments": [{"entity_id": "16623611_2_Ent1", "role": "Treatment", "text": "olanzapine", "start": 24, "end": 25}, {"entity_id": "16623611_2_Ent2", "role": "Treatment_Drug", "text": "olanzapine", "start": 24, "end": 25}, {"entity_id": "16623611_2_Ent0", "role": "Effect", "text": "metabolic changes manifested as uncontrolled diabetes mellitus and weight gain", "start": 26, "end": 36}]}], "entity_mentions": [{"id": "16623611_2_Ent1", "text": "olanzapine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "16623611_2_Ent2", "text": "olanzapine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "16623611_2_Ent0", "text": "metabolic changes manifested as uncontrolled diabetes mellitus and weight gain", "entity_type": "Entity", "start": 26, "end": 36}], "lang": "en"}
{"doc_id": "16629074_1", "wnd_id": "16629074_1_1", "text": "PURPOSE : To report a case of traumatic flap dehiscence and Enterobacter keratitis 34 months after LASIK .", "tokens": ["PURPOSE", ":", "To", "report", "a", "case", "of", "traumatic", "flap", "dehiscence", "and", "Enterobacter", "keratitis", "34", "months", "after", "LASIK", "."], "event_mentions": [{"id": "16629074_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 15, "end": 16}, "arguments": [{"entity_id": "16629074_1_Ent0", "role": "Effect", "text": "traumatic flap dehiscence and Enterobacter keratitis", "start": 7, "end": 13}, {"entity_id": "16629074_1_Ent2", "role": "Treatment_Time_elapsed", "text": "34 months after", "start": 13, "end": 16}, {"entity_id": "16629074_1_Ent1", "role": "Treatment", "text": "34 months after LASIK", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "16629074_1_Ent0", "text": "traumatic flap dehiscence and Enterobacter keratitis", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "16629074_1_Ent2", "text": "34 months after", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "16629074_1_Ent1", "text": "34 months after LASIK", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "16678268_1", "wnd_id": "16678268_1_1", "text": "Severe adenovirus pneumonia ( AVP ) following infliximab infusion for the treatment of Crohn 's disease .", "tokens": ["Severe", "adenovirus", "pneumonia", "(", "AVP", ")", "following", "infliximab", "infusion", "for", "the", "treatment", "of", "Crohn", "'s", "disease", "."], "event_mentions": [{"id": "16678268_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 6, "end": 7}, "arguments": [{"entity_id": "16678268_1_Ent0", "role": "Effect", "text": "adenovirus pneumonia", "start": 1, "end": 3}, {"entity_id": "16678268_1_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 7, "end": 8}, {"entity_id": "16678268_1_Ent1", "role": "Treatment", "text": "infliximab infusion", "start": 7, "end": 9}, {"entity_id": "16678268_1_Ent3", "role": "Treatment_Route", "text": "infusion", "start": 8, "end": 9}, {"entity_id": "16678268_1_Ent4", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "16678268_1_Ent0", "text": "adenovirus pneumonia", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "16678268_1_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16678268_1_Ent1", "text": "infliximab infusion", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "16678268_1_Ent3", "text": "infusion", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16678268_1_Ent4", "text": "Crohn 's disease", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "16682062_1", "wnd_id": "16682062_1_1", "text": "First case of ivermectin - induced severe hepatitis .", "tokens": ["First", "case", "of", "ivermectin", "-", "induced", "severe", "hepatitis", "."], "event_mentions": [{"id": "16682062_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "16682062_1_Ent1", "role": "Treatment", "text": "ivermectin", "start": 3, "end": 4}, {"entity_id": "16682062_1_Ent2", "role": "Treatment_Drug", "text": "ivermectin", "start": 3, "end": 4}, {"entity_id": "16682062_1_Ent0", "role": "Effect", "text": "severe hepatitis .", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "16682062_1_Ent1", "text": "ivermectin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16682062_1_Ent2", "text": "ivermectin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16682062_1_Ent0", "text": "severe hepatitis .", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "16682062_3", "wnd_id": "16682062_3_1", "text": "We report the case of a 20 - year - old woman originally from Cameroon who was infected by the L. loa parasite and developed severe hepatitis , identified 1 month after a single dose of ivermectin .", "tokens": ["We", "report", "the", "case", "of", "a", "20", "-", "year", "-", "old", "woman", "originally", "from", "Cameroon", "who", "was", "infected", "by", "the", "L.", "loa", "parasite", "and", "developed", "severe", "hepatitis", ",", "identified", "1", "month", "after", "a", "single", "dose", "of", "ivermectin", "."], "event_mentions": [{"id": "16682062_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 24, "end": 25}, "arguments": [{"entity_id": "16682062_3_Ent1", "role": "Subject_Age", "text": "20 - year - old", "start": 6, "end": 11}, {"entity_id": "16682062_3_Ent0", "role": "Subject", "text": "20 - year - old woman originally from Cameroon who was infected by the L. loa parasite", "start": 6, "end": 23}, {"entity_id": "16682062_3_Ent2", "role": "Subject_Gender", "text": "woman", "start": 11, "end": 12}, {"entity_id": "16682062_3_Ent3", "role": "Subject_Race", "text": "Cameroon", "start": 14, "end": 15}, {"entity_id": "16682062_3_Ent6", "role": "Treatment_Disorder", "text": "infected by the L. loa parasite", "start": 17, "end": 23}, {"entity_id": "16682062_3_Ent4", "role": "Effect", "text": "severe hepatitis", "start": 25, "end": 27}, {"entity_id": "16682062_3_Ent7", "role": "Treatment_Time_elapsed", "text": "1 month", "start": 29, "end": 31}, {"entity_id": "16682062_3_Ent5", "role": "Treatment", "text": "1 month after a single dose of ivermectin", "start": 29, "end": 37}, {"entity_id": "16682062_3_Ent8", "role": "Treatment_Dosage", "text": "single dose", "start": 33, "end": 35}, {"entity_id": "16682062_3_Ent9", "role": "Treatment_Drug", "text": "ivermectin", "start": 36, "end": 37}]}], "entity_mentions": [{"id": "16682062_3_Ent1", "text": "20 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "16682062_3_Ent0", "text": "20 - year - old woman originally from Cameroon who was infected by the L. loa parasite", "entity_type": "Entity", "start": 6, "end": 23}, {"id": "16682062_3_Ent2", "text": "woman", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16682062_3_Ent3", "text": "Cameroon", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16682062_3_Ent6", "text": "infected by the L. loa parasite", "entity_type": "Entity", "start": 17, "end": 23}, {"id": "16682062_3_Ent4", "text": "severe hepatitis", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "16682062_3_Ent7", "text": "1 month", "entity_type": "Entity", "start": 29, "end": 31}, {"id": "16682062_3_Ent5", "text": "1 month after a single dose of ivermectin", "entity_type": "Entity", "start": 29, "end": 37}, {"id": "16682062_3_Ent8", "text": "single dose", "entity_type": "Entity", "start": 33, "end": 35}, {"id": "16682062_3_Ent9", "text": "ivermectin", "entity_type": "Entity", "start": 36, "end": 37}], "lang": "en"}
{"doc_id": "16816519_9", "wnd_id": "16816519_9_1", "text": "The bilateral ptosis markedly improved after 7 days of pyridoxine and pyridostigmine treatment and completely resolved after two weeks .", "tokens": ["The", "bilateral", "ptosis", "markedly", "improved", "after", "7", "days", "of", "pyridoxine", "and", "pyridostigmine", "treatment", "and", "completely", "resolved", "after", "two", "weeks", "."], "event_mentions": [{"id": "16816519_9_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "improved", "start": 4, "end": 5}, "arguments": [{"entity_id": "16816519_9_Ent1", "role": "Treatment_Time_elapsed", "text": "7 days", "start": 6, "end": 8}, {"entity_id": "16816519_9_Ent2", "role": "Treatment_Drug", "text": "pyridoxine", "start": 9, "end": 10}, {"entity_id": "16816519_9_Ent4", "role": "Combination_Drug", "text": "pyridoxine", "start": 9, "end": 10}, {"entity_id": "16816519_9_Ent0", "role": "Treatment", "text": "pyridoxine and pyridostigmine treatment", "start": 9, "end": 13}, {"entity_id": "16816519_9_Ent3", "role": "Treatment_Drug", "text": "pyridostigmine", "start": 11, "end": 12}, {"entity_id": "16816519_9_Ent5", "role": "Combination_Drug", "text": "pyridostigmine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "16816519_9_Ent1", "text": "7 days", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "16816519_9_Ent2", "text": "pyridoxine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16816519_9_Ent4", "text": "pyridoxine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16816519_9_Ent0", "text": "pyridoxine and pyridostigmine treatment", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "16816519_9_Ent3", "text": "pyridostigmine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16816519_9_Ent5", "text": "pyridostigmine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "16843118_2", "wnd_id": "16843118_2_1", "text": "Morphine , an opium alkaloid , frequently causes side effects such as hyperhidrosis and facial flushing , but serious cutaneous adverse drug reactions are seldom observed .", "tokens": ["Morphine", ",", "an", "opium", "alkaloid", ",", "frequently", "causes", "side", "effects", "such", "as", "hyperhidrosis", "and", "facial", "flushing", ",", "but", "serious", "cutaneous", "adverse", "drug", "reactions", "are", "seldom", "observed", "."], "event_mentions": [{"id": "16843118_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causes", "start": 7, "end": 8}, "arguments": [{"entity_id": "16843118_2_Ent2", "role": "Treatment", "text": "Morphine", "start": 0, "end": 1}, {"entity_id": "16843118_2_Ent3", "role": "Treatment_Drug", "text": "Morphine", "start": 0, "end": 1}, {"entity_id": "16843118_2_Ent0", "role": "Effect", "text": "hyperhidrosis", "start": 12, "end": 13}, {"entity_id": "16843118_2_Ent1", "role": "Effect", "text": "facial flushing", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "16843118_2_Ent2", "text": "Morphine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16843118_2_Ent3", "text": "Morphine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16843118_2_Ent0", "text": "hyperhidrosis", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16843118_2_Ent1", "text": "facial flushing", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "16882112_1", "wnd_id": "16882112_1_1", "text": "Lithium and venlafaxine interaction : a case of serotonin syndrome .", "tokens": ["Lithium", "and", "venlafaxine", "interaction", ":", "a", "case", "of", "serotonin", "syndrome", "."], "event_mentions": [{"id": "16882112_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "case", "start": 6, "end": 7}, "arguments": [{"entity_id": "16882112_1_Ent2", "role": "Treatment_Drug", "text": "Lithium", "start": 0, "end": 1}, {"entity_id": "16882112_1_Ent4", "role": "Combination_Drug", "text": "Lithium", "start": 0, "end": 1}, {"entity_id": "16882112_1_Ent1", "role": "Treatment", "text": "Lithium and venlafaxine interaction", "start": 0, "end": 4}, {"entity_id": "16882112_1_Ent3", "role": "Treatment_Drug", "text": "venlafaxine", "start": 2, "end": 3}, {"entity_id": "16882112_1_Ent5", "role": "Combination_Drug", "text": "venlafaxine", "start": 2, "end": 3}, {"entity_id": "16882112_1_Ent0", "role": "Effect", "text": "serotonin syndrome", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "16882112_1_Ent2", "text": "Lithium", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16882112_1_Ent4", "text": "Lithium", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16882112_1_Ent1", "text": "Lithium and venlafaxine interaction", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "16882112_1_Ent3", "text": "venlafaxine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16882112_1_Ent5", "text": "venlafaxine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16882112_1_Ent0", "text": "serotonin syndrome", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "16939867_2", "wnd_id": "16939867_2_1", "text": "This case study is the second report of localized purpura after prolonged lamotrigine treatment suggesting this may be an atypical lamotrigine - induced drug reaction .", "tokens": ["This", "case", "study", "is", "the", "second", "report", "of", "localized", "purpura", "after", "prolonged", "lamotrigine", "treatment", "suggesting", "this", "may", "be", "an", "atypical", "lamotrigine", "-", "induced", "drug", "reaction", "."], "event_mentions": [{"id": "16939867_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 22, "end": 23}, "arguments": [{"entity_id": "16939867_2_Ent0", "role": "Effect", "text": "localized purpura", "start": 8, "end": 10}, {"entity_id": "16939867_2_Ent4", "role": "Treatment_Duration", "text": "prolonged", "start": 11, "end": 12}, {"entity_id": "16939867_2_Ent2", "role": "Treatment", "text": "lamotrigine", "start": 20, "end": 21}, {"entity_id": "16939867_2_Ent3", "role": "Treatment_Drug", "text": "lamotrigine", "start": 20, "end": 21}, {"entity_id": "16939867_2_Ent1", "role": "Effect", "text": "drug reaction", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "16939867_2_Ent0", "text": "localized purpura", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "16939867_2_Ent4", "text": "prolonged", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16939867_2_Ent2", "text": "lamotrigine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "16939867_2_Ent3", "text": "lamotrigine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "16939867_2_Ent1", "text": "drug reaction", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "16945058_2", "wnd_id": "16945058_2_1", "text": "This report describes a case of acute compromise of renal function associated with hypotension in a 7 - year - old boy treated with the ACE inhibitor lisinopril and the ARB losartan .", "tokens": ["This", "report", "describes", "a", "case", "of", "acute", "compromise", "of", "renal", "function", "associated", "with", "hypotension", "in", "a", "7", "-", "year", "-", "old", "boy", "treated", "with", "the", "ACE", "inhibitor", "lisinopril", "and", "the", "ARB", "losartan", "."], "event_mentions": [{"id": "16945058_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 11, "end": 12}, "arguments": [{"entity_id": "16945058_2_Ent3", "role": "Effect", "text": "acute compromise of renal function", "start": 6, "end": 11}, {"entity_id": "16945058_2_Ent4", "role": "Effect", "text": "hypotension", "start": 13, "end": 14}, {"entity_id": "16945058_2_Ent0", "role": "Subject", "text": "a 7 - year - old boy", "start": 15, "end": 22}, {"entity_id": "16945058_2_Ent1", "role": "Subject_Age", "text": "7 - year - old", "start": 16, "end": 21}, {"entity_id": "16945058_2_Ent2", "role": "Subject_Gender", "text": "boy", "start": 21, "end": 22}, {"entity_id": "16945058_2_Ent5", "role": "Treatment", "text": "ACE inhibitor lisinopril and the ARB losartan", "start": 25, "end": 32}, {"entity_id": "16945058_2_Ent6", "role": "Treatment_Drug", "text": "lisinopril", "start": 27, "end": 28}, {"entity_id": "16945058_2_Ent8", "role": "Combination_Drug", "text": "lisinopril", "start": 27, "end": 28}, {"entity_id": "16945058_2_Ent7", "role": "Treatment_Drug", "text": "losartan", "start": 31, "end": 32}, {"entity_id": "16945058_2_Ent9", "role": "Combination_Drug", "text": "losartan", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "16945058_2_Ent3", "text": "acute compromise of renal function", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "16945058_2_Ent4", "text": "hypotension", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16945058_2_Ent0", "text": "a 7 - year - old boy", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "16945058_2_Ent1", "text": "7 - year - old", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "16945058_2_Ent2", "text": "boy", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16945058_2_Ent5", "text": "ACE inhibitor lisinopril and the ARB losartan", "entity_type": "Entity", "start": 25, "end": 32}, {"id": "16945058_2_Ent6", "text": "lisinopril", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "16945058_2_Ent8", "text": "lisinopril", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "16945058_2_Ent7", "text": "losartan", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "16945058_2_Ent9", "text": "losartan", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "16948177_1", "wnd_id": "16948177_1_1", "text": "Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non - Hodgkin 's lymphoma .", "tokens": ["Bronchiolitis", "obliterans", "with", "organizing", "pneumonia", "after", "rituximab", "therapy", "for", "non", "-", "Hodgkin", "'s", "lymphoma", "."], "event_mentions": [{"id": "16948177_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 5, "end": 6}, "arguments": [{"entity_id": "16948177_1_Ent0", "role": "Effect", "text": "Bronchiolitis obliterans with organizing pneumonia", "start": 0, "end": 5}, {"entity_id": "16948177_1_Ent2", "role": "Treatment_Drug", "text": "rituximab", "start": 6, "end": 7}, {"entity_id": "16948177_1_Ent1", "role": "Treatment", "text": "rituximab therapy", "start": 6, "end": 8}, {"entity_id": "16948177_1_Ent3", "role": "Treatment_Disorder", "text": "non - Hodgkin 's lymphoma", "start": 9, "end": 14}]}], "entity_mentions": [{"id": "16948177_1_Ent0", "text": "Bronchiolitis obliterans with organizing pneumonia", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "16948177_1_Ent2", "text": "rituximab", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16948177_1_Ent1", "text": "rituximab therapy", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "16948177_1_Ent3", "text": "non - Hodgkin 's lymphoma", "entity_type": "Entity", "start": 9, "end": 14}], "lang": "en"}
{"doc_id": "16948177_2", "wnd_id": "16948177_2_1", "text": "Moreover , these findings suggest that the incidence of BOOP following rituximab therapy may be higher than has been previously appreciated .", "tokens": ["Moreover", ",", "these", "findings", "suggest", "that", "the", "incidence", "of", "BOOP", "following", "rituximab", "therapy", "may", "be", "higher", "than", "has", "been", "previously", "appreciated", "."], "event_mentions": [{"id": "16948177_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 10, "end": 11}, "arguments": [{"entity_id": "16948177_2_Ent0", "role": "Effect", "text": "BOOP", "start": 9, "end": 10}, {"entity_id": "16948177_2_Ent2", "role": "Treatment_Drug", "text": "rituximab", "start": 11, "end": 12}, {"entity_id": "16948177_2_Ent1", "role": "Treatment", "text": "rituximab therapy", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "16948177_2_Ent0", "text": "BOOP", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16948177_2_Ent2", "text": "rituximab", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16948177_2_Ent1", "text": "rituximab therapy", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "1695794_3", "wnd_id": "1695794_3_1", "text": "Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia .", "tokens": ["Previous", "therapy", "with", "antiarrhythmics", "had", "resulted", "in", "intolerable", "adverse", "effects", "or", "no", "effect", "on", "the", "arrhythmia", "."], "event_mentions": [{"id": "1695794_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 5, "end": 6}, "arguments": [{"entity_id": "1695794_3_Ent1", "role": "Treatment", "text": "antiarrhythmics", "start": 3, "end": 4}, {"entity_id": "1695794_3_Ent3", "role": "Treatment_Drug", "text": "antiarrhythmics", "start": 3, "end": 4}, {"entity_id": "1695794_3_Ent0", "role": "Effect", "text": "intolerable adverse effects", "start": 7, "end": 10}, {"entity_id": "1695794_3_Ent2", "role": "Treatment_Disorder", "text": "arrhythmia", "start": 15, "end": 16}]}, {"id": "1695794_3_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "effect", "start": 12, "end": 13}, "arguments": [{"entity_id": "1695794_3_Ent4", "role": "Treatment", "text": "antiarrhythmics", "start": 3, "end": 4}, {"entity_id": "1695794_3_Ent6", "role": "Treatment_Drug", "text": "antiarrhythmics", "start": 3, "end": 4}, {"entity_id": "1695794_3_Ent5", "role": "Treatment_Disorder", "text": "arrhythmia", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "1695794_3_Ent1", "text": "antiarrhythmics", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1695794_3_Ent3", "text": "antiarrhythmics", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1695794_3_Ent4", "text": "antiarrhythmics", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1695794_3_Ent6", "text": "antiarrhythmics", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1695794_3_Ent0", "text": "intolerable adverse effects", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "1695794_3_Ent2", "text": "arrhythmia", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "1695794_3_Ent5", "text": "arrhythmia", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "1695794_4", "wnd_id": "1695794_4_1", "text": "She had been taking rifampin prior to admission for acid - fast bacilli .", "tokens": ["She", "had", "been", "taking", "rifampin", "prior", "to", "admission", "for", "acid", "-", "fast", "bacilli", "."], "event_mentions": [{"id": "1695794_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "taking", "start": 3, "end": 4}, "arguments": [{"entity_id": "1695794_4_Ent0", "role": "Subject", "text": "She", "start": 0, "end": 1}, {"entity_id": "1695794_4_Ent1", "role": "Subject_Gender", "text": "She", "start": 0, "end": 1}, {"entity_id": "1695794_4_Ent2", "role": "Treatment", "text": "rifampin", "start": 4, "end": 5}, {"entity_id": "1695794_4_Ent3", "role": "Treatment_Disorder", "text": "acid - fast bacilli", "start": 9, "end": 13}]}], "entity_mentions": [{"id": "1695794_4_Ent0", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1695794_4_Ent1", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1695794_4_Ent2", "text": "rifampin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "1695794_4_Ent3", "text": "acid - fast bacilli", "entity_type": "Entity", "start": 9, "end": 13}], "lang": "en"}
{"doc_id": "16968538_4", "wnd_id": "16968538_4_1", "text": "We present a case of hemolytic - uremic syndrome that developed during the 4th cycle of combination chemotherapy with oxaliplatin , 5 - fluorouracil and leucovorin .", "tokens": ["We", "present", "a", "case", "of", "hemolytic", "-", "uremic", "syndrome", "that", "developed", "during", "the", "4th", "cycle", "of", "combination", "chemotherapy", "with", "oxaliplatin", ",", "5", "-", "fluorouracil", "and", "leucovorin", "."], "event_mentions": [{"id": "16968538_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "16968538_4_Ent0", "role": "Effect", "text": "hemolytic - uremic syndrome", "start": 5, "end": 9}, {"entity_id": "16968538_4_Ent1", "role": "Treatment", "text": "during the 4th cycle of combination chemotherapy with oxaliplatin , 5 - fluorouracil and leucovorin", "start": 11, "end": 26}, {"entity_id": "16968538_4_Ent2", "role": "Treatment_Drug", "text": "oxaliplatin", "start": 19, "end": 20}, {"entity_id": "16968538_4_Ent3", "role": "Treatment_Drug", "text": "fluorouracil", "start": 23, "end": 24}, {"entity_id": "16968538_4_Ent4", "role": "Treatment_Drug", "text": "leucovorin", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "16968538_4_Ent0", "text": "hemolytic - uremic syndrome", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "16968538_4_Ent1", "text": "during the 4th cycle of combination chemotherapy with oxaliplatin , 5 - fluorouracil and leucovorin", "entity_type": "Entity", "start": 11, "end": 26}, {"id": "16968538_4_Ent2", "text": "oxaliplatin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16968538_4_Ent3", "text": "fluorouracil", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "16968538_4_Ent4", "text": "leucovorin", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "16968538_6", "wnd_id": "16968538_6_1", "text": "Three cycles of chemotherapy had been administered without complications when , at the beginning of the fourth cycle , the patient developed clinical and laboratory abnormalities consistent with the development of the hemolytic - uremic syndrome .", "tokens": ["Three", "cycles", "of", "chemotherapy", "had", "been", "administered", "without", "complications", "when", ",", "at", "the", "beginning", "of", "the", "fourth", "cycle", ",", "the", "patient", "developed", "clinical", "and", "laboratory", "abnormalities", "consistent", "with", "the", "development", "of", "the", "hemolytic", "-", "uremic", "syndrome", "."], "event_mentions": [{"id": "16968538_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 21, "end": 22}, "arguments": [{"entity_id": "16968538_6_Ent2", "role": "Treatment", "text": "chemotherapy", "start": 3, "end": 4}, {"entity_id": "16968538_6_Ent4", "role": "Treatment_Drug", "text": "chemotherapy", "start": 3, "end": 4}, {"entity_id": "16968538_6_Ent3", "role": "Treatment", "text": "at the beginning of the fourth cycle", "start": 11, "end": 18}, {"entity_id": "16968538_6_Ent5", "role": "Treatment_Duration", "text": "fourth cycle", "start": 16, "end": 18}, {"entity_id": "16968538_6_Ent0", "role": "Subject", "text": "the patient", "start": 19, "end": 21}, {"entity_id": "16968538_6_Ent1", "role": "Effect", "text": "hemolytic - uremic syndrome .", "start": 32, "end": 37}]}], "entity_mentions": [{"id": "16968538_6_Ent2", "text": "chemotherapy", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16968538_6_Ent4", "text": "chemotherapy", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16968538_6_Ent3", "text": "at the beginning of the fourth cycle", "entity_type": "Entity", "start": 11, "end": 18}, {"id": "16968538_6_Ent5", "text": "fourth cycle", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "16968538_6_Ent0", "text": "the patient", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "16968538_6_Ent1", "text": "hemolytic - uremic syndrome .", "entity_type": "Entity", "start": 32, "end": 37}], "lang": "en"}
{"doc_id": "16968538_8", "wnd_id": "16968538_8_1", "text": "CONCLUSION : The hemolytic - uremic syndrome may be a rare complication of oxaliplatin - based chemotherapy .", "tokens": ["CONCLUSION", ":", "The", "hemolytic", "-", "uremic", "syndrome", "may", "be", "a", "rare", "complication", "of", "oxaliplatin", "-", "based", "chemotherapy", "."], "event_mentions": [{"id": "16968538_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 11, "end": 12}, "arguments": [{"entity_id": "16968538_8_Ent0", "role": "Effect", "text": "hemolytic - uremic syndrome", "start": 3, "end": 7}, {"entity_id": "16968538_8_Ent2", "role": "Treatment_Drug", "text": "oxaliplatin", "start": 13, "end": 14}, {"entity_id": "16968538_8_Ent1", "role": "Treatment", "text": "oxaliplatin - based chemotherapy", "start": 13, "end": 17}, {"entity_id": "16968538_8_Ent3", "role": "Treatment_Route", "text": "chemotherapy", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "16968538_8_Ent0", "text": "hemolytic - uremic syndrome", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "16968538_8_Ent2", "text": "oxaliplatin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16968538_8_Ent1", "text": "oxaliplatin - based chemotherapy", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "16968538_8_Ent3", "text": "chemotherapy", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "16997047_3", "wnd_id": "16997047_3_1", "text": "Recurrent hyponatremia associated with citalopram and mirtazapine .", "tokens": ["Recurrent", "hyponatremia", "associated", "with", "citalopram", "and", "mirtazapine", "."], "event_mentions": [{"id": "16997047_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "16997047_3_Ent0", "role": "Effect", "text": "Recurrent hyponatremia", "start": 0, "end": 2}, {"entity_id": "16997047_3_Ent2", "role": "Treatment_Drug", "text": "citalopram", "start": 4, "end": 5}, {"entity_id": "16997047_3_Ent1", "role": "Treatment", "text": "citalopram and mirtazapine", "start": 4, "end": 7}, {"entity_id": "16997047_3_Ent3", "role": "Treatment_Drug", "text": "mirtazapine", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "16997047_3_Ent0", "text": "Recurrent hyponatremia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16997047_3_Ent2", "text": "citalopram", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16997047_3_Ent1", "text": "citalopram and mirtazapine", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "16997047_3_Ent3", "text": "mirtazapine", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "17016002_2", "wnd_id": "17016002_2_1", "text": "Acute eosinophilic pneumonia caused by calcium stearate , an additive agent for an oral antihistaminic medication .", "tokens": ["Acute", "eosinophilic", "pneumonia", "caused", "by", "calcium", "stearate", ",", "an", "additive", "agent", "for", "an", "oral", "antihistaminic", "medication", "."], "event_mentions": [{"id": "17016002_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 3, "end": 4}, "arguments": [{"entity_id": "17016002_2_Ent0", "role": "Effect", "text": "Acute eosinophilic pneumonia", "start": 0, "end": 3}, {"entity_id": "17016002_2_Ent2", "role": "Treatment_Drug", "text": "calcium stearate", "start": 5, "end": 7}, {"entity_id": "17016002_2_Ent1", "role": "Treatment", "text": "calcium stearate , an additive agent for an oral antihistaminic medication", "start": 5, "end": 16}, {"entity_id": "17016002_2_Ent3", "role": "Treatment_Route", "text": "oral", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "17016002_2_Ent0", "text": "Acute eosinophilic pneumonia", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "17016002_2_Ent2", "text": "calcium stearate", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "17016002_2_Ent1", "text": "calcium stearate , an additive agent for an oral antihistaminic medication", "entity_type": "Entity", "start": 5, "end": 16}, {"id": "17016002_2_Ent3", "text": "oral", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "17016002_3", "wnd_id": "17016002_3_1", "text": "Therefore , we concluded that this patient 's pulmonary disease was caused by calcium stearate , an additive for an antihistaminic drug .", "tokens": ["Therefore", ",", "we", "concluded", "that", "this", "patient", "'s", "pulmonary", "disease", "was", "caused", "by", "calcium", "stearate", ",", "an", "additive", "for", "an", "antihistaminic", "drug", "."], "event_mentions": [{"id": "17016002_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 11, "end": 12}, "arguments": [{"entity_id": "17016002_3_Ent0", "role": "Subject", "text": "this patient 's", "start": 5, "end": 8}, {"entity_id": "17016002_3_Ent1", "role": "Effect", "text": "pulmonary disease", "start": 8, "end": 10}, {"entity_id": "17016002_3_Ent2", "role": "Treatment", "text": "calcium stearate", "start": 13, "end": 15}, {"entity_id": "17016002_3_Ent4", "role": "Treatment_Drug", "text": "calcium stearate", "start": 13, "end": 15}, {"entity_id": "17016002_3_Ent3", "role": "Treatment", "text": "an additive for an antihistaminic drug", "start": 16, "end": 22}]}], "entity_mentions": [{"id": "17016002_3_Ent0", "text": "this patient 's", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "17016002_3_Ent1", "text": "pulmonary disease", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "17016002_3_Ent2", "text": "calcium stearate", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "17016002_3_Ent4", "text": "calcium stearate", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "17016002_3_Ent3", "text": "an additive for an antihistaminic drug", "entity_type": "Entity", "start": 16, "end": 22}], "lang": "en"}
{"doc_id": "17039658_2", "wnd_id": "17039658_2_1", "text": "This eruption appears to be a distinct cutaneous toxicity of PLD .", "tokens": ["This", "eruption", "appears", "to", "be", "a", "distinct", "cutaneous", "toxicity", "of", "PLD", "."], "event_mentions": [{"id": "17039658_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 9, "end": 10}, "arguments": [{"entity_id": "17039658_2_Ent0", "role": "Effect", "text": "eruption", "start": 1, "end": 2}, {"entity_id": "17039658_2_Ent1", "role": "Effect", "text": "distinct cutaneous toxicity", "start": 6, "end": 9}, {"entity_id": "17039658_2_Ent2", "role": "Treatment", "text": "PLD", "start": 10, "end": 11}, {"entity_id": "17039658_2_Ent3", "role": "Treatment_Drug", "text": "PLD", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "17039658_2_Ent0", "text": "eruption", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "17039658_2_Ent1", "text": "distinct cutaneous toxicity", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "17039658_2_Ent2", "text": "PLD", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17039658_2_Ent3", "text": "PLD", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "17044380_2", "wnd_id": "17044380_2_1", "text": "Warfarin - induced skin necrosis and heparin - induced thrombocytopenia following mitral valve replacement for marantic endocarditis .", "tokens": ["Warfarin", "-", "induced", "skin", "necrosis", "and", "heparin", "-", "induced", "thrombocytopenia", "following", "mitral", "valve", "replacement", "for", "marantic", "endocarditis", "."], "event_mentions": [{"id": "17044380_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "17044380_2_Ent1", "role": "Treatment", "text": "Warfarin", "start": 0, "end": 1}, {"entity_id": "17044380_2_Ent2", "role": "Treatment_Drug", "text": "Warfarin", "start": 0, "end": 1}, {"entity_id": "17044380_2_Ent0", "role": "Effect", "text": "skin necrosis", "start": 3, "end": 5}]}, {"id": "17044380_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "17044380_2_Ent4", "role": "Treatment", "text": "heparin", "start": 6, "end": 7}, {"entity_id": "17044380_2_Ent6", "role": "Treatment_Drug", "text": "heparin", "start": 6, "end": 7}, {"entity_id": "17044380_2_Ent3", "role": "Effect", "text": "thrombocytopenia", "start": 9, "end": 10}, {"entity_id": "17044380_2_Ent5", "role": "Treatment_Disorder", "text": "marantic endocarditis", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "17044380_2_Ent1", "text": "Warfarin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17044380_2_Ent2", "text": "Warfarin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17044380_2_Ent0", "text": "skin necrosis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "17044380_2_Ent4", "text": "heparin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17044380_2_Ent6", "text": "heparin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17044380_2_Ent3", "text": "thrombocytopenia", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17044380_2_Ent5", "text": "marantic endocarditis", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "17090724_2", "wnd_id": "17090724_2_1", "text": "OBJECTIVE : To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity .", "tokens": ["OBJECTIVE", ":", "To", "report", "the", "clinical", "course", "of", "a", "woman", "with", "cryptococcal", "meningitis", "and", "no", "previous", "cardiac", "disease", "who", "developed", "a", "fatal", "cardiac", "arrhythmia", "after", "an", "acute", "overdose", "of", "amphotericin", "B", "and", "to", "review", "its", "toxicity", "."], "event_mentions": [{"id": "17090724_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 19, "end": 20}, "arguments": [{"entity_id": "17090724_2_Ent0", "role": "Subject", "text": "a woman with cryptococcal meningitis and no previous cardiac disease", "start": 8, "end": 18}, {"entity_id": "17090724_2_Ent1", "role": "Subject_Gender", "text": "woman", "start": 9, "end": 10}, {"entity_id": "17090724_2_Ent4", "role": "Treatment_Disorder", "text": "cryptococcal meningitis", "start": 11, "end": 13}, {"entity_id": "17090724_2_Ent2", "role": "Effect", "text": "a fatal cardiac arrhythmia", "start": 20, "end": 24}, {"entity_id": "17090724_2_Ent3", "role": "Treatment", "text": "an acute overdose of amphotericin B", "start": 25, "end": 31}, {"entity_id": "17090724_2_Ent6", "role": "Treatment_Dosage", "text": "overdose", "start": 27, "end": 28}, {"entity_id": "17090724_2_Ent5", "role": "Treatment_Drug", "text": "amphotericin B", "start": 29, "end": 31}]}], "entity_mentions": [{"id": "17090724_2_Ent0", "text": "a woman with cryptococcal meningitis and no previous cardiac disease", "entity_type": "Entity", "start": 8, "end": 18}, {"id": "17090724_2_Ent1", "text": "woman", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17090724_2_Ent4", "text": "cryptococcal meningitis", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "17090724_2_Ent2", "text": "a fatal cardiac arrhythmia", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "17090724_2_Ent3", "text": "an acute overdose of amphotericin B", "entity_type": "Entity", "start": 25, "end": 31}, {"id": "17090724_2_Ent6", "text": "overdose", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "17090724_2_Ent5", "text": "amphotericin B", "entity_type": "Entity", "start": 29, "end": 31}], "lang": "en"}
{"doc_id": "1711090_2", "wnd_id": "1711090_2_1", "text": "The clinical effect and safety of Lp - TAE alone and combined with radiofrequency ( RF ) capacitive hyperthermia ( HT ) were evaluated in 20 patients with hepatocellular carcinoma ( HCC ) associated with cirrhosis of the liver .", "tokens": ["The", "clinical", "effect", "and", "safety", "of", "Lp", "-", "TAE", "alone", "and", "combined", "with", "radiofrequency", "(", "RF", ")", "capacitive", "hyperthermia", "(", "HT", ")", "were", "evaluated", "in", "20", "patients", "with", "hepatocellular", "carcinoma", "(", "HCC", ")", "associated", "with", "cirrhosis", "of", "the", "liver", "."], "event_mentions": [{"id": "1711090_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "effect and safety", "start": 2, "end": 5}, "arguments": [{"entity_id": "1711090_2_Ent4", "role": "Treatment_Drug", "text": "Lp - TAE", "start": 6, "end": 9}, {"entity_id": "1711090_2_Ent7", "role": "Combination_Drug", "text": "Lp - TAE", "start": 6, "end": 9}, {"entity_id": "1711090_2_Ent3", "role": "Treatment", "text": "Lp - TAE alone and combined with radiofrequency ( RF ) capacitive hyperthermia ( HT )", "start": 6, "end": 22}, {"entity_id": "1711090_2_Ent5", "role": "Treatment_Drug", "text": "radiofrequency ( RF ) capacitive hyperthermia", "start": 13, "end": 19}, {"entity_id": "1711090_2_Ent8", "role": "Combination_Drug", "text": "radiofrequency ( RF ) capacitive hyperthermia", "start": 13, "end": 19}, {"entity_id": "1711090_2_Ent1", "role": "Subject_Population", "text": "20", "start": 25, "end": 26}, {"entity_id": "1711090_2_Ent0", "role": "Subject", "text": "20 patients with hepatocellular carcinoma ( HCC )", "start": 25, "end": 33}, {"entity_id": "1711090_2_Ent2", "role": "Subject_Disorder", "text": "hepatocellular carcinoma", "start": 28, "end": 30}, {"entity_id": "1711090_2_Ent6", "role": "Treatment_Disorder", "text": "cirrhosis of the liver", "start": 35, "end": 39}]}], "entity_mentions": [{"id": "1711090_2_Ent4", "text": "Lp - TAE", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "1711090_2_Ent7", "text": "Lp - TAE", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "1711090_2_Ent3", "text": "Lp - TAE alone and combined with radiofrequency ( RF ) capacitive hyperthermia ( HT )", "entity_type": "Entity", "start": 6, "end": 22}, {"id": "1711090_2_Ent5", "text": "radiofrequency ( RF ) capacitive hyperthermia", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "1711090_2_Ent8", "text": "radiofrequency ( RF ) capacitive hyperthermia", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "1711090_2_Ent1", "text": "20", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "1711090_2_Ent0", "text": "20 patients with hepatocellular carcinoma ( HCC )", "entity_type": "Entity", "start": 25, "end": 33}, {"id": "1711090_2_Ent2", "text": "hepatocellular carcinoma", "entity_type": "Entity", "start": 28, "end": 30}, {"id": "1711090_2_Ent6", "text": "cirrhosis of the liver", "entity_type": "Entity", "start": 35, "end": 39}], "lang": "en"}
{"doc_id": "17122225_1", "wnd_id": "17122225_1_1", "text": "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs .", "tokens": ["Serotonin", "syndrome", "from", "the", "interaction", "of", "cyclobenzaprine", "with", "other", "serotoninergic", "drugs", "."], "event_mentions": [{"id": "17122225_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 2, "end": 3}, "arguments": [{"entity_id": "17122225_1_Ent0", "role": "Effect", "text": "Serotonin syndrome", "start": 0, "end": 2}, {"entity_id": "17122225_1_Ent1", "role": "Treatment", "text": "interaction of cyclobenzaprine with other serotoninergic drugs", "start": 4, "end": 11}, {"entity_id": "17122225_1_Ent2", "role": "Treatment_Drug", "text": "cyclobenzaprine", "start": 6, "end": 7}, {"entity_id": "17122225_1_Ent3", "role": "Treatment_Drug", "text": "serotoninergic drugs", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "17122225_1_Ent0", "text": "Serotonin syndrome", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17122225_1_Ent1", "text": "interaction of cyclobenzaprine with other serotoninergic drugs", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "17122225_1_Ent2", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17122225_1_Ent3", "text": "serotoninergic drugs", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "17122225_4", "wnd_id": "17122225_4_1", "text": "We report two cases of severe serotonin syndrome induced by the administration of cyclobenzaprine in postoperative patients already receiving another proserotoninergic drug ( phenelzine in one case and duloxetine in the other ) .", "tokens": ["We", "report", "two", "cases", "of", "severe", "serotonin", "syndrome", "induced", "by", "the", "administration", "of", "cyclobenzaprine", "in", "postoperative", "patients", "already", "receiving", "another", "proserotoninergic", "drug", "(", "phenelzine", "in", "one", "case", "and", "duloxetine", "in", "the", "other", ")", "."], "event_mentions": [{"id": "17122225_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "17122225_4_Ent2", "role": "Effect", "text": "serotonin syndrome", "start": 6, "end": 8}, {"entity_id": "17122225_4_Ent3", "role": "Treatment", "text": "cyclobenzaprine", "start": 13, "end": 14}, {"entity_id": "17122225_4_Ent6", "role": "Combination_Drug", "text": "cyclobenzaprine", "start": 13, "end": 14}, {"entity_id": "17122225_4_Ent1", "role": "Subject_Disorder", "text": "postoperative", "start": 15, "end": 16}, {"entity_id": "17122225_4_Ent0", "role": "Subject", "text": "postoperative patients", "start": 15, "end": 17}, {"entity_id": "17122225_4_Ent4", "role": "Treatment", "text": "duloxetine", "start": 28, "end": 29}, {"entity_id": "17122225_4_Ent5", "role": "Treatment_Drug", "text": "duloxetine", "start": 28, "end": 29}, {"entity_id": "17122225_4_Ent7", "role": "Combination_Drug", "text": "duloxetine", "start": 28, "end": 29}]}, {"id": "17122225_4_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "17122225_4_Ent10", "role": "Effect", "text": "serotonin syndrome", "start": 6, "end": 8}, {"entity_id": "17122225_4_Ent11", "role": "Treatment", "text": "cyclobenzaprine", "start": 13, "end": 14}, {"entity_id": "17122225_4_Ent13", "role": "Treatment_Drug", "text": "cyclobenzaprine", "start": 13, "end": 14}, {"entity_id": "17122225_4_Ent15", "role": "Combination_Drug", "text": "cyclobenzaprine", "start": 13, "end": 14}, {"entity_id": "17122225_4_Ent9", "role": "Subject_Disorder", "text": "postoperative", "start": 15, "end": 16}, {"entity_id": "17122225_4_Ent8", "role": "Subject", "text": "postoperative patients", "start": 15, "end": 17}, {"entity_id": "17122225_4_Ent12", "role": "Treatment", "text": "phenelzine", "start": 23, "end": 24}, {"entity_id": "17122225_4_Ent14", "role": "Treatment_Drug", "text": "phenelzine", "start": 23, "end": 24}, {"entity_id": "17122225_4_Ent16", "role": "Combination_Drug", "text": "phenelzine", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "17122225_4_Ent2", "text": "serotonin syndrome", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17122225_4_Ent10", "text": "serotonin syndrome", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17122225_4_Ent3", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17122225_4_Ent6", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17122225_4_Ent11", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17122225_4_Ent13", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17122225_4_Ent15", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17122225_4_Ent1", "text": "postoperative", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "17122225_4_Ent9", "text": "postoperative", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "17122225_4_Ent0", "text": "postoperative patients", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "17122225_4_Ent8", "text": "postoperative patients", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "17122225_4_Ent12", "text": "phenelzine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "17122225_4_Ent14", "text": "phenelzine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "17122225_4_Ent16", "text": "phenelzine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "17122225_4_Ent4", "text": "duloxetine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "17122225_4_Ent5", "text": "duloxetine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "17122225_4_Ent7", "text": "duloxetine", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "17157086_1", "wnd_id": "17157086_1_1", "text": "Fatal liver failure following food supplements during chronic treatment with montelukast .", "tokens": ["Fatal", "liver", "failure", "following", "food", "supplements", "during", "chronic", "treatment", "with", "montelukast", "."], "event_mentions": [{"id": "17157086_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "17157086_1_Ent0", "role": "Effect", "text": "Fatal liver failure", "start": 0, "end": 3}, {"entity_id": "17157086_1_Ent2", "role": "Treatment_Drug", "text": "food supplements", "start": 4, "end": 6}, {"entity_id": "17157086_1_Ent4", "role": "Combination_Drug", "text": "food supplements", "start": 4, "end": 6}, {"entity_id": "17157086_1_Ent1", "role": "Treatment", "text": "food supplements during chronic treatment with montelukast", "start": 4, "end": 11}, {"entity_id": "17157086_1_Ent3", "role": "Treatment_Drug", "text": "montelukast", "start": 10, "end": 11}, {"entity_id": "17157086_1_Ent5", "role": "Combination_Drug", "text": "montelukast", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "17157086_1_Ent0", "text": "Fatal liver failure", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "17157086_1_Ent2", "text": "food supplements", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "17157086_1_Ent4", "text": "food supplements", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "17157086_1_Ent1", "text": "food supplements during chronic treatment with montelukast", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "17157086_1_Ent3", "text": "montelukast", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17157086_1_Ent5", "text": "montelukast", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "17157086_5", "wnd_id": "17157086_5_1", "text": "We speculate on a causal relationship between the assumption of the additives and the fatal hepatitis and envisage a synergy between the additives and montelukast , which per se has well been studied as a hepatotoxic drug .", "tokens": ["We", "speculate", "on", "a", "causal", "relationship", "between", "the", "assumption", "of", "the", "additives", "and", "the", "fatal", "hepatitis", "and", "envisage", "a", "synergy", "between", "the", "additives", "and", "montelukast", ",", "which", "per", "se", "has", "well", "been", "studied", "as", "a", "hepatotoxic", "drug", "."], "event_mentions": [{"id": "17157086_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "relationship", "start": 5, "end": 6}, "arguments": [{"entity_id": "17157086_5_Ent0", "role": "Effect", "text": "the fatal hepatitis", "start": 13, "end": 16}, {"entity_id": "17157086_5_Ent1", "role": "Treatment", "text": "montelukast", "start": 24, "end": 25}, {"entity_id": "17157086_5_Ent2", "role": "Treatment_Drug", "text": "montelukast", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "17157086_5_Ent0", "text": "the fatal hepatitis", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "17157086_5_Ent1", "text": "montelukast", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "17157086_5_Ent2", "text": "montelukast", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "17167851_1", "wnd_id": "17167851_1_1", "text": "Hepatotoxicity induced by cyproterone acetate : a report of three cases .", "tokens": ["Hepatotoxicity", "induced", "by", "cyproterone", "acetate", ":", "a", "report", "of", "three", "cases", "."], "event_mentions": [{"id": "17167851_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced by", "start": 1, "end": 3}, "arguments": [{"entity_id": "17167851_1_Ent0", "role": "Effect", "text": "Hepatotoxicity", "start": 0, "end": 1}, {"entity_id": "17167851_1_Ent1", "role": "Treatment", "text": "cyproterone acetate", "start": 3, "end": 5}, {"entity_id": "17167851_1_Ent2", "role": "Treatment_Drug", "text": "cyproterone acetate", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "17167851_1_Ent0", "text": "Hepatotoxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17167851_1_Ent1", "text": "cyproterone acetate", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "17167851_1_Ent2", "text": "cyproterone acetate", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "17167851_2", "wnd_id": "17167851_2_1", "text": "Three male patients aged 78 - 83 years are presented , in whom severe hepatotoxic reactions emerged after CPA administration .", "tokens": ["Three", "male", "patients", "aged", "78", "-", "83", "years", "are", "presented", ",", "in", "whom", "severe", "hepatotoxic", "reactions", "emerged", "after", "CPA", "administration", "."], "event_mentions": [{"id": "17167851_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 17, "end": 18}, "arguments": [{"entity_id": "17167851_2_Ent1", "role": "Subject_Population", "text": "Three", "start": 0, "end": 1}, {"entity_id": "17167851_2_Ent0", "role": "Subject", "text": "Three male patients aged 78 - 83 years", "start": 0, "end": 8}, {"entity_id": "17167851_2_Ent2", "role": "Subject_Gender", "text": "male", "start": 1, "end": 2}, {"entity_id": "17167851_2_Ent3", "role": "Subject_Age", "text": "78 - 83 years", "start": 4, "end": 8}, {"entity_id": "17167851_2_Ent4", "role": "Effect", "text": "severe hepatotoxic reactions", "start": 13, "end": 16}, {"entity_id": "17167851_2_Ent5", "role": "Treatment", "text": "CPA", "start": 18, "end": 19}, {"entity_id": "17167851_2_Ent6", "role": "Treatment_Drug", "text": "CPA", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "17167851_2_Ent1", "text": "Three", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17167851_2_Ent0", "text": "Three male patients aged 78 - 83 years", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "17167851_2_Ent2", "text": "male", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "17167851_2_Ent3", "text": "78 - 83 years", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "17167851_2_Ent4", "text": "severe hepatotoxic reactions", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "17167851_2_Ent5", "text": "CPA", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17167851_2_Ent6", "text": "CPA", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "17176478_2", "wnd_id": "17176478_2_1", "text": "Leishmania infantum leishmaniasis in corticosteroid -- treated patients .", "tokens": ["Leishmania", "infantum", "leishmaniasis", "in", "corticosteroid", "--", "treated", "patients", "."], "event_mentions": [{"id": "17176478_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 6, "end": 7}, "arguments": [{"entity_id": "17176478_2_Ent0", "role": "Effect", "text": "Leishmania infantum leishmaniasis", "start": 0, "end": 3}, {"entity_id": "17176478_2_Ent1", "role": "Treatment", "text": "corticosteroid", "start": 4, "end": 5}, {"entity_id": "17176478_2_Ent2", "role": "Treatment_Drug", "text": "corticosteroid", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "17176478_2_Ent0", "text": "Leishmania infantum leishmaniasis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "17176478_2_Ent1", "text": "corticosteroid", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17176478_2_Ent2", "text": "corticosteroid", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "17189581_1", "wnd_id": "17189581_1_1", "text": "Mild serotonin syndrome associated with concurrent linezolid and fluoxetine .", "tokens": ["Mild", "serotonin", "syndrome", "associated", "with", "concurrent", "linezolid", "and", "fluoxetine", "."], "event_mentions": [{"id": "17189581_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "17189581_1_Ent0", "role": "Effect", "text": "serotonin syndrome", "start": 1, "end": 3}, {"entity_id": "17189581_1_Ent1", "role": "Treatment", "text": "concurrent linezolid and fluoxetine", "start": 5, "end": 9}, {"entity_id": "17189581_1_Ent2", "role": "Treatment_Drug", "text": "linezolid", "start": 6, "end": 7}, {"entity_id": "17189581_1_Ent4", "role": "Combination_Drug", "text": "linezolid", "start": 6, "end": 7}, {"entity_id": "17189581_1_Ent3", "role": "Treatment_Drug", "text": "fluoxetine", "start": 8, "end": 9}, {"entity_id": "17189581_1_Ent5", "role": "Combination_Drug", "text": "fluoxetine", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "17189581_1_Ent0", "text": "serotonin syndrome", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "17189581_1_Ent1", "text": "concurrent linezolid and fluoxetine", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "17189581_1_Ent2", "text": "linezolid", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17189581_1_Ent4", "text": "linezolid", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17189581_1_Ent3", "text": "fluoxetine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17189581_1_Ent5", "text": "fluoxetine", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "17189581_2", "wnd_id": "17189581_2_1", "text": "A case of serotonin syndrome that developed during concurrent linezolid and fluoxetine is presented .", "tokens": ["A", "case", "of", "serotonin", "syndrome", "that", "developed", "during", "concurrent", "linezolid", "and", "fluoxetine", "is", "presented", "."], "event_mentions": [{"id": "17189581_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "17189581_2_Ent0", "role": "Effect", "text": "serotonin syndrome", "start": 3, "end": 5}, {"entity_id": "17189581_2_Ent1", "role": "Treatment", "text": "concurrent linezolid and fluoxetine", "start": 8, "end": 12}, {"entity_id": "17189581_2_Ent2", "role": "Treatment_Drug", "text": "linezolid", "start": 9, "end": 10}, {"entity_id": "17189581_2_Ent4", "role": "Combination_Drug", "text": "linezolid", "start": 9, "end": 10}, {"entity_id": "17189581_2_Ent3", "role": "Treatment_Drug", "text": "fluoxetine", "start": 11, "end": 12}, {"entity_id": "17189581_2_Ent5", "role": "Combination_Drug", "text": "fluoxetine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "17189581_2_Ent0", "text": "serotonin syndrome", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "17189581_2_Ent1", "text": "concurrent linezolid and fluoxetine", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "17189581_2_Ent2", "text": "linezolid", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17189581_2_Ent4", "text": "linezolid", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17189581_2_Ent3", "text": "fluoxetine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17189581_2_Ent5", "text": "fluoxetine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "17224428_2", "wnd_id": "17224428_2_1", "text": "We report the case of a man , treated with mesalazine for Crohn 's disease who developed drug - induced pericarditis .", "tokens": ["We", "report", "the", "case", "of", "a", "man", ",", "treated", "with", "mesalazine", "for", "Crohn", "'s", "disease", "who", "developed", "drug", "-", "induced", "pericarditis", "."], "event_mentions": [{"id": "17224428_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 16, "end": 17}, "arguments": [{"entity_id": "17224428_2_Ent0", "role": "Subject", "text": "a man", "start": 5, "end": 7}, {"entity_id": "17224428_2_Ent1", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "17224428_2_Ent3", "role": "Treatment", "text": "mesalazine", "start": 10, "end": 11}, {"entity_id": "17224428_2_Ent5", "role": "Treatment_Drug", "text": "mesalazine", "start": 10, "end": 11}, {"entity_id": "17224428_2_Ent4", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 12, "end": 15}, {"entity_id": "17224428_2_Ent2", "role": "Effect", "text": "drug - induced pericarditis", "start": 17, "end": 21}]}], "entity_mentions": [{"id": "17224428_2_Ent0", "text": "a man", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "17224428_2_Ent1", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17224428_2_Ent3", "text": "mesalazine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17224428_2_Ent5", "text": "mesalazine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17224428_2_Ent4", "text": "Crohn 's disease", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "17224428_2_Ent2", "text": "drug - induced pericarditis", "entity_type": "Entity", "start": 17, "end": 21}], "lang": "en"}
{"doc_id": "17228132_3", "wnd_id": "17228132_3_1", "text": "Hepatotoxicity seen with erlotinib , a small molecule tyrosine kinase inhibitor to EGFR , is usually transient with mild elevation of transaminases .", "tokens": ["Hepatotoxicity", "seen", "with", "erlotinib", ",", "a", "small", "molecule", "tyrosine", "kinase", "inhibitor", "to", "EGFR", ",", "is", "usually", "transient", "with", "mild", "elevation", "of", "transaminases", "."], "event_mentions": [{"id": "17228132_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "seen", "start": 1, "end": 2}, "arguments": [{"entity_id": "17228132_3_Ent0", "role": "Effect", "text": "Hepatotoxicity", "start": 0, "end": 1}, {"entity_id": "17228132_3_Ent2", "role": "Treatment", "text": "erlotinib", "start": 3, "end": 4}, {"entity_id": "17228132_3_Ent3", "role": "Treatment_Drug", "text": "erlotinib", "start": 3, "end": 4}, {"entity_id": "17228132_3_Ent1", "role": "Effect", "text": "transient with mild elevation of transaminases", "start": 16, "end": 22}]}], "entity_mentions": [{"id": "17228132_3_Ent0", "text": "Hepatotoxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17228132_3_Ent2", "text": "erlotinib", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17228132_3_Ent3", "text": "erlotinib", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17228132_3_Ent1", "text": "transient with mild elevation of transaminases", "entity_type": "Entity", "start": 16, "end": 22}], "lang": "en"}
{"doc_id": "17228132_8", "wnd_id": "17228132_8_1", "text": "Hepatotoxicity resolved once erlotinib was discontinued and serum transaminases returned to baseline normal values .", "tokens": ["Hepatotoxicity", "resolved", "once", "erlotinib", "was", "discontinued", "and", "serum", "transaminases", "returned", "to", "baseline", "normal", "values", "."], "event_mentions": [{"id": "17228132_8_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "discontinued", "start": 5, "end": 6}, "arguments": [{"entity_id": "17228132_8_Ent0", "role": "Effect", "text": "Hepatotoxicity", "start": 0, "end": 1}, {"entity_id": "17228132_8_Ent2", "role": "Treatment_Disorder", "text": "Hepatotoxicity", "start": 0, "end": 1}, {"entity_id": "17228132_8_Ent1", "role": "Treatment", "text": "erlotinib", "start": 3, "end": 4}, {"entity_id": "17228132_8_Ent3", "role": "Treatment_Drug", "text": "erlotinib", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "17228132_8_Ent0", "text": "Hepatotoxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17228132_8_Ent2", "text": "Hepatotoxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17228132_8_Ent1", "text": "erlotinib", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17228132_8_Ent3", "text": "erlotinib", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "17241588_1", "wnd_id": "17241588_1_1", "text": "RESULTS : A clinical diagnosis of fixed drug eruption owing to use of the PDE5 inhibitor tadalafil ( Cialis ) was made .", "tokens": ["RESULTS", ":", "A", "clinical", "diagnosis", "of", "fixed", "drug", "eruption", "owing", "to", "use", "of", "the", "PDE5", "inhibitor", "tadalafil", "(", "Cialis", ")", "was", "made", "."], "event_mentions": [{"id": "17241588_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "owing", "start": 9, "end": 10}, "arguments": [{"entity_id": "17241588_1_Ent0", "role": "Effect", "text": "fixed drug eruption", "start": 6, "end": 9}, {"entity_id": "17241588_1_Ent1", "role": "Treatment", "text": "PDE5 inhibitor tadalafil ( Cialis )", "start": 14, "end": 20}, {"entity_id": "17241588_1_Ent2", "role": "Treatment_Drug", "text": "tadalafil", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "17241588_1_Ent0", "text": "fixed drug eruption", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "17241588_1_Ent1", "text": "PDE5 inhibitor tadalafil ( Cialis )", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "17241588_1_Ent2", "text": "tadalafil", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "17260498_4", "wnd_id": "17260498_4_1", "text": "The case is presented of a 72 - year - old man with hormone - refractory prostate cancer and weekly administration of 30 mg / m2 docetaxel who developed subacute interstitial pneumonitis - related pulmonary fibrosis after seven doses and died despite mechanical ventilation and high - dose corticosteroid treatment .", "tokens": ["The", "case", "is", "presented", "of", "a", "72", "-", "year", "-", "old", "man", "with", "hormone", "-", "refractory", "prostate", "cancer", "and", "weekly", "administration", "of", "30", "mg", "/", "m2", "docetaxel", "who", "developed", "subacute", "interstitial", "pneumonitis", "-", "related", "pulmonary", "fibrosis", "after", "seven", "doses", "and", "died", "despite", "mechanical", "ventilation", "and", "high", "-", "dose", "corticosteroid", "treatment", "."], "event_mentions": [{"id": "17260498_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 28, "end": 29}, "arguments": [{"entity_id": "17260498_4_Ent0", "role": "Subject", "text": "a 72 - year - old man with hormone - refractory prostate cancer", "start": 5, "end": 18}, {"entity_id": "17260498_4_Ent1", "role": "Subject_Age", "text": "72 - year - old", "start": 6, "end": 11}, {"entity_id": "17260498_4_Ent2", "role": "Subject_Gender", "text": "man", "start": 11, "end": 12}, {"entity_id": "17260498_4_Ent15", "role": "Treatment_Disorder", "text": "hormone - refractory prostate cancer", "start": 13, "end": 18}, {"entity_id": "17260498_4_Ent8", "role": "Treatment_Freq", "text": "weekly", "start": 19, "end": 20}, {"entity_id": "17260498_4_Ent5", "role": "Treatment", "text": "weekly administration of 30 mg / m2 docetaxel", "start": 19, "end": 27}, {"entity_id": "17260498_4_Ent9", "role": "Treatment_Route", "text": "administration", "start": 20, "end": 21}, {"entity_id": "17260498_4_Ent10", "role": "Treatment_Dosage", "text": "30 mg / m2", "start": 22, "end": 26}, {"entity_id": "17260498_4_Ent13", "role": "Treatment_Drug", "text": "docetaxel", "start": 26, "end": 27}, {"entity_id": "17260498_4_Ent3", "role": "Effect", "text": "subacute interstitial pneumonitis - related pulmonary fibrosis", "start": 29, "end": 36}, {"entity_id": "17260498_4_Ent6", "role": "Treatment", "text": "seven doses", "start": 37, "end": 39}, {"entity_id": "17260498_4_Ent11", "role": "Treatment_Dosage", "text": "seven doses", "start": 37, "end": 39}, {"entity_id": "17260498_4_Ent4", "role": "Effect", "text": "and died", "start": 39, "end": 41}, {"entity_id": "17260498_4_Ent7", "role": "Treatment", "text": "despite mechanical ventilation and high - dose corticosteroid treatment", "start": 41, "end": 50}, {"entity_id": "17260498_4_Ent12", "role": "Treatment_Dosage", "text": "high - dose", "start": 45, "end": 48}, {"entity_id": "17260498_4_Ent14", "role": "Treatment_Drug", "text": "corticosteroid", "start": 48, "end": 49}]}], "entity_mentions": [{"id": "17260498_4_Ent0", "text": "a 72 - year - old man with hormone - refractory prostate cancer", "entity_type": "Entity", "start": 5, "end": 18}, {"id": "17260498_4_Ent1", "text": "72 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "17260498_4_Ent2", "text": "man", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17260498_4_Ent15", "text": "hormone - refractory prostate cancer", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "17260498_4_Ent8", "text": "weekly", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "17260498_4_Ent5", "text": "weekly administration of 30 mg / m2 docetaxel", "entity_type": "Entity", "start": 19, "end": 27}, {"id": "17260498_4_Ent9", "text": "administration", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "17260498_4_Ent10", "text": "30 mg / m2", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "17260498_4_Ent13", "text": "docetaxel", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "17260498_4_Ent3", "text": "subacute interstitial pneumonitis - related pulmonary fibrosis", "entity_type": "Entity", "start": 29, "end": 36}, {"id": "17260498_4_Ent6", "text": "seven doses", "entity_type": "Entity", "start": 37, "end": 39}, {"id": "17260498_4_Ent11", "text": "seven doses", "entity_type": "Entity", "start": 37, "end": 39}, {"id": "17260498_4_Ent4", "text": "and died", "entity_type": "Entity", "start": 39, "end": 41}, {"id": "17260498_4_Ent7", "text": "despite mechanical ventilation and high - dose corticosteroid treatment", "entity_type": "Entity", "start": 41, "end": 50}, {"id": "17260498_4_Ent12", "text": "high - dose", "entity_type": "Entity", "start": 45, "end": 48}, {"id": "17260498_4_Ent14", "text": "corticosteroid", "entity_type": "Entity", "start": 48, "end": 49}], "lang": "en"}
{"doc_id": "17266059_1", "wnd_id": "17266059_1_1", "text": "The patient presented with fulminant microangiopathic hemolytic anemia and thrombocytopenia within 48 hr of initiating therapy with trimethoprim - sulfamethoxazole .", "tokens": ["The", "patient", "presented", "with", "fulminant", "microangiopathic", "hemolytic", "anemia", "and", "thrombocytopenia", "within", "48", "hr", "of", "initiating", "therapy", "with", "trimethoprim", "-", "sulfamethoxazole", "."], "event_mentions": [{"id": "17266059_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 2, "end": 3}, "arguments": [{"entity_id": "17266059_1_Ent0", "role": "Subject", "text": "The patient", "start": 0, "end": 2}, {"entity_id": "17266059_1_Ent1", "role": "Effect", "text": "fulminant microangiopathic hemolytic anemia and thrombocytopenia", "start": 4, "end": 10}, {"entity_id": "17266059_1_Ent2", "role": "Treatment", "text": "within 48 hr of initiating therapy with trimethoprim - sulfamethoxazole", "start": 10, "end": 20}, {"entity_id": "17266059_1_Ent3", "role": "Treatment_Time_elapsed", "text": "48 hr", "start": 11, "end": 13}, {"entity_id": "17266059_1_Ent4", "role": "Treatment_Drug", "text": "trimethoprim", "start": 17, "end": 18}, {"entity_id": "17266059_1_Ent6", "role": "Combination_Drug", "text": "trimethoprim", "start": 17, "end": 18}, {"entity_id": "17266059_1_Ent5", "role": "Treatment_Drug", "text": "sulfamethoxazole", "start": 19, "end": 20}, {"entity_id": "17266059_1_Ent7", "role": "Combination_Drug", "text": "sulfamethoxazole", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "17266059_1_Ent0", "text": "The patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17266059_1_Ent1", "text": "fulminant microangiopathic hemolytic anemia and thrombocytopenia", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "17266059_1_Ent2", "text": "within 48 hr of initiating therapy with trimethoprim - sulfamethoxazole", "entity_type": "Entity", "start": 10, "end": 20}, {"id": "17266059_1_Ent3", "text": "48 hr", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "17266059_1_Ent4", "text": "trimethoprim", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "17266059_1_Ent6", "text": "trimethoprim", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "17266059_1_Ent5", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "17266059_1_Ent7", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "17275666_4", "wnd_id": "17275666_4_1", "text": "Similar to antiarrhythmic drugs aggravating particular arrhythmias , antiepileptic drugs can paradoxically induce new seizure types or exacerbate existing ones .", "tokens": ["Similar", "to", "antiarrhythmic", "drugs", "aggravating", "particular", "arrhythmias", ",", "antiepileptic", "drugs", "can", "paradoxically", "induce", "new", "seizure", "types", "or", "exacerbate", "existing", "ones", "."], "event_mentions": [{"id": "17275666_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 12, "end": 13}, "arguments": [{"entity_id": "17275666_4_Ent2", "role": "Treatment_Drug", "text": "antiarrhythmic drugs", "start": 2, "end": 4}, {"entity_id": "17275666_4_Ent1", "role": "Treatment", "text": "antiepileptic drugs", "start": 8, "end": 10}, {"entity_id": "17275666_4_Ent3", "role": "Treatment_Drug", "text": "antiepileptic drugs", "start": 8, "end": 10}, {"entity_id": "17275666_4_Ent0", "role": "Effect", "text": "new seizure types or exacerbate existing ones", "start": 13, "end": 20}]}], "entity_mentions": [{"id": "17275666_4_Ent2", "text": "antiarrhythmic drugs", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "17275666_4_Ent1", "text": "antiepileptic drugs", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "17275666_4_Ent3", "text": "antiepileptic drugs", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "17275666_4_Ent0", "text": "new seizure types or exacerbate existing ones", "entity_type": "Entity", "start": 13, "end": 20}], "lang": "en"}
{"doc_id": "17277758_1", "wnd_id": "17277758_1_1", "text": "Acute endophthalmitis following intravitreal bevacizumab ( Avastin ) injection .", "tokens": ["Acute", "endophthalmitis", "following", "intravitreal", "bevacizumab", "(", "Avastin", ")", "injection", "."], "event_mentions": [{"id": "17277758_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "17277758_1_Ent0", "role": "Effect", "text": "Acute endophthalmitis", "start": 0, "end": 2}, {"entity_id": "17277758_1_Ent2", "role": "Treatment_Route", "text": "intravitreal", "start": 3, "end": 4}, {"entity_id": "17277758_1_Ent1", "role": "Treatment", "text": "intravitreal bevacizumab ( Avastin ) injection", "start": 3, "end": 9}, {"entity_id": "17277758_1_Ent4", "role": "Treatment_Drug", "text": "bevacizumab", "start": 4, "end": 5}, {"entity_id": "17277758_1_Ent3", "role": "Treatment_Route", "text": "injection", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "17277758_1_Ent0", "text": "Acute endophthalmitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17277758_1_Ent2", "text": "intravitreal", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17277758_1_Ent1", "text": "intravitreal bevacizumab ( Avastin ) injection", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "17277758_1_Ent4", "text": "bevacizumab", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17277758_1_Ent3", "text": "injection", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "17277758_4", "wnd_id": "17277758_4_1", "text": "PURPOSE : To report two cases of acute endophthalmitis following intravitreal bevacizumab injection .", "tokens": ["PURPOSE", ":", "To", "report", "two", "cases", "of", "acute", "endophthalmitis", "following", "intravitreal", "bevacizumab", "injection", "."], "event_mentions": [{"id": "17277758_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 9, "end": 10}, "arguments": [{"entity_id": "17277758_4_Ent1", "role": "Subject_Population", "text": "two", "start": 4, "end": 5}, {"entity_id": "17277758_4_Ent0", "role": "Subject", "text": "two cases", "start": 4, "end": 6}, {"entity_id": "17277758_4_Ent2", "role": "Effect", "text": "acute endophthalmitis", "start": 7, "end": 9}, {"entity_id": "17277758_4_Ent4", "role": "Treatment_Route", "text": "intravitreal", "start": 10, "end": 11}, {"entity_id": "17277758_4_Ent3", "role": "Treatment", "text": "intravitreal bevacizumab injection", "start": 10, "end": 13}, {"entity_id": "17277758_4_Ent6", "role": "Treatment_Drug", "text": "bevacizumab", "start": 11, "end": 12}, {"entity_id": "17277758_4_Ent5", "role": "Treatment_Route", "text": "injection", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "17277758_4_Ent1", "text": "two", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17277758_4_Ent0", "text": "two cases", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "17277758_4_Ent2", "text": "acute endophthalmitis", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "17277758_4_Ent4", "text": "intravitreal", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17277758_4_Ent3", "text": "intravitreal bevacizumab injection", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "17277758_4_Ent6", "text": "bevacizumab", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17277758_4_Ent5", "text": "injection", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "17285101_1", "wnd_id": "17285101_1_1", "text": "Pulmonary hypertension during lithium therapy : clinical case study .", "tokens": ["Pulmonary", "hypertension", "during", "lithium", "therapy", ":", "clinical", "case", "study", "."], "event_mentions": [{"id": "17285101_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 2, "end": 3}, "arguments": [{"entity_id": "17285101_1_Ent0", "role": "Effect", "text": "Pulmonary hypertension", "start": 0, "end": 2}, {"entity_id": "17285101_1_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 3, "end": 4}, {"entity_id": "17285101_1_Ent1", "role": "Treatment", "text": "lithium therapy", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "17285101_1_Ent0", "text": "Pulmonary hypertension", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17285101_1_Ent2", "text": "lithium", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17285101_1_Ent1", "text": "lithium therapy", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "17319250_1", "wnd_id": "17319250_1_1", "text": "Of particular interest in this patient is the fluctuation of the QT interval at a stable dose of methadone , suggesting that a single normal electrocardiogram ( ECG ) does not guarantee that the patient is not at risk of ventricular arrhythmias .", "tokens": ["Of", "particular", "interest", "in", "this", "patient", "is", "the", "fluctuation", "of", "the", "QT", "interval", "at", "a", "stable", "dose", "of", "methadone", ",", "suggesting", "that", "a", "single", "normal", "electrocardiogram", "(", "ECG", ")", "does", "not", "guarantee", "that", "the", "patient", "is", "not", "at", "risk", "of", "ventricular", "arrhythmias", "."], "event_mentions": [{"id": "17319250_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "at", "start": 13, "end": 14}, "arguments": [{"entity_id": "17319250_1_Ent0", "role": "Subject", "text": "this patient", "start": 4, "end": 6}, {"entity_id": "17319250_1_Ent1", "role": "Effect", "text": "fluctuation of the QT interval", "start": 8, "end": 13}, {"entity_id": "17319250_1_Ent4", "role": "Treatment_Dosage", "text": "a stable dose", "start": 14, "end": 17}, {"entity_id": "17319250_1_Ent2", "role": "Treatment", "text": "a stable dose of methadone", "start": 14, "end": 19}, {"entity_id": "17319250_1_Ent3", "role": "Treatment_Drug", "text": "methadone", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "17319250_1_Ent0", "text": "this patient", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "17319250_1_Ent1", "text": "fluctuation of the QT interval", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "17319250_1_Ent4", "text": "a stable dose", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "17319250_1_Ent2", "text": "a stable dose of methadone", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "17319250_1_Ent3", "text": "methadone", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "17319250_2", "wnd_id": "17319250_2_1", "text": "We present a case report of a patient who developed a prolonged QT while being treated with oral methadone for a chronic pain syndrome .", "tokens": ["We", "present", "a", "case", "report", "of", "a", "patient", "who", "developed", "a", "prolonged", "QT", "while", "being", "treated", "with", "oral", "methadone", "for", "a", "chronic", "pain", "syndrome", "."], "event_mentions": [{"id": "17319250_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 15, "end": 16}, "arguments": [{"entity_id": "17319250_2_Ent0", "role": "Subject", "text": "a patient", "start": 6, "end": 8}, {"entity_id": "17319250_2_Ent1", "role": "Effect", "text": "prolonged QT", "start": 11, "end": 13}, {"entity_id": "17319250_2_Ent4", "role": "Treatment_Route", "text": "oral", "start": 17, "end": 18}, {"entity_id": "17319250_2_Ent2", "role": "Treatment", "text": "oral methadone", "start": 17, "end": 19}, {"entity_id": "17319250_2_Ent3", "role": "Treatment_Drug", "text": "methadone", "start": 18, "end": 19}, {"entity_id": "17319250_2_Ent5", "role": "Treatment_Disorder", "text": "chronic pain syndrome", "start": 21, "end": 24}]}], "entity_mentions": [{"id": "17319250_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17319250_2_Ent1", "text": "prolonged QT", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "17319250_2_Ent4", "text": "oral", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "17319250_2_Ent2", "text": "oral methadone", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "17319250_2_Ent3", "text": "methadone", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17319250_2_Ent5", "text": "chronic pain syndrome", "entity_type": "Entity", "start": 21, "end": 24}], "lang": "en"}
{"doc_id": "17324248_1", "wnd_id": "17324248_1_1", "text": "AIMS : To present a case of piloerection after replacing fluvoxamine maleate with milnacipran hydrochloride , and to analyse this effect based on receptor occupancy theory .", "tokens": ["AIMS", ":", "To", "present", "a", "case", "of", "piloerection", "after", "replacing", "fluvoxamine", "maleate", "with", "milnacipran", "hydrochloride", ",", "and", "to", "analyse", "this", "effect", "based", "on", "receptor", "occupancy", "theory", "."], "event_mentions": [{"id": "17324248_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 8, "end": 9}, "arguments": [{"entity_id": "17324248_1_Ent0", "role": "Effect", "text": "piloerection", "start": 7, "end": 8}, {"entity_id": "17324248_1_Ent1", "role": "Treatment", "text": "fluvoxamine maleate", "start": 10, "end": 12}, {"entity_id": "17324248_1_Ent2", "role": "Treatment_Drug", "text": "fluvoxamine maleate", "start": 10, "end": 12}, {"entity_id": "17324248_1_Ent3", "role": "Treatment_Drug", "text": "milnacipran hydrochloride", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "17324248_1_Ent0", "text": "piloerection", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17324248_1_Ent1", "text": "fluvoxamine maleate", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "17324248_1_Ent2", "text": "fluvoxamine maleate", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "17324248_1_Ent3", "text": "milnacipran hydrochloride", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "17324248_2", "wnd_id": "17324248_2_1", "text": "CONCLUSIONS : The piloerection observed after the replacement of fluvoxamine with milnacipran in this patient appears to have been due to an increase in the alpha(1) - adrenoceptor occupancy by endogenous norepinephrine induced by milnacipran .", "tokens": ["CONCLUSIONS", ":", "The", "piloerection", "observed", "after", "the", "replacement", "of", "fluvoxamine", "with", "milnacipran", "in", "this", "patient", "appears", "to", "have", "been", "due", "to", "an", "increase", "in", "the", "alpha(1)", "-", "adrenoceptor", "occupancy", "by", "endogenous", "norepinephrine", "induced", "by", "milnacipran", "."], "event_mentions": [{"id": "17324248_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "observed", "start": 4, "end": 5}, "arguments": [{"entity_id": "17324248_2_Ent4", "role": "Effect", "text": "piloerection", "start": 3, "end": 4}, {"entity_id": "17324248_2_Ent5", "role": "Treatment", "text": "milnacipran", "start": 11, "end": 12}, {"entity_id": "17324248_2_Ent6", "role": "Treatment_Drug", "text": "milnacipran", "start": 11, "end": 12}, {"entity_id": "17324248_2_Ent3", "role": "Subject", "text": "this patient", "start": 13, "end": 15}]}, {"id": "17324248_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 32, "end": 33}, "arguments": [{"entity_id": "17324248_2_Ent0", "role": "Effect", "text": "an increase in the alpha(1) - adrenoceptor occupancy by endogenous norepinephrine", "start": 21, "end": 32}, {"entity_id": "17324248_2_Ent1", "role": "Treatment", "text": "milnacipran", "start": 34, "end": 35}, {"entity_id": "17324248_2_Ent2", "role": "Treatment_Drug", "text": "milnacipran", "start": 34, "end": 35}]}], "entity_mentions": [{"id": "17324248_2_Ent4", "text": "piloerection", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17324248_2_Ent5", "text": "milnacipran", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17324248_2_Ent6", "text": "milnacipran", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17324248_2_Ent3", "text": "this patient", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "17324248_2_Ent0", "text": "an increase in the alpha(1) - adrenoceptor occupancy by endogenous norepinephrine", "entity_type": "Entity", "start": 21, "end": 32}, {"id": "17324248_2_Ent1", "text": "milnacipran", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "17324248_2_Ent2", "text": "milnacipran", "entity_type": "Entity", "start": 34, "end": 35}], "lang": "en"}
{"doc_id": "17331261_3", "wnd_id": "17331261_3_1", "text": "Inhaled tobramycin solution - associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis : a case report .", "tokens": ["Inhaled", "tobramycin", "solution", "-", "associated", "recurrent", "eosinophilia", "and", "severe", "persistent", "bronchospasm", "in", "a", "patient", "with", "cystic", "fibrosis", ":", "a", "case", "report", "."], "event_mentions": [{"id": "17331261_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "17331261_3_Ent5", "role": "Treatment_Route", "text": "Inhaled", "start": 0, "end": 1}, {"entity_id": "17331261_3_Ent2", "role": "Treatment", "text": "Inhaled tobramycin", "start": 0, "end": 2}, {"entity_id": "17331261_3_Ent4", "role": "Treatment_Drug", "text": "tobramycin", "start": 1, "end": 2}, {"entity_id": "17331261_3_Ent1", "role": "Effect", "text": "recurrent eosinophilia and severe persistent bronchospasm", "start": 5, "end": 11}, {"entity_id": "17331261_3_Ent0", "role": "Subject", "text": "a patient with cystic fibrosis", "start": 12, "end": 17}, {"entity_id": "17331261_3_Ent3", "role": "Treatment_Disorder", "text": "cystic fibrosis", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "17331261_3_Ent5", "text": "Inhaled", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17331261_3_Ent2", "text": "Inhaled tobramycin", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17331261_3_Ent4", "text": "tobramycin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "17331261_3_Ent1", "text": "recurrent eosinophilia and severe persistent bronchospasm", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "17331261_3_Ent0", "text": "a patient with cystic fibrosis", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "17331261_3_Ent3", "text": "cystic fibrosis", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "17364199_1", "wnd_id": "17364199_1_1", "text": "Tuberculous uveitis after treatment with etanercept .", "tokens": ["Tuberculous", "uveitis", "after", "treatment", "with", "etanercept", "."], "event_mentions": [{"id": "17364199_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "17364199_1_Ent0", "role": "Effect", "text": "Tuberculous uveitis", "start": 0, "end": 2}, {"entity_id": "17364199_1_Ent1", "role": "Treatment", "text": "etanercept", "start": 5, "end": 6}, {"entity_id": "17364199_1_Ent2", "role": "Treatment_Drug", "text": "etanercept", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "17364199_1_Ent0", "text": "Tuberculous uveitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17364199_1_Ent1", "text": "etanercept", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17364199_1_Ent2", "text": "etanercept", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "17364199_4", "wnd_id": "17364199_4_1", "text": "We report the first case of tuberculous uveitis due to etanercept .", "tokens": ["We", "report", "the", "first", "case", "of", "tuberculous", "uveitis", "due", "to", "etanercept", "."], "event_mentions": [{"id": "17364199_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 8, "end": 10}, "arguments": [{"entity_id": "17364199_4_Ent0", "role": "Effect", "text": "tuberculous uveitis", "start": 6, "end": 8}, {"entity_id": "17364199_4_Ent1", "role": "Treatment", "text": "etanercept", "start": 10, "end": 11}, {"entity_id": "17364199_4_Ent2", "role": "Treatment_Drug", "text": "etanercept", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "17364199_4_Ent0", "text": "tuberculous uveitis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17364199_4_Ent1", "text": "etanercept", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17364199_4_Ent2", "text": "etanercept", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "17381671_2", "wnd_id": "17381671_2_1", "text": "To report a case of serotonin syndrome associated with interaction between fentanyl and citalopram , as evidenced by medication history , clinical features and reversal following discontinuation of fentanyl .", "tokens": ["To", "report", "a", "case", "of", "serotonin", "syndrome", "associated", "with", "interaction", "between", "fentanyl", "and", "citalopram", ",", "as", "evidenced", "by", "medication", "history", ",", "clinical", "features", "and", "reversal", "following", "discontinuation", "of", "fentanyl", "."], "event_mentions": [{"id": "17381671_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "17381671_2_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "17381671_2_Ent1", "role": "Effect", "text": "serotonin syndrome", "start": 5, "end": 7}, {"entity_id": "17381671_2_Ent2", "role": "Treatment", "text": "interaction between fentanyl and citalopram", "start": 9, "end": 14}, {"entity_id": "17381671_2_Ent3", "role": "Treatment_Drug", "text": "fentanyl", "start": 11, "end": 12}, {"entity_id": "17381671_2_Ent5", "role": "Combination_Drug", "text": "fentanyl", "start": 11, "end": 12}, {"entity_id": "17381671_2_Ent4", "role": "Treatment_Drug", "text": "citalopram", "start": 13, "end": 14}, {"entity_id": "17381671_2_Ent6", "role": "Combination_Drug", "text": "citalopram", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "17381671_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "17381671_2_Ent1", "text": "serotonin syndrome", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "17381671_2_Ent2", "text": "interaction between fentanyl and citalopram", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "17381671_2_Ent3", "text": "fentanyl", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17381671_2_Ent5", "text": "fentanyl", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17381671_2_Ent4", "text": "citalopram", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17381671_2_Ent6", "text": "citalopram", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "17381671_3", "wnd_id": "17381671_3_1", "text": "A 65 - year - old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion , agitation , tachycardia , tremors , myoclonic jerks and unsteady gait , consistent with serotonin syndrome , following initiation of fentanyl , and all symptoms and signs resolved following discontinuation of fentanyl .", "tokens": ["A", "65", "-", "year", "-", "old", "patient", "chronically", "treated", "with", "the", "selective", "serotonin", "reuptake", "inhibitor", "(", "SSRI", ")", "citalopram", "developed", "confusion", ",", "agitation", ",", "tachycardia", ",", "tremors", ",", "myoclonic", "jerks", "and", "unsteady", "gait", ",", "consistent", "with", "serotonin", "syndrome", ",", "following", "initiation", "of", "fentanyl", ",", "and", "all", "symptoms", "and", "signs", "resolved", "following", "discontinuation", "of", "fentanyl", "."], "event_mentions": [{"id": "17381671_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 19, "end": 20}, "arguments": [{"entity_id": "17381671_3_Ent0", "role": "Subject", "text": "A 65 - year - old patient", "start": 0, "end": 7}, {"entity_id": "17381671_3_Ent1", "role": "Subject_Age", "text": "65 - year - old", "start": 1, "end": 6}, {"entity_id": "17381671_3_Ent7", "role": "Treatment_Time_elapsed", "text": "chronically", "start": 7, "end": 8}, {"entity_id": "17381671_3_Ent3", "role": "Treatment", "text": "chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram", "start": 7, "end": 19}, {"entity_id": "17381671_3_Ent5", "role": "Treatment_Drug", "text": "citalopram", "start": 18, "end": 19}, {"entity_id": "17381671_3_Ent8", "role": "Combination_Drug", "text": "citalopram", "start": 18, "end": 19}, {"entity_id": "17381671_3_Ent2", "role": "Effect", "text": "confusion , agitation , tachycardia , tremors , myoclonic jerks and unsteady gait , consistent with serotonin syndrome", "start": 20, "end": 38}, {"entity_id": "17381671_3_Ent4", "role": "Treatment", "text": "following initiation of fentanyl", "start": 39, "end": 43}, {"entity_id": "17381671_3_Ent6", "role": "Treatment_Drug", "text": "fentanyl", "start": 42, "end": 43}, {"entity_id": "17381671_3_Ent9", "role": "Combination_Drug", "text": "fentanyl", "start": 42, "end": 43}]}], "entity_mentions": [{"id": "17381671_3_Ent0", "text": "A 65 - year - old patient", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "17381671_3_Ent1", "text": "65 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "17381671_3_Ent7", "text": "chronically", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17381671_3_Ent3", "text": "chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram", "entity_type": "Entity", "start": 7, "end": 19}, {"id": "17381671_3_Ent5", "text": "citalopram", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17381671_3_Ent8", "text": "citalopram", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17381671_3_Ent2", "text": "confusion , agitation , tachycardia , tremors , myoclonic jerks and unsteady gait , consistent with serotonin syndrome", "entity_type": "Entity", "start": 20, "end": 38}, {"id": "17381671_3_Ent4", "text": "following initiation of fentanyl", "entity_type": "Entity", "start": 39, "end": 43}, {"id": "17381671_3_Ent6", "text": "fentanyl", "entity_type": "Entity", "start": 42, "end": 43}, {"id": "17381671_3_Ent9", "text": "fentanyl", "entity_type": "Entity", "start": 42, "end": 43}], "lang": "en"}
{"doc_id": "17381671_7", "wnd_id": "17381671_7_1", "text": "SSRIs and fentanyl are commonly co - administered , especially in the setting of chronic or malignant pain , as underlying depression may contribute to the pathogenesis of pain .", "tokens": ["SSRIs", "and", "fentanyl", "are", "commonly", "co", "-", "administered", ",", "especially", "in", "the", "setting", "of", "chronic", "or", "malignant", "pain", ",", "as", "underlying", "depression", "may", "contribute", "to", "the", "pathogenesis", "of", "pain", "."], "event_mentions": [{"id": "17381671_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "in", "start": 10, "end": 11}, "arguments": [{"entity_id": "17381671_7_Ent3", "role": "Treatment_Drug", "text": "SSRIs", "start": 0, "end": 1}, {"entity_id": "17381671_7_Ent5", "role": "Combination_Drug", "text": "SSRIs", "start": 0, "end": 1}, {"entity_id": "17381671_7_Ent0", "role": "Treatment", "text": "SSRIs and fentanyl are commonly co - administered", "start": 0, "end": 8}, {"entity_id": "17381671_7_Ent4", "role": "Treatment_Drug", "text": "fentanyl", "start": 2, "end": 3}, {"entity_id": "17381671_7_Ent6", "role": "Combination_Drug", "text": "fentanyl", "start": 2, "end": 3}, {"entity_id": "17381671_7_Ent1", "role": "Treatment_Disorder", "text": "chronic or malignant pain", "start": 14, "end": 18}, {"entity_id": "17381671_7_Ent2", "role": "Treatment_Disorder", "text": "underlying depression", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "17381671_7_Ent3", "text": "SSRIs", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17381671_7_Ent5", "text": "SSRIs", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17381671_7_Ent0", "text": "SSRIs and fentanyl are commonly co - administered", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "17381671_7_Ent4", "text": "fentanyl", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17381671_7_Ent6", "text": "fentanyl", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17381671_7_Ent1", "text": "chronic or malignant pain", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "17381671_7_Ent2", "text": "underlying depression", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "17381671_8", "wnd_id": "17381671_8_1", "text": "Healthcare professionals should be aware of the possible development of serotonin syndrome as a complication of initiation of fentanyl and other phenylpiperidine opioids in patients treated with SSRIs .", "tokens": ["Healthcare", "professionals", "should", "be", "aware", "of", "the", "possible", "development", "of", "serotonin", "syndrome", "as", "a", "complication", "of", "initiation", "of", "fentanyl", "and", "other", "phenylpiperidine", "opioids", "in", "patients", "treated", "with", "SSRIs", "."], "event_mentions": [{"id": "17381671_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 8, "end": 9}, "arguments": [{"entity_id": "17381671_8_Ent1", "role": "Effect", "text": "serotonin syndrome", "start": 10, "end": 12}, {"entity_id": "17381671_8_Ent4", "role": "Treatment_Drug", "text": "fentanyl", "start": 18, "end": 19}, {"entity_id": "17381671_8_Ent8", "role": "Combination_Drug", "text": "fentanyl", "start": 18, "end": 19}, {"entity_id": "17381671_8_Ent2", "role": "Treatment", "text": "fentanyl and other phenylpiperidine opioids", "start": 18, "end": 23}, {"entity_id": "17381671_8_Ent5", "role": "Treatment_Drug", "text": "phenylpiperidine opioids", "start": 21, "end": 23}, {"entity_id": "17381671_8_Ent7", "role": "Combination_Drug", "text": "phenylpiperidine opioids", "start": 21, "end": 23}, {"entity_id": "17381671_8_Ent0", "role": "Subject", "text": "patients", "start": 24, "end": 25}, {"entity_id": "17381671_8_Ent3", "role": "Treatment", "text": "treated with SSRIs", "start": 25, "end": 28}, {"entity_id": "17381671_8_Ent6", "role": "Treatment_Drug", "text": "SSRIs", "start": 27, "end": 28}, {"entity_id": "17381671_8_Ent9", "role": "Combination_Drug", "text": "SSRIs", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "17381671_8_Ent1", "text": "serotonin syndrome", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "17381671_8_Ent4", "text": "fentanyl", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17381671_8_Ent8", "text": "fentanyl", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17381671_8_Ent2", "text": "fentanyl and other phenylpiperidine opioids", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "17381671_8_Ent5", "text": "phenylpiperidine opioids", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "17381671_8_Ent7", "text": "phenylpiperidine opioids", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "17381671_8_Ent0", "text": "patients", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "17381671_8_Ent3", "text": "treated with SSRIs", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "17381671_8_Ent6", "text": "SSRIs", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "17381671_8_Ent9", "text": "SSRIs", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "17383767_2", "wnd_id": "17383767_2_1", "text": "Brain metastases are a frequent finding in patients with advanced non - small cell lung cancer and concomitant administration of antiepileptic and chemotherapeutic drugs or epidermal growth factor receptor ( EGFR ) inhibitor is necessary in many cases .", "tokens": ["Brain", "metastases", "are", "a", "frequent", "finding", "in", "patients", "with", "advanced", "non", "-", "small", "cell", "lung", "cancer", "and", "concomitant", "administration", "of", "antiepileptic", "and", "chemotherapeutic", "drugs", "or", "epidermal", "growth", "factor", "receptor", "(", "EGFR", ")", "inhibitor", "is", "necessary", "in", "many", "cases", "."], "event_mentions": [{"id": "17383767_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "necessary", "start": 34, "end": 35}, "arguments": [{"entity_id": "17383767_2_Ent6", "role": "Treatment_Disorder", "text": "Brain metastases", "start": 0, "end": 2}, {"entity_id": "17383767_2_Ent0", "role": "Subject", "text": "patients with advanced non - small cell lung cancer", "start": 7, "end": 16}, {"entity_id": "17383767_2_Ent1", "role": "Subject_Disorder", "text": "advanced non - small cell lung cancer", "start": 9, "end": 16}, {"entity_id": "17383767_2_Ent2", "role": "Treatment", "text": "concomitant administration of antiepileptic and chemotherapeutic drugs or epidermal growth factor receptor ( EGFR ) inhibitor", "start": 17, "end": 33}, {"entity_id": "17383767_2_Ent3", "role": "Treatment_Drug", "text": "antiepileptic", "start": 20, "end": 21}, {"entity_id": "17383767_2_Ent7", "role": "Combination_Drug", "text": "antiepileptic", "start": 20, "end": 21}, {"entity_id": "17383767_2_Ent4", "role": "Treatment_Drug", "text": "chemotherapeutic", "start": 22, "end": 23}, {"entity_id": "17383767_2_Ent8", "role": "Combination_Drug", "text": "chemotherapeutic", "start": 22, "end": 23}, {"entity_id": "17383767_2_Ent5", "role": "Treatment_Drug", "text": "epidermal growth factor receptor ( EGFR ) inhibitor", "start": 25, "end": 33}]}], "entity_mentions": [{"id": "17383767_2_Ent6", "text": "Brain metastases", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17383767_2_Ent0", "text": "patients with advanced non - small cell lung cancer", "entity_type": "Entity", "start": 7, "end": 16}, {"id": "17383767_2_Ent1", "text": "advanced non - small cell lung cancer", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "17383767_2_Ent2", "text": "concomitant administration of antiepileptic and chemotherapeutic drugs or epidermal growth factor receptor ( EGFR ) inhibitor", "entity_type": "Entity", "start": 17, "end": 33}, {"id": "17383767_2_Ent3", "text": "antiepileptic", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "17383767_2_Ent7", "text": "antiepileptic", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "17383767_2_Ent4", "text": "chemotherapeutic", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "17383767_2_Ent8", "text": "chemotherapeutic", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "17383767_2_Ent5", "text": "epidermal growth factor receptor ( EGFR ) inhibitor", "entity_type": "Entity", "start": 25, "end": 33}], "lang": "en"}
{"doc_id": "17387702_1", "wnd_id": "17387702_1_1", "text": "Renal failure after high - dose methotrexate in a child homozygous for MTHFR C677 T polymorphism .", "tokens": ["Renal", "failure", "after", "high", "-", "dose", "methotrexate", "in", "a", "child", "homozygous", "for", "MTHFR", "C677", "T", "polymorphism", "."], "event_mentions": [{"id": "17387702_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "17387702_1_Ent3", "role": "Effect", "text": "Renal failure", "start": 0, "end": 2}, {"entity_id": "17387702_1_Ent5", "role": "Treatment_Dosage", "text": "high - dose", "start": 3, "end": 6}, {"entity_id": "17387702_1_Ent4", "role": "Treatment", "text": "high - dose methotrexate", "start": 3, "end": 7}, {"entity_id": "17387702_1_Ent6", "role": "Treatment_Drug", "text": "methotrexate", "start": 6, "end": 7}, {"entity_id": "17387702_1_Ent0", "role": "Subject", "text": "a child homozygous for MTHFR C677 T polymorphism", "start": 8, "end": 16}, {"entity_id": "17387702_1_Ent1", "role": "Subject_Age", "text": "child", "start": 9, "end": 10}, {"entity_id": "17387702_1_Ent2", "role": "Subject_Disorder", "text": "homozygous for MTHFR C677 T polymorphism", "start": 10, "end": 16}]}], "entity_mentions": [{"id": "17387702_1_Ent3", "text": "Renal failure", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17387702_1_Ent5", "text": "high - dose", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "17387702_1_Ent4", "text": "high - dose methotrexate", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "17387702_1_Ent6", "text": "methotrexate", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17387702_1_Ent0", "text": "a child homozygous for MTHFR C677 T polymorphism", "entity_type": "Entity", "start": 8, "end": 16}, {"id": "17387702_1_Ent1", "text": "child", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17387702_1_Ent2", "text": "homozygous for MTHFR C677 T polymorphism", "entity_type": "Entity", "start": 10, "end": 16}], "lang": "en"}
{"doc_id": "17420198_2", "wnd_id": "17420198_2_1", "text": "A case of extrapyramidal symptoms ( EPS ) following administration of aripiprazole to a man with developmental disabilities who had never received antipsychotic medications and had no history of movement disorders is presented .", "tokens": ["A", "case", "of", "extrapyramidal", "symptoms", "(", "EPS", ")", "following", "administration", "of", "aripiprazole", "to", "a", "man", "with", "developmental", "disabilities", "who", "had", "never", "received", "antipsychotic", "medications", "and", "had", "no", "history", "of", "movement", "disorders", "is", "presented", "."], "event_mentions": [{"id": "17420198_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 8, "end": 9}, "arguments": [{"entity_id": "17420198_2_Ent3", "role": "Effect", "text": "extrapyramidal symptoms ( EPS )", "start": 3, "end": 8}, {"entity_id": "17420198_2_Ent4", "role": "Treatment", "text": "aripiprazole", "start": 11, "end": 12}, {"entity_id": "17420198_2_Ent5", "role": "Treatment_Drug", "text": "aripiprazole", "start": 11, "end": 12}, {"entity_id": "17420198_2_Ent0", "role": "Subject", "text": "a man with developmental disabilities who had never received antipsychotic medications and had no history of movement disorders is presented", "start": 13, "end": 33}, {"entity_id": "17420198_2_Ent1", "role": "Subject_Gender", "text": "man", "start": 14, "end": 15}, {"entity_id": "17420198_2_Ent2", "role": "Subject_Disorder", "text": "developmental disabilities", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "17420198_2_Ent3", "text": "extrapyramidal symptoms ( EPS )", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "17420198_2_Ent4", "text": "aripiprazole", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17420198_2_Ent5", "text": "aripiprazole", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17420198_2_Ent0", "text": "a man with developmental disabilities who had never received antipsychotic medications and had no history of movement disorders is presented", "entity_type": "Entity", "start": 13, "end": 33}, {"id": "17420198_2_Ent1", "text": "man", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17420198_2_Ent2", "text": "developmental disabilities", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "17420198_5", "wnd_id": "17420198_5_1", "text": "He developed episodic movements possibly consistent with EPS secondary to aripiprazole usage .", "tokens": ["He", "developed", "episodic", "movements", "possibly", "consistent", "with", "EPS", "secondary", "to", "aripiprazole", "usage", "."], "event_mentions": [{"id": "17420198_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 1, "end": 2}, "arguments": [{"entity_id": "17420198_5_Ent0", "role": "Effect", "text": "episodic movements possibly consistent with EPS", "start": 2, "end": 8}, {"entity_id": "17420198_5_Ent1", "role": "Treatment", "text": "secondary to aripiprazole usage", "start": 8, "end": 12}, {"entity_id": "17420198_5_Ent2", "role": "Treatment_Drug", "text": "aripiprazole", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "17420198_5_Ent0", "text": "episodic movements possibly consistent with EPS", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "17420198_5_Ent1", "text": "secondary to aripiprazole usage", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "17420198_5_Ent2", "text": "aripiprazole", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "17438184_3", "wnd_id": "17438184_3_1", "text": "OBSERVATIONS : A 48 - year - old woman presented with disfiguring facial edema 10 weeks after she began antiviral therapy with peginterferon alfa - 2a and ribavirin for chronic hepatitis C infection .", "tokens": ["OBSERVATIONS", ":", "A", "48", "-", "year", "-", "old", "woman", "presented", "with", "disfiguring", "facial", "edema", "10", "weeks", "after", "she", "began", "antiviral", "therapy", "with", "peginterferon", "alfa", "-", "2a", "and", "ribavirin", "for", "chronic", "hepatitis", "C", "infection", "."], "event_mentions": [{"id": "17438184_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 16, "end": 17}, "arguments": [{"entity_id": "17438184_3_Ent0", "role": "Subject", "text": "A 48 - year - old woman", "start": 2, "end": 9}, {"entity_id": "17438184_3_Ent1", "role": "Subject_Age", "text": "48 - year - old", "start": 3, "end": 8}, {"entity_id": "17438184_3_Ent2", "role": "Subject_Gender", "text": "woman", "start": 8, "end": 9}, {"entity_id": "17438184_3_Ent3", "role": "Effect", "text": "disfiguring facial edema", "start": 11, "end": 14}, {"entity_id": "17438184_3_Ent4", "role": "Treatment", "text": "10 weeks", "start": 14, "end": 16}, {"entity_id": "17438184_3_Ent7", "role": "Treatment_Time_elapsed", "text": "10 weeks", "start": 14, "end": 16}, {"entity_id": "17438184_3_Ent5", "role": "Treatment", "text": "antiviral therapy with peginterferon alfa - 2a and ribavirin", "start": 19, "end": 28}, {"entity_id": "17438184_3_Ent8", "role": "Treatment_Drug", "text": "peginterferon alfa - 2a", "start": 22, "end": 26}, {"entity_id": "17438184_3_Ent10", "role": "Combination_Drug", "text": "peginterferon alfa - 2a", "start": 22, "end": 26}, {"entity_id": "17438184_3_Ent9", "role": "Treatment_Drug", "text": "ribavirin", "start": 27, "end": 28}, {"entity_id": "17438184_3_Ent11", "role": "Combination_Drug", "text": "ribavirin", "start": 27, "end": 28}, {"entity_id": "17438184_3_Ent6", "role": "Treatment_Disorder", "text": "chronic hepatitis C infection", "start": 29, "end": 33}]}], "entity_mentions": [{"id": "17438184_3_Ent0", "text": "A 48 - year - old woman", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "17438184_3_Ent1", "text": "48 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "17438184_3_Ent2", "text": "woman", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17438184_3_Ent3", "text": "disfiguring facial edema", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "17438184_3_Ent4", "text": "10 weeks", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "17438184_3_Ent7", "text": "10 weeks", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "17438184_3_Ent5", "text": "antiviral therapy with peginterferon alfa - 2a and ribavirin", "entity_type": "Entity", "start": 19, "end": 28}, {"id": "17438184_3_Ent8", "text": "peginterferon alfa - 2a", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "17438184_3_Ent10", "text": "peginterferon alfa - 2a", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "17438184_3_Ent9", "text": "ribavirin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "17438184_3_Ent11", "text": "ribavirin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "17438184_3_Ent6", "text": "chronic hepatitis C infection", "entity_type": "Entity", "start": 29, "end": 33}], "lang": "en"}
{"doc_id": "17444802_2", "wnd_id": "17444802_2_1", "text": "AIMS : The aim of this study was to report on the effectiveness and tumor side effects of topical interferon ( INF ) alpha 2 - beta in a case of conjunctiva - cornea intraepithelial neoplasia ( CIN ) of a patient that rejected any surgical procedure .", "tokens": ["AIMS", ":", "The", "aim", "of", "this", "study", "was", "to", "report", "on", "the", "effectiveness", "and", "tumor", "side", "effects", "of", "topical", "interferon", "(", "INF", ")", "alpha", "2", "-", "beta", "in", "a", "case", "of", "conjunctiva", "-", "cornea", "intraepithelial", "neoplasia", "(", "CIN", ")", "of", "a", "patient", "that", "rejected", "any", "surgical", "procedure", "."], "event_mentions": [{"id": "17444802_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effects", "start": 15, "end": 17}, "arguments": [{"entity_id": "17444802_2_Ent1", "role": "Effect", "text": "tumor side effects", "start": 14, "end": 17}, {"entity_id": "17444802_2_Ent3", "role": "Treatment_Route", "text": "topical", "start": 18, "end": 19}, {"entity_id": "17444802_2_Ent2", "role": "Treatment", "text": "topical interferon ( INF ) alpha 2 - beta", "start": 18, "end": 27}, {"entity_id": "17444802_2_Ent4", "role": "Treatment_Drug", "text": "interferon", "start": 19, "end": 20}, {"entity_id": "17444802_2_Ent5", "role": "Treatment_Drug", "text": "alpha 2 - beta", "start": 23, "end": 27}, {"entity_id": "17444802_2_Ent6", "role": "Treatment_Disorder", "text": "conjunctiva - cornea intraepithelial neoplasia", "start": 31, "end": 36}, {"entity_id": "17444802_2_Ent0", "role": "Subject", "text": "conjunctiva - cornea intraepithelial neoplasia ( CIN ) of a patient that rejected any surgical procedure", "start": 31, "end": 47}]}], "entity_mentions": [{"id": "17444802_2_Ent1", "text": "tumor side effects", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "17444802_2_Ent3", "text": "topical", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17444802_2_Ent2", "text": "topical interferon ( INF ) alpha 2 - beta", "entity_type": "Entity", "start": 18, "end": 27}, {"id": "17444802_2_Ent4", "text": "interferon", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "17444802_2_Ent5", "text": "alpha 2 - beta", "entity_type": "Entity", "start": 23, "end": 27}, {"id": "17444802_2_Ent6", "text": "conjunctiva - cornea intraepithelial neoplasia", "entity_type": "Entity", "start": 31, "end": 36}, {"id": "17444802_2_Ent0", "text": "conjunctiva - cornea intraepithelial neoplasia ( CIN ) of a patient that rejected any surgical procedure", "entity_type": "Entity", "start": 31, "end": 47}], "lang": "en"}
{"doc_id": "17448102_1", "wnd_id": "17448102_1_1", "text": "Managing cardiovascular collapse in severe flecainide overdose without recourse to extracorporeal therapy .", "tokens": ["Managing", "cardiovascular", "collapse", "in", "severe", "flecainide", "overdose", "without", "recourse", "to", "extracorporeal", "therapy", "."], "event_mentions": [{"id": "17448102_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 3, "end": 4}, "arguments": [{"entity_id": "17448102_1_Ent0", "role": "Effect", "text": "cardiovascular collapse", "start": 1, "end": 3}, {"entity_id": "17448102_1_Ent1", "role": "Treatment", "text": "severe flecainide overdose", "start": 4, "end": 7}, {"entity_id": "17448102_1_Ent2", "role": "Treatment_Drug", "text": "flecainide", "start": 5, "end": 6}, {"entity_id": "17448102_1_Ent3", "role": "Treatment_Dosage", "text": "overdose", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "17448102_1_Ent0", "text": "cardiovascular collapse", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "17448102_1_Ent1", "text": "severe flecainide overdose", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "17448102_1_Ent2", "text": "flecainide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17448102_1_Ent3", "text": "overdose", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "17473493_2", "wnd_id": "17473493_2_1", "text": "This is the first histologically confirmed case of NASH that was aggravated by raloxifene .", "tokens": ["This", "is", "the", "first", "histologically", "confirmed", "case", "of", "NASH", "that", "was", "aggravated", "by", "raloxifene", "."], "event_mentions": [{"id": "17473493_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "aggravated", "start": 11, "end": 12}, "arguments": [{"entity_id": "17473493_2_Ent0", "role": "Subject", "text": "the first histologically confirmed case", "start": 2, "end": 7}, {"entity_id": "17473493_2_Ent1", "role": "Effect", "text": "NASH", "start": 8, "end": 9}, {"entity_id": "17473493_2_Ent2", "role": "Treatment", "text": "raloxifene", "start": 13, "end": 14}, {"entity_id": "17473493_2_Ent3", "role": "Treatment_Drug", "text": "raloxifene", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "17473493_2_Ent0", "text": "the first histologically confirmed case", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "17473493_2_Ent1", "text": "NASH", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17473493_2_Ent2", "text": "raloxifene", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17473493_2_Ent3", "text": "raloxifene", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "17509184_1", "wnd_id": "17509184_1_1", "text": "A 40 - year - old man with advanced HIV infection and Mycobacterium avium complex infection experienced rapid cognitive decline after commencement of ethambutol , and symptoms fully resolved with cessation .", "tokens": ["A", "40", "-", "year", "-", "old", "man", "with", "advanced", "HIV", "infection", "and", "Mycobacterium", "avium", "complex", "infection", "experienced", "rapid", "cognitive", "decline", "after", "commencement", "of", "ethambutol", ",", "and", "symptoms", "fully", "resolved", "with", "cessation", "."], "event_mentions": [{"id": "17509184_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 20, "end": 21}, "arguments": [{"entity_id": "17509184_1_Ent1", "role": "Subject_Age", "text": "40 - year - old", "start": 1, "end": 6}, {"entity_id": "17509184_1_Ent0", "role": "Subject", "text": "40 - year - old man with advanced HIV infection and Mycobacterium avium complex infection", "start": 1, "end": 16}, {"entity_id": "17509184_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "17509184_1_Ent8", "role": "Treatment_Disorder", "text": "HIV infection", "start": 9, "end": 11}, {"entity_id": "17509184_1_Ent7", "role": "Treatment_Disorder", "text": "Mycobacterium avium complex infection", "start": 12, "end": 16}, {"entity_id": "17509184_1_Ent3", "role": "Effect", "text": "rapid cognitive decline", "start": 17, "end": 20}, {"entity_id": "17509184_1_Ent4", "role": "Treatment", "text": "commencement of ethambutol", "start": 21, "end": 24}, {"entity_id": "17509184_1_Ent5", "role": "Treatment_Drug", "text": "ethambutol", "start": 23, "end": 24}, {"entity_id": "17509184_1_Ent6", "role": "Treatment_Disorder", "text": "ethambutol", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "17509184_1_Ent1", "text": "40 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "17509184_1_Ent0", "text": "40 - year - old man with advanced HIV infection and Mycobacterium avium complex infection", "entity_type": "Entity", "start": 1, "end": 16}, {"id": "17509184_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17509184_1_Ent8", "text": "HIV infection", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "17509184_1_Ent7", "text": "Mycobacterium avium complex infection", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "17509184_1_Ent3", "text": "rapid cognitive decline", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "17509184_1_Ent4", "text": "commencement of ethambutol", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "17509184_1_Ent5", "text": "ethambutol", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "17509184_1_Ent6", "text": "ethambutol", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "17551408_1", "wnd_id": "17551408_1_1", "text": "We postulate that gastritis caused by dexamethasone , mucositis caused by doxorubicin , and the unique anatomic nature of a Meckel diverticulum may have contributed to this extremely unlikely and previously unreported event .", "tokens": ["We", "postulate", "that", "gastritis", "caused", "by", "dexamethasone", ",", "mucositis", "caused", "by", "doxorubicin", ",", "and", "the", "unique", "anatomic", "nature", "of", "a", "Meckel", "diverticulum", "may", "have", "contributed", "to", "this", "extremely", "unlikely", "and", "previously", "unreported", "event", "."], "event_mentions": [{"id": "17551408_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 4, "end": 5}, "arguments": [{"entity_id": "17551408_1_Ent0", "role": "Effect", "text": "gastritis", "start": 3, "end": 4}, {"entity_id": "17551408_1_Ent1", "role": "Treatment", "text": "dexamethasone", "start": 6, "end": 7}, {"entity_id": "17551408_1_Ent2", "role": "Treatment_Drug", "text": "dexamethasone", "start": 6, "end": 7}]}, {"id": "17551408_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 9, "end": 10}, "arguments": [{"entity_id": "17551408_1_Ent3", "role": "Effect", "text": "mucositis", "start": 8, "end": 9}, {"entity_id": "17551408_1_Ent4", "role": "Treatment", "text": "doxorubicin", "start": 11, "end": 12}, {"entity_id": "17551408_1_Ent5", "role": "Treatment_Drug", "text": "doxorubicin", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "17551408_1_Ent0", "text": "gastritis", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17551408_1_Ent1", "text": "dexamethasone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17551408_1_Ent2", "text": "dexamethasone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17551408_1_Ent3", "text": "mucositis", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17551408_1_Ent4", "text": "doxorubicin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17551408_1_Ent5", "text": "doxorubicin", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "17556909_2", "wnd_id": "17556909_2_1", "text": "Paralytic ileus in patients undergoing bortezomib treatment has been reported , although a definite attribution to bortezomib administration has not been established .", "tokens": ["Paralytic", "ileus", "in", "patients", "undergoing", "bortezomib", "treatment", "has", "been", "reported", ",", "although", "a", "definite", "attribution", "to", "bortezomib", "administration", "has", "not", "been", "established", "."], "event_mentions": [{"id": "17556909_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 9, "end": 10}, "arguments": [{"entity_id": "17556909_2_Ent1", "role": "Effect", "text": "Paralytic ileus", "start": 0, "end": 2}, {"entity_id": "17556909_2_Ent0", "role": "Subject", "text": "patients", "start": 3, "end": 4}, {"entity_id": "17556909_2_Ent3", "role": "Treatment_Drug", "text": "bortezomib", "start": 5, "end": 6}, {"entity_id": "17556909_2_Ent2", "role": "Treatment", "text": "bortezomib treatment", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "17556909_2_Ent1", "text": "Paralytic ileus", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17556909_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17556909_2_Ent3", "text": "bortezomib", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17556909_2_Ent2", "text": "bortezomib treatment", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "17556909_3", "wnd_id": "17556909_3_1", "text": "We report a myeloma patient who developed severe paralytic ileus during bortezomib therapy , which presented in the context of progressive constipation without other known causes and which regressed promptly with medical management after drug cessation , suggesting a direct causal relationship .", "tokens": ["We", "report", "a", "myeloma", "patient", "who", "developed", "severe", "paralytic", "ileus", "during", "bortezomib", "therapy", ",", "which", "presented", "in", "the", "context", "of", "progressive", "constipation", "without", "other", "known", "causes", "and", "which", "regressed", "promptly", "with", "medical", "management", "after", "drug", "cessation", ",", "suggesting", "a", "direct", "causal", "relationship", "."], "event_mentions": [{"id": "17556909_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "17556909_3_Ent0", "role": "Subject", "text": "a myeloma patient", "start": 2, "end": 5}, {"entity_id": "17556909_3_Ent4", "role": "Treatment_Disorder", "text": "myeloma", "start": 3, "end": 4}, {"entity_id": "17556909_3_Ent1", "role": "Effect", "text": "paralytic ileus", "start": 8, "end": 10}, {"entity_id": "17556909_3_Ent5", "role": "Treatment_Drug", "text": "bortezomib", "start": 11, "end": 12}, {"entity_id": "17556909_3_Ent3", "role": "Treatment", "text": "bortezomib therapy", "start": 11, "end": 13}, {"entity_id": "17556909_3_Ent2", "role": "Effect", "text": "presented in the context of progressive constipation without other known causes and which regressed promptly with medical management after drug cessation", "start": 15, "end": 36}]}], "entity_mentions": [{"id": "17556909_3_Ent0", "text": "a myeloma patient", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "17556909_3_Ent4", "text": "myeloma", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17556909_3_Ent1", "text": "paralytic ileus", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "17556909_3_Ent5", "text": "bortezomib", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17556909_3_Ent3", "text": "bortezomib therapy", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "17556909_3_Ent2", "text": "presented in the context of progressive constipation without other known causes and which regressed promptly with medical management after drug cessation", "entity_type": "Entity", "start": 15, "end": 36}], "lang": "en"}
{"doc_id": "1756352_2", "wnd_id": "1756352_2_1", "text": "Delusional parasitosis associated with phenelzine .", "tokens": ["Delusional", "parasitosis", "associated", "with", "phenelzine", "."], "event_mentions": [{"id": "1756352_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "1756352_2_Ent0", "role": "Effect", "text": "Delusional parasitosis", "start": 0, "end": 2}, {"entity_id": "1756352_2_Ent1", "role": "Treatment", "text": "phenelzine", "start": 4, "end": 5}, {"entity_id": "1756352_2_Ent2", "role": "Treatment_Drug", "text": "phenelzine", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "1756352_2_Ent0", "text": "Delusional parasitosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1756352_2_Ent1", "text": "phenelzine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "1756352_2_Ent2", "text": "phenelzine", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "1759924_1", "wnd_id": "1759924_1_1", "text": "Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene .", "tokens": ["Fulminant", "metoclopramide", "induced", "neuroleptic", "malignant", "syndrome", "rapidly", "responsive", "to", "intravenous", "dantrolene", "."], "event_mentions": [{"id": "1759924_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "1759924_1_Ent1", "role": "Treatment", "text": "Fulminant metoclopramide", "start": 0, "end": 2}, {"entity_id": "1759924_1_Ent2", "role": "Treatment_Drug", "text": "metoclopramide", "start": 1, "end": 2}, {"entity_id": "1759924_1_Ent0", "role": "Effect", "text": "neuroleptic malignant syndrome", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "1759924_1_Ent1", "text": "Fulminant metoclopramide", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1759924_1_Ent2", "text": "metoclopramide", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "1759924_1_Ent0", "text": "neuroleptic malignant syndrome", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "17655376_2", "wnd_id": "17655376_2_1", "text": "Oral dapsone has been available for over 60 years and has been used to treat severe acne vulgaris ; however , the oral formulation is known to cause dose - dependent haematological reactions and is currently indicated only for diseases such as dermatitis herpetiformis and Hansen 's disease .", "tokens": ["Oral", "dapsone", "has", "been", "available", "for", "over", "60", "years", "and", "has", "been", "used", "to", "treat", "severe", "acne", "vulgaris", ";", "however", ",", "the", "oral", "formulation", "is", "known", "to", "cause", "dose", "-", "dependent", "haematological", "reactions", "and", "is", "currently", "indicated", "only", "for", "diseases", "such", "as", "dermatitis", "herpetiformis", "and", "Hansen", "'s", "disease", "."], "event_mentions": [{"id": "17655376_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 27, "end": 28}, "arguments": [{"entity_id": "17655376_2_Ent3", "role": "Treatment_Route", "text": "Oral", "start": 0, "end": 1}, {"entity_id": "17655376_2_Ent1", "role": "Treatment", "text": "Oral dapsone", "start": 0, "end": 2}, {"entity_id": "17655376_2_Ent2", "role": "Treatment_Drug", "text": "dapsone", "start": 1, "end": 2}, {"entity_id": "17655376_2_Ent0", "role": "Effect", "text": "dose - dependent haematological reactions", "start": 28, "end": 33}, {"entity_id": "17655376_2_Ent4", "role": "Treatment_Disorder", "text": "dermatitis herpetiformis", "start": 42, "end": 44}, {"entity_id": "17655376_2_Ent5", "role": "Treatment_Disorder", "text": "Hansen 's disease", "start": 45, "end": 48}]}], "entity_mentions": [{"id": "17655376_2_Ent3", "text": "Oral", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17655376_2_Ent1", "text": "Oral dapsone", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17655376_2_Ent2", "text": "dapsone", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "17655376_2_Ent0", "text": "dose - dependent haematological reactions", "entity_type": "Entity", "start": 28, "end": 33}, {"id": "17655376_2_Ent4", "text": "dermatitis herpetiformis", "entity_type": "Entity", "start": 42, "end": 44}, {"id": "17655376_2_Ent5", "text": "Hansen 's disease", "entity_type": "Entity", "start": 45, "end": 48}], "lang": "en"}
{"doc_id": "17655517_1", "wnd_id": "17655517_1_1", "text": "Linezolid - associated peripheral and optic neuropathy , lactic acidosis , and serotonin syndrome .", "tokens": ["Linezolid", "-", "associated", "peripheral", "and", "optic", "neuropathy", ",", "lactic", "acidosis", ",", "and", "serotonin", "syndrome", "."], "event_mentions": [{"id": "17655517_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "17655517_1_Ent1", "role": "Treatment", "text": "Linezolid", "start": 0, "end": 1}, {"entity_id": "17655517_1_Ent2", "role": "Treatment_Drug", "text": "Linezolid", "start": 0, "end": 1}, {"entity_id": "17655517_1_Ent0", "role": "Effect", "text": "peripheral and optic neuropathy , lactic acidosis , and serotonin syndrome .", "start": 3, "end": 15}]}], "entity_mentions": [{"id": "17655517_1_Ent1", "text": "Linezolid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17655517_1_Ent2", "text": "Linezolid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17655517_1_Ent0", "text": "peripheral and optic neuropathy , lactic acidosis , and serotonin syndrome .", "entity_type": "Entity", "start": 3, "end": 15}], "lang": "en"}
{"doc_id": "17655517_2", "wnd_id": "17655517_2_1", "text": "Linezolid is an oxazolidinone antibacterial agent indicated for serious gram - positive infections .", "tokens": ["Linezolid", "is", "an", "oxazolidinone", "antibacterial", "agent", "indicated", "for", "serious", "gram", "-", "positive", "infections", "."], "event_mentions": [{"id": "17655517_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "indicated", "start": 6, "end": 7}, "arguments": [{"entity_id": "17655517_2_Ent0", "role": "Treatment", "text": "Linezolid", "start": 0, "end": 1}, {"entity_id": "17655517_2_Ent2", "role": "Treatment_Drug", "text": "Linezolid", "start": 0, "end": 1}, {"entity_id": "17655517_2_Ent1", "role": "Treatment_Disorder", "text": "serious gram - positive infections", "start": 8, "end": 13}]}], "entity_mentions": [{"id": "17655517_2_Ent0", "text": "Linezolid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17655517_2_Ent2", "text": "Linezolid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17655517_2_Ent1", "text": "serious gram - positive infections", "entity_type": "Entity", "start": 8, "end": 13}], "lang": "en"}
{"doc_id": "17655517_5", "wnd_id": "17655517_5_1", "text": "Peripheral and optic neuropathy was usually seen after several months of linezolid therapy ( median 5 mo ) , lactic acidosis after several weeks ( median 6 wks ) , and serotonin syndrome after several days ( median 4 days ) .", "tokens": ["Peripheral", "and", "optic", "neuropathy", "was", "usually", "seen", "after", "several", "months", "of", "linezolid", "therapy", "(", "median", "5", "mo", ")", ",", "lactic", "acidosis", "after", "several", "weeks", "(", "median", "6", "wks", ")", ",", "and", "serotonin", "syndrome", "after", "several", "days", "(", "median", "4", "days", ")", "."], "event_mentions": [{"id": "17655517_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "17655517_5_Ent0", "role": "Effect", "text": "Peripheral and optic neuropathy", "start": 0, "end": 4}, {"entity_id": "17655517_5_Ent4", "role": "Treatment_Time_elapsed", "text": "several months", "start": 8, "end": 10}, {"entity_id": "17655517_5_Ent2", "role": "Treatment", "text": "several months of linezolid therapy ( median 5 mo )", "start": 8, "end": 18}, {"entity_id": "17655517_5_Ent3", "role": "Treatment_Drug", "text": "linezolid", "start": 11, "end": 12}, {"entity_id": "17655517_5_Ent1", "role": "Effect", "text": "lactic acidosis after several weeks ( median 6 wks ) , and serotonin syndrome after several days ( median 4 days )", "start": 19, "end": 41}]}], "entity_mentions": [{"id": "17655517_5_Ent0", "text": "Peripheral and optic neuropathy", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "17655517_5_Ent4", "text": "several months", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "17655517_5_Ent2", "text": "several months of linezolid therapy ( median 5 mo )", "entity_type": "Entity", "start": 8, "end": 18}, {"id": "17655517_5_Ent3", "text": "linezolid", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17655517_5_Ent1", "text": "lactic acidosis after several weeks ( median 6 wks ) , and serotonin syndrome after several days ( median 4 days )", "entity_type": "Entity", "start": 19, "end": 41}], "lang": "en"}
{"doc_id": "17655517_9", "wnd_id": "17655517_9_1", "text": "Patients receiving linezolid for more than 28 days should be monitored for signs of peripheral and optic neuropathy .", "tokens": ["Patients", "receiving", "linezolid", "for", "more", "than", "28", "days", "should", "be", "monitored", "for", "signs", "of", "peripheral", "and", "optic", "neuropathy", "."], "event_mentions": [{"id": "17655517_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "monitored", "start": 10, "end": 11}, "arguments": [{"entity_id": "17655517_9_Ent0", "role": "Subject", "text": "Patients", "start": 0, "end": 1}, {"entity_id": "17655517_9_Ent3", "role": "Treatment_Drug", "text": "linezolid", "start": 2, "end": 3}, {"entity_id": "17655517_9_Ent2", "role": "Treatment", "text": "linezolid for more than 28 days", "start": 2, "end": 8}, {"entity_id": "17655517_9_Ent4", "role": "Treatment_Duration", "text": "28 days", "start": 6, "end": 8}, {"entity_id": "17655517_9_Ent1", "role": "Effect", "text": "peripheral and optic neuropathy", "start": 14, "end": 18}]}], "entity_mentions": [{"id": "17655517_9_Ent0", "text": "Patients", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17655517_9_Ent3", "text": "linezolid", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17655517_9_Ent2", "text": "linezolid for more than 28 days", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "17655517_9_Ent4", "text": "28 days", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17655517_9_Ent1", "text": "peripheral and optic neuropathy", "entity_type": "Entity", "start": 14, "end": 18}], "lang": "en"}
{"doc_id": "1765991_4", "wnd_id": "1765991_4_1", "text": "We assume that rIFN - gamma induced the de novo development of SLE in our patient .", "tokens": ["We", "assume", "that", "rIFN", "-", "gamma", "induced", "the", "de", "novo", "development", "of", "SLE", "in", "our", "patient", "."], "event_mentions": [{"id": "1765991_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "1765991_4_Ent2", "role": "Treatment", "text": "rIFN - gamma", "start": 3, "end": 6}, {"entity_id": "1765991_4_Ent3", "role": "Treatment_Drug", "text": "rIFN - gamma", "start": 3, "end": 6}, {"entity_id": "1765991_4_Ent1", "role": "Effect", "text": "the de novo development of SLE", "start": 7, "end": 13}, {"entity_id": "1765991_4_Ent0", "role": "Subject", "text": "our patient", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "1765991_4_Ent2", "text": "rIFN - gamma", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "1765991_4_Ent3", "text": "rIFN - gamma", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "1765991_4_Ent1", "text": "the de novo development of SLE", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "1765991_4_Ent0", "text": "our patient", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "17665812_1", "wnd_id": "17665812_1_1", "text": "Clozapine - induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies .", "tokens": ["Clozapine", "-", "induced", "eosinophilia", "and", "switch", "to", "quetiapine", "in", "a", "patient", "with", "chronic", "schizophrenia", "with", "suicidal", "tendencies", "."], "event_mentions": [{"id": "17665812_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "17665812_1_Ent2", "role": "Treatment", "text": "Clozapine", "start": 0, "end": 1}, {"entity_id": "17665812_1_Ent4", "role": "Treatment_Drug", "text": "Clozapine", "start": 0, "end": 1}, {"entity_id": "17665812_1_Ent1", "role": "Effect", "text": "eosinophilia", "start": 3, "end": 4}, {"entity_id": "17665812_1_Ent0", "role": "Subject", "text": "a patient with chronic schizophrenia with suicidal tendencies", "start": 9, "end": 17}, {"entity_id": "17665812_1_Ent3", "role": "Treatment_Disorder", "text": "chronic schizophrenia with suicidal tendencies", "start": 12, "end": 17}]}, {"id": "17665812_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "switch", "start": 5, "end": 6}, "arguments": [{"entity_id": "17665812_1_Ent6", "role": "Treatment", "text": "quetiapine", "start": 7, "end": 8}, {"entity_id": "17665812_1_Ent7", "role": "Treatment_Drug", "text": "quetiapine", "start": 7, "end": 8}, {"entity_id": "17665812_1_Ent5", "role": "Subject", "text": "a patient with chronic schizophrenia with suicidal tendencies", "start": 9, "end": 17}]}], "entity_mentions": [{"id": "17665812_1_Ent2", "text": "Clozapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17665812_1_Ent4", "text": "Clozapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17665812_1_Ent1", "text": "eosinophilia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17665812_1_Ent6", "text": "quetiapine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17665812_1_Ent7", "text": "quetiapine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17665812_1_Ent0", "text": "a patient with chronic schizophrenia with suicidal tendencies", "entity_type": "Entity", "start": 9, "end": 17}, {"id": "17665812_1_Ent5", "text": "a patient with chronic schizophrenia with suicidal tendencies", "entity_type": "Entity", "start": 9, "end": 17}, {"id": "17665812_1_Ent3", "text": "chronic schizophrenia with suicidal tendencies", "entity_type": "Entity", "start": 12, "end": 17}], "lang": "en"}
{"doc_id": "17667887_8", "wnd_id": "17667887_8_1", "text": "In both cases , we believe that serotonin syndrome was produced by a combination of an antidepressant and an atypical antipsychotic .", "tokens": ["In", "both", "cases", ",", "we", "believe", "that", "serotonin", "syndrome", "was", "produced", "by", "a", "combination", "of", "an", "antidepressant", "and", "an", "atypical", "antipsychotic", "."], "event_mentions": [{"id": "17667887_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "produced", "start": 10, "end": 11}, "arguments": [{"entity_id": "17667887_8_Ent0", "role": "Subject", "text": "In both cases", "start": 0, "end": 3}, {"entity_id": "17667887_8_Ent1", "role": "Subject_Population", "text": "both", "start": 1, "end": 2}, {"entity_id": "17667887_8_Ent2", "role": "Effect", "text": "serotonin syndrome", "start": 7, "end": 9}, {"entity_id": "17667887_8_Ent3", "role": "Treatment", "text": "a combination of an antidepressant and an atypical antipsychotic", "start": 12, "end": 21}, {"entity_id": "17667887_8_Ent4", "role": "Treatment_Drug", "text": "antidepressant", "start": 16, "end": 17}, {"entity_id": "17667887_8_Ent6", "role": "Combination_Drug", "text": "antidepressant", "start": 16, "end": 17}, {"entity_id": "17667887_8_Ent5", "role": "Treatment_Drug", "text": "atypical antipsychotic", "start": 19, "end": 21}, {"entity_id": "17667887_8_Ent7", "role": "Combination_Drug", "text": "atypical antipsychotic", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "17667887_8_Ent0", "text": "In both cases", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "17667887_8_Ent1", "text": "both", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "17667887_8_Ent2", "text": "serotonin syndrome", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "17667887_8_Ent3", "text": "a combination of an antidepressant and an atypical antipsychotic", "entity_type": "Entity", "start": 12, "end": 21}, {"id": "17667887_8_Ent4", "text": "antidepressant", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17667887_8_Ent6", "text": "antidepressant", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17667887_8_Ent5", "text": "atypical antipsychotic", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "17667887_8_Ent7", "text": "atypical antipsychotic", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "17671884_7", "wnd_id": "17671884_7_1", "text": "One previous study of four transplant patients whose immediate post - transplantation immunosuppression utilized corticosteroids , cyclosporine , MMF , and anti - T - lymphocyte globulin noted anemia in 13 % of them .", "tokens": ["One", "previous", "study", "of", "four", "transplant", "patients", "whose", "immediate", "post", "-", "transplantation", "immunosuppression", "utilized", "corticosteroids", ",", "cyclosporine", ",", "MMF", ",", "and", "anti", "-", "T", "-", "lymphocyte", "globulin", "noted", "anemia", "in", "13", "%", "of", "them", "."], "event_mentions": [{"id": "17671884_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "noted", "start": 27, "end": 28}, "arguments": [{"entity_id": "17671884_7_Ent1", "role": "Subject_Population", "text": "four", "start": 4, "end": 5}, {"entity_id": "17671884_7_Ent0", "role": "Subject", "text": "four transplant patients", "start": 4, "end": 7}, {"entity_id": "17671884_7_Ent2", "role": "Subject_Disorder", "text": "transplant", "start": 5, "end": 6}, {"entity_id": "17671884_7_Ent4", "role": "Treatment", "text": "immediate post - transplantation immunosuppression utilized corticosteroids , cyclosporine , MMF , and anti - T - lymphocyte globulin", "start": 8, "end": 27}, {"entity_id": "17671884_7_Ent9", "role": "Treatment_Disorder", "text": "post - transplantation immunosuppression", "start": 9, "end": 13}, {"entity_id": "17671884_7_Ent5", "role": "Treatment_Drug", "text": "corticosteroids", "start": 14, "end": 15}, {"entity_id": "17671884_7_Ent10", "role": "Combination_Drug", "text": "corticosteroids", "start": 14, "end": 15}, {"entity_id": "17671884_7_Ent6", "role": "Treatment_Drug", "text": "cyclosporine", "start": 16, "end": 17}, {"entity_id": "17671884_7_Ent11", "role": "Combination_Drug", "text": "cyclosporine", "start": 16, "end": 17}, {"entity_id": "17671884_7_Ent7", "role": "Treatment_Drug", "text": "MMF", "start": 18, "end": 19}, {"entity_id": "17671884_7_Ent12", "role": "Combination_Drug", "text": "MMF", "start": 18, "end": 19}, {"entity_id": "17671884_7_Ent8", "role": "Treatment_Drug", "text": "anti - T - lymphocyte globulin", "start": 21, "end": 27}, {"entity_id": "17671884_7_Ent13", "role": "Combination_Drug", "text": "anti - T - lymphocyte globulin", "start": 21, "end": 27}, {"entity_id": "17671884_7_Ent3", "role": "Effect", "text": "anemia", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "17671884_7_Ent1", "text": "four", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17671884_7_Ent0", "text": "four transplant patients", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "17671884_7_Ent2", "text": "transplant", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17671884_7_Ent4", "text": "immediate post - transplantation immunosuppression utilized corticosteroids , cyclosporine , MMF , and anti - T - lymphocyte globulin", "entity_type": "Entity", "start": 8, "end": 27}, {"id": "17671884_7_Ent9", "text": "post - transplantation immunosuppression", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "17671884_7_Ent5", "text": "corticosteroids", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17671884_7_Ent10", "text": "corticosteroids", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17671884_7_Ent6", "text": "cyclosporine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17671884_7_Ent11", "text": "cyclosporine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17671884_7_Ent7", "text": "MMF", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17671884_7_Ent12", "text": "MMF", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17671884_7_Ent8", "text": "anti - T - lymphocyte globulin", "entity_type": "Entity", "start": 21, "end": 27}, {"id": "17671884_7_Ent13", "text": "anti - T - lymphocyte globulin", "entity_type": "Entity", "start": 21, "end": 27}, {"id": "17671884_7_Ent3", "text": "anemia", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "17671884_9", "wnd_id": "17671884_9_1", "text": "This report suggests that anemia can occur due to MMF , in particular when it is given with prednisone , a side effect well documented in the transplantation literature when the triple combination of MMF , cyclosporine and prednisone is used .", "tokens": ["This", "report", "suggests", "that", "anemia", "can", "occur", "due", "to", "MMF", ",", "in", "particular", "when", "it", "is", "given", "with", "prednisone", ",", "a", "side", "effect", "well", "documented", "in", "the", "transplantation", "literature", "when", "the", "triple", "combination", "of", "MMF", ",", "cyclosporine", "and", "prednisone", "is", "used", "."], "event_mentions": [{"id": "17671884_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 7, "end": 8}, "arguments": [{"entity_id": "17671884_9_Ent0", "role": "Effect", "text": "anemia", "start": 4, "end": 5}, {"entity_id": "17671884_9_Ent1", "role": "Treatment", "text": "MMF", "start": 9, "end": 10}, {"entity_id": "17671884_9_Ent3", "role": "Treatment_Drug", "text": "MMF", "start": 9, "end": 10}, {"entity_id": "17671884_9_Ent5", "role": "Combination_Drug", "text": "MMF", "start": 9, "end": 10}, {"entity_id": "17671884_9_Ent2", "role": "Treatment", "text": "prednisone", "start": 18, "end": 19}, {"entity_id": "17671884_9_Ent4", "role": "Treatment_Drug", "text": "prednisone", "start": 18, "end": 19}, {"entity_id": "17671884_9_Ent6", "role": "Combination_Drug", "text": "prednisone", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "17671884_9_Ent0", "text": "anemia", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17671884_9_Ent1", "text": "MMF", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17671884_9_Ent3", "text": "MMF", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17671884_9_Ent5", "text": "MMF", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17671884_9_Ent2", "text": "prednisone", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17671884_9_Ent4", "text": "prednisone", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17671884_9_Ent6", "text": "prednisone", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "17675030_2", "wnd_id": "17675030_2_1", "text": "Clinical profile of oxcarbazepine - related angioneurotic edema : case report and review .", "tokens": ["Clinical", "profile", "of", "oxcarbazepine", "-", "related", "angioneurotic", "edema", ":", "case", "report", "and", "review", "."], "event_mentions": [{"id": "17675030_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 5, "end": 6}, "arguments": [{"entity_id": "17675030_2_Ent2", "role": "Treatment", "text": "oxcarbazepine", "start": 3, "end": 4}, {"entity_id": "17675030_2_Ent3", "role": "Treatment_Drug", "text": "oxcarbazepine", "start": 3, "end": 4}, {"entity_id": "17675030_2_Ent1", "role": "Effect", "text": "angioneurotic edema", "start": 6, "end": 8}, {"entity_id": "17675030_2_Ent0", "role": "Subject", "text": "case", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "17675030_2_Ent2", "text": "oxcarbazepine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17675030_2_Ent3", "text": "oxcarbazepine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17675030_2_Ent1", "text": "angioneurotic edema", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17675030_2_Ent0", "text": "case", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "17697264_2", "wnd_id": "17697264_2_1", "text": "One case of tacrolimus - induced hepatic VOD developing after lung transplantation ( LT ) has been recently reported .", "tokens": ["One", "case", "of", "tacrolimus", "-", "induced", "hepatic", "VOD", "developing", "after", "lung", "transplantation", "(", "LT", ")", "has", "been", "recently", "reported", "."], "event_mentions": [{"id": "17697264_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "17697264_2_Ent1", "role": "Treatment", "text": "tacrolimus", "start": 3, "end": 4}, {"entity_id": "17697264_2_Ent3", "role": "Treatment_Drug", "text": "tacrolimus", "start": 3, "end": 4}, {"entity_id": "17697264_2_Ent0", "role": "Effect", "text": "hepatic VOD", "start": 6, "end": 8}, {"entity_id": "17697264_2_Ent2", "role": "Treatment", "text": "after lung transplantation ( LT )", "start": 9, "end": 15}]}], "entity_mentions": [{"id": "17697264_2_Ent1", "text": "tacrolimus", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17697264_2_Ent3", "text": "tacrolimus", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17697264_2_Ent0", "text": "hepatic VOD", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17697264_2_Ent2", "text": "after lung transplantation ( LT )", "entity_type": "Entity", "start": 9, "end": 15}], "lang": "en"}
{"doc_id": "17710018_2", "wnd_id": "17710018_2_1", "text": "Because etoposide - induced pulmonary toxicity is an uncommon but serious adverse event , clinicians must be vigilant about the possibility of it , so that the optimal treatment can start as soon as possible .", "tokens": ["Because", "etoposide", "-", "induced", "pulmonary", "toxicity", "is", "an", "uncommon", "but", "serious", "adverse", "event", ",", "clinicians", "must", "be", "vigilant", "about", "the", "possibility", "of", "it", ",", "so", "that", "the", "optimal", "treatment", "can", "start", "as", "soon", "as", "possible", "."], "event_mentions": [{"id": "17710018_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "17710018_2_Ent1", "role": "Treatment", "text": "etoposide", "start": 1, "end": 2}, {"entity_id": "17710018_2_Ent2", "role": "Treatment_Drug", "text": "etoposide", "start": 1, "end": 2}, {"entity_id": "17710018_2_Ent0", "role": "Effect", "text": "pulmonary toxicity", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "17710018_2_Ent1", "text": "etoposide", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "17710018_2_Ent2", "text": "etoposide", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "17710018_2_Ent0", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "1772299_1", "wnd_id": "1772299_1_1", "text": "Detection of antineutrophil cytoplasmic antibody in a patient with L - tryptophan induced eosinophilia - myalgia syndrome .", "tokens": ["Detection", "of", "antineutrophil", "cytoplasmic", "antibody", "in", "a", "patient", "with", "L", "-", "tryptophan", "induced", "eosinophilia", "-", "myalgia", "syndrome", "."], "event_mentions": [{"id": "1772299_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 12, "end": 13}, "arguments": [{"entity_id": "1772299_1_Ent0", "role": "Subject", "text": "patient", "start": 7, "end": 8}, {"entity_id": "1772299_1_Ent2", "role": "Treatment", "text": "L - tryptophan", "start": 9, "end": 12}, {"entity_id": "1772299_1_Ent3", "role": "Treatment_Drug", "text": "L - tryptophan", "start": 9, "end": 12}, {"entity_id": "1772299_1_Ent1", "role": "Effect", "text": "eosinophilia - myalgia syndrome", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "1772299_1_Ent0", "text": "patient", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1772299_1_Ent2", "text": "L - tryptophan", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "1772299_1_Ent3", "text": "L - tryptophan", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "1772299_1_Ent1", "text": "eosinophilia - myalgia syndrome", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "17725438_2", "wnd_id": "17725438_2_1", "text": "Rifampin - induced hypothyroidism without underlying thyroid disease .", "tokens": ["Rifampin", "-", "induced", "hypothyroidism", "without", "underlying", "thyroid", "disease", "."], "event_mentions": [{"id": "17725438_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "17725438_2_Ent1", "role": "Treatment", "text": "Rifampin", "start": 0, "end": 1}, {"entity_id": "17725438_2_Ent2", "role": "Treatment_Drug", "text": "Rifampin", "start": 0, "end": 1}, {"entity_id": "17725438_2_Ent0", "role": "Effect", "text": "hypothyroidism without underlying thyroid disease", "start": 3, "end": 8}]}], "entity_mentions": [{"id": "17725438_2_Ent1", "text": "Rifampin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17725438_2_Ent2", "text": "Rifampin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17725438_2_Ent0", "text": "hypothyroidism without underlying thyroid disease", "entity_type": "Entity", "start": 3, "end": 8}], "lang": "en"}
{"doc_id": "17763133_1", "wnd_id": "17763133_1_1", "text": "Cyclosporine is a potent inhibitor of simvastatin metabolism , and may therefore facilitate simvastatin - induced rhabdomyolysis .", "tokens": ["Cyclosporine", "is", "a", "potent", "inhibitor", "of", "simvastatin", "metabolism", ",", "and", "may", "therefore", "facilitate", "simvastatin", "-", "induced", "rhabdomyolysis", "."], "event_mentions": [{"id": "17763133_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "facilitate", "start": 12, "end": 13}, "arguments": [{"entity_id": "17763133_1_Ent1", "role": "Treatment_Drug", "text": "Cyclosporine", "start": 0, "end": 1}, {"entity_id": "17763133_1_Ent0", "role": "Treatment", "text": "Cyclosporine is a potent inhibitor of simvastatin metabolism", "start": 0, "end": 8}]}], "entity_mentions": [{"id": "17763133_1_Ent1", "text": "Cyclosporine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17763133_1_Ent0", "text": "Cyclosporine is a potent inhibitor of simvastatin metabolism", "entity_type": "Entity", "start": 0, "end": 8}], "lang": "en"}
{"doc_id": "17763133_2", "wnd_id": "17763133_2_1", "text": "Discontinuation of simvastatin and cyclosporine resulted in resolution of rhabdomyolysis and normalization of renal function .", "tokens": ["Discontinuation", "of", "simvastatin", "and", "cyclosporine", "resulted", "in", "resolution", "of", "rhabdomyolysis", "and", "normalization", "of", "renal", "function", "."], "event_mentions": [{"id": "17763133_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resulted", "start": 5, "end": 6}, "arguments": [{"entity_id": "17763133_2_Ent1", "role": "Treatment", "text": "Discontinuation of simvastatin and cyclosporine", "start": 0, "end": 5}, {"entity_id": "17763133_2_Ent3", "role": "Treatment_Drug", "text": "simvastatin", "start": 2, "end": 3}, {"entity_id": "17763133_2_Ent4", "role": "Treatment_Drug", "text": "cyclosporine", "start": 4, "end": 5}, {"entity_id": "17763133_2_Ent2", "role": "Treatment_Disorder", "text": "rhabdomyolysis", "start": 9, "end": 10}, {"entity_id": "17763133_2_Ent0", "role": "Effect", "text": "normalization of renal function", "start": 11, "end": 15}]}], "entity_mentions": [{"id": "17763133_2_Ent1", "text": "Discontinuation of simvastatin and cyclosporine", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "17763133_2_Ent3", "text": "simvastatin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17763133_2_Ent4", "text": "cyclosporine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17763133_2_Ent2", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17763133_2_Ent0", "text": "normalization of renal function", "entity_type": "Entity", "start": 11, "end": 15}], "lang": "en"}
{"doc_id": "17763133_3", "wnd_id": "17763133_3_1", "text": "Simvastatin - induced rhabdomyolysis following cyclosporine treatment for uveitis .", "tokens": ["Simvastatin", "-", "induced", "rhabdomyolysis", "following", "cyclosporine", "treatment", "for", "uveitis", "."], "event_mentions": [{"id": "17763133_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "17763133_3_Ent2", "role": "Treatment", "text": "Simvastatin", "start": 0, "end": 1}, {"entity_id": "17763133_3_Ent3", "role": "Treatment_Drug", "text": "Simvastatin", "start": 0, "end": 1}, {"entity_id": "17763133_3_Ent7", "role": "Combination_Drug", "text": "Simvastatin", "start": 0, "end": 1}, {"entity_id": "17763133_3_Ent0", "role": "Effect", "text": "rhabdomyolysis", "start": 3, "end": 4}, {"entity_id": "17763133_3_Ent4", "role": "Treatment_Drug", "text": "cyclosporine", "start": 5, "end": 6}, {"entity_id": "17763133_3_Ent6", "role": "Combination_Drug", "text": "cyclosporine", "start": 5, "end": 6}, {"entity_id": "17763133_3_Ent1", "role": "Treatment", "text": "cyclosporine treatment", "start": 5, "end": 7}, {"entity_id": "17763133_3_Ent5", "role": "Treatment_Disorder", "text": "uveitis", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "17763133_3_Ent2", "text": "Simvastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17763133_3_Ent3", "text": "Simvastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17763133_3_Ent7", "text": "Simvastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17763133_3_Ent0", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17763133_3_Ent4", "text": "cyclosporine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17763133_3_Ent6", "text": "cyclosporine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17763133_3_Ent1", "text": "cyclosporine treatment", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "17763133_3_Ent5", "text": "uveitis", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "17823522_5", "wnd_id": "17823522_5_1", "text": "It is tempting to speculate that interferon alpha may be involved in the pathogenesis of lichen nitidus .", "tokens": ["It", "is", "tempting", "to", "speculate", "that", "interferon", "alpha", "may", "be", "involved", "in", "the", "pathogenesis", "of", "lichen", "nitidus", "."], "event_mentions": [{"id": "17823522_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "involved", "start": 10, "end": 11}, "arguments": [{"entity_id": "17823522_5_Ent1", "role": "Treatment", "text": "interferon alpha", "start": 6, "end": 8}, {"entity_id": "17823522_5_Ent2", "role": "Treatment_Drug", "text": "interferon alpha", "start": 6, "end": 8}, {"entity_id": "17823522_5_Ent0", "role": "Effect", "text": "lichen nitidus", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "17823522_5_Ent1", "text": "interferon alpha", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17823522_5_Ent2", "text": "interferon alpha", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17823522_5_Ent0", "text": "lichen nitidus", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "17873198_1", "wnd_id": "17873198_1_1", "text": "Interstitial lung disease ( ILD ) related to therapy with the drug gefitinib has been well reported .", "tokens": ["Interstitial", "lung", "disease", "(", "ILD", ")", "related", "to", "therapy", "with", "the", "drug", "gefitinib", "has", "been", "well", "reported", "."], "event_mentions": [{"id": "17873198_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 6, "end": 7}, "arguments": [{"entity_id": "17873198_1_Ent0", "role": "Effect", "text": "Interstitial lung disease ( ILD )", "start": 0, "end": 6}, {"entity_id": "17873198_1_Ent1", "role": "Treatment", "text": "therapy with the drug gefitinib", "start": 8, "end": 13}, {"entity_id": "17873198_1_Ent2", "role": "Treatment_Drug", "text": "gefitinib", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "17873198_1_Ent0", "text": "Interstitial lung disease ( ILD )", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "17873198_1_Ent1", "text": "therapy with the drug gefitinib", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "17873198_1_Ent2", "text": "gefitinib", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "17873198_5", "wnd_id": "17873198_5_1", "text": "We report a case of fatal pulmonary toxicity in a patient with advanced non - small cell lung cancer who received erlotinib .", "tokens": ["We", "report", "a", "case", "of", "fatal", "pulmonary", "toxicity", "in", "a", "patient", "with", "advanced", "non", "-", "small", "cell", "lung", "cancer", "who", "received", "erlotinib", "."], "event_mentions": [{"id": "17873198_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "received", "start": 20, "end": 21}, "arguments": [{"entity_id": "17873198_5_Ent1", "role": "Effect", "text": "pulmonary toxicity", "start": 6, "end": 8}, {"entity_id": "17873198_5_Ent0", "role": "Subject", "text": "a patient with advanced non - small cell lung cancer", "start": 9, "end": 19}, {"entity_id": "17873198_5_Ent3", "role": "Treatment_Disorder", "text": "advanced non - small cell lung cancer", "start": 12, "end": 19}, {"entity_id": "17873198_5_Ent2", "role": "Treatment", "text": "erlotinib", "start": 21, "end": 22}, {"entity_id": "17873198_5_Ent4", "role": "Treatment_Drug", "text": "erlotinib", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "17873198_5_Ent1", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17873198_5_Ent0", "text": "a patient with advanced non - small cell lung cancer", "entity_type": "Entity", "start": 9, "end": 19}, {"id": "17873198_5_Ent3", "text": "advanced non - small cell lung cancer", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "17873198_5_Ent2", "text": "erlotinib", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "17873198_5_Ent4", "text": "erlotinib", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "17921794_2", "wnd_id": "17921794_2_1", "text": "Rapid onset of muscle weakness ( rhabdomyolysis ) associated with the combined use of simvastatin and colchicine .", "tokens": ["Rapid", "onset", "of", "muscle", "weakness", "(", "rhabdomyolysis", ")", "associated", "with", "the", "combined", "use", "of", "simvastatin", "and", "colchicine", "."], "event_mentions": [{"id": "17921794_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 8, "end": 10}, "arguments": [{"entity_id": "17921794_2_Ent0", "role": "Effect", "text": "Rapid onset of muscle weakness ( rhabdomyolysis )", "start": 0, "end": 8}, {"entity_id": "17921794_2_Ent1", "role": "Treatment", "text": "the combined use of simvastatin and colchicine", "start": 10, "end": 17}, {"entity_id": "17921794_2_Ent2", "role": "Treatment_Drug", "text": "simvastatin", "start": 14, "end": 15}, {"entity_id": "17921794_2_Ent4", "role": "Combination_Drug", "text": "simvastatin", "start": 14, "end": 15}, {"entity_id": "17921794_2_Ent3", "role": "Treatment_Drug", "text": "colchicine", "start": 16, "end": 17}, {"entity_id": "17921794_2_Ent5", "role": "Combination_Drug", "text": "colchicine", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "17921794_2_Ent0", "text": "Rapid onset of muscle weakness ( rhabdomyolysis )", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "17921794_2_Ent1", "text": "the combined use of simvastatin and colchicine", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "17921794_2_Ent2", "text": "simvastatin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17921794_2_Ent4", "text": "simvastatin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17921794_2_Ent3", "text": "colchicine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17921794_2_Ent5", "text": "colchicine", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "17952482_1", "wnd_id": "17952482_1_1", "text": "A 58 - year - old woman with rheumatoid arthritis ( RA ) developed fever , skin eruptions , leukocytopenia , and thrombocytopenia , 3 weeks after treatment with sulfasalazine .", "tokens": ["A", "58", "-", "year", "-", "old", "woman", "with", "rheumatoid", "arthritis", "(", "RA", ")", "developed", "fever", ",", "skin", "eruptions", ",", "leukocytopenia", ",", "and", "thrombocytopenia", ",", "3", "weeks", "after", "treatment", "with", "sulfasalazine", "."], "event_mentions": [{"id": "17952482_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "17952482_1_Ent1", "role": "Subject_Age", "text": "58 - year - old", "start": 1, "end": 6}, {"entity_id": "17952482_1_Ent0", "role": "Subject", "text": "58 - year - old woman with rheumatoid arthritis ( RA )", "start": 1, "end": 13}, {"entity_id": "17952482_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "17952482_1_Ent7", "role": "Treatment_Disorder", "text": "rheumatoid arthritis ( RA )", "start": 8, "end": 13}, {"entity_id": "17952482_1_Ent3", "role": "Effect", "text": "fever , skin eruptions , leukocytopenia , and thrombocytopenia", "start": 14, "end": 23}, {"entity_id": "17952482_1_Ent6", "role": "Treatment_Time_elapsed", "text": "3 weeks after", "start": 24, "end": 27}, {"entity_id": "17952482_1_Ent4", "role": "Treatment", "text": "3 weeks after treatment with sulfasalazine", "start": 24, "end": 30}, {"entity_id": "17952482_1_Ent5", "role": "Treatment_Drug", "text": "sulfasalazine", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "17952482_1_Ent1", "text": "58 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "17952482_1_Ent0", "text": "58 - year - old woman with rheumatoid arthritis ( RA )", "entity_type": "Entity", "start": 1, "end": 13}, {"id": "17952482_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17952482_1_Ent7", "text": "rheumatoid arthritis ( RA )", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "17952482_1_Ent3", "text": "fever , skin eruptions , leukocytopenia , and thrombocytopenia", "entity_type": "Entity", "start": 14, "end": 23}, {"id": "17952482_1_Ent6", "text": "3 weeks after", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "17952482_1_Ent4", "text": "3 weeks after treatment with sulfasalazine", "entity_type": "Entity", "start": 24, "end": 30}, {"id": "17952482_1_Ent5", "text": "sulfasalazine", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "17959575_18", "wnd_id": "17959575_18_1", "text": "PURPOSE : The occurrence of myoclonus associated with continuous i.v . infusion of dobutamine in a patient with end - stage renal disease ( ESRD ) is described .", "tokens": ["PURPOSE", ":", "The", "occurrence", "of", "myoclonus", "associated", "with", "continuous", "i.v", ".", "infusion", "of", "dobutamine", "in", "a", "patient", "with", "end", "-", "stage", "renal", "disease", "(", "ESRD", ")", "is", "described", "."], "event_mentions": [{"id": "17959575_18_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 6, "end": 8}, "arguments": [{"entity_id": "17959575_18_Ent2", "role": "Effect", "text": "myoclonus", "start": 5, "end": 6}, {"entity_id": "17959575_18_Ent3", "role": "Treatment", "text": "continuous i.v . infusion of dobutamine", "start": 8, "end": 14}, {"entity_id": "17959575_18_Ent5", "role": "Treatment_Route", "text": "infusion", "start": 11, "end": 12}, {"entity_id": "17959575_18_Ent4", "role": "Treatment_Drug", "text": "dobutamine", "start": 13, "end": 14}, {"entity_id": "17959575_18_Ent0", "role": "Subject", "text": "a patient with end - stage renal disease ( ESRD )", "start": 15, "end": 26}, {"entity_id": "17959575_18_Ent1", "role": "Subject_Disorder", "text": "end - stage renal disease ( ESRD )", "start": 18, "end": 26}]}], "entity_mentions": [{"id": "17959575_18_Ent2", "text": "myoclonus", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17959575_18_Ent3", "text": "continuous i.v . infusion of dobutamine", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "17959575_18_Ent5", "text": "infusion", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17959575_18_Ent4", "text": "dobutamine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17959575_18_Ent0", "text": "a patient with end - stage renal disease ( ESRD )", "entity_type": "Entity", "start": 15, "end": 26}, {"id": "17959575_18_Ent1", "text": "end - stage renal disease ( ESRD )", "entity_type": "Entity", "start": 18, "end": 26}], "lang": "en"}
{"doc_id": "17965530_1", "wnd_id": "17965530_1_1", "text": "Reports of colonic perforation as a result of the administration of calcium polystyrene sulfonate and sorbitol are rare .", "tokens": ["Reports", "of", "colonic", "perforation", "as", "a", "result", "of", "the", "administration", "of", "calcium", "polystyrene", "sulfonate", "and", "sorbitol", "are", "rare", "."], "event_mentions": [{"id": "17965530_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "result", "start": 6, "end": 7}, "arguments": [{"entity_id": "17965530_1_Ent0", "role": "Effect", "text": "colonic perforation", "start": 2, "end": 4}, {"entity_id": "17965530_1_Ent5", "role": "Treatment_Route", "text": "the administration", "start": 8, "end": 10}, {"entity_id": "17965530_1_Ent1", "role": "Treatment", "text": "calcium polystyrene sulfonate", "start": 11, "end": 14}, {"entity_id": "17965530_1_Ent3", "role": "Treatment_Drug", "text": "calcium polystyrene sulfonate", "start": 11, "end": 14}, {"entity_id": "17965530_1_Ent6", "role": "Combination_Drug", "text": "calcium polystyrene sulfonate", "start": 11, "end": 14}, {"entity_id": "17965530_1_Ent2", "role": "Treatment", "text": "sorbitol", "start": 15, "end": 16}, {"entity_id": "17965530_1_Ent4", "role": "Treatment_Drug", "text": "sorbitol", "start": 15, "end": 16}, {"entity_id": "17965530_1_Ent7", "role": "Combination_Drug", "text": "sorbitol", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "17965530_1_Ent0", "text": "colonic perforation", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "17965530_1_Ent5", "text": "the administration", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "17965530_1_Ent1", "text": "calcium polystyrene sulfonate", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "17965530_1_Ent3", "text": "calcium polystyrene sulfonate", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "17965530_1_Ent6", "text": "calcium polystyrene sulfonate", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "17965530_1_Ent2", "text": "sorbitol", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "17965530_1_Ent4", "text": "sorbitol", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "17965530_1_Ent7", "text": "sorbitol", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "18006091_1", "wnd_id": "18006091_1_1", "text": "Sustained monomorphic ventricular tachycardia after adenosine infusion .", "tokens": ["Sustained", "monomorphic", "ventricular", "tachycardia", "after", "adenosine", "infusion", "."], "event_mentions": [{"id": "18006091_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 4, "end": 5}, "arguments": [{"entity_id": "18006091_1_Ent0", "role": "Effect", "text": "Sustained monomorphic ventricular tachycardia", "start": 0, "end": 4}, {"entity_id": "18006091_1_Ent2", "role": "Treatment_Drug", "text": "adenosine", "start": 5, "end": 6}, {"entity_id": "18006091_1_Ent1", "role": "Treatment", "text": "adenosine infusion .", "start": 5, "end": 8}, {"entity_id": "18006091_1_Ent3", "role": "Treatment_Route", "text": "infusion", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "18006091_1_Ent0", "text": "Sustained monomorphic ventricular tachycardia", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "18006091_1_Ent2", "text": "adenosine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18006091_1_Ent1", "text": "adenosine infusion .", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "18006091_1_Ent3", "text": "infusion", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "18020545_1", "wnd_id": "18020545_1_1", "text": "Surprisingly , we found that three patients appeared to develop tardive OGC while taking clozapine .", "tokens": ["Surprisingly", ",", "we", "found", "that", "three", "patients", "appeared", "to", "develop", "tardive", "OGC", "while", "taking", "clozapine", "."], "event_mentions": [{"id": "18020545_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 9, "end": 10}, "arguments": [{"entity_id": "18020545_1_Ent1", "role": "Subject_Population", "text": "three", "start": 5, "end": 6}, {"entity_id": "18020545_1_Ent0", "role": "Subject", "text": "three patients", "start": 5, "end": 7}, {"entity_id": "18020545_1_Ent2", "role": "Effect", "text": "tardive OGC", "start": 10, "end": 12}, {"entity_id": "18020545_1_Ent3", "role": "Treatment", "text": "clozapine", "start": 14, "end": 15}, {"entity_id": "18020545_1_Ent4", "role": "Treatment_Drug", "text": "clozapine", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "18020545_1_Ent1", "text": "three", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18020545_1_Ent0", "text": "three patients", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "18020545_1_Ent2", "text": "tardive OGC", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "18020545_1_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18020545_1_Ent4", "text": "clozapine", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "18022748_11", "wnd_id": "18022748_11_1", "text": "While CYP form induction by Pyrethrins , Phenobarbital and related compounds can be associated with liver and thyroid gland tumour formation in rodents , epidemiological data for Phenobarbital suggests that such effects do not occur in humans .", "tokens": ["While", "CYP", "form", "induction", "by", "Pyrethrins", ",", "Phenobarbital", "and", "related", "compounds", "can", "be", "associated", "with", "liver", "and", "thyroid", "gland", "tumour", "formation", "in", "rodents", ",", "epidemiological", "data", "for", "Phenobarbital", "suggests", "that", "such", "effects", "do", "not", "occur", "in", "humans", "."], "event_mentions": [{"id": "18022748_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induction", "start": 3, "end": 4}, "arguments": [{"entity_id": "18022748_11_Ent2", "role": "Treatment_Drug", "text": "Pyrethrins", "start": 5, "end": 6}, {"entity_id": "18022748_11_Ent7", "role": "Combination_Drug", "text": "Pyrethrins", "start": 5, "end": 6}, {"entity_id": "18022748_11_Ent1", "role": "Treatment", "text": "Pyrethrins , Phenobarbital and related compounds", "start": 5, "end": 11}, {"entity_id": "18022748_11_Ent3", "role": "Treatment_Drug", "text": "Phenobarbital", "start": 7, "end": 8}, {"entity_id": "18022748_11_Ent6", "role": "Combination_Drug", "text": "Phenobarbital", "start": 7, "end": 8}, {"entity_id": "18022748_11_Ent4", "role": "Treatment_Drug", "text": "related compounds", "start": 9, "end": 11}, {"entity_id": "18022748_11_Ent5", "role": "Combination_Drug", "text": "related compounds", "start": 9, "end": 11}, {"entity_id": "18022748_11_Ent0", "role": "Effect", "text": "liver and thyroid gland tumour formation in rodents", "start": 15, "end": 23}]}], "entity_mentions": [{"id": "18022748_11_Ent2", "text": "Pyrethrins", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18022748_11_Ent7", "text": "Pyrethrins", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18022748_11_Ent1", "text": "Pyrethrins , Phenobarbital and related compounds", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "18022748_11_Ent3", "text": "Phenobarbital", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18022748_11_Ent6", "text": "Phenobarbital", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18022748_11_Ent4", "text": "related compounds", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "18022748_11_Ent5", "text": "related compounds", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "18022748_11_Ent0", "text": "liver and thyroid gland tumour formation in rodents", "entity_type": "Entity", "start": 15, "end": 23}], "lang": "en"}
{"doc_id": "180258_2", "wnd_id": "180258_2_1", "text": "Two patients are described who developed sensory neuropathy after the ingestion of 30.6 and 114 g metronidazole respectively .", "tokens": ["Two", "patients", "are", "described", "who", "developed", "sensory", "neuropathy", "after", "the", "ingestion", "of", "30.6", "and", "114", "g", "metronidazole", "respectively", "."], "event_mentions": [{"id": "180258_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 8, "end": 9}, "arguments": [{"entity_id": "180258_2_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "180258_2_Ent0", "role": "Subject", "text": "Two patients", "start": 0, "end": 2}, {"entity_id": "180258_2_Ent2", "role": "Effect", "text": "sensory neuropathy", "start": 6, "end": 8}, {"entity_id": "180258_2_Ent3", "role": "Treatment", "text": "the ingestion of 30.6 and 114 g metronidazole", "start": 9, "end": 17}, {"entity_id": "180258_2_Ent6", "role": "Treatment_Dosage", "text": "30.6", "start": 12, "end": 13}, {"entity_id": "180258_2_Ent5", "role": "Treatment_Dosage", "text": "114 g", "start": 14, "end": 16}, {"entity_id": "180258_2_Ent7", "role": "Treatment_Dosage", "text": "g", "start": 15, "end": 16}, {"entity_id": "180258_2_Ent4", "role": "Treatment_Drug", "text": "metronidazole", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "180258_2_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "180258_2_Ent0", "text": "Two patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "180258_2_Ent2", "text": "sensory neuropathy", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "180258_2_Ent3", "text": "the ingestion of 30.6 and 114 g metronidazole", "entity_type": "Entity", "start": 9, "end": 17}, {"id": "180258_2_Ent6", "text": "30.6", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "180258_2_Ent5", "text": "114 g", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "180258_2_Ent7", "text": "g", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "180258_2_Ent4", "text": "metronidazole", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "18067642_2", "wnd_id": "18067642_2_1", "text": "Amiodarone is well recognized as an anti - arrhythmic drug containing a high dose of iodine with considerable potential to cause thyroid dysfunction .", "tokens": ["Amiodarone", "is", "well", "recognized", "as", "an", "anti", "-", "arrhythmic", "drug", "containing", "a", "high", "dose", "of", "iodine", "with", "considerable", "potential", "to", "cause", "thyroid", "dysfunction", "."], "event_mentions": [{"id": "18067642_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "recognized", "start": 3, "end": 4}, "arguments": [{"entity_id": "18067642_2_Ent1", "role": "Treatment", "text": "Amiodarone", "start": 0, "end": 1}, {"entity_id": "18067642_2_Ent2", "role": "Treatment_Drug", "text": "Amiodarone", "start": 0, "end": 1}, {"entity_id": "18067642_2_Ent0", "role": "Effect", "text": "potential to cause thyroid dysfunction", "start": 18, "end": 23}]}], "entity_mentions": [{"id": "18067642_2_Ent1", "text": "Amiodarone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18067642_2_Ent2", "text": "Amiodarone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18067642_2_Ent0", "text": "potential to cause thyroid dysfunction", "entity_type": "Entity", "start": 18, "end": 23}], "lang": "en"}
{"doc_id": "18067642_3", "wnd_id": "18067642_3_1", "text": "Histopathology of the thyroid in amiodarone - induced hypothyroidism .", "tokens": ["Histopathology", "of", "the", "thyroid", "in", "amiodarone", "-", "induced", "hypothyroidism", "."], "event_mentions": [{"id": "18067642_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "18067642_3_Ent1", "role": "Treatment", "text": "amiodarone", "start": 5, "end": 6}, {"entity_id": "18067642_3_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 5, "end": 6}, {"entity_id": "18067642_3_Ent0", "role": "Effect", "text": "hypothyroidism", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "18067642_3_Ent1", "text": "amiodarone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18067642_3_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18067642_3_Ent0", "text": "hypothyroidism", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "18071101_1", "wnd_id": "18071101_1_1", "text": "Although adverse effects are usually mild , the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation .", "tokens": ["Although", "adverse", "effects", "are", "usually", "mild", ",", "the", "author", "reports", "here", "a", "case", "of", "leucocytopenia", "and", "thrombocytopenia", "with", "quetiapine", "treatment", "that", "required", "its", "discontinuation", "."], "event_mentions": [{"id": "18071101_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 17, "end": 18}, "arguments": [{"entity_id": "18071101_1_Ent0", "role": "Subject", "text": "a case", "start": 11, "end": 13}, {"entity_id": "18071101_1_Ent1", "role": "Effect", "text": "leucocytopenia and thrombocytopenia", "start": 14, "end": 17}, {"entity_id": "18071101_1_Ent2", "role": "Treatment", "text": "quetiapine", "start": 18, "end": 19}, {"entity_id": "18071101_1_Ent3", "role": "Treatment_Drug", "text": "quetiapine", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "18071101_1_Ent0", "text": "a case", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "18071101_1_Ent1", "text": "leucocytopenia and thrombocytopenia", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "18071101_1_Ent2", "text": "quetiapine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "18071101_1_Ent3", "text": "quetiapine", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "18076602_1", "wnd_id": "18076602_1_1", "text": "Amphotericin B - induced cutaneous leucocytoclastic vasculitis : case report .", "tokens": ["Amphotericin", "B", "-", "induced", "cutaneous", "leucocytoclastic", "vasculitis", ":", "case", "report", "."], "event_mentions": [{"id": "18076602_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "18076602_1_Ent1", "role": "Treatment", "text": "Amphotericin B", "start": 0, "end": 2}, {"entity_id": "18076602_1_Ent2", "role": "Treatment_Drug", "text": "Amphotericin B", "start": 0, "end": 2}, {"entity_id": "18076602_1_Ent0", "role": "Effect", "text": "cutaneous leucocytoclastic vasculitis", "start": 4, "end": 7}]}], "entity_mentions": [{"id": "18076602_1_Ent1", "text": "Amphotericin B", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18076602_1_Ent2", "text": "Amphotericin B", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18076602_1_Ent0", "text": "cutaneous leucocytoclastic vasculitis", "entity_type": "Entity", "start": 4, "end": 7}], "lang": "en"}
{"doc_id": "18079582_2", "wnd_id": "18079582_2_1", "text": "Transient asymptomatic bradycardia in patients on infusional 5 - fluorouracil .", "tokens": ["Transient", "asymptomatic", "bradycardia", "in", "patients", "on", "infusional", "5", "-", "fluorouracil", "."], "event_mentions": [{"id": "18079582_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "on", "start": 5, "end": 6}, "arguments": [{"entity_id": "18079582_2_Ent1", "role": "Effect", "text": "Transient asymptomatic bradycardia", "start": 0, "end": 3}, {"entity_id": "18079582_2_Ent0", "role": "Subject", "text": "patients", "start": 4, "end": 5}, {"entity_id": "18079582_2_Ent3", "role": "Treatment_Route", "text": "infusional", "start": 6, "end": 7}, {"entity_id": "18079582_2_Ent2", "role": "Treatment", "text": "infusional 5 - fluorouracil .", "start": 6, "end": 11}, {"entity_id": "18079582_2_Ent4", "role": "Treatment_Drug", "text": "5 - fluorouracil", "start": 7, "end": 10}]}], "entity_mentions": [{"id": "18079582_2_Ent1", "text": "Transient asymptomatic bradycardia", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18079582_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18079582_2_Ent3", "text": "infusional", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18079582_2_Ent2", "text": "infusional 5 - fluorouracil .", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "18079582_2_Ent4", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 7, "end": 10}], "lang": "en"}
{"doc_id": "18203308_1", "wnd_id": "18203308_1_1", "text": "New onset of CD may be considered as an immune - mediated injury induced by etanercept .", "tokens": ["New", "onset", "of", "CD", "may", "be", "considered", "as", "an", "immune", "-", "mediated", "injury", "induced", "by", "etanercept", "."], "event_mentions": [{"id": "18203308_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 13, "end": 14}, "arguments": [{"entity_id": "18203308_1_Ent0", "role": "Effect", "text": "CD", "start": 3, "end": 4}, {"entity_id": "18203308_1_Ent1", "role": "Effect", "text": "immune - mediated injury", "start": 9, "end": 13}, {"entity_id": "18203308_1_Ent2", "role": "Treatment", "text": "etanercept", "start": 15, "end": 16}, {"entity_id": "18203308_1_Ent3", "role": "Treatment_Drug", "text": "etanercept", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "18203308_1_Ent0", "text": "CD", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18203308_1_Ent1", "text": "immune - mediated injury", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "18203308_1_Ent2", "text": "etanercept", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18203308_1_Ent3", "text": "etanercept", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "18258513_1", "wnd_id": "18258513_1_1", "text": "While doxorubicin was administered , the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum .", "tokens": ["While", "doxorubicin", "was", "administered", ",", "the", "patient", "presented", "thoracic", "pain", "and", "breathing", "distress", "due", "to", "superior", "vena", "cava", "perforation", "by", "the", "central", "catheter", "and", "subsequent", "extravasation", "of", "the", "drug", "into", "the", "mediastinum", "."], "event_mentions": [{"id": "18258513_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 7, "end": 8}, "arguments": [{"entity_id": "18258513_1_Ent2", "role": "Treatment", "text": "doxorubicin", "start": 1, "end": 2}, {"entity_id": "18258513_1_Ent3", "role": "Treatment_Drug", "text": "doxorubicin", "start": 1, "end": 2}, {"entity_id": "18258513_1_Ent0", "role": "Subject", "text": "patient", "start": 6, "end": 7}, {"entity_id": "18258513_1_Ent1", "role": "Effect", "text": "thoracic pain and breathing distress", "start": 8, "end": 13}]}], "entity_mentions": [{"id": "18258513_1_Ent2", "text": "doxorubicin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "18258513_1_Ent3", "text": "doxorubicin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "18258513_1_Ent0", "text": "patient", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18258513_1_Ent1", "text": "thoracic pain and breathing distress", "entity_type": "Entity", "start": 8, "end": 13}], "lang": "en"}
{"doc_id": "18294121_1", "wnd_id": "18294121_1_1", "text": "According to the Naranjo adverse drug reaction probability scale , the likelihood that temozolomide was responsible for the adverse drug reaction of fever was probable ( score of 6 ) .", "tokens": ["According", "to", "the", "Naranjo", "adverse", "drug", "reaction", "probability", "scale", ",", "the", "likelihood", "that", "temozolomide", "was", "responsible", "for", "the", "adverse", "drug", "reaction", "of", "fever", "was", "probable", "(", "score", "of", "6", ")", "."], "event_mentions": [{"id": "18294121_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse drug reaction", "start": 18, "end": 21}, "arguments": [{"entity_id": "18294121_1_Ent1", "role": "Treatment", "text": "temozolomide", "start": 13, "end": 14}, {"entity_id": "18294121_1_Ent2", "role": "Treatment_Drug", "text": "temozolomide", "start": 13, "end": 14}, {"entity_id": "18294121_1_Ent0", "role": "Effect", "text": "fever", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "18294121_1_Ent1", "text": "temozolomide", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18294121_1_Ent2", "text": "temozolomide", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18294121_1_Ent0", "text": "fever", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "18306483_1", "wnd_id": "18306483_1_1", "text": "Rituximab - CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma .", "tokens": ["Rituximab", "-", "CHOP", "induced", "interstitial", "pneumonitis", "in", "patients", "with", "disseminated", "extranodal", "marginal", "zone", "B", "cell", "lymphoma", "."], "event_mentions": [{"id": "18306483_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "18306483_1_Ent2", "role": "Treatment", "text": "Rituximab - CHOP", "start": 0, "end": 3}, {"entity_id": "18306483_1_Ent4", "role": "Treatment_Drug", "text": "Rituximab - CHOP", "start": 0, "end": 3}, {"entity_id": "18306483_1_Ent1", "role": "Effect", "text": "interstitial pneumonitis", "start": 4, "end": 6}, {"entity_id": "18306483_1_Ent0", "role": "Subject", "text": "patients with disseminated extranodal marginal zone B cell lymphoma", "start": 7, "end": 16}, {"entity_id": "18306483_1_Ent3", "role": "Treatment_Disorder", "text": "disseminated extranodal marginal zone B cell lymphoma", "start": 9, "end": 16}]}], "entity_mentions": [{"id": "18306483_1_Ent2", "text": "Rituximab - CHOP", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18306483_1_Ent4", "text": "Rituximab - CHOP", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18306483_1_Ent1", "text": "interstitial pneumonitis", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "18306483_1_Ent0", "text": "patients with disseminated extranodal marginal zone B cell lymphoma", "entity_type": "Entity", "start": 7, "end": 16}, {"id": "18306483_1_Ent3", "text": "disseminated extranodal marginal zone B cell lymphoma", "entity_type": "Entity", "start": 9, "end": 16}], "lang": "en"}
{"doc_id": "1834424_1", "wnd_id": "1834424_1_1", "text": "A 30 - year - old pharmacist suffered from acute allergic contact dermatitis due to 4 - chloro - 7 - nitrobenzofurazan ( NBD - Cl ) .", "tokens": ["A", "30", "-", "year", "-", "old", "pharmacist", "suffered", "from", "acute", "allergic", "contact", "dermatitis", "due", "to", "4", "-", "chloro", "-", "7", "-", "nitrobenzofurazan", "(", "NBD", "-", "Cl", ")", "."], "event_mentions": [{"id": "1834424_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suffered", "start": 7, "end": 8}, "arguments": [{"entity_id": "1834424_1_Ent0", "role": "Subject", "text": "A 30 - year - old pharmacist", "start": 0, "end": 7}, {"entity_id": "1834424_1_Ent1", "role": "Subject_Age", "text": "30 - year - old", "start": 1, "end": 6}, {"entity_id": "1834424_1_Ent2", "role": "Effect", "text": "acute allergic contact dermatitis", "start": 9, "end": 13}, {"entity_id": "1834424_1_Ent4", "role": "Treatment_Drug", "text": "4 - chloro - 7 - nitrobenzofurazan", "start": 15, "end": 22}, {"entity_id": "1834424_1_Ent3", "role": "Treatment", "text": "4 - chloro - 7 - nitrobenzofurazan ( NBD - Cl )", "start": 15, "end": 27}]}], "entity_mentions": [{"id": "1834424_1_Ent0", "text": "A 30 - year - old pharmacist", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "1834424_1_Ent1", "text": "30 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "1834424_1_Ent2", "text": "acute allergic contact dermatitis", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "1834424_1_Ent4", "text": "4 - chloro - 7 - nitrobenzofurazan", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "1834424_1_Ent3", "text": "4 - chloro - 7 - nitrobenzofurazan ( NBD - Cl )", "entity_type": "Entity", "start": 15, "end": 27}], "lang": "en"}
{"doc_id": "18344734_1", "wnd_id": "18344734_1_1", "text": "Photo - onycholysis caused by olanzapine and aripiprazole .", "tokens": ["Photo", "-", "onycholysis", "caused", "by", "olanzapine", "and", "aripiprazole", "."], "event_mentions": [{"id": "18344734_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 3, "end": 4}, "arguments": [{"entity_id": "18344734_1_Ent0", "role": "Effect", "text": "Photo - onycholysis", "start": 0, "end": 3}, {"entity_id": "18344734_1_Ent2", "role": "Treatment_Drug", "text": "olanzapine", "start": 5, "end": 6}, {"entity_id": "18344734_1_Ent1", "role": "Treatment", "text": "olanzapine and aripiprazole", "start": 5, "end": 8}, {"entity_id": "18344734_1_Ent3", "role": "Treatment_Drug", "text": "aripiprazole", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "18344734_1_Ent0", "text": "Photo - onycholysis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18344734_1_Ent2", "text": "olanzapine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18344734_1_Ent1", "text": "olanzapine and aripiprazole", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "18344734_1_Ent3", "text": "aripiprazole", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "18347524_2", "wnd_id": "18347524_2_1", "text": "We report the case of a young man , affected by rheumatoid arthritis who developed a rapid - onset short - of - breath , hemoptysis , and severe weakness , about 2 weeks after the administration of leflunomide .", "tokens": ["We", "report", "the", "case", "of", "a", "young", "man", ",", "affected", "by", "rheumatoid", "arthritis", "who", "developed", "a", "rapid", "-", "onset", "short", "-", "of", "-", "breath", ",", "hemoptysis", ",", "and", "severe", "weakness", ",", "about", "2", "weeks", "after", "the", "administration", "of", "leflunomide", "."], "event_mentions": [{"id": "18347524_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "18347524_2_Ent0", "role": "Subject", "text": "a young man", "start": 5, "end": 8}, {"entity_id": "18347524_2_Ent1", "role": "Subject_Age", "text": "young", "start": 6, "end": 7}, {"entity_id": "18347524_2_Ent4", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 11, "end": 13}, {"entity_id": "18347524_2_Ent2", "role": "Effect", "text": "a rapid - onset short - of - breath , hemoptysis , and severe weakness", "start": 15, "end": 30}, {"entity_id": "18347524_2_Ent3", "role": "Treatment", "text": "about 2 weeks after the administration of leflunomide", "start": 31, "end": 39}, {"entity_id": "18347524_2_Ent6", "role": "Treatment_Time_elapsed", "text": "2 weeks", "start": 32, "end": 34}, {"entity_id": "18347524_2_Ent7", "role": "Treatment_Route", "text": "the administration", "start": 35, "end": 37}, {"entity_id": "18347524_2_Ent5", "role": "Treatment_Drug", "text": "leflunomide", "start": 38, "end": 39}]}], "entity_mentions": [{"id": "18347524_2_Ent0", "text": "a young man", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "18347524_2_Ent1", "text": "young", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18347524_2_Ent4", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "18347524_2_Ent2", "text": "a rapid - onset short - of - breath , hemoptysis , and severe weakness", "entity_type": "Entity", "start": 15, "end": 30}, {"id": "18347524_2_Ent3", "text": "about 2 weeks after the administration of leflunomide", "entity_type": "Entity", "start": 31, "end": 39}, {"id": "18347524_2_Ent6", "text": "2 weeks", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "18347524_2_Ent7", "text": "the administration", "entity_type": "Entity", "start": 35, "end": 37}, {"id": "18347524_2_Ent5", "text": "leflunomide", "entity_type": "Entity", "start": 38, "end": 39}], "lang": "en"}
{"doc_id": "18364401_4", "wnd_id": "18364401_4_1", "text": "Subsequently , he developed hyperglycemia ( fasting blood glucose 138 mg / dL ) that resolved when olanzapine was stopped and recurred ( fasting blood glucose 150 mg / dL ) after 2 days of rechallenge with olanzapine 2.5 mg twice daily .", "tokens": ["Subsequently", ",", "he", "developed", "hyperglycemia", "(", "fasting", "blood", "glucose", "138", "mg", "/", "dL", ")", "that", "resolved", "when", "olanzapine", "was", "stopped", "and", "recurred", "(", "fasting", "blood", "glucose", "150", "mg", "/", "dL", ")", "after", "2", "days", "of", "rechallenge", "with", "olanzapine", "2.5", "mg", "twice", "daily", "."], "event_mentions": [{"id": "18364401_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 15, "end": 16}, "arguments": [{"entity_id": "18364401_4_Ent1", "role": "Treatment_Disorder", "text": "hyperglycemia ( fasting blood glucose 138 mg / dL )", "start": 4, "end": 14}, {"entity_id": "18364401_4_Ent2", "role": "Treatment_Drug", "text": "olanzapine", "start": 17, "end": 18}, {"entity_id": "18364401_4_Ent0", "role": "Treatment", "text": "olanzapine was stopped", "start": 17, "end": 20}]}, {"id": "18364401_4_Evt1", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 31, "end": 32}, "arguments": [{"entity_id": "18364401_4_Ent3", "role": "Effect", "text": "hyperglycemia", "start": 4, "end": 5}, {"entity_id": "18364401_4_Ent4", "role": "Effect", "text": "recurred ( fasting blood glucose 150 mg / dL )", "start": 21, "end": 31}, {"entity_id": "18364401_4_Ent6", "role": "Treatment_Time_elapsed", "text": "2 days", "start": 32, "end": 34}, {"entity_id": "18364401_4_Ent5", "role": "Treatment", "text": "2 days of rechallenge with olanzapine 2.5 mg twice daily", "start": 32, "end": 42}, {"entity_id": "18364401_4_Ent7", "role": "Treatment_Drug", "text": "olanzapine", "start": 37, "end": 38}, {"entity_id": "18364401_4_Ent8", "role": "Treatment_Dosage", "text": "2.5 mg", "start": 38, "end": 40}, {"entity_id": "18364401_4_Ent9", "role": "Treatment_Freq", "text": "twice daily", "start": 40, "end": 42}]}], "entity_mentions": [{"id": "18364401_4_Ent3", "text": "hyperglycemia", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18364401_4_Ent1", "text": "hyperglycemia ( fasting blood glucose 138 mg / dL )", "entity_type": "Entity", "start": 4, "end": 14}, {"id": "18364401_4_Ent2", "text": "olanzapine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18364401_4_Ent0", "text": "olanzapine was stopped", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "18364401_4_Ent4", "text": "recurred ( fasting blood glucose 150 mg / dL )", "entity_type": "Entity", "start": 21, "end": 31}, {"id": "18364401_4_Ent6", "text": "2 days", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "18364401_4_Ent5", "text": "2 days of rechallenge with olanzapine 2.5 mg twice daily", "entity_type": "Entity", "start": 32, "end": 42}, {"id": "18364401_4_Ent7", "text": "olanzapine", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "18364401_4_Ent8", "text": "2.5 mg", "entity_type": "Entity", "start": 38, "end": 40}, {"id": "18364401_4_Ent9", "text": "twice daily", "entity_type": "Entity", "start": 40, "end": 42}], "lang": "en"}
{"doc_id": "18425523_4", "wnd_id": "18425523_4_1", "text": "Persisent ocular hypertension following intravitreal ranibizumab .", "tokens": ["Persisent", "ocular", "hypertension", "following", "intravitreal", "ranibizumab", "."], "event_mentions": [{"id": "18425523_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "18425523_4_Ent0", "role": "Effect", "text": "Persisent ocular hypertension", "start": 0, "end": 3}, {"entity_id": "18425523_4_Ent1", "role": "Treatment", "text": "intravitreal ranibizumab", "start": 4, "end": 6}, {"entity_id": "18425523_4_Ent2", "role": "Treatment_Drug", "text": "ranibizumab", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "18425523_4_Ent0", "text": "Persisent ocular hypertension", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18425523_4_Ent1", "text": "intravitreal ranibizumab", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "18425523_4_Ent2", "text": "ranibizumab", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "18445989_2", "wnd_id": "18445989_2_1", "text": "Clomiphene is a first line treatment for anovulation , a common cause of infertility .", "tokens": ["Clomiphene", "is", "a", "first", "line", "treatment", "for", "anovulation", ",", "a", "common", "cause", "of", "infertility", "."], "event_mentions": [{"id": "18445989_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 5, "end": 6}, "arguments": [{"entity_id": "18445989_2_Ent0", "role": "Treatment", "text": "Clomiphene", "start": 0, "end": 1}, {"entity_id": "18445989_2_Ent1", "role": "Treatment_Drug", "text": "Clomiphene", "start": 0, "end": 1}, {"entity_id": "18445989_2_Ent2", "role": "Treatment_Disorder", "text": "anovulation", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "18445989_2_Ent0", "text": "Clomiphene", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18445989_2_Ent1", "text": "Clomiphene", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18445989_2_Ent2", "text": "anovulation", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "18446030_1", "wnd_id": "18446030_1_1", "text": "Disseminated eruptive giant mollusca contagiosa in an adult psoriasis patient during efalizumab therapy .", "tokens": ["Disseminated", "eruptive", "giant", "mollusca", "contagiosa", "in", "an", "adult", "psoriasis", "patient", "during", "efalizumab", "therapy", "."], "event_mentions": [{"id": "18446030_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 10, "end": 11}, "arguments": [{"entity_id": "18446030_1_Ent2", "role": "Effect", "text": "Disseminated eruptive giant mollusca contagiosa", "start": 0, "end": 5}, {"entity_id": "18446030_1_Ent0", "role": "Subject", "text": "an adult psoriasis patient", "start": 6, "end": 10}, {"entity_id": "18446030_1_Ent1", "role": "Subject_Age", "text": "adult", "start": 7, "end": 8}, {"entity_id": "18446030_1_Ent4", "role": "Treatment_Disorder", "text": "psoriasis", "start": 8, "end": 9}, {"entity_id": "18446030_1_Ent5", "role": "Treatment_Drug", "text": "efalizumab", "start": 11, "end": 12}, {"entity_id": "18446030_1_Ent3", "role": "Treatment", "text": "efalizumab therapy", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "18446030_1_Ent2", "text": "Disseminated eruptive giant mollusca contagiosa", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "18446030_1_Ent0", "text": "an adult psoriasis patient", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "18446030_1_Ent1", "text": "adult", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18446030_1_Ent4", "text": "psoriasis", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18446030_1_Ent5", "text": "efalizumab", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "18446030_1_Ent3", "text": "efalizumab therapy", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "18465737_2", "wnd_id": "18465737_2_1", "text": "The authors report one case of incomplete posterior hyaloid detachment ( PHD ) following intravitreal pegaptanib to treat DME .", "tokens": ["The", "authors", "report", "one", "case", "of", "incomplete", "posterior", "hyaloid", "detachment", "(", "PHD", ")", "following", "intravitreal", "pegaptanib", "to", "treat", "DME", "."], "event_mentions": [{"id": "18465737_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 13, "end": 14}, "arguments": [{"entity_id": "18465737_2_Ent0", "role": "Subject", "text": "one case", "start": 3, "end": 5}, {"entity_id": "18465737_2_Ent1", "role": "Effect", "text": "incomplete posterior hyaloid detachment ( PHD )", "start": 6, "end": 13}, {"entity_id": "18465737_2_Ent3", "role": "Treatment_Route", "text": "intravitreal", "start": 14, "end": 15}, {"entity_id": "18465737_2_Ent2", "role": "Treatment", "text": "intravitreal pegaptanib", "start": 14, "end": 16}, {"entity_id": "18465737_2_Ent4", "role": "Treatment_Drug", "text": "pegaptanib", "start": 15, "end": 16}, {"entity_id": "18465737_2_Ent5", "role": "Treatment_Disorder", "text": "DME", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "18465737_2_Ent0", "text": "one case", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "18465737_2_Ent1", "text": "incomplete posterior hyaloid detachment ( PHD )", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "18465737_2_Ent3", "text": "intravitreal", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18465737_2_Ent2", "text": "intravitreal pegaptanib", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "18465737_2_Ent4", "text": "pegaptanib", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18465737_2_Ent5", "text": "DME", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "18492617_1", "wnd_id": "18492617_1_1", "text": "Our findings reveal that even in patients without a history of seizures , pregabalin can cause a cortical negative myoclonus .", "tokens": ["Our", "findings", "reveal", "that", "even", "in", "patients", "without", "a", "history", "of", "seizures", ",", "pregabalin", "can", "cause", "a", "cortical", "negative", "myoclonus", "."], "event_mentions": [{"id": "18492617_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 15, "end": 16}, "arguments": [{"entity_id": "18492617_1_Ent0", "role": "Subject", "text": "patients without a history of seizures", "start": 6, "end": 12}, {"entity_id": "18492617_1_Ent2", "role": "Treatment", "text": "pregabalin", "start": 13, "end": 14}, {"entity_id": "18492617_1_Ent3", "role": "Treatment_Drug", "text": "pregabalin", "start": 13, "end": 14}, {"entity_id": "18492617_1_Ent1", "role": "Effect", "text": "cortical negative myoclonus", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "18492617_1_Ent0", "text": "patients without a history of seizures", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "18492617_1_Ent2", "text": "pregabalin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18492617_1_Ent3", "text": "pregabalin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18492617_1_Ent1", "text": "cortical negative myoclonus", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "1849334_2", "wnd_id": "1849334_2_1", "text": "We report on 7 patients ( 2 women , 5 men ) with chronic renal failure , who developed under a high dosage of the new diuretic muzolimine ( range 240 to 1440 mg per day ) fatal neuromyeloencephalopathy .", "tokens": ["We", "report", "on", "7", "patients", "(", "2", "women", ",", "5", "men", ")", "with", "chronic", "renal", "failure", ",", "who", "developed", "under", "a", "high", "dosage", "of", "the", "new", "diuretic", "muzolimine", "(", "range", "240", "to", "1440", "mg", "per", "day", ")", "fatal", "neuromyeloencephalopathy", "."], "event_mentions": [{"id": "1849334_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 18, "end": 19}, "arguments": [{"entity_id": "1849334_2_Ent2", "role": "Subject_Population", "text": "7", "start": 3, "end": 4}, {"entity_id": "1849334_2_Ent0", "role": "Subject", "text": "7 patients ( 2 women , 5 men ) with chronic renal failure", "start": 3, "end": 16}, {"entity_id": "1849334_2_Ent1", "role": "Subject_Disorder", "text": "chronic renal failure", "start": 13, "end": 16}, {"entity_id": "1849334_2_Ent4", "role": "Treatment", "text": "a high dosage of the new diuretic muzolimine ( range 240 to 1440 mg per day )", "start": 20, "end": 37}, {"entity_id": "1849334_2_Ent5", "role": "Treatment_Drug", "text": "diuretic muzolimine", "start": 26, "end": 28}, {"entity_id": "1849334_2_Ent7", "role": "Treatment_Dosage", "text": "range 240 to 1440 mg", "start": 29, "end": 34}, {"entity_id": "1849334_2_Ent6", "role": "Treatment_Freq", "text": "per day", "start": 34, "end": 36}, {"entity_id": "1849334_2_Ent3", "role": "Effect", "text": "fatal neuromyeloencephalopathy", "start": 37, "end": 39}]}], "entity_mentions": [{"id": "1849334_2_Ent2", "text": "7", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1849334_2_Ent0", "text": "7 patients ( 2 women , 5 men ) with chronic renal failure", "entity_type": "Entity", "start": 3, "end": 16}, {"id": "1849334_2_Ent1", "text": "chronic renal failure", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "1849334_2_Ent4", "text": "a high dosage of the new diuretic muzolimine ( range 240 to 1440 mg per day )", "entity_type": "Entity", "start": 20, "end": 37}, {"id": "1849334_2_Ent5", "text": "diuretic muzolimine", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "1849334_2_Ent7", "text": "range 240 to 1440 mg", "entity_type": "Entity", "start": 29, "end": 34}, {"id": "1849334_2_Ent6", "text": "per day", "entity_type": "Entity", "start": 34, "end": 36}, {"id": "1849334_2_Ent3", "text": "fatal neuromyeloencephalopathy", "entity_type": "Entity", "start": 37, "end": 39}], "lang": "en"}
{"doc_id": "18504683_3", "wnd_id": "18504683_3_1", "text": "We report 3 cases of children with acute lymphoblastic leukemia who developed seizures and altered sensorium after L - asparaginase therapy .", "tokens": ["We", "report", "3", "cases", "of", "children", "with", "acute", "lymphoblastic", "leukemia", "who", "developed", "seizures", "and", "altered", "sensorium", "after", "L", "-", "asparaginase", "therapy", "."], "event_mentions": [{"id": "18504683_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 16, "end": 17}, "arguments": [{"entity_id": "18504683_3_Ent1", "role": "Subject_Population", "text": "3", "start": 2, "end": 3}, {"entity_id": "18504683_3_Ent0", "role": "Subject", "text": "3 cases of children with acute lymphoblastic leukemia", "start": 2, "end": 10}, {"entity_id": "18504683_3_Ent2", "role": "Subject_Age", "text": "children", "start": 5, "end": 6}, {"entity_id": "18504683_3_Ent5", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukemia", "start": 7, "end": 10}, {"entity_id": "18504683_3_Ent3", "role": "Effect", "text": "seizures and altered sensorium", "start": 12, "end": 16}, {"entity_id": "18504683_3_Ent4", "role": "Treatment", "text": "L - asparaginase", "start": 17, "end": 20}, {"entity_id": "18504683_3_Ent6", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "18504683_3_Ent1", "text": "3", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18504683_3_Ent0", "text": "3 cases of children with acute lymphoblastic leukemia", "entity_type": "Entity", "start": 2, "end": 10}, {"id": "18504683_3_Ent2", "text": "children", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18504683_3_Ent5", "text": "acute lymphoblastic leukemia", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "18504683_3_Ent3", "text": "seizures and altered sensorium", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "18504683_3_Ent4", "text": "L - asparaginase", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "18504683_3_Ent6", "text": "L - asparaginase", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "18523232_2", "wnd_id": "18523232_2_1", "text": "CONCLUSIONS : Prolonged exposure to itraconazole , administered either continuously or intermittently , may precipitate severe and irreversible hepatotoxic events .", "tokens": ["CONCLUSIONS", ":", "Prolonged", "exposure", "to", "itraconazole", ",", "administered", "either", "continuously", "or", "intermittently", ",", "may", "precipitate", "severe", "and", "irreversible", "hepatotoxic", "events", "."], "event_mentions": [{"id": "18523232_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "precipitate", "start": 14, "end": 15}, "arguments": [{"entity_id": "18523232_2_Ent3", "role": "Treatment_Dosage", "text": "Prolonged exposure", "start": 2, "end": 4}, {"entity_id": "18523232_2_Ent1", "role": "Treatment", "text": "Prolonged exposure to itraconazole , administered either continuously or intermittently", "start": 2, "end": 12}, {"entity_id": "18523232_2_Ent2", "role": "Treatment_Drug", "text": "itraconazole", "start": 5, "end": 6}, {"entity_id": "18523232_2_Ent4", "role": "Treatment_Route", "text": "continuously or intermittently", "start": 9, "end": 12}, {"entity_id": "18523232_2_Ent0", "role": "Effect", "text": "severe and irreversible hepatotoxic events", "start": 15, "end": 20}]}], "entity_mentions": [{"id": "18523232_2_Ent3", "text": "Prolonged exposure", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "18523232_2_Ent1", "text": "Prolonged exposure to itraconazole , administered either continuously or intermittently", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "18523232_2_Ent2", "text": "itraconazole", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18523232_2_Ent4", "text": "continuously or intermittently", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "18523232_2_Ent0", "text": "severe and irreversible hepatotoxic events", "entity_type": "Entity", "start": 15, "end": 20}], "lang": "en"}
{"doc_id": "18533420_1", "wnd_id": "18533420_1_1", "text": "CONCLUSIONS : Intrathecal baclofen can impair sexual function and ejaculation in some patients .", "tokens": ["CONCLUSIONS", ":", "Intrathecal", "baclofen", "can", "impair", "sexual", "function", "and", "ejaculation", "in", "some", "patients", "."], "event_mentions": [{"id": "18533420_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "impair", "start": 5, "end": 6}, "arguments": [{"entity_id": "18533420_1_Ent3", "role": "Treatment_Route", "text": "Intrathecal", "start": 2, "end": 3}, {"entity_id": "18533420_1_Ent2", "role": "Treatment", "text": "Intrathecal baclofen", "start": 2, "end": 4}, {"entity_id": "18533420_1_Ent4", "role": "Treatment_Drug", "text": "baclofen", "start": 3, "end": 4}, {"entity_id": "18533420_1_Ent1", "role": "Effect", "text": "impair sexual function and ejaculation", "start": 5, "end": 10}, {"entity_id": "18533420_1_Ent0", "role": "Subject", "text": "some patients", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "18533420_1_Ent3", "text": "Intrathecal", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18533420_1_Ent2", "text": "Intrathecal baclofen", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "18533420_1_Ent4", "text": "baclofen", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18533420_1_Ent1", "text": "impair sexual function and ejaculation", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "18533420_1_Ent0", "text": "some patients", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "18569796_1", "wnd_id": "18569796_1_1", "text": "CONCLUSION : Alendronate led to nodular scleritis and rechallenge caused recurrence of scleritis .", "tokens": ["CONCLUSION", ":", "Alendronate", "led", "to", "nodular", "scleritis", "and", "rechallenge", "caused", "recurrence", "of", "scleritis", "."], "event_mentions": [{"id": "18569796_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "led to", "start": 3, "end": 5}, "arguments": [{"entity_id": "18569796_1_Ent1", "role": "Treatment", "text": "Alendronate", "start": 2, "end": 3}, {"entity_id": "18569796_1_Ent2", "role": "Treatment_Drug", "text": "Alendronate", "start": 2, "end": 3}, {"entity_id": "18569796_1_Ent0", "role": "Effect", "text": "nodular scleritis", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "18569796_1_Ent1", "text": "Alendronate", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18569796_1_Ent2", "text": "Alendronate", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18569796_1_Ent0", "text": "nodular scleritis", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "18569796_3", "wnd_id": "18569796_3_1", "text": "PURPOSE : To report a case of nodular scleritis following alendronate sodium .", "tokens": ["PURPOSE", ":", "To", "report", "a", "case", "of", "nodular", "scleritis", "following", "alendronate", "sodium", "."], "event_mentions": [{"id": "18569796_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 9, "end": 10}, "arguments": [{"entity_id": "18569796_3_Ent0", "role": "Effect", "text": "nodular scleritis", "start": 7, "end": 9}, {"entity_id": "18569796_3_Ent1", "role": "Treatment", "text": "alendronate sodium", "start": 10, "end": 12}, {"entity_id": "18569796_3_Ent2", "role": "Treatment_Drug", "text": "alendronate sodium", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "18569796_3_Ent0", "text": "nodular scleritis", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "18569796_3_Ent1", "text": "alendronate sodium", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "18569796_3_Ent2", "text": "alendronate sodium", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "18585545_3", "wnd_id": "18585545_3_1", "text": "Here , we describe levofloxacin - induced delirium with psychotic features in a relatively young , otherwise healthy female .", "tokens": ["Here", ",", "we", "describe", "levofloxacin", "-", "induced", "delirium", "with", "psychotic", "features", "in", "a", "relatively", "young", ",", "otherwise", "healthy", "female", "."], "event_mentions": [{"id": "18585545_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "18585545_3_Ent2", "role": "Treatment", "text": "levofloxacin", "start": 4, "end": 5}, {"entity_id": "18585545_3_Ent3", "role": "Treatment_Drug", "text": "levofloxacin", "start": 4, "end": 5}, {"entity_id": "18585545_3_Ent1", "role": "Effect", "text": "delirium with psychotic features", "start": 7, "end": 11}, {"entity_id": "18585545_3_Ent0", "role": "Subject", "text": "relatively young , otherwise healthy female", "start": 13, "end": 19}]}], "entity_mentions": [{"id": "18585545_3_Ent2", "text": "levofloxacin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18585545_3_Ent3", "text": "levofloxacin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18585545_3_Ent1", "text": "delirium with psychotic features", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "18585545_3_Ent0", "text": "relatively young , otherwise healthy female", "entity_type": "Entity", "start": 13, "end": 19}], "lang": "en"}
{"doc_id": "18585545_5", "wnd_id": "18585545_5_1", "text": "RESULTS : A previously healthy 42 - year - old woman presented with acute - onset delirium with psychotic features as a consequence of levofloxacin therapy .", "tokens": ["RESULTS", ":", "A", "previously", "healthy", "42", "-", "year", "-", "old", "woman", "presented", "with", "acute", "-", "onset", "delirium", "with", "psychotic", "features", "as", "a", "consequence", "of", "levofloxacin", "therapy", "."], "event_mentions": [{"id": "18585545_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "as a consequence of", "start": 20, "end": 24}, "arguments": [{"entity_id": "18585545_5_Ent0", "role": "Subject", "text": "A previously healthy 42 - year - old woman", "start": 2, "end": 11}, {"entity_id": "18585545_5_Ent1", "role": "Subject_Age", "text": "42 - year - old", "start": 5, "end": 10}, {"entity_id": "18585545_5_Ent2", "role": "Subject_Gender", "text": "woman", "start": 10, "end": 11}, {"entity_id": "18585545_5_Ent3", "role": "Effect", "text": "acute - onset delirium with psychotic features", "start": 13, "end": 20}, {"entity_id": "18585545_5_Ent5", "role": "Treatment_Drug", "text": "levofloxacin", "start": 24, "end": 25}, {"entity_id": "18585545_5_Ent4", "role": "Treatment", "text": "levofloxacin therapy", "start": 24, "end": 26}]}], "entity_mentions": [{"id": "18585545_5_Ent0", "text": "A previously healthy 42 - year - old woman", "entity_type": "Entity", "start": 2, "end": 11}, {"id": "18585545_5_Ent1", "text": "42 - year - old", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "18585545_5_Ent2", "text": "woman", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18585545_5_Ent3", "text": "acute - onset delirium with psychotic features", "entity_type": "Entity", "start": 13, "end": 20}, {"id": "18585545_5_Ent5", "text": "levofloxacin", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "18585545_5_Ent4", "text": "levofloxacin therapy", "entity_type": "Entity", "start": 24, "end": 26}], "lang": "en"}
{"doc_id": "18622319_2", "wnd_id": "18622319_2_1", "text": "Otolaryngologists should be made aware of a newer cause of nasal septal perforations resulting from the more recent antiangiogenic therapy used to treat malignancies .", "tokens": ["Otolaryngologists", "should", "be", "made", "aware", "of", "a", "newer", "cause", "of", "nasal", "septal", "perforations", "resulting", "from", "the", "more", "recent", "antiangiogenic", "therapy", "used", "to", "treat", "malignancies", "."], "event_mentions": [{"id": "18622319_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 13, "end": 14}, "arguments": [{"entity_id": "18622319_2_Ent0", "role": "Effect", "text": "nasal septal perforations", "start": 10, "end": 13}, {"entity_id": "18622319_2_Ent1", "role": "Treatment", "text": "the more recent antiangiogenic therapy", "start": 15, "end": 20}, {"entity_id": "18622319_2_Ent2", "role": "Treatment_Drug", "text": "the more recent antiangiogenic therapy", "start": 15, "end": 20}, {"entity_id": "18622319_2_Ent3", "role": "Treatment_Disorder", "text": "malignancies", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "18622319_2_Ent0", "text": "nasal septal perforations", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "18622319_2_Ent1", "text": "the more recent antiangiogenic therapy", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "18622319_2_Ent2", "text": "the more recent antiangiogenic therapy", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "18622319_2_Ent3", "text": "malignancies", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "18648015_2", "wnd_id": "18648015_2_1", "text": "CONCLUSIONS : Cefazolin was a probable cause of this patient 's leukopenia .", "tokens": ["CONCLUSIONS", ":", "Cefazolin", "was", "a", "probable", "cause", "of", "this", "patient", "'s", "leukopenia", "."], "event_mentions": [{"id": "18648015_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 6, "end": 7}, "arguments": [{"entity_id": "18648015_2_Ent2", "role": "Treatment", "text": "Cefazolin", "start": 2, "end": 3}, {"entity_id": "18648015_2_Ent3", "role": "Treatment_Drug", "text": "Cefazolin", "start": 2, "end": 3}, {"entity_id": "18648015_2_Ent0", "role": "Subject", "text": "patient", "start": 9, "end": 10}, {"entity_id": "18648015_2_Ent1", "role": "Effect", "text": "leukopenia", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "18648015_2_Ent2", "text": "Cefazolin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18648015_2_Ent3", "text": "Cefazolin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18648015_2_Ent0", "text": "patient", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18648015_2_Ent1", "text": "leukopenia", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "18672645_1", "wnd_id": "18672645_1_1", "text": "The patient expired after seven cycles of treatment had been completed because of pulmonary fibrosis and the drug toxicity of bleomycin .", "tokens": ["The", "patient", "expired", "after", "seven", "cycles", "of", "treatment", "had", "been", "completed", "because", "of", "pulmonary", "fibrosis", "and", "the", "drug", "toxicity", "of", "bleomycin", "."], "event_mentions": [{"id": "18672645_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "18672645_1_Ent0", "role": "Subject", "text": "The patient", "start": 0, "end": 2}, {"entity_id": "18672645_1_Ent1", "role": "Effect", "text": "expired", "start": 2, "end": 3}, {"entity_id": "18672645_1_Ent4", "role": "Treatment_Duration", "text": "seven cycles", "start": 4, "end": 6}, {"entity_id": "18672645_1_Ent2", "role": "Treatment", "text": "seven cycles of treatment", "start": 4, "end": 8}, {"entity_id": "18672645_1_Ent3", "role": "Treatment", "text": "drug toxicity of bleomycin", "start": 17, "end": 21}, {"entity_id": "18672645_1_Ent5", "role": "Treatment_Drug", "text": "bleomycin", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "18672645_1_Ent0", "text": "The patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18672645_1_Ent1", "text": "expired", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18672645_1_Ent4", "text": "seven cycles", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "18672645_1_Ent2", "text": "seven cycles of treatment", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "18672645_1_Ent3", "text": "drug toxicity of bleomycin", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "18672645_1_Ent5", "text": "bleomycin", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "18675768_6", "wnd_id": "18675768_6_1", "text": "Three months after starting citalopram , she experienced episodes of chest tightness and dizziness .", "tokens": ["Three", "months", "after", "starting", "citalopram", ",", "she", "experienced", "episodes", "of", "chest", "tightness", "and", "dizziness", "."], "event_mentions": [{"id": "18675768_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 7, "end": 8}, "arguments": [{"entity_id": "18675768_6_Ent5", "role": "Treatment_Time_elapsed", "text": "Three months", "start": 0, "end": 2}, {"entity_id": "18675768_6_Ent3", "role": "Treatment", "text": "citalopram", "start": 4, "end": 5}, {"entity_id": "18675768_6_Ent4", "role": "Treatment_Drug", "text": "citalopram", "start": 4, "end": 5}, {"entity_id": "18675768_6_Ent0", "role": "Subject", "text": "she", "start": 6, "end": 7}, {"entity_id": "18675768_6_Ent1", "role": "Subject_Gender", "text": "she", "start": 6, "end": 7}, {"entity_id": "18675768_6_Ent2", "role": "Effect", "text": "chest tightness and dizziness", "start": 10, "end": 14}]}], "entity_mentions": [{"id": "18675768_6_Ent5", "text": "Three months", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18675768_6_Ent3", "text": "citalopram", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18675768_6_Ent4", "text": "citalopram", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18675768_6_Ent0", "text": "she", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18675768_6_Ent1", "text": "she", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18675768_6_Ent2", "text": "chest tightness and dizziness", "entity_type": "Entity", "start": 10, "end": 14}], "lang": "en"}
{"doc_id": "18691992_1", "wnd_id": "18691992_1_1", "text": "BACKGROUND : Hydroxyurea is a cytostatic agent used to treat myeloproliferative disorders and long - term treatment is associated with mucocutaneous adverse events and nail hyperpigmentation .", "tokens": ["BACKGROUND", ":", "Hydroxyurea", "is", "a", "cytostatic", "agent", "used", "to", "treat", "myeloproliferative", "disorders", "and", "long", "-", "term", "treatment", "is", "associated", "with", "mucocutaneous", "adverse", "events", "and", "nail", "hyperpigmentation", "."], "event_mentions": [{"id": "18691992_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 18, "end": 19}, "arguments": [{"entity_id": "18691992_1_Ent2", "role": "Treatment_Drug", "text": "Hydroxyurea", "start": 2, "end": 3}, {"entity_id": "18691992_1_Ent1", "role": "Treatment", "text": "Hydroxyurea is a cytostatic agent", "start": 2, "end": 7}, {"entity_id": "18691992_1_Ent3", "role": "Treatment_Disorder", "text": "myeloproliferative disorders", "start": 10, "end": 12}, {"entity_id": "18691992_1_Ent0", "role": "Effect", "text": "mucocutaneous adverse events and nail hyperpigmentation", "start": 20, "end": 26}]}], "entity_mentions": [{"id": "18691992_1_Ent2", "text": "Hydroxyurea", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18691992_1_Ent1", "text": "Hydroxyurea is a cytostatic agent", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "18691992_1_Ent3", "text": "myeloproliferative disorders", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "18691992_1_Ent0", "text": "mucocutaneous adverse events and nail hyperpigmentation", "entity_type": "Entity", "start": 20, "end": 26}], "lang": "en"}
{"doc_id": "18691992_2", "wnd_id": "18691992_2_1", "text": "Based on the Naranjo algorithm , the adverse reaction observed was probably related to the hydroxyurea treatment ( score = 6 ) ; however , the hydroxyurea chemotherapy could not be discontinued because of the myeloproliferative disorder .", "tokens": ["Based", "on", "the", "Naranjo", "algorithm", ",", "the", "adverse", "reaction", "observed", "was", "probably", "related", "to", "the", "hydroxyurea", "treatment", "(", "score", "=", "6", ")", ";", "however", ",", "the", "hydroxyurea", "chemotherapy", "could", "not", "be", "discontinued", "because", "of", "the", "myeloproliferative", "disorder", "."], "event_mentions": [{"id": "18691992_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 12, "end": 13}, "arguments": [{"entity_id": "18691992_2_Ent2", "role": "Treatment_Drug", "text": "hydroxyurea", "start": 15, "end": 16}, {"entity_id": "18691992_2_Ent3", "role": "Treatment_Drug", "text": "hydroxyurea", "start": 26, "end": 27}, {"entity_id": "18691992_2_Ent1", "role": "Treatment", "text": "hydroxyurea chemotherapy", "start": 26, "end": 28}, {"entity_id": "18691992_2_Ent4", "role": "Treatment_Route", "text": "chemotherapy", "start": 27, "end": 28}, {"entity_id": "18691992_2_Ent0", "role": "Effect", "text": "myeloproliferative disorder", "start": 35, "end": 37}]}], "entity_mentions": [{"id": "18691992_2_Ent2", "text": "hydroxyurea", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18691992_2_Ent3", "text": "hydroxyurea", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "18691992_2_Ent1", "text": "hydroxyurea chemotherapy", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "18691992_2_Ent4", "text": "chemotherapy", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "18691992_2_Ent0", "text": "myeloproliferative disorder", "entity_type": "Entity", "start": 35, "end": 37}], "lang": "en"}
{"doc_id": "18717612_1", "wnd_id": "18717612_1_1", "text": "Ceftriaxone - induced fixed drug eruption : first report .", "tokens": ["Ceftriaxone", "-", "induced", "fixed", "drug", "eruption", ":", "first", "report", "."], "event_mentions": [{"id": "18717612_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "18717612_1_Ent1", "role": "Treatment", "text": "Ceftriaxone", "start": 0, "end": 1}, {"entity_id": "18717612_1_Ent2", "role": "Treatment_Drug", "text": "Ceftriaxone", "start": 0, "end": 1}, {"entity_id": "18717612_1_Ent0", "role": "Effect", "text": "fixed drug eruption", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "18717612_1_Ent1", "text": "Ceftriaxone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18717612_1_Ent2", "text": "Ceftriaxone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18717612_1_Ent0", "text": "fixed drug eruption", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "18751717_2", "wnd_id": "18751717_2_1", "text": "BACKGROUND : We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis ( ASPPC ) that developed after intravitreal triamcinolone acetonide ( IVTA ) injection .", "tokens": ["BACKGROUND", ":", "We", "describe", "the", "ophthalmic", "features", "and", "clinical", "course", "of", "two", "cases", "of", "acute", "syphilitic", "posterior", "placoid", "chorioretinitis", "(", "ASPPC", ")", "that", "developed", "after", "intravitreal", "triamcinolone", "acetonide", "(", "IVTA", ")", "injection", "."], "event_mentions": [{"id": "18751717_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 23, "end": 24}, "arguments": [{"entity_id": "18751717_2_Ent0", "role": "Effect", "text": "acute syphilitic posterior placoid chorioretinitis", "start": 14, "end": 19}, {"entity_id": "18751717_2_Ent1", "role": "Treatment", "text": "intravitreal triamcinolone acetonide ( IVTA ) injection", "start": 25, "end": 32}, {"entity_id": "18751717_2_Ent2", "role": "Treatment_Drug", "text": "triamcinolone acetonide ( IVTA )", "start": 26, "end": 31}, {"entity_id": "18751717_2_Ent3", "role": "Treatment_Route", "text": "injection", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "18751717_2_Ent0", "text": "acute syphilitic posterior placoid chorioretinitis", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "18751717_2_Ent1", "text": "intravitreal triamcinolone acetonide ( IVTA ) injection", "entity_type": "Entity", "start": 25, "end": 32}, {"id": "18751717_2_Ent2", "text": "triamcinolone acetonide ( IVTA )", "entity_type": "Entity", "start": 26, "end": 31}, {"id": "18751717_2_Ent3", "text": "injection", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "18755414_1", "wnd_id": "18755414_1_1", "text": "Hemorrhage from a falx meningioma after internal use of low - dose aspirin .", "tokens": ["Hemorrhage", "from", "a", "falx", "meningioma", "after", "internal", "use", "of", "low", "-", "dose", "aspirin", "."], "event_mentions": [{"id": "18755414_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 5, "end": 6}, "arguments": [{"entity_id": "18755414_1_Ent0", "role": "Effect", "text": "Hemorrhage from a falx meningioma", "start": 0, "end": 5}, {"entity_id": "18755414_1_Ent5", "role": "Treatment_Disorder", "text": "falx meningioma", "start": 3, "end": 5}, {"entity_id": "18755414_1_Ent4", "role": "Treatment_Route", "text": "internal", "start": 6, "end": 7}, {"entity_id": "18755414_1_Ent1", "role": "Treatment", "text": "internal use of low - dose aspirin", "start": 6, "end": 13}, {"entity_id": "18755414_1_Ent3", "role": "Treatment_Dosage", "text": "low - dose", "start": 9, "end": 12}, {"entity_id": "18755414_1_Ent2", "role": "Treatment_Drug", "text": "aspirin", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "18755414_1_Ent0", "text": "Hemorrhage from a falx meningioma", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "18755414_1_Ent5", "text": "falx meningioma", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "18755414_1_Ent4", "text": "internal", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18755414_1_Ent1", "text": "internal use of low - dose aspirin", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "18755414_1_Ent3", "text": "low - dose", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "18755414_1_Ent2", "text": "aspirin", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "18765315_1", "wnd_id": "18765315_1_1", "text": "Acute coronary syndromes can be associated with the infusion of rituximab .", "tokens": ["Acute", "coronary", "syndromes", "can", "be", "associated", "with", "the", "infusion", "of", "rituximab", "."], "event_mentions": [{"id": "18765315_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "18765315_1_Ent0", "role": "Effect", "text": "Acute coronary syndromes", "start": 0, "end": 3}, {"entity_id": "18765315_1_Ent3", "role": "Treatment_Route", "text": "infusion", "start": 8, "end": 9}, {"entity_id": "18765315_1_Ent1", "role": "Treatment", "text": "infusion of rituximab", "start": 8, "end": 11}, {"entity_id": "18765315_1_Ent2", "role": "Treatment_Drug", "text": "rituximab", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "18765315_1_Ent0", "text": "Acute coronary syndromes", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18765315_1_Ent3", "text": "infusion", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18765315_1_Ent1", "text": "infusion of rituximab", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "18765315_1_Ent2", "text": "rituximab", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "18855892_3", "wnd_id": "18855892_3_1", "text": "In patients with methotrexate - induced anaphylaxis , discontinuation of treatment may increase the risk of death due to cancer progression .", "tokens": ["In", "patients", "with", "methotrexate", "-", "induced", "anaphylaxis", ",", "discontinuation", "of", "treatment", "may", "increase", "the", "risk", "of", "death", "due", "to", "cancer", "progression", "."], "event_mentions": [{"id": "18855892_3_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "18855892_3_Ent5", "role": "Treatment", "text": "methotrexate", "start": 3, "end": 4}, {"entity_id": "18855892_3_Ent6", "role": "Treatment_Drug", "text": "methotrexate", "start": 3, "end": 4}, {"entity_id": "18855892_3_Ent4", "role": "Effect", "text": "anaphylaxis", "start": 6, "end": 7}]}, {"id": "18855892_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "discontinuation", "start": 8, "end": 9}, "arguments": [{"entity_id": "18855892_3_Ent0", "role": "Subject", "text": "In patients with methotrexate - induced anaphylaxis", "start": 0, "end": 7}, {"entity_id": "18855892_3_Ent3", "role": "Treatment_Disorder", "text": "methotrexate - induced anaphylaxis", "start": 3, "end": 7}, {"entity_id": "18855892_3_Ent2", "role": "Treatment", "text": "treatment", "start": 10, "end": 11}, {"entity_id": "18855892_3_Ent1", "role": "Effect", "text": "death due to cancer progression", "start": 16, "end": 21}]}], "entity_mentions": [{"id": "18855892_3_Ent0", "text": "In patients with methotrexate - induced anaphylaxis", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "18855892_3_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18855892_3_Ent6", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18855892_3_Ent3", "text": "methotrexate - induced anaphylaxis", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "18855892_3_Ent4", "text": "anaphylaxis", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18855892_3_Ent2", "text": "treatment", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18855892_3_Ent1", "text": "death due to cancer progression", "entity_type": "Entity", "start": 16, "end": 21}], "lang": "en"}
{"doc_id": "18957000_2", "wnd_id": "18957000_2_1", "text": "Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing thrombosis who are receiving heparin therapy .", "tokens": ["Clinicians", "should", "be", "cognizant", "of", "this", "possibility", "and", "consider", "a", "diagnosis", "of", "HDAs", "in", "patients", "with", "ongoing", "thrombosis", "who", "are", "receiving", "heparin", "therapy", "."], "event_mentions": [{"id": "18957000_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 20, "end": 21}, "arguments": [{"entity_id": "18957000_2_Ent1", "role": "Effect", "text": "HDAs", "start": 12, "end": 13}, {"entity_id": "18957000_2_Ent0", "role": "Subject", "text": "patients", "start": 14, "end": 15}, {"entity_id": "18957000_2_Ent2", "role": "Effect", "text": "thrombosis", "start": 17, "end": 18}, {"entity_id": "18957000_2_Ent3", "role": "Treatment", "text": "heparin", "start": 21, "end": 22}, {"entity_id": "18957000_2_Ent4", "role": "Treatment_Drug", "text": "heparin", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "18957000_2_Ent1", "text": "HDAs", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18957000_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18957000_2_Ent2", "text": "thrombosis", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18957000_2_Ent3", "text": "heparin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "18957000_2_Ent4", "text": "heparin", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "18991509_1", "wnd_id": "18991509_1_1", "text": "Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1 - infected patient receiving therapy with ritonavir - lopinavir .", "tokens": ["Iatrogenic", "Cushing", "syndrome", "after", "epidural", "triamcinolone", "injections", "in", "an", "HIV", "type", "1", "-", "infected", "patient", "receiving", "therapy", "with", "ritonavir", "-", "lopinavir", "."], "event_mentions": [{"id": "18991509_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "18991509_1_Ent1", "role": "Effect", "text": "Iatrogenic Cushing syndrome", "start": 0, "end": 3}, {"entity_id": "18991509_1_Ent5", "role": "Treatment_Drug", "text": "epidural triamcinolone", "start": 4, "end": 6}, {"entity_id": "18991509_1_Ent8", "role": "Combination_Drug", "text": "epidural triamcinolone", "start": 4, "end": 6}, {"entity_id": "18991509_1_Ent3", "role": "Treatment", "text": "epidural triamcinolone injections", "start": 4, "end": 7}, {"entity_id": "18991509_1_Ent7", "role": "Treatment_Route", "text": "injections", "start": 6, "end": 7}, {"entity_id": "18991509_1_Ent0", "role": "Subject", "text": "an HIV type 1 - infected patient", "start": 8, "end": 15}, {"entity_id": "18991509_1_Ent4", "role": "Treatment_Disorder", "text": "HIV type 1", "start": 9, "end": 12}, {"entity_id": "18991509_1_Ent2", "role": "Treatment", "text": "receiving therapy with ritonavir - lopinavir", "start": 15, "end": 21}, {"entity_id": "18991509_1_Ent6", "role": "Treatment_Drug", "text": "ritonavir - lopinavir", "start": 18, "end": 21}, {"entity_id": "18991509_1_Ent9", "role": "Combination_Drug", "text": "ritonavir - lopinavir", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "18991509_1_Ent1", "text": "Iatrogenic Cushing syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18991509_1_Ent5", "text": "epidural triamcinolone", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "18991509_1_Ent8", "text": "epidural triamcinolone", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "18991509_1_Ent3", "text": "epidural triamcinolone injections", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "18991509_1_Ent7", "text": "injections", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18991509_1_Ent0", "text": "an HIV type 1 - infected patient", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "18991509_1_Ent4", "text": "HIV type 1", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "18991509_1_Ent2", "text": "receiving therapy with ritonavir - lopinavir", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "18991509_1_Ent6", "text": "ritonavir - lopinavir", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "18991509_1_Ent9", "text": "ritonavir - lopinavir", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "19003750_1", "wnd_id": "19003750_1_1", "text": "A 22 - year - old drug - abuser injected flunitrazepam tablets dissolved in tap water into her left femoral artery and presented with clinical signs of acute ischaemia of the left leg .", "tokens": ["A", "22", "-", "year", "-", "old", "drug", "-", "abuser", "injected", "flunitrazepam", "tablets", "dissolved", "in", "tap", "water", "into", "her", "left", "femoral", "artery", "and", "presented", "with", "clinical", "signs", "of", "acute", "ischaemia", "of", "the", "left", "leg", "."], "event_mentions": [{"id": "19003750_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 22, "end": 23}, "arguments": [{"entity_id": "19003750_1_Ent0", "role": "Subject", "text": "A 22 - year - old drug - abuser", "start": 0, "end": 9}, {"entity_id": "19003750_1_Ent1", "role": "Subject_Age", "text": "22 - year - old", "start": 1, "end": 6}, {"entity_id": "19003750_1_Ent2", "role": "Subject_Disorder", "text": "drug - abuser", "start": 6, "end": 9}, {"entity_id": "19003750_1_Ent6", "role": "Treatment_Route", "text": "injected", "start": 9, "end": 10}, {"entity_id": "19003750_1_Ent4", "role": "Treatment", "text": "injected flunitrazepam tablets dissolved in tap water into her left femoral artery", "start": 9, "end": 21}, {"entity_id": "19003750_1_Ent5", "role": "Treatment_Drug", "text": "flunitrazepam", "start": 10, "end": 11}, {"entity_id": "19003750_1_Ent7", "role": "Treatment_Route", "text": "tablets dissolved in tap water", "start": 11, "end": 16}, {"entity_id": "19003750_1_Ent3", "role": "Effect", "text": "acute ischaemia of the left leg", "start": 27, "end": 33}]}], "entity_mentions": [{"id": "19003750_1_Ent0", "text": "A 22 - year - old drug - abuser", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "19003750_1_Ent1", "text": "22 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "19003750_1_Ent2", "text": "drug - abuser", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "19003750_1_Ent6", "text": "injected", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19003750_1_Ent4", "text": "injected flunitrazepam tablets dissolved in tap water into her left femoral artery", "entity_type": "Entity", "start": 9, "end": 21}, {"id": "19003750_1_Ent5", "text": "flunitrazepam", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19003750_1_Ent7", "text": "tablets dissolved in tap water", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "19003750_1_Ent3", "text": "acute ischaemia of the left leg", "entity_type": "Entity", "start": 27, "end": 33}], "lang": "en"}
{"doc_id": "19039026_1", "wnd_id": "19039026_1_1", "text": "Biopsy - proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib : a class effect ?", "tokens": ["Biopsy", "-", "proven", "acute", "interstitial", "nephritis", "associated", "with", "the", "tyrosine", "kinase", "inhibitor", "sunitinib", ":", "a", "class", "effect", "?"], "event_mentions": [{"id": "19039026_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "19039026_1_Ent0", "role": "Effect", "text": "acute interstitial nephritis", "start": 3, "end": 6}, {"entity_id": "19039026_1_Ent1", "role": "Treatment", "text": "tyrosine kinase inhibitor sunitinib", "start": 9, "end": 13}, {"entity_id": "19039026_1_Ent2", "role": "Treatment_Drug", "text": "sunitinib", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "19039026_1_Ent0", "text": "acute interstitial nephritis", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "19039026_1_Ent1", "text": "tyrosine kinase inhibitor sunitinib", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "19039026_1_Ent2", "text": "sunitinib", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "19047493_1", "wnd_id": "19047493_1_1", "text": "Extrapyramidal symptoms are well - documented complications of therapy with haloperidol , even when small doses are used .", "tokens": ["Extrapyramidal", "symptoms", "are", "well", "-", "documented", "complications", "of", "therapy", "with", "haloperidol", ",", "even", "when", "small", "doses", "are", "used", "."], "event_mentions": [{"id": "19047493_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complications", "start": 6, "end": 7}, "arguments": [{"entity_id": "19047493_1_Ent0", "role": "Effect", "text": "Extrapyramidal symptoms", "start": 0, "end": 2}, {"entity_id": "19047493_1_Ent1", "role": "Treatment", "text": "haloperidol", "start": 10, "end": 11}, {"entity_id": "19047493_1_Ent3", "role": "Treatment_Drug", "text": "haloperidol", "start": 10, "end": 11}, {"entity_id": "19047493_1_Ent2", "role": "Treatment", "text": "small doses", "start": 14, "end": 16}, {"entity_id": "19047493_1_Ent4", "role": "Treatment_Dosage", "text": "small doses", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "19047493_1_Ent0", "text": "Extrapyramidal symptoms", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19047493_1_Ent1", "text": "haloperidol", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19047493_1_Ent3", "text": "haloperidol", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19047493_1_Ent2", "text": "small doses", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "19047493_1_Ent4", "text": "small doses", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "19047493_2", "wnd_id": "19047493_2_1", "text": "This report highlights a case of drug - induced dysphagia in a patient receiving haloperidol for obsessive nocturnal thoughts and auditory disturbances .", "tokens": ["This", "report", "highlights", "a", "case", "of", "drug", "-", "induced", "dysphagia", "in", "a", "patient", "receiving", "haloperidol", "for", "obsessive", "nocturnal", "thoughts", "and", "auditory", "disturbances", "."], "event_mentions": [{"id": "19047493_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "19047493_2_Ent1", "role": "Effect", "text": "dysphagia", "start": 9, "end": 10}, {"entity_id": "19047493_2_Ent0", "role": "Subject", "text": "a patient", "start": 11, "end": 13}, {"entity_id": "19047493_2_Ent2", "role": "Treatment", "text": "haloperidol", "start": 14, "end": 15}, {"entity_id": "19047493_2_Ent3", "role": "Treatment_Drug", "text": "haloperidol", "start": 14, "end": 15}, {"entity_id": "19047493_2_Ent4", "role": "Treatment_Disorder", "text": "obsessive nocturnal thoughts and auditory disturbances", "start": 16, "end": 22}]}], "entity_mentions": [{"id": "19047493_2_Ent1", "text": "dysphagia", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19047493_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "19047493_2_Ent2", "text": "haloperidol", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "19047493_2_Ent3", "text": "haloperidol", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "19047493_2_Ent4", "text": "obsessive nocturnal thoughts and auditory disturbances", "entity_type": "Entity", "start": 16, "end": 22}], "lang": "en"}
{"doc_id": "19058340_1", "wnd_id": "19058340_1_1", "text": "A 52 year - old male patient diagnosed of ankylosing spondylitis presented with an iron deficiency anemia after a ten - month treatment of methotrexate .", "tokens": ["A", "52", "year", "-", "old", "male", "patient", "diagnosed", "of", "ankylosing", "spondylitis", "presented", "with", "an", "iron", "deficiency", "anemia", "after", "a", "ten", "-", "month", "treatment", "of", "methotrexate", "."], "event_mentions": [{"id": "19058340_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 11, "end": 12}, "arguments": [{"entity_id": "19058340_1_Ent0", "role": "Subject", "text": "A 52 year - old male patient diagnosed of ankylosing spondylitis", "start": 0, "end": 11}, {"entity_id": "19058340_1_Ent1", "role": "Subject_Age", "text": "52 year - old", "start": 1, "end": 5}, {"entity_id": "19058340_1_Ent2", "role": "Subject_Gender", "text": "male", "start": 5, "end": 6}, {"entity_id": "19058340_1_Ent7", "role": "Treatment_Disorder", "text": "ankylosing spondylitis", "start": 9, "end": 11}, {"entity_id": "19058340_1_Ent3", "role": "Effect", "text": "an iron deficiency anemia", "start": 13, "end": 17}, {"entity_id": "19058340_1_Ent4", "role": "Treatment", "text": "a ten - month treatment of methotrexate", "start": 18, "end": 25}, {"entity_id": "19058340_1_Ent5", "role": "Treatment_Time_elapsed", "text": "ten - month", "start": 19, "end": 22}, {"entity_id": "19058340_1_Ent6", "role": "Treatment_Drug", "text": "methotrexate", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "19058340_1_Ent0", "text": "A 52 year - old male patient diagnosed of ankylosing spondylitis", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "19058340_1_Ent1", "text": "52 year - old", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "19058340_1_Ent2", "text": "male", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19058340_1_Ent7", "text": "ankylosing spondylitis", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "19058340_1_Ent3", "text": "an iron deficiency anemia", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "19058340_1_Ent4", "text": "a ten - month treatment of methotrexate", "entity_type": "Entity", "start": 18, "end": 25}, {"id": "19058340_1_Ent5", "text": "ten - month", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "19058340_1_Ent6", "text": "methotrexate", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "19071894_7", "wnd_id": "19071894_7_1", "text": "Renal toxicity signs , induced by amphotericin B , progression of infection after fluconazole , and likely in vivo resistance to this triazole made this case difficult to treat .", "tokens": ["Renal", "toxicity", "signs", ",", "induced", "by", "amphotericin", "B", ",", "progression", "of", "infection", "after", "fluconazole", ",", "and", "likely", "in", "vivo", "resistance", "to", "this", "triazole", "made", "this", "case", "difficult", "to", "treat", "."], "event_mentions": [{"id": "19071894_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "19071894_7_Ent0", "role": "Effect", "text": "Renal toxicity signs", "start": 0, "end": 3}, {"entity_id": "19071894_7_Ent1", "role": "Treatment", "text": "amphotericin B", "start": 6, "end": 8}, {"entity_id": "19071894_7_Ent2", "role": "Treatment_Drug", "text": "amphotericin B", "start": 6, "end": 8}]}, {"id": "19071894_7_Evt1", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 12, "end": 13}, "arguments": [{"entity_id": "19071894_7_Ent3", "role": "Effect", "text": "infection", "start": 11, "end": 12}, {"entity_id": "19071894_7_Ent4", "role": "Treatment", "text": "fluconazole", "start": 13, "end": 14}, {"entity_id": "19071894_7_Ent5", "role": "Treatment_Drug", "text": "fluconazole", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "19071894_7_Ent0", "text": "Renal toxicity signs", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19071894_7_Ent1", "text": "amphotericin B", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "19071894_7_Ent2", "text": "amphotericin B", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "19071894_7_Ent3", "text": "infection", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19071894_7_Ent4", "text": "fluconazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19071894_7_Ent5", "text": "fluconazole", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "19104709_3", "wnd_id": "19104709_3_1", "text": "We report the case of a 51 - year - old man in whom IFN - alpha treatment was followed by recurrence of Graves ' disease 10 years after thyroidectomy was performed and the patient was declared cured .", "tokens": ["We", "report", "the", "case", "of", "a", "51", "-", "year", "-", "old", "man", "in", "whom", "IFN", "-", "alpha", "treatment", "was", "followed", "by", "recurrence", "of", "Graves", "'", "disease", "10", "years", "after", "thyroidectomy", "was", "performed", "and", "the", "patient", "was", "declared", "cured", "."], "event_mentions": [{"id": "19104709_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "followed", "start": 19, "end": 20}, "arguments": [{"entity_id": "19104709_3_Ent0", "role": "Subject", "text": "a 51 - year - old man", "start": 5, "end": 12}, {"entity_id": "19104709_3_Ent1", "role": "Subject_Age", "text": "51 - year - old", "start": 6, "end": 11}, {"entity_id": "19104709_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 11, "end": 12}, {"entity_id": "19104709_3_Ent6", "role": "Treatment_Drug", "text": "IFN - alpha", "start": 14, "end": 17}, {"entity_id": "19104709_3_Ent4", "role": "Treatment", "text": "IFN - alpha treatment", "start": 14, "end": 18}, {"entity_id": "19104709_3_Ent3", "role": "Effect", "text": "recurrence of Graves ' disease", "start": 21, "end": 26}, {"entity_id": "19104709_3_Ent5", "role": "Treatment", "text": "10 years after thyroidectomy", "start": 26, "end": 30}]}], "entity_mentions": [{"id": "19104709_3_Ent0", "text": "a 51 - year - old man", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "19104709_3_Ent1", "text": "51 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "19104709_3_Ent2", "text": "man", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19104709_3_Ent6", "text": "IFN - alpha", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "19104709_3_Ent4", "text": "IFN - alpha treatment", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "19104709_3_Ent3", "text": "recurrence of Graves ' disease", "entity_type": "Entity", "start": 21, "end": 26}, {"id": "19104709_3_Ent5", "text": "10 years after thyroidectomy", "entity_type": "Entity", "start": 26, "end": 30}], "lang": "en"}
{"doc_id": "19112808_2", "wnd_id": "19112808_2_1", "text": "The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin .", "tokens": ["The", "authors", "describe", "a", "case", "of", "interstitial", "granulomatous", "dermatitis", "associated", "with", "darifenacin", "."], "event_mentions": [{"id": "19112808_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "19112808_2_Ent0", "role": "Effect", "text": "interstitial granulomatous dermatitis", "start": 6, "end": 9}, {"entity_id": "19112808_2_Ent1", "role": "Treatment", "text": "darifenacin", "start": 11, "end": 12}, {"entity_id": "19112808_2_Ent2", "role": "Treatment_Drug", "text": "darifenacin", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "19112808_2_Ent0", "text": "interstitial granulomatous dermatitis", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "19112808_2_Ent1", "text": "darifenacin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19112808_2_Ent2", "text": "darifenacin", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "19122478_5", "wnd_id": "19122478_5_1", "text": "We report the first case of chlorambucil - induced DRESS syndrome in a 70 - year - old man recently diagnosed with chronic lymphocytic leukaemia .", "tokens": ["We", "report", "the", "first", "case", "of", "chlorambucil", "-", "induced", "DRESS", "syndrome", "in", "a", "70", "-", "year", "-", "old", "man", "recently", "diagnosed", "with", "chronic", "lymphocytic", "leukaemia", "."], "event_mentions": [{"id": "19122478_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "19122478_5_Ent4", "role": "Treatment", "text": "chlorambucil", "start": 6, "end": 7}, {"entity_id": "19122478_5_Ent5", "role": "Treatment_Drug", "text": "chlorambucil", "start": 6, "end": 7}, {"entity_id": "19122478_5_Ent3", "role": "Effect", "text": "DRESS syndrome", "start": 9, "end": 11}, {"entity_id": "19122478_5_Ent0", "role": "Subject", "text": "a 70 - year - old man", "start": 12, "end": 19}, {"entity_id": "19122478_5_Ent1", "role": "Subject_Age", "text": "70 - year - old", "start": 13, "end": 18}, {"entity_id": "19122478_5_Ent2", "role": "Subject_Gender", "text": "man", "start": 18, "end": 19}, {"entity_id": "19122478_5_Ent6", "role": "Treatment_Disorder", "text": "chronic lymphocytic leukaemia", "start": 22, "end": 25}]}], "entity_mentions": [{"id": "19122478_5_Ent4", "text": "chlorambucil", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19122478_5_Ent5", "text": "chlorambucil", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19122478_5_Ent3", "text": "DRESS syndrome", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "19122478_5_Ent0", "text": "a 70 - year - old man", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "19122478_5_Ent1", "text": "70 - year - old", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "19122478_5_Ent2", "text": "man", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "19122478_5_Ent6", "text": "chronic lymphocytic leukaemia", "entity_type": "Entity", "start": 22, "end": 25}], "lang": "en"}
{"doc_id": "19226083_16", "wnd_id": "19226083_16_1", "text": "Linezolid is a popular choice of antibiotic , especially for the treatment of orthopedic - related MRSA infections .", "tokens": ["Linezolid", "is", "a", "popular", "choice", "of", "antibiotic", ",", "especially", "for", "the", "treatment", "of", "orthopedic", "-", "related", "MRSA", "infections", "."], "event_mentions": [{"id": "19226083_16_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 11, "end": 12}, "arguments": [{"entity_id": "19226083_16_Ent0", "role": "Treatment", "text": "Linezolid", "start": 0, "end": 1}, {"entity_id": "19226083_16_Ent2", "role": "Treatment_Drug", "text": "Linezolid", "start": 0, "end": 1}, {"entity_id": "19226083_16_Ent1", "role": "Treatment_Disorder", "text": "orthopedic - related MRSA infections", "start": 13, "end": 18}]}], "entity_mentions": [{"id": "19226083_16_Ent0", "text": "Linezolid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19226083_16_Ent2", "text": "Linezolid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19226083_16_Ent1", "text": "orthopedic - related MRSA infections", "entity_type": "Entity", "start": 13, "end": 18}], "lang": "en"}
{"doc_id": "19226083_17", "wnd_id": "19226083_17_1", "text": "Patients who commonly require linezolid as an antimicrobial are those with complex infections where other antibiotic treatment has failed .", "tokens": ["Patients", "who", "commonly", "require", "linezolid", "as", "an", "antimicrobial", "are", "those", "with", "complex", "infections", "where", "other", "antibiotic", "treatment", "has", "failed", "."], "event_mentions": [{"id": "19226083_17_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "require", "start": 3, "end": 4}, "arguments": [{"entity_id": "19226083_17_Ent0", "role": "Subject", "text": "Patients", "start": 0, "end": 1}, {"entity_id": "19226083_17_Ent3", "role": "Treatment_Drug", "text": "linezolid", "start": 4, "end": 5}, {"entity_id": "19226083_17_Ent2", "role": "Treatment", "text": "linezolid as an antimicrobial", "start": 4, "end": 8}, {"entity_id": "19226083_17_Ent1", "role": "Subject", "text": "complex infections", "start": 11, "end": 13}, {"entity_id": "19226083_17_Ent4", "role": "Treatment_Disorder", "text": "complex infections", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "19226083_17_Ent0", "text": "Patients", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19226083_17_Ent3", "text": "linezolid", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19226083_17_Ent2", "text": "linezolid as an antimicrobial", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "19226083_17_Ent1", "text": "complex infections", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "19226083_17_Ent4", "text": "complex infections", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "19266307_2", "wnd_id": "19266307_2_1", "text": "MATERIALS AND METHODS : We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin .", "tokens": ["MATERIALS", "AND", "METHODS", ":", "We", "present", "two", "cases", "of", "significant", "morbidity", "related", "to", "primary", "and", "secondary", "perforation", "of", "the", "bladder", "following", "two", "instillations", "of", "epirubicin", "."], "event_mentions": [{"id": "19266307_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 20, "end": 21}, "arguments": [{"entity_id": "19266307_2_Ent1", "role": "Subject_Population", "text": "two", "start": 6, "end": 7}, {"entity_id": "19266307_2_Ent0", "role": "Subject", "text": "two cases", "start": 6, "end": 8}, {"entity_id": "19266307_2_Ent2", "role": "Effect", "text": "significant morbidity related to primary and secondary perforation of the bladder", "start": 9, "end": 20}, {"entity_id": "19266307_2_Ent3", "role": "Treatment", "text": "two instillations of epirubicin", "start": 21, "end": 25}, {"entity_id": "19266307_2_Ent4", "role": "Treatment_Route", "text": "instillations", "start": 22, "end": 23}, {"entity_id": "19266307_2_Ent5", "role": "Treatment_Drug", "text": "epirubicin", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "19266307_2_Ent1", "text": "two", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19266307_2_Ent0", "text": "two cases", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "19266307_2_Ent2", "text": "significant morbidity related to primary and secondary perforation of the bladder", "entity_type": "Entity", "start": 9, "end": 20}, {"id": "19266307_2_Ent3", "text": "two instillations of epirubicin", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "19266307_2_Ent4", "text": "instillations", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "19266307_2_Ent5", "text": "epirubicin", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "19318596_1", "wnd_id": "19318596_1_1", "text": "Cyclosporine - induced pain syndrome in a child undergoing hematopoietic stem cell transplant .", "tokens": ["Cyclosporine", "-", "induced", "pain", "syndrome", "in", "a", "child", "undergoing", "hematopoietic", "stem", "cell", "transplant", "."], "event_mentions": [{"id": "19318596_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "19318596_1_Ent4", "role": "Treatment", "text": "Cyclosporine", "start": 0, "end": 1}, {"entity_id": "19318596_1_Ent5", "role": "Treatment_Drug", "text": "Cyclosporine", "start": 0, "end": 1}, {"entity_id": "19318596_1_Ent3", "role": "Effect", "text": "pain syndrome", "start": 3, "end": 5}, {"entity_id": "19318596_1_Ent0", "role": "Subject", "text": "a child undergoing hematopoietic stem cell transplant", "start": 6, "end": 13}, {"entity_id": "19318596_1_Ent1", "role": "Subject_Age", "text": "child", "start": 7, "end": 8}, {"entity_id": "19318596_1_Ent2", "role": "Subject_Disorder", "text": "hematopoietic stem cell transplant", "start": 9, "end": 13}]}], "entity_mentions": [{"id": "19318596_1_Ent4", "text": "Cyclosporine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19318596_1_Ent5", "text": "Cyclosporine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19318596_1_Ent3", "text": "pain syndrome", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "19318596_1_Ent0", "text": "a child undergoing hematopoietic stem cell transplant", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "19318596_1_Ent1", "text": "child", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19318596_1_Ent2", "text": "hematopoietic stem cell transplant", "entity_type": "Entity", "start": 9, "end": 13}], "lang": "en"}
{"doc_id": "19318596_4", "wnd_id": "19318596_4_1", "text": "With the first cyclosporine dose , the patient complained of leg pain that was most severe during the cyclosporine infusion .", "tokens": ["With", "the", "first", "cyclosporine", "dose", ",", "the", "patient", "complained", "of", "leg", "pain", "that", "was", "most", "severe", "during", "the", "cyclosporine", "infusion", "."], "event_mentions": [{"id": "19318596_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complained", "start": 8, "end": 9}, "arguments": [{"entity_id": "19318596_4_Ent0", "role": "Subject", "text": "With", "start": 0, "end": 1}, {"entity_id": "19318596_4_Ent2", "role": "Treatment", "text": "first cyclosporine dose", "start": 2, "end": 5}, {"entity_id": "19318596_4_Ent3", "role": "Treatment_Drug", "text": "cyclosporine", "start": 3, "end": 4}, {"entity_id": "19318596_4_Ent1", "role": "Effect", "text": "leg pain", "start": 10, "end": 12}, {"entity_id": "19318596_4_Ent4", "role": "Treatment_Route", "text": "infusion", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "19318596_4_Ent0", "text": "With", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19318596_4_Ent2", "text": "first cyclosporine dose", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "19318596_4_Ent3", "text": "cyclosporine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19318596_4_Ent1", "text": "leg pain", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "19318596_4_Ent4", "text": "infusion", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "19331262_4", "wnd_id": "19331262_4_1", "text": "This report describes a case of neuroleptic malignant syndrome due to risperidone in a child with Joubert syndrome .", "tokens": ["This", "report", "describes", "a", "case", "of", "neuroleptic", "malignant", "syndrome", "due", "to", "risperidone", "in", "a", "child", "with", "Joubert", "syndrome", "."], "event_mentions": [{"id": "19331262_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 9, "end": 11}, "arguments": [{"entity_id": "19331262_4_Ent2", "role": "Effect", "text": "neuroleptic malignant syndrome", "start": 6, "end": 9}, {"entity_id": "19331262_4_Ent3", "role": "Treatment", "text": "risperidone", "start": 11, "end": 12}, {"entity_id": "19331262_4_Ent5", "role": "Treatment_Drug", "text": "risperidone", "start": 11, "end": 12}, {"entity_id": "19331262_4_Ent0", "role": "Subject", "text": "a child with Joubert syndrome", "start": 13, "end": 18}, {"entity_id": "19331262_4_Ent1", "role": "Subject_Age", "text": "child", "start": 14, "end": 15}, {"entity_id": "19331262_4_Ent4", "role": "Treatment_Disorder", "text": "Joubert syndrome", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "19331262_4_Ent2", "text": "neuroleptic malignant syndrome", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "19331262_4_Ent3", "text": "risperidone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19331262_4_Ent5", "text": "risperidone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19331262_4_Ent0", "text": "a child with Joubert syndrome", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "19331262_4_Ent1", "text": "child", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "19331262_4_Ent4", "text": "Joubert syndrome", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "19365885_2", "wnd_id": "19365885_2_1", "text": "Hypoglycemia induced by long - acting somatostatin analogues in a patient with nonfunctional neuroendocrine tumor .", "tokens": ["Hypoglycemia", "induced", "by", "long", "-", "acting", "somatostatin", "analogues", "in", "a", "patient", "with", "nonfunctional", "neuroendocrine", "tumor", "."], "event_mentions": [{"id": "19365885_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "19365885_2_Ent1", "role": "Effect", "text": "Hypoglycemia", "start": 0, "end": 1}, {"entity_id": "19365885_2_Ent2", "role": "Treatment", "text": "long - acting somatostatin analogues", "start": 3, "end": 8}, {"entity_id": "19365885_2_Ent4", "role": "Treatment_Drug", "text": "long - acting somatostatin analogues", "start": 3, "end": 8}, {"entity_id": "19365885_2_Ent0", "role": "Subject", "text": "a patient with nonfunctional neuroendocrine tumor", "start": 9, "end": 15}, {"entity_id": "19365885_2_Ent3", "role": "Treatment_Disorder", "text": "nonfunctional neuroendocrine tumor", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "19365885_2_Ent1", "text": "Hypoglycemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19365885_2_Ent2", "text": "long - acting somatostatin analogues", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "19365885_2_Ent4", "text": "long - acting somatostatin analogues", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "19365885_2_Ent0", "text": "a patient with nonfunctional neuroendocrine tumor", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "19365885_2_Ent3", "text": "nonfunctional neuroendocrine tumor", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "19365885_3", "wnd_id": "19365885_3_1", "text": "In these patients , long - acting octreotide may trigger serious hypoglycemia .", "tokens": ["In", "these", "patients", ",", "long", "-", "acting", "octreotide", "may", "trigger", "serious", "hypoglycemia", "."], "event_mentions": [{"id": "19365885_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "trigger", "start": 9, "end": 10}, "arguments": [{"entity_id": "19365885_3_Ent0", "role": "Subject", "text": "these patients", "start": 1, "end": 3}, {"entity_id": "19365885_3_Ent2", "role": "Treatment", "text": "long - acting octreotide", "start": 4, "end": 8}, {"entity_id": "19365885_3_Ent3", "role": "Treatment_Drug", "text": "octreotide", "start": 7, "end": 8}, {"entity_id": "19365885_3_Ent1", "role": "Effect", "text": "serious hypoglycemia", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "19365885_3_Ent0", "text": "these patients", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "19365885_3_Ent2", "text": "long - acting octreotide", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "19365885_3_Ent3", "text": "octreotide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19365885_3_Ent1", "text": "serious hypoglycemia", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "19402273_1", "wnd_id": "19402273_1_1", "text": "Isoniazid causing breast tissue enlargement has been very rarely reported .", "tokens": ["Isoniazid", "causing", "breast", "tissue", "enlargement", "has", "been", "very", "rarely", "reported", "."], "event_mentions": [{"id": "19402273_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causing", "start": 1, "end": 2}, "arguments": [{"entity_id": "19402273_1_Ent1", "role": "Treatment", "text": "Isoniazid", "start": 0, "end": 1}, {"entity_id": "19402273_1_Ent2", "role": "Treatment_Drug", "text": "Isoniazid", "start": 0, "end": 1}, {"entity_id": "19402273_1_Ent0", "role": "Effect", "text": "breast tissue enlargement", "start": 2, "end": 5}]}], "entity_mentions": [{"id": "19402273_1_Ent1", "text": "Isoniazid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19402273_1_Ent2", "text": "Isoniazid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19402273_1_Ent0", "text": "breast tissue enlargement", "entity_type": "Entity", "start": 2, "end": 5}], "lang": "en"}
{"doc_id": "19423610_7", "wnd_id": "19423610_7_1", "text": "Methylene blue has been found to be a potent inhibitor of monoamine oxidase ( MAO ) , and several cases of serotonin toxicity have been reported recently following its administration .", "tokens": ["Methylene", "blue", "has", "been", "found", "to", "be", "a", "potent", "inhibitor", "of", "monoamine", "oxidase", "(", "MAO", ")", ",", "and", "several", "cases", "of", "serotonin", "toxicity", "have", "been", "reported", "recently", "following", "its", "administration", "."], "event_mentions": [{"id": "19423610_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 27, "end": 28}, "arguments": [{"entity_id": "19423610_7_Ent2", "role": "Treatment", "text": "Methylene blue", "start": 0, "end": 2}, {"entity_id": "19423610_7_Ent3", "role": "Treatment_Drug", "text": "Methylene blue", "start": 0, "end": 2}, {"entity_id": "19423610_7_Ent0", "role": "Subject", "text": "several cases", "start": 18, "end": 20}, {"entity_id": "19423610_7_Ent1", "role": "Effect", "text": "serotonin toxicity", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "19423610_7_Ent2", "text": "Methylene blue", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19423610_7_Ent3", "text": "Methylene blue", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19423610_7_Ent0", "text": "several cases", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "19423610_7_Ent1", "text": "serotonin toxicity", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "19423610_9", "wnd_id": "19423610_9_1", "text": "Methylene blue is used in a variety of surgical settings as well as for treatment of various types of hypotensive shock and methemoglobinaemia .", "tokens": ["Methylene", "blue", "is", "used", "in", "a", "variety", "of", "surgical", "settings", "as", "well", "as", "for", "treatment", "of", "various", "types", "of", "hypotensive", "shock", "and", "methemoglobinaemia", "."], "event_mentions": [{"id": "19423610_9_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 14, "end": 15}, "arguments": [{"entity_id": "19423610_9_Ent0", "role": "Treatment", "text": "Methylene blue", "start": 0, "end": 2}, {"entity_id": "19423610_9_Ent3", "role": "Treatment_Drug", "text": "Methylene blue", "start": 0, "end": 2}, {"entity_id": "19423610_9_Ent1", "role": "Treatment_Disorder", "text": "hypotensive shock", "start": 19, "end": 21}, {"entity_id": "19423610_9_Ent2", "role": "Treatment_Disorder", "text": "methemoglobinaemia", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "19423610_9_Ent0", "text": "Methylene blue", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19423610_9_Ent3", "text": "Methylene blue", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19423610_9_Ent1", "text": "hypotensive shock", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "19423610_9_Ent2", "text": "methemoglobinaemia", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "19520277_2", "wnd_id": "19520277_2_1", "text": "The case of a 4 - year - old girl with valproate - induced stupor and electroencephalographic pattern of increased fast activity is reported .", "tokens": ["The", "case", "of", "a", "4", "-", "year", "-", "old", "girl", "with", "valproate", "-", "induced", "stupor", "and", "electroencephalographic", "pattern", "of", "increased", "fast", "activity", "is", "reported", "."], "event_mentions": [{"id": "19520277_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 13, "end": 14}, "arguments": [{"entity_id": "19520277_2_Ent0", "role": "Subject", "text": "a 4 - year - old girl", "start": 3, "end": 10}, {"entity_id": "19520277_2_Ent1", "role": "Subject_Age", "text": "4 - year - old", "start": 4, "end": 9}, {"entity_id": "19520277_2_Ent2", "role": "Subject_Gender", "text": "girl", "start": 9, "end": 10}, {"entity_id": "19520277_2_Ent4", "role": "Treatment", "text": "valproate", "start": 11, "end": 12}, {"entity_id": "19520277_2_Ent5", "role": "Treatment_Drug", "text": "valproate", "start": 11, "end": 12}, {"entity_id": "19520277_2_Ent3", "role": "Effect", "text": "stupor and electroencephalographic pattern of increased fast activity", "start": 14, "end": 22}]}], "entity_mentions": [{"id": "19520277_2_Ent0", "text": "a 4 - year - old girl", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "19520277_2_Ent1", "text": "4 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "19520277_2_Ent2", "text": "girl", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19520277_2_Ent4", "text": "valproate", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19520277_2_Ent5", "text": "valproate", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19520277_2_Ent3", "text": "stupor and electroencephalographic pattern of increased fast activity", "entity_type": "Entity", "start": 14, "end": 22}], "lang": "en"}
{"doc_id": "19531695_14", "wnd_id": "19531695_14_1", "text": "Because toxicity may occur when flecainide is prescribed with paroxetine and other potent CYP2D6 inhibitors , flecainide plasma concentrations should be monitored closely with commencement of CYP2D6 inhibitors .", "tokens": ["Because", "toxicity", "may", "occur", "when", "flecainide", "is", "prescribed", "with", "paroxetine", "and", "other", "potent", "CYP2D6", "inhibitors", ",", "flecainide", "plasma", "concentrations", "should", "be", "monitored", "closely", "with", "commencement", "of", "CYP2D6", "inhibitors", "."], "event_mentions": [{"id": "19531695_14_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 3, "end": 4}, "arguments": [{"entity_id": "19531695_14_Ent0", "role": "Effect", "text": "toxicity", "start": 1, "end": 2}, {"entity_id": "19531695_14_Ent2", "role": "Treatment_Drug", "text": "flecainide", "start": 5, "end": 6}, {"entity_id": "19531695_14_Ent4", "role": "Combination_Drug", "text": "flecainide", "start": 5, "end": 6}, {"entity_id": "19531695_14_Ent1", "role": "Treatment", "text": "flecainide is prescribed with paroxetine and other potent CYP2D6 inhibitors", "start": 5, "end": 15}, {"entity_id": "19531695_14_Ent3", "role": "Treatment_Drug", "text": "paroxetine", "start": 9, "end": 10}, {"entity_id": "19531695_14_Ent5", "role": "Combination_Drug", "text": "paroxetine", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "19531695_14_Ent0", "text": "toxicity", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "19531695_14_Ent2", "text": "flecainide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19531695_14_Ent4", "text": "flecainide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19531695_14_Ent1", "text": "flecainide is prescribed with paroxetine and other potent CYP2D6 inhibitors", "entity_type": "Entity", "start": 5, "end": 15}, {"id": "19531695_14_Ent3", "text": "paroxetine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19531695_14_Ent5", "text": "paroxetine", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "19540093_5", "wnd_id": "19540093_5_1", "text": "We recommend that clinicians monitor patients for signs and symptoms of pancreatitis , including abdominal pain , during treatment with tigecycline .", "tokens": ["We", "recommend", "that", "clinicians", "monitor", "patients", "for", "signs", "and", "symptoms", "of", "pancreatitis", ",", "including", "abdominal", "pain", ",", "during", "treatment", "with", "tigecycline", "."], "event_mentions": [{"id": "19540093_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 18, "end": 19}, "arguments": [{"entity_id": "19540093_5_Ent0", "role": "Effect", "text": "pancreatitis , including abdominal pain", "start": 11, "end": 16}, {"entity_id": "19540093_5_Ent1", "role": "Treatment", "text": "tigecycline", "start": 20, "end": 21}, {"entity_id": "19540093_5_Ent2", "role": "Treatment_Drug", "text": "tigecycline", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "19540093_5_Ent0", "text": "pancreatitis , including abdominal pain", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "19540093_5_Ent1", "text": "tigecycline", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "19540093_5_Ent2", "text": "tigecycline", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "1954704_2", "wnd_id": "1954704_2_1", "text": "We report a case of biopsy proven myositis whose symptoms began within 10 days of receiving leuprolide acetate therapy for prostate cancer .", "tokens": ["We", "report", "a", "case", "of", "biopsy", "proven", "myositis", "whose", "symptoms", "began", "within", "10", "days", "of", "receiving", "leuprolide", "acetate", "therapy", "for", "prostate", "cancer", "."], "event_mentions": [{"id": "1954704_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "symptoms began", "start": 9, "end": 11}, "arguments": [{"entity_id": "1954704_2_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "1954704_2_Ent1", "role": "Effect", "text": "myositis", "start": 7, "end": 8}, {"entity_id": "1954704_2_Ent2", "role": "Treatment", "text": "within 10 days of receiving leuprolide acetate therapy", "start": 11, "end": 19}, {"entity_id": "1954704_2_Ent4", "role": "Treatment_Time_elapsed", "text": "10 days", "start": 12, "end": 14}, {"entity_id": "1954704_2_Ent3", "role": "Treatment_Drug", "text": "leuprolide acetate", "start": 16, "end": 18}, {"entity_id": "1954704_2_Ent5", "role": "Treatment_Disorder", "text": "prostate cancer", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "1954704_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "1954704_2_Ent1", "text": "myositis", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1954704_2_Ent2", "text": "within 10 days of receiving leuprolide acetate therapy", "entity_type": "Entity", "start": 11, "end": 19}, {"id": "1954704_2_Ent4", "text": "10 days", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "1954704_2_Ent3", "text": "leuprolide acetate", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "1954704_2_Ent5", "text": "prostate cancer", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "19567656_2", "wnd_id": "19567656_2_1", "text": "DISCUSSION : The Naranjo probability scale indicated a probable relationship between sertraline treatment and the onset of rhabdomyolysis .", "tokens": ["DISCUSSION", ":", "The", "Naranjo", "probability", "scale", "indicated", "a", "probable", "relationship", "between", "sertraline", "treatment", "and", "the", "onset", "of", "rhabdomyolysis", "."], "event_mentions": [{"id": "19567656_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "relationship", "start": 9, "end": 10}, "arguments": [{"entity_id": "19567656_2_Ent1", "role": "Treatment", "text": "sertraline", "start": 11, "end": 12}, {"entity_id": "19567656_2_Ent2", "role": "Treatment_Drug", "text": "sertraline", "start": 11, "end": 12}, {"entity_id": "19567656_2_Ent0", "role": "Effect", "text": "rhabdomyolysis", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "19567656_2_Ent1", "text": "sertraline", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19567656_2_Ent2", "text": "sertraline", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19567656_2_Ent0", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "19567656_3", "wnd_id": "19567656_3_1", "text": "OBJECTIVE : To describe a case of sertraline - induced rhabdomyolysis in an elderly patient with dementia and comorbidities .", "tokens": ["OBJECTIVE", ":", "To", "describe", "a", "case", "of", "sertraline", "-", "induced", "rhabdomyolysis", "in", "an", "elderly", "patient", "with", "dementia", "and", "comorbidities", "."], "event_mentions": [{"id": "19567656_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "19567656_3_Ent3", "role": "Treatment", "text": "sertraline", "start": 7, "end": 8}, {"entity_id": "19567656_3_Ent6", "role": "Treatment_Drug", "text": "sertraline", "start": 7, "end": 8}, {"entity_id": "19567656_3_Ent2", "role": "Effect", "text": "rhabdomyolysis", "start": 10, "end": 11}, {"entity_id": "19567656_3_Ent0", "role": "Subject", "text": "an elderly patient with dementia and comorbidities", "start": 12, "end": 19}, {"entity_id": "19567656_3_Ent1", "role": "Subject_Age", "text": "elderly", "start": 13, "end": 14}, {"entity_id": "19567656_3_Ent5", "role": "Treatment_Disorder", "text": "dementia", "start": 16, "end": 17}, {"entity_id": "19567656_3_Ent4", "role": "Treatment_Disorder", "text": "comorbidities", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "19567656_3_Ent3", "text": "sertraline", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19567656_3_Ent6", "text": "sertraline", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19567656_3_Ent2", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19567656_3_Ent0", "text": "an elderly patient with dementia and comorbidities", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "19567656_3_Ent1", "text": "elderly", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19567656_3_Ent5", "text": "dementia", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "19567656_3_Ent4", "text": "comorbidities", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "19653965_2", "wnd_id": "19653965_2_1", "text": "Transient cardiac arrhythmias related to lopinavir / ritonavir in two patients with HIV infection .", "tokens": ["Transient", "cardiac", "arrhythmias", "related", "to", "lopinavir", "/", "ritonavir", "in", "two", "patients", "with", "HIV", "infection", "."], "event_mentions": [{"id": "19653965_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 3, "end": 4}, "arguments": [{"entity_id": "19653965_2_Ent2", "role": "Effect", "text": "Transient cardiac arrhythmias", "start": 0, "end": 3}, {"entity_id": "19653965_2_Ent5", "role": "Treatment_Drug", "text": "lopinavir", "start": 5, "end": 6}, {"entity_id": "19653965_2_Ent7", "role": "Combination_Drug", "text": "lopinavir", "start": 5, "end": 6}, {"entity_id": "19653965_2_Ent3", "role": "Treatment", "text": "lopinavir / ritonavir", "start": 5, "end": 8}, {"entity_id": "19653965_2_Ent6", "role": "Treatment_Drug", "text": "ritonavir", "start": 7, "end": 8}, {"entity_id": "19653965_2_Ent8", "role": "Combination_Drug", "text": "ritonavir", "start": 7, "end": 8}, {"entity_id": "19653965_2_Ent1", "role": "Subject_Population", "text": "two", "start": 9, "end": 10}, {"entity_id": "19653965_2_Ent0", "role": "Subject", "text": "two patients with HIV infection", "start": 9, "end": 14}, {"entity_id": "19653965_2_Ent4", "role": "Treatment_Disorder", "text": "HIV infection", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "19653965_2_Ent2", "text": "Transient cardiac arrhythmias", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19653965_2_Ent5", "text": "lopinavir", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19653965_2_Ent7", "text": "lopinavir", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19653965_2_Ent3", "text": "lopinavir / ritonavir", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "19653965_2_Ent6", "text": "ritonavir", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19653965_2_Ent8", "text": "ritonavir", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19653965_2_Ent1", "text": "two", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19653965_2_Ent0", "text": "two patients with HIV infection", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "19653965_2_Ent4", "text": "HIV infection", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "19667003_14", "wnd_id": "19667003_14_1", "text": "CONCLUSION : A 26 - year - old man with bipolar disorder developed hyperammonemia three weeks after initiating carbamazepine therapy .", "tokens": ["CONCLUSION", ":", "A", "26", "-", "year", "-", "old", "man", "with", "bipolar", "disorder", "developed", "hyperammonemia", "three", "weeks", "after", "initiating", "carbamazepine", "therapy", "."], "event_mentions": [{"id": "19667003_14_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "19667003_14_Ent0", "role": "Subject", "text": "A 26 - year - old man with bipolar disorder", "start": 2, "end": 12}, {"entity_id": "19667003_14_Ent1", "role": "Subject_Age", "text": "26 - year - old", "start": 3, "end": 8}, {"entity_id": "19667003_14_Ent2", "role": "Subject_Gender", "text": "man", "start": 8, "end": 9}, {"entity_id": "19667003_14_Ent7", "role": "Treatment_Disorder", "text": "bipolar disorder", "start": 10, "end": 12}, {"entity_id": "19667003_14_Ent3", "role": "Effect", "text": "hyperammonemia", "start": 13, "end": 14}, {"entity_id": "19667003_14_Ent5", "role": "Treatment_Time_elapsed", "text": "three weeks", "start": 14, "end": 16}, {"entity_id": "19667003_14_Ent4", "role": "Treatment", "text": "three weeks after initiating carbamazepine therapy", "start": 14, "end": 20}, {"entity_id": "19667003_14_Ent6", "role": "Treatment_Drug", "text": "carbamazepine", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "19667003_14_Ent0", "text": "A 26 - year - old man with bipolar disorder", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "19667003_14_Ent1", "text": "26 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "19667003_14_Ent2", "text": "man", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19667003_14_Ent7", "text": "bipolar disorder", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "19667003_14_Ent3", "text": "hyperammonemia", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19667003_14_Ent5", "text": "three weeks", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "19667003_14_Ent4", "text": "three weeks after initiating carbamazepine therapy", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "19667003_14_Ent6", "text": "carbamazepine", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "1966850_1", "wnd_id": "1966850_1_1", "text": "Adriamycin - induced cardiomyopathy aggravated by cis - platinum nephrotoxicity requiring dialysis .", "tokens": ["Adriamycin", "-", "induced", "cardiomyopathy", "aggravated", "by", "cis", "-", "platinum", "nephrotoxicity", "requiring", "dialysis", "."], "event_mentions": [{"id": "1966850_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "1966850_1_Ent1", "role": "Treatment", "text": "Adriamycin", "start": 0, "end": 1}, {"entity_id": "1966850_1_Ent2", "role": "Treatment_Drug", "text": "Adriamycin", "start": 0, "end": 1}, {"entity_id": "1966850_1_Ent0", "role": "Effect", "text": "cardiomyopathy", "start": 3, "end": 4}]}, {"id": "1966850_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "nephrotoxicity", "start": 9, "end": 10}, "arguments": [{"entity_id": "1966850_1_Ent4", "role": "Treatment", "text": "cis - platinum", "start": 6, "end": 9}, {"entity_id": "1966850_1_Ent5", "role": "Treatment_Drug", "text": "cis - platinum", "start": 6, "end": 9}, {"entity_id": "1966850_1_Ent3", "role": "Effect", "text": "nephrotoxicity requiring dialysis", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "1966850_1_Ent1", "text": "Adriamycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1966850_1_Ent2", "text": "Adriamycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1966850_1_Ent0", "text": "cardiomyopathy", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1966850_1_Ent4", "text": "cis - platinum", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "1966850_1_Ent5", "text": "cis - platinum", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "1966850_1_Ent3", "text": "nephrotoxicity requiring dialysis", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "19707032_4", "wnd_id": "19707032_4_1", "text": "CONCLUSIONS : Patients receiving intravitreal injections of bevacizumab should be evaluated for potential systemic risk factors such as carotid insufficiency , coagulopathy and poorly controlled diabetes mellitus .", "tokens": ["CONCLUSIONS", ":", "Patients", "receiving", "intravitreal", "injections", "of", "bevacizumab", "should", "be", "evaluated", "for", "potential", "systemic", "risk", "factors", "such", "as", "carotid", "insufficiency", ",", "coagulopathy", "and", "poorly", "controlled", "diabetes", "mellitus", "."], "event_mentions": [{"id": "19707032_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "risk", "start": 14, "end": 15}, "arguments": [{"entity_id": "19707032_4_Ent3", "role": "Treatment_Route", "text": "intravitreal injections", "start": 4, "end": 6}, {"entity_id": "19707032_4_Ent1", "role": "Treatment", "text": "intravitreal injections of bevacizumab", "start": 4, "end": 8}, {"entity_id": "19707032_4_Ent2", "role": "Treatment_Drug", "text": "bevacizumab", "start": 7, "end": 8}, {"entity_id": "19707032_4_Ent0", "role": "Effect", "text": "carotid insufficiency , coagulopathy and poorly controlled diabetes mellitus", "start": 18, "end": 27}]}], "entity_mentions": [{"id": "19707032_4_Ent3", "text": "intravitreal injections", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "19707032_4_Ent1", "text": "intravitreal injections of bevacizumab", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "19707032_4_Ent2", "text": "bevacizumab", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19707032_4_Ent0", "text": "carotid insufficiency , coagulopathy and poorly controlled diabetes mellitus", "entity_type": "Entity", "start": 18, "end": 27}], "lang": "en"}
{"doc_id": "19754002_2", "wnd_id": "19754002_2_1", "text": "We report on a serious side effect in a severely depressed 55 - year - old woman , who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants , atypical antipsychotic drugs , the mood stabilizer lithium and the lipid - lowering drug pravastatin .", "tokens": ["We", "report", "on", "a", "serious", "side", "effect", "in", "a", "severely", "depressed", "55", "-", "year", "-", "old", "woman", ",", "who", "presented", "an", "erythematous", "pigmented", "skin", "rash", "on", "the", "whole", "body", "under", "combination", "treatment", "with", "antidepressants", ",", "atypical", "antipsychotic", "drugs", ",", "the", "mood", "stabilizer", "lithium", "and", "the", "lipid", "-", "lowering", "drug", "pravastatin", "."], "event_mentions": [{"id": "19754002_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 19, "end": 20}, "arguments": [{"entity_id": "19754002_2_Ent5", "role": "Treatment_Disorder", "text": "depressed", "start": 10, "end": 11}, {"entity_id": "19754002_2_Ent0", "role": "Subject", "text": "depressed 55 - year - old woman", "start": 10, "end": 17}, {"entity_id": "19754002_2_Ent1", "role": "Subject_Age", "text": "55 - year - old", "start": 11, "end": 16}, {"entity_id": "19754002_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 16, "end": 17}, {"entity_id": "19754002_2_Ent3", "role": "Effect", "text": "erythematous pigmented skin rash on the whole body", "start": 21, "end": 29}, {"entity_id": "19754002_2_Ent4", "role": "Treatment", "text": "combination treatment with antidepressants , atypical antipsychotic drugs , the mood stabilizer lithium and the lipid - lowering drug pravastatin", "start": 30, "end": 50}, {"entity_id": "19754002_2_Ent6", "role": "Treatment_Drug", "text": "antidepressants", "start": 33, "end": 34}, {"entity_id": "19754002_2_Ent10", "role": "Combination_Drug", "text": "antidepressants", "start": 33, "end": 34}, {"entity_id": "19754002_2_Ent7", "role": "Treatment_Drug", "text": "atypical antipsychotic", "start": 35, "end": 37}, {"entity_id": "19754002_2_Ent11", "role": "Combination_Drug", "text": "atypical antipsychotic", "start": 35, "end": 37}, {"entity_id": "19754002_2_Ent8", "role": "Treatment_Drug", "text": "lithium", "start": 42, "end": 43}, {"entity_id": "19754002_2_Ent12", "role": "Combination_Drug", "text": "lithium", "start": 42, "end": 43}, {"entity_id": "19754002_2_Ent9", "role": "Treatment_Drug", "text": "pravastatin", "start": 49, "end": 50}, {"entity_id": "19754002_2_Ent13", "role": "Combination_Drug", "text": "pravastatin", "start": 49, "end": 50}]}], "entity_mentions": [{"id": "19754002_2_Ent5", "text": "depressed", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19754002_2_Ent0", "text": "depressed 55 - year - old woman", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "19754002_2_Ent1", "text": "55 - year - old", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "19754002_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "19754002_2_Ent3", "text": "erythematous pigmented skin rash on the whole body", "entity_type": "Entity", "start": 21, "end": 29}, {"id": "19754002_2_Ent4", "text": "combination treatment with antidepressants , atypical antipsychotic drugs , the mood stabilizer lithium and the lipid - lowering drug pravastatin", "entity_type": "Entity", "start": 30, "end": 50}, {"id": "19754002_2_Ent6", "text": "antidepressants", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "19754002_2_Ent10", "text": "antidepressants", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "19754002_2_Ent7", "text": "atypical antipsychotic", "entity_type": "Entity", "start": 35, "end": 37}, {"id": "19754002_2_Ent11", "text": "atypical antipsychotic", "entity_type": "Entity", "start": 35, "end": 37}, {"id": "19754002_2_Ent8", "text": "lithium", "entity_type": "Entity", "start": 42, "end": 43}, {"id": "19754002_2_Ent12", "text": "lithium", "entity_type": "Entity", "start": 42, "end": 43}, {"id": "19754002_2_Ent9", "text": "pravastatin", "entity_type": "Entity", "start": 49, "end": 50}, {"id": "19754002_2_Ent13", "text": "pravastatin", "entity_type": "Entity", "start": 49, "end": 50}], "lang": "en"}
{"doc_id": "19754002_4", "wnd_id": "19754002_4_1", "text": "The allergic reaction started to develop after co - administration of pravastatin .", "tokens": ["The", "allergic", "reaction", "started", "to", "develop", "after", "co", "-", "administration", "of", "pravastatin", "."], "event_mentions": [{"id": "19754002_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 5, "end": 6}, "arguments": [{"entity_id": "19754002_4_Ent0", "role": "Effect", "text": "allergic reaction", "start": 1, "end": 3}, {"entity_id": "19754002_4_Ent1", "role": "Treatment", "text": "co - administration of pravastatin", "start": 7, "end": 12}, {"entity_id": "19754002_4_Ent2", "role": "Treatment_Drug", "text": "pravastatin", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "19754002_4_Ent0", "text": "allergic reaction", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "19754002_4_Ent1", "text": "co - administration of pravastatin", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "19754002_4_Ent2", "text": "pravastatin", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "19755414_10", "wnd_id": "19755414_10_1", "text": "The use of telithromycin in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid adverse effects .", "tokens": ["The", "use", "of", "telithromycin", "in", "patients", "receiving", "multiple", "doses", "of", "oxycodone", "for", "pain", "relief", "may", "increase", "the", "risk", "of", "opioid", "adverse", "effects", "."], "event_mentions": [{"id": "19755414_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increase the risk", "start": 15, "end": 18}, "arguments": [{"entity_id": "19755414_10_Ent2", "role": "Treatment", "text": "telithromycin", "start": 3, "end": 4}, {"entity_id": "19755414_10_Ent3", "role": "Treatment_Drug", "text": "telithromycin", "start": 3, "end": 4}, {"entity_id": "19755414_10_Ent0", "role": "Subject", "text": "patients receiving multiple doses of oxycodone for pain relief", "start": 5, "end": 14}, {"entity_id": "19755414_10_Ent1", "role": "Effect", "text": "opioid adverse effects", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "19755414_10_Ent2", "text": "telithromycin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19755414_10_Ent3", "text": "telithromycin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19755414_10_Ent0", "text": "patients receiving multiple doses of oxycodone for pain relief", "entity_type": "Entity", "start": 5, "end": 14}, {"id": "19755414_10_Ent1", "text": "opioid adverse effects", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "19782276_10", "wnd_id": "19782276_10_1", "text": "Concomitant administration of cytarabine might have affected his liver function and there might have been interaction between the drugs .", "tokens": ["Concomitant", "administration", "of", "cytarabine", "might", "have", "affected", "his", "liver", "function", "and", "there", "might", "have", "been", "interaction", "between", "the", "drugs", "."], "event_mentions": [{"id": "19782276_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "affected", "start": 6, "end": 7}, "arguments": [{"entity_id": "19782276_10_Ent1", "role": "Treatment", "text": "cytarabine", "start": 3, "end": 4}, {"entity_id": "19782276_10_Ent2", "role": "Treatment_Drug", "text": "cytarabine", "start": 3, "end": 4}, {"entity_id": "19782276_10_Ent0", "role": "Effect", "text": "liver function", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "19782276_10_Ent1", "text": "cytarabine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19782276_10_Ent2", "text": "cytarabine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19782276_10_Ent0", "text": "liver function", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "19798640_1", "wnd_id": "19798640_1_1", "text": "A 40 - year - old man with relapsing - remitting multiple sclerosis ( MS ) developed primary central nervous system lymphoma ( PCNSL ) after having received 21 doses of natalizumab monotherapy .", "tokens": ["A", "40", "-", "year", "-", "old", "man", "with", "relapsing", "-", "remitting", "multiple", "sclerosis", "(", "MS", ")", "developed", "primary", "central", "nervous", "system", "lymphoma", "(", "PCNSL", ")", "after", "having", "received", "21", "doses", "of", "natalizumab", "monotherapy", "."], "event_mentions": [{"id": "19798640_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 16, "end": 17}, "arguments": [{"entity_id": "19798640_1_Ent1", "role": "Subject_Age", "text": "40 - year - old", "start": 1, "end": 6}, {"entity_id": "19798640_1_Ent0", "role": "Subject", "text": "40 - year - old man with relapsing - remitting multiple sclerosis ( MS )", "start": 1, "end": 16}, {"entity_id": "19798640_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "19798640_1_Ent5", "role": "Treatment_Disorder", "text": "relapsing - remitting multiple sclerosis ( MS )", "start": 8, "end": 16}, {"entity_id": "19798640_1_Ent3", "role": "Effect", "text": "primary central nervous system lymphoma ( PCNSL )", "start": 17, "end": 25}, {"entity_id": "19798640_1_Ent6", "role": "Treatment_Dosage", "text": "21 doses", "start": 28, "end": 30}, {"entity_id": "19798640_1_Ent4", "role": "Treatment", "text": "21 doses of natalizumab monotherapy", "start": 28, "end": 33}, {"entity_id": "19798640_1_Ent7", "role": "Treatment_Drug", "text": "natalizumab", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "19798640_1_Ent1", "text": "40 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "19798640_1_Ent0", "text": "40 - year - old man with relapsing - remitting multiple sclerosis ( MS )", "entity_type": "Entity", "start": 1, "end": 16}, {"id": "19798640_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19798640_1_Ent5", "text": "relapsing - remitting multiple sclerosis ( MS )", "entity_type": "Entity", "start": 8, "end": 16}, {"id": "19798640_1_Ent3", "text": "primary central nervous system lymphoma ( PCNSL )", "entity_type": "Entity", "start": 17, "end": 25}, {"id": "19798640_1_Ent6", "text": "21 doses", "entity_type": "Entity", "start": 28, "end": 30}, {"id": "19798640_1_Ent4", "text": "21 doses of natalizumab monotherapy", "entity_type": "Entity", "start": 28, "end": 33}, {"id": "19798640_1_Ent7", "text": "natalizumab", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "19815480_1", "wnd_id": "19815480_1_1", "text": "The first patient is undergoing hemodialysis and , though responding to sunitinib , is having significant fatigue and hypertension .", "tokens": ["The", "first", "patient", "is", "undergoing", "hemodialysis", "and", ",", "though", "responding", "to", "sunitinib", ",", "is", "having", "significant", "fatigue", "and", "hypertension", "."], "event_mentions": [{"id": "19815480_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "having", "start": 14, "end": 15}, "arguments": [{"entity_id": "19815480_1_Ent0", "role": "Subject", "text": "The first patient", "start": 0, "end": 3}, {"entity_id": "19815480_1_Ent2", "role": "Treatment", "text": "sunitinib", "start": 11, "end": 12}, {"entity_id": "19815480_1_Ent3", "role": "Treatment_Drug", "text": "sunitinib", "start": 11, "end": 12}, {"entity_id": "19815480_1_Ent1", "role": "Effect", "text": "significant fatigue and hypertension", "start": 15, "end": 19}]}], "entity_mentions": [{"id": "19815480_1_Ent0", "text": "The first patient", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19815480_1_Ent2", "text": "sunitinib", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19815480_1_Ent3", "text": "sunitinib", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19815480_1_Ent1", "text": "significant fatigue and hypertension", "entity_type": "Entity", "start": 15, "end": 19}], "lang": "en"}
{"doc_id": "19857154_4", "wnd_id": "19857154_4_1", "text": "We describe two patients who experienced serious quetiapine adverse effects potentially mediated through an interaction with ritonavir - boosted atazanavir .", "tokens": ["We", "describe", "two", "patients", "who", "experienced", "serious", "quetiapine", "adverse", "effects", "potentially", "mediated", "through", "an", "interaction", "with", "ritonavir", "-", "boosted", "atazanavir", "."], "event_mentions": [{"id": "19857154_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 5, "end": 6}, "arguments": [{"entity_id": "19857154_4_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "19857154_4_Ent0", "role": "Subject", "text": "two patients", "start": 2, "end": 4}, {"entity_id": "19857154_4_Ent2", "role": "Effect", "text": "serious quetiapine adverse effects", "start": 6, "end": 10}, {"entity_id": "19857154_4_Ent4", "role": "Treatment_Drug", "text": "ritonavir", "start": 16, "end": 17}, {"entity_id": "19857154_4_Ent6", "role": "Combination_Drug", "text": "ritonavir", "start": 16, "end": 17}, {"entity_id": "19857154_4_Ent3", "role": "Treatment", "text": "ritonavir - boosted atazanavir", "start": 16, "end": 20}, {"entity_id": "19857154_4_Ent5", "role": "Treatment_Drug", "text": "atazanavir", "start": 19, "end": 20}, {"entity_id": "19857154_4_Ent7", "role": "Combination_Drug", "text": "atazanavir", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "19857154_4_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "19857154_4_Ent0", "text": "two patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "19857154_4_Ent2", "text": "serious quetiapine adverse effects", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "19857154_4_Ent4", "text": "ritonavir", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "19857154_4_Ent6", "text": "ritonavir", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "19857154_4_Ent3", "text": "ritonavir - boosted atazanavir", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "19857154_4_Ent5", "text": "atazanavir", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "19857154_4_Ent7", "text": "atazanavir", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "19857154_5", "wnd_id": "19857154_5_1", "text": "The first patient was a 57 - year - old man with HIV and bipolar disease who developed rapid and severe weight gain when quetiapine was added to a stable atazanavir - ritonavir - based antiretroviral regimen .", "tokens": ["The", "first", "patient", "was", "a", "57", "-", "year", "-", "old", "man", "with", "HIV", "and", "bipolar", "disease", "who", "developed", "rapid", "and", "severe", "weight", "gain", "when", "quetiapine", "was", "added", "to", "a", "stable", "atazanavir", "-", "ritonavir", "-", "based", "antiretroviral", "regimen", "."], "event_mentions": [{"id": "19857154_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 17, "end": 18}, "arguments": [{"entity_id": "19857154_5_Ent0", "role": "Subject", "text": "a 57 - year - old man with HIV and bipolar disease", "start": 4, "end": 16}, {"entity_id": "19857154_5_Ent1", "role": "Subject_Age", "text": "57 - year - old", "start": 5, "end": 10}, {"entity_id": "19857154_5_Ent2", "role": "Subject_Gender", "text": "man", "start": 10, "end": 11}, {"entity_id": "19857154_5_Ent5", "role": "Treatment_Disorder", "text": "HIV", "start": 12, "end": 13}, {"entity_id": "19857154_5_Ent6", "role": "Treatment_Disorder", "text": "bipolar disease", "start": 14, "end": 16}, {"entity_id": "19857154_5_Ent3", "role": "Effect", "text": "rapid and severe weight gain", "start": 18, "end": 23}, {"entity_id": "19857154_5_Ent9", "role": "Treatment_Drug", "text": "quetiapine", "start": 24, "end": 25}, {"entity_id": "19857154_5_Ent10", "role": "Combination_Drug", "text": "quetiapine", "start": 24, "end": 25}, {"entity_id": "19857154_5_Ent4", "role": "Treatment", "text": "quetiapine was added to a stable atazanavir - ritonavir - based antiretroviral regimen", "start": 24, "end": 37}, {"entity_id": "19857154_5_Ent7", "role": "Treatment_Drug", "text": "atazanavir", "start": 30, "end": 31}, {"entity_id": "19857154_5_Ent11", "role": "Combination_Drug", "text": "atazanavir", "start": 30, "end": 31}, {"entity_id": "19857154_5_Ent8", "role": "Treatment_Drug", "text": "ritonavir", "start": 32, "end": 33}, {"entity_id": "19857154_5_Ent12", "role": "Combination_Drug", "text": "ritonavir", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "19857154_5_Ent0", "text": "a 57 - year - old man with HIV and bipolar disease", "entity_type": "Entity", "start": 4, "end": 16}, {"id": "19857154_5_Ent1", "text": "57 - year - old", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "19857154_5_Ent2", "text": "man", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19857154_5_Ent5", "text": "HIV", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19857154_5_Ent6", "text": "bipolar disease", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "19857154_5_Ent3", "text": "rapid and severe weight gain", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "19857154_5_Ent9", "text": "quetiapine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "19857154_5_Ent10", "text": "quetiapine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "19857154_5_Ent4", "text": "quetiapine was added to a stable atazanavir - ritonavir - based antiretroviral regimen", "entity_type": "Entity", "start": 24, "end": 37}, {"id": "19857154_5_Ent7", "text": "atazanavir", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "19857154_5_Ent11", "text": "atazanavir", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "19857154_5_Ent8", "text": "ritonavir", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "19857154_5_Ent12", "text": "ritonavir", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "1988604_2", "wnd_id": "1988604_2_1", "text": "Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy ; however , it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient .", "tokens": ["Thrombin", "is", "highly", "effective", "for", "stopping", "intractable", "arterial", "hemorrhage", "during", "stereotactic", "brain", "biopsy", ";", "however", ",", "it", "is", "a", "vasospastic", "agent", "and", "may", "have", "been", "responsible", "for", "the", "cerebral", "infarctions", "in", "one", "patient", "."], "event_mentions": [{"id": "1988604_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "stopping", "start": 5, "end": 6}, "arguments": [{"entity_id": "1988604_2_Ent1", "role": "Treatment", "text": "Thrombin", "start": 0, "end": 1}, {"entity_id": "1988604_2_Ent3", "role": "Treatment_Drug", "text": "Thrombin", "start": 0, "end": 1}, {"entity_id": "1988604_2_Ent0", "role": "Effect", "text": "highly effective", "start": 2, "end": 4}, {"entity_id": "1988604_2_Ent2", "role": "Treatment_Disorder", "text": "intractable arterial hemorrhage", "start": 6, "end": 9}]}, {"id": "1988604_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "responsible", "start": 25, "end": 26}, "arguments": [{"entity_id": "1988604_2_Ent7", "role": "Treatment", "text": "Thrombin", "start": 0, "end": 1}, {"entity_id": "1988604_2_Ent9", "role": "Treatment_Drug", "text": "Thrombin", "start": 0, "end": 1}, {"entity_id": "1988604_2_Ent8", "role": "Treatment_Disorder", "text": "intractable arterial hemorrhage", "start": 6, "end": 9}, {"entity_id": "1988604_2_Ent6", "role": "Effect", "text": "cerebral infarctions", "start": 28, "end": 30}, {"entity_id": "1988604_2_Ent5", "role": "Subject_Population", "text": "one", "start": 31, "end": 32}, {"entity_id": "1988604_2_Ent4", "role": "Subject", "text": "one patient", "start": 31, "end": 33}]}], "entity_mentions": [{"id": "1988604_2_Ent1", "text": "Thrombin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1988604_2_Ent3", "text": "Thrombin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1988604_2_Ent7", "text": "Thrombin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1988604_2_Ent9", "text": "Thrombin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1988604_2_Ent0", "text": "highly effective", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "1988604_2_Ent2", "text": "intractable arterial hemorrhage", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "1988604_2_Ent8", "text": "intractable arterial hemorrhage", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "1988604_2_Ent6", "text": "cerebral infarctions", "entity_type": "Entity", "start": 28, "end": 30}, {"id": "1988604_2_Ent5", "text": "one", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "1988604_2_Ent4", "text": "one patient", "entity_type": "Entity", "start": 31, "end": 33}], "lang": "en"}
{"doc_id": "19897274_1", "wnd_id": "19897274_1_1", "text": "However , a recent post - marketing survey in Japan revealed that interstitial pneumonia occurred in 4 among approximately 2 000 Japanese patients treated with sorafenib .", "tokens": ["However", ",", "a", "recent", "post", "-", "marketing", "survey", "in", "Japan", "revealed", "that", "interstitial", "pneumonia", "occurred", "in", "4", "among", "approximately", "2", "000", "Japanese", "patients", "treated", "with", "sorafenib", "."], "event_mentions": [{"id": "19897274_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 14, "end": 15}, "arguments": [{"entity_id": "19897274_1_Ent3", "role": "Effect", "text": "interstitial pneumonia", "start": 12, "end": 14}, {"entity_id": "19897274_1_Ent2", "role": "Subject_Population", "text": "4 among approximately 2 000", "start": 16, "end": 21}, {"entity_id": "19897274_1_Ent0", "role": "Subject", "text": "4 among approximately 2 000 Japanese patients", "start": 16, "end": 23}, {"entity_id": "19897274_1_Ent1", "role": "Subject_Race", "text": "Japanese", "start": 21, "end": 22}, {"entity_id": "19897274_1_Ent4", "role": "Treatment", "text": "sorafenib", "start": 25, "end": 26}, {"entity_id": "19897274_1_Ent5", "role": "Treatment_Drug", "text": "sorafenib", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "19897274_1_Ent3", "text": "interstitial pneumonia", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "19897274_1_Ent2", "text": "4 among approximately 2 000", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "19897274_1_Ent0", "text": "4 among approximately 2 000 Japanese patients", "entity_type": "Entity", "start": 16, "end": 23}, {"id": "19897274_1_Ent1", "text": "Japanese", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "19897274_1_Ent4", "text": "sorafenib", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "19897274_1_Ent5", "text": "sorafenib", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "1993143_1", "wnd_id": "1993143_1_1", "text": "Of 371 patients treated with 8MOP , three ( 0.8 % ) developed an acute dermatitis in the PUVA - treated areas .", "tokens": ["Of", "371", "patients", "treated", "with", "8MOP", ",", "three", "(", "0.8", "%", ")", "developed", "an", "acute", "dermatitis", "in", "the", "PUVA", "-", "treated", "areas", "."], "event_mentions": [{"id": "1993143_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "1993143_1_Ent0", "role": "Subject", "text": "Of 371 patients", "start": 0, "end": 3}, {"entity_id": "1993143_1_Ent2", "role": "Subject_Population", "text": "371", "start": 1, "end": 2}, {"entity_id": "1993143_1_Ent5", "role": "Treatment", "text": "treated with 8MOP", "start": 3, "end": 6}, {"entity_id": "1993143_1_Ent6", "role": "Treatment_Drug", "text": "8MOP", "start": 5, "end": 6}, {"entity_id": "1993143_1_Ent1", "role": "Subject", "text": "three ( 0.8 % )", "start": 7, "end": 12}, {"entity_id": "1993143_1_Ent3", "role": "Subject_Population", "text": "three ( 0.8 % )", "start": 7, "end": 12}, {"entity_id": "1993143_1_Ent4", "role": "Effect", "text": "acute dermatitis", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "1993143_1_Ent0", "text": "Of 371 patients", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "1993143_1_Ent2", "text": "371", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "1993143_1_Ent5", "text": "treated with 8MOP", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "1993143_1_Ent6", "text": "8MOP", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1993143_1_Ent1", "text": "three ( 0.8 % )", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "1993143_1_Ent3", "text": "three ( 0.8 % )", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "1993143_1_Ent4", "text": "acute dermatitis", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "19995222_2", "wnd_id": "19995222_2_1", "text": "CONCLUSIONS : These results suggest that clozapine may cause TD ; however , the prevalence is low and the severity is relatively mild , with no or mild self - reported discomfort .", "tokens": ["CONCLUSIONS", ":", "These", "results", "suggest", "that", "clozapine", "may", "cause", "TD", ";", "however", ",", "the", "prevalence", "is", "low", "and", "the", "severity", "is", "relatively", "mild", ",", "with", "no", "or", "mild", "self", "-", "reported", "discomfort", "."], "event_mentions": [{"id": "19995222_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 8, "end": 9}, "arguments": [{"entity_id": "19995222_2_Ent1", "role": "Treatment", "text": "clozapine", "start": 6, "end": 7}, {"entity_id": "19995222_2_Ent2", "role": "Treatment_Drug", "text": "clozapine", "start": 6, "end": 7}, {"entity_id": "19995222_2_Ent0", "role": "Effect", "text": "TD", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "19995222_2_Ent1", "text": "clozapine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19995222_2_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19995222_2_Ent0", "text": "TD", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "20020238_3", "wnd_id": "20020238_3_1", "text": "Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin .", "tokens": ["Retinopathy", "in", "hepatitis", "C", "patients", "due", "to", "combination", "therapy", "with", "pegylated", "interferon", "and", "ribavirin", "."], "event_mentions": [{"id": "20020238_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 5, "end": 6}, "arguments": [{"entity_id": "20020238_3_Ent1", "role": "Effect", "text": "Retinopathy", "start": 0, "end": 1}, {"entity_id": "20020238_3_Ent3", "role": "Treatment_Disorder", "text": "hepatitis C", "start": 2, "end": 4}, {"entity_id": "20020238_3_Ent0", "role": "Subject", "text": "hepatitis C patients", "start": 2, "end": 5}, {"entity_id": "20020238_3_Ent4", "role": "Treatment_Drug", "text": "pegylated interferon", "start": 10, "end": 12}, {"entity_id": "20020238_3_Ent6", "role": "Combination_Drug", "text": "pegylated interferon", "start": 10, "end": 12}, {"entity_id": "20020238_3_Ent2", "role": "Treatment", "text": "pegylated interferon and ribavirin", "start": 10, "end": 14}, {"entity_id": "20020238_3_Ent5", "role": "Treatment_Drug", "text": "ribavirin", "start": 13, "end": 14}, {"entity_id": "20020238_3_Ent7", "role": "Combination_Drug", "text": "ribavirin", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "20020238_3_Ent1", "text": "Retinopathy", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20020238_3_Ent3", "text": "hepatitis C", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "20020238_3_Ent0", "text": "hepatitis C patients", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "20020238_3_Ent4", "text": "pegylated interferon", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "20020238_3_Ent6", "text": "pegylated interferon", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "20020238_3_Ent2", "text": "pegylated interferon and ribavirin", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "20020238_3_Ent5", "text": "ribavirin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "20020238_3_Ent7", "text": "ribavirin", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "20110001_1", "wnd_id": "20110001_1_1", "text": "CONCLUSIONS : We present a case of a patient with CML who developed KS 12 months after starting treatment with imatinib 400 mg / d .", "tokens": ["CONCLUSIONS", ":", "We", "present", "a", "case", "of", "a", "patient", "with", "CML", "who", "developed", "KS", "12", "months", "after", "starting", "treatment", "with", "imatinib", "400", "mg", "/", "d", "."], "event_mentions": [{"id": "20110001_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "20110001_1_Ent0", "role": "Subject", "text": "a patient", "start": 7, "end": 9}, {"entity_id": "20110001_1_Ent1", "role": "Effect", "text": "KS", "start": 13, "end": 14}, {"entity_id": "20110001_1_Ent2", "role": "Treatment", "text": "12 months", "start": 14, "end": 16}, {"entity_id": "20110001_1_Ent4", "role": "Treatment_Time_elapsed", "text": "12 months", "start": 14, "end": 16}, {"entity_id": "20110001_1_Ent5", "role": "Treatment_Drug", "text": "imatinib", "start": 20, "end": 21}, {"entity_id": "20110001_1_Ent3", "role": "Treatment", "text": "imatinib 400 mg / d", "start": 20, "end": 25}, {"entity_id": "20110001_1_Ent6", "role": "Treatment_Dosage", "text": "400 mg / d", "start": 21, "end": 25}]}], "entity_mentions": [{"id": "20110001_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "20110001_1_Ent1", "text": "KS", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "20110001_1_Ent2", "text": "12 months", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "20110001_1_Ent4", "text": "12 months", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "20110001_1_Ent5", "text": "imatinib", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "20110001_1_Ent3", "text": "imatinib 400 mg / d", "entity_type": "Entity", "start": 20, "end": 25}, {"id": "20110001_1_Ent6", "text": "400 mg / d", "entity_type": "Entity", "start": 21, "end": 25}], "lang": "en"}
{"doc_id": "2011096_5", "wnd_id": "2011096_5_1", "text": "Neurotoxicity can occur at any time using high - dose cytosine therapy .", "tokens": ["Neurotoxicity", "can", "occur", "at", "any", "time", "using", "high", "-", "dose", "cytosine", "therapy", "."], "event_mentions": [{"id": "2011096_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 2, "end": 3}, "arguments": [{"entity_id": "2011096_5_Ent0", "role": "Effect", "text": "Neurotoxicity", "start": 0, "end": 1}, {"entity_id": "2011096_5_Ent2", "role": "Treatment_Dosage", "text": "high - dose", "start": 7, "end": 10}, {"entity_id": "2011096_5_Ent1", "role": "Treatment", "text": "high - dose cytosine", "start": 7, "end": 11}, {"entity_id": "2011096_5_Ent3", "role": "Treatment_Drug", "text": "cytosine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "2011096_5_Ent0", "text": "Neurotoxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2011096_5_Ent2", "text": "high - dose", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "2011096_5_Ent1", "text": "high - dose cytosine", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "2011096_5_Ent3", "text": "cytosine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "20118434_3", "wnd_id": "20118434_3_1", "text": "METHOD : The authors followed a patient with chronic HCV who received interferon and ribavirin and who developed hallucinations ultimately requiring psychiatric hospitalization .", "tokens": ["METHOD", ":", "The", "authors", "followed", "a", "patient", "with", "chronic", "HCV", "who", "received", "interferon", "and", "ribavirin", "and", "who", "developed", "hallucinations", "ultimately", "requiring", "psychiatric", "hospitalization", "."], "event_mentions": [{"id": "20118434_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 17, "end": 18}, "arguments": [{"entity_id": "20118434_3_Ent0", "role": "Subject", "text": "a patient with chronic HCV", "start": 5, "end": 10}, {"entity_id": "20118434_3_Ent5", "role": "Treatment_Disorder", "text": "chronic HCV", "start": 8, "end": 10}, {"entity_id": "20118434_3_Ent3", "role": "Treatment_Drug", "text": "interferon", "start": 12, "end": 13}, {"entity_id": "20118434_3_Ent6", "role": "Combination_Drug", "text": "interferon", "start": 12, "end": 13}, {"entity_id": "20118434_3_Ent2", "role": "Treatment", "text": "interferon and ribavirin", "start": 12, "end": 15}, {"entity_id": "20118434_3_Ent4", "role": "Treatment_Drug", "text": "ribavirin", "start": 14, "end": 15}, {"entity_id": "20118434_3_Ent7", "role": "Combination_Drug", "text": "ribavirin", "start": 14, "end": 15}, {"entity_id": "20118434_3_Ent1", "role": "Effect", "text": "hallucinations", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "20118434_3_Ent0", "text": "a patient with chronic HCV", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "20118434_3_Ent5", "text": "chronic HCV", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "20118434_3_Ent3", "text": "interferon", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "20118434_3_Ent6", "text": "interferon", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "20118434_3_Ent2", "text": "interferon and ribavirin", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "20118434_3_Ent4", "text": "ribavirin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "20118434_3_Ent7", "text": "ribavirin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "20118434_3_Ent1", "text": "hallucinations", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "20118434_4", "wnd_id": "20118434_4_1", "text": "OBJECTIVE : The authors described a case of interferon - induced psychosis as a framework to review the literature and discuss the decision to pursue antiviral treatment in psychiatrically ill patients with hepatitis C.", "tokens": ["OBJECTIVE", ":", "The", "authors", "described", "a", "case", "of", "interferon", "-", "induced", "psychosis", "as", "a", "framework", "to", "review", "the", "literature", "and", "discuss", "the", "decision", "to", "pursue", "antiviral", "treatment", "in", "psychiatrically", "ill", "patients", "with", "hepatitis", "C."], "event_mentions": [{"id": "20118434_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "20118434_4_Ent3", "role": "Treatment", "text": "interferon", "start": 8, "end": 9}, {"entity_id": "20118434_4_Ent4", "role": "Treatment_Drug", "text": "interferon", "start": 8, "end": 9}, {"entity_id": "20118434_4_Ent2", "role": "Effect", "text": "psychosis", "start": 11, "end": 12}, {"entity_id": "20118434_4_Ent1", "role": "Subject_Disorder", "text": "psychiatrically ill", "start": 28, "end": 30}, {"entity_id": "20118434_4_Ent0", "role": "Subject", "text": "psychiatrically ill patients with hepatitis C.", "start": 28, "end": 34}, {"entity_id": "20118434_4_Ent5", "role": "Treatment_Disorder", "text": "hepatitis C.", "start": 32, "end": 34}]}], "entity_mentions": [{"id": "20118434_4_Ent3", "text": "interferon", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "20118434_4_Ent4", "text": "interferon", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "20118434_4_Ent2", "text": "psychosis", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "20118434_4_Ent1", "text": "psychiatrically ill", "entity_type": "Entity", "start": 28, "end": 30}, {"id": "20118434_4_Ent0", "text": "psychiatrically ill patients with hepatitis C.", "entity_type": "Entity", "start": 28, "end": 34}, {"id": "20118434_4_Ent5", "text": "hepatitis C.", "entity_type": "Entity", "start": 32, "end": 34}], "lang": "en"}
{"doc_id": "20126479_1", "wnd_id": "20126479_1_1", "text": "CONCLUSIONS : SD - OCT and AO detected abnormalities that correlate topographically with visual field loss from hydroxychloroquine toxicity as demonstrated by HVF 10 - 2 and may be useful in the detection of subclinical abnormalities that precede symptoms or objective visual field loss .", "tokens": ["CONCLUSIONS", ":", "SD", "-", "OCT", "and", "AO", "detected", "abnormalities", "that", "correlate", "topographically", "with", "visual", "field", "loss", "from", "hydroxychloroquine", "toxicity", "as", "demonstrated", "by", "HVF", "10", "-", "2", "and", "may", "be", "useful", "in", "the", "detection", "of", "subclinical", "abnormalities", "that", "precede", "symptoms", "or", "objective", "visual", "field", "loss", "."], "event_mentions": [{"id": "20126479_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 16, "end": 17}, "arguments": [{"entity_id": "20126479_1_Ent0", "role": "Effect", "text": "visual field loss", "start": 13, "end": 16}, {"entity_id": "20126479_1_Ent1", "role": "Treatment", "text": "hydroxychloroquine", "start": 17, "end": 18}, {"entity_id": "20126479_1_Ent2", "role": "Treatment_Drug", "text": "hydroxychloroquine", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "20126479_1_Ent0", "text": "visual field loss", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "20126479_1_Ent1", "text": "hydroxychloroquine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "20126479_1_Ent2", "text": "hydroxychloroquine", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "2012922_1", "wnd_id": "2012922_1_1", "text": "Transient trazodone - induced hypomanic symptoms occurred in three depressed patients .", "tokens": ["Transient", "trazodone", "-", "induced", "hypomanic", "symptoms", "occurred", "in", "three", "depressed", "patients", "."], "event_mentions": [{"id": "2012922_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "2012922_1_Ent3", "role": "Treatment", "text": "trazodone", "start": 1, "end": 2}, {"entity_id": "2012922_1_Ent5", "role": "Treatment_Drug", "text": "trazodone", "start": 1, "end": 2}, {"entity_id": "2012922_1_Ent2", "role": "Effect", "text": "hypomanic symptoms", "start": 4, "end": 6}, {"entity_id": "2012922_1_Ent1", "role": "Subject_Population", "text": "three", "start": 8, "end": 9}, {"entity_id": "2012922_1_Ent0", "role": "Subject", "text": "three depressed patients", "start": 8, "end": 11}, {"entity_id": "2012922_1_Ent4", "role": "Treatment_Disorder", "text": "depressed", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "2012922_1_Ent3", "text": "trazodone", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "2012922_1_Ent5", "text": "trazodone", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "2012922_1_Ent2", "text": "hypomanic symptoms", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "2012922_1_Ent1", "text": "three", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2012922_1_Ent0", "text": "three depressed patients", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "2012922_1_Ent4", "text": "depressed", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "20178709_1", "wnd_id": "20178709_1_1", "text": "A case of aseptic pleuropericarditis in a patient with chronic plaque psoriasis under methotrexate therapy .", "tokens": ["A", "case", "of", "aseptic", "pleuropericarditis", "in", "a", "patient", "with", "chronic", "plaque", "psoriasis", "under", "methotrexate", "therapy", "."], "event_mentions": [{"id": "20178709_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 5, "end": 6}, "arguments": [{"entity_id": "20178709_1_Ent1", "role": "Effect", "text": "aseptic pleuropericarditis", "start": 3, "end": 5}, {"entity_id": "20178709_1_Ent0", "role": "Subject", "text": "a patient with chronic plaque psoriasis", "start": 6, "end": 12}, {"entity_id": "20178709_1_Ent4", "role": "Treatment_Disorder", "text": "chronic plaque psoriasis", "start": 9, "end": 12}, {"entity_id": "20178709_1_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 13, "end": 14}, {"entity_id": "20178709_1_Ent2", "role": "Treatment", "text": "methotrexate therapy", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "20178709_1_Ent1", "text": "aseptic pleuropericarditis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "20178709_1_Ent0", "text": "a patient with chronic plaque psoriasis", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "20178709_1_Ent4", "text": "chronic plaque psoriasis", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "20178709_1_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "20178709_1_Ent2", "text": "methotrexate therapy", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "20180933_2", "wnd_id": "20180933_2_1", "text": "Artemether - lumefantrine ( AL ) is first - line treatment for uncomplicated malaria in many African countries .", "tokens": ["Artemether", "-", "lumefantrine", "(", "AL", ")", "is", "first", "-", "line", "treatment", "for", "uncomplicated", "malaria", "in", "many", "African", "countries", "."], "event_mentions": [{"id": "20180933_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "first - line treatment", "start": 7, "end": 11}, "arguments": [{"entity_id": "20180933_2_Ent2", "role": "Treatment_Drug", "text": "Artemether - lumefantrine", "start": 0, "end": 3}, {"entity_id": "20180933_2_Ent0", "role": "Treatment", "text": "Artemether - lumefantrine ( AL )", "start": 0, "end": 6}, {"entity_id": "20180933_2_Ent1", "role": "Treatment_Disorder", "text": "uncomplicated malaria", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "20180933_2_Ent2", "text": "Artemether - lumefantrine", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "20180933_2_Ent0", "text": "Artemether - lumefantrine ( AL )", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "20180933_2_Ent1", "text": "uncomplicated malaria", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "20203465_3", "wnd_id": "20203465_3_1", "text": "We report the case of an 87 - year - old white woman with myasthenia gravis who presented with nausea , shortness of breath , azotemia , and hyperkalemia shortly after completing a course of intravenous immunoglobulin ( IVIG ) .", "tokens": ["We", "report", "the", "case", "of", "an", "87", "-", "year", "-", "old", "white", "woman", "with", "myasthenia", "gravis", "who", "presented", "with", "nausea", ",", "shortness", "of", "breath", ",", "azotemia", ",", "and", "hyperkalemia", "shortly", "after", "completing", "a", "course", "of", "intravenous", "immunoglobulin", "(", "IVIG", ")", "."], "event_mentions": [{"id": "20203465_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 17, "end": 18}, "arguments": [{"entity_id": "20203465_3_Ent0", "role": "Subject", "text": "an 87 - year - old white woman with myasthenia gravis", "start": 5, "end": 16}, {"entity_id": "20203465_3_Ent1", "role": "Subject_Age", "text": "87 - year - old", "start": 6, "end": 11}, {"entity_id": "20203465_3_Ent2", "role": "Subject_Race", "text": "white", "start": 11, "end": 12}, {"entity_id": "20203465_3_Ent3", "role": "Subject_Gender", "text": "woman", "start": 12, "end": 13}, {"entity_id": "20203465_3_Ent7", "role": "Treatment_Disorder", "text": "myasthenia gravis", "start": 14, "end": 16}, {"entity_id": "20203465_3_Ent4", "role": "Effect", "text": "nausea , shortness of breath , azotemia , and hyperkalemia", "start": 19, "end": 29}, {"entity_id": "20203465_3_Ent8", "role": "Treatment_Route", "text": "intravenous", "start": 35, "end": 36}, {"entity_id": "20203465_3_Ent5", "role": "Treatment", "text": "intravenous immunoglobulin", "start": 35, "end": 37}, {"entity_id": "20203465_3_Ent6", "role": "Treatment_Drug", "text": "immunoglobulin", "start": 36, "end": 37}]}], "entity_mentions": [{"id": "20203465_3_Ent0", "text": "an 87 - year - old white woman with myasthenia gravis", "entity_type": "Entity", "start": 5, "end": 16}, {"id": "20203465_3_Ent1", "text": "87 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "20203465_3_Ent2", "text": "white", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "20203465_3_Ent3", "text": "woman", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "20203465_3_Ent7", "text": "myasthenia gravis", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "20203465_3_Ent4", "text": "nausea , shortness of breath , azotemia , and hyperkalemia", "entity_type": "Entity", "start": 19, "end": 29}, {"id": "20203465_3_Ent8", "text": "intravenous", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "20203465_3_Ent5", "text": "intravenous immunoglobulin", "entity_type": "Entity", "start": 35, "end": 37}, {"id": "20203465_3_Ent6", "text": "immunoglobulin", "entity_type": "Entity", "start": 36, "end": 37}], "lang": "en"}
{"doc_id": "20234160_2", "wnd_id": "20234160_2_1", "text": "Vancomycin is widely used against methicillin - resistant Staphylococcus aureus infections , but it is associated with many adverse effects such as nephrotoxicity , ototoxicity , gastrointestinal disturbances , blood disorders , and two types of hypersensitivity reactions - an anaphylactoid reaction known as \" red man syndrome \" and anaphylaxis .", "tokens": ["Vancomycin", "is", "widely", "used", "against", "methicillin", "-", "resistant", "Staphylococcus", "aureus", "infections", ",", "but", "it", "is", "associated", "with", "many", "adverse", "effects", "such", "as", "nephrotoxicity", ",", "ototoxicity", ",", "gastrointestinal", "disturbances", ",", "blood", "disorders", ",", "and", "two", "types", "of", "hypersensitivity", "reactions", "-", "an", "anaphylactoid", "reaction", "known", "as", "\"", "red", "man", "syndrome", "\"", "and", "anaphylaxis", "."], "event_mentions": [{"id": "20234160_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 15, "end": 16}, "arguments": [{"entity_id": "20234160_2_Ent1", "role": "Treatment", "text": "Vancomycin", "start": 0, "end": 1}, {"entity_id": "20234160_2_Ent3", "role": "Treatment_Drug", "text": "Vancomycin", "start": 0, "end": 1}, {"entity_id": "20234160_2_Ent2", "role": "Treatment_Disorder", "text": "methicillin - resistant Staphylococcus aureus infections", "start": 5, "end": 11}, {"entity_id": "20234160_2_Ent0", "role": "Effect", "text": "nephrotoxicity , ototoxicity , gastrointestinal disturbances , blood disorders , and two types of hypersensitivity reactions - an anaphylactoid reaction known as \" red man syndrome \" and anaphylaxis", "start": 22, "end": 51}]}], "entity_mentions": [{"id": "20234160_2_Ent1", "text": "Vancomycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20234160_2_Ent3", "text": "Vancomycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20234160_2_Ent2", "text": "methicillin - resistant Staphylococcus aureus infections", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "20234160_2_Ent0", "text": "nephrotoxicity , ototoxicity , gastrointestinal disturbances , blood disorders , and two types of hypersensitivity reactions - an anaphylactoid reaction known as \" red man syndrome \" and anaphylaxis", "entity_type": "Entity", "start": 22, "end": 51}], "lang": "en"}
{"doc_id": "2028358_1", "wnd_id": "2028358_1_1", "text": "Four patients in whom pulmonary oedema developed during tocolysis with hexoprenaline are described and the aetiological factors and pathogenesis of this potentially lethal complication discussed .", "tokens": ["Four", "patients", "in", "whom", "pulmonary", "oedema", "developed", "during", "tocolysis", "with", "hexoprenaline", "are", "described", "and", "the", "aetiological", "factors", "and", "pathogenesis", "of", "this", "potentially", "lethal", "complication", "discussed", "."], "event_mentions": [{"id": "2028358_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "2028358_1_Ent1", "role": "Subject_Population", "text": "Four", "start": 0, "end": 1}, {"entity_id": "2028358_1_Ent0", "role": "Subject", "text": "Four patients", "start": 0, "end": 2}, {"entity_id": "2028358_1_Ent2", "role": "Effect", "text": "pulmonary oedema", "start": 4, "end": 6}, {"entity_id": "2028358_1_Ent3", "role": "Treatment", "text": "tocolysis with hexoprenaline", "start": 8, "end": 11}, {"entity_id": "2028358_1_Ent4", "role": "Treatment_Drug", "text": "hexoprenaline", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "2028358_1_Ent1", "text": "Four", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2028358_1_Ent0", "text": "Four patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2028358_1_Ent2", "text": "pulmonary oedema", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "2028358_1_Ent3", "text": "tocolysis with hexoprenaline", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "2028358_1_Ent4", "text": "hexoprenaline", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "20298401_7", "wnd_id": "20298401_7_1", "text": "Six days after taking erlotinib , a chest radiograph showed rapid progression of reticular infiltration in both lung fields .", "tokens": ["Six", "days", "after", "taking", "erlotinib", ",", "a", "chest", "radiograph", "showed", "rapid", "progression", "of", "reticular", "infiltration", "in", "both", "lung", "fields", "."], "event_mentions": [{"id": "20298401_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "20298401_7_Ent1", "role": "Treatment", "text": "Six days", "start": 0, "end": 2}, {"entity_id": "20298401_7_Ent3", "role": "Treatment_Time_elapsed", "text": "Six days", "start": 0, "end": 2}, {"entity_id": "20298401_7_Ent2", "role": "Treatment", "text": "erlotinib", "start": 4, "end": 5}, {"entity_id": "20298401_7_Ent4", "role": "Treatment_Drug", "text": "erlotinib", "start": 4, "end": 5}, {"entity_id": "20298401_7_Ent0", "role": "Effect", "text": "rapid progression of reticular infiltration in both lung fields", "start": 10, "end": 19}]}], "entity_mentions": [{"id": "20298401_7_Ent1", "text": "Six days", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "20298401_7_Ent3", "text": "Six days", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "20298401_7_Ent2", "text": "erlotinib", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "20298401_7_Ent4", "text": "erlotinib", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "20298401_7_Ent0", "text": "rapid progression of reticular infiltration in both lung fields", "entity_type": "Entity", "start": 10, "end": 19}], "lang": "en"}
{"doc_id": "2038845_1", "wnd_id": "2038845_1_1", "text": "This case presentation is of a patient who had the clinical appearance of epiglottitis , but actually had an oro - pharyngeal dystonic reaction to prochlorperazine .", "tokens": ["This", "case", "presentation", "is", "of", "a", "patient", "who", "had", "the", "clinical", "appearance", "of", "epiglottitis", ",", "but", "actually", "had", "an", "oro", "-", "pharyngeal", "dystonic", "reaction", "to", "prochlorperazine", "."], "event_mentions": [{"id": "2038845_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 17, "end": 18}, "arguments": [{"entity_id": "2038845_1_Ent0", "role": "Subject", "text": "a patient", "start": 5, "end": 7}, {"entity_id": "2038845_1_Ent1", "role": "Effect", "text": "clinical appearance of epiglottitis", "start": 10, "end": 14}, {"entity_id": "2038845_1_Ent2", "role": "Effect", "text": "actually had an oro - pharyngeal dystonic reaction", "start": 16, "end": 24}, {"entity_id": "2038845_1_Ent3", "role": "Treatment", "text": "prochlorperazine", "start": 25, "end": 26}, {"entity_id": "2038845_1_Ent4", "role": "Treatment_Drug", "text": "prochlorperazine", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "2038845_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "2038845_1_Ent1", "text": "clinical appearance of epiglottitis", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "2038845_1_Ent2", "text": "actually had an oro - pharyngeal dystonic reaction", "entity_type": "Entity", "start": 16, "end": 24}, {"id": "2038845_1_Ent3", "text": "prochlorperazine", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "2038845_1_Ent4", "text": "prochlorperazine", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "20412003_2", "wnd_id": "20412003_2_1", "text": "Although this combination agent has been associated with a hypersensitivity syndrome involving cutaneous skin eruptions , pediatric cases of TMP - SMX - induced hepatotoxicity are rare .", "tokens": ["Although", "this", "combination", "agent", "has", "been", "associated", "with", "a", "hypersensitivity", "syndrome", "involving", "cutaneous", "skin", "eruptions", ",", "pediatric", "cases", "of", "TMP", "-", "SMX", "-", "induced", "hepatotoxicity", "are", "rare", "."], "event_mentions": [{"id": "20412003_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 23, "end": 24}, "arguments": [{"entity_id": "20412003_2_Ent1", "role": "Subject_Age", "text": "pediatric", "start": 16, "end": 17}, {"entity_id": "20412003_2_Ent0", "role": "Subject", "text": "pediatric cases", "start": 16, "end": 18}, {"entity_id": "20412003_2_Ent3", "role": "Treatment", "text": "TMP - SMX", "start": 19, "end": 22}, {"entity_id": "20412003_2_Ent4", "role": "Treatment_Drug", "text": "TMP - SMX", "start": 19, "end": 22}, {"entity_id": "20412003_2_Ent2", "role": "Effect", "text": "hepatotoxicity", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "20412003_2_Ent1", "text": "pediatric", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "20412003_2_Ent0", "text": "pediatric cases", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "20412003_2_Ent3", "text": "TMP - SMX", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "20412003_2_Ent4", "text": "TMP - SMX", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "20412003_2_Ent2", "text": "hepatotoxicity", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "2051906_2", "wnd_id": "2051906_2_1", "text": "It is believed that this is the first reported case of reversible azathioprine - induced cholestasis associated with histological evidence of bile duct injury .", "tokens": ["It", "is", "believed", "that", "this", "is", "the", "first", "reported", "case", "of", "reversible", "azathioprine", "-", "induced", "cholestasis", "associated", "with", "histological", "evidence", "of", "bile", "duct", "injury", "."], "event_mentions": [{"id": "2051906_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 14, "end": 15}, "arguments": [{"entity_id": "2051906_2_Ent1", "role": "Treatment", "text": "azathioprine", "start": 12, "end": 13}, {"entity_id": "2051906_2_Ent2", "role": "Treatment_Drug", "text": "azathioprine", "start": 12, "end": 13}, {"entity_id": "2051906_2_Ent0", "role": "Effect", "text": "cholestasis", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "2051906_2_Ent1", "text": "azathioprine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "2051906_2_Ent2", "text": "azathioprine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "2051906_2_Ent0", "text": "cholestasis", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "20628041_1", "wnd_id": "20628041_1_1", "text": "An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant - like syndrome and prolonged ICU stay .", "tokens": ["An", "interaction", "between", "levodopa", "and", "enteral", "nutrition", "resulting", "in", "neuroleptic", "malignant", "-", "like", "syndrome", "and", "prolonged", "ICU", "stay", "."], "event_mentions": [{"id": "20628041_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 7, "end": 8}, "arguments": [{"entity_id": "20628041_1_Ent2", "role": "Treatment_Drug", "text": "levodopa", "start": 3, "end": 4}, {"entity_id": "20628041_1_Ent1", "role": "Treatment", "text": "levodopa and enteral nutrition", "start": 3, "end": 7}, {"entity_id": "20628041_1_Ent0", "role": "Effect", "text": "neuroleptic malignant - like syndrome and prolonged ICU stay", "start": 9, "end": 18}]}], "entity_mentions": [{"id": "20628041_1_Ent2", "text": "levodopa", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "20628041_1_Ent1", "text": "levodopa and enteral nutrition", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "20628041_1_Ent0", "text": "neuroleptic malignant - like syndrome and prolonged ICU stay", "entity_type": "Entity", "start": 9, "end": 18}], "lang": "en"}
{"doc_id": "20925534_10", "wnd_id": "20925534_10_1", "text": "In all , 51 patients had a gastrointestinal event ; the event rate was 1.1 % with omeprazole and 2.9 % with placebo at 180 days ( hazard ratio with omeprazole , 0.34 , 95 % confidence interval [ CI ] , 0.18 to 0.63 ; P<0.001 ) .", "tokens": ["In", "all", ",", "51", "patients", "had", "a", "gastrointestinal", "event", ";", "the", "event", "rate", "was", "1.1", "%", "with", "omeprazole", "and", "2.9", "%", "with", "placebo", "at", "180", "days", "(", "hazard", "ratio", "with", "omeprazole", ",", "0.34", ",", "95", "%", "confidence", "interval", "[", "CI", "]", ",", "0.18", "to", "0.63", ";", "P<0.001", ")", "."], "event_mentions": [{"id": "20925534_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 5, "end": 6}, "arguments": [{"entity_id": "20925534_10_Ent1", "role": "Subject_Population", "text": "51", "start": 3, "end": 4}, {"entity_id": "20925534_10_Ent0", "role": "Subject", "text": "51 patients", "start": 3, "end": 5}, {"entity_id": "20925534_10_Ent2", "role": "Effect", "text": "gastrointestinal event", "start": 7, "end": 9}, {"entity_id": "20925534_10_Ent3", "role": "Treatment", "text": "1.1 % with omeprazole and 2.9 % with placebo", "start": 14, "end": 23}, {"entity_id": "20925534_10_Ent4", "role": "Treatment_Drug", "text": "omeprazole", "start": 17, "end": 18}, {"entity_id": "20925534_10_Ent5", "role": "Treatment_Drug", "text": "placebo", "start": 22, "end": 23}, {"entity_id": "20925534_10_Ent6", "role": "Treatment_Time_elapsed", "text": "180 days", "start": 24, "end": 26}]}], "entity_mentions": [{"id": "20925534_10_Ent1", "text": "51", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "20925534_10_Ent0", "text": "51 patients", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "20925534_10_Ent2", "text": "gastrointestinal event", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "20925534_10_Ent3", "text": "1.1 % with omeprazole and 2.9 % with placebo", "entity_type": "Entity", "start": 14, "end": 23}, {"id": "20925534_10_Ent4", "text": "omeprazole", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "20925534_10_Ent5", "text": "placebo", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "20925534_10_Ent6", "text": "180 days", "entity_type": "Entity", "start": 24, "end": 26}], "lang": "en"}
{"doc_id": "20925534_3", "wnd_id": "20925534_3_1", "text": "Proton - pump inhibitors ( PPIs ) are believed to decrease the risk of such complications , though no randomized trial has proved this in patients receiving dual antiplatelet therapy .", "tokens": ["Proton", "-", "pump", "inhibitors", "(", "PPIs", ")", "are", "believed", "to", "decrease", "the", "risk", "of", "such", "complications", ",", "though", "no", "randomized", "trial", "has", "proved", "this", "in", "patients", "receiving", "dual", "antiplatelet", "therapy", "."], "event_mentions": [{"id": "20925534_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "believed", "start": 8, "end": 9}, "arguments": [{"entity_id": "20925534_3_Ent0", "role": "Treatment", "text": "Proton - pump inhibitors ( PPIs )", "start": 0, "end": 7}, {"entity_id": "20925534_3_Ent1", "role": "Treatment_Drug", "text": "Proton - pump inhibitors ( PPIs )", "start": 0, "end": 7}, {"entity_id": "20925534_3_Ent2", "role": "Treatment_Drug", "text": "antiplatelet", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "20925534_3_Ent0", "text": "Proton - pump inhibitors ( PPIs )", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "20925534_3_Ent1", "text": "Proton - pump inhibitors ( PPIs )", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "20925534_3_Ent2", "text": "antiplatelet", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "21045170_11", "wnd_id": "21045170_11_1", "text": "Caution should be used when coadministering enfuvirtide and niacin to HIV - infected patients .", "tokens": ["Caution", "should", "be", "used", "when", "coadministering", "enfuvirtide", "and", "niacin", "to", "HIV", "-", "infected", "patients", "."], "event_mentions": [{"id": "21045170_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "used", "start": 3, "end": 4}, "arguments": [{"entity_id": "21045170_11_Ent1", "role": "Effect", "text": "Caution", "start": 0, "end": 1}, {"entity_id": "21045170_11_Ent2", "role": "Treatment", "text": "coadministering enfuvirtide and niacin", "start": 5, "end": 9}, {"entity_id": "21045170_11_Ent3", "role": "Treatment_Drug", "text": "enfuvirtide", "start": 6, "end": 7}, {"entity_id": "21045170_11_Ent6", "role": "Combination_Drug", "text": "enfuvirtide", "start": 6, "end": 7}, {"entity_id": "21045170_11_Ent4", "role": "Treatment_Drug", "text": "niacin", "start": 8, "end": 9}, {"entity_id": "21045170_11_Ent7", "role": "Combination_Drug", "text": "niacin", "start": 8, "end": 9}, {"entity_id": "21045170_11_Ent5", "role": "Treatment_Disorder", "text": "HIV", "start": 10, "end": 11}, {"entity_id": "21045170_11_Ent0", "role": "Subject", "text": "HIV - infected patients", "start": 10, "end": 14}]}], "entity_mentions": [{"id": "21045170_11_Ent1", "text": "Caution", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "21045170_11_Ent2", "text": "coadministering enfuvirtide and niacin", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "21045170_11_Ent3", "text": "enfuvirtide", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21045170_11_Ent6", "text": "enfuvirtide", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21045170_11_Ent4", "text": "niacin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "21045170_11_Ent7", "text": "niacin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "21045170_11_Ent5", "text": "HIV", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "21045170_11_Ent0", "text": "HIV - infected patients", "entity_type": "Entity", "start": 10, "end": 14}], "lang": "en"}
{"doc_id": "21189363_3", "wnd_id": "21189363_3_1", "text": "A 53 - year - old African American male with HIV was prescribed warfarin 5 mg / day for 12 months after diagnosis of idiopathic deep vein thrombosis and bilateral pulmonary emboli ( target INR 2.5 [ range 2.0 - 3.0 ] ) .", "tokens": ["A", "53", "-", "year", "-", "old", "African", "American", "male", "with", "HIV", "was", "prescribed", "warfarin", "5", "mg", "/", "day", "for", "12", "months", "after", "diagnosis", "of", "idiopathic", "deep", "vein", "thrombosis", "and", "bilateral", "pulmonary", "emboli", "(", "target", "INR", "2.5", "[", "range", "2.0", "-", "3.0", "]", ")", "."], "event_mentions": [{"id": "21189363_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "prescribed", "start": 12, "end": 13}, "arguments": [{"entity_id": "21189363_3_Ent0", "role": "Subject", "text": "A 53 - year - old African American male with HIV", "start": 0, "end": 11}, {"entity_id": "21189363_3_Ent1", "role": "Subject_Age", "text": "53 - year - old", "start": 1, "end": 6}, {"entity_id": "21189363_3_Ent2", "role": "Subject_Race", "text": "African American", "start": 6, "end": 8}, {"entity_id": "21189363_3_Ent3", "role": "Subject_Gender", "text": "male", "start": 8, "end": 9}, {"entity_id": "21189363_3_Ent4", "role": "Subject_Disorder", "text": "HIV", "start": 10, "end": 11}, {"entity_id": "21189363_3_Ent6", "role": "Treatment_Drug", "text": "warfarin", "start": 13, "end": 14}, {"entity_id": "21189363_3_Ent5", "role": "Treatment", "text": "warfarin 5 mg / day for 12 months", "start": 13, "end": 21}, {"entity_id": "21189363_3_Ent7", "role": "Treatment_Dosage", "text": "5 mg / day", "start": 14, "end": 18}, {"entity_id": "21189363_3_Ent8", "role": "Treatment_Duration", "text": "12 months", "start": 19, "end": 21}, {"entity_id": "21189363_3_Ent9", "role": "Treatment_Disorder", "text": "idiopathic deep vein thrombosis and bilateral pulmonary emboli", "start": 24, "end": 32}]}], "entity_mentions": [{"id": "21189363_3_Ent0", "text": "A 53 - year - old African American male with HIV", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "21189363_3_Ent1", "text": "53 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "21189363_3_Ent2", "text": "African American", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "21189363_3_Ent3", "text": "male", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "21189363_3_Ent4", "text": "HIV", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "21189363_3_Ent6", "text": "warfarin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "21189363_3_Ent5", "text": "warfarin 5 mg / day for 12 months", "entity_type": "Entity", "start": 13, "end": 21}, {"id": "21189363_3_Ent7", "text": "5 mg / day", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "21189363_3_Ent8", "text": "12 months", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "21189363_3_Ent9", "text": "idiopathic deep vein thrombosis and bilateral pulmonary emboli", "entity_type": "Entity", "start": 24, "end": 32}], "lang": "en"}
{"doc_id": "21350204_12", "wnd_id": "21350204_12_1", "text": "The results from the present study suggest that tissue plasminogen activator treatment appears to be safe in patients with acute ischemic stroke taking warfarin with an international normalized ratio < 1.7 and may reduce the risk of poor functional outcome .", "tokens": ["The", "results", "from", "the", "present", "study", "suggest", "that", "tissue", "plasminogen", "activator", "treatment", "appears", "to", "be", "safe", "in", "patients", "with", "acute", "ischemic", "stroke", "taking", "warfarin", "with", "an", "international", "normalized", "ratio", "<", "1.7", "and", "may", "reduce", "the", "risk", "of", "poor", "functional", "outcome", "."], "event_mentions": [{"id": "21350204_12_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "appears", "start": 12, "end": 13}, "arguments": [{"entity_id": "21350204_12_Ent5", "role": "Treatment_Drug", "text": "tissue plasminogen activator", "start": 8, "end": 11}, {"entity_id": "21350204_12_Ent7", "role": "Combination_Drug", "text": "tissue plasminogen activator", "start": 8, "end": 11}, {"entity_id": "21350204_12_Ent3", "role": "Treatment", "text": "tissue plasminogen activator treatment", "start": 8, "end": 12}, {"entity_id": "21350204_12_Ent0", "role": "Subject", "text": "patients with acute ischemic stroke", "start": 17, "end": 22}, {"entity_id": "21350204_12_Ent4", "role": "Treatment_Disorder", "text": "acute ischemic stroke", "start": 19, "end": 22}, {"entity_id": "21350204_12_Ent2", "role": "Treatment", "text": "taking warfarin with an international normalized ratio < 1.7", "start": 22, "end": 31}, {"entity_id": "21350204_12_Ent6", "role": "Treatment_Drug", "text": "warfarin", "start": 23, "end": 24}, {"entity_id": "21350204_12_Ent8", "role": "Combination_Drug", "text": "warfarin", "start": 23, "end": 24}, {"entity_id": "21350204_12_Ent1", "role": "Effect", "text": "may reduce the risk of poor functional outcome", "start": 32, "end": 40}]}], "entity_mentions": [{"id": "21350204_12_Ent5", "text": "tissue plasminogen activator", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "21350204_12_Ent7", "text": "tissue plasminogen activator", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "21350204_12_Ent3", "text": "tissue plasminogen activator treatment", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "21350204_12_Ent0", "text": "patients with acute ischemic stroke", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "21350204_12_Ent4", "text": "acute ischemic stroke", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "21350204_12_Ent2", "text": "taking warfarin with an international normalized ratio < 1.7", "entity_type": "Entity", "start": 22, "end": 31}, {"id": "21350204_12_Ent6", "text": "warfarin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "21350204_12_Ent8", "text": "warfarin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "21350204_12_Ent1", "text": "may reduce the risk of poor functional outcome", "entity_type": "Entity", "start": 32, "end": 40}], "lang": "en"}
{"doc_id": "21350204_9", "wnd_id": "21350204_9_1", "text": "Our cohort included 1739 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator of whom 125 ( 7.2 % ) were receiving warfarin before admission and had an international normalized ratio < 1.7 .", "tokens": ["Our", "cohort", "included", "1739", "patients", "with", "acute", "ischemic", "stroke", "treated", "with", "intravenous", "tissue", "plasminogen", "activator", "of", "whom", "125", "(", "7.2", "%", ")", "were", "receiving", "warfarin", "before", "admission", "and", "had", "an", "international", "normalized", "ratio", "<", "1.7", "."], "event_mentions": [{"id": "21350204_9_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 9, "end": 10}, "arguments": [{"entity_id": "21350204_9_Ent1", "role": "Subject_Population", "text": "1739", "start": 3, "end": 4}, {"entity_id": "21350204_9_Ent0", "role": "Subject", "text": "1739 patients", "start": 3, "end": 5}, {"entity_id": "21350204_9_Ent3", "role": "Treatment_Route", "text": "intravenous", "start": 11, "end": 12}, {"entity_id": "21350204_9_Ent2", "role": "Treatment", "text": "intravenous tissue plasminogen activator", "start": 11, "end": 15}, {"entity_id": "21350204_9_Ent4", "role": "Treatment_Drug", "text": "tissue plasminogen activator", "start": 12, "end": 15}]}, {"id": "21350204_9_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "receiving", "start": 23, "end": 24}, "arguments": [{"entity_id": "21350204_9_Ent7", "role": "Treatment_Disorder", "text": "acute ischemic stroke", "start": 6, "end": 9}, {"entity_id": "21350204_9_Ent5", "role": "Subject", "text": "125 ( 7.2 % )", "start": 17, "end": 22}, {"entity_id": "21350204_9_Ent8", "role": "Treatment_Drug", "text": "warfarin", "start": 24, "end": 25}, {"entity_id": "21350204_9_Ent6", "role": "Treatment", "text": "warfarin before admission", "start": 24, "end": 27}]}], "entity_mentions": [{"id": "21350204_9_Ent1", "text": "1739", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "21350204_9_Ent0", "text": "1739 patients", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "21350204_9_Ent7", "text": "acute ischemic stroke", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "21350204_9_Ent3", "text": "intravenous", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "21350204_9_Ent2", "text": "intravenous tissue plasminogen activator", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "21350204_9_Ent4", "text": "tissue plasminogen activator", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "21350204_9_Ent5", "text": "125 ( 7.2 % )", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "21350204_9_Ent8", "text": "warfarin", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "21350204_9_Ent6", "text": "warfarin before admission", "entity_type": "Entity", "start": 24, "end": 27}], "lang": "en"}
{"doc_id": "21416219_1", "wnd_id": "21416219_1_1", "text": "Long - term efficacy of adding fenofibric acid to moderate - dose statin therapy in patients with persistent elevated triglycerides .", "tokens": ["Long", "-", "term", "efficacy", "of", "adding", "fenofibric", "acid", "to", "moderate", "-", "dose", "statin", "therapy", "in", "patients", "with", "persistent", "elevated", "triglycerides", "."], "event_mentions": [{"id": "21416219_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "efficacy", "start": 3, "end": 4}, "arguments": [{"entity_id": "21416219_1_Ent1", "role": "Treatment", "text": "adding fenofibric acid to moderate - dose statin therapy", "start": 5, "end": 14}, {"entity_id": "21416219_1_Ent3", "role": "Treatment_Drug", "text": "fenofibric acid", "start": 6, "end": 8}, {"entity_id": "21416219_1_Ent6", "role": "Combination_Drug", "text": "fenofibric acid", "start": 6, "end": 8}, {"entity_id": "21416219_1_Ent5", "role": "Treatment_Dosage", "text": "moderate - dose", "start": 9, "end": 12}, {"entity_id": "21416219_1_Ent4", "role": "Treatment_Drug", "text": "statin", "start": 12, "end": 13}, {"entity_id": "21416219_1_Ent7", "role": "Combination_Drug", "text": "statin", "start": 12, "end": 13}, {"entity_id": "21416219_1_Ent0", "role": "Subject", "text": "patients with persistent elevated triglycerides", "start": 15, "end": 20}, {"entity_id": "21416219_1_Ent2", "role": "Treatment_Disorder", "text": "persistent elevated triglycerides", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "21416219_1_Ent1", "text": "adding fenofibric acid to moderate - dose statin therapy", "entity_type": "Entity", "start": 5, "end": 14}, {"id": "21416219_1_Ent3", "text": "fenofibric acid", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "21416219_1_Ent6", "text": "fenofibric acid", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "21416219_1_Ent5", "text": "moderate - dose", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "21416219_1_Ent4", "text": "statin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "21416219_1_Ent7", "text": "statin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "21416219_1_Ent0", "text": "patients with persistent elevated triglycerides", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "21416219_1_Ent2", "text": "persistent elevated triglycerides", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "21417793_2", "wnd_id": "21417793_2_1", "text": "Prompted by the advent of potentially life - threatening neuromuscular symptoms following initiation of linezolid therapy in two patients receiving treatment with a serotonin reuptake inhibitor antidepressant , an evaluation was conducted to determine the incidence and characteristics of symptomatic serotonin toxicity among hospitalized patients receiving combined treatment with these medications .", "tokens": ["Prompted", "by", "the", "advent", "of", "potentially", "life", "-", "threatening", "neuromuscular", "symptoms", "following", "initiation", "of", "linezolid", "therapy", "in", "two", "patients", "receiving", "treatment", "with", "a", "serotonin", "reuptake", "inhibitor", "antidepressant", ",", "an", "evaluation", "was", "conducted", "to", "determine", "the", "incidence", "and", "characteristics", "of", "symptomatic", "serotonin", "toxicity", "among", "hospitalized", "patients", "receiving", "combined", "treatment", "with", "these", "medications", "."], "event_mentions": [{"id": "21417793_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 11, "end": 12}, "arguments": [{"entity_id": "21417793_2_Ent2", "role": "Effect", "text": "life - threatening neuromuscular symptoms", "start": 6, "end": 11}, {"entity_id": "21417793_2_Ent3", "role": "Treatment", "text": "linezolid", "start": 14, "end": 15}, {"entity_id": "21417793_2_Ent6", "role": "Treatment_Drug", "text": "linezolid", "start": 14, "end": 15}, {"entity_id": "21417793_2_Ent7", "role": "Combination_Drug", "text": "linezolid", "start": 14, "end": 15}, {"entity_id": "21417793_2_Ent1", "role": "Subject_Population", "text": "two", "start": 17, "end": 18}, {"entity_id": "21417793_2_Ent0", "role": "Subject", "text": "two patients", "start": 17, "end": 19}, {"entity_id": "21417793_2_Ent4", "role": "Treatment", "text": "with a serotonin reuptake inhibitor antidepressant", "start": 21, "end": 27}, {"entity_id": "21417793_2_Ent5", "role": "Treatment_Drug", "text": "serotonin reuptake inhibitor antidepressant", "start": 23, "end": 27}, {"entity_id": "21417793_2_Ent8", "role": "Combination_Drug", "text": "serotonin reuptake inhibitor antidepressant", "start": 23, "end": 27}]}], "entity_mentions": [{"id": "21417793_2_Ent2", "text": "life - threatening neuromuscular symptoms", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "21417793_2_Ent3", "text": "linezolid", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "21417793_2_Ent6", "text": "linezolid", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "21417793_2_Ent7", "text": "linezolid", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "21417793_2_Ent1", "text": "two", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "21417793_2_Ent0", "text": "two patients", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "21417793_2_Ent4", "text": "with a serotonin reuptake inhibitor antidepressant", "entity_type": "Entity", "start": 21, "end": 27}, {"id": "21417793_2_Ent5", "text": "serotonin reuptake inhibitor antidepressant", "entity_type": "Entity", "start": 23, "end": 27}, {"id": "21417793_2_Ent8", "text": "serotonin reuptake inhibitor antidepressant", "entity_type": "Entity", "start": 23, "end": 27}], "lang": "en"}
{"doc_id": "21448111_3", "wnd_id": "21448111_3_1", "text": "Many types of medicaments can cause akathisia as an adverse event of their use and they include : antipsychotics , antidepressants , antiemetics , antihistamines , and psychoactive substances .", "tokens": ["Many", "types", "of", "medicaments", "can", "cause", "akathisia", "as", "an", "adverse", "event", "of", "their", "use", "and", "they", "include", ":", "antipsychotics", ",", "antidepressants", ",", "antiemetics", ",", "antihistamines", ",", "and", "psychoactive", "substances", "."], "event_mentions": [{"id": "21448111_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse event", "start": 9, "end": 11}, "arguments": [{"entity_id": "21448111_3_Ent0", "role": "Effect", "text": "akathisia", "start": 6, "end": 7}, {"entity_id": "21448111_3_Ent2", "role": "Treatment_Drug", "text": "antipsychotics", "start": 18, "end": 19}, {"entity_id": "21448111_3_Ent7", "role": "Combination_Drug", "text": "antipsychotics", "start": 18, "end": 19}, {"entity_id": "21448111_3_Ent1", "role": "Treatment", "text": "antipsychotics , antidepressants , antiemetics , antihistamines , and psychoactive substances", "start": 18, "end": 29}, {"entity_id": "21448111_3_Ent3", "role": "Treatment_Drug", "text": "antidepressants", "start": 20, "end": 21}, {"entity_id": "21448111_3_Ent8", "role": "Combination_Drug", "text": "antidepressants", "start": 20, "end": 21}, {"entity_id": "21448111_3_Ent4", "role": "Treatment_Drug", "text": "antiemetics", "start": 22, "end": 23}, {"entity_id": "21448111_3_Ent9", "role": "Combination_Drug", "text": "antiemetics", "start": 22, "end": 23}, {"entity_id": "21448111_3_Ent5", "role": "Treatment_Drug", "text": "antihistamines", "start": 24, "end": 25}, {"entity_id": "21448111_3_Ent10", "role": "Combination_Drug", "text": "antihistamines", "start": 24, "end": 25}, {"entity_id": "21448111_3_Ent6", "role": "Treatment_Drug", "text": "psychoactive substances .", "start": 27, "end": 30}, {"entity_id": "21448111_3_Ent11", "role": "Combination_Drug", "text": "psychoactive substances .", "start": 27, "end": 30}]}], "entity_mentions": [{"id": "21448111_3_Ent0", "text": "akathisia", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21448111_3_Ent2", "text": "antipsychotics", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "21448111_3_Ent7", "text": "antipsychotics", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "21448111_3_Ent1", "text": "antipsychotics , antidepressants , antiemetics , antihistamines , and psychoactive substances", "entity_type": "Entity", "start": 18, "end": 29}, {"id": "21448111_3_Ent3", "text": "antidepressants", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "21448111_3_Ent8", "text": "antidepressants", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "21448111_3_Ent4", "text": "antiemetics", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "21448111_3_Ent9", "text": "antiemetics", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "21448111_3_Ent5", "text": "antihistamines", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "21448111_3_Ent10", "text": "antihistamines", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "21448111_3_Ent6", "text": "psychoactive substances .", "entity_type": "Entity", "start": 27, "end": 30}, {"id": "21448111_3_Ent11", "text": "psychoactive substances .", "entity_type": "Entity", "start": 27, "end": 30}], "lang": "en"}
{"doc_id": "21512888_7", "wnd_id": "21512888_7_1", "text": "Patient was on warfarin for a prior deep venous thrombosis .", "tokens": ["Patient", "was", "on", "warfarin", "for", "a", "prior", "deep", "venous", "thrombosis", "."], "event_mentions": [{"id": "21512888_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 4, "end": 5}, "arguments": [{"entity_id": "21512888_7_Ent0", "role": "Treatment", "text": "warfarin", "start": 3, "end": 4}, {"entity_id": "21512888_7_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 3, "end": 4}, {"entity_id": "21512888_7_Ent1", "role": "Treatment_Disorder", "text": "a prior deep venous thrombosis", "start": 5, "end": 10}]}], "entity_mentions": [{"id": "21512888_7_Ent0", "text": "warfarin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "21512888_7_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "21512888_7_Ent1", "text": "a prior deep venous thrombosis", "entity_type": "Entity", "start": 5, "end": 10}], "lang": "en"}
{"doc_id": "21512888_8", "wnd_id": "21512888_8_1", "text": "After treatment with levetiracetam , seizures recurred and intravenous loading with valproic acid was administered , but resulted in a rapid increase in international normalized ratio ( INR ) to 7.6 .", "tokens": ["After", "treatment", "with", "levetiracetam", ",", "seizures", "recurred", "and", "intravenous", "loading", "with", "valproic", "acid", "was", "administered", ",", "but", "resulted", "in", "a", "rapid", "increase", "in", "international", "normalized", "ratio", "(", "INR", ")", "to", "7.6", "."], "event_mentions": [{"id": "21512888_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "recurred", "start": 6, "end": 7}, "arguments": [{"entity_id": "21512888_8_Ent1", "role": "Treatment", "text": "levetiracetam", "start": 3, "end": 4}, {"entity_id": "21512888_8_Ent2", "role": "Treatment_Drug", "text": "levetiracetam", "start": 3, "end": 4}, {"entity_id": "21512888_8_Ent0", "role": "Effect", "text": "seizures", "start": 5, "end": 6}]}, {"id": "21512888_8_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "administered", "start": 14, "end": 15}, "arguments": [{"entity_id": "21512888_8_Ent4", "role": "Treatment_Disorder", "text": "seizures", "start": 5, "end": 6}, {"entity_id": "21512888_8_Ent5", "role": "Treatment_Route", "text": "intravenous", "start": 8, "end": 9}, {"entity_id": "21512888_8_Ent3", "role": "Treatment", "text": "intravenous loading with valproic acid", "start": 8, "end": 13}, {"entity_id": "21512888_8_Ent6", "role": "Treatment_Drug", "text": "valproic acid", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "21512888_8_Ent1", "text": "levetiracetam", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "21512888_8_Ent2", "text": "levetiracetam", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "21512888_8_Ent0", "text": "seizures", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "21512888_8_Ent4", "text": "seizures", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "21512888_8_Ent5", "text": "intravenous", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "21512888_8_Ent3", "text": "intravenous loading with valproic acid", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "21512888_8_Ent6", "text": "valproic acid", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "21515865_1", "wnd_id": "21515865_1_1", "text": "Moxifloxacin - acetaminophen - warfarin interaction during bacille Calmette - Guerin treatment for bladder cancer .", "tokens": ["Moxifloxacin", "-", "acetaminophen", "-", "warfarin", "interaction", "during", "bacille", "Calmette", "-", "Guerin", "treatment", "for", "bladder", "cancer", "."], "event_mentions": [{"id": "21515865_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 6, "end": 7}, "arguments": [{"entity_id": "21515865_1_Ent2", "role": "Treatment_Drug", "text": "Moxifloxacin", "start": 0, "end": 1}, {"entity_id": "21515865_1_Ent9", "role": "Combination_Drug", "text": "Moxifloxacin", "start": 0, "end": 1}, {"entity_id": "21515865_1_Ent0", "role": "Treatment", "text": "Moxifloxacin - acetaminophen - warfarin interaction", "start": 0, "end": 6}, {"entity_id": "21515865_1_Ent3", "role": "Treatment_Drug", "text": "acetaminophen", "start": 2, "end": 3}, {"entity_id": "21515865_1_Ent8", "role": "Combination_Drug", "text": "acetaminophen", "start": 2, "end": 3}, {"entity_id": "21515865_1_Ent4", "role": "Treatment_Drug", "text": "warfarin", "start": 4, "end": 5}, {"entity_id": "21515865_1_Ent7", "role": "Combination_Drug", "text": "warfarin", "start": 4, "end": 5}, {"entity_id": "21515865_1_Ent5", "role": "Treatment_Drug", "text": "bacille Calmette - Guerin", "start": 7, "end": 11}, {"entity_id": "21515865_1_Ent10", "role": "Combination_Drug", "text": "bacille Calmette - Guerin", "start": 7, "end": 11}, {"entity_id": "21515865_1_Ent1", "role": "Treatment", "text": "bacille Calmette - Guerin treatment", "start": 7, "end": 12}, {"entity_id": "21515865_1_Ent6", "role": "Treatment_Disorder", "text": "bladder cancer", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "21515865_1_Ent2", "text": "Moxifloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "21515865_1_Ent9", "text": "Moxifloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "21515865_1_Ent0", "text": "Moxifloxacin - acetaminophen - warfarin interaction", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "21515865_1_Ent3", "text": "acetaminophen", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "21515865_1_Ent8", "text": "acetaminophen", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "21515865_1_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "21515865_1_Ent7", "text": "warfarin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "21515865_1_Ent5", "text": "bacille Calmette - Guerin", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "21515865_1_Ent10", "text": "bacille Calmette - Guerin", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "21515865_1_Ent1", "text": "bacille Calmette - Guerin treatment", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "21515865_1_Ent6", "text": "bladder cancer", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "21515865_4", "wnd_id": "21515865_4_1", "text": "On the day before this visit , he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer .", "tokens": ["On", "the", "day", "before", "this", "visit", ",", "he", "had", "received", "the", "third", "of", "six", "serial", "weekly", "BCG", "bladder", "instillations", "for", "the", "treatment", "of", "bladder", "cancer", "."], "event_mentions": [{"id": "21515865_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "received", "start": 9, "end": 10}, "arguments": [{"entity_id": "21515865_4_Ent0", "role": "Subject", "text": "he", "start": 7, "end": 8}, {"entity_id": "21515865_4_Ent2", "role": "Subject_Gender", "text": "he", "start": 7, "end": 8}, {"entity_id": "21515865_4_Ent3", "role": "Treatment", "text": "the third of six serial weekly BCG bladder instillations", "start": 10, "end": 19}, {"entity_id": "21515865_4_Ent7", "role": "Treatment_Freq", "text": "weekly", "start": 15, "end": 16}, {"entity_id": "21515865_4_Ent6", "role": "Treatment_Drug", "text": "BCG", "start": 16, "end": 17}, {"entity_id": "21515865_4_Ent4", "role": "Treatment_Route", "text": "bladder instillations", "start": 17, "end": 19}, {"entity_id": "21515865_4_Ent1", "role": "Subject", "text": "bladder cancer", "start": 23, "end": 25}, {"entity_id": "21515865_4_Ent5", "role": "Treatment_Disorder", "text": "bladder cancer", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "21515865_4_Ent0", "text": "he", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "21515865_4_Ent2", "text": "he", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "21515865_4_Ent3", "text": "the third of six serial weekly BCG bladder instillations", "entity_type": "Entity", "start": 10, "end": 19}, {"id": "21515865_4_Ent7", "text": "weekly", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "21515865_4_Ent6", "text": "BCG", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "21515865_4_Ent4", "text": "bladder instillations", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "21515865_4_Ent1", "text": "bladder cancer", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "21515865_4_Ent5", "text": "bladder cancer", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "2154663_3", "wnd_id": "2154663_3_1", "text": "We report a case of radiotherapy - enhanced aminoglutethimide skin toxicity in a patient with metastatic breast cancer .", "tokens": ["We", "report", "a", "case", "of", "radiotherapy", "-", "enhanced", "aminoglutethimide", "skin", "toxicity", "in", "a", "patient", "with", "metastatic", "breast", "cancer", "."], "event_mentions": [{"id": "2154663_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 10, "end": 11}, "arguments": [{"entity_id": "2154663_3_Ent2", "role": "Treatment", "text": "radiotherapy - enhanced aminoglutethimide", "start": 5, "end": 9}, {"entity_id": "2154663_3_Ent4", "role": "Treatment_Drug", "text": "aminoglutethimide", "start": 8, "end": 9}, {"entity_id": "2154663_3_Ent1", "role": "Effect", "text": "skin toxicity", "start": 9, "end": 11}, {"entity_id": "2154663_3_Ent0", "role": "Subject", "text": "a patient with metastatic breast cancer", "start": 12, "end": 18}, {"entity_id": "2154663_3_Ent3", "role": "Treatment_Disorder", "text": "metastatic breast cancer", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "2154663_3_Ent2", "text": "radiotherapy - enhanced aminoglutethimide", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "2154663_3_Ent4", "text": "aminoglutethimide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2154663_3_Ent1", "text": "skin toxicity", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "2154663_3_Ent0", "text": "a patient with metastatic breast cancer", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "2154663_3_Ent3", "text": "metastatic breast cancer", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "21630612_1", "wnd_id": "21630612_1_1", "text": "Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis : a case report and review of the literature .", "tokens": ["Concomitant", "use", "of", "simvastatin", "and", "amiodarone", "resulting", "in", "severe", "rhabdomyolysis", ":", "a", "case", "report", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "21630612_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 6, "end": 7}, "arguments": [{"entity_id": "21630612_1_Ent2", "role": "Treatment", "text": "Concomitant use of simvastatin and amiodarone", "start": 0, "end": 6}, {"entity_id": "21630612_1_Ent3", "role": "Treatment_Drug", "text": "simvastatin", "start": 3, "end": 4}, {"entity_id": "21630612_1_Ent5", "role": "Combination_Drug", "text": "simvastatin", "start": 3, "end": 4}, {"entity_id": "21630612_1_Ent4", "role": "Treatment_Drug", "text": "amiodarone", "start": 5, "end": 6}, {"entity_id": "21630612_1_Ent6", "role": "Combination_Drug", "text": "amiodarone", "start": 5, "end": 6}, {"entity_id": "21630612_1_Ent1", "role": "Effect", "text": "rhabdomyolysis", "start": 9, "end": 10}, {"entity_id": "21630612_1_Ent0", "role": "Subject", "text": "a case", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "21630612_1_Ent2", "text": "Concomitant use of simvastatin and amiodarone", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "21630612_1_Ent3", "text": "simvastatin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "21630612_1_Ent5", "text": "simvastatin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "21630612_1_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "21630612_1_Ent6", "text": "amiodarone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "21630612_1_Ent1", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "21630612_1_Ent0", "text": "a case", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "21630612_2", "wnd_id": "21630612_2_1", "text": "Myopathy , including rhabdomyolysis , is a well - known , albeit rare complication of statin therapy .", "tokens": ["Myopathy", ",", "including", "rhabdomyolysis", ",", "is", "a", "well", "-", "known", ",", "albeit", "rare", "complication", "of", "statin", "therapy", "."], "event_mentions": [{"id": "21630612_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 13, "end": 14}, "arguments": [{"entity_id": "21630612_2_Ent0", "role": "Effect", "text": "Myopathy , including rhabdomyolysis", "start": 0, "end": 4}, {"entity_id": "21630612_2_Ent1", "role": "Treatment", "text": "statin", "start": 15, "end": 16}, {"entity_id": "21630612_2_Ent2", "role": "Treatment_Drug", "text": "statin", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "21630612_2_Ent0", "text": "Myopathy , including rhabdomyolysis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "21630612_2_Ent1", "text": "statin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "21630612_2_Ent2", "text": "statin", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "21630612_4", "wnd_id": "21630612_4_1", "text": "We report a case of severe simvastatin - induced rhabdomyolysis triggered by the addition of amiodarone to previously well - tolerated chronic statin therapy .", "tokens": ["We", "report", "a", "case", "of", "severe", "simvastatin", "-", "induced", "rhabdomyolysis", "triggered", "by", "the", "addition", "of", "amiodarone", "to", "previously", "well", "-", "tolerated", "chronic", "statin", "therapy", "."], "event_mentions": [{"id": "21630612_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "21630612_4_Ent1", "role": "Treatment", "text": "simvastatin", "start": 6, "end": 7}, {"entity_id": "21630612_4_Ent3", "role": "Treatment_Drug", "text": "simvastatin", "start": 6, "end": 7}, {"entity_id": "21630612_4_Ent8", "role": "Combination_Drug", "text": "simvastatin", "start": 6, "end": 7}, {"entity_id": "21630612_4_Ent0", "role": "Effect", "text": "rhabdomyolysis", "start": 9, "end": 10}, {"entity_id": "21630612_4_Ent2", "role": "Treatment", "text": "the addition of amiodarone to previously well - tolerated chronic statin therapy", "start": 12, "end": 24}, {"entity_id": "21630612_4_Ent4", "role": "Treatment_Drug", "text": "amiodarone", "start": 15, "end": 16}, {"entity_id": "21630612_4_Ent7", "role": "Combination_Drug", "text": "amiodarone", "start": 15, "end": 16}, {"entity_id": "21630612_4_Ent6", "role": "Treatment_Time_elapsed", "text": "chronic", "start": 21, "end": 22}, {"entity_id": "21630612_4_Ent5", "role": "Treatment_Drug", "text": "statin", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "21630612_4_Ent1", "text": "simvastatin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21630612_4_Ent3", "text": "simvastatin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21630612_4_Ent8", "text": "simvastatin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21630612_4_Ent0", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "21630612_4_Ent2", "text": "the addition of amiodarone to previously well - tolerated chronic statin therapy", "entity_type": "Entity", "start": 12, "end": 24}, {"id": "21630612_4_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "21630612_4_Ent7", "text": "amiodarone", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "21630612_4_Ent6", "text": "chronic", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "21630612_4_Ent5", "text": "statin", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "21715267_2", "wnd_id": "21715267_2_1", "text": "Moxifloxacin and lomefloxacin are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections .", "tokens": ["Moxifloxacin", "and", "lomefloxacin", "are", "fluoroquinolone", "antibiotics", "used", "in", "treating", "urinary", "and", "respiratory", "tract", "infections", "."], "event_mentions": [{"id": "21715267_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treating", "start": 8, "end": 9}, "arguments": [{"entity_id": "21715267_2_Ent2", "role": "Treatment_Drug", "text": "Moxifloxacin", "start": 0, "end": 1}, {"entity_id": "21715267_2_Ent0", "role": "Treatment", "text": "Moxifloxacin and lomefloxacin", "start": 0, "end": 3}, {"entity_id": "21715267_2_Ent3", "role": "Treatment_Drug", "text": "lomefloxacin", "start": 2, "end": 3}, {"entity_id": "21715267_2_Ent1", "role": "Treatment", "text": "fluoroquinolone antibiotics", "start": 4, "end": 6}, {"entity_id": "21715267_2_Ent4", "role": "Treatment_Drug", "text": "fluoroquinolone antibiotics", "start": 4, "end": 6}, {"entity_id": "21715267_2_Ent5", "role": "Treatment_Disorder", "text": "urinary and respiratory tract infections", "start": 9, "end": 14}]}], "entity_mentions": [{"id": "21715267_2_Ent2", "text": "Moxifloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "21715267_2_Ent0", "text": "Moxifloxacin and lomefloxacin", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "21715267_2_Ent3", "text": "lomefloxacin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "21715267_2_Ent1", "text": "fluoroquinolone antibiotics", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "21715267_2_Ent4", "text": "fluoroquinolone antibiotics", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "21715267_2_Ent5", "text": "urinary and respiratory tract infections", "entity_type": "Entity", "start": 9, "end": 14}], "lang": "en"}
{"doc_id": "21751542_4", "wnd_id": "21751542_4_1", "text": "Angiotensin converting enzyme blockers and their influence on the endothelial dysfunction , but the risk of hyperpotassemia are showed .", "tokens": ["Angiotensin", "converting", "enzyme", "blockers", "and", "their", "influence", "on", "the", "endothelial", "dysfunction", ",", "but", "the", "risk", "of", "hyperpotassemia", "are", "showed", "."], "event_mentions": [{"id": "21751542_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "showed", "start": 18, "end": 19}, "arguments": [{"entity_id": "21751542_4_Ent1", "role": "Treatment", "text": "Angiotensin converting enzyme blockers", "start": 0, "end": 4}, {"entity_id": "21751542_4_Ent2", "role": "Treatment_Drug", "text": "Angiotensin converting enzyme blockers", "start": 0, "end": 4}, {"entity_id": "21751542_4_Ent0", "role": "Effect", "text": "hyperpotassemia", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "21751542_4_Ent1", "text": "Angiotensin converting enzyme blockers", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "21751542_4_Ent2", "text": "Angiotensin converting enzyme blockers", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "21751542_4_Ent0", "text": "hyperpotassemia", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "21751692_3", "wnd_id": "21751692_3_1", "text": "We retrospectively reviewed the records of 7 pediatric oncology patients who received low - dose ketamine in conjunction with propofol for total intravenous anesthesia ( TIVA ) repeatedly for radiation therapy .", "tokens": ["We", "retrospectively", "reviewed", "the", "records", "of", "7", "pediatric", "oncology", "patients", "who", "received", "low", "-", "dose", "ketamine", "in", "conjunction", "with", "propofol", "for", "total", "intravenous", "anesthesia", "(", "TIVA", ")", "repeatedly", "for", "radiation", "therapy", "."], "event_mentions": [{"id": "21751692_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "received", "start": 11, "end": 12}, "arguments": [{"entity_id": "21751692_3_Ent1", "role": "Subject_Population", "text": "7", "start": 6, "end": 7}, {"entity_id": "21751692_3_Ent0", "role": "Subject", "text": "7 pediatric oncology patients", "start": 6, "end": 10}, {"entity_id": "21751692_3_Ent2", "role": "Subject_Age", "text": "pediatric", "start": 7, "end": 8}, {"entity_id": "21751692_3_Ent7", "role": "Treatment_Disorder", "text": "oncology", "start": 8, "end": 9}, {"entity_id": "21751692_3_Ent6", "role": "Treatment_Dosage", "text": "low - dose", "start": 12, "end": 15}, {"entity_id": "21751692_3_Ent3", "role": "Treatment", "text": "low - dose ketamine in conjunction with propofol for total intravenous anesthesia ( TIVA ) repeatedly for radiation therapy", "start": 12, "end": 31}, {"entity_id": "21751692_3_Ent5", "role": "Treatment_Drug", "text": "ketamine", "start": 15, "end": 16}, {"entity_id": "21751692_3_Ent9", "role": "Combination_Drug", "text": "ketamine", "start": 15, "end": 16}, {"entity_id": "21751692_3_Ent4", "role": "Treatment_Drug", "text": "propofol", "start": 19, "end": 20}, {"entity_id": "21751692_3_Ent8", "role": "Combination_Drug", "text": "propofol", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "21751692_3_Ent1", "text": "7", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21751692_3_Ent0", "text": "7 pediatric oncology patients", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "21751692_3_Ent2", "text": "pediatric", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "21751692_3_Ent7", "text": "oncology", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "21751692_3_Ent6", "text": "low - dose", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "21751692_3_Ent3", "text": "low - dose ketamine in conjunction with propofol for total intravenous anesthesia ( TIVA ) repeatedly for radiation therapy", "entity_type": "Entity", "start": 12, "end": 31}, {"id": "21751692_3_Ent5", "text": "ketamine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "21751692_3_Ent9", "text": "ketamine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "21751692_3_Ent4", "text": "propofol", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "21751692_3_Ent8", "text": "propofol", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "21751692_4", "wnd_id": "21751692_4_1", "text": "EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low - dose ketamine was added to propofol .", "tokens": ["EA", "signs", "were", "observed", "in", "all", "7", "patients", "in", "association", "with", "propofol", "TIVA", "but", "did", "not", "recur", "in", "any", "of", "123", "subsequent", "anesthetics", "sessions", "during", "which", "low", "-", "dose", "ketamine", "was", "added", "to", "propofol", "."], "event_mentions": [{"id": "21751692_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "observed", "start": 3, "end": 4}, "arguments": [{"entity_id": "21751692_4_Ent2", "role": "Effect", "text": "EA signs", "start": 0, "end": 2}, {"entity_id": "21751692_4_Ent0", "role": "Subject", "text": "all 7 patients", "start": 5, "end": 8}, {"entity_id": "21751692_4_Ent1", "role": "Subject_Population", "text": "7", "start": 6, "end": 7}, {"entity_id": "21751692_4_Ent5", "role": "Treatment_Drug", "text": "propofol", "start": 11, "end": 12}, {"entity_id": "21751692_4_Ent3", "role": "Treatment", "text": "propofol TIVA", "start": 11, "end": 13}, {"entity_id": "21751692_4_Ent8", "role": "Treatment_Route", "text": "TIVA", "start": 12, "end": 13}, {"entity_id": "21751692_4_Ent9", "role": "Treatment_Dosage", "text": "low - dose", "start": 26, "end": 29}, {"entity_id": "21751692_4_Ent4", "role": "Treatment", "text": "low - dose ketamine was added to propofol", "start": 26, "end": 34}, {"entity_id": "21751692_4_Ent6", "role": "Treatment_Drug", "text": "ketamine", "start": 29, "end": 30}, {"entity_id": "21751692_4_Ent11", "role": "Combination_Drug", "text": "ketamine", "start": 29, "end": 30}, {"entity_id": "21751692_4_Ent7", "role": "Treatment_Drug", "text": "propofol", "start": 33, "end": 34}, {"entity_id": "21751692_4_Ent10", "role": "Combination_Drug", "text": "propofol", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "21751692_4_Ent2", "text": "EA signs", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "21751692_4_Ent0", "text": "all 7 patients", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "21751692_4_Ent1", "text": "7", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21751692_4_Ent5", "text": "propofol", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "21751692_4_Ent3", "text": "propofol TIVA", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "21751692_4_Ent8", "text": "TIVA", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "21751692_4_Ent9", "text": "low - dose", "entity_type": "Entity", "start": 26, "end": 29}, {"id": "21751692_4_Ent4", "text": "low - dose ketamine was added to propofol", "entity_type": "Entity", "start": 26, "end": 34}, {"id": "21751692_4_Ent6", "text": "ketamine", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "21751692_4_Ent11", "text": "ketamine", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "21751692_4_Ent7", "text": "propofol", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "21751692_4_Ent10", "text": "propofol", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "21881031_11", "wnd_id": "21881031_11_1", "text": "Cisplatin was the common drug in the cases presented and therefore could be related to the INR elevations .", "tokens": ["Cisplatin", "was", "the", "common", "drug", "in", "the", "cases", "presented", "and", "therefore", "could", "be", "related", "to", "the", "INR", "elevations", "."], "event_mentions": [{"id": "21881031_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 13, "end": 14}, "arguments": [{"entity_id": "21881031_11_Ent2", "role": "Treatment", "text": "Cisplatin", "start": 0, "end": 1}, {"entity_id": "21881031_11_Ent3", "role": "Treatment_Drug", "text": "Cisplatin", "start": 0, "end": 1}, {"entity_id": "21881031_11_Ent0", "role": "Subject", "text": "the cases", "start": 6, "end": 8}, {"entity_id": "21881031_11_Ent1", "role": "Effect", "text": "INR elevations", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "21881031_11_Ent2", "text": "Cisplatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "21881031_11_Ent3", "text": "Cisplatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "21881031_11_Ent0", "text": "the cases", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "21881031_11_Ent1", "text": "INR elevations", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "21881031_5", "wnd_id": "21881031_5_1", "text": "Granisetron hydrochloride ( 3 mg on days 1 , 8 , and 15 ) and dexamethasone ( 13.2 mg on day 1 and 6.6 mg on days 2 , 3 , 8 , and 15 ) were used prior to irinotecan administration in both patients .", "tokens": ["Granisetron", "hydrochloride", "(", "3", "mg", "on", "days", "1", ",", "8", ",", "and", "15", ")", "and", "dexamethasone", "(", "13.2", "mg", "on", "day", "1", "and", "6.6", "mg", "on", "days", "2", ",", "3", ",", "8", ",", "and", "15", ")", "were", "used", "prior", "to", "irinotecan", "administration", "in", "both", "patients", "."], "event_mentions": [{"id": "21881031_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "used", "start": 37, "end": 38}, "arguments": [{"entity_id": "21881031_5_Ent3", "role": "Treatment_Drug", "text": "Granisetron hydrochloride", "start": 0, "end": 2}, {"entity_id": "21881031_5_Ent12", "role": "Combination_Drug", "text": "Granisetron hydrochloride", "start": 0, "end": 2}, {"entity_id": "21881031_5_Ent1", "role": "Treatment", "text": "Granisetron hydrochloride ( 3 mg on days 1 , 8 , and 15 ) and dexamethasone ( 13.2 mg on day 1 and 6.6 mg on days 2 , 3 , 8 , and 15 )", "start": 0, "end": 36}, {"entity_id": "21881031_5_Ent5", "role": "Treatment_Dosage", "text": "3 mg", "start": 3, "end": 5}, {"entity_id": "21881031_5_Ent9", "role": "Treatment_Freq", "text": "on days 1 , 8 , and 15", "start": 5, "end": 13}, {"entity_id": "21881031_5_Ent4", "role": "Treatment_Drug", "text": "dexamethasone", "start": 15, "end": 16}, {"entity_id": "21881031_5_Ent11", "role": "Combination_Drug", "text": "dexamethasone", "start": 15, "end": 16}, {"entity_id": "21881031_5_Ent6", "role": "Treatment_Dosage", "text": "13.2 mg", "start": 17, "end": 19}, {"entity_id": "21881031_5_Ent8", "role": "Treatment_Freq", "text": "on day 1", "start": 19, "end": 22}, {"entity_id": "21881031_5_Ent7", "role": "Treatment_Dosage", "text": "6.6 mg", "start": 23, "end": 25}, {"entity_id": "21881031_5_Ent10", "role": "Treatment_Freq", "text": "on days 2 , 3 , 8 , and 15", "start": 25, "end": 35}, {"entity_id": "21881031_5_Ent2", "role": "Treatment", "text": "irinotecan", "start": 40, "end": 41}, {"entity_id": "21881031_5_Ent0", "role": "Subject", "text": "both patients", "start": 43, "end": 45}]}], "entity_mentions": [{"id": "21881031_5_Ent3", "text": "Granisetron hydrochloride", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "21881031_5_Ent12", "text": "Granisetron hydrochloride", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "21881031_5_Ent1", "text": "Granisetron hydrochloride ( 3 mg on days 1 , 8 , and 15 ) and dexamethasone ( 13.2 mg on day 1 and 6.6 mg on days 2 , 3 , 8 , and 15 )", "entity_type": "Entity", "start": 0, "end": 36}, {"id": "21881031_5_Ent5", "text": "3 mg", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "21881031_5_Ent9", "text": "on days 1 , 8 , and 15", "entity_type": "Entity", "start": 5, "end": 13}, {"id": "21881031_5_Ent4", "text": "dexamethasone", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "21881031_5_Ent11", "text": "dexamethasone", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "21881031_5_Ent6", "text": "13.2 mg", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "21881031_5_Ent8", "text": "on day 1", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "21881031_5_Ent7", "text": "6.6 mg", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "21881031_5_Ent10", "text": "on days 2 , 3 , 8 , and 15", "entity_type": "Entity", "start": 25, "end": 35}, {"id": "21881031_5_Ent2", "text": "irinotecan", "entity_type": "Entity", "start": 40, "end": 41}, {"id": "21881031_5_Ent0", "text": "both patients", "entity_type": "Entity", "start": 43, "end": 45}], "lang": "en"}
{"doc_id": "2196696_1", "wnd_id": "2196696_1_1", "text": "Disulfiram - induced hepatitis .", "tokens": ["Disulfiram", "-", "induced", "hepatitis", "."], "event_mentions": [{"id": "2196696_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "2196696_1_Ent1", "role": "Treatment", "text": "Disulfiram", "start": 0, "end": 1}, {"entity_id": "2196696_1_Ent2", "role": "Treatment_Drug", "text": "Disulfiram", "start": 0, "end": 1}, {"entity_id": "2196696_1_Ent0", "role": "Effect", "text": "hepatitis", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "2196696_1_Ent1", "text": "Disulfiram", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2196696_1_Ent2", "text": "Disulfiram", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2196696_1_Ent0", "text": "hepatitis", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "22010004_3", "wnd_id": "22010004_3_1", "text": "A 69 - year - old white female whose anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily ( 17.5 mg / wk ) presented to an anticoagulation clinic with a critically elevated INR of greater than 12.3 after a dose increase in extended - release niacin ( Niaspan ) from 500 mg to 1000 mg daily the previous week .", "tokens": ["A", "69", "-", "year", "-", "old", "white", "female", "whose", "anticoagulation", "treatment", "had", "been", "stable", "for", "18", "months", "with", "warfarin", "2.5", "mg", "daily", "(", "17.5", "mg", "/", "wk", ")", "presented", "to", "an", "anticoagulation", "clinic", "with", "a", "critically", "elevated", "INR", "of", "greater", "than", "12.3", "after", "a", "dose", "increase", "in", "extended", "-", "release", "niacin", "(", "Niaspan", ")", "from", "500", "mg", "to", "1000", "mg", "daily", "the", "previous", "week", "."], "event_mentions": [{"id": "22010004_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 42, "end": 43}, "arguments": [{"entity_id": "22010004_3_Ent1", "role": "Subject_Age", "text": "69 - year - old", "start": 1, "end": 6}, {"entity_id": "22010004_3_Ent0", "role": "Subject", "text": "69 - year - old white female", "start": 1, "end": 8}, {"entity_id": "22010004_3_Ent2", "role": "Subject_Race", "text": "white", "start": 6, "end": 7}, {"entity_id": "22010004_3_Ent3", "role": "Subject_Gender", "text": "female", "start": 7, "end": 8}, {"entity_id": "22010004_3_Ent5", "role": "Treatment", "text": "anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily ( 17.5 mg / wk )", "start": 9, "end": 28}, {"entity_id": "22010004_3_Ent8", "role": "Treatment_Drug", "text": "warfarin", "start": 18, "end": 19}, {"entity_id": "22010004_3_Ent14", "role": "Combination_Drug", "text": "warfarin", "start": 18, "end": 19}, {"entity_id": "22010004_3_Ent10", "role": "Treatment_Dosage", "text": "2.5 mg", "start": 19, "end": 21}, {"entity_id": "22010004_3_Ent12", "role": "Treatment_Freq", "text": "daily", "start": 21, "end": 22}, {"entity_id": "22010004_3_Ent4", "role": "Effect", "text": "elevated INR of greater than 12.3", "start": 36, "end": 42}, {"entity_id": "22010004_3_Ent6", "role": "Treatment", "text": "dose increase in extended - release niacin ( Niaspan ) from 500 mg to 1000 mg daily the previous week", "start": 44, "end": 64}, {"entity_id": "22010004_3_Ent7", "role": "Treatment_Drug", "text": "extended - release niacin", "start": 47, "end": 51}, {"entity_id": "22010004_3_Ent13", "role": "Combination_Drug", "text": "extended - release niacin", "start": 47, "end": 51}, {"entity_id": "22010004_3_Ent9", "role": "Treatment_Dosage", "text": "1000 mg", "start": 58, "end": 60}, {"entity_id": "22010004_3_Ent11", "role": "Treatment_Freq", "text": "daily", "start": 60, "end": 61}]}], "entity_mentions": [{"id": "22010004_3_Ent1", "text": "69 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "22010004_3_Ent0", "text": "69 - year - old white female", "entity_type": "Entity", "start": 1, "end": 8}, {"id": "22010004_3_Ent2", "text": "white", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "22010004_3_Ent3", "text": "female", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "22010004_3_Ent5", "text": "anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily ( 17.5 mg / wk )", "entity_type": "Entity", "start": 9, "end": 28}, {"id": "22010004_3_Ent8", "text": "warfarin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "22010004_3_Ent14", "text": "warfarin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "22010004_3_Ent10", "text": "2.5 mg", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "22010004_3_Ent12", "text": "daily", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "22010004_3_Ent4", "text": "elevated INR of greater than 12.3", "entity_type": "Entity", "start": 36, "end": 42}, {"id": "22010004_3_Ent6", "text": "dose increase in extended - release niacin ( Niaspan ) from 500 mg to 1000 mg daily the previous week", "entity_type": "Entity", "start": 44, "end": 64}, {"id": "22010004_3_Ent7", "text": "extended - release niacin", "entity_type": "Entity", "start": 47, "end": 51}, {"id": "22010004_3_Ent13", "text": "extended - release niacin", "entity_type": "Entity", "start": 47, "end": 51}, {"id": "22010004_3_Ent9", "text": "1000 mg", "entity_type": "Entity", "start": 58, "end": 60}, {"id": "22010004_3_Ent11", "text": "daily", "entity_type": "Entity", "start": 60, "end": 61}], "lang": "en"}
{"doc_id": "2204409_1", "wnd_id": "2204409_1_1", "text": "An episode of leukoencephalopathy is reported in a 13 - year - old girl who , after standard radiotherapy for a posterior fossa medulloblastoma , received 8 treatments with a protocol containing a 4 - hour infusion of 500 mg / m2 methotrexate and 12 mg intrathecal methotrexate .", "tokens": ["An", "episode", "of", "leukoencephalopathy", "is", "reported", "in", "a", "13", "-", "year", "-", "old", "girl", "who", ",", "after", "standard", "radiotherapy", "for", "a", "posterior", "fossa", "medulloblastoma", ",", "received", "8", "treatments", "with", "a", "protocol", "containing", "a", "4", "-", "hour", "infusion", "of", "500", "mg", "/", "m2", "methotrexate", "and", "12", "mg", "intrathecal", "methotrexate", "."], "event_mentions": [{"id": "2204409_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 16, "end": 17}, "arguments": [{"entity_id": "2204409_1_Ent3", "role": "Effect", "text": "leukoencephalopathy", "start": 3, "end": 4}, {"entity_id": "2204409_1_Ent1", "role": "Subject_Age", "text": "13 - year - old", "start": 8, "end": 13}, {"entity_id": "2204409_1_Ent0", "role": "Subject", "text": "13 - year - old girl who", "start": 8, "end": 15}, {"entity_id": "2204409_1_Ent2", "role": "Subject_Gender", "text": "girl", "start": 13, "end": 14}, {"entity_id": "2204409_1_Ent4", "role": "Treatment", "text": "standard radiotherapy for a posterior fossa medulloblastoma , received 8 treatments with a protocol containing a 4 - hour infusion of 500 mg / m2 methotrexate and 12 mg intrathecal methotrexate", "start": 17, "end": 48}, {"entity_id": "2204409_1_Ent5", "role": "Treatment_Drug", "text": "radiotherapy", "start": 18, "end": 19}, {"entity_id": "2204409_1_Ent8", "role": "Treatment_Route", "text": "infusion", "start": 36, "end": 37}, {"entity_id": "2204409_1_Ent9", "role": "Treatment_Dosage", "text": "500 mg / m2", "start": 38, "end": 42}, {"entity_id": "2204409_1_Ent6", "role": "Treatment_Drug", "text": "methotrexate", "start": 42, "end": 43}, {"entity_id": "2204409_1_Ent10", "role": "Treatment_Dosage", "text": "12 mg", "start": 44, "end": 46}, {"entity_id": "2204409_1_Ent7", "role": "Treatment_Drug", "text": "intrathecal methotrexate", "start": 46, "end": 48}]}], "entity_mentions": [{"id": "2204409_1_Ent3", "text": "leukoencephalopathy", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2204409_1_Ent1", "text": "13 - year - old", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "2204409_1_Ent0", "text": "13 - year - old girl who", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "2204409_1_Ent2", "text": "girl", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "2204409_1_Ent4", "text": "standard radiotherapy for a posterior fossa medulloblastoma , received 8 treatments with a protocol containing a 4 - hour infusion of 500 mg / m2 methotrexate and 12 mg intrathecal methotrexate", "entity_type": "Entity", "start": 17, "end": 48}, {"id": "2204409_1_Ent5", "text": "radiotherapy", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "2204409_1_Ent8", "text": "infusion", "entity_type": "Entity", "start": 36, "end": 37}, {"id": "2204409_1_Ent9", "text": "500 mg / m2", "entity_type": "Entity", "start": 38, "end": 42}, {"id": "2204409_1_Ent6", "text": "methotrexate", "entity_type": "Entity", "start": 42, "end": 43}, {"id": "2204409_1_Ent10", "text": "12 mg", "entity_type": "Entity", "start": 44, "end": 46}, {"id": "2204409_1_Ent7", "text": "intrathecal methotrexate", "entity_type": "Entity", "start": 46, "end": 48}], "lang": "en"}
{"doc_id": "2224786_1", "wnd_id": "2224786_1_1", "text": "A 62 - year - old woman who was being treated for squamous cell carcinoma of the head and neck developed a chemotherapy - related hemolytic - uremic syndrome during the second cycle of neoadjuvant chemotherapy consisting of cisplatin , bleomycin , and methotrexate .", "tokens": ["A", "62", "-", "year", "-", "old", "woman", "who", "was", "being", "treated", "for", "squamous", "cell", "carcinoma", "of", "the", "head", "and", "neck", "developed", "a", "chemotherapy", "-", "related", "hemolytic", "-", "uremic", "syndrome", "during", "the", "second", "cycle", "of", "neoadjuvant", "chemotherapy", "consisting", "of", "cisplatin", ",", "bleomycin", ",", "and", "methotrexate", "."], "event_mentions": [{"id": "2224786_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 20, "end": 21}, "arguments": [{"entity_id": "2224786_1_Ent0", "role": "Subject", "text": "A 62 - year - old woman who was being treated for squamous cell carcinoma of the head and neck", "start": 0, "end": 20}, {"entity_id": "2224786_1_Ent1", "role": "Subject_Age", "text": "62 - year - old", "start": 1, "end": 6}, {"entity_id": "2224786_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "2224786_1_Ent5", "role": "Treatment_Disorder", "text": "squamous cell carcinoma of the head and neck", "start": 12, "end": 20}, {"entity_id": "2224786_1_Ent3", "role": "Effect", "text": "a chemotherapy - related hemolytic - uremic syndrome", "start": 21, "end": 29}, {"entity_id": "2224786_1_Ent4", "role": "Treatment", "text": "the second cycle of neoadjuvant chemotherapy consisting of cisplatin , bleomycin , and methotrexate", "start": 30, "end": 44}, {"entity_id": "2224786_1_Ent6", "role": "Treatment_Dosage", "text": "second cycle", "start": 31, "end": 33}, {"entity_id": "2224786_1_Ent7", "role": "Treatment_Drug", "text": "cisplatin", "start": 38, "end": 39}, {"entity_id": "2224786_1_Ent10", "role": "Combination_Drug", "text": "cisplatin", "start": 38, "end": 39}, {"entity_id": "2224786_1_Ent8", "role": "Treatment_Drug", "text": "bleomycin", "start": 40, "end": 41}, {"entity_id": "2224786_1_Ent11", "role": "Combination_Drug", "text": "bleomycin", "start": 40, "end": 41}, {"entity_id": "2224786_1_Ent9", "role": "Treatment_Drug", "text": "methotrexate", "start": 43, "end": 44}, {"entity_id": "2224786_1_Ent12", "role": "Combination_Drug", "text": "methotrexate", "start": 43, "end": 44}]}], "entity_mentions": [{"id": "2224786_1_Ent0", "text": "A 62 - year - old woman who was being treated for squamous cell carcinoma of the head and neck", "entity_type": "Entity", "start": 0, "end": 20}, {"id": "2224786_1_Ent1", "text": "62 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "2224786_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2224786_1_Ent5", "text": "squamous cell carcinoma of the head and neck", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "2224786_1_Ent3", "text": "a chemotherapy - related hemolytic - uremic syndrome", "entity_type": "Entity", "start": 21, "end": 29}, {"id": "2224786_1_Ent4", "text": "the second cycle of neoadjuvant chemotherapy consisting of cisplatin , bleomycin , and methotrexate", "entity_type": "Entity", "start": 30, "end": 44}, {"id": "2224786_1_Ent6", "text": "second cycle", "entity_type": "Entity", "start": 31, "end": 33}, {"id": "2224786_1_Ent7", "text": "cisplatin", "entity_type": "Entity", "start": 38, "end": 39}, {"id": "2224786_1_Ent10", "text": "cisplatin", "entity_type": "Entity", "start": 38, "end": 39}, {"id": "2224786_1_Ent8", "text": "bleomycin", "entity_type": "Entity", "start": 40, "end": 41}, {"id": "2224786_1_Ent11", "text": "bleomycin", "entity_type": "Entity", "start": 40, "end": 41}, {"id": "2224786_1_Ent9", "text": "methotrexate", "entity_type": "Entity", "start": 43, "end": 44}, {"id": "2224786_1_Ent12", "text": "methotrexate", "entity_type": "Entity", "start": 43, "end": 44}], "lang": "en"}
{"doc_id": "22293514_5", "wnd_id": "22293514_5_1", "text": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite , N - desmethylclobazam , causing neurotoxic symptoms .", "tokens": ["We", "report", "a", "case", "in", "which", "a", "potential", "drug", "interaction", "between", "clobazam", "and", "etravirine", "may", "have", "led", "to", "increased", "concentrations", "of", "clobazam", "and", "its", "pharmacologically", "active", "metabolite", ",", "N", "-", "desmethylclobazam", ",", "causing", "neurotoxic", "symptoms", "."], "event_mentions": [{"id": "22293514_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "led", "start": 16, "end": 17}, "arguments": [{"entity_id": "22293514_5_Ent2", "role": "Treatment", "text": "interaction between clobazam and etravirine", "start": 9, "end": 14}, {"entity_id": "22293514_5_Ent4", "role": "Treatment_Drug", "text": "clobazam", "start": 11, "end": 12}, {"entity_id": "22293514_5_Ent5", "role": "Combination_Drug", "text": "clobazam", "start": 11, "end": 12}, {"entity_id": "22293514_5_Ent3", "role": "Treatment_Drug", "text": "etravirine", "start": 13, "end": 14}, {"entity_id": "22293514_5_Ent6", "role": "Combination_Drug", "text": "etravirine", "start": 13, "end": 14}, {"entity_id": "22293514_5_Ent0", "role": "Effect", "text": "increased concentrations of clobazam and its pharmacologically active metabolite , N - desmethylclobazam", "start": 18, "end": 31}, {"entity_id": "22293514_5_Ent1", "role": "Effect", "text": "neurotoxic symptoms", "start": 33, "end": 35}]}], "entity_mentions": [{"id": "22293514_5_Ent2", "text": "interaction between clobazam and etravirine", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "22293514_5_Ent4", "text": "clobazam", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "22293514_5_Ent5", "text": "clobazam", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "22293514_5_Ent3", "text": "etravirine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "22293514_5_Ent6", "text": "etravirine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "22293514_5_Ent0", "text": "increased concentrations of clobazam and its pharmacologically active metabolite , N - desmethylclobazam", "entity_type": "Entity", "start": 18, "end": 31}, {"id": "22293514_5_Ent1", "text": "neurotoxic symptoms", "entity_type": "Entity", "start": 33, "end": 35}], "lang": "en"}
{"doc_id": "2229534_1", "wnd_id": "2229534_1_1", "text": "Awareness of this route of intoxication might be important in patients in whom neurologic or psychiatric symptoms develop while large amounts of lidocaine cream are being used .", "tokens": ["Awareness", "of", "this", "route", "of", "intoxication", "might", "be", "important", "in", "patients", "in", "whom", "neurologic", "or", "psychiatric", "symptoms", "develop", "while", "large", "amounts", "of", "lidocaine", "cream", "are", "being", "used", "."], "event_mentions": [{"id": "2229534_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 17, "end": 18}, "arguments": [{"entity_id": "2229534_1_Ent0", "role": "Effect", "text": "neurologic or psychiatric symptoms", "start": 13, "end": 17}, {"entity_id": "2229534_1_Ent4", "role": "Treatment_Dosage", "text": "large amounts", "start": 19, "end": 21}, {"entity_id": "2229534_1_Ent1", "role": "Treatment", "text": "large amounts of lidocaine cream are being used", "start": 19, "end": 27}, {"entity_id": "2229534_1_Ent2", "role": "Treatment_Drug", "text": "lidocaine", "start": 22, "end": 23}, {"entity_id": "2229534_1_Ent3", "role": "Treatment_Route", "text": "cream", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "2229534_1_Ent0", "text": "neurologic or psychiatric symptoms", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "2229534_1_Ent4", "text": "large amounts", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "2229534_1_Ent1", "text": "large amounts of lidocaine cream are being used", "entity_type": "Entity", "start": 19, "end": 27}, {"id": "2229534_1_Ent2", "text": "lidocaine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "2229534_1_Ent3", "text": "cream", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "22372628_1", "wnd_id": "22372628_1_1", "text": "Long - term safety and efficacy in patients with uncontrolled partial - onset seizures treated with adjunctive lacosamide : results from a Phase III open - label extension trial .", "tokens": ["Long", "-", "term", "safety", "and", "efficacy", "in", "patients", "with", "uncontrolled", "partial", "-", "onset", "seizures", "treated", "with", "adjunctive", "lacosamide", ":", "results", "from", "a", "Phase", "III", "open", "-", "label", "extension", "trial", "."], "event_mentions": [{"id": "22372628_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 14, "end": 15}, "arguments": [{"entity_id": "22372628_1_Ent0", "role": "Subject", "text": "patients with uncontrolled partial - onset seizures", "start": 7, "end": 14}, {"entity_id": "22372628_1_Ent3", "role": "Treatment_Disorder", "text": "uncontrolled partial - onset seizures", "start": 9, "end": 14}, {"entity_id": "22372628_1_Ent1", "role": "Treatment", "text": "adjunctive lacosamide", "start": 16, "end": 18}, {"entity_id": "22372628_1_Ent2", "role": "Treatment_Drug", "text": "lacosamide", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "22372628_1_Ent0", "text": "patients with uncontrolled partial - onset seizures", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "22372628_1_Ent3", "text": "uncontrolled partial - onset seizures", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "22372628_1_Ent1", "text": "adjunctive lacosamide", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "22372628_1_Ent2", "text": "lacosamide", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "22372628_2", "wnd_id": "22372628_2_1", "text": "To evaluate the long - term ( up to 5 years exposure ) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial - onset seizures taking one to three concomitant antiepileptic drugs ( AEDs ) in open - label extension trial SP756 ( NCT00522275 ) .", "tokens": ["To", "evaluate", "the", "long", "-", "term", "(", "up", "to", "5", "years", "exposure", ")", "safety", "and", "efficacy", "of", "lacosamide", "as", "adjunctive", "therapy", "in", "patients", "with", "uncontrolled", "partial", "-", "onset", "seizures", "taking", "one", "to", "three", "concomitant", "antiepileptic", "drugs", "(", "AEDs", ")", "in", "open", "-", "label", "extension", "trial", "SP756", "(", "NCT00522275", ")", "."], "event_mentions": [{"id": "22372628_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "in", "start": 21, "end": 22}, "arguments": [{"entity_id": "22372628_2_Ent0", "role": "Treatment", "text": "long - term ( up to 5 years exposure )", "start": 3, "end": 13}, {"entity_id": "22372628_2_Ent6", "role": "Treatment_Duration", "text": "long - term ( up to 5 years exposure )", "start": 3, "end": 13}, {"entity_id": "22372628_2_Ent4", "role": "Treatment_Drug", "text": "lacosamide", "start": 17, "end": 18}, {"entity_id": "22372628_2_Ent7", "role": "Combination_Drug", "text": "lacosamide", "start": 17, "end": 18}, {"entity_id": "22372628_2_Ent1", "role": "Treatment", "text": "lacosamide as adjunctive therapy", "start": 17, "end": 21}, {"entity_id": "22372628_2_Ent3", "role": "Treatment_Disorder", "text": "uncontrolled partial - onset seizures", "start": 24, "end": 29}, {"entity_id": "22372628_2_Ent2", "role": "Treatment", "text": "taking one to three concomitant antiepileptic drugs ( AEDs )", "start": 29, "end": 39}, {"entity_id": "22372628_2_Ent5", "role": "Treatment_Drug", "text": "antiepileptic drugs", "start": 34, "end": 36}, {"entity_id": "22372628_2_Ent8", "role": "Combination_Drug", "text": "antiepileptic drugs", "start": 34, "end": 36}]}], "entity_mentions": [{"id": "22372628_2_Ent0", "text": "long - term ( up to 5 years exposure )", "entity_type": "Entity", "start": 3, "end": 13}, {"id": "22372628_2_Ent6", "text": "long - term ( up to 5 years exposure )", "entity_type": "Entity", "start": 3, "end": 13}, {"id": "22372628_2_Ent4", "text": "lacosamide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "22372628_2_Ent7", "text": "lacosamide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "22372628_2_Ent1", "text": "lacosamide as adjunctive therapy", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "22372628_2_Ent3", "text": "uncontrolled partial - onset seizures", "entity_type": "Entity", "start": 24, "end": 29}, {"id": "22372628_2_Ent2", "text": "taking one to three concomitant antiepileptic drugs ( AEDs )", "entity_type": "Entity", "start": 29, "end": 39}, {"id": "22372628_2_Ent5", "text": "antiepileptic drugs", "entity_type": "Entity", "start": 34, "end": 36}, {"id": "22372628_2_Ent8", "text": "antiepileptic drugs", "entity_type": "Entity", "start": 34, "end": 36}], "lang": "en"}
{"doc_id": "2241449_2", "wnd_id": "2241449_2_1", "text": "Sulfadiazine crystalluria revisited .", "tokens": ["Sulfadiazine", "crystalluria", "revisited", "."], "event_mentions": [{"id": "2241449_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "revisited", "start": 2, "end": 3}, "arguments": [{"entity_id": "2241449_2_Ent1", "role": "Treatment", "text": "Sulfadiazine", "start": 0, "end": 1}, {"entity_id": "2241449_2_Ent2", "role": "Treatment_Drug", "text": "Sulfadiazine", "start": 0, "end": 1}, {"entity_id": "2241449_2_Ent0", "role": "Effect", "text": "crystalluria", "start": 1, "end": 2}]}], "entity_mentions": [{"id": "2241449_2_Ent1", "text": "Sulfadiazine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2241449_2_Ent2", "text": "Sulfadiazine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2241449_2_Ent0", "text": "crystalluria", "entity_type": "Entity", "start": 1, "end": 2}], "lang": "en"}
{"doc_id": "22550162_3", "wnd_id": "22550162_3_1", "text": "The patient was placed on omeprazole after his first cycle of high - dose methotrexate for stress ulcer prophylaxis , and it was discontinued before the start of the first day of the patient 's second round of high - dose methotrexate .", "tokens": ["The", "patient", "was", "placed", "on", "omeprazole", "after", "his", "first", "cycle", "of", "high", "-", "dose", "methotrexate", "for", "stress", "ulcer", "prophylaxis", ",", "and", "it", "was", "discontinued", "before", "the", "start", "of", "the", "first", "day", "of", "the", "patient", "'s", "second", "round", "of", "high", "-", "dose", "methotrexate", "."], "event_mentions": [{"id": "22550162_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "prophylaxis", "start": 18, "end": 19}, "arguments": [{"entity_id": "22550162_3_Ent0", "role": "Subject", "text": "The patient", "start": 0, "end": 2}, {"entity_id": "22550162_3_Ent5", "role": "Treatment_Drug", "text": "omeprazole", "start": 5, "end": 6}, {"entity_id": "22550162_3_Ent6", "role": "Treatment_Dosage", "text": "high - dose", "start": 11, "end": 14}, {"entity_id": "22550162_3_Ent1", "role": "Treatment", "text": "methotrexate", "start": 14, "end": 15}, {"entity_id": "22550162_3_Ent4", "role": "Treatment_Drug", "text": "methotrexate", "start": 14, "end": 15}, {"entity_id": "22550162_3_Ent2", "role": "Treatment_Disorder", "text": "stress ulcer", "start": 16, "end": 18}, {"entity_id": "22550162_3_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 41, "end": 42}]}], "entity_mentions": [{"id": "22550162_3_Ent0", "text": "The patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "22550162_3_Ent5", "text": "omeprazole", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "22550162_3_Ent6", "text": "high - dose", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "22550162_3_Ent1", "text": "methotrexate", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "22550162_3_Ent4", "text": "methotrexate", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "22550162_3_Ent2", "text": "stress ulcer", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "22550162_3_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 41, "end": 42}], "lang": "en"}
{"doc_id": "22677303_12", "wnd_id": "22677303_12_1", "text": "Interactions between warfarin and cloxacillin can result in serious adverse reactions .", "tokens": ["Interactions", "between", "warfarin", "and", "cloxacillin", "can", "result", "in", "serious", "adverse", "reactions", "."], "event_mentions": [{"id": "22677303_12_Evt0", "event_type": "Adverse_event", "trigger": {"text": "result", "start": 6, "end": 7}, "arguments": [{"entity_id": "22677303_12_Ent1", "role": "Treatment", "text": "Interactions between warfarin and cloxacillin", "start": 0, "end": 5}, {"entity_id": "22677303_12_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 2, "end": 3}, {"entity_id": "22677303_12_Ent4", "role": "Combination_Drug", "text": "warfarin", "start": 2, "end": 3}, {"entity_id": "22677303_12_Ent3", "role": "Treatment_Drug", "text": "cloxacillin", "start": 4, "end": 5}, {"entity_id": "22677303_12_Ent5", "role": "Combination_Drug", "text": "cloxacillin", "start": 4, "end": 5}, {"entity_id": "22677303_12_Ent0", "role": "Effect", "text": "serious adverse reactions", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "22677303_12_Ent1", "text": "Interactions between warfarin and cloxacillin", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "22677303_12_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "22677303_12_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "22677303_12_Ent3", "text": "cloxacillin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "22677303_12_Ent5", "text": "cloxacillin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "22677303_12_Ent0", "text": "serious adverse reactions", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "22735246_5", "wnd_id": "22735246_5_1", "text": "This is the first reported fatality due to this drug interaction and only the second case of serotonin syndrome reported with oxcarbazepine .", "tokens": ["This", "is", "the", "first", "reported", "fatality", "due", "to", "this", "drug", "interaction", "and", "only", "the", "second", "case", "of", "serotonin", "syndrome", "reported", "with", "oxcarbazepine", "."], "event_mentions": [{"id": "22735246_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 19, "end": 20}, "arguments": [{"entity_id": "22735246_5_Ent0", "role": "Effect", "text": "serotonin syndrome", "start": 17, "end": 19}, {"entity_id": "22735246_5_Ent1", "role": "Treatment", "text": "oxcarbazepine", "start": 21, "end": 22}, {"entity_id": "22735246_5_Ent2", "role": "Treatment_Drug", "text": "oxcarbazepine", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "22735246_5_Ent0", "text": "serotonin syndrome", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "22735246_5_Ent1", "text": "oxcarbazepine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "22735246_5_Ent2", "text": "oxcarbazepine", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "228648_1", "wnd_id": "228648_1_1", "text": "Prenatal cytomegalovirus ( CMV ) infection associated with severe brain damage was detected in an infant whose mother had been treated with prednisolone and azathioprine for systemic lupus erythematosus ( SLE ) .", "tokens": ["Prenatal", "cytomegalovirus", "(", "CMV", ")", "infection", "associated", "with", "severe", "brain", "damage", "was", "detected", "in", "an", "infant", "whose", "mother", "had", "been", "treated", "with", "prednisolone", "and", "azathioprine", "for", "systemic", "lupus", "erythematosus", "(", "SLE", ")", "."], "event_mentions": [{"id": "228648_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 20, "end": 21}, "arguments": [{"entity_id": "228648_1_Ent2", "role": "Effect", "text": "Prenatal cytomegalovirus ( CMV ) infection associated with severe brain damage", "start": 0, "end": 11}, {"entity_id": "228648_1_Ent0", "role": "Subject", "text": "an infant whose mother had been treated with prednisolone and azathioprine for systemic lupus erythematosus ( SLE )", "start": 14, "end": 32}, {"entity_id": "228648_1_Ent1", "role": "Subject_Age", "text": "infant", "start": 15, "end": 16}, {"entity_id": "228648_1_Ent4", "role": "Treatment_Drug", "text": "prednisolone", "start": 22, "end": 23}, {"entity_id": "228648_1_Ent6", "role": "Combination_Drug", "text": "prednisolone", "start": 22, "end": 23}, {"entity_id": "228648_1_Ent3", "role": "Treatment", "text": "prednisolone and azathioprine", "start": 22, "end": 25}, {"entity_id": "228648_1_Ent5", "role": "Treatment_Drug", "text": "azathioprine", "start": 24, "end": 25}, {"entity_id": "228648_1_Ent7", "role": "Combination_Drug", "text": "azathioprine", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "228648_1_Ent2", "text": "Prenatal cytomegalovirus ( CMV ) infection associated with severe brain damage", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "228648_1_Ent0", "text": "an infant whose mother had been treated with prednisolone and azathioprine for systemic lupus erythematosus ( SLE )", "entity_type": "Entity", "start": 14, "end": 32}, {"id": "228648_1_Ent1", "text": "infant", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "228648_1_Ent4", "text": "prednisolone", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "228648_1_Ent6", "text": "prednisolone", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "228648_1_Ent3", "text": "prednisolone and azathioprine", "entity_type": "Entity", "start": 22, "end": 25}, {"id": "228648_1_Ent5", "text": "azathioprine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "228648_1_Ent7", "text": "azathioprine", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "2295443_3", "wnd_id": "2295443_3_1", "text": "This report presents a case of colon perforation which occurred 4 months after treatment with intraperitoneal chromic phosphate for stage IB ovarian papillary serous cystadenocarcinoma .", "tokens": ["This", "report", "presents", "a", "case", "of", "colon", "perforation", "which", "occurred", "4", "months", "after", "treatment", "with", "intraperitoneal", "chromic", "phosphate", "for", "stage", "IB", "ovarian", "papillary", "serous", "cystadenocarcinoma", "."], "event_mentions": [{"id": "2295443_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 9, "end": 10}, "arguments": [{"entity_id": "2295443_3_Ent0", "role": "Effect", "text": "colon perforation", "start": 6, "end": 8}, {"entity_id": "2295443_3_Ent3", "role": "Treatment_Time_elapsed", "text": "4 months", "start": 10, "end": 12}, {"entity_id": "2295443_3_Ent4", "role": "Treatment_Route", "text": "intraperitoneal", "start": 15, "end": 16}, {"entity_id": "2295443_3_Ent1", "role": "Treatment", "text": "intraperitoneal chromic phosphate", "start": 15, "end": 18}, {"entity_id": "2295443_3_Ent2", "role": "Treatment_Drug", "text": "chromic phosphate", "start": 16, "end": 18}, {"entity_id": "2295443_3_Ent5", "role": "Treatment_Disorder", "text": "stage IB ovarian papillary serous cystadenocarcinoma", "start": 19, "end": 25}]}], "entity_mentions": [{"id": "2295443_3_Ent0", "text": "colon perforation", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "2295443_3_Ent3", "text": "4 months", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "2295443_3_Ent4", "text": "intraperitoneal", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "2295443_3_Ent1", "text": "intraperitoneal chromic phosphate", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "2295443_3_Ent2", "text": "chromic phosphate", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "2295443_3_Ent5", "text": "stage IB ovarian papillary serous cystadenocarcinoma", "entity_type": "Entity", "start": 19, "end": 25}], "lang": "en"}
{"doc_id": "2320800_2", "wnd_id": "2320800_2_1", "text": "A sixty - year - old woman with advanced breast cancer , previously treated with cisplatin , developed an irreversible lethal renal failure with anuria , the day after 5 g / m2 bolus ifosfamide .", "tokens": ["A", "sixty", "-", "year", "-", "old", "woman", "with", "advanced", "breast", "cancer", ",", "previously", "treated", "with", "cisplatin", ",", "developed", "an", "irreversible", "lethal", "renal", "failure", "with", "anuria", ",", "the", "day", "after", "5", "g", "/", "m2", "bolus", "ifosfamide", "."], "event_mentions": [{"id": "2320800_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 17, "end": 18}, "arguments": [{"entity_id": "2320800_2_Ent0", "role": "Subject", "text": "A sixty - year - old woman with advanced breast cancer , previously treated with cisplatin", "start": 0, "end": 16}, {"entity_id": "2320800_2_Ent1", "role": "Subject_Age", "text": "sixty - year - old", "start": 1, "end": 6}, {"entity_id": "2320800_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "2320800_2_Ent5", "role": "Treatment_Disorder", "text": "advanced breast cancer", "start": 8, "end": 11}, {"entity_id": "2320800_2_Ent3", "role": "Effect", "text": "an irreversible lethal renal failure with anuria", "start": 18, "end": 25}, {"entity_id": "2320800_2_Ent6", "role": "Treatment_Time_elapsed", "text": "the day after", "start": 26, "end": 29}, {"entity_id": "2320800_2_Ent4", "role": "Treatment", "text": "the day after 5 g / m2 bolus ifosfamide", "start": 26, "end": 35}, {"entity_id": "2320800_2_Ent7", "role": "Treatment_Dosage", "text": "5 g / m2", "start": 29, "end": 33}, {"entity_id": "2320800_2_Ent8", "role": "Treatment_Drug", "text": "ifosfamide", "start": 34, "end": 35}]}], "entity_mentions": [{"id": "2320800_2_Ent0", "text": "A sixty - year - old woman with advanced breast cancer , previously treated with cisplatin", "entity_type": "Entity", "start": 0, "end": 16}, {"id": "2320800_2_Ent1", "text": "sixty - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "2320800_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2320800_2_Ent5", "text": "advanced breast cancer", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "2320800_2_Ent3", "text": "an irreversible lethal renal failure with anuria", "entity_type": "Entity", "start": 18, "end": 25}, {"id": "2320800_2_Ent6", "text": "the day after", "entity_type": "Entity", "start": 26, "end": 29}, {"id": "2320800_2_Ent4", "text": "the day after 5 g / m2 bolus ifosfamide", "entity_type": "Entity", "start": 26, "end": 35}, {"id": "2320800_2_Ent7", "text": "5 g / m2", "entity_type": "Entity", "start": 29, "end": 33}, {"id": "2320800_2_Ent8", "text": "ifosfamide", "entity_type": "Entity", "start": 34, "end": 35}], "lang": "en"}
{"doc_id": "2329972_2", "wnd_id": "2329972_2_1", "text": "Severe acute encephalopathy following inadvertent intrathecal doxorubicin administration .", "tokens": ["Severe", "acute", "encephalopathy", "following", "inadvertent", "intrathecal", "doxorubicin", "administration", "."], "event_mentions": [{"id": "2329972_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "2329972_2_Ent0", "role": "Effect", "text": "Severe acute encephalopathy", "start": 0, "end": 3}, {"entity_id": "2329972_2_Ent2", "role": "Treatment_Route", "text": "intrathecal", "start": 5, "end": 6}, {"entity_id": "2329972_2_Ent1", "role": "Treatment", "text": "intrathecal doxorubicin administration", "start": 5, "end": 8}, {"entity_id": "2329972_2_Ent3", "role": "Treatment_Drug", "text": "doxorubicin", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "2329972_2_Ent0", "text": "Severe acute encephalopathy", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2329972_2_Ent2", "text": "intrathecal", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2329972_2_Ent1", "text": "intrathecal doxorubicin administration", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "2329972_2_Ent3", "text": "doxorubicin", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "23471710_2", "wnd_id": "23471710_2_1", "text": "Two drugs commonly used in triple - drug therapy for treatment of a Helicobacter pylori infection , clarithromycin and omeprazole , have rarely been associated with hypoglycemia when given alone .", "tokens": ["Two", "drugs", "commonly", "used", "in", "triple", "-", "drug", "therapy", "for", "treatment", "of", "a", "Helicobacter", "pylori", "infection", ",", "clarithromycin", "and", "omeprazole", ",", "have", "rarely", "been", "associated", "with", "hypoglycemia", "when", "given", "alone", "."], "event_mentions": [{"id": "23471710_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 24, "end": 25}, "arguments": [{"entity_id": "23471710_2_Ent4", "role": "Treatment_Disorder", "text": "a Helicobacter pylori infection", "start": 12, "end": 16}, {"entity_id": "23471710_2_Ent2", "role": "Treatment_Drug", "text": "clarithromycin", "start": 17, "end": 18}, {"entity_id": "23471710_2_Ent5", "role": "Combination_Drug", "text": "clarithromycin", "start": 17, "end": 18}, {"entity_id": "23471710_2_Ent1", "role": "Treatment", "text": "clarithromycin and omeprazole", "start": 17, "end": 20}, {"entity_id": "23471710_2_Ent3", "role": "Treatment_Drug", "text": "omeprazole", "start": 19, "end": 20}, {"entity_id": "23471710_2_Ent6", "role": "Combination_Drug", "text": "omeprazole", "start": 19, "end": 20}, {"entity_id": "23471710_2_Ent0", "role": "Effect", "text": "hypoglycemia", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "23471710_2_Ent4", "text": "a Helicobacter pylori infection", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "23471710_2_Ent2", "text": "clarithromycin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "23471710_2_Ent5", "text": "clarithromycin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "23471710_2_Ent1", "text": "clarithromycin and omeprazole", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "23471710_2_Ent3", "text": "omeprazole", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "23471710_2_Ent6", "text": "omeprazole", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "23471710_2_Ent0", "text": "hypoglycemia", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "2357706_2", "wnd_id": "2357706_2_1", "text": "Tardive dyskinesia induced by sulpiride .", "tokens": ["Tardive", "dyskinesia", "induced", "by", "sulpiride", "."], "event_mentions": [{"id": "2357706_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "2357706_2_Ent0", "role": "Effect", "text": "Tardive dyskinesia", "start": 0, "end": 2}, {"entity_id": "2357706_2_Ent1", "role": "Treatment", "text": "sulpiride", "start": 4, "end": 5}, {"entity_id": "2357706_2_Ent2", "role": "Treatment_Drug", "text": "sulpiride", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "2357706_2_Ent0", "text": "Tardive dyskinesia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2357706_2_Ent1", "text": "sulpiride", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "2357706_2_Ent2", "text": "sulpiride", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "2357706_3", "wnd_id": "2357706_3_1", "text": "These cases indicate that sulpiride can cause tardive dyskinesia and that this drug should be administered with caution .", "tokens": ["These", "cases", "indicate", "that", "sulpiride", "can", "cause", "tardive", "dyskinesia", "and", "that", "this", "drug", "should", "be", "administered", "with", "caution", "."], "event_mentions": [{"id": "2357706_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 6, "end": 7}, "arguments": [{"entity_id": "2357706_3_Ent1", "role": "Treatment", "text": "sulpiride", "start": 4, "end": 5}, {"entity_id": "2357706_3_Ent2", "role": "Treatment_Drug", "text": "sulpiride", "start": 4, "end": 5}, {"entity_id": "2357706_3_Ent0", "role": "Effect", "text": "tardive dyskinesia", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "2357706_3_Ent1", "text": "sulpiride", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "2357706_3_Ent2", "text": "sulpiride", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "2357706_3_Ent0", "text": "tardive dyskinesia", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "2369419_3", "wnd_id": "2369419_3_1", "text": "This is the third report of reversible hepatic decompensation associated with prolonged MTX therapy in patients with rheumatoid arthritis .", "tokens": ["This", "is", "the", "third", "report", "of", "reversible", "hepatic", "decompensation", "associated", "with", "prolonged", "MTX", "therapy", "in", "patients", "with", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "2369419_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "2369419_3_Ent1", "role": "Effect", "text": "reversible hepatic decompensation", "start": 6, "end": 9}, {"entity_id": "2369419_3_Ent2", "role": "Treatment", "text": "MTX", "start": 12, "end": 13}, {"entity_id": "2369419_3_Ent4", "role": "Treatment_Drug", "text": "MTX", "start": 12, "end": 13}, {"entity_id": "2369419_3_Ent0", "role": "Subject", "text": "patients with rheumatoid arthritis", "start": 15, "end": 19}, {"entity_id": "2369419_3_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "2369419_3_Ent1", "text": "reversible hepatic decompensation", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "2369419_3_Ent2", "text": "MTX", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "2369419_3_Ent4", "text": "MTX", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "2369419_3_Ent0", "text": "patients with rheumatoid arthritis", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "2369419_3_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "2378415_3", "wnd_id": "2378415_3_1", "text": "Transtentorial herniation caused by an intracranial mass lesion following high - dose methotrexate .", "tokens": ["Transtentorial", "herniation", "caused", "by", "an", "intracranial", "mass", "lesion", "following", "high", "-", "dose", "methotrexate", "."], "event_mentions": [{"id": "2378415_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 8, "end": 9}, "arguments": [{"entity_id": "2378415_3_Ent1", "role": "Effect", "text": "Transtentorial herniation", "start": 0, "end": 2}, {"entity_id": "2378415_3_Ent0", "role": "Effect", "text": "an intracranial mass lesion", "start": 4, "end": 8}, {"entity_id": "2378415_3_Ent4", "role": "Treatment_Dosage", "text": "high - dose", "start": 9, "end": 12}, {"entity_id": "2378415_3_Ent2", "role": "Treatment", "text": "high - dose methotrexate", "start": 9, "end": 13}, {"entity_id": "2378415_3_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "2378415_3_Ent1", "text": "Transtentorial herniation", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2378415_3_Ent0", "text": "an intracranial mass lesion", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "2378415_3_Ent4", "text": "high - dose", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "2378415_3_Ent2", "text": "high - dose methotrexate", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "2378415_3_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "2394154_1", "wnd_id": "2394154_1_1", "text": "Fever , pulmonary infiltrates , and pleural effusion following acyclovir therapy for herpes zoster ophthalmicus .", "tokens": ["Fever", ",", "pulmonary", "infiltrates", ",", "and", "pleural", "effusion", "following", "acyclovir", "therapy", "for", "herpes", "zoster", "ophthalmicus", "."], "event_mentions": [{"id": "2394154_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 8, "end": 9}, "arguments": [{"entity_id": "2394154_1_Ent0", "role": "Effect", "text": "Fever , pulmonary infiltrates , and pleural effusion", "start": 0, "end": 8}, {"entity_id": "2394154_1_Ent3", "role": "Treatment_Drug", "text": "acyclovir", "start": 9, "end": 10}, {"entity_id": "2394154_1_Ent1", "role": "Treatment", "text": "acyclovir therapy for herpes zoster ophthalmicus", "start": 9, "end": 15}, {"entity_id": "2394154_1_Ent2", "role": "Treatment_Disorder", "text": "herpes zoster ophthalmicus", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "2394154_1_Ent0", "text": "Fever , pulmonary infiltrates , and pleural effusion", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "2394154_1_Ent3", "text": "acyclovir", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "2394154_1_Ent1", "text": "acyclovir therapy for herpes zoster ophthalmicus", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "2394154_1_Ent2", "text": "herpes zoster ophthalmicus", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "2394154_4", "wnd_id": "2394154_4_1", "text": "To our knowledge , the syndrome of fever , pulmonary infiltrates , and pleural effusion following use of acyclovir has not been previously reported .", "tokens": ["To", "our", "knowledge", ",", "the", "syndrome", "of", "fever", ",", "pulmonary", "infiltrates", ",", "and", "pleural", "effusion", "following", "use", "of", "acyclovir", "has", "not", "been", "previously", "reported", "."], "event_mentions": [{"id": "2394154_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 15, "end": 16}, "arguments": [{"entity_id": "2394154_4_Ent0", "role": "Effect", "text": "fever , pulmonary infiltrates , and pleural effusion", "start": 7, "end": 15}, {"entity_id": "2394154_4_Ent1", "role": "Treatment", "text": "acyclovir", "start": 18, "end": 19}, {"entity_id": "2394154_4_Ent2", "role": "Treatment_Drug", "text": "acyclovir", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "2394154_4_Ent0", "text": "fever , pulmonary infiltrates , and pleural effusion", "entity_type": "Entity", "start": 7, "end": 15}, {"id": "2394154_4_Ent1", "text": "acyclovir", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "2394154_4_Ent2", "text": "acyclovir", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "23970584_3", "wnd_id": "23970584_3_1", "text": "A 55 - year - old HIV - positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia .", "tokens": ["A", "55", "-", "year", "-", "old", "HIV", "-", "positive", "African", "woman", "received", "a", "single", "epidural", "triamcinolone", "injection", "for", "pain", "relief", "of", "postherpetic", "neuralgia", "."], "event_mentions": [{"id": "23970584_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "received", "start": 11, "end": 12}, "arguments": [{"entity_id": "23970584_3_Ent0", "role": "Subject", "text": "A 55 - year - old HIV - positive African woman", "start": 0, "end": 11}, {"entity_id": "23970584_3_Ent1", "role": "Subject_Age", "text": "55 - year - old", "start": 1, "end": 6}, {"entity_id": "23970584_3_Ent2", "role": "Subject_Disorder", "text": "HIV", "start": 6, "end": 7}, {"entity_id": "23970584_3_Ent3", "role": "Subject_Race", "text": "African", "start": 9, "end": 10}, {"entity_id": "23970584_3_Ent4", "role": "Subject_Gender", "text": "woman", "start": 10, "end": 11}, {"entity_id": "23970584_3_Ent5", "role": "Treatment", "text": "a single epidural triamcinolone injection", "start": 12, "end": 17}, {"entity_id": "23970584_3_Ent7", "role": "Treatment_Drug", "text": "triamcinolone", "start": 15, "end": 16}, {"entity_id": "23970584_3_Ent8", "role": "Treatment_Route", "text": "injection", "start": 16, "end": 17}, {"entity_id": "23970584_3_Ent6", "role": "Treatment_Disorder", "text": "pain relief of postherpetic neuralgia", "start": 18, "end": 23}]}], "entity_mentions": [{"id": "23970584_3_Ent0", "text": "A 55 - year - old HIV - positive African woman", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "23970584_3_Ent1", "text": "55 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "23970584_3_Ent2", "text": "HIV", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "23970584_3_Ent3", "text": "African", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "23970584_3_Ent4", "text": "woman", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "23970584_3_Ent5", "text": "a single epidural triamcinolone injection", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "23970584_3_Ent7", "text": "triamcinolone", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "23970584_3_Ent8", "text": "injection", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "23970584_3_Ent6", "text": "pain relief of postherpetic neuralgia", "entity_type": "Entity", "start": 18, "end": 23}], "lang": "en"}
{"doc_id": "24163322_7", "wnd_id": "24163322_7_1", "text": "Bismuth subsalicylate 30 mL every 4 hours was prescribed for diarrhea .", "tokens": ["Bismuth", "subsalicylate", "30", "mL", "every", "4", "hours", "was", "prescribed", "for", "diarrhea", "."], "event_mentions": [{"id": "24163322_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "prescribed", "start": 8, "end": 9}, "arguments": [{"entity_id": "24163322_7_Ent1", "role": "Treatment_Drug", "text": "Bismuth subsalicylate", "start": 0, "end": 2}, {"entity_id": "24163322_7_Ent0", "role": "Treatment", "text": "Bismuth subsalicylate 30 mL every 4 hours", "start": 0, "end": 7}, {"entity_id": "24163322_7_Ent2", "role": "Treatment_Dosage", "text": "30 mL", "start": 2, "end": 4}, {"entity_id": "24163322_7_Ent3", "role": "Treatment_Freq", "text": "every 4 hours", "start": 4, "end": 7}, {"entity_id": "24163322_7_Ent4", "role": "Treatment_Disorder", "text": "diarrhea", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "24163322_7_Ent1", "text": "Bismuth subsalicylate", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "24163322_7_Ent0", "text": "Bismuth subsalicylate 30 mL every 4 hours", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "24163322_7_Ent2", "text": "30 mL", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "24163322_7_Ent3", "text": "every 4 hours", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "24163322_7_Ent4", "text": "diarrhea", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "2429270_5", "wnd_id": "2429270_5_1", "text": "The pro - arrhythmic effects of procainamide may be explained on the basis of both its vagolytic action on the atrioventricular node as well as by prolongation of refractoriness in the accessory pathway .", "tokens": ["The", "pro", "-", "arrhythmic", "effects", "of", "procainamide", "may", "be", "explained", "on", "the", "basis", "of", "both", "its", "vagolytic", "action", "on", "the", "atrioventricular", "node", "as", "well", "as", "by", "prolongation", "of", "refractoriness", "in", "the", "accessory", "pathway", "."], "event_mentions": [{"id": "2429270_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 5, "end": 6}, "arguments": [{"entity_id": "2429270_5_Ent0", "role": "Effect", "text": "pro - arrhythmic effects", "start": 1, "end": 5}, {"entity_id": "2429270_5_Ent1", "role": "Treatment", "text": "procainamide", "start": 6, "end": 7}, {"entity_id": "2429270_5_Ent2", "role": "Treatment_Drug", "text": "procainamide", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "2429270_5_Ent0", "text": "pro - arrhythmic effects", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "2429270_5_Ent1", "text": "procainamide", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2429270_5_Ent2", "text": "procainamide", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "24318743_1", "wnd_id": "24318743_1_1", "text": "Weekly AUC2 carboplatin in acquired platinum - resistant ovarian cancer with or without oral phenoxodiol , a sensitizer of platinum cytotoxicity : the phase III OVATURE multicenter randomized study .", "tokens": ["Weekly", "AUC2", "carboplatin", "in", "acquired", "platinum", "-", "resistant", "ovarian", "cancer", "with", "or", "without", "oral", "phenoxodiol", ",", "a", "sensitizer", "of", "platinum", "cytotoxicity", ":", "the", "phase", "III", "OVATURE", "multicenter", "randomized", "study", "."], "event_mentions": [{"id": "24318743_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "in", "start": 3, "end": 4}, "arguments": [{"entity_id": "24318743_1_Ent2", "role": "Treatment_Freq", "text": "Weekly", "start": 0, "end": 1}, {"entity_id": "24318743_1_Ent0", "role": "Treatment", "text": "Weekly AUC2 carboplatin", "start": 0, "end": 3}, {"entity_id": "24318743_1_Ent3", "role": "Treatment_Drug", "text": "AUC2 carboplatin", "start": 1, "end": 3}, {"entity_id": "24318743_1_Ent8", "role": "Combination_Drug", "text": "AUC2 carboplatin", "start": 1, "end": 3}, {"entity_id": "24318743_1_Ent5", "role": "Treatment_Disorder", "text": "platinum - resistant ovarian cancer", "start": 5, "end": 10}, {"entity_id": "24318743_1_Ent1", "role": "Treatment", "text": "with or without oral phenoxodiol", "start": 10, "end": 15}, {"entity_id": "24318743_1_Ent6", "role": "Treatment_Route", "text": "oral", "start": 13, "end": 14}, {"entity_id": "24318743_1_Ent4", "role": "Treatment_Drug", "text": "phenoxodiol", "start": 14, "end": 15}, {"entity_id": "24318743_1_Ent7", "role": "Combination_Drug", "text": "phenoxodiol", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "24318743_1_Ent2", "text": "Weekly", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "24318743_1_Ent0", "text": "Weekly AUC2 carboplatin", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "24318743_1_Ent3", "text": "AUC2 carboplatin", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "24318743_1_Ent8", "text": "AUC2 carboplatin", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "24318743_1_Ent5", "text": "platinum - resistant ovarian cancer", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "24318743_1_Ent1", "text": "with or without oral phenoxodiol", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "24318743_1_Ent6", "text": "oral", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "24318743_1_Ent4", "text": "phenoxodiol", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "24318743_1_Ent7", "text": "phenoxodiol", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "24318743_14", "wnd_id": "24318743_14_1", "text": "Orally delivered PXD showed no evidence of clinical activity , when combined with weekly AUC2 - carboplatin in PROC .", "tokens": ["Orally", "delivered", "PXD", "showed", "no", "evidence", "of", "clinical", "activity", ",", "when", "combined", "with", "weekly", "AUC2", "-", "carboplatin", "in", "PROC", "."], "event_mentions": [{"id": "24318743_14_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "clinical activity", "start": 7, "end": 9}, "arguments": [{"entity_id": "24318743_14_Ent3", "role": "Treatment_Route", "text": "Orally", "start": 0, "end": 1}, {"entity_id": "24318743_14_Ent0", "role": "Treatment", "text": "Orally delivered PXD", "start": 0, "end": 3}, {"entity_id": "24318743_14_Ent4", "role": "Treatment_Drug", "text": "PXD", "start": 2, "end": 3}, {"entity_id": "24318743_14_Ent7", "role": "Combination_Drug", "text": "PXD", "start": 2, "end": 3}, {"entity_id": "24318743_14_Ent6", "role": "Treatment_Freq", "text": "weekly", "start": 13, "end": 14}, {"entity_id": "24318743_14_Ent1", "role": "Treatment", "text": "weekly AUC2 - carboplatin", "start": 13, "end": 17}, {"entity_id": "24318743_14_Ent5", "role": "Treatment_Drug", "text": "AUC2 - carboplatin", "start": 14, "end": 17}, {"entity_id": "24318743_14_Ent8", "role": "Combination_Drug", "text": "AUC2 - carboplatin", "start": 14, "end": 17}, {"entity_id": "24318743_14_Ent2", "role": "Treatment_Disorder", "text": "PROC", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "24318743_14_Ent3", "text": "Orally", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "24318743_14_Ent0", "text": "Orally delivered PXD", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "24318743_14_Ent4", "text": "PXD", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "24318743_14_Ent7", "text": "PXD", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "24318743_14_Ent6", "text": "weekly", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "24318743_14_Ent1", "text": "weekly AUC2 - carboplatin", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "24318743_14_Ent5", "text": "AUC2 - carboplatin", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "24318743_14_Ent8", "text": "AUC2 - carboplatin", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "24318743_14_Ent2", "text": "PROC", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "24429012_10", "wnd_id": "24429012_10_1", "text": "Concurrent use of vismodegib and warfarin was deemed the probable cause of acute INR elevation in this case , suggesting the need for close monitoring of INR values in patients receiving this combination of drugs .", "tokens": ["Concurrent", "use", "of", "vismodegib", "and", "warfarin", "was", "deemed", "the", "probable", "cause", "of", "acute", "INR", "elevation", "in", "this", "case", ",", "suggesting", "the", "need", "for", "close", "monitoring", "of", "INR", "values", "in", "patients", "receiving", "this", "combination", "of", "drugs", "."], "event_mentions": [{"id": "24429012_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 10, "end": 11}, "arguments": [{"entity_id": "24429012_10_Ent2", "role": "Treatment_Drug", "text": "vismodegib", "start": 3, "end": 4}, {"entity_id": "24429012_10_Ent4", "role": "Combination_Drug", "text": "vismodegib", "start": 3, "end": 4}, {"entity_id": "24429012_10_Ent1", "role": "Treatment", "text": "vismodegib and warfarin", "start": 3, "end": 6}, {"entity_id": "24429012_10_Ent3", "role": "Treatment_Drug", "text": "warfarin", "start": 5, "end": 6}, {"entity_id": "24429012_10_Ent5", "role": "Combination_Drug", "text": "warfarin", "start": 5, "end": 6}, {"entity_id": "24429012_10_Ent0", "role": "Effect", "text": "acute INR elevation", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "24429012_10_Ent2", "text": "vismodegib", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "24429012_10_Ent4", "text": "vismodegib", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "24429012_10_Ent1", "text": "vismodegib and warfarin", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "24429012_10_Ent3", "text": "warfarin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "24429012_10_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "24429012_10_Ent0", "text": "acute INR elevation", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "2445709_2", "wnd_id": "2445709_2_1", "text": "Peripheral neuropathy and cerebellar syndrome associated with amiodarone therapy .", "tokens": ["Peripheral", "neuropathy", "and", "cerebellar", "syndrome", "associated", "with", "amiodarone", "therapy", "."], "event_mentions": [{"id": "2445709_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "2445709_2_Ent0", "role": "Effect", "text": "Peripheral neuropathy and cerebellar syndrome", "start": 0, "end": 5}, {"entity_id": "2445709_2_Ent1", "role": "Treatment", "text": "amiodarone", "start": 7, "end": 8}, {"entity_id": "2445709_2_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "2445709_2_Ent0", "text": "Peripheral neuropathy and cerebellar syndrome", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "2445709_2_Ent1", "text": "amiodarone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2445709_2_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "24477376_4", "wnd_id": "24477376_4_1", "text": "The patient was previously on phenytoin and was initiated on ticagrelor for antiplatelet therapy following stent placement .", "tokens": ["The", "patient", "was", "previously", "on", "phenytoin", "and", "was", "initiated", "on", "ticagrelor", "for", "antiplatelet", "therapy", "following", "stent", "placement", "."], "event_mentions": [{"id": "24477376_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 11, "end": 12}, "arguments": [{"entity_id": "24477376_4_Ent0", "role": "Subject", "text": "The patient", "start": 0, "end": 2}, {"entity_id": "24477376_4_Ent1", "role": "Treatment", "text": "previously on phenytoin", "start": 3, "end": 6}, {"entity_id": "24477376_4_Ent5", "role": "Treatment_Drug", "text": "phenytoin", "start": 5, "end": 6}, {"entity_id": "24477376_4_Ent2", "role": "Treatment", "text": "initiated on ticagrelor", "start": 8, "end": 11}, {"entity_id": "24477376_4_Ent6", "role": "Treatment_Drug", "text": "ticagrelor", "start": 10, "end": 11}, {"entity_id": "24477376_4_Ent4", "role": "Treatment_Disorder", "text": "antiplatelet therapy", "start": 12, "end": 14}, {"entity_id": "24477376_4_Ent3", "role": "Treatment", "text": "following stent placement", "start": 14, "end": 17}]}], "entity_mentions": [{"id": "24477376_4_Ent0", "text": "The patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "24477376_4_Ent1", "text": "previously on phenytoin", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "24477376_4_Ent5", "text": "phenytoin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "24477376_4_Ent2", "text": "initiated on ticagrelor", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "24477376_4_Ent6", "text": "ticagrelor", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "24477376_4_Ent4", "text": "antiplatelet therapy", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "24477376_4_Ent3", "text": "following stent placement", "entity_type": "Entity", "start": 14, "end": 17}], "lang": "en"}
{"doc_id": "24477376_5", "wnd_id": "24477376_5_1", "text": "While the patient was receiving both drugs , platelet aggregation studies revealed less platelet inhibition than would be expected in a patient not taking a concomitant inducer of ticagrelor metabolism .", "tokens": ["While", "the", "patient", "was", "receiving", "both", "drugs", ",", "platelet", "aggregation", "studies", "revealed", "less", "platelet", "inhibition", "than", "would", "be", "expected", "in", "a", "patient", "not", "taking", "a", "concomitant", "inducer", "of", "ticagrelor", "metabolism", "."], "event_mentions": [{"id": "24477376_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "revealed", "start": 11, "end": 12}, "arguments": [{"entity_id": "24477376_5_Ent1", "role": "Effect", "text": "less platelet inhibition than would be expected", "start": 12, "end": 19}, {"entity_id": "24477376_5_Ent0", "role": "Subject", "text": "a patient", "start": 20, "end": 22}, {"entity_id": "24477376_5_Ent2", "role": "Treatment", "text": "taking a concomitant inducer of ticagrelor metabolism .", "start": 23, "end": 31}, {"entity_id": "24477376_5_Ent4", "role": "Treatment_Drug", "text": "inducer of ticagrelor metabolism", "start": 26, "end": 30}, {"entity_id": "24477376_5_Ent5", "role": "Combination_Drug", "text": "inducer of ticagrelor metabolism", "start": 26, "end": 30}, {"entity_id": "24477376_5_Ent3", "role": "Treatment_Drug", "text": "ticagrelor", "start": 28, "end": 29}, {"entity_id": "24477376_5_Ent6", "role": "Combination_Drug", "text": "ticagrelor", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "24477376_5_Ent1", "text": "less platelet inhibition than would be expected", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "24477376_5_Ent0", "text": "a patient", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "24477376_5_Ent2", "text": "taking a concomitant inducer of ticagrelor metabolism .", "entity_type": "Entity", "start": 23, "end": 31}, {"id": "24477376_5_Ent4", "text": "inducer of ticagrelor metabolism", "entity_type": "Entity", "start": 26, "end": 30}, {"id": "24477376_5_Ent5", "text": "inducer of ticagrelor metabolism", "entity_type": "Entity", "start": 26, "end": 30}, {"id": "24477376_5_Ent3", "text": "ticagrelor", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "24477376_5_Ent6", "text": "ticagrelor", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "24477376_7", "wnd_id": "24477376_7_1", "text": "Dual antiplatelet therapy with aspirin and a P2Y12 receptor antagonist following placement of coronary stents is critical to prevent stent thrombosis and subsequent myocardial infarction .", "tokens": ["Dual", "antiplatelet", "therapy", "with", "aspirin", "and", "a", "P2Y12", "receptor", "antagonist", "following", "placement", "of", "coronary", "stents", "is", "critical", "to", "prevent", "stent", "thrombosis", "and", "subsequent", "myocardial", "infarction", "."], "event_mentions": [{"id": "24477376_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "prevent", "start": 18, "end": 19}, "arguments": [{"entity_id": "24477376_7_Ent2", "role": "Treatment_Drug", "text": "aspirin", "start": 4, "end": 5}, {"entity_id": "24477376_7_Ent4", "role": "Combination_Drug", "text": "aspirin", "start": 4, "end": 5}, {"entity_id": "24477376_7_Ent0", "role": "Treatment", "text": "aspirin and a P2Y12 receptor antagonist following placement of coronary stents", "start": 4, "end": 15}, {"entity_id": "24477376_7_Ent3", "role": "Treatment_Drug", "text": "P2Y12 receptor antagonist", "start": 7, "end": 10}, {"entity_id": "24477376_7_Ent5", "role": "Combination_Drug", "text": "P2Y12 receptor antagonist", "start": 7, "end": 10}, {"entity_id": "24477376_7_Ent1", "role": "Treatment_Disorder", "text": "stent thrombosis and subsequent myocardial infarction", "start": 19, "end": 25}]}], "entity_mentions": [{"id": "24477376_7_Ent2", "text": "aspirin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "24477376_7_Ent4", "text": "aspirin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "24477376_7_Ent0", "text": "aspirin and a P2Y12 receptor antagonist following placement of coronary stents", "entity_type": "Entity", "start": 4, "end": 15}, {"id": "24477376_7_Ent3", "text": "P2Y12 receptor antagonist", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "24477376_7_Ent5", "text": "P2Y12 receptor antagonist", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "24477376_7_Ent1", "text": "stent thrombosis and subsequent myocardial infarction", "entity_type": "Entity", "start": 19, "end": 25}], "lang": "en"}
{"doc_id": "24791374_2", "wnd_id": "24791374_2_1", "text": "We describe a rare case of severe drug - drug interaction between propafenone and mirtazapine leading to propafenone toxicity .", "tokens": ["We", "describe", "a", "rare", "case", "of", "severe", "drug", "-", "drug", "interaction", "between", "propafenone", "and", "mirtazapine", "leading", "to", "propafenone", "toxicity", "."], "event_mentions": [{"id": "24791374_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "leading", "start": 15, "end": 16}, "arguments": [{"entity_id": "24791374_2_Ent0", "role": "Subject", "text": "a rare case", "start": 2, "end": 5}, {"entity_id": "24791374_2_Ent3", "role": "Treatment_Drug", "text": "propafenone", "start": 12, "end": 13}, {"entity_id": "24791374_2_Ent5", "role": "Combination_Drug", "text": "propafenone", "start": 12, "end": 13}, {"entity_id": "24791374_2_Ent2", "role": "Treatment", "text": "propafenone and mirtazapine", "start": 12, "end": 15}, {"entity_id": "24791374_2_Ent4", "role": "Treatment_Drug", "text": "mirtazapine", "start": 14, "end": 15}, {"entity_id": "24791374_2_Ent6", "role": "Combination_Drug", "text": "mirtazapine", "start": 14, "end": 15}, {"entity_id": "24791374_2_Ent1", "role": "Effect", "text": "propafenone toxicity", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "24791374_2_Ent0", "text": "a rare case", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "24791374_2_Ent3", "text": "propafenone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "24791374_2_Ent5", "text": "propafenone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "24791374_2_Ent2", "text": "propafenone and mirtazapine", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "24791374_2_Ent4", "text": "mirtazapine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "24791374_2_Ent6", "text": "mirtazapine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "24791374_2_Ent1", "text": "propafenone toxicity", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "24846936_2", "wnd_id": "24846936_2_1", "text": "This is the first report of a fatal outcome from serotonin toxicity , precipitated by an interaction between methylene blue and venlafaxine .", "tokens": ["This", "is", "the", "first", "report", "of", "a", "fatal", "outcome", "from", "serotonin", "toxicity", ",", "precipitated", "by", "an", "interaction", "between", "methylene", "blue", "and", "venlafaxine", "."], "event_mentions": [{"id": "24846936_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "precipitated", "start": 13, "end": 14}, "arguments": [{"entity_id": "24846936_2_Ent0", "role": "Effect", "text": "serotonin toxicity", "start": 10, "end": 12}, {"entity_id": "24846936_2_Ent1", "role": "Treatment", "text": "methylene blue", "start": 18, "end": 20}, {"entity_id": "24846936_2_Ent3", "role": "Treatment_Drug", "text": "methylene blue", "start": 18, "end": 20}, {"entity_id": "24846936_2_Ent5", "role": "Combination_Drug", "text": "methylene blue", "start": 18, "end": 20}, {"entity_id": "24846936_2_Ent2", "role": "Treatment", "text": "venlafaxine", "start": 21, "end": 22}, {"entity_id": "24846936_2_Ent4", "role": "Treatment_Drug", "text": "venlafaxine", "start": 21, "end": 22}, {"entity_id": "24846936_2_Ent6", "role": "Combination_Drug", "text": "venlafaxine", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "24846936_2_Ent0", "text": "serotonin toxicity", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "24846936_2_Ent1", "text": "methylene blue", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "24846936_2_Ent3", "text": "methylene blue", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "24846936_2_Ent5", "text": "methylene blue", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "24846936_2_Ent2", "text": "venlafaxine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "24846936_2_Ent4", "text": "venlafaxine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "24846936_2_Ent6", "text": "venlafaxine", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "24927617_5", "wnd_id": "24927617_5_1", "text": "At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug - drug interaction was suspected .", "tokens": ["At", "admission", "simvastatin", "and", "all", "antiviral", "drugs", "were", "discontinued", "because", "toxicity", "due", "to", "a", "drug", "-", "drug", "interaction", "was", "suspected", "."], "event_mentions": [{"id": "24927617_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 11, "end": 12}, "arguments": [{"entity_id": "24927617_5_Ent2", "role": "Treatment_Drug", "text": "simvastatin", "start": 2, "end": 3}, {"entity_id": "24927617_5_Ent1", "role": "Treatment", "text": "simvastatin and all antiviral drugs", "start": 2, "end": 7}, {"entity_id": "24927617_5_Ent0", "role": "Effect", "text": "toxicity", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "24927617_5_Ent2", "text": "simvastatin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "24927617_5_Ent1", "text": "simvastatin and all antiviral drugs", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "24927617_5_Ent0", "text": "toxicity", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "25157214_11", "wnd_id": "25157214_11_1", "text": "These findings suggest that prophylactic antibiotic use is unlikely to have a major impact on the recovery time from rocuronium - induced NMB with sugammadex reversal .", "tokens": ["These", "findings", "suggest", "that", "prophylactic", "antibiotic", "use", "is", "unlikely", "to", "have", "a", "major", "impact", "on", "the", "recovery", "time", "from", "rocuronium", "-", "induced", "NMB", "with", "sugammadex", "reversal", "."], "event_mentions": [{"id": "25157214_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "use", "start": 6, "end": 7}, "arguments": [{"entity_id": "25157214_11_Ent1", "role": "Treatment", "text": "prophylactic antibiotic", "start": 4, "end": 6}, {"entity_id": "25157214_11_Ent3", "role": "Treatment_Drug", "text": "prophylactic antibiotic", "start": 4, "end": 6}, {"entity_id": "25157214_11_Ent0", "role": "Effect", "text": "unlikely to have a major impact on the recovery time", "start": 8, "end": 18}, {"entity_id": "25157214_11_Ent2", "role": "Treatment_Disorder", "text": "rocuronium - induced NMB with sugammadex reversal", "start": 19, "end": 26}]}, {"id": "25157214_11_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 21, "end": 22}, "arguments": [{"entity_id": "25157214_11_Ent5", "role": "Treatment", "text": "rocuronium", "start": 19, "end": 20}, {"entity_id": "25157214_11_Ent6", "role": "Treatment_Drug", "text": "rocuronium", "start": 19, "end": 20}, {"entity_id": "25157214_11_Ent4", "role": "Effect", "text": "NMB with sugammadex reversal", "start": 22, "end": 26}]}], "entity_mentions": [{"id": "25157214_11_Ent1", "text": "prophylactic antibiotic", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "25157214_11_Ent3", "text": "prophylactic antibiotic", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "25157214_11_Ent0", "text": "unlikely to have a major impact on the recovery time", "entity_type": "Entity", "start": 8, "end": 18}, {"id": "25157214_11_Ent5", "text": "rocuronium", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "25157214_11_Ent6", "text": "rocuronium", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "25157214_11_Ent2", "text": "rocuronium - induced NMB with sugammadex reversal", "entity_type": "Entity", "start": 19, "end": 26}, {"id": "25157214_11_Ent4", "text": "NMB with sugammadex reversal", "entity_type": "Entity", "start": 22, "end": 26}], "lang": "en"}
{"doc_id": "25407257_1", "wnd_id": "25407257_1_1", "text": "First case report of suspected onset of convulsive seizures due to co - administration of valproic acid and tebipenem .", "tokens": ["First", "case", "report", "of", "suspected", "onset", "of", "convulsive", "seizures", "due", "to", "co", "-", "administration", "of", "valproic", "acid", "and", "tebipenem", "."], "event_mentions": [{"id": "25407257_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 9, "end": 10}, "arguments": [{"entity_id": "25407257_1_Ent0", "role": "Effect", "text": "convulsive seizures", "start": 7, "end": 9}, {"entity_id": "25407257_1_Ent1", "role": "Treatment", "text": "co - administration of valproic acid and tebipenem", "start": 11, "end": 19}, {"entity_id": "25407257_1_Ent2", "role": "Treatment_Drug", "text": "valproic acid", "start": 15, "end": 17}, {"entity_id": "25407257_1_Ent4", "role": "Combination_Drug", "text": "valproic acid", "start": 15, "end": 17}, {"entity_id": "25407257_1_Ent3", "role": "Treatment_Drug", "text": "tebipenem", "start": 18, "end": 19}, {"entity_id": "25407257_1_Ent5", "role": "Combination_Drug", "text": "tebipenem", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "25407257_1_Ent0", "text": "convulsive seizures", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "25407257_1_Ent1", "text": "co - administration of valproic acid and tebipenem", "entity_type": "Entity", "start": 11, "end": 19}, {"id": "25407257_1_Ent2", "text": "valproic acid", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "25407257_1_Ent4", "text": "valproic acid", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "25407257_1_Ent3", "text": "tebipenem", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "25407257_1_Ent5", "text": "tebipenem", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "25407257_4", "wnd_id": "25407257_4_1", "text": "A 6 - year - old boy ( weight : 16 kg , at the start of treatment ) began sodium valproate ( valproate syrup 5 % ) treatment for epilepsy in February 2012 .", "tokens": ["A", "6", "-", "year", "-", "old", "boy", "(", "weight", ":", "16", "kg", ",", "at", "the", "start", "of", "treatment", ")", "began", "sodium", "valproate", "(", "valproate", "syrup", "5", "%", ")", "treatment", "for", "epilepsy", "in", "February", "2012", "."], "event_mentions": [{"id": "25407257_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 28, "end": 29}, "arguments": [{"entity_id": "25407257_4_Ent0", "role": "Subject", "text": "A 6 - year - old boy ( weight : 16 kg , at the start of treatment )", "start": 0, "end": 19}, {"entity_id": "25407257_4_Ent1", "role": "Subject_Age", "text": "6 - year - old", "start": 1, "end": 6}, {"entity_id": "25407257_4_Ent2", "role": "Subject_Gender", "text": "boy", "start": 6, "end": 7}, {"entity_id": "25407257_4_Ent5", "role": "Treatment_Drug", "text": "sodium valproate", "start": 20, "end": 22}, {"entity_id": "25407257_4_Ent3", "role": "Treatment", "text": "sodium valproate ( valproate syrup 5 % )", "start": 20, "end": 28}, {"entity_id": "25407257_4_Ent4", "role": "Treatment_Disorder", "text": "epilepsy", "start": 30, "end": 31}]}], "entity_mentions": [{"id": "25407257_4_Ent0", "text": "A 6 - year - old boy ( weight : 16 kg , at the start of treatment )", "entity_type": "Entity", "start": 0, "end": 19}, {"id": "25407257_4_Ent1", "text": "6 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "25407257_4_Ent2", "text": "boy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "25407257_4_Ent5", "text": "sodium valproate", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "25407257_4_Ent3", "text": "sodium valproate ( valproate syrup 5 % )", "entity_type": "Entity", "start": 20, "end": 28}, {"id": "25407257_4_Ent4", "text": "epilepsy", "entity_type": "Entity", "start": 30, "end": 31}], "lang": "en"}
{"doc_id": "2549018_3", "wnd_id": "2549018_3_1", "text": "Fluoxetine - induced akathisia : clinical and theoretical implications .", "tokens": ["Fluoxetine", "-", "induced", "akathisia", ":", "clinical", "and", "theoretical", "implications", "."], "event_mentions": [{"id": "2549018_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "2549018_3_Ent1", "role": "Treatment", "text": "Fluoxetine", "start": 0, "end": 1}, {"entity_id": "2549018_3_Ent2", "role": "Treatment_Drug", "text": "Fluoxetine", "start": 0, "end": 1}, {"entity_id": "2549018_3_Ent0", "role": "Effect", "text": "akathisia", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "2549018_3_Ent1", "text": "Fluoxetine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2549018_3_Ent2", "text": "Fluoxetine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2549018_3_Ent0", "text": "akathisia", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "25515435_1", "wnd_id": "25515435_1_1", "text": "Warfarin and boceprevir interaction causing subtherapeutic international normalized ratio : a case report .", "tokens": ["Warfarin", "and", "boceprevir", "interaction", "causing", "subtherapeutic", "international", "normalized", "ratio", ":", "a", "case", "report", "."], "event_mentions": [{"id": "25515435_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causing", "start": 4, "end": 5}, "arguments": [{"entity_id": "25515435_1_Ent1", "role": "Treatment", "text": "Warfarin", "start": 0, "end": 1}, {"entity_id": "25515435_1_Ent3", "role": "Treatment_Drug", "text": "Warfarin", "start": 0, "end": 1}, {"entity_id": "25515435_1_Ent5", "role": "Combination_Drug", "text": "Warfarin", "start": 0, "end": 1}, {"entity_id": "25515435_1_Ent2", "role": "Treatment", "text": "boceprevir", "start": 2, "end": 3}, {"entity_id": "25515435_1_Ent4", "role": "Treatment_Drug", "text": "boceprevir", "start": 2, "end": 3}, {"entity_id": "25515435_1_Ent6", "role": "Combination_Drug", "text": "boceprevir", "start": 2, "end": 3}, {"entity_id": "25515435_1_Ent0", "role": "Effect", "text": "subtherapeutic international normalized ratio", "start": 5, "end": 9}]}], "entity_mentions": [{"id": "25515435_1_Ent1", "text": "Warfarin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "25515435_1_Ent3", "text": "Warfarin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "25515435_1_Ent5", "text": "Warfarin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "25515435_1_Ent2", "text": "boceprevir", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "25515435_1_Ent4", "text": "boceprevir", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "25515435_1_Ent6", "text": "boceprevir", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "25515435_1_Ent0", "text": "subtherapeutic international normalized ratio", "entity_type": "Entity", "start": 5, "end": 9}], "lang": "en"}
{"doc_id": "25538343_1", "wnd_id": "25538343_1_1", "text": "Duloxetine - induced hyponatremia in an elderly patient treated with thiazide diuretics .", "tokens": ["Duloxetine", "-", "induced", "hyponatremia", "in", "an", "elderly", "patient", "treated", "with", "thiazide", "diuretics", "."], "event_mentions": [{"id": "25538343_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "25538343_1_Ent3", "role": "Treatment", "text": "Duloxetine", "start": 0, "end": 1}, {"entity_id": "25538343_1_Ent4", "role": "Treatment_Drug", "text": "Duloxetine", "start": 0, "end": 1}, {"entity_id": "25538343_1_Ent7", "role": "Combination_Drug", "text": "Duloxetine", "start": 0, "end": 1}, {"entity_id": "25538343_1_Ent2", "role": "Effect", "text": "hyponatremia", "start": 3, "end": 4}, {"entity_id": "25538343_1_Ent0", "role": "Subject", "text": "an elderly patient treated with thiazide diuretics", "start": 5, "end": 12}, {"entity_id": "25538343_1_Ent1", "role": "Subject_Age", "text": "elderly", "start": 6, "end": 7}, {"entity_id": "25538343_1_Ent5", "role": "Treatment_Drug", "text": "thiazide diuretics", "start": 10, "end": 12}, {"entity_id": "25538343_1_Ent6", "role": "Combination_Drug", "text": "thiazide diuretics", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "25538343_1_Ent3", "text": "Duloxetine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "25538343_1_Ent4", "text": "Duloxetine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "25538343_1_Ent7", "text": "Duloxetine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "25538343_1_Ent2", "text": "hyponatremia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "25538343_1_Ent0", "text": "an elderly patient treated with thiazide diuretics", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "25538343_1_Ent1", "text": "elderly", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "25538343_1_Ent5", "text": "thiazide diuretics", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "25538343_1_Ent6", "text": "thiazide diuretics", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "25540831_7", "wnd_id": "25540831_7_1", "text": "Most physicians are aware of serotonin syndrome secondary to antidepressants but do not think about other classes of medications such as analgesics .", "tokens": ["Most", "physicians", "are", "aware", "of", "serotonin", "syndrome", "secondary", "to", "antidepressants", "but", "do", "not", "think", "about", "other", "classes", "of", "medications", "such", "as", "analgesics", "."], "event_mentions": [{"id": "25540831_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 7, "end": 8}, "arguments": [{"entity_id": "25540831_7_Ent0", "role": "Effect", "text": "serotonin syndrome", "start": 5, "end": 7}, {"entity_id": "25540831_7_Ent1", "role": "Treatment", "text": "antidepressants", "start": 9, "end": 10}, {"entity_id": "25540831_7_Ent2", "role": "Treatment_Drug", "text": "antidepressants", "start": 9, "end": 10}, {"entity_id": "25540831_7_Ent3", "role": "Treatment_Drug", "text": "analgesics", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "25540831_7_Ent0", "text": "serotonin syndrome", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "25540831_7_Ent1", "text": "antidepressants", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "25540831_7_Ent2", "text": "antidepressants", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "25540831_7_Ent3", "text": "analgesics", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "2554727_4", "wnd_id": "2554727_4_1", "text": "We describe a patient with acute leukemia who developed Horner 's syndrome and a severe demyelinating peripheral neuropathy leading to death after receiving high - dose cytosine arabinoside .", "tokens": ["We", "describe", "a", "patient", "with", "acute", "leukemia", "who", "developed", "Horner", "'s", "syndrome", "and", "a", "severe", "demyelinating", "peripheral", "neuropathy", "leading", "to", "death", "after", "receiving", "high", "-", "dose", "cytosine", "arabinoside", "."], "event_mentions": [{"id": "2554727_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "2554727_4_Ent0", "role": "Subject", "text": "a patient with acute leukemia", "start": 2, "end": 7}, {"entity_id": "2554727_4_Ent3", "role": "Treatment_Disorder", "text": "acute leukemia", "start": 5, "end": 7}, {"entity_id": "2554727_4_Ent1", "role": "Effect", "text": "Horner 's syndrome and a severe demyelinating peripheral neuropathy leading to death", "start": 9, "end": 21}, {"entity_id": "2554727_4_Ent5", "role": "Treatment_Dosage", "text": "high - dose", "start": 23, "end": 26}, {"entity_id": "2554727_4_Ent2", "role": "Treatment", "text": "high - dose cytosine arabinoside .", "start": 23, "end": 29}, {"entity_id": "2554727_4_Ent4", "role": "Treatment_Drug", "text": "cytosine arabinoside", "start": 26, "end": 28}]}], "entity_mentions": [{"id": "2554727_4_Ent0", "text": "a patient with acute leukemia", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "2554727_4_Ent3", "text": "acute leukemia", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "2554727_4_Ent1", "text": "Horner 's syndrome and a severe demyelinating peripheral neuropathy leading to death", "entity_type": "Entity", "start": 9, "end": 21}, {"id": "2554727_4_Ent5", "text": "high - dose", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "2554727_4_Ent2", "text": "high - dose cytosine arabinoside .", "entity_type": "Entity", "start": 23, "end": 29}, {"id": "2554727_4_Ent4", "text": "cytosine arabinoside", "entity_type": "Entity", "start": 26, "end": 28}], "lang": "en"}
{"doc_id": "25671244_1", "wnd_id": "25671244_1_1", "text": "Serotonin syndrome following metaxalone overdose and therapeutic use of a selective serotonin reuptake inhibitor .", "tokens": ["Serotonin", "syndrome", "following", "metaxalone", "overdose", "and", "therapeutic", "use", "of", "a", "selective", "serotonin", "reuptake", "inhibitor", "."], "event_mentions": [{"id": "25671244_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "25671244_1_Ent0", "role": "Effect", "text": "Serotonin syndrome", "start": 0, "end": 2}, {"entity_id": "25671244_1_Ent2", "role": "Treatment_Drug", "text": "metaxalone", "start": 3, "end": 4}, {"entity_id": "25671244_1_Ent5", "role": "Combination_Drug", "text": "metaxalone", "start": 3, "end": 4}, {"entity_id": "25671244_1_Ent1", "role": "Treatment", "text": "metaxalone overdose", "start": 3, "end": 5}, {"entity_id": "25671244_1_Ent4", "role": "Treatment_Dosage", "text": "overdose", "start": 4, "end": 5}, {"entity_id": "25671244_1_Ent3", "role": "Treatment_Drug", "text": "selective serotonin reuptake inhibitor", "start": 10, "end": 14}, {"entity_id": "25671244_1_Ent6", "role": "Combination_Drug", "text": "selective serotonin reuptake inhibitor", "start": 10, "end": 14}]}], "entity_mentions": [{"id": "25671244_1_Ent0", "text": "Serotonin syndrome", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "25671244_1_Ent2", "text": "metaxalone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "25671244_1_Ent5", "text": "metaxalone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "25671244_1_Ent1", "text": "metaxalone overdose", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "25671244_1_Ent4", "text": "overdose", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "25671244_1_Ent3", "text": "selective serotonin reuptake inhibitor", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "25671244_1_Ent6", "text": "selective serotonin reuptake inhibitor", "entity_type": "Entity", "start": 10, "end": 14}], "lang": "en"}
{"doc_id": "25671244_2", "wnd_id": "25671244_2_1", "text": "Metaxalone has only recently been associated with serotonin syndrome .", "tokens": ["Metaxalone", "has", "only", "recently", "been", "associated", "with", "serotonin", "syndrome", "."], "event_mentions": [{"id": "25671244_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "25671244_2_Ent1", "role": "Treatment", "text": "Metaxalone", "start": 0, "end": 1}, {"entity_id": "25671244_2_Ent2", "role": "Treatment_Drug", "text": "Metaxalone", "start": 0, "end": 1}, {"entity_id": "25671244_2_Ent0", "role": "Effect", "text": "serotonin syndrome", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "25671244_2_Ent1", "text": "Metaxalone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "25671244_2_Ent2", "text": "Metaxalone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "25671244_2_Ent0", "text": "serotonin syndrome", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "2595431_1", "wnd_id": "2595431_1_1", "text": "Metoclopramide - induced parkinsonism is not rare , and appropriate dose reduction in patients with renal failure will help reduce the incidence of this morbidity .", "tokens": ["Metoclopramide", "-", "induced", "parkinsonism", "is", "not", "rare", ",", "and", "appropriate", "dose", "reduction", "in", "patients", "with", "renal", "failure", "will", "help", "reduce", "the", "incidence", "of", "this", "morbidity", "."], "event_mentions": [{"id": "2595431_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "2595431_1_Ent3", "role": "Treatment", "text": "Metoclopramide", "start": 0, "end": 1}, {"entity_id": "2595431_1_Ent4", "role": "Treatment_Drug", "text": "Metoclopramide", "start": 0, "end": 1}, {"entity_id": "2595431_1_Ent2", "role": "Effect", "text": "parkinsonism", "start": 3, "end": 4}, {"entity_id": "2595431_1_Ent0", "role": "Subject", "text": "patients with renal failure", "start": 13, "end": 17}, {"entity_id": "2595431_1_Ent1", "role": "Subject_Disorder", "text": "renal failure", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "2595431_1_Ent3", "text": "Metoclopramide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2595431_1_Ent4", "text": "Metoclopramide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2595431_1_Ent2", "text": "parkinsonism", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2595431_1_Ent0", "text": "patients with renal failure", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "2595431_1_Ent1", "text": "renal failure", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "2595431_3", "wnd_id": "2595431_3_1", "text": "Their parkinsonism improved on discontinuation of metoclopramide therapy .", "tokens": ["Their", "parkinsonism", "improved", "on", "discontinuation", "of", "metoclopramide", "therapy", "."], "event_mentions": [{"id": "2595431_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "improved", "start": 2, "end": 3}, "arguments": [{"entity_id": "2595431_3_Ent0", "role": "Subject", "text": "Their parkinsonism", "start": 0, "end": 2}, {"entity_id": "2595431_3_Ent3", "role": "Treatment_Disorder", "text": "parkinsonism", "start": 1, "end": 2}, {"entity_id": "2595431_3_Ent1", "role": "Treatment", "text": "discontinuation of metoclopramide therapy", "start": 4, "end": 8}, {"entity_id": "2595431_3_Ent2", "role": "Treatment_Drug", "text": "metoclopramide", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "2595431_3_Ent0", "text": "Their parkinsonism", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2595431_3_Ent3", "text": "parkinsonism", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "2595431_3_Ent1", "text": "discontinuation of metoclopramide therapy", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "2595431_3_Ent2", "text": "metoclopramide", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "25957434_3", "wnd_id": "25957434_3_1", "text": "We report a case of bullous eruption , one month after starting nicardipine and lercanidipine .", "tokens": ["We", "report", "a", "case", "of", "bullous", "eruption", ",", "one", "month", "after", "starting", "nicardipine", "and", "lercanidipine", "."], "event_mentions": [{"id": "25957434_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 10, "end": 11}, "arguments": [{"entity_id": "25957434_3_Ent0", "role": "Effect", "text": "bullous eruption ,", "start": 5, "end": 8}, {"entity_id": "25957434_3_Ent2", "role": "Treatment_Time_elapsed", "text": "one month", "start": 8, "end": 10}, {"entity_id": "25957434_3_Ent1", "role": "Treatment", "text": "starting nicardipine and lercanidipine .", "start": 11, "end": 16}, {"entity_id": "25957434_3_Ent3", "role": "Treatment_Drug", "text": "nicardipine", "start": 12, "end": 13}, {"entity_id": "25957434_3_Ent5", "role": "Combination_Drug", "text": "nicardipine", "start": 12, "end": 13}, {"entity_id": "25957434_3_Ent4", "role": "Treatment_Drug", "text": "lercanidipine", "start": 14, "end": 15}, {"entity_id": "25957434_3_Ent6", "role": "Combination_Drug", "text": "lercanidipine", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "25957434_3_Ent0", "text": "bullous eruption ,", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "25957434_3_Ent2", "text": "one month", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "25957434_3_Ent1", "text": "starting nicardipine and lercanidipine .", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "25957434_3_Ent3", "text": "nicardipine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "25957434_3_Ent5", "text": "nicardipine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "25957434_3_Ent4", "text": "lercanidipine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "25957434_3_Ent6", "text": "lercanidipine", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "2690546_2", "wnd_id": "2690546_2_1", "text": "Amiodarone induced torsades de pointe .", "tokens": ["Amiodarone", "induced", "torsades", "de", "pointe", "."], "event_mentions": [{"id": "2690546_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "2690546_2_Ent1", "role": "Treatment", "text": "Amiodarone", "start": 0, "end": 1}, {"entity_id": "2690546_2_Ent2", "role": "Treatment_Drug", "text": "Amiodarone", "start": 0, "end": 1}, {"entity_id": "2690546_2_Ent0", "role": "Effect", "text": "torsades de pointe", "start": 2, "end": 5}]}], "entity_mentions": [{"id": "2690546_2_Ent1", "text": "Amiodarone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2690546_2_Ent2", "text": "Amiodarone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2690546_2_Ent0", "text": "torsades de pointe", "entity_type": "Entity", "start": 2, "end": 5}], "lang": "en"}
{"doc_id": "2728526_1", "wnd_id": "2728526_1_1", "text": "Rifampin - associated thrombocytopenia secondary to poor compliance .", "tokens": ["Rifampin", "-", "associated", "thrombocytopenia", "secondary", "to", "poor", "compliance", "."], "event_mentions": [{"id": "2728526_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "2728526_1_Ent1", "role": "Treatment", "text": "Rifampin", "start": 0, "end": 1}, {"entity_id": "2728526_1_Ent2", "role": "Treatment_Drug", "text": "Rifampin", "start": 0, "end": 1}, {"entity_id": "2728526_1_Ent0", "role": "Effect", "text": "thrombocytopenia secondary to poor compliance", "start": 3, "end": 8}]}], "entity_mentions": [{"id": "2728526_1_Ent1", "text": "Rifampin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2728526_1_Ent2", "text": "Rifampin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2728526_1_Ent0", "text": "thrombocytopenia secondary to poor compliance", "entity_type": "Entity", "start": 3, "end": 8}], "lang": "en"}
{"doc_id": "2746565_1", "wnd_id": "2746565_1_1", "text": "Ibuprofen rarely causes lower gastrointestinal adverse reactions but has been implicated in systemic and local side effects in patients with lupus .", "tokens": ["Ibuprofen", "rarely", "causes", "lower", "gastrointestinal", "adverse", "reactions", "but", "has", "been", "implicated", "in", "systemic", "and", "local", "side", "effects", "in", "patients", "with", "lupus", "."], "event_mentions": [{"id": "2746565_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "implicated in", "start": 10, "end": 12}, "arguments": [{"entity_id": "2746565_1_Ent1", "role": "Treatment", "text": "Ibuprofen", "start": 0, "end": 1}, {"entity_id": "2746565_1_Ent2", "role": "Treatment_Drug", "text": "Ibuprofen", "start": 0, "end": 1}, {"entity_id": "2746565_1_Ent0", "role": "Effect", "text": "systemic and local side effects in patients with lupus", "start": 12, "end": 21}]}], "entity_mentions": [{"id": "2746565_1_Ent1", "text": "Ibuprofen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2746565_1_Ent2", "text": "Ibuprofen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2746565_1_Ent0", "text": "systemic and local side effects in patients with lupus", "entity_type": "Entity", "start": 12, "end": 21}], "lang": "en"}
{"doc_id": "2768785_1", "wnd_id": "2768785_1_1", "text": "Intravenous cytarabine and methotrexate appear to act synergistically to enhance the potential for central nervous system toxicity .", "tokens": ["Intravenous", "cytarabine", "and", "methotrexate", "appear", "to", "act", "synergistically", "to", "enhance", "the", "potential", "for", "central", "nervous", "system", "toxicity", "."], "event_mentions": [{"id": "2768785_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "enhance", "start": 9, "end": 10}, "arguments": [{"entity_id": "2768785_1_Ent4", "role": "Treatment_Route", "text": "Intravenous", "start": 0, "end": 1}, {"entity_id": "2768785_1_Ent1", "role": "Treatment", "text": "Intravenous cytarabine and methotrexate", "start": 0, "end": 4}, {"entity_id": "2768785_1_Ent3", "role": "Treatment_Drug", "text": "cytarabine", "start": 1, "end": 2}, {"entity_id": "2768785_1_Ent6", "role": "Combination_Drug", "text": "cytarabine", "start": 1, "end": 2}, {"entity_id": "2768785_1_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 3, "end": 4}, {"entity_id": "2768785_1_Ent5", "role": "Combination_Drug", "text": "methotrexate", "start": 3, "end": 4}, {"entity_id": "2768785_1_Ent0", "role": "Effect", "text": "central nervous system toxicity", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "2768785_1_Ent4", "text": "Intravenous", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2768785_1_Ent1", "text": "Intravenous cytarabine and methotrexate", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "2768785_1_Ent3", "text": "cytarabine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "2768785_1_Ent6", "text": "cytarabine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "2768785_1_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2768785_1_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2768785_1_Ent0", "text": "central nervous system toxicity", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "2781955_1", "wnd_id": "2781955_1_1", "text": "Dexamethasone treatment of amiodarone - induced thyrotoxicosis ( AIT ) with or without persistent administration of the drug .", "tokens": ["Dexamethasone", "treatment", "of", "amiodarone", "-", "induced", "thyrotoxicosis", "(", "AIT", ")", "with", "or", "without", "persistent", "administration", "of", "the", "drug", "."], "event_mentions": [{"id": "2781955_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "2781955_1_Ent1", "role": "Treatment", "text": "amiodarone", "start": 3, "end": 4}, {"entity_id": "2781955_1_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 3, "end": 4}, {"entity_id": "2781955_1_Ent0", "role": "Effect", "text": "thyrotoxicosis ( AIT )", "start": 6, "end": 10}]}], "entity_mentions": [{"id": "2781955_1_Ent1", "text": "amiodarone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2781955_1_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2781955_1_Ent0", "text": "thyrotoxicosis ( AIT )", "entity_type": "Entity", "start": 6, "end": 10}], "lang": "en"}
{"doc_id": "278642_1", "wnd_id": "278642_1_1", "text": "Acute myelogenous leukemia in patients receiving chlorambucil as long - term adjuvant chemotherapy for stage II breast cancer .", "tokens": ["Acute", "myelogenous", "leukemia", "in", "patients", "receiving", "chlorambucil", "as", "long", "-", "term", "adjuvant", "chemotherapy", "for", "stage", "II", "breast", "cancer", "."], "event_mentions": [{"id": "278642_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 3, "end": 4}, "arguments": [{"entity_id": "278642_1_Ent1", "role": "Effect", "text": "Acute myelogenous leukemia", "start": 0, "end": 3}, {"entity_id": "278642_1_Ent0", "role": "Subject", "text": "patients", "start": 4, "end": 5}, {"entity_id": "278642_1_Ent2", "role": "Treatment", "text": "receiving chlorambucil as long - term adjuvant chemotherapy", "start": 5, "end": 13}, {"entity_id": "278642_1_Ent3", "role": "Treatment_Drug", "text": "chlorambucil", "start": 6, "end": 7}, {"entity_id": "278642_1_Ent5", "role": "Treatment_Route", "text": "chemotherapy", "start": 12, "end": 13}, {"entity_id": "278642_1_Ent4", "role": "Treatment_Disorder", "text": "stage II breast cancer .", "start": 14, "end": 19}]}], "entity_mentions": [{"id": "278642_1_Ent1", "text": "Acute myelogenous leukemia", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "278642_1_Ent0", "text": "patients", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "278642_1_Ent2", "text": "receiving chlorambucil as long - term adjuvant chemotherapy", "entity_type": "Entity", "start": 5, "end": 13}, {"id": "278642_1_Ent3", "text": "chlorambucil", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "278642_1_Ent5", "text": "chemotherapy", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "278642_1_Ent4", "text": "stage II breast cancer .", "entity_type": "Entity", "start": 14, "end": 19}], "lang": "en"}
{"doc_id": "278642_2", "wnd_id": "278642_2_1", "text": "After the chlorambucil was discontinued , the wbc count began to slowly rise and the patient developed clinical AML .", "tokens": ["After", "the", "chlorambucil", "was", "discontinued", ",", "the", "wbc", "count", "began", "to", "slowly", "rise", "and", "the", "patient", "developed", "clinical", "AML", "."], "event_mentions": [{"id": "278642_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 16, "end": 17}, "arguments": [{"entity_id": "278642_2_Ent3", "role": "Treatment", "text": "chlorambucil", "start": 2, "end": 3}, {"entity_id": "278642_2_Ent4", "role": "Treatment_Drug", "text": "chlorambucil", "start": 2, "end": 3}, {"entity_id": "278642_2_Ent1", "role": "Effect", "text": "wbc count began to slowly rise", "start": 7, "end": 13}, {"entity_id": "278642_2_Ent0", "role": "Subject", "text": "the patient", "start": 14, "end": 16}, {"entity_id": "278642_2_Ent2", "role": "Effect", "text": "clinical AML", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "278642_2_Ent3", "text": "chlorambucil", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "278642_2_Ent4", "text": "chlorambucil", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "278642_2_Ent1", "text": "wbc count began to slowly rise", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "278642_2_Ent0", "text": "the patient", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "278642_2_Ent2", "text": "clinical AML", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "2796025_2", "wnd_id": "2796025_2_1", "text": "This panic anxiety was not relieved by taking etizolam and flunitrazepam again , but subsided rapidly by the re - administration of mianserin 30 mg / day , and because of that the depressive symptom also disappeared .", "tokens": ["This", "panic", "anxiety", "was", "not", "relieved", "by", "taking", "etizolam", "and", "flunitrazepam", "again", ",", "but", "subsided", "rapidly", "by", "the", "re", "-", "administration", "of", "mianserin", "30", "mg", "/", "day", ",", "and", "because", "of", "that", "the", "depressive", "symptom", "also", "disappeared", "."], "event_mentions": [{"id": "2796025_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "subsided", "start": 14, "end": 15}, "arguments": [{"entity_id": "2796025_2_Ent3", "role": "Treatment_Disorder", "text": "panic anxiety", "start": 1, "end": 3}, {"entity_id": "2796025_2_Ent6", "role": "Treatment_Drug", "text": "etizolam", "start": 8, "end": 9}, {"entity_id": "2796025_2_Ent9", "role": "Combination_Drug", "text": "etizolam", "start": 8, "end": 9}, {"entity_id": "2796025_2_Ent1", "role": "Treatment", "text": "etizolam and flunitrazepam", "start": 8, "end": 11}, {"entity_id": "2796025_2_Ent5", "role": "Treatment_Drug", "text": "flunitrazepam", "start": 10, "end": 11}, {"entity_id": "2796025_2_Ent10", "role": "Combination_Drug", "text": "flunitrazepam", "start": 10, "end": 11}, {"entity_id": "2796025_2_Ent7", "role": "Treatment_Drug", "text": "mianserin", "start": 22, "end": 23}, {"entity_id": "2796025_2_Ent11", "role": "Combination_Drug", "text": "mianserin", "start": 22, "end": 23}, {"entity_id": "2796025_2_Ent2", "role": "Treatment", "text": "mianserin 30 mg / day", "start": 22, "end": 27}, {"entity_id": "2796025_2_Ent8", "role": "Treatment_Dosage", "text": "30 mg / day", "start": 23, "end": 27}, {"entity_id": "2796025_2_Ent0", "role": "Effect", "text": "because of that the depressive symptom also disappeared", "start": 29, "end": 37}, {"entity_id": "2796025_2_Ent4", "role": "Treatment_Disorder", "text": "depressive symptom", "start": 33, "end": 35}]}], "entity_mentions": [{"id": "2796025_2_Ent3", "text": "panic anxiety", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "2796025_2_Ent6", "text": "etizolam", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2796025_2_Ent9", "text": "etizolam", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2796025_2_Ent1", "text": "etizolam and flunitrazepam", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "2796025_2_Ent5", "text": "flunitrazepam", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "2796025_2_Ent10", "text": "flunitrazepam", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "2796025_2_Ent7", "text": "mianserin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "2796025_2_Ent11", "text": "mianserin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "2796025_2_Ent2", "text": "mianserin 30 mg / day", "entity_type": "Entity", "start": 22, "end": 27}, {"id": "2796025_2_Ent8", "text": "30 mg / day", "entity_type": "Entity", "start": 23, "end": 27}, {"id": "2796025_2_Ent0", "text": "because of that the depressive symptom also disappeared", "entity_type": "Entity", "start": 29, "end": 37}, {"id": "2796025_2_Ent4", "text": "depressive symptom", "entity_type": "Entity", "start": 33, "end": 35}], "lang": "en"}
{"doc_id": "2811895_2", "wnd_id": "2811895_2_1", "text": "Life - threatening cranial dystonia following trihexyphenidyl withdrawal .", "tokens": ["Life", "-", "threatening", "cranial", "dystonia", "following", "trihexyphenidyl", "withdrawal", "."], "event_mentions": [{"id": "2811895_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 5, "end": 6}, "arguments": [{"entity_id": "2811895_2_Ent0", "role": "Effect", "text": "cranial dystonia", "start": 3, "end": 5}, {"entity_id": "2811895_2_Ent2", "role": "Treatment_Drug", "text": "trihexyphenidyl", "start": 6, "end": 7}, {"entity_id": "2811895_2_Ent1", "role": "Treatment", "text": "trihexyphenidyl withdrawal", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "2811895_2_Ent0", "text": "cranial dystonia", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "2811895_2_Ent2", "text": "trihexyphenidyl", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2811895_2_Ent1", "text": "trihexyphenidyl withdrawal", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "2862137_1", "wnd_id": "2862137_1_1", "text": "A case is presented in which a 68 - year - old man became delirious after being withdrawn from a low dosage of alprazolam .", "tokens": ["A", "case", "is", "presented", "in", "which", "a", "68", "-", "year", "-", "old", "man", "became", "delirious", "after", "being", "withdrawn", "from", "a", "low", "dosage", "of", "alprazolam", "."], "event_mentions": [{"id": "2862137_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 15, "end": 16}, "arguments": [{"entity_id": "2862137_1_Ent1", "role": "Subject_Age", "text": "68 - year - old", "start": 7, "end": 12}, {"entity_id": "2862137_1_Ent0", "role": "Subject", "text": "68 - year - old man", "start": 7, "end": 13}, {"entity_id": "2862137_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 12, "end": 13}, {"entity_id": "2862137_1_Ent3", "role": "Effect", "text": "delirious", "start": 14, "end": 15}, {"entity_id": "2862137_1_Ent4", "role": "Treatment", "text": "withdrawn from a low dosage of alprazolam", "start": 17, "end": 24}, {"entity_id": "2862137_1_Ent6", "role": "Treatment_Dosage", "text": "low dosage", "start": 20, "end": 22}, {"entity_id": "2862137_1_Ent5", "role": "Treatment_Drug", "text": "alprazolam", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "2862137_1_Ent1", "text": "68 - year - old", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "2862137_1_Ent0", "text": "68 - year - old man", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "2862137_1_Ent2", "text": "man", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "2862137_1_Ent3", "text": "delirious", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "2862137_1_Ent4", "text": "withdrawn from a low dosage of alprazolam", "entity_type": "Entity", "start": 17, "end": 24}, {"id": "2862137_1_Ent6", "text": "low dosage", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "2862137_1_Ent5", "text": "alprazolam", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "2862137_2", "wnd_id": "2862137_2_1", "text": "Alprazolam withdrawal delirium unresponsive to diazepam : case report .", "tokens": ["Alprazolam", "withdrawal", "delirium", "unresponsive", "to", "diazepam", ":", "case", "report", "."], "event_mentions": [{"id": "2862137_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "to", "start": 4, "end": 5}, "arguments": [{"entity_id": "2862137_2_Ent1", "role": "Treatment_Disorder", "text": "Alprazolam withdrawal delirium", "start": 0, "end": 3}, {"entity_id": "2862137_2_Ent0", "role": "Treatment", "text": "diazepam", "start": 5, "end": 6}, {"entity_id": "2862137_2_Ent2", "role": "Treatment_Drug", "text": "diazepam", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "2862137_2_Ent1", "text": "Alprazolam withdrawal delirium", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2862137_2_Ent0", "text": "diazepam", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2862137_2_Ent2", "text": "diazepam", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "2894766_1", "wnd_id": "2894766_1_1", "text": "It is suggested that the patient had sulfasalazine - induced lupus , which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms .", "tokens": ["It", "is", "suggested", "that", "the", "patient", "had", "sulfasalazine", "-", "induced", "lupus", ",", "which", "manifested", "with", "serositis", "and", "pulmonary", "parenchymal", "involvement", "in", "the", "absence", "of", "joint", "symptoms", "."], "event_mentions": [{"id": "2894766_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "2894766_1_Ent1", "role": "Treatment", "text": "sulfasalazine", "start": 7, "end": 8}, {"entity_id": "2894766_1_Ent2", "role": "Treatment_Drug", "text": "sulfasalazine", "start": 7, "end": 8}, {"entity_id": "2894766_1_Ent0", "role": "Effect", "text": "lupus , which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms", "start": 10, "end": 26}]}], "entity_mentions": [{"id": "2894766_1_Ent1", "text": "sulfasalazine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2894766_1_Ent2", "text": "sulfasalazine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2894766_1_Ent0", "text": "lupus , which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms", "entity_type": "Entity", "start": 10, "end": 26}], "lang": "en"}
{"doc_id": "2931445_1", "wnd_id": "2931445_1_1", "text": "L - Thyroxine - induced leukopenia in a patient with Hashimoto 's disease : involvement of suppressor - cytotoxic T cells .", "tokens": ["L", "-", "Thyroxine", "-", "induced", "leukopenia", "in", "a", "patient", "with", "Hashimoto", "'s", "disease", ":", "involvement", "of", "suppressor", "-", "cytotoxic", "T", "cells", "."], "event_mentions": [{"id": "2931445_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "2931445_1_Ent2", "role": "Treatment", "text": "L - Thyroxine", "start": 0, "end": 3}, {"entity_id": "2931445_1_Ent3", "role": "Treatment_Drug", "text": "L - Thyroxine", "start": 0, "end": 3}, {"entity_id": "2931445_1_Ent1", "role": "Effect", "text": "leukopenia", "start": 5, "end": 6}, {"entity_id": "2931445_1_Ent0", "role": "Subject", "text": "a patient with Hashimoto 's disease", "start": 7, "end": 13}, {"entity_id": "2931445_1_Ent4", "role": "Treatment_Disorder", "text": "Hashimoto 's disease", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "2931445_1_Ent2", "text": "L - Thyroxine", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2931445_1_Ent3", "text": "L - Thyroxine", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2931445_1_Ent1", "text": "leukopenia", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2931445_1_Ent0", "text": "a patient with Hashimoto 's disease", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "2931445_1_Ent4", "text": "Hashimoto 's disease", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "2937155_1", "wnd_id": "2937155_1_1", "text": "A patient receiving vancomycin for a serious staphylococcal infection had a lupus - like syndrome characterized by a malar rash , pain and erythema of the cartilage of both ears , and tender erythematous and hemorrhagic lesions of the finger tips .", "tokens": ["A", "patient", "receiving", "vancomycin", "for", "a", "serious", "staphylococcal", "infection", "had", "a", "lupus", "-", "like", "syndrome", "characterized", "by", "a", "malar", "rash", ",", "pain", "and", "erythema", "of", "the", "cartilage", "of", "both", "ears", ",", "and", "tender", "erythematous", "and", "hemorrhagic", "lesions", "of", "the", "finger", "tips", "."], "event_mentions": [{"id": "2937155_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 9, "end": 10}, "arguments": [{"entity_id": "2937155_1_Ent1", "role": "Treatment", "text": "vancomycin", "start": 3, "end": 4}, {"entity_id": "2937155_1_Ent2", "role": "Treatment_Drug", "text": "vancomycin", "start": 3, "end": 4}, {"entity_id": "2937155_1_Ent3", "role": "Treatment_Disorder", "text": "serious staphylococcal infection", "start": 6, "end": 9}, {"entity_id": "2937155_1_Ent0", "role": "Effect", "text": "a lupus - like syndrome characterized by a malar rash , pain and erythema of the cartilage of both ears , and tender erythematous and hemorrhagic lesions of the finger tips", "start": 10, "end": 41}]}], "entity_mentions": [{"id": "2937155_1_Ent1", "text": "vancomycin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2937155_1_Ent2", "text": "vancomycin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2937155_1_Ent3", "text": "serious staphylococcal infection", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "2937155_1_Ent0", "text": "a lupus - like syndrome characterized by a malar rash , pain and erythema of the cartilage of both ears , and tender erythematous and hemorrhagic lesions of the finger tips", "entity_type": "Entity", "start": 10, "end": 41}], "lang": "en"}
{"doc_id": "2937155_2", "wnd_id": "2937155_2_1", "text": "The possible development of a drug - induced vasculitis or lupus - like syndrome should be added to the list of rare toxic effects of vancomycin .", "tokens": ["The", "possible", "development", "of", "a", "drug", "-", "induced", "vasculitis", "or", "lupus", "-", "like", "syndrome", "should", "be", "added", "to", "the", "list", "of", "rare", "toxic", "effects", "of", "vancomycin", "."], "event_mentions": [{"id": "2937155_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 2, "end": 3}, "arguments": [{"entity_id": "2937155_2_Ent0", "role": "Effect", "text": "drug - induced vasculitis or lupus - like syndrome", "start": 5, "end": 14}, {"entity_id": "2937155_2_Ent1", "role": "Treatment", "text": "vancomycin", "start": 25, "end": 26}, {"entity_id": "2937155_2_Ent2", "role": "Treatment_Drug", "text": "vancomycin", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "2937155_2_Ent0", "text": "drug - induced vasculitis or lupus - like syndrome", "entity_type": "Entity", "start": 5, "end": 14}, {"id": "2937155_2_Ent1", "text": "vancomycin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "2937155_2_Ent2", "text": "vancomycin", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "3067748_2", "wnd_id": "3067748_2_1", "text": "Histological examination of the dacryolith suggested its derivation from breakdown products of adrenaline .", "tokens": ["Histological", "examination", "of", "the", "dacryolith", "suggested", "its", "derivation", "from", "breakdown", "products", "of", "adrenaline", "."], "event_mentions": [{"id": "3067748_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 8, "end": 9}, "arguments": [{"entity_id": "3067748_2_Ent0", "role": "Effect", "text": "dacryolith", "start": 4, "end": 5}, {"entity_id": "3067748_2_Ent1", "role": "Treatment", "text": "breakdown products of adrenaline", "start": 9, "end": 13}, {"entity_id": "3067748_2_Ent2", "role": "Treatment_Drug", "text": "adrenaline", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "3067748_2_Ent0", "text": "dacryolith", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3067748_2_Ent1", "text": "breakdown products of adrenaline", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "3067748_2_Ent2", "text": "adrenaline", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "3115809_3", "wnd_id": "3115809_3_1", "text": "Isoniazid and ethambutol as a cause of optic neuropathy .", "tokens": ["Isoniazid", "and", "ethambutol", "as", "a", "cause", "of", "optic", "neuropathy", "."], "event_mentions": [{"id": "3115809_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 5, "end": 6}, "arguments": [{"entity_id": "3115809_3_Ent2", "role": "Treatment_Drug", "text": "Isoniazid", "start": 0, "end": 1}, {"entity_id": "3115809_3_Ent4", "role": "Combination_Drug", "text": "Isoniazid", "start": 0, "end": 1}, {"entity_id": "3115809_3_Ent1", "role": "Treatment", "text": "Isoniazid and ethambutol", "start": 0, "end": 3}, {"entity_id": "3115809_3_Ent3", "role": "Treatment_Drug", "text": "ethambutol", "start": 2, "end": 3}, {"entity_id": "3115809_3_Ent5", "role": "Combination_Drug", "text": "ethambutol", "start": 2, "end": 3}, {"entity_id": "3115809_3_Ent0", "role": "Effect", "text": "optic neuropathy", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "3115809_3_Ent2", "text": "Isoniazid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3115809_3_Ent4", "text": "Isoniazid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3115809_3_Ent1", "text": "Isoniazid and ethambutol", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "3115809_3_Ent3", "text": "ethambutol", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "3115809_3_Ent5", "text": "ethambutol", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "3115809_3_Ent0", "text": "optic neuropathy", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "3124393_2", "wnd_id": "3124393_2_1", "text": "Calcification and ossification of the spinal arachnoid after intrathecal administration of Depo - Medrol .", "tokens": ["Calcification", "and", "ossification", "of", "the", "spinal", "arachnoid", "after", "intrathecal", "administration", "of", "Depo", "-", "Medrol", "."], "event_mentions": [{"id": "3124393_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "3124393_2_Ent0", "role": "Effect", "text": "Calcification and ossification of the spinal arachnoid", "start": 0, "end": 7}, {"entity_id": "3124393_2_Ent2", "role": "Treatment_Route", "text": "intrathecal", "start": 8, "end": 9}, {"entity_id": "3124393_2_Ent1", "role": "Treatment", "text": "intrathecal administration of Depo - Medrol", "start": 8, "end": 14}, {"entity_id": "3124393_2_Ent3", "role": "Treatment_Drug", "text": "Depo - Medrol", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "3124393_2_Ent0", "text": "Calcification and ossification of the spinal arachnoid", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "3124393_2_Ent2", "text": "intrathecal", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3124393_2_Ent1", "text": "intrathecal administration of Depo - Medrol", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "3124393_2_Ent3", "text": "Depo - Medrol", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "3128415_1", "wnd_id": "3128415_1_1", "text": "A young woman with epilepsy had tonic - clonic seizures during antineoplastic therapy with adriamycin and cisplatin .", "tokens": ["A", "young", "woman", "with", "epilepsy", "had", "tonic", "-", "clonic", "seizures", "during", "antineoplastic", "therapy", "with", "adriamycin", "and", "cisplatin", "."], "event_mentions": [{"id": "3128415_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 5, "end": 6}, "arguments": [{"entity_id": "3128415_1_Ent0", "role": "Subject", "text": "A young woman with epilepsy", "start": 0, "end": 5}, {"entity_id": "3128415_1_Ent1", "role": "Subject_Age", "text": "young", "start": 1, "end": 2}, {"entity_id": "3128415_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 2, "end": 3}, {"entity_id": "3128415_1_Ent7", "role": "Treatment_Disorder", "text": "epilepsy", "start": 4, "end": 5}, {"entity_id": "3128415_1_Ent3", "role": "Effect", "text": "tonic - clonic seizures", "start": 6, "end": 10}, {"entity_id": "3128415_1_Ent4", "role": "Treatment", "text": "antineoplastic therapy with adriamycin and cisplatin .", "start": 11, "end": 18}, {"entity_id": "3128415_1_Ent5", "role": "Treatment_Drug", "text": "adriamycin", "start": 14, "end": 15}, {"entity_id": "3128415_1_Ent8", "role": "Combination_Drug", "text": "adriamycin", "start": 14, "end": 15}, {"entity_id": "3128415_1_Ent6", "role": "Treatment_Drug", "text": "cisplatin", "start": 16, "end": 17}, {"entity_id": "3128415_1_Ent9", "role": "Combination_Drug", "text": "cisplatin", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "3128415_1_Ent0", "text": "A young woman with epilepsy", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "3128415_1_Ent1", "text": "young", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3128415_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "3128415_1_Ent7", "text": "epilepsy", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3128415_1_Ent3", "text": "tonic - clonic seizures", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "3128415_1_Ent4", "text": "antineoplastic therapy with adriamycin and cisplatin .", "entity_type": "Entity", "start": 11, "end": 18}, {"id": "3128415_1_Ent5", "text": "adriamycin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "3128415_1_Ent8", "text": "adriamycin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "3128415_1_Ent6", "text": "cisplatin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "3128415_1_Ent9", "text": "cisplatin", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "3136101_1", "wnd_id": "3136101_1_1", "text": "Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms .", "tokens": ["Hyperkalemia", "as", "a", "late", "side", "effect", "of", "prolonged", "adrenocorticotropic", "hormone", "therapy", "for", "infantile", "spasms", "."], "event_mentions": [{"id": "3136101_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 6, "end": 7}, "arguments": [{"entity_id": "3136101_1_Ent2", "role": "Effect", "text": "Hyperkalemia", "start": 0, "end": 1}, {"entity_id": "3136101_1_Ent3", "role": "Treatment", "text": "adrenocorticotropic hormone", "start": 8, "end": 10}, {"entity_id": "3136101_1_Ent5", "role": "Treatment_Drug", "text": "adrenocorticotropic hormone", "start": 8, "end": 10}, {"entity_id": "3136101_1_Ent1", "role": "Subject_Age", "text": "infantile", "start": 12, "end": 13}, {"entity_id": "3136101_1_Ent0", "role": "Subject", "text": "infantile spasms", "start": 12, "end": 14}, {"entity_id": "3136101_1_Ent4", "role": "Treatment_Disorder", "text": "infantile spasms", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "3136101_1_Ent2", "text": "Hyperkalemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3136101_1_Ent3", "text": "adrenocorticotropic hormone", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "3136101_1_Ent5", "text": "adrenocorticotropic hormone", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "3136101_1_Ent1", "text": "infantile", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "3136101_1_Ent0", "text": "infantile spasms", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "3136101_1_Ent4", "text": "infantile spasms", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "313865_1", "wnd_id": "313865_1_1", "text": "Three patients , in whom tumour overkill by cytotoxic treatment , including high dose methotrexate with folinic acid rescue , resulted in the ' phosphate shower syndrome ' ( hyper - uricaemia , hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany , with metabolic acidosis and acute renal impairment ) are described .", "tokens": ["Three", "patients", ",", "in", "whom", "tumour", "overkill", "by", "cytotoxic", "treatment", ",", "including", "high", "dose", "methotrexate", "with", "folinic", "acid", "rescue", ",", "resulted", "in", "the", "'", "phosphate", "shower", "syndrome", "'", "(", "hyper", "-", "uricaemia", ",", "hyperkalaemia", "and", "hyperphosphataemia", "with", "hypocalcaemia", "and", "tetany", ",", "with", "metabolic", "acidosis", "and", "acute", "renal", "impairment", ")", "are", "described", "."], "event_mentions": [{"id": "313865_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 20, "end": 21}, "arguments": [{"entity_id": "313865_1_Ent1", "role": "Subject_Population", "text": "Three", "start": 0, "end": 1}, {"entity_id": "313865_1_Ent0", "role": "Subject", "text": "Three patients", "start": 0, "end": 2}, {"entity_id": "313865_1_Ent4", "role": "Treatment_Disorder", "text": "tumour", "start": 5, "end": 6}, {"entity_id": "313865_1_Ent5", "role": "Treatment_Drug", "text": "cytotoxic", "start": 8, "end": 9}, {"entity_id": "313865_1_Ent11", "role": "Combination_Drug", "text": "cytotoxic", "start": 8, "end": 9}, {"entity_id": "313865_1_Ent3", "role": "Treatment", "text": "cytotoxic treatment , including high dose methotrexate with folinic acid rescue", "start": 8, "end": 19}, {"entity_id": "313865_1_Ent8", "role": "Treatment_Dosage", "text": "high dose", "start": 12, "end": 14}, {"entity_id": "313865_1_Ent6", "role": "Treatment_Drug", "text": "methotrexate", "start": 14, "end": 15}, {"entity_id": "313865_1_Ent10", "role": "Combination_Drug", "text": "methotrexate", "start": 14, "end": 15}, {"entity_id": "313865_1_Ent7", "role": "Treatment_Drug", "text": "folinic acid rescue", "start": 16, "end": 19}, {"entity_id": "313865_1_Ent9", "role": "Combination_Drug", "text": "folinic acid rescue", "start": 16, "end": 19}, {"entity_id": "313865_1_Ent2", "role": "Effect", "text": "' phosphate shower syndrome ' ( hyper - uricaemia , hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany , with metabolic acidosis and acute renal impairment )", "start": 23, "end": 49}]}], "entity_mentions": [{"id": "313865_1_Ent1", "text": "Three", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "313865_1_Ent0", "text": "Three patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "313865_1_Ent4", "text": "tumour", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "313865_1_Ent5", "text": "cytotoxic", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "313865_1_Ent11", "text": "cytotoxic", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "313865_1_Ent3", "text": "cytotoxic treatment , including high dose methotrexate with folinic acid rescue", "entity_type": "Entity", "start": 8, "end": 19}, {"id": "313865_1_Ent8", "text": "high dose", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "313865_1_Ent6", "text": "methotrexate", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "313865_1_Ent10", "text": "methotrexate", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "313865_1_Ent7", "text": "folinic acid rescue", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "313865_1_Ent9", "text": "folinic acid rescue", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "313865_1_Ent2", "text": "' phosphate shower syndrome ' ( hyper - uricaemia , hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany , with metabolic acidosis and acute renal impairment )", "entity_type": "Entity", "start": 23, "end": 49}], "lang": "en"}
{"doc_id": "3143551_1", "wnd_id": "3143551_1_1", "text": "Accordingly , camptocormia is a dose - dependent side effect of valproate .", "tokens": ["Accordingly", ",", "camptocormia", "is", "a", "dose", "-", "dependent", "side", "effect", "of", "valproate", "."], "event_mentions": [{"id": "3143551_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "effect", "start": 9, "end": 10}, "arguments": [{"entity_id": "3143551_1_Ent0", "role": "Effect", "text": "camptocormia", "start": 2, "end": 3}, {"entity_id": "3143551_1_Ent1", "role": "Treatment", "text": "valproate", "start": 11, "end": 12}, {"entity_id": "3143551_1_Ent2", "role": "Treatment_Drug", "text": "valproate", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "3143551_1_Ent0", "text": "camptocormia", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "3143551_1_Ent1", "text": "valproate", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "3143551_1_Ent2", "text": "valproate", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "3143551_4", "wnd_id": "3143551_4_1", "text": "Four weeks earlier she had developed hepatopathy during a regimen of carbamazepine , lynestrenol and sodium valproate .", "tokens": ["Four", "weeks", "earlier", "she", "had", "developed", "hepatopathy", "during", "a", "regimen", "of", "carbamazepine", ",", "lynestrenol", "and", "sodium", "valproate", "."], "event_mentions": [{"id": "3143551_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "3143551_4_Ent0", "role": "Subject", "text": "she", "start": 3, "end": 4}, {"entity_id": "3143551_4_Ent1", "role": "Subject_Gender", "text": "she", "start": 3, "end": 4}, {"entity_id": "3143551_4_Ent2", "role": "Effect", "text": "hepatopathy", "start": 6, "end": 7}, {"entity_id": "3143551_4_Ent4", "role": "Treatment_Drug", "text": "carbamazepine", "start": 11, "end": 12}, {"entity_id": "3143551_4_Ent3", "role": "Treatment", "text": "carbamazepine , lynestrenol and sodium valproate", "start": 11, "end": 17}, {"entity_id": "3143551_4_Ent5", "role": "Treatment_Drug", "text": "lynestrenol", "start": 13, "end": 14}, {"entity_id": "3143551_4_Ent6", "role": "Treatment_Drug", "text": "sodium valproate", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "3143551_4_Ent0", "text": "she", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3143551_4_Ent1", "text": "she", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3143551_4_Ent2", "text": "hepatopathy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3143551_4_Ent4", "text": "carbamazepine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "3143551_4_Ent3", "text": "carbamazepine , lynestrenol and sodium valproate", "entity_type": "Entity", "start": 11, "end": 17}, {"id": "3143551_4_Ent5", "text": "lynestrenol", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "3143551_4_Ent6", "text": "sodium valproate", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "3149484_2", "wnd_id": "3149484_2_1", "text": "Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures .", "tokens": ["Paradoxical", "precipitation", "of", "tonic", "seizures", "by", "lorazepam", "in", "a", "child", "with", "atypical", "absence", "seizures", "."], "event_mentions": [{"id": "3149484_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "precipitation", "start": 1, "end": 2}, "arguments": [{"entity_id": "3149484_2_Ent2", "role": "Effect", "text": "Paradoxical precipitation of tonic seizures", "start": 0, "end": 5}, {"entity_id": "3149484_2_Ent3", "role": "Treatment", "text": "lorazepam", "start": 6, "end": 7}, {"entity_id": "3149484_2_Ent5", "role": "Treatment_Drug", "text": "lorazepam", "start": 6, "end": 7}, {"entity_id": "3149484_2_Ent1", "role": "Subject_Age", "text": "child", "start": 9, "end": 10}, {"entity_id": "3149484_2_Ent0", "role": "Subject", "text": "child with atypical absence seizures", "start": 9, "end": 14}, {"entity_id": "3149484_2_Ent4", "role": "Treatment_Disorder", "text": "absence seizures", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "3149484_2_Ent2", "text": "Paradoxical precipitation of tonic seizures", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "3149484_2_Ent3", "text": "lorazepam", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3149484_2_Ent5", "text": "lorazepam", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3149484_2_Ent1", "text": "child", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "3149484_2_Ent0", "text": "child with atypical absence seizures", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "3149484_2_Ent4", "text": "absence seizures", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "3171334_5", "wnd_id": "3171334_5_1", "text": "Visual loss after a single small dose of vincristine has never been reported .", "tokens": ["Visual", "loss", "after", "a", "single", "small", "dose", "of", "vincristine", "has", "never", "been", "reported", "."], "event_mentions": [{"id": "3171334_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "3171334_5_Ent0", "role": "Effect", "text": "Visual loss", "start": 0, "end": 2}, {"entity_id": "3171334_5_Ent1", "role": "Treatment", "text": "a single small dose of vincristine", "start": 3, "end": 9}, {"entity_id": "3171334_5_Ent3", "role": "Treatment_Duration", "text": "single", "start": 4, "end": 5}, {"entity_id": "3171334_5_Ent4", "role": "Treatment_Dosage", "text": "small dose", "start": 5, "end": 7}, {"entity_id": "3171334_5_Ent2", "role": "Treatment_Duration", "text": "dose", "start": 6, "end": 7}, {"entity_id": "3171334_5_Ent5", "role": "Treatment_Drug", "text": "vincristine", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "3171334_5_Ent0", "text": "Visual loss", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3171334_5_Ent1", "text": "a single small dose of vincristine", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "3171334_5_Ent3", "text": "single", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3171334_5_Ent4", "text": "small dose", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "3171334_5_Ent2", "text": "dose", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3171334_5_Ent5", "text": "vincristine", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "3195622_3", "wnd_id": "3195622_3_1", "text": "Case report : dapsone hypersensitivity syndrome associated with treatment of the bite of a brown recluse spider .", "tokens": ["Case", "report", ":", "dapsone", "hypersensitivity", "syndrome", "associated", "with", "treatment", "of", "the", "bite", "of", "a", "brown", "recluse", "spider", "."], "event_mentions": [{"id": "3195622_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "3195622_3_Ent1", "role": "Treatment", "text": "dapsone", "start": 3, "end": 4}, {"entity_id": "3195622_3_Ent2", "role": "Treatment_Drug", "text": "dapsone", "start": 3, "end": 4}, {"entity_id": "3195622_3_Ent0", "role": "Effect", "text": "hypersensitivity syndrome", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "3195622_3_Ent1", "text": "dapsone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3195622_3_Ent2", "text": "dapsone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3195622_3_Ent0", "text": "hypersensitivity syndrome", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "3242521_1", "wnd_id": "3242521_1_1", "text": "Intraventricular nafcillin - induced seizures in a neonate .", "tokens": ["Intraventricular", "nafcillin", "-", "induced", "seizures", "in", "a", "neonate", "."], "event_mentions": [{"id": "3242521_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "3242521_1_Ent2", "role": "Effect", "text": "Intraventricular", "start": 0, "end": 1}, {"entity_id": "3242521_1_Ent4", "role": "Treatment", "text": "nafcillin", "start": 1, "end": 2}, {"entity_id": "3242521_1_Ent5", "role": "Treatment_Drug", "text": "nafcillin", "start": 1, "end": 2}, {"entity_id": "3242521_1_Ent3", "role": "Effect", "text": "seizures", "start": 4, "end": 5}, {"entity_id": "3242521_1_Ent0", "role": "Subject", "text": "a neonate", "start": 6, "end": 8}, {"entity_id": "3242521_1_Ent1", "role": "Subject_Age", "text": "neonate", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "3242521_1_Ent2", "text": "Intraventricular", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3242521_1_Ent4", "text": "nafcillin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3242521_1_Ent5", "text": "nafcillin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3242521_1_Ent3", "text": "seizures", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3242521_1_Ent0", "text": "a neonate", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "3242521_1_Ent1", "text": "neonate", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "3277077_1", "wnd_id": "3277077_1_1", "text": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline .", "tokens": ["Renal", "hypophosphatemia", "in", "this", "patient", "was", "caused", "by", "the", "erroneous", "intake", "of", "1", "g", "doxycycline", "."], "event_mentions": [{"id": "3277077_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 6, "end": 7}, "arguments": [{"entity_id": "3277077_1_Ent1", "role": "Effect", "text": "Renal hypophosphatemia", "start": 0, "end": 2}, {"entity_id": "3277077_1_Ent0", "role": "Subject", "text": "this patient", "start": 3, "end": 5}, {"entity_id": "3277077_1_Ent2", "role": "Treatment", "text": "the erroneous intake of 1 g doxycycline .", "start": 8, "end": 16}, {"entity_id": "3277077_1_Ent4", "role": "Treatment_Dosage", "text": "1 g", "start": 12, "end": 14}, {"entity_id": "3277077_1_Ent3", "role": "Treatment_Drug", "text": "doxycycline", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "3277077_1_Ent1", "text": "Renal hypophosphatemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3277077_1_Ent0", "text": "this patient", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "3277077_1_Ent2", "text": "the erroneous intake of 1 g doxycycline .", "entity_type": "Entity", "start": 8, "end": 16}, {"id": "3277077_1_Ent4", "text": "1 g", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "3277077_1_Ent3", "text": "doxycycline", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "3318771_1", "wnd_id": "3318771_1_1", "text": "We also describe a case of timolol - induced ocular pemphigoid .", "tokens": ["We", "also", "describe", "a", "case", "of", "timolol", "-", "induced", "ocular", "pemphigoid", "."], "event_mentions": [{"id": "3318771_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "3318771_1_Ent0", "role": "Subject", "text": "a case", "start": 3, "end": 5}, {"entity_id": "3318771_1_Ent2", "role": "Treatment", "text": "timolol", "start": 6, "end": 7}, {"entity_id": "3318771_1_Ent3", "role": "Treatment_Drug", "text": "timolol", "start": 6, "end": 7}, {"entity_id": "3318771_1_Ent1", "role": "Effect", "text": "ocular pemphigoid", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "3318771_1_Ent0", "text": "a case", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "3318771_1_Ent2", "text": "timolol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3318771_1_Ent3", "text": "timolol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3318771_1_Ent1", "text": "ocular pemphigoid", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "3335488_1", "wnd_id": "3335488_1_1", "text": "The observations suggest that testicular swelling and pain are side effects of desipramine .", "tokens": ["The", "observations", "suggest", "that", "testicular", "swelling", "and", "pain", "are", "side", "effects", "of", "desipramine", "."], "event_mentions": [{"id": "3335488_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effects", "start": 9, "end": 11}, "arguments": [{"entity_id": "3335488_1_Ent0", "role": "Effect", "text": "testicular swelling and pain", "start": 4, "end": 8}, {"entity_id": "3335488_1_Ent1", "role": "Treatment", "text": "desipramine", "start": 12, "end": 13}, {"entity_id": "3335488_1_Ent2", "role": "Treatment_Drug", "text": "desipramine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "3335488_1_Ent0", "text": "testicular swelling and pain", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "3335488_1_Ent1", "text": "desipramine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "3335488_1_Ent2", "text": "desipramine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "3343188_2", "wnd_id": "3343188_2_1", "text": "Benzocaine - induced methemoglobinemia has been reported in man , dogs , and cats .", "tokens": ["Benzocaine", "-", "induced", "methemoglobinemia", "has", "been", "reported", "in", "man", ",", "dogs", ",", "and", "cats", "."], "event_mentions": [{"id": "3343188_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "3343188_2_Ent2", "role": "Treatment", "text": "Benzocaine", "start": 0, "end": 1}, {"entity_id": "3343188_2_Ent3", "role": "Treatment_Drug", "text": "Benzocaine", "start": 0, "end": 1}, {"entity_id": "3343188_2_Ent1", "role": "Effect", "text": "methemoglobinemia", "start": 3, "end": 4}, {"entity_id": "3343188_2_Ent0", "role": "Subject", "text": "man , dogs , and cats", "start": 8, "end": 14}]}], "entity_mentions": [{"id": "3343188_2_Ent2", "text": "Benzocaine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3343188_2_Ent3", "text": "Benzocaine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3343188_2_Ent1", "text": "methemoglobinemia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3343188_2_Ent0", "text": "man , dogs , and cats", "entity_type": "Entity", "start": 8, "end": 14}], "lang": "en"}
{"doc_id": "3359700_3", "wnd_id": "3359700_3_1", "text": "Unexpected severe reversible cyclosporine A - induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease .", "tokens": ["Unexpected", "severe", "reversible", "cyclosporine", "A", "-", "induced", "nephrotoxicity", "in", "a", "patient", "with", "systemic", "lupus", "erythematosus", "and", "tubulointerstitial", "renal", "disease", "."], "event_mentions": [{"id": "3359700_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "3359700_3_Ent2", "role": "Treatment", "text": "cyclosporine A", "start": 3, "end": 5}, {"entity_id": "3359700_3_Ent3", "role": "Treatment_Drug", "text": "cyclosporine A", "start": 3, "end": 5}, {"entity_id": "3359700_3_Ent1", "role": "Effect", "text": "nephrotoxicity", "start": 7, "end": 8}, {"entity_id": "3359700_3_Ent0", "role": "Subject", "text": "a patient with systemic lupus erythematosus and tubulointerstitial renal disease", "start": 9, "end": 19}, {"entity_id": "3359700_3_Ent4", "role": "Treatment_Disorder", "text": "systemic lupus erythematosus", "start": 12, "end": 15}, {"entity_id": "3359700_3_Ent5", "role": "Treatment_Disorder", "text": "tubulointerstitial renal disease", "start": 16, "end": 19}]}], "entity_mentions": [{"id": "3359700_3_Ent2", "text": "cyclosporine A", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "3359700_3_Ent3", "text": "cyclosporine A", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "3359700_3_Ent1", "text": "nephrotoxicity", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "3359700_3_Ent0", "text": "a patient with systemic lupus erythematosus and tubulointerstitial renal disease", "entity_type": "Entity", "start": 9, "end": 19}, {"id": "3359700_3_Ent4", "text": "systemic lupus erythematosus", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "3359700_3_Ent5", "text": "tubulointerstitial renal disease", "entity_type": "Entity", "start": 16, "end": 19}], "lang": "en"}
{"doc_id": "3365032_2", "wnd_id": "3365032_2_1", "text": "Polymyositis after propylthiouracil treatment for hyperthyroidism .", "tokens": ["Polymyositis", "after", "propylthiouracil", "treatment", "for", "hyperthyroidism", "."], "event_mentions": [{"id": "3365032_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 1, "end": 2}, "arguments": [{"entity_id": "3365032_2_Ent0", "role": "Effect", "text": "Polymyositis", "start": 0, "end": 1}, {"entity_id": "3365032_2_Ent1", "role": "Treatment", "text": "propylthiouracil", "start": 2, "end": 3}, {"entity_id": "3365032_2_Ent2", "role": "Treatment_Drug", "text": "propylthiouracil", "start": 2, "end": 3}, {"entity_id": "3365032_2_Ent3", "role": "Treatment_Disorder", "text": "hyperthyroidism", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "3365032_2_Ent0", "text": "Polymyositis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3365032_2_Ent1", "text": "propylthiouracil", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "3365032_2_Ent2", "text": "propylthiouracil", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "3365032_2_Ent3", "text": "hyperthyroidism", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "3379435_3", "wnd_id": "3379435_3_1", "text": "Three senile patients developed fatal acute encephalopathy while receiving calcium hopantenate .", "tokens": ["Three", "senile", "patients", "developed", "fatal", "acute", "encephalopathy", "while", "receiving", "calcium", "hopantenate", "."], "event_mentions": [{"id": "3379435_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 3, "end": 4}, "arguments": [{"entity_id": "3379435_3_Ent1", "role": "Subject_Population", "text": "Three", "start": 0, "end": 1}, {"entity_id": "3379435_3_Ent0", "role": "Subject", "text": "Three senile patients", "start": 0, "end": 3}, {"entity_id": "3379435_3_Ent2", "role": "Subject_Age", "text": "senile", "start": 1, "end": 2}, {"entity_id": "3379435_3_Ent3", "role": "Effect", "text": "encephalopathy", "start": 6, "end": 7}, {"entity_id": "3379435_3_Ent4", "role": "Treatment", "text": "calcium hopantenate", "start": 9, "end": 11}, {"entity_id": "3379435_3_Ent5", "role": "Treatment_Drug", "text": "calcium hopantenate", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "3379435_3_Ent1", "text": "Three", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3379435_3_Ent0", "text": "Three senile patients", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "3379435_3_Ent2", "text": "senile", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3379435_3_Ent3", "text": "encephalopathy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3379435_3_Ent4", "text": "calcium hopantenate", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "3379435_3_Ent5", "text": "calcium hopantenate", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "3410226_2", "wnd_id": "3410226_2_1", "text": "We report a 46 - yr - old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide .", "tokens": ["We", "report", "a", "46", "-", "yr", "-", "old", "woman", "with", "ovarian", "carcinoma", "who", "developed", "porphyria", "cutanea", "tarda", "while", "undergoing", "treatment", "with", "cisplatin", "and", "cyclophosphamide", "."], "event_mentions": [{"id": "3410226_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "3410226_2_Ent0", "role": "Subject", "text": "a 46 - yr - old woman with ovarian carcinoma", "start": 2, "end": 12}, {"entity_id": "3410226_2_Ent1", "role": "Subject_Age", "text": "46 - yr - old", "start": 3, "end": 8}, {"entity_id": "3410226_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 8, "end": 9}, {"entity_id": "3410226_2_Ent7", "role": "Treatment_Disorder", "text": "ovarian carcinoma", "start": 10, "end": 12}, {"entity_id": "3410226_2_Ent3", "role": "Effect", "text": "porphyria cutanea tarda", "start": 14, "end": 17}, {"entity_id": "3410226_2_Ent5", "role": "Treatment_Drug", "text": "cisplatin", "start": 21, "end": 22}, {"entity_id": "3410226_2_Ent8", "role": "Combination_Drug", "text": "cisplatin", "start": 21, "end": 22}, {"entity_id": "3410226_2_Ent4", "role": "Treatment", "text": "cisplatin and cyclophosphamide", "start": 21, "end": 24}, {"entity_id": "3410226_2_Ent6", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 23, "end": 24}, {"entity_id": "3410226_2_Ent9", "role": "Combination_Drug", "text": "cyclophosphamide", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "3410226_2_Ent0", "text": "a 46 - yr - old woman with ovarian carcinoma", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "3410226_2_Ent1", "text": "46 - yr - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "3410226_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3410226_2_Ent7", "text": "ovarian carcinoma", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "3410226_2_Ent3", "text": "porphyria cutanea tarda", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "3410226_2_Ent5", "text": "cisplatin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "3410226_2_Ent8", "text": "cisplatin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "3410226_2_Ent4", "text": "cisplatin and cyclophosphamide", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "3410226_2_Ent6", "text": "cyclophosphamide", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "3410226_2_Ent9", "text": "cyclophosphamide", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "3430507_1", "wnd_id": "3430507_1_1", "text": "D - penicillamine induced crescentic glomerulonephritis : report and review of the literature .", "tokens": ["D", "-", "penicillamine", "induced", "crescentic", "glomerulonephritis", ":", "report", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "3430507_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "3430507_1_Ent1", "role": "Treatment", "text": "D - penicillamine", "start": 0, "end": 3}, {"entity_id": "3430507_1_Ent2", "role": "Treatment_Drug", "text": "D - penicillamine", "start": 0, "end": 3}, {"entity_id": "3430507_1_Ent0", "role": "Effect", "text": "crescentic glomerulonephritis", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "3430507_1_Ent1", "text": "D - penicillamine", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "3430507_1_Ent2", "text": "D - penicillamine", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "3430507_1_Ent0", "text": "crescentic glomerulonephritis", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "3470173_2", "wnd_id": "3470173_2_1", "text": "Cytarabine - induced cerebellar syndrome : case report and literature review .", "tokens": ["Cytarabine", "-", "induced", "cerebellar", "syndrome", ":", "case", "report", "and", "literature", "review", "."], "event_mentions": [{"id": "3470173_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "3470173_2_Ent1", "role": "Treatment", "text": "Cytarabine", "start": 0, "end": 1}, {"entity_id": "3470173_2_Ent2", "role": "Treatment_Drug", "text": "Cytarabine", "start": 0, "end": 1}, {"entity_id": "3470173_2_Ent0", "role": "Effect", "text": "cerebellar syndrome", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "3470173_2_Ent1", "text": "Cytarabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3470173_2_Ent2", "text": "Cytarabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3470173_2_Ent0", "text": "cerebellar syndrome", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "3470173_3", "wnd_id": "3470173_3_1", "text": "During the first treatment , dysarthria and ataxia were seen after completion of the patient 's eighth and final dose of HDARAC .", "tokens": ["During", "the", "first", "treatment", ",", "dysarthria", "and", "ataxia", "were", "seen", "after", "completion", "of", "the", "patient", "'s", "eighth", "and", "final", "dose", "of", "HDARAC", "."], "event_mentions": [{"id": "3470173_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "seen", "start": 9, "end": 10}, "arguments": [{"entity_id": "3470173_3_Ent1", "role": "Effect", "text": "dysarthria and ataxia", "start": 5, "end": 8}, {"entity_id": "3470173_3_Ent0", "role": "Subject", "text": "the patient 's", "start": 13, "end": 16}, {"entity_id": "3470173_3_Ent2", "role": "Treatment", "text": "HDARAC", "start": 21, "end": 22}, {"entity_id": "3470173_3_Ent3", "role": "Treatment_Drug", "text": "HDARAC", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "3470173_3_Ent1", "text": "dysarthria and ataxia", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "3470173_3_Ent0", "text": "the patient 's", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "3470173_3_Ent2", "text": "HDARAC", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "3470173_3_Ent3", "text": "HDARAC", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "3470173_4", "wnd_id": "3470173_4_1", "text": "The neurotoxicity seen with HDARAC is dose - related and has occurred in up to 60 percent of treated patients .", "tokens": ["The", "neurotoxicity", "seen", "with", "HDARAC", "is", "dose", "-", "related", "and", "has", "occurred", "in", "up", "to", "60", "percent", "of", "treated", "patients", "."], "event_mentions": [{"id": "3470173_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 8, "end": 9}, "arguments": [{"entity_id": "3470173_4_Ent2", "role": "Effect", "text": "neurotoxicity", "start": 1, "end": 2}, {"entity_id": "3470173_4_Ent3", "role": "Treatment", "text": "HDARAC", "start": 4, "end": 5}, {"entity_id": "3470173_4_Ent4", "role": "Treatment_Drug", "text": "HDARAC", "start": 4, "end": 5}, {"entity_id": "3470173_4_Ent1", "role": "Subject_Population", "text": "60 percent", "start": 15, "end": 17}, {"entity_id": "3470173_4_Ent0", "role": "Subject", "text": "60 percent of treated patients", "start": 15, "end": 20}]}], "entity_mentions": [{"id": "3470173_4_Ent2", "text": "neurotoxicity", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3470173_4_Ent3", "text": "HDARAC", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3470173_4_Ent4", "text": "HDARAC", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3470173_4_Ent1", "text": "60 percent", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "3470173_4_Ent0", "text": "60 percent of treated patients", "entity_type": "Entity", "start": 15, "end": 20}], "lang": "en"}
{"doc_id": "3493797_1", "wnd_id": "3493797_1_1", "text": "A woman with a 20 - year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs , developed a B - cell lymphoma of the lip following 4 1/2 years of treatment with razoxane .", "tokens": ["A", "woman", "with", "a", "20", "-", "year", "history", "of", "acral", "pustular", "psoriasis", "of", "Hallopeau", "and", "recurrent", "pustular", "lesions", "of", "the", "forearms", "and", "lower", "legs", ",", "developed", "a", "B", "-", "cell", "lymphoma", "of", "the", "lip", "following", "4", "1/2", "years", "of", "treatment", "with", "razoxane", "."], "event_mentions": [{"id": "3493797_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 25, "end": 26}, "arguments": [{"entity_id": "3493797_1_Ent0", "role": "Subject", "text": "A woman with a 20 - year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs", "start": 0, "end": 24}, {"entity_id": "3493797_1_Ent1", "role": "Subject_Gender", "text": "woman", "start": 1, "end": 2}, {"entity_id": "3493797_1_Ent6", "role": "Treatment_Disorder", "text": "acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs", "start": 9, "end": 24}, {"entity_id": "3493797_1_Ent2", "role": "Effect", "text": "a B - cell lymphoma of the lip", "start": 26, "end": 34}, {"entity_id": "3493797_1_Ent4", "role": "Treatment_Duration", "text": "following 4 1/2 years", "start": 34, "end": 38}, {"entity_id": "3493797_1_Ent3", "role": "Treatment", "text": "4 1/2 years of treatment with razoxane", "start": 35, "end": 42}, {"entity_id": "3493797_1_Ent5", "role": "Treatment_Drug", "text": "razoxane", "start": 41, "end": 42}]}], "entity_mentions": [{"id": "3493797_1_Ent0", "text": "A woman with a 20 - year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs", "entity_type": "Entity", "start": 0, "end": 24}, {"id": "3493797_1_Ent1", "text": "woman", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3493797_1_Ent6", "text": "acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs", "entity_type": "Entity", "start": 9, "end": 24}, {"id": "3493797_1_Ent2", "text": "a B - cell lymphoma of the lip", "entity_type": "Entity", "start": 26, "end": 34}, {"id": "3493797_1_Ent4", "text": "following 4 1/2 years", "entity_type": "Entity", "start": 34, "end": 38}, {"id": "3493797_1_Ent3", "text": "4 1/2 years of treatment with razoxane", "entity_type": "Entity", "start": 35, "end": 42}, {"id": "3493797_1_Ent5", "text": "razoxane", "entity_type": "Entity", "start": 41, "end": 42}], "lang": "en"}
{"doc_id": "3501467_2", "wnd_id": "3501467_2_1", "text": "Hypogammaglobulinemia associated with gold therapy : evidence for a partial maturation blockade of B cells .", "tokens": ["Hypogammaglobulinemia", "associated", "with", "gold", "therapy", ":", "evidence", "for", "a", "partial", "maturation", "blockade", "of", "B", "cells", "."], "event_mentions": [{"id": "3501467_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "3501467_2_Ent0", "role": "Effect", "text": "Hypogammaglobulinemia", "start": 0, "end": 1}, {"entity_id": "3501467_2_Ent3", "role": "Treatment_Drug", "text": "gold", "start": 3, "end": 4}, {"entity_id": "3501467_2_Ent2", "role": "Treatment", "text": "gold therapy", "start": 3, "end": 5}, {"entity_id": "3501467_2_Ent1", "role": "Effect", "text": "a partial maturation blockade of B cells", "start": 8, "end": 15}]}], "entity_mentions": [{"id": "3501467_2_Ent0", "text": "Hypogammaglobulinemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3501467_2_Ent3", "text": "gold", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3501467_2_Ent2", "text": "gold therapy", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "3501467_2_Ent1", "text": "a partial maturation blockade of B cells", "entity_type": "Entity", "start": 8, "end": 15}], "lang": "en"}
{"doc_id": "3513544_2", "wnd_id": "3513544_2_1", "text": "We report the first case of herpes esophagitis in a renal transplant patient treated with Cyclosporine A while on chronic steroid therapy .", "tokens": ["We", "report", "the", "first", "case", "of", "herpes", "esophagitis", "in", "a", "renal", "transplant", "patient", "treated", "with", "Cyclosporine", "A", "while", "on", "chronic", "steroid", "therapy", "."], "event_mentions": [{"id": "3513544_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 8, "end": 9}, "arguments": [{"entity_id": "3513544_2_Ent1", "role": "Effect", "text": "herpes esophagitis", "start": 6, "end": 8}, {"entity_id": "3513544_2_Ent0", "role": "Subject", "text": "a renal transplant patient", "start": 9, "end": 13}, {"entity_id": "3513544_2_Ent5", "role": "Treatment_Disorder", "text": "renal transplant", "start": 10, "end": 12}, {"entity_id": "3513544_2_Ent3", "role": "Treatment_Drug", "text": "Cyclosporine A", "start": 15, "end": 17}, {"entity_id": "3513544_2_Ent6", "role": "Combination_Drug", "text": "Cyclosporine A", "start": 15, "end": 17}, {"entity_id": "3513544_2_Ent2", "role": "Treatment", "text": "Cyclosporine A while on chronic steroid therapy", "start": 15, "end": 22}, {"entity_id": "3513544_2_Ent4", "role": "Treatment_Drug", "text": "chronic steroid", "start": 19, "end": 21}, {"entity_id": "3513544_2_Ent7", "role": "Combination_Drug", "text": "chronic steroid", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "3513544_2_Ent1", "text": "herpes esophagitis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "3513544_2_Ent0", "text": "a renal transplant patient", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "3513544_2_Ent5", "text": "renal transplant", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "3513544_2_Ent3", "text": "Cyclosporine A", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "3513544_2_Ent6", "text": "Cyclosporine A", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "3513544_2_Ent2", "text": "Cyclosporine A while on chronic steroid therapy", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "3513544_2_Ent4", "text": "chronic steroid", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "3513544_2_Ent7", "text": "chronic steroid", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "3549808_1", "wnd_id": "3549808_1_1", "text": "One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction .", "tokens": ["One", "of", "the", "subjects", "who", "was", "using", "extemporaneous", "topical", "minoxidil", "had", "hypertension", "and", "arteriosclerotic", "disease", "and", "the", "other", "died", "of", "a", "myocardial", "infarction", "."], "event_mentions": [{"id": "3549808_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 10, "end": 11}, "arguments": [{"entity_id": "3549808_1_Ent1", "role": "Subject_Population", "text": "One", "start": 0, "end": 1}, {"entity_id": "3549808_1_Ent0", "role": "Subject", "text": "One of the subjects", "start": 0, "end": 4}, {"entity_id": "3549808_1_Ent3", "role": "Treatment", "text": "extemporaneous topical minoxidil", "start": 7, "end": 10}, {"entity_id": "3549808_1_Ent4", "role": "Treatment_Route", "text": "topical", "start": 8, "end": 9}, {"entity_id": "3549808_1_Ent5", "role": "Treatment_Drug", "text": "minoxidil", "start": 9, "end": 10}, {"entity_id": "3549808_1_Ent2", "role": "Effect", "text": "hypertension and arteriosclerotic disease", "start": 11, "end": 15}]}, {"id": "3549808_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "died", "start": 18, "end": 19}, "arguments": [{"entity_id": "3549808_1_Ent8", "role": "Treatment", "text": "extemporaneous topical minoxidil", "start": 7, "end": 10}, {"entity_id": "3549808_1_Ent9", "role": "Treatment_Route", "text": "topical", "start": 8, "end": 9}, {"entity_id": "3549808_1_Ent10", "role": "Treatment_Drug", "text": "minoxidil", "start": 9, "end": 10}, {"entity_id": "3549808_1_Ent6", "role": "Subject", "text": "the other", "start": 16, "end": 18}, {"entity_id": "3549808_1_Ent7", "role": "Effect", "text": "died of a myocardial infarction", "start": 18, "end": 23}]}], "entity_mentions": [{"id": "3549808_1_Ent1", "text": "One", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3549808_1_Ent0", "text": "One of the subjects", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "3549808_1_Ent3", "text": "extemporaneous topical minoxidil", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "3549808_1_Ent8", "text": "extemporaneous topical minoxidil", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "3549808_1_Ent4", "text": "topical", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3549808_1_Ent9", "text": "topical", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3549808_1_Ent5", "text": "minoxidil", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "3549808_1_Ent10", "text": "minoxidil", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "3549808_1_Ent2", "text": "hypertension and arteriosclerotic disease", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "3549808_1_Ent6", "text": "the other", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "3549808_1_Ent7", "text": "died of a myocardial infarction", "entity_type": "Entity", "start": 18, "end": 23}], "lang": "en"}
{"doc_id": "3569037_2", "wnd_id": "3569037_2_1", "text": "Hypersensitivity reaction following chloramphenicol administration in a patient with typhoid fever .", "tokens": ["Hypersensitivity", "reaction", "following", "chloramphenicol", "administration", "in", "a", "patient", "with", "typhoid", "fever", "."], "event_mentions": [{"id": "3569037_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "3569037_2_Ent1", "role": "Effect", "text": "Hypersensitivity reaction", "start": 0, "end": 2}, {"entity_id": "3569037_2_Ent2", "role": "Treatment", "text": "chloramphenicol", "start": 3, "end": 4}, {"entity_id": "3569037_2_Ent3", "role": "Treatment_Drug", "text": "chloramphenicol", "start": 3, "end": 4}, {"entity_id": "3569037_2_Ent0", "role": "Subject", "text": "a patient with typhoid fever", "start": 6, "end": 11}, {"entity_id": "3569037_2_Ent4", "role": "Treatment_Disorder", "text": "typhoid fever", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "3569037_2_Ent1", "text": "Hypersensitivity reaction", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3569037_2_Ent2", "text": "chloramphenicol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3569037_2_Ent3", "text": "chloramphenicol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3569037_2_Ent0", "text": "a patient with typhoid fever", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "3569037_2_Ent4", "text": "typhoid fever", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "3579660_2", "wnd_id": "3579660_2_1", "text": "To develop information on the relative rarity or frequency of neurologic worsening with the initiation of penicillamine therapy , we conducted a retrospective survey of 25 additional patients with Wilson 's disease who met the criteria of presenting with neurologic disease and having been treated with penicillamine .", "tokens": ["To", "develop", "information", "on", "the", "relative", "rarity", "or", "frequency", "of", "neurologic", "worsening", "with", "the", "initiation", "of", "penicillamine", "therapy", ",", "we", "conducted", "a", "retrospective", "survey", "of", "25", "additional", "patients", "with", "Wilson", "'s", "disease", "who", "met", "the", "criteria", "of", "presenting", "with", "neurologic", "disease", "and", "having", "been", "treated", "with", "penicillamine", "."], "event_mentions": [{"id": "3579660_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presenting", "start": 37, "end": 38}, "arguments": [{"entity_id": "3579660_2_Ent1", "role": "Subject_Population", "text": "25", "start": 25, "end": 26}, {"entity_id": "3579660_2_Ent0", "role": "Subject", "text": "25 additional patients with Wilson 's disease", "start": 25, "end": 32}, {"entity_id": "3579660_2_Ent5", "role": "Treatment_Disorder", "text": "Wilson 's disease", "start": 29, "end": 32}, {"entity_id": "3579660_2_Ent2", "role": "Effect", "text": "neurologic disease", "start": 39, "end": 41}, {"entity_id": "3579660_2_Ent3", "role": "Treatment", "text": "penicillamine", "start": 46, "end": 47}, {"entity_id": "3579660_2_Ent4", "role": "Treatment_Drug", "text": "penicillamine", "start": 46, "end": 47}]}], "entity_mentions": [{"id": "3579660_2_Ent1", "text": "25", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "3579660_2_Ent0", "text": "25 additional patients with Wilson 's disease", "entity_type": "Entity", "start": 25, "end": 32}, {"id": "3579660_2_Ent5", "text": "Wilson 's disease", "entity_type": "Entity", "start": 29, "end": 32}, {"id": "3579660_2_Ent2", "text": "neurologic disease", "entity_type": "Entity", "start": 39, "end": 41}, {"id": "3579660_2_Ent3", "text": "penicillamine", "entity_type": "Entity", "start": 46, "end": 47}, {"id": "3579660_2_Ent4", "text": "penicillamine", "entity_type": "Entity", "start": 46, "end": 47}], "lang": "en"}
{"doc_id": "3612639_1", "wnd_id": "3612639_1_1", "text": "Pulmonary edema as a delayed complication of ritodrine therapy .", "tokens": ["Pulmonary", "edema", "as", "a", "delayed", "complication", "of", "ritodrine", "therapy", "."], "event_mentions": [{"id": "3612639_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 5, "end": 6}, "arguments": [{"entity_id": "3612639_1_Ent0", "role": "Effect", "text": "Pulmonary edema", "start": 0, "end": 2}, {"entity_id": "3612639_1_Ent1", "role": "Treatment", "text": "ritodrine", "start": 7, "end": 8}, {"entity_id": "3612639_1_Ent2", "role": "Treatment_Drug", "text": "ritodrine", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "3612639_1_Ent0", "text": "Pulmonary edema", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3612639_1_Ent1", "text": "ritodrine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "3612639_1_Ent2", "text": "ritodrine", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "3612639_2", "wnd_id": "3612639_2_1", "text": "Pulmonary edema occurred 24 hours after intravenous ritodrine therapy and 10 hours after subcutaneous terbutaline therapy .", "tokens": ["Pulmonary", "edema", "occurred", "24", "hours", "after", "intravenous", "ritodrine", "therapy", "and", "10", "hours", "after", "subcutaneous", "terbutaline", "therapy", "."], "event_mentions": [{"id": "3612639_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 2, "end": 3}, "arguments": [{"entity_id": "3612639_2_Ent0", "role": "Effect", "text": "Pulmonary edema", "start": 0, "end": 2}, {"entity_id": "3612639_2_Ent2", "role": "Treatment_Time_elapsed", "text": "24 hours", "start": 3, "end": 5}, {"entity_id": "3612639_2_Ent1", "role": "Treatment", "text": "24 hours after intravenous ritodrine therapy and 10 hours after subcutaneous terbutaline therapy", "start": 3, "end": 16}, {"entity_id": "3612639_2_Ent4", "role": "Treatment_Route", "text": "intravenous", "start": 6, "end": 7}, {"entity_id": "3612639_2_Ent6", "role": "Treatment_Drug", "text": "ritodrine", "start": 7, "end": 8}, {"entity_id": "3612639_2_Ent8", "role": "Combination_Drug", "text": "ritodrine", "start": 7, "end": 8}, {"entity_id": "3612639_2_Ent3", "role": "Treatment_Time_elapsed", "text": "10 hours", "start": 10, "end": 12}, {"entity_id": "3612639_2_Ent5", "role": "Treatment_Route", "text": "subcutaneous", "start": 13, "end": 14}, {"entity_id": "3612639_2_Ent7", "role": "Treatment_Drug", "text": "terbutaline", "start": 14, "end": 15}, {"entity_id": "3612639_2_Ent9", "role": "Combination_Drug", "text": "terbutaline", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "3612639_2_Ent0", "text": "Pulmonary edema", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3612639_2_Ent2", "text": "24 hours", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "3612639_2_Ent1", "text": "24 hours after intravenous ritodrine therapy and 10 hours after subcutaneous terbutaline therapy", "entity_type": "Entity", "start": 3, "end": 16}, {"id": "3612639_2_Ent4", "text": "intravenous", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3612639_2_Ent6", "text": "ritodrine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "3612639_2_Ent8", "text": "ritodrine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "3612639_2_Ent3", "text": "10 hours", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "3612639_2_Ent5", "text": "subcutaneous", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "3612639_2_Ent7", "text": "terbutaline", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "3612639_2_Ent9", "text": "terbutaline", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "3628148_2", "wnd_id": "3628148_2_1", "text": "We describe rupture of a cerebral arterial aneurysm in a 32 year old hypertensive woman following the introduction of nifedipine treatment .", "tokens": ["We", "describe", "rupture", "of", "a", "cerebral", "arterial", "aneurysm", "in", "a", "32", "year", "old", "hypertensive", "woman", "following", "the", "introduction", "of", "nifedipine", "treatment", "."], "event_mentions": [{"id": "3628148_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 15, "end": 16}, "arguments": [{"entity_id": "3628148_2_Ent3", "role": "Effect", "text": "rupture of a cerebral arterial aneurysm", "start": 2, "end": 8}, {"entity_id": "3628148_2_Ent0", "role": "Subject", "text": "a 32 year old hypertensive woman", "start": 9, "end": 15}, {"entity_id": "3628148_2_Ent1", "role": "Subject_Age", "text": "32 year old", "start": 10, "end": 13}, {"entity_id": "3628148_2_Ent5", "role": "Treatment_Disorder", "text": "hypertensive", "start": 13, "end": 14}, {"entity_id": "3628148_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 14, "end": 15}, {"entity_id": "3628148_2_Ent6", "role": "Treatment_Drug", "text": "nifedipine", "start": 19, "end": 20}, {"entity_id": "3628148_2_Ent4", "role": "Treatment", "text": "nifedipine treatment", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "3628148_2_Ent3", "text": "rupture of a cerebral arterial aneurysm", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "3628148_2_Ent0", "text": "a 32 year old hypertensive woman", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "3628148_2_Ent1", "text": "32 year old", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "3628148_2_Ent5", "text": "hypertensive", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "3628148_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "3628148_2_Ent6", "text": "nifedipine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "3628148_2_Ent4", "text": "nifedipine treatment", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "3659584_5", "wnd_id": "3659584_5_1", "text": "Although rare , massive pulmonary embolus must be considered to be a major risk of thrombolytic therapy for deep venous thrombosis .", "tokens": ["Although", "rare", ",", "massive", "pulmonary", "embolus", "must", "be", "considered", "to", "be", "a", "major", "risk", "of", "thrombolytic", "therapy", "for", "deep", "venous", "thrombosis", "."], "event_mentions": [{"id": "3659584_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "risk", "start": 13, "end": 14}, "arguments": [{"entity_id": "3659584_5_Ent0", "role": "Effect", "text": "massive pulmonary embolus", "start": 3, "end": 6}, {"entity_id": "3659584_5_Ent1", "role": "Treatment", "text": "thrombolytic", "start": 15, "end": 16}, {"entity_id": "3659584_5_Ent2", "role": "Treatment_Drug", "text": "thrombolytic", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "3659584_5_Ent0", "text": "massive pulmonary embolus", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "3659584_5_Ent1", "text": "thrombolytic", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "3659584_5_Ent2", "text": "thrombolytic", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "3688031_3", "wnd_id": "3688031_3_1", "text": "The patient 's defects may be due to methimazole teratogenicity or could represent a previously undescribed syndrome affecting ectodermal structures .", "tokens": ["The", "patient", "'s", "defects", "may", "be", "due", "to", "methimazole", "teratogenicity", "or", "could", "represent", "a", "previously", "undescribed", "syndrome", "affecting", "ectodermal", "structures", "."], "event_mentions": [{"id": "3688031_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 6, "end": 7}, "arguments": [{"entity_id": "3688031_3_Ent1", "role": "Treatment", "text": "methimazole", "start": 8, "end": 9}, {"entity_id": "3688031_3_Ent2", "role": "Treatment_Drug", "text": "methimazole", "start": 8, "end": 9}, {"entity_id": "3688031_3_Ent0", "role": "Effect", "text": "teratogenicity", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "3688031_3_Ent1", "text": "methimazole", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3688031_3_Ent2", "text": "methimazole", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3688031_3_Ent0", "text": "teratogenicity", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "3718111_1", "wnd_id": "3718111_1_1", "text": "He became hyperkalemic on rechallenge with timolol and normokalemic following its withdrawal .", "tokens": ["He", "became", "hyperkalemic", "on", "rechallenge", "with", "timolol", "and", "normokalemic", "following", "its", "withdrawal", "."], "event_mentions": [{"id": "3718111_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 9, "end": 10}, "arguments": [{"entity_id": "3718111_1_Ent0", "role": "Subject", "text": "He", "start": 0, "end": 1}, {"entity_id": "3718111_1_Ent1", "role": "Subject_Gender", "text": "He", "start": 0, "end": 1}, {"entity_id": "3718111_1_Ent2", "role": "Effect", "text": "hyperkalemic", "start": 2, "end": 3}, {"entity_id": "3718111_1_Ent3", "role": "Treatment", "text": "timolol", "start": 6, "end": 7}, {"entity_id": "3718111_1_Ent4", "role": "Treatment_Drug", "text": "timolol", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "3718111_1_Ent0", "text": "He", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3718111_1_Ent1", "text": "He", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3718111_1_Ent2", "text": "hyperkalemic", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "3718111_1_Ent3", "text": "timolol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3718111_1_Ent4", "text": "timolol", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "3806824_1", "wnd_id": "3806824_1_1", "text": "Fibrosis of corpus cavernosum after intracavernous injection of phentolamine / papaverine .", "tokens": ["Fibrosis", "of", "corpus", "cavernosum", "after", "intracavernous", "injection", "of", "phentolamine", "/", "papaverine", "."], "event_mentions": [{"id": "3806824_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 4, "end": 5}, "arguments": [{"entity_id": "3806824_1_Ent0", "role": "Effect", "text": "Fibrosis of corpus cavernosum", "start": 0, "end": 4}, {"entity_id": "3806824_1_Ent4", "role": "Treatment_Route", "text": "intracavernous injection", "start": 5, "end": 7}, {"entity_id": "3806824_1_Ent1", "role": "Treatment", "text": "intracavernous injection of phentolamine / papaverine", "start": 5, "end": 11}, {"entity_id": "3806824_1_Ent2", "role": "Treatment_Drug", "text": "phentolamine", "start": 8, "end": 9}, {"entity_id": "3806824_1_Ent5", "role": "Combination_Drug", "text": "phentolamine", "start": 8, "end": 9}, {"entity_id": "3806824_1_Ent3", "role": "Treatment_Drug", "text": "papaverine", "start": 10, "end": 11}, {"entity_id": "3806824_1_Ent6", "role": "Combination_Drug", "text": "papaverine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "3806824_1_Ent0", "text": "Fibrosis of corpus cavernosum", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "3806824_1_Ent4", "text": "intracavernous injection", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "3806824_1_Ent1", "text": "intracavernous injection of phentolamine / papaverine", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "3806824_1_Ent2", "text": "phentolamine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3806824_1_Ent5", "text": "phentolamine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3806824_1_Ent3", "text": "papaverine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "3806824_1_Ent6", "text": "papaverine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "3917429_1", "wnd_id": "3917429_1_1", "text": "Controversy concerning the nephrotoxicity of lithium is discussed , and recommendations for the evaluation of renal failure during lithium therapy are provided .", "tokens": ["Controversy", "concerning", "the", "nephrotoxicity", "of", "lithium", "is", "discussed", ",", "and", "recommendations", "for", "the", "evaluation", "of", "renal", "failure", "during", "lithium", "therapy", "are", "provided", "."], "event_mentions": [{"id": "3917429_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 4, "end": 5}, "arguments": [{"entity_id": "3917429_1_Ent0", "role": "Effect", "text": "nephrotoxicity", "start": 3, "end": 4}, {"entity_id": "3917429_1_Ent2", "role": "Treatment", "text": "lithium", "start": 5, "end": 6}, {"entity_id": "3917429_1_Ent3", "role": "Treatment_Drug", "text": "lithium", "start": 5, "end": 6}, {"entity_id": "3917429_1_Ent1", "role": "Effect", "text": "evaluation of renal failure", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "3917429_1_Ent0", "text": "nephrotoxicity", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3917429_1_Ent2", "text": "lithium", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3917429_1_Ent3", "text": "lithium", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3917429_1_Ent1", "text": "evaluation of renal failure", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "3941210_1", "wnd_id": "3941210_1_1", "text": "Atrioventricular block complicating amiodarone - induced hypothyroidism in a patient with pre - excitation and rate - dependent bilateral bundle branch block .", "tokens": ["Atrioventricular", "block", "complicating", "amiodarone", "-", "induced", "hypothyroidism", "in", "a", "patient", "with", "pre", "-", "excitation", "and", "rate", "-", "dependent", "bilateral", "bundle", "branch", "block", "."], "event_mentions": [{"id": "3941210_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "3941210_1_Ent3", "role": "Subject_Disorder", "text": "Atrioventricular block", "start": 0, "end": 2}, {"entity_id": "3941210_1_Ent5", "role": "Treatment", "text": "amiodarone", "start": 3, "end": 4}, {"entity_id": "3941210_1_Ent6", "role": "Treatment_Drug", "text": "amiodarone", "start": 3, "end": 4}, {"entity_id": "3941210_1_Ent4", "role": "Effect", "text": "hypothyroidism", "start": 6, "end": 7}, {"entity_id": "3941210_1_Ent0", "role": "Subject", "text": "a patient with pre - excitation and rate - dependent bilateral bundle branch block", "start": 8, "end": 22}, {"entity_id": "3941210_1_Ent1", "role": "Subject_Disorder", "text": "pre - excitation", "start": 11, "end": 14}, {"entity_id": "3941210_1_Ent2", "role": "Subject_Disorder", "text": "rate - dependent bilateral bundle branch block", "start": 15, "end": 22}]}], "entity_mentions": [{"id": "3941210_1_Ent3", "text": "Atrioventricular block", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3941210_1_Ent5", "text": "amiodarone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3941210_1_Ent6", "text": "amiodarone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3941210_1_Ent4", "text": "hypothyroidism", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3941210_1_Ent0", "text": "a patient with pre - excitation and rate - dependent bilateral bundle branch block", "entity_type": "Entity", "start": 8, "end": 22}, {"id": "3941210_1_Ent1", "text": "pre - excitation", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "3941210_1_Ent2", "text": "rate - dependent bilateral bundle branch block", "entity_type": "Entity", "start": 15, "end": 22}], "lang": "en"}
{"doc_id": "3969689_4", "wnd_id": "3969689_4_1", "text": "Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine .", "tokens": ["Careful", "observations", "on", "hepatotoxicity", "are", "suggested", "when", "acetaminophen", "is", "prescribed", "with", "caffeine", "."], "event_mentions": [{"id": "3969689_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 10, "end": 11}, "arguments": [{"entity_id": "3969689_4_Ent0", "role": "Effect", "text": "hepatotoxicity", "start": 3, "end": 4}, {"entity_id": "3969689_4_Ent1", "role": "Treatment", "text": "acetaminophen", "start": 7, "end": 8}, {"entity_id": "3969689_4_Ent3", "role": "Treatment_Drug", "text": "acetaminophen", "start": 7, "end": 8}, {"entity_id": "3969689_4_Ent2", "role": "Treatment", "text": "caffeine", "start": 11, "end": 12}, {"entity_id": "3969689_4_Ent4", "role": "Treatment_Drug", "text": "caffeine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "3969689_4_Ent0", "text": "hepatotoxicity", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3969689_4_Ent1", "text": "acetaminophen", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "3969689_4_Ent3", "text": "acetaminophen", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "3969689_4_Ent2", "text": "caffeine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "3969689_4_Ent4", "text": "caffeine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "3970339_1", "wnd_id": "3970339_1_1", "text": "A patient presented with a painful , oedematous , cyanosed hand having injected a solution of diamorphine and methylphenidate into his radial artery .", "tokens": ["A", "patient", "presented", "with", "a", "painful", ",", "oedematous", ",", "cyanosed", "hand", "having", "injected", "a", "solution", "of", "diamorphine", "and", "methylphenidate", "into", "his", "radial", "artery", "."], "event_mentions": [{"id": "3970339_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 2, "end": 3}, "arguments": [{"entity_id": "3970339_1_Ent0", "role": "Subject", "text": "A patient", "start": 0, "end": 2}, {"entity_id": "3970339_1_Ent1", "role": "Effect", "text": "painful , oedematous , cyanosed hand", "start": 5, "end": 11}, {"entity_id": "3970339_1_Ent3", "role": "Treatment_Route", "text": "injected", "start": 12, "end": 13}, {"entity_id": "3970339_1_Ent2", "role": "Treatment", "text": "injected a solution of diamorphine and methylphenidate into his radial artery", "start": 12, "end": 23}, {"entity_id": "3970339_1_Ent5", "role": "Treatment_Drug", "text": "diamorphine", "start": 16, "end": 17}, {"entity_id": "3970339_1_Ent7", "role": "Combination_Drug", "text": "diamorphine", "start": 16, "end": 17}, {"entity_id": "3970339_1_Ent6", "role": "Treatment_Drug", "text": "methylphenidate", "start": 18, "end": 19}, {"entity_id": "3970339_1_Ent8", "role": "Combination_Drug", "text": "methylphenidate", "start": 18, "end": 19}, {"entity_id": "3970339_1_Ent4", "role": "Treatment_Route", "text": "into his radial artery", "start": 19, "end": 23}]}], "entity_mentions": [{"id": "3970339_1_Ent0", "text": "A patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3970339_1_Ent1", "text": "painful , oedematous , cyanosed hand", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "3970339_1_Ent3", "text": "injected", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "3970339_1_Ent2", "text": "injected a solution of diamorphine and methylphenidate into his radial artery", "entity_type": "Entity", "start": 12, "end": 23}, {"id": "3970339_1_Ent5", "text": "diamorphine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "3970339_1_Ent7", "text": "diamorphine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "3970339_1_Ent6", "text": "methylphenidate", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "3970339_1_Ent8", "text": "methylphenidate", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "3970339_1_Ent4", "text": "into his radial artery", "entity_type": "Entity", "start": 19, "end": 23}], "lang": "en"}
{"doc_id": "3970339_2", "wnd_id": "3970339_2_1", "text": "Ischaemia following selfadministered intra - arterial injection of methylphenidate and diamorphine .", "tokens": ["Ischaemia", "following", "selfadministered", "intra", "-", "arterial", "injection", "of", "methylphenidate", "and", "diamorphine", "."], "event_mentions": [{"id": "3970339_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 1, "end": 2}, "arguments": [{"entity_id": "3970339_2_Ent0", "role": "Effect", "text": "Ischaemia", "start": 0, "end": 1}, {"entity_id": "3970339_2_Ent1", "role": "Treatment", "text": "selfadministered intra - arterial injection of methylphenidate and diamorphine", "start": 2, "end": 11}, {"entity_id": "3970339_2_Ent4", "role": "Treatment_Route", "text": "intra - arterial injection", "start": 3, "end": 7}, {"entity_id": "3970339_2_Ent2", "role": "Treatment_Drug", "text": "methylphenidate", "start": 8, "end": 9}, {"entity_id": "3970339_2_Ent5", "role": "Combination_Drug", "text": "methylphenidate", "start": 8, "end": 9}, {"entity_id": "3970339_2_Ent3", "role": "Treatment_Drug", "text": "diamorphine", "start": 10, "end": 11}, {"entity_id": "3970339_2_Ent6", "role": "Combination_Drug", "text": "diamorphine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "3970339_2_Ent0", "text": "Ischaemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3970339_2_Ent1", "text": "selfadministered intra - arterial injection of methylphenidate and diamorphine", "entity_type": "Entity", "start": 2, "end": 11}, {"id": "3970339_2_Ent4", "text": "intra - arterial injection", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "3970339_2_Ent2", "text": "methylphenidate", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3970339_2_Ent5", "text": "methylphenidate", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3970339_2_Ent3", "text": "diamorphine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "3970339_2_Ent6", "text": "diamorphine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "3977377_1", "wnd_id": "3977377_1_1", "text": "Chronic photosensitivity associated with hydrochlorothiazide ingestion occurred in four patients .", "tokens": ["Chronic", "photosensitivity", "associated", "with", "hydrochlorothiazide", "ingestion", "occurred", "in", "four", "patients", "."], "event_mentions": [{"id": "3977377_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "3977377_1_Ent2", "role": "Effect", "text": "Chronic photosensitivity", "start": 0, "end": 2}, {"entity_id": "3977377_1_Ent4", "role": "Treatment_Drug", "text": "hydrochlorothiazide", "start": 4, "end": 5}, {"entity_id": "3977377_1_Ent3", "role": "Treatment", "text": "hydrochlorothiazide ingestion", "start": 4, "end": 6}, {"entity_id": "3977377_1_Ent5", "role": "Treatment_Route", "text": "ingestion", "start": 5, "end": 6}, {"entity_id": "3977377_1_Ent1", "role": "Subject_Population", "text": "four", "start": 8, "end": 9}, {"entity_id": "3977377_1_Ent0", "role": "Subject", "text": "four patients", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "3977377_1_Ent2", "text": "Chronic photosensitivity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3977377_1_Ent4", "text": "hydrochlorothiazide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3977377_1_Ent3", "text": "hydrochlorothiazide ingestion", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "3977377_1_Ent5", "text": "ingestion", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3977377_1_Ent1", "text": "four", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3977377_1_Ent0", "text": "four patients", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "4004433_4", "wnd_id": "4004433_4_1", "text": "While most physicians are aware of heparin - induced thrombocytopenia and skin necrosis , the association of heparin and hyperkalemia is less well recognized .", "tokens": ["While", "most", "physicians", "are", "aware", "of", "heparin", "-", "induced", "thrombocytopenia", "and", "skin", "necrosis", ",", "the", "association", "of", "heparin", "and", "hyperkalemia", "is", "less", "well", "recognized", "."], "event_mentions": [{"id": "4004433_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "4004433_4_Ent1", "role": "Treatment", "text": "heparin", "start": 6, "end": 7}, {"entity_id": "4004433_4_Ent2", "role": "Treatment_Drug", "text": "heparin", "start": 6, "end": 7}, {"entity_id": "4004433_4_Ent0", "role": "Effect", "text": "thrombocytopenia and skin necrosis", "start": 9, "end": 13}]}], "entity_mentions": [{"id": "4004433_4_Ent1", "text": "heparin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "4004433_4_Ent2", "text": "heparin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "4004433_4_Ent0", "text": "thrombocytopenia and skin necrosis", "entity_type": "Entity", "start": 9, "end": 13}], "lang": "en"}
{"doc_id": "4014301_4", "wnd_id": "4014301_4_1", "text": "This report describes the first case of insulin - induced cardiac failure in a patient without underlying heart disease .", "tokens": ["This", "report", "describes", "the", "first", "case", "of", "insulin", "-", "induced", "cardiac", "failure", "in", "a", "patient", "without", "underlying", "heart", "disease", "."], "event_mentions": [{"id": "4014301_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "4014301_4_Ent2", "role": "Treatment", "text": "insulin", "start": 7, "end": 8}, {"entity_id": "4014301_4_Ent3", "role": "Treatment_Drug", "text": "insulin", "start": 7, "end": 8}, {"entity_id": "4014301_4_Ent1", "role": "Effect", "text": "cardiac failure", "start": 10, "end": 12}, {"entity_id": "4014301_4_Ent0", "role": "Subject", "text": "a patient without underlying heart disease", "start": 13, "end": 19}]}], "entity_mentions": [{"id": "4014301_4_Ent2", "text": "insulin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "4014301_4_Ent3", "text": "insulin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "4014301_4_Ent1", "text": "cardiac failure", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "4014301_4_Ent0", "text": "a patient without underlying heart disease", "entity_type": "Entity", "start": 13, "end": 19}], "lang": "en"}
{"doc_id": "4036917_3", "wnd_id": "4036917_3_1", "text": "These findings support previous studies that showed that the use of aspirin during the antecedent illness may be a risk factor for the development of RS .", "tokens": ["These", "findings", "support", "previous", "studies", "that", "showed", "that", "the", "use", "of", "aspirin", "during", "the", "antecedent", "illness", "may", "be", "a", "risk", "factor", "for", "the", "development", "of", "RS", "."], "event_mentions": [{"id": "4036917_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 23, "end": 24}, "arguments": [{"entity_id": "4036917_3_Ent1", "role": "Treatment", "text": "aspirin", "start": 11, "end": 12}, {"entity_id": "4036917_3_Ent3", "role": "Treatment_Drug", "text": "aspirin", "start": 11, "end": 12}, {"entity_id": "4036917_3_Ent2", "role": "Treatment_Disorder", "text": "the antecedent illness", "start": 13, "end": 16}, {"entity_id": "4036917_3_Ent0", "role": "Effect", "text": "RS", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "4036917_3_Ent1", "text": "aspirin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "4036917_3_Ent3", "text": "aspirin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "4036917_3_Ent2", "text": "the antecedent illness", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "4036917_3_Ent0", "text": "RS", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "4038927_1", "wnd_id": "4038927_1_1", "text": "Atrial fibrillation was induced by diltiazem in two patients and verapamil induced syncope in one patient .", "tokens": ["Atrial", "fibrillation", "was", "induced", "by", "diltiazem", "in", "two", "patients", "and", "verapamil", "induced", "syncope", "in", "one", "patient", "."], "event_mentions": [{"id": "4038927_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "4038927_1_Ent2", "role": "Effect", "text": "Atrial fibrillation", "start": 0, "end": 2}, {"entity_id": "4038927_1_Ent3", "role": "Treatment", "text": "diltiazem", "start": 5, "end": 6}, {"entity_id": "4038927_1_Ent4", "role": "Treatment_Drug", "text": "diltiazem", "start": 5, "end": 6}, {"entity_id": "4038927_1_Ent1", "role": "Subject_Population", "text": "two", "start": 7, "end": 8}, {"entity_id": "4038927_1_Ent0", "role": "Subject", "text": "two patients", "start": 7, "end": 9}]}, {"id": "4038927_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 11, "end": 12}, "arguments": [{"entity_id": "4038927_1_Ent8", "role": "Treatment", "text": "verapamil", "start": 10, "end": 11}, {"entity_id": "4038927_1_Ent9", "role": "Treatment_Drug", "text": "verapamil", "start": 10, "end": 11}, {"entity_id": "4038927_1_Ent7", "role": "Effect", "text": "syncope", "start": 12, "end": 13}, {"entity_id": "4038927_1_Ent6", "role": "Subject_Population", "text": "one", "start": 14, "end": 15}, {"entity_id": "4038927_1_Ent5", "role": "Subject", "text": "one patient", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "4038927_1_Ent2", "text": "Atrial fibrillation", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "4038927_1_Ent3", "text": "diltiazem", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "4038927_1_Ent4", "text": "diltiazem", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "4038927_1_Ent1", "text": "two", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "4038927_1_Ent0", "text": "two patients", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "4038927_1_Ent8", "text": "verapamil", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "4038927_1_Ent9", "text": "verapamil", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "4038927_1_Ent7", "text": "syncope", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "4038927_1_Ent6", "text": "one", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "4038927_1_Ent5", "text": "one patient", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "4051280_2", "wnd_id": "4051280_2_1", "text": "Propranolol - induced hypertension in treatment of cocaine intoxication .", "tokens": ["Propranolol", "-", "induced", "hypertension", "in", "treatment", "of", "cocaine", "intoxication", "."], "event_mentions": [{"id": "4051280_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "4051280_2_Ent1", "role": "Treatment", "text": "Propranolol", "start": 0, "end": 1}, {"entity_id": "4051280_2_Ent2", "role": "Treatment_Drug", "text": "Propranolol", "start": 0, "end": 1}, {"entity_id": "4051280_2_Ent0", "role": "Effect", "text": "hypertension", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "4051280_2_Ent1", "text": "Propranolol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "4051280_2_Ent2", "text": "Propranolol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "4051280_2_Ent0", "text": "hypertension", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "4066620_3", "wnd_id": "4066620_3_1", "text": "The elicitation of a movement disorder by trazodone : case report .", "tokens": ["The", "elicitation", "of", "a", "movement", "disorder", "by", "trazodone", ":", "case", "report", "."], "event_mentions": [{"id": "4066620_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "by", "start": 6, "end": 7}, "arguments": [{"entity_id": "4066620_3_Ent0", "role": "Effect", "text": "movement disorder", "start": 4, "end": 6}, {"entity_id": "4066620_3_Ent1", "role": "Treatment", "text": "trazodone", "start": 7, "end": 8}, {"entity_id": "4066620_3_Ent2", "role": "Treatment_Drug", "text": "trazodone", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "4066620_3_Ent0", "text": "movement disorder", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "4066620_3_Ent1", "text": "trazodone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "4066620_3_Ent2", "text": "trazodone", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "4082283_1", "wnd_id": "4082283_1_1", "text": "Rifampicin - induced renal failure .", "tokens": ["Rifampicin", "-", "induced", "renal", "failure", "."], "event_mentions": [{"id": "4082283_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "4082283_1_Ent1", "role": "Treatment", "text": "Rifampicin", "start": 0, "end": 1}, {"entity_id": "4082283_1_Ent2", "role": "Treatment_Drug", "text": "Rifampicin", "start": 0, "end": 1}, {"entity_id": "4082283_1_Ent0", "role": "Effect", "text": "renal failure", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "4082283_1_Ent1", "text": "Rifampicin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "4082283_1_Ent2", "text": "Rifampicin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "4082283_1_Ent0", "text": "renal failure", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "426502_2", "wnd_id": "426502_2_1", "text": "Inappropriate antidiuretic hormone following adenine arabinoside administration .", "tokens": ["Inappropriate", "antidiuretic", "hormone", "following", "adenine", "arabinoside", "administration", "."], "event_mentions": [{"id": "426502_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "426502_2_Ent0", "role": "Effect", "text": "Inappropriate antidiuretic hormone", "start": 0, "end": 3}, {"entity_id": "426502_2_Ent1", "role": "Treatment", "text": "adenine arabinoside", "start": 4, "end": 6}, {"entity_id": "426502_2_Ent2", "role": "Treatment_Drug", "text": "adenine arabinoside", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "426502_2_Ent0", "text": "Inappropriate antidiuretic hormone", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "426502_2_Ent1", "text": "adenine arabinoside", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "426502_2_Ent2", "text": "adenine arabinoside", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "440873_2", "wnd_id": "440873_2_1", "text": "In one child , a second course of carbamazepine resulted in a return of the dystonia .", "tokens": ["In", "one", "child", ",", "a", "second", "course", "of", "carbamazepine", "resulted", "in", "a", "return", "of", "the", "dystonia", "."], "event_mentions": [{"id": "440873_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 9, "end": 10}, "arguments": [{"entity_id": "440873_2_Ent1", "role": "Subject_Population", "text": "one", "start": 1, "end": 2}, {"entity_id": "440873_2_Ent0", "role": "Subject", "text": "one child", "start": 1, "end": 3}, {"entity_id": "440873_2_Ent2", "role": "Subject_Age", "text": "child", "start": 2, "end": 3}, {"entity_id": "440873_2_Ent4", "role": "Treatment", "text": "a second course of carbamazepine", "start": 4, "end": 9}, {"entity_id": "440873_2_Ent5", "role": "Treatment_Duration", "text": "second course", "start": 5, "end": 7}, {"entity_id": "440873_2_Ent6", "role": "Treatment_Drug", "text": "carbamazepine", "start": 8, "end": 9}, {"entity_id": "440873_2_Ent3", "role": "Effect", "text": "a return of the dystonia", "start": 11, "end": 16}]}], "entity_mentions": [{"id": "440873_2_Ent1", "text": "one", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "440873_2_Ent0", "text": "one child", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "440873_2_Ent2", "text": "child", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "440873_2_Ent4", "text": "a second course of carbamazepine", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "440873_2_Ent5", "text": "second course", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "440873_2_Ent6", "text": "carbamazepine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "440873_2_Ent3", "text": "a return of the dystonia", "entity_type": "Entity", "start": 11, "end": 16}], "lang": "en"}
{"doc_id": "448845_2", "wnd_id": "448845_2_1", "text": "Carbonic anhydrase inhibitors used in the treatment of glaucoma , seizure disorders , and hypertension are rarely associated with blood dyscrasias .", "tokens": ["Carbonic", "anhydrase", "inhibitors", "used", "in", "the", "treatment", "of", "glaucoma", ",", "seizure", "disorders", ",", "and", "hypertension", "are", "rarely", "associated", "with", "blood", "dyscrasias", "."], "event_mentions": [{"id": "448845_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "rarely associated", "start": 16, "end": 18}, "arguments": [{"entity_id": "448845_2_Ent1", "role": "Treatment", "text": "Carbonic anhydrase inhibitors", "start": 0, "end": 3}, {"entity_id": "448845_2_Ent2", "role": "Treatment_Drug", "text": "Carbonic anhydrase inhibitors", "start": 0, "end": 3}, {"entity_id": "448845_2_Ent3", "role": "Treatment_Disorder", "text": "glaucoma , seizure disorders , and hypertension", "start": 8, "end": 15}, {"entity_id": "448845_2_Ent0", "role": "Effect", "text": "blood dyscrasias", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "448845_2_Ent1", "text": "Carbonic anhydrase inhibitors", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "448845_2_Ent2", "text": "Carbonic anhydrase inhibitors", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "448845_2_Ent3", "text": "glaucoma , seizure disorders , and hypertension", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "448845_2_Ent0", "text": "blood dyscrasias", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "536470_2", "wnd_id": "536470_2_1", "text": "While sulindac failed to affect significantly warfarin - induced hypoprothrombinemia in normal male volunteers , it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin .", "tokens": ["While", "sulindac", "failed", "to", "affect", "significantly", "warfarin", "-", "induced", "hypoprothrombinemia", "in", "normal", "male", "volunteers", ",", "it", "markedly", "prolonged", "prothrombin", "time", "in", "a", "patient", "with", "a", "renal", "tubular", "defect", "who", "had", "been", "anticoagulated", "with", "warfarin", "."], "event_mentions": [{"id": "536470_2_Evt2", "event_type": "Adverse_event", "trigger": {"text": "affect", "start": 4, "end": 5}, "arguments": [{"entity_id": "536470_2_Ent15", "role": "Treatment", "text": "sulindac", "start": 1, "end": 2}, {"entity_id": "536470_2_Ent16", "role": "Treatment_Drug", "text": "sulindac", "start": 1, "end": 2}, {"entity_id": "536470_2_Ent14", "role": "Effect", "text": "affect significantly warfarin - induced hypoprothrombinemia", "start": 4, "end": 10}, {"entity_id": "536470_2_Ent12", "role": "Subject", "text": "normal male volunteers", "start": 11, "end": 14}, {"entity_id": "536470_2_Ent13", "role": "Subject_Gender", "text": "male", "start": 12, "end": 13}]}, {"id": "536470_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "536470_2_Ent10", "role": "Treatment", "text": "warfarin", "start": 6, "end": 7}, {"entity_id": "536470_2_Ent11", "role": "Treatment_Drug", "text": "warfarin", "start": 6, "end": 7}, {"entity_id": "536470_2_Ent9", "role": "Effect", "text": "hypoprothrombinemia", "start": 9, "end": 10}]}, {"id": "536470_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 20, "end": 21}, "arguments": [{"entity_id": "536470_2_Ent3", "role": "Treatment", "text": "sulindac", "start": 1, "end": 2}, {"entity_id": "536470_2_Ent5", "role": "Treatment_Drug", "text": "sulindac", "start": 1, "end": 2}, {"entity_id": "536470_2_Ent8", "role": "Combination_Drug", "text": "sulindac", "start": 1, "end": 2}, {"entity_id": "536470_2_Ent2", "role": "Effect", "text": "markedly prolonged prothrombin time", "start": 16, "end": 20}, {"entity_id": "536470_2_Ent0", "role": "Subject", "text": "a patient with a renal tubular defect", "start": 21, "end": 28}, {"entity_id": "536470_2_Ent1", "role": "Subject_Disorder", "text": "renal tubular defect", "start": 25, "end": 28}, {"entity_id": "536470_2_Ent4", "role": "Treatment", "text": "had been anticoagulated with warfarin", "start": 29, "end": 34}, {"entity_id": "536470_2_Ent6", "role": "Treatment_Drug", "text": "warfarin", "start": 33, "end": 34}, {"entity_id": "536470_2_Ent7", "role": "Combination_Drug", "text": "warfarin", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "536470_2_Ent3", "text": "sulindac", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "536470_2_Ent5", "text": "sulindac", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "536470_2_Ent8", "text": "sulindac", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "536470_2_Ent15", "text": "sulindac", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "536470_2_Ent16", "text": "sulindac", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "536470_2_Ent14", "text": "affect significantly warfarin - induced hypoprothrombinemia", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "536470_2_Ent10", "text": "warfarin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "536470_2_Ent11", "text": "warfarin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "536470_2_Ent9", "text": "hypoprothrombinemia", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "536470_2_Ent12", "text": "normal male volunteers", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "536470_2_Ent13", "text": "male", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "536470_2_Ent2", "text": "markedly prolonged prothrombin time", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "536470_2_Ent0", "text": "a patient with a renal tubular defect", "entity_type": "Entity", "start": 21, "end": 28}, {"id": "536470_2_Ent1", "text": "renal tubular defect", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "536470_2_Ent4", "text": "had been anticoagulated with warfarin", "entity_type": "Entity", "start": 29, "end": 34}, {"id": "536470_2_Ent6", "text": "warfarin", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "536470_2_Ent7", "text": "warfarin", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "6093724_1", "wnd_id": "6093724_1_1", "text": "A healthy , 30 - year - old man , exposed to sulindac on two separate occasions , had an incapacitating isolated idential sensory neuropathy .", "tokens": ["A", "healthy", ",", "30", "-", "year", "-", "old", "man", ",", "exposed", "to", "sulindac", "on", "two", "separate", "occasions", ",", "had", "an", "incapacitating", "isolated", "idential", "sensory", "neuropathy", "."], "event_mentions": [{"id": "6093724_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exposed", "start": 10, "end": 11}, "arguments": [{"entity_id": "6093724_1_Ent0", "role": "Subject", "text": "A healthy , 30 - year - old man", "start": 0, "end": 9}, {"entity_id": "6093724_1_Ent1", "role": "Subject_Age", "text": "30 - year - old", "start": 3, "end": 8}, {"entity_id": "6093724_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 8, "end": 9}, {"entity_id": "6093724_1_Ent4", "role": "Treatment", "text": "sulindac", "start": 12, "end": 13}, {"entity_id": "6093724_1_Ent5", "role": "Treatment_Drug", "text": "sulindac", "start": 12, "end": 13}, {"entity_id": "6093724_1_Ent3", "role": "Effect", "text": "incapacitating isolated idential sensory neuropathy", "start": 20, "end": 25}]}], "entity_mentions": [{"id": "6093724_1_Ent0", "text": "A healthy , 30 - year - old man", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "6093724_1_Ent1", "text": "30 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "6093724_1_Ent2", "text": "man", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6093724_1_Ent4", "text": "sulindac", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "6093724_1_Ent5", "text": "sulindac", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "6093724_1_Ent3", "text": "incapacitating isolated idential sensory neuropathy", "entity_type": "Entity", "start": 20, "end": 25}], "lang": "en"}
{"doc_id": "6149250_4", "wnd_id": "6149250_4_1", "text": "The second patient suffered from high blood pressure , which was controlled with beta - blocker drugs .", "tokens": ["The", "second", "patient", "suffered", "from", "high", "blood", "pressure", ",", "which", "was", "controlled", "with", "beta", "-", "blocker", "drugs", "."], "event_mentions": [{"id": "6149250_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "controlled", "start": 11, "end": 12}, "arguments": [{"entity_id": "6149250_4_Ent0", "role": "Subject", "text": "The second patient suffered from high blood pressure", "start": 0, "end": 8}, {"entity_id": "6149250_4_Ent2", "role": "Treatment_Disorder", "text": "high blood pressure", "start": 5, "end": 8}, {"entity_id": "6149250_4_Ent1", "role": "Treatment", "text": "beta - blocker drugs", "start": 13, "end": 17}, {"entity_id": "6149250_4_Ent3", "role": "Treatment_Drug", "text": "beta - blocker drugs", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "6149250_4_Ent0", "text": "The second patient suffered from high blood pressure", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "6149250_4_Ent2", "text": "high blood pressure", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "6149250_4_Ent1", "text": "beta - blocker drugs", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "6149250_4_Ent3", "text": "beta - blocker drugs", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "6149250_5", "wnd_id": "6149250_5_1", "text": "Both patients developed severe complications when treated with aminoglutethimide as a cancer hormonal therapy .", "tokens": ["Both", "patients", "developed", "severe", "complications", "when", "treated", "with", "aminoglutethimide", "as", "a", "cancer", "hormonal", "therapy", "."], "event_mentions": [{"id": "6149250_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "6149250_5_Ent0", "role": "Subject", "text": "Both patients", "start": 0, "end": 2}, {"entity_id": "6149250_5_Ent1", "role": "Effect", "text": "severe complications", "start": 3, "end": 5}, {"entity_id": "6149250_5_Ent2", "role": "Treatment", "text": "aminoglutethimide", "start": 8, "end": 9}, {"entity_id": "6149250_5_Ent4", "role": "Treatment_Drug", "text": "aminoglutethimide", "start": 8, "end": 9}, {"entity_id": "6149250_5_Ent3", "role": "Treatment_Disorder", "text": "cancer", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "6149250_5_Ent0", "text": "Both patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6149250_5_Ent1", "text": "severe complications", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "6149250_5_Ent2", "text": "aminoglutethimide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6149250_5_Ent4", "text": "aminoglutethimide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6149250_5_Ent3", "text": "cancer", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "6159523_1", "wnd_id": "6159523_1_1", "text": "Anaphylactoid reaction to 50 % solution of dextrose .", "tokens": ["Anaphylactoid", "reaction", "to", "50", "%", "solution", "of", "dextrose", "."], "event_mentions": [{"id": "6159523_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 2, "end": 3}, "arguments": [{"entity_id": "6159523_1_Ent0", "role": "Effect", "text": "Anaphylactoid reaction", "start": 0, "end": 2}, {"entity_id": "6159523_1_Ent1", "role": "Treatment", "text": "50 % solution of dextrose", "start": 3, "end": 8}, {"entity_id": "6159523_1_Ent2", "role": "Treatment_Drug", "text": "dextrose", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "6159523_1_Ent0", "text": "Anaphylactoid reaction", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6159523_1_Ent1", "text": "50 % solution of dextrose", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "6159523_1_Ent2", "text": "dextrose", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "6159523_3", "wnd_id": "6159523_3_1", "text": "Investigations suggested that the dextrose , rather than any additives , was responsible for the reaction .", "tokens": ["Investigations", "suggested", "that", "the", "dextrose", ",", "rather", "than", "any", "additives", ",", "was", "responsible", "for", "the", "reaction", "."], "event_mentions": [{"id": "6159523_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "responsible", "start": 12, "end": 13}, "arguments": [{"entity_id": "6159523_3_Ent1", "role": "Treatment", "text": "dextrose", "start": 4, "end": 5}, {"entity_id": "6159523_3_Ent2", "role": "Treatment_Drug", "text": "dextrose", "start": 4, "end": 5}, {"entity_id": "6159523_3_Ent0", "role": "Effect", "text": "the reaction", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "6159523_3_Ent1", "text": "dextrose", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6159523_3_Ent2", "text": "dextrose", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6159523_3_Ent0", "text": "the reaction", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "6159523_6", "wnd_id": "6159523_6_1", "text": "We suggest that the treatment of hypoglycaemia with 50 % solution of dextrose is associated with a significant risk factor in those diabetic individuals who are either allergic or are receiving beta - adrenoreceptor blocking drugs .", "tokens": ["We", "suggest", "that", "the", "treatment", "of", "hypoglycaemia", "with", "50", "%", "solution", "of", "dextrose", "is", "associated", "with", "a", "significant", "risk", "factor", "in", "those", "diabetic", "individuals", "who", "are", "either", "allergic", "or", "are", "receiving", "beta", "-", "adrenoreceptor", "blocking", "drugs", "."], "event_mentions": [{"id": "6159523_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 14, "end": 15}, "arguments": [{"entity_id": "6159523_6_Ent4", "role": "Treatment_Disorder", "text": "hypoglycaemia", "start": 6, "end": 7}, {"entity_id": "6159523_6_Ent6", "role": "Treatment_Route", "text": "50 % solution", "start": 8, "end": 11}, {"entity_id": "6159523_6_Ent3", "role": "Treatment", "text": "50 % solution of dextrose", "start": 8, "end": 13}, {"entity_id": "6159523_6_Ent5", "role": "Treatment_Drug", "text": "dextrose", "start": 12, "end": 13}, {"entity_id": "6159523_6_Ent2", "role": "Effect", "text": "a significant risk factor", "start": 16, "end": 20}, {"entity_id": "6159523_6_Ent1", "role": "Subject_Disorder", "text": "diabetic", "start": 22, "end": 23}, {"entity_id": "6159523_6_Ent0", "role": "Subject", "text": "diabetic individuals who are either allergic or are receiving beta - adrenoreceptor blocking drugs", "start": 22, "end": 36}]}], "entity_mentions": [{"id": "6159523_6_Ent4", "text": "hypoglycaemia", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6159523_6_Ent6", "text": "50 % solution", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "6159523_6_Ent3", "text": "50 % solution of dextrose", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "6159523_6_Ent5", "text": "dextrose", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "6159523_6_Ent2", "text": "a significant risk factor", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "6159523_6_Ent1", "text": "diabetic", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "6159523_6_Ent0", "text": "diabetic individuals who are either allergic or are receiving beta - adrenoreceptor blocking drugs", "entity_type": "Entity", "start": 22, "end": 36}], "lang": "en"}
{"doc_id": "6233326_1", "wnd_id": "6233326_1_1", "text": "Optic neuropathy associated with penicillamine therapy in a patient with rheumatoid arthritis .", "tokens": ["Optic", "neuropathy", "associated", "with", "penicillamine", "therapy", "in", "a", "patient", "with", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "6233326_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "6233326_1_Ent1", "role": "Effect", "text": "Optic neuropathy", "start": 0, "end": 2}, {"entity_id": "6233326_1_Ent2", "role": "Treatment", "text": "penicillamine", "start": 4, "end": 5}, {"entity_id": "6233326_1_Ent4", "role": "Treatment_Drug", "text": "penicillamine", "start": 4, "end": 5}, {"entity_id": "6233326_1_Ent0", "role": "Subject", "text": "a patient with rheumatoid arthritis", "start": 7, "end": 12}, {"entity_id": "6233326_1_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "6233326_1_Ent1", "text": "Optic neuropathy", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6233326_1_Ent2", "text": "penicillamine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6233326_1_Ent4", "text": "penicillamine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6233326_1_Ent0", "text": "a patient with rheumatoid arthritis", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "6233326_1_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "6233326_3", "wnd_id": "6233326_3_1", "text": "The case resembles two previously reported cases of optic neuropathy which occurred in patients with Wilson 's disease who were receiving penicillamine .", "tokens": ["The", "case", "resembles", "two", "previously", "reported", "cases", "of", "optic", "neuropathy", "which", "occurred", "in", "patients", "with", "Wilson", "'s", "disease", "who", "were", "receiving", "penicillamine", "."], "event_mentions": [{"id": "6233326_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 11, "end": 12}, "arguments": [{"entity_id": "6233326_3_Ent1", "role": "Effect", "text": "optic neuropathy", "start": 8, "end": 10}, {"entity_id": "6233326_3_Ent0", "role": "Subject", "text": "patients with Wilson 's disease", "start": 13, "end": 18}, {"entity_id": "6233326_3_Ent4", "role": "Treatment_Disorder", "text": "Wilson 's disease", "start": 15, "end": 18}, {"entity_id": "6233326_3_Ent2", "role": "Treatment", "text": "penicillamine", "start": 21, "end": 22}, {"entity_id": "6233326_3_Ent3", "role": "Treatment_Drug", "text": "penicillamine", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "6233326_3_Ent1", "text": "optic neuropathy", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "6233326_3_Ent0", "text": "patients with Wilson 's disease", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "6233326_3_Ent4", "text": "Wilson 's disease", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "6233326_3_Ent2", "text": "penicillamine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "6233326_3_Ent3", "text": "penicillamine", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "6236730_1", "wnd_id": "6236730_1_1", "text": "A patient developed transient , acute myopia while on isotretinoin ( Accutane ) therapy for acne .", "tokens": ["A", "patient", "developed", "transient", ",", "acute", "myopia", "while", "on", "isotretinoin", "(", "Accutane", ")", "therapy", "for", "acne", "."], "event_mentions": [{"id": "6236730_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "6236730_1_Ent1", "role": "Subject", "text": "A patient", "start": 0, "end": 2}, {"entity_id": "6236730_1_Ent2", "role": "Effect", "text": "transient , acute myopia", "start": 3, "end": 7}, {"entity_id": "6236730_1_Ent5", "role": "Treatment_Drug", "text": "isotretinoin", "start": 9, "end": 10}, {"entity_id": "6236730_1_Ent3", "role": "Treatment", "text": "isotretinoin ( Accutane )", "start": 9, "end": 13}, {"entity_id": "6236730_1_Ent0", "role": "Subject", "text": "acne", "start": 15, "end": 16}, {"entity_id": "6236730_1_Ent4", "role": "Treatment_Disorder", "text": "acne", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "6236730_1_Ent1", "text": "A patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6236730_1_Ent2", "text": "transient , acute myopia", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "6236730_1_Ent5", "text": "isotretinoin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "6236730_1_Ent3", "text": "isotretinoin ( Accutane )", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "6236730_1_Ent0", "text": "acne", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "6236730_1_Ent4", "text": "acne", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "6239881_1", "wnd_id": "6239881_1_1", "text": "Allergic contact dermatitis to compound tincture of benzoin .", "tokens": ["Allergic", "contact", "dermatitis", "to", "compound", "tincture", "of", "benzoin", "."], "event_mentions": [{"id": "6239881_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 3, "end": 4}, "arguments": [{"entity_id": "6239881_1_Ent0", "role": "Effect", "text": "Allergic contact dermatitis", "start": 0, "end": 3}, {"entity_id": "6239881_1_Ent1", "role": "Treatment", "text": "compound tincture of benzoin", "start": 4, "end": 8}, {"entity_id": "6239881_1_Ent2", "role": "Treatment_Drug", "text": "benzoin", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "6239881_1_Ent0", "text": "Allergic contact dermatitis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "6239881_1_Ent1", "text": "compound tincture of benzoin", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "6239881_1_Ent2", "text": "benzoin", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "6239881_2", "wnd_id": "6239881_2_1", "text": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described .", "tokens": ["Nineteen", "cases", "of", "allergic", "contact", "dermatitis", "to", "compound", "tincture", "of", "benzoin", "are", "described", "."], "event_mentions": [{"id": "6239881_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "described", "start": 12, "end": 13}, "arguments": [{"entity_id": "6239881_2_Ent1", "role": "Subject_Population", "text": "Nineteen", "start": 0, "end": 1}, {"entity_id": "6239881_2_Ent0", "role": "Subject", "text": "Nineteen cases", "start": 0, "end": 2}, {"entity_id": "6239881_2_Ent2", "role": "Effect", "text": "allergic contact dermatitis", "start": 3, "end": 6}, {"entity_id": "6239881_2_Ent3", "role": "Treatment", "text": "compound tincture of benzoin", "start": 7, "end": 11}, {"entity_id": "6239881_2_Ent4", "role": "Treatment_Drug", "text": "benzoin", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "6239881_2_Ent1", "text": "Nineteen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6239881_2_Ent0", "text": "Nineteen cases", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6239881_2_Ent2", "text": "allergic contact dermatitis", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "6239881_2_Ent3", "text": "compound tincture of benzoin", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "6239881_2_Ent4", "text": "benzoin", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "6245286_2", "wnd_id": "6245286_2_1", "text": "In three of these patients the infection was clinically unsuspected ; in the fourth , cutaneous herpes zoster developed after administration of 300 mg of cytarabine daily for the preceding five days .", "tokens": ["In", "three", "of", "these", "patients", "the", "infection", "was", "clinically", "unsuspected", ";", "in", "the", "fourth", ",", "cutaneous", "herpes", "zoster", "developed", "after", "administration", "of", "300", "mg", "of", "cytarabine", "daily", "for", "the", "preceding", "five", "days", "."], "event_mentions": [{"id": "6245286_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 18, "end": 19}, "arguments": [{"entity_id": "6245286_2_Ent1", "role": "Subject_Population", "text": "three", "start": 1, "end": 2}, {"entity_id": "6245286_2_Ent0", "role": "Subject", "text": "three of these patients", "start": 1, "end": 5}, {"entity_id": "6245286_2_Ent2", "role": "Effect", "text": "cutaneous herpes zoster", "start": 15, "end": 18}, {"entity_id": "6245286_2_Ent4", "role": "Treatment_Dosage", "text": "300 mg", "start": 22, "end": 24}, {"entity_id": "6245286_2_Ent3", "role": "Treatment", "text": "300 mg of cytarabine daily for the preceding five days", "start": 22, "end": 32}, {"entity_id": "6245286_2_Ent5", "role": "Treatment_Drug", "text": "cytarabine", "start": 25, "end": 26}, {"entity_id": "6245286_2_Ent6", "role": "Treatment_Freq", "text": "daily", "start": 26, "end": 27}, {"entity_id": "6245286_2_Ent7", "role": "Treatment_Duration", "text": "preceding five days", "start": 29, "end": 32}]}], "entity_mentions": [{"id": "6245286_2_Ent1", "text": "three", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "6245286_2_Ent0", "text": "three of these patients", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "6245286_2_Ent2", "text": "cutaneous herpes zoster", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "6245286_2_Ent4", "text": "300 mg", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "6245286_2_Ent3", "text": "300 mg of cytarabine daily for the preceding five days", "entity_type": "Entity", "start": 22, "end": 32}, {"id": "6245286_2_Ent5", "text": "cytarabine", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "6245286_2_Ent6", "text": "daily", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "6245286_2_Ent7", "text": "preceding five days", "entity_type": "Entity", "start": 29, "end": 32}], "lang": "en"}
{"doc_id": "6245286_3", "wnd_id": "6245286_3_1", "text": "Visceral herpesvirus infections in leukemic patients receiving cytarabine .", "tokens": ["Visceral", "herpesvirus", "infections", "in", "leukemic", "patients", "receiving", "cytarabine", "."], "event_mentions": [{"id": "6245286_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 3, "end": 4}, "arguments": [{"entity_id": "6245286_3_Ent1", "role": "Effect", "text": "Visceral herpesvirus infections", "start": 0, "end": 3}, {"entity_id": "6245286_3_Ent4", "role": "Treatment_Disorder", "text": "leukemic", "start": 4, "end": 5}, {"entity_id": "6245286_3_Ent0", "role": "Subject", "text": "leukemic patients", "start": 4, "end": 6}, {"entity_id": "6245286_3_Ent2", "role": "Treatment", "text": "cytarabine", "start": 7, "end": 8}, {"entity_id": "6245286_3_Ent3", "role": "Treatment_Drug", "text": "cytarabine .", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "6245286_3_Ent1", "text": "Visceral herpesvirus infections", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "6245286_3_Ent4", "text": "leukemic", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6245286_3_Ent0", "text": "leukemic patients", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "6245286_3_Ent2", "text": "cytarabine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6245286_3_Ent3", "text": "cytarabine .", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "6311654_3", "wnd_id": "6311654_3_1", "text": "In six cases CT scans did not return to their original state after ACTH therapy .", "tokens": ["In", "six", "cases", "CT", "scans", "did", "not", "return", "to", "their", "original", "state", "after", "ACTH", "therapy", "."], "event_mentions": [{"id": "6311654_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 12, "end": 13}, "arguments": [{"entity_id": "6311654_3_Ent1", "role": "Subject_Population", "text": "six", "start": 1, "end": 2}, {"entity_id": "6311654_3_Ent0", "role": "Subject", "text": "six cases", "start": 1, "end": 3}, {"entity_id": "6311654_3_Ent2", "role": "Effect", "text": "CT scans did not return to their original state", "start": 3, "end": 12}, {"entity_id": "6311654_3_Ent3", "role": "Treatment", "text": "ACTH", "start": 13, "end": 14}, {"entity_id": "6311654_3_Ent4", "role": "Treatment_Drug", "text": "ACTH", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "6311654_3_Ent1", "text": "six", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "6311654_3_Ent0", "text": "six cases", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "6311654_3_Ent2", "text": "CT scans did not return to their original state", "entity_type": "Entity", "start": 3, "end": 12}, {"id": "6311654_3_Ent3", "text": "ACTH", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "6311654_3_Ent4", "text": "ACTH", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "6311654_5", "wnd_id": "6311654_5_1", "text": "There was a good correlation between the total dose of ACTH and the percentage decrease of brain parenchyma .", "tokens": ["There", "was", "a", "good", "correlation", "between", "the", "total", "dose", "of", "ACTH", "and", "the", "percentage", "decrease", "of", "brain", "parenchyma", "."], "event_mentions": [{"id": "6311654_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "correlation", "start": 4, "end": 5}, "arguments": [{"entity_id": "6311654_5_Ent1", "role": "Treatment", "text": "total dose of ACTH", "start": 7, "end": 11}, {"entity_id": "6311654_5_Ent2", "role": "Treatment_Drug", "text": "ACTH", "start": 10, "end": 11}, {"entity_id": "6311654_5_Ent0", "role": "Effect", "text": "percentage decrease of brain parenchyma", "start": 13, "end": 18}]}], "entity_mentions": [{"id": "6311654_5_Ent1", "text": "total dose of ACTH", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "6311654_5_Ent2", "text": "ACTH", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "6311654_5_Ent0", "text": "percentage decrease of brain parenchyma", "entity_type": "Entity", "start": 13, "end": 18}], "lang": "en"}
{"doc_id": "6324592_1", "wnd_id": "6324592_1_1", "text": "Disulfiram - like reactions with newer cephalosporins : cefmenoxime .", "tokens": ["Disulfiram", "-", "like", "reactions", "with", "newer", "cephalosporins", ":", "cefmenoxime", "."], "event_mentions": [{"id": "6324592_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 4, "end": 5}, "arguments": [{"entity_id": "6324592_1_Ent0", "role": "Effect", "text": "Disulfiram - like reactions", "start": 0, "end": 4}, {"entity_id": "6324592_1_Ent1", "role": "Treatment", "text": "cefmenoxime", "start": 8, "end": 9}, {"entity_id": "6324592_1_Ent2", "role": "Treatment_Drug", "text": "cefmenoxime", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "6324592_1_Ent0", "text": "Disulfiram - like reactions", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "6324592_1_Ent1", "text": "cefmenoxime", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6324592_1_Ent2", "text": "cefmenoxime", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "6329575_1", "wnd_id": "6329575_1_1", "text": "k bipolar manic - depressive patient , developed while on lithium prophylaxis , akathisia at therapeutic serum lithium levels and subsequently bucco - linguo - masticatory dyskinesia .", "tokens": ["k", "bipolar", "manic", "-", "depressive", "patient", ",", "developed", "while", "on", "lithium", "prophylaxis", ",", "akathisia", "at", "therapeutic", "serum", "lithium", "levels", "and", "subsequently", "bucco", "-", "linguo", "-", "masticatory", "dyskinesia", "."], "event_mentions": [{"id": "6329575_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "6329575_1_Ent5", "role": "Treatment_Disorder", "text": "k bipolar manic - depressive", "start": 0, "end": 5}, {"entity_id": "6329575_1_Ent0", "role": "Subject", "text": "k bipolar manic - depressive patient", "start": 0, "end": 6}, {"entity_id": "6329575_1_Ent3", "role": "Treatment", "text": "lithium", "start": 10, "end": 11}, {"entity_id": "6329575_1_Ent6", "role": "Treatment_Drug", "text": "lithium", "start": 10, "end": 11}, {"entity_id": "6329575_1_Ent2", "role": "Effect", "text": "akathisia", "start": 13, "end": 14}, {"entity_id": "6329575_1_Ent4", "role": "Treatment", "text": "at therapeutic serum lithium levels", "start": 14, "end": 19}, {"entity_id": "6329575_1_Ent1", "role": "Effect", "text": "bucco - linguo - masticatory dyskinesia", "start": 21, "end": 27}]}], "entity_mentions": [{"id": "6329575_1_Ent5", "text": "k bipolar manic - depressive", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "6329575_1_Ent0", "text": "k bipolar manic - depressive patient", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "6329575_1_Ent3", "text": "lithium", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "6329575_1_Ent6", "text": "lithium", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "6329575_1_Ent2", "text": "akathisia", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "6329575_1_Ent4", "text": "at therapeutic serum lithium levels", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "6329575_1_Ent1", "text": "bucco - linguo - masticatory dyskinesia", "entity_type": "Entity", "start": 21, "end": 27}], "lang": "en"}
{"doc_id": "6353252_3", "wnd_id": "6353252_3_1", "text": "We report 5 cases of acute reversible renal failure coinciding with the onset of treatment with captopril in patients with severe drug - resistant hypertension .", "tokens": ["We", "report", "5", "cases", "of", "acute", "reversible", "renal", "failure", "coinciding", "with", "the", "onset", "of", "treatment", "with", "captopril", "in", "patients", "with", "severe", "drug", "-", "resistant", "hypertension", "."], "event_mentions": [{"id": "6353252_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "onset of treatment", "start": 12, "end": 15}, "arguments": [{"entity_id": "6353252_3_Ent1", "role": "Effect", "text": "acute reversible renal failure", "start": 5, "end": 9}, {"entity_id": "6353252_3_Ent2", "role": "Treatment", "text": "captopril", "start": 16, "end": 17}, {"entity_id": "6353252_3_Ent3", "role": "Treatment_Drug", "text": "captopril", "start": 16, "end": 17}, {"entity_id": "6353252_3_Ent0", "role": "Subject", "text": "patients with severe drug - resistant hypertension", "start": 18, "end": 25}, {"entity_id": "6353252_3_Ent4", "role": "Treatment_Disorder", "text": "severe drug - resistant hypertension", "start": 20, "end": 25}]}], "entity_mentions": [{"id": "6353252_3_Ent1", "text": "acute reversible renal failure", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "6353252_3_Ent2", "text": "captopril", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "6353252_3_Ent3", "text": "captopril", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "6353252_3_Ent0", "text": "patients with severe drug - resistant hypertension", "entity_type": "Entity", "start": 18, "end": 25}, {"id": "6353252_3_Ent4", "text": "severe drug - resistant hypertension", "entity_type": "Entity", "start": 20, "end": 25}], "lang": "en"}
{"doc_id": "6405633_1", "wnd_id": "6405633_1_1", "text": "Treatment of lithium tremor with metoprolol .", "tokens": ["Treatment", "of", "lithium", "tremor", "with", "metoprolol", "."], "event_mentions": [{"id": "6405633_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Treatment of", "start": 0, "end": 2}, "arguments": [{"entity_id": "6405633_1_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 2, "end": 3}, {"entity_id": "6405633_1_Ent1", "role": "Treatment_Disorder", "text": "lithium tremor", "start": 2, "end": 4}, {"entity_id": "6405633_1_Ent0", "role": "Treatment", "text": "metoprolol", "start": 5, "end": 6}, {"entity_id": "6405633_1_Ent3", "role": "Treatment_Drug", "text": "metoprolol", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "6405633_1_Ent2", "text": "lithium", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "6405633_1_Ent1", "text": "lithium tremor", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "6405633_1_Ent0", "text": "metoprolol", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "6405633_1_Ent3", "text": "metoprolol", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "6405633_2", "wnd_id": "6405633_2_1", "text": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced tremor during lithium carbonate therapy .", "tokens": ["Two", "patients", "with", "bipolar", "affective", "disorder", "and", "a", "history", "of", "bronchospastic", "phenomena", "experienced", "tremor", "during", "lithium", "carbonate", "therapy", "."], "event_mentions": [{"id": "6405633_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 12, "end": 13}, "arguments": [{"entity_id": "6405633_2_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "6405633_2_Ent0", "role": "Subject", "text": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena", "start": 0, "end": 12}, {"entity_id": "6405633_2_Ent6", "role": "Treatment_Disorder", "text": "bipolar affective disorder", "start": 3, "end": 6}, {"entity_id": "6405633_2_Ent2", "role": "Subject_Disorder", "text": "a history of bronchospastic phenomena", "start": 7, "end": 12}, {"entity_id": "6405633_2_Ent3", "role": "Effect", "text": "tremor", "start": 13, "end": 14}, {"entity_id": "6405633_2_Ent5", "role": "Treatment_Drug", "text": "lithium carbonate", "start": 15, "end": 17}, {"entity_id": "6405633_2_Ent4", "role": "Treatment", "text": "lithium carbonate therapy", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "6405633_2_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6405633_2_Ent0", "text": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "6405633_2_Ent6", "text": "bipolar affective disorder", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "6405633_2_Ent2", "text": "a history of bronchospastic phenomena", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "6405633_2_Ent3", "text": "tremor", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "6405633_2_Ent5", "text": "lithium carbonate", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "6405633_2_Ent4", "text": "lithium carbonate therapy", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "6414095_1", "wnd_id": "6414095_1_1", "text": "Transient hemiparesis caused by phenytoin toxicity .", "tokens": ["Transient", "hemiparesis", "caused", "by", "phenytoin", "toxicity", "."], "event_mentions": [{"id": "6414095_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 2, "end": 3}, "arguments": [{"entity_id": "6414095_1_Ent0", "role": "Effect", "text": "Transient hemiparesis", "start": 0, "end": 2}, {"entity_id": "6414095_1_Ent2", "role": "Treatment_Drug", "text": "phenytoin", "start": 4, "end": 5}, {"entity_id": "6414095_1_Ent1", "role": "Treatment", "text": "phenytoin toxicity", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "6414095_1_Ent0", "text": "Transient hemiparesis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6414095_1_Ent2", "text": "phenytoin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6414095_1_Ent1", "text": "phenytoin toxicity", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "6484655_2", "wnd_id": "6484655_2_1", "text": "Ampicillin - associated seizures .", "tokens": ["Ampicillin", "-", "associated", "seizures", "."], "event_mentions": [{"id": "6484655_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "6484655_2_Ent1", "role": "Treatment", "text": "Ampicillin", "start": 0, "end": 1}, {"entity_id": "6484655_2_Ent2", "role": "Treatment_Drug", "text": "Ampicillin", "start": 0, "end": 1}, {"entity_id": "6484655_2_Ent0", "role": "Effect", "text": "seizures", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "6484655_2_Ent1", "text": "Ampicillin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6484655_2_Ent2", "text": "Ampicillin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6484655_2_Ent0", "text": "seizures", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "6498095_2", "wnd_id": "6498095_2_1", "text": "Pemphigus foliaceus induced by rifampicin .", "tokens": ["Pemphigus", "foliaceus", "induced", "by", "rifampicin", "."], "event_mentions": [{"id": "6498095_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "6498095_2_Ent0", "role": "Effect", "text": "Pemphigus foliaceus", "start": 0, "end": 2}, {"entity_id": "6498095_2_Ent1", "role": "Treatment", "text": "rifampicin", "start": 4, "end": 5}, {"entity_id": "6498095_2_Ent2", "role": "Treatment_Drug", "text": "rifampicin", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "6498095_2_Ent0", "text": "Pemphigus foliaceus", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6498095_2_Ent1", "text": "rifampicin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6498095_2_Ent2", "text": "rifampicin", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "6529939_3", "wnd_id": "6529939_3_1", "text": "The abnormal rhythm disappeared with the withdrawal of propranolol and when the drug was restarted a 2/1 S - A block was seen .", "tokens": ["The", "abnormal", "rhythm", "disappeared", "with", "the", "withdrawal", "of", "propranolol", "and", "when", "the", "drug", "was", "restarted", "a", "2/1", "S", "-", "A", "block", "was", "seen", "."], "event_mentions": [{"id": "6529939_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "seen", "start": 22, "end": 23}, "arguments": [{"entity_id": "6529939_3_Ent1", "role": "Treatment", "text": "propranolol", "start": 8, "end": 9}, {"entity_id": "6529939_3_Ent2", "role": "Treatment_Drug", "text": "propranolol", "start": 8, "end": 9}, {"entity_id": "6529939_3_Ent0", "role": "Effect", "text": "2/1 S - A block", "start": 16, "end": 21}]}], "entity_mentions": [{"id": "6529939_3_Ent1", "text": "propranolol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6529939_3_Ent2", "text": "propranolol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6529939_3_Ent0", "text": "2/1 S - A block", "entity_type": "Entity", "start": 16, "end": 21}], "lang": "en"}
{"doc_id": "6529939_4", "wnd_id": "6529939_4_1", "text": "This was accepted as evidence for propranolol being the cause of this conduction disorder .", "tokens": ["This", "was", "accepted", "as", "evidence", "for", "propranolol", "being", "the", "cause", "of", "this", "conduction", "disorder", "."], "event_mentions": [{"id": "6529939_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 9, "end": 10}, "arguments": [{"entity_id": "6529939_4_Ent1", "role": "Treatment", "text": "propranolol", "start": 6, "end": 7}, {"entity_id": "6529939_4_Ent2", "role": "Treatment_Drug", "text": "propranolol", "start": 6, "end": 7}, {"entity_id": "6529939_4_Ent0", "role": "Effect", "text": "conduction disorder", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "6529939_4_Ent1", "text": "propranolol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6529939_4_Ent2", "text": "propranolol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6529939_4_Ent0", "text": "conduction disorder", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "6572542_4", "wnd_id": "6572542_4_1", "text": "Two patients treated for chronic myeloid leukemia with high doses of CCNU ( 1100 mg / m2 and 1240 mg / m2 , respectively ) developed a fatal pulmonary fibrosis .", "tokens": ["Two", "patients", "treated", "for", "chronic", "myeloid", "leukemia", "with", "high", "doses", "of", "CCNU", "(", "1100", "mg", "/", "m2", "and", "1240", "mg", "/", "m2", ",", "respectively", ")", "developed", "a", "fatal", "pulmonary", "fibrosis", "."], "event_mentions": [{"id": "6572542_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 25, "end": 26}, "arguments": [{"entity_id": "6572542_4_Ent2", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "6572542_4_Ent0", "role": "Subject", "text": "Two patients", "start": 0, "end": 2}, {"entity_id": "6572542_4_Ent1", "role": "Subject", "text": "chronic myeloid leukemia", "start": 4, "end": 7}, {"entity_id": "6572542_4_Ent5", "role": "Treatment_Disorder", "text": "chronic myeloid leukemia", "start": 4, "end": 7}, {"entity_id": "6572542_4_Ent6", "role": "Treatment_Drug", "text": "CCNU", "start": 11, "end": 12}, {"entity_id": "6572542_4_Ent4", "role": "Treatment", "text": "CCNU ( 1100 mg / m2 and 1240 mg / m2 , respectively )", "start": 11, "end": 25}, {"entity_id": "6572542_4_Ent7", "role": "Treatment_Dosage", "text": "1100 mg / m2", "start": 13, "end": 17}, {"entity_id": "6572542_4_Ent8", "role": "Treatment_Dosage", "text": "1240 mg / m2", "start": 18, "end": 22}, {"entity_id": "6572542_4_Ent3", "role": "Effect", "text": "pulmonary fibrosis", "start": 28, "end": 30}]}], "entity_mentions": [{"id": "6572542_4_Ent2", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6572542_4_Ent0", "text": "Two patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6572542_4_Ent1", "text": "chronic myeloid leukemia", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "6572542_4_Ent5", "text": "chronic myeloid leukemia", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "6572542_4_Ent6", "text": "CCNU", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "6572542_4_Ent4", "text": "CCNU ( 1100 mg / m2 and 1240 mg / m2 , respectively )", "entity_type": "Entity", "start": 11, "end": 25}, {"id": "6572542_4_Ent7", "text": "1100 mg / m2", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "6572542_4_Ent8", "text": "1240 mg / m2", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "6572542_4_Ent3", "text": "pulmonary fibrosis", "entity_type": "Entity", "start": 28, "end": 30}], "lang": "en"}
{"doc_id": "6610943_1", "wnd_id": "6610943_1_1", "text": "Myoglobinuria and acute renal failure associated with intravenous vasopressin infusion .", "tokens": ["Myoglobinuria", "and", "acute", "renal", "failure", "associated", "with", "intravenous", "vasopressin", "infusion", "."], "event_mentions": [{"id": "6610943_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "6610943_1_Ent0", "role": "Effect", "text": "Myoglobinuria and acute renal failure", "start": 0, "end": 5}, {"entity_id": "6610943_1_Ent2", "role": "Treatment_Route", "text": "intravenous", "start": 7, "end": 8}, {"entity_id": "6610943_1_Ent1", "role": "Treatment", "text": "intravenous vasopressin infusion", "start": 7, "end": 10}, {"entity_id": "6610943_1_Ent4", "role": "Treatment_Drug", "text": "vasopressin", "start": 8, "end": 9}, {"entity_id": "6610943_1_Ent3", "role": "Treatment_Route", "text": "infusion", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "6610943_1_Ent0", "text": "Myoglobinuria and acute renal failure", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "6610943_1_Ent2", "text": "intravenous", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6610943_1_Ent1", "text": "intravenous vasopressin infusion", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "6610943_1_Ent4", "text": "vasopressin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6610943_1_Ent3", "text": "infusion", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "6614033_1", "wnd_id": "6614033_1_1", "text": "A major limitation in the use of amphotericin B is its potential to cause nephrotoxicity .", "tokens": ["A", "major", "limitation", "in", "the", "use", "of", "amphotericin", "B", "is", "its", "potential", "to", "cause", "nephrotoxicity", "."], "event_mentions": [{"id": "6614033_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 13, "end": 14}, "arguments": [{"entity_id": "6614033_1_Ent1", "role": "Treatment", "text": "amphotericin B", "start": 7, "end": 9}, {"entity_id": "6614033_1_Ent2", "role": "Treatment_Drug", "text": "amphotericin B", "start": 7, "end": 9}, {"entity_id": "6614033_1_Ent0", "role": "Effect", "text": "nephrotoxicity", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "6614033_1_Ent1", "text": "amphotericin B", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "6614033_1_Ent2", "text": "amphotericin B", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "6614033_1_Ent0", "text": "nephrotoxicity", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "6614033_3", "wnd_id": "6614033_3_1", "text": "Experience with five patients in whom impaired renal function developed early during amphotericin B therapy is reported .", "tokens": ["Experience", "with", "five", "patients", "in", "whom", "impaired", "renal", "function", "developed", "early", "during", "amphotericin", "B", "therapy", "is", "reported", "."], "event_mentions": [{"id": "6614033_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "6614033_3_Ent1", "role": "Subject_Population", "text": "five", "start": 2, "end": 3}, {"entity_id": "6614033_3_Ent0", "role": "Subject", "text": "five patients", "start": 2, "end": 4}, {"entity_id": "6614033_3_Ent2", "role": "Effect", "text": "impaired renal function", "start": 6, "end": 9}, {"entity_id": "6614033_3_Ent4", "role": "Treatment_Drug", "text": "amphotericin B", "start": 12, "end": 14}, {"entity_id": "6614033_3_Ent3", "role": "Treatment", "text": "amphotericin B therapy", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "6614033_3_Ent1", "text": "five", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "6614033_3_Ent0", "text": "five patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "6614033_3_Ent2", "text": "impaired renal function", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "6614033_3_Ent4", "text": "amphotericin B", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "6614033_3_Ent3", "text": "amphotericin B therapy", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "6618859_1", "wnd_id": "6618859_1_1", "text": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered .", "tokens": ["Gynecomastia", "developed", "in", "two", "epileptic", "patients", "some", "months", "after", "the", "addition", "of", "oral", "fluoresone", "750", "mg", "daily", "to", "the", "phenobarbital", "and", "phenytoin", "already", "being", "administered", "."], "event_mentions": [{"id": "6618859_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 1, "end": 2}, "arguments": [{"entity_id": "6618859_1_Ent2", "role": "Effect", "text": "Gynecomastia", "start": 0, "end": 1}, {"entity_id": "6618859_1_Ent1", "role": "Subject_Population", "text": "two", "start": 3, "end": 4}, {"entity_id": "6618859_1_Ent0", "role": "Subject", "text": "two epileptic patients", "start": 3, "end": 6}, {"entity_id": "6618859_1_Ent10", "role": "Treatment_Disorder", "text": "epileptic", "start": 4, "end": 5}, {"entity_id": "6618859_1_Ent11", "role": "Treatment_Time_elapsed", "text": "some months after", "start": 6, "end": 9}, {"entity_id": "6618859_1_Ent3", "role": "Treatment", "text": "some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered", "start": 6, "end": 25}, {"entity_id": "6618859_1_Ent4", "role": "Treatment_Route", "text": "oral", "start": 12, "end": 13}, {"entity_id": "6618859_1_Ent5", "role": "Treatment_Drug", "text": "fluoresone", "start": 13, "end": 14}, {"entity_id": "6618859_1_Ent12", "role": "Combination_Drug", "text": "fluoresone", "start": 13, "end": 14}, {"entity_id": "6618859_1_Ent8", "role": "Treatment_Dosage", "text": "750 mg", "start": 14, "end": 16}, {"entity_id": "6618859_1_Ent9", "role": "Treatment_Freq", "text": "daily", "start": 16, "end": 17}, {"entity_id": "6618859_1_Ent6", "role": "Treatment_Drug", "text": "phenobarbital", "start": 19, "end": 20}, {"entity_id": "6618859_1_Ent13", "role": "Combination_Drug", "text": "phenobarbital", "start": 19, "end": 20}, {"entity_id": "6618859_1_Ent7", "role": "Treatment_Drug", "text": "phenytoin", "start": 21, "end": 22}, {"entity_id": "6618859_1_Ent14", "role": "Combination_Drug", "text": "phenytoin", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "6618859_1_Ent2", "text": "Gynecomastia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6618859_1_Ent1", "text": "two", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6618859_1_Ent0", "text": "two epileptic patients", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "6618859_1_Ent10", "text": "epileptic", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6618859_1_Ent11", "text": "some months after", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "6618859_1_Ent3", "text": "some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered", "entity_type": "Entity", "start": 6, "end": 25}, {"id": "6618859_1_Ent4", "text": "oral", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "6618859_1_Ent5", "text": "fluoresone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "6618859_1_Ent12", "text": "fluoresone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "6618859_1_Ent8", "text": "750 mg", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "6618859_1_Ent9", "text": "daily", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "6618859_1_Ent6", "text": "phenobarbital", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "6618859_1_Ent13", "text": "phenobarbital", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "6618859_1_Ent7", "text": "phenytoin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "6618859_1_Ent14", "text": "phenytoin", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "6625005_1", "wnd_id": "6625005_1_1", "text": "Case report of withdrawal dyskinesia associated with amoxapine .", "tokens": ["Case", "report", "of", "withdrawal", "dyskinesia", "associated", "with", "amoxapine", "."], "event_mentions": [{"id": "6625005_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "6625005_1_Ent0", "role": "Subject", "text": "Case", "start": 0, "end": 1}, {"entity_id": "6625005_1_Ent1", "role": "Effect", "text": "withdrawal dyskinesia", "start": 3, "end": 5}, {"entity_id": "6625005_1_Ent2", "role": "Treatment", "text": "amoxapine", "start": 7, "end": 8}, {"entity_id": "6625005_1_Ent3", "role": "Treatment_Drug", "text": "amoxapine", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "6625005_1_Ent0", "text": "Case", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6625005_1_Ent1", "text": "withdrawal dyskinesia", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "6625005_1_Ent2", "text": "amoxapine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6625005_1_Ent3", "text": "amoxapine", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "6683487_2", "wnd_id": "6683487_2_1", "text": "Thrombotic thrombocytopenic purpura ( TTP ) developed in a patient with seropositive rheumatoid arthritis ( RA ) after 2 1/2 months of treatment with penicillamine .", "tokens": ["Thrombotic", "thrombocytopenic", "purpura", "(", "TTP", ")", "developed", "in", "a", "patient", "with", "seropositive", "rheumatoid", "arthritis", "(", "RA", ")", "after", "2", "1/2", "months", "of", "treatment", "with", "penicillamine", "."], "event_mentions": [{"id": "6683487_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "6683487_2_Ent1", "role": "Effect", "text": "Thrombotic thrombocytopenic purpura ( TTP )", "start": 0, "end": 6}, {"entity_id": "6683487_2_Ent0", "role": "Subject", "text": "a patient with seropositive rheumatoid arthritis ( RA )", "start": 8, "end": 17}, {"entity_id": "6683487_2_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 12, "end": 14}, {"entity_id": "6683487_2_Ent5", "role": "Treatment_Duration", "text": "2 1/2 months", "start": 18, "end": 21}, {"entity_id": "6683487_2_Ent2", "role": "Treatment", "text": "2 1/2 months of treatment with penicillamine", "start": 18, "end": 25}, {"entity_id": "6683487_2_Ent4", "role": "Treatment_Drug", "text": "penicillamine", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "6683487_2_Ent1", "text": "Thrombotic thrombocytopenic purpura ( TTP )", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "6683487_2_Ent0", "text": "a patient with seropositive rheumatoid arthritis ( RA )", "entity_type": "Entity", "start": 8, "end": 17}, {"id": "6683487_2_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "6683487_2_Ent5", "text": "2 1/2 months", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "6683487_2_Ent2", "text": "2 1/2 months of treatment with penicillamine", "entity_type": "Entity", "start": 18, "end": 25}, {"id": "6683487_2_Ent4", "text": "penicillamine", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "6683487_4", "wnd_id": "6683487_4_1", "text": "To our knowledge , no prior cases of penicillamine - induced TTP in RA have been reported .", "tokens": ["To", "our", "knowledge", ",", "no", "prior", "cases", "of", "penicillamine", "-", "induced", "TTP", "in", "RA", "have", "been", "reported", "."], "event_mentions": [{"id": "6683487_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "6683487_4_Ent1", "role": "Treatment", "text": "penicillamine", "start": 8, "end": 9}, {"entity_id": "6683487_4_Ent2", "role": "Treatment_Drug", "text": "penicillamine", "start": 8, "end": 9}, {"entity_id": "6683487_4_Ent0", "role": "Effect", "text": "TTP", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "6683487_4_Ent1", "text": "penicillamine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6683487_4_Ent2", "text": "penicillamine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6683487_4_Ent0", "text": "TTP", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "6692713_3", "wnd_id": "6692713_3_1", "text": "To our knowledge , this recurrence of amiodarone pulmonary toxicity has not been reported previously .", "tokens": ["To", "our", "knowledge", ",", "this", "recurrence", "of", "amiodarone", "pulmonary", "toxicity", "has", "not", "been", "reported", "previously", "."], "event_mentions": [{"id": "6692713_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 9, "end": 10}, "arguments": [{"entity_id": "6692713_3_Ent1", "role": "Treatment", "text": "amiodarone", "start": 7, "end": 8}, {"entity_id": "6692713_3_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 7, "end": 8}, {"entity_id": "6692713_3_Ent0", "role": "Effect", "text": "pulmonary toxicity", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "6692713_3_Ent1", "text": "amiodarone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6692713_3_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6692713_3_Ent0", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "6693840_3", "wnd_id": "6693840_3_1", "text": "No other endogenous or exogenous cause for the gynecomastia could be found except for the theophylline .", "tokens": ["No", "other", "endogenous", "or", "exogenous", "cause", "for", "the", "gynecomastia", "could", "be", "found", "except", "for", "the", "theophylline", "."], "event_mentions": [{"id": "6693840_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 5, "end": 6}, "arguments": [{"entity_id": "6693840_3_Ent0", "role": "Effect", "text": "gynecomastia", "start": 8, "end": 9}, {"entity_id": "6693840_3_Ent1", "role": "Treatment", "text": "theophylline", "start": 15, "end": 16}, {"entity_id": "6693840_3_Ent2", "role": "Treatment_Drug", "text": "theophylline", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "6693840_3_Ent0", "text": "gynecomastia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6693840_3_Ent1", "text": "theophylline", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "6693840_3_Ent2", "text": "theophylline", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "6697887_2", "wnd_id": "6697887_2_1", "text": "The incidence of oral - verapamil - induced hypotension in the presence of concomitant beta - adrenergic blockade by the oral route is quite rare .", "tokens": ["The", "incidence", "of", "oral", "-", "verapamil", "-", "induced", "hypotension", "in", "the", "presence", "of", "concomitant", "beta", "-", "adrenergic", "blockade", "by", "the", "oral", "route", "is", "quite", "rare", "."], "event_mentions": [{"id": "6697887_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "6697887_2_Ent4", "role": "Treatment_Route", "text": "oral", "start": 3, "end": 4}, {"entity_id": "6697887_2_Ent1", "role": "Treatment", "text": "oral - verapamil", "start": 3, "end": 6}, {"entity_id": "6697887_2_Ent3", "role": "Treatment_Drug", "text": "verapamil", "start": 5, "end": 6}, {"entity_id": "6697887_2_Ent0", "role": "Effect", "text": "hypotension", "start": 8, "end": 9}, {"entity_id": "6697887_2_Ent2", "role": "Treatment", "text": "in the presence of concomitant beta - adrenergic blockade", "start": 9, "end": 18}, {"entity_id": "6697887_2_Ent5", "role": "Treatment_Route", "text": "oral", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "6697887_2_Ent4", "text": "oral", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6697887_2_Ent1", "text": "oral - verapamil", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "6697887_2_Ent3", "text": "verapamil", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "6697887_2_Ent0", "text": "hypotension", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6697887_2_Ent2", "text": "in the presence of concomitant beta - adrenergic blockade", "entity_type": "Entity", "start": 9, "end": 18}, {"id": "6697887_2_Ent5", "text": "oral", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "6725214_1", "wnd_id": "6725214_1_1", "text": "A case of priapism associated with trazodone is described .", "tokens": ["A", "case", "of", "priapism", "associated", "with", "trazodone", "is", "described", "."], "event_mentions": [{"id": "6725214_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "6725214_1_Ent0", "role": "Subject", "text": "A case", "start": 0, "end": 2}, {"entity_id": "6725214_1_Ent1", "role": "Effect", "text": "priapism", "start": 3, "end": 4}, {"entity_id": "6725214_1_Ent2", "role": "Treatment", "text": "trazodone", "start": 6, "end": 7}, {"entity_id": "6725214_1_Ent3", "role": "Treatment_Drug", "text": "trazodone", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "6725214_1_Ent0", "text": "A case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6725214_1_Ent1", "text": "priapism", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6725214_1_Ent2", "text": "trazodone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6725214_1_Ent3", "text": "trazodone", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "6731466_6", "wnd_id": "6731466_6_1", "text": "This observation adds another dimension to the previously reported renal complications of nonsteroidal anti - inflammatory agents , especially zomepirac .", "tokens": ["This", "observation", "adds", "another", "dimension", "to", "the", "previously", "reported", "renal", "complications", "of", "nonsteroidal", "anti", "-", "inflammatory", "agents", ",", "especially", "zomepirac", "."], "event_mentions": [{"id": "6731466_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 8, "end": 9}, "arguments": [{"entity_id": "6731466_6_Ent0", "role": "Effect", "text": "renal complications", "start": 9, "end": 11}, {"entity_id": "6731466_6_Ent2", "role": "Treatment_Drug", "text": "nonsteroidal anti - inflammatory", "start": 12, "end": 16}, {"entity_id": "6731466_6_Ent1", "role": "Treatment", "text": "nonsteroidal anti - inflammatory agents , especially zomepirac", "start": 12, "end": 20}, {"entity_id": "6731466_6_Ent3", "role": "Treatment_Drug", "text": "zomepirac", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "6731466_6_Ent0", "text": "renal complications", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "6731466_6_Ent2", "text": "nonsteroidal anti - inflammatory", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "6731466_6_Ent1", "text": "nonsteroidal anti - inflammatory agents , especially zomepirac", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "6731466_6_Ent3", "text": "zomepirac", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "6738830_2", "wnd_id": "6738830_2_1", "text": "Unique behavioral change with cinepazide in parkinsonism .", "tokens": ["Unique", "behavioral", "change", "with", "cinepazide", "in", "parkinsonism", "."], "event_mentions": [{"id": "6738830_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 3, "end": 4}, "arguments": [{"entity_id": "6738830_2_Ent0", "role": "Effect", "text": "Unique behavioral change", "start": 0, "end": 3}, {"entity_id": "6738830_2_Ent1", "role": "Treatment", "text": "cinepazide", "start": 4, "end": 5}, {"entity_id": "6738830_2_Ent3", "role": "Treatment_Drug", "text": "cinepazide", "start": 4, "end": 5}, {"entity_id": "6738830_2_Ent2", "role": "Treatment_Disorder", "text": "parkinsonism", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "6738830_2_Ent0", "text": "Unique behavioral change", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "6738830_2_Ent1", "text": "cinepazide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6738830_2_Ent3", "text": "cinepazide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6738830_2_Ent2", "text": "parkinsonism", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "6788011_3", "wnd_id": "6788011_3_1", "text": "Gold - salt therapy may result in damage to proximal tubules that leak renal tubular antigens , which in turn complex with autoantibody and produce an autoimmune membranous nephropathy .", "tokens": ["Gold", "-", "salt", "therapy", "may", "result", "in", "damage", "to", "proximal", "tubules", "that", "leak", "renal", "tubular", "antigens", ",", "which", "in", "turn", "complex", "with", "autoantibody", "and", "produce", "an", "autoimmune", "membranous", "nephropathy", "."], "event_mentions": [{"id": "6788011_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "result", "start": 5, "end": 6}, "arguments": [{"entity_id": "6788011_3_Ent1", "role": "Treatment", "text": "Gold - salt", "start": 0, "end": 3}, {"entity_id": "6788011_3_Ent2", "role": "Treatment_Drug", "text": "Gold - salt", "start": 0, "end": 3}, {"entity_id": "6788011_3_Ent0", "role": "Effect", "text": "damage to proximal tubules", "start": 7, "end": 11}]}], "entity_mentions": [{"id": "6788011_3_Ent1", "text": "Gold - salt", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "6788011_3_Ent2", "text": "Gold - salt", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "6788011_3_Ent0", "text": "damage to proximal tubules", "entity_type": "Entity", "start": 7, "end": 11}], "lang": "en"}
{"doc_id": "6794018_1", "wnd_id": "6794018_1_1", "text": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61 - year - old diabetic patient who presented wit hypoglycaemic coma .", "tokens": ["Intrahepatic", "cholestasis", "and", "cutaneous", "bullae", "associated", "with", "glibenclamide", "therapy", "are", "described", "in", "a", "61", "-", "year", "-", "old", "diabetic", "patient", "who", "presented", "wit", "hypoglycaemic", "coma", "."], "event_mentions": [{"id": "6794018_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "6794018_1_Ent3", "role": "Effect", "text": "Intrahepatic cholestasis and cutaneous bullae", "start": 0, "end": 5}, {"entity_id": "6794018_1_Ent4", "role": "Treatment", "text": "glibenclamide", "start": 7, "end": 8}, {"entity_id": "6794018_1_Ent5", "role": "Treatment_Drug", "text": "glibenclamide", "start": 7, "end": 8}, {"entity_id": "6794018_1_Ent0", "role": "Subject", "text": "a 61 - year - old diabetic patient who presented wit hypoglycaemic coma", "start": 12, "end": 25}, {"entity_id": "6794018_1_Ent2", "role": "Subject_Age", "text": "61 - year - old", "start": 13, "end": 18}, {"entity_id": "6794018_1_Ent6", "role": "Treatment_Disorder", "text": "diabetic", "start": 18, "end": 19}, {"entity_id": "6794018_1_Ent1", "role": "Subject_Disorder", "text": "hypoglycaemic coma", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "6794018_1_Ent3", "text": "Intrahepatic cholestasis and cutaneous bullae", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "6794018_1_Ent4", "text": "glibenclamide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6794018_1_Ent5", "text": "glibenclamide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6794018_1_Ent0", "text": "a 61 - year - old diabetic patient who presented wit hypoglycaemic coma", "entity_type": "Entity", "start": 12, "end": 25}, {"id": "6794018_1_Ent2", "text": "61 - year - old", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "6794018_1_Ent6", "text": "diabetic", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "6794018_1_Ent1", "text": "hypoglycaemic coma", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "681921_1", "wnd_id": "681921_1_1", "text": "Catatonia associated with disulfiram therapy .", "tokens": ["Catatonia", "associated", "with", "disulfiram", "therapy", "."], "event_mentions": [{"id": "681921_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "681921_1_Ent0", "role": "Effect", "text": "Catatonia", "start": 0, "end": 1}, {"entity_id": "681921_1_Ent2", "role": "Treatment_Drug", "text": "disulfiram", "start": 3, "end": 4}, {"entity_id": "681921_1_Ent1", "role": "Treatment", "text": "disulfiram therapy", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "681921_1_Ent0", "text": "Catatonia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "681921_1_Ent2", "text": "disulfiram", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "681921_1_Ent1", "text": "disulfiram therapy", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "6830388_1", "wnd_id": "6830388_1_1", "text": "Since early symptoms of the toxic effects of theophylline can mimic peptic ulcer disease , cimetidine might be prescribed for the gastrointestinal symptoms with subsequent worsening of theophylline poisoning .", "tokens": ["Since", "early", "symptoms", "of", "the", "toxic", "effects", "of", "theophylline", "can", "mimic", "peptic", "ulcer", "disease", ",", "cimetidine", "might", "be", "prescribed", "for", "the", "gastrointestinal", "symptoms", "with", "subsequent", "worsening", "of", "theophylline", "poisoning", "."], "event_mentions": [{"id": "6830388_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "prescribed", "start": 18, "end": 19}, "arguments": [{"entity_id": "6830388_1_Ent0", "role": "Treatment", "text": "cimetidine", "start": 15, "end": 16}, {"entity_id": "6830388_1_Ent2", "role": "Treatment_Drug", "text": "cimetidine", "start": 15, "end": 16}, {"entity_id": "6830388_1_Ent1", "role": "Treatment_Disorder", "text": "gastrointestinal symptoms", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "6830388_1_Ent0", "text": "cimetidine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "6830388_1_Ent2", "text": "cimetidine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "6830388_1_Ent1", "text": "gastrointestinal symptoms", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "6833205_1", "wnd_id": "6833205_1_1", "text": "A case of SIADH associated with desipramine treatment in an elderly depressed woman is described .", "tokens": ["A", "case", "of", "SIADH", "associated", "with", "desipramine", "treatment", "in", "an", "elderly", "depressed", "woman", "is", "described", "."], "event_mentions": [{"id": "6833205_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "6833205_1_Ent3", "role": "Effect", "text": "SIADH", "start": 3, "end": 4}, {"entity_id": "6833205_1_Ent6", "role": "Treatment_Drug", "text": "desipramine", "start": 6, "end": 7}, {"entity_id": "6833205_1_Ent4", "role": "Treatment", "text": "desipramine treatment", "start": 6, "end": 8}, {"entity_id": "6833205_1_Ent0", "role": "Subject", "text": "an elderly depressed woman", "start": 9, "end": 13}, {"entity_id": "6833205_1_Ent1", "role": "Subject_Age", "text": "elderly", "start": 10, "end": 11}, {"entity_id": "6833205_1_Ent5", "role": "Treatment_Disorder", "text": "depressed", "start": 11, "end": 12}, {"entity_id": "6833205_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "6833205_1_Ent3", "text": "SIADH", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6833205_1_Ent6", "text": "desipramine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6833205_1_Ent4", "text": "desipramine treatment", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "6833205_1_Ent0", "text": "an elderly depressed woman", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "6833205_1_Ent1", "text": "elderly", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "6833205_1_Ent5", "text": "depressed", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "6833205_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "6860059_2", "wnd_id": "6860059_2_1", "text": "We report a case of fatal fulminant hepatitis caused by the use of disulfiram in a man with previously normal hepatocellular function .", "tokens": ["We", "report", "a", "case", "of", "fatal", "fulminant", "hepatitis", "caused", "by", "the", "use", "of", "disulfiram", "in", "a", "man", "with", "previously", "normal", "hepatocellular", "function", "."], "event_mentions": [{"id": "6860059_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 8, "end": 9}, "arguments": [{"entity_id": "6860059_2_Ent2", "role": "Effect", "text": "fatal fulminant hepatitis", "start": 5, "end": 8}, {"entity_id": "6860059_2_Ent3", "role": "Treatment", "text": "disulfiram", "start": 13, "end": 14}, {"entity_id": "6860059_2_Ent4", "role": "Treatment_Drug", "text": "disulfiram", "start": 13, "end": 14}, {"entity_id": "6860059_2_Ent0", "role": "Subject", "text": "a man", "start": 15, "end": 17}, {"entity_id": "6860059_2_Ent1", "role": "Subject_Gender", "text": "man", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "6860059_2_Ent2", "text": "fatal fulminant hepatitis", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "6860059_2_Ent3", "text": "disulfiram", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "6860059_2_Ent4", "text": "disulfiram", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "6860059_2_Ent0", "text": "a man", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "6860059_2_Ent1", "text": "man", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "6873616_1", "wnd_id": "6873616_1_1", "text": "A 55 - yr - old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy .", "tokens": ["A", "55", "-", "yr", "-", "old", "man", "developed", "prolonged", "jaundice", "and", "sicca", "complex", "after", "a", "course", "of", "thiabendazole", "therapy", "."], "event_mentions": [{"id": "6873616_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 13, "end": 14}, "arguments": [{"entity_id": "6873616_1_Ent0", "role": "Subject", "text": "A 55 - yr - old man", "start": 0, "end": 7}, {"entity_id": "6873616_1_Ent1", "role": "Subject_Age", "text": "55 - yr - old", "start": 1, "end": 6}, {"entity_id": "6873616_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "6873616_1_Ent3", "role": "Effect", "text": "prolonged jaundice and sicca complex", "start": 8, "end": 13}, {"entity_id": "6873616_1_Ent4", "role": "Treatment", "text": "a course of thiabendazole", "start": 14, "end": 18}, {"entity_id": "6873616_1_Ent5", "role": "Treatment_Drug", "text": "thiabendazole", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "6873616_1_Ent0", "text": "A 55 - yr - old man", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "6873616_1_Ent1", "text": "55 - yr - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "6873616_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6873616_1_Ent3", "text": "prolonged jaundice and sicca complex", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "6873616_1_Ent4", "text": "a course of thiabendazole", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "6873616_1_Ent5", "text": "thiabendazole", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "6947095_1", "wnd_id": "6947095_1_1", "text": "Dural sinus thrombosis developed in two children with acute lymphoblastic leukemia during induction treatment with vincristine sulfate , prednisone , and asparaginase .", "tokens": ["Dural", "sinus", "thrombosis", "developed", "in", "two", "children", "with", "acute", "lymphoblastic", "leukemia", "during", "induction", "treatment", "with", "vincristine", "sulfate", ",", "prednisone", ",", "and", "asparaginase", "."], "event_mentions": [{"id": "6947095_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 3, "end": 4}, "arguments": [{"entity_id": "6947095_1_Ent3", "role": "Effect", "text": "Dural sinus thrombosis", "start": 0, "end": 3}, {"entity_id": "6947095_1_Ent1", "role": "Subject_Population", "text": "two", "start": 5, "end": 6}, {"entity_id": "6947095_1_Ent0", "role": "Subject", "text": "two children with acute lymphoblastic leukemia", "start": 5, "end": 11}, {"entity_id": "6947095_1_Ent2", "role": "Subject_Age", "text": "children", "start": 6, "end": 7}, {"entity_id": "6947095_1_Ent8", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukemia", "start": 8, "end": 11}, {"entity_id": "6947095_1_Ent4", "role": "Treatment", "text": "induction treatment with vincristine sulfate , prednisone , and asparaginase", "start": 12, "end": 22}, {"entity_id": "6947095_1_Ent5", "role": "Treatment_Drug", "text": "vincristine sulfate", "start": 15, "end": 17}, {"entity_id": "6947095_1_Ent9", "role": "Combination_Drug", "text": "vincristine sulfate", "start": 15, "end": 17}, {"entity_id": "6947095_1_Ent6", "role": "Treatment_Drug", "text": "prednisone", "start": 18, "end": 19}, {"entity_id": "6947095_1_Ent10", "role": "Combination_Drug", "text": "prednisone", "start": 18, "end": 19}, {"entity_id": "6947095_1_Ent7", "role": "Treatment_Drug", "text": "asparaginase", "start": 21, "end": 22}, {"entity_id": "6947095_1_Ent11", "role": "Combination_Drug", "text": "asparaginase", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "6947095_1_Ent3", "text": "Dural sinus thrombosis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "6947095_1_Ent1", "text": "two", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "6947095_1_Ent0", "text": "two children with acute lymphoblastic leukemia", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "6947095_1_Ent2", "text": "children", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6947095_1_Ent8", "text": "acute lymphoblastic leukemia", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "6947095_1_Ent4", "text": "induction treatment with vincristine sulfate , prednisone , and asparaginase", "entity_type": "Entity", "start": 12, "end": 22}, {"id": "6947095_1_Ent5", "text": "vincristine sulfate", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "6947095_1_Ent9", "text": "vincristine sulfate", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "6947095_1_Ent6", "text": "prednisone", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "6947095_1_Ent10", "text": "prednisone", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "6947095_1_Ent7", "text": "asparaginase", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "6947095_1_Ent11", "text": "asparaginase", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "7035691_2", "wnd_id": "7035691_2_1", "text": "We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with transient anuria after the administration of captopril .", "tokens": ["We", "report", "on", "a", "patient", "with", "renal", "artery", "stenosis", "who", "had", "only", "1", "kidney", "and", "in", "whom", "acute", "renal", "impairment", "developed", "with", "transient", "anuria", "after", "the", "administration", "of", "captopril", "."], "event_mentions": [{"id": "7035691_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 24, "end": 25}, "arguments": [{"entity_id": "7035691_2_Ent0", "role": "Subject", "text": "a patient with renal artery stenosis who had only 1 kidney", "start": 3, "end": 14}, {"entity_id": "7035691_2_Ent1", "role": "Subject_Disorder", "text": "renal artery stenosis who had only 1 kidney", "start": 6, "end": 14}, {"entity_id": "7035691_2_Ent2", "role": "Effect", "text": "acute renal impairment developed with transient anuria", "start": 17, "end": 24}, {"entity_id": "7035691_2_Ent3", "role": "Treatment", "text": "the administration of captopril", "start": 25, "end": 29}, {"entity_id": "7035691_2_Ent4", "role": "Treatment_Drug", "text": "captopril", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "7035691_2_Ent0", "text": "a patient with renal artery stenosis who had only 1 kidney", "entity_type": "Entity", "start": 3, "end": 14}, {"id": "7035691_2_Ent1", "text": "renal artery stenosis who had only 1 kidney", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "7035691_2_Ent2", "text": "acute renal impairment developed with transient anuria", "entity_type": "Entity", "start": 17, "end": 24}, {"id": "7035691_2_Ent3", "text": "the administration of captopril", "entity_type": "Entity", "start": 25, "end": 29}, {"id": "7035691_2_Ent4", "text": "captopril", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "7056119_2", "wnd_id": "7056119_2_1", "text": "A 44 - year - old woman is described in whom amiodarone , disopyramide , and quinidine , administered alone separately , induced atypical ventricular tachycardia ( AVT , torsade de pointes ) .", "tokens": ["A", "44", "-", "year", "-", "old", "woman", "is", "described", "in", "whom", "amiodarone", ",", "disopyramide", ",", "and", "quinidine", ",", "administered", "alone", "separately", ",", "induced", "atypical", "ventricular", "tachycardia", "(", "AVT", ",", "torsade", "de", "pointes", ")", "."], "event_mentions": [{"id": "7056119_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 22, "end": 23}, "arguments": [{"entity_id": "7056119_2_Ent0", "role": "Subject", "text": "A 44 - year - old woman", "start": 0, "end": 7}, {"entity_id": "7056119_2_Ent1", "role": "Subject_Age", "text": "44 - year - old", "start": 1, "end": 6}, {"entity_id": "7056119_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "7056119_2_Ent5", "role": "Treatment_Drug", "text": "amiodarone", "start": 11, "end": 12}, {"entity_id": "7056119_2_Ent4", "role": "Treatment", "text": "amiodarone , disopyramide , and quinidine", "start": 11, "end": 17}, {"entity_id": "7056119_2_Ent6", "role": "Treatment_Drug", "text": "disopyramide", "start": 13, "end": 14}, {"entity_id": "7056119_2_Ent7", "role": "Treatment_Drug", "text": "quinidine", "start": 16, "end": 17}, {"entity_id": "7056119_2_Ent3", "role": "Effect", "text": "atypical ventricular tachycardia ( AVT , torsade de pointes )", "start": 23, "end": 33}]}], "entity_mentions": [{"id": "7056119_2_Ent0", "text": "A 44 - year - old woman", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "7056119_2_Ent1", "text": "44 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "7056119_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7056119_2_Ent5", "text": "amiodarone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7056119_2_Ent4", "text": "amiodarone , disopyramide , and quinidine", "entity_type": "Entity", "start": 11, "end": 17}, {"id": "7056119_2_Ent6", "text": "disopyramide", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "7056119_2_Ent7", "text": "quinidine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "7056119_2_Ent3", "text": "atypical ventricular tachycardia ( AVT , torsade de pointes )", "entity_type": "Entity", "start": 23, "end": 33}], "lang": "en"}
{"doc_id": "7056119_4", "wnd_id": "7056119_4_1", "text": "Because of a recurrence of paroxysmal atrial fibrillation , the dose of the drug was increased to 1.4 g / day ; 24 hours later AVT with syncope developed but responded promptly to atropine .", "tokens": ["Because", "of", "a", "recurrence", "of", "paroxysmal", "atrial", "fibrillation", ",", "the", "dose", "of", "the", "drug", "was", "increased", "to", "1.4", "g", "/", "day", ";", "24", "hours", "later", "AVT", "with", "syncope", "developed", "but", "responded", "promptly", "to", "atropine", "."], "event_mentions": [{"id": "7056119_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 28, "end": 29}, "arguments": [{"entity_id": "7056119_4_Ent0", "role": "Subject", "text": "paroxysmal atrial fibrillation", "start": 5, "end": 8}, {"entity_id": "7056119_4_Ent1", "role": "Subject_Disorder", "text": "paroxysmal atrial fibrillation", "start": 5, "end": 8}, {"entity_id": "7056119_4_Ent3", "role": "Treatment", "text": "the dose of the drug was increased to 1.4 g / day", "start": 9, "end": 21}, {"entity_id": "7056119_4_Ent6", "role": "Treatment_Drug", "text": "the drug", "start": 12, "end": 14}, {"entity_id": "7056119_4_Ent5", "role": "Treatment_Dosage", "text": "1.4 g / day", "start": 17, "end": 21}, {"entity_id": "7056119_4_Ent4", "role": "Treatment_Time_elapsed", "text": "24 hours", "start": 22, "end": 24}, {"entity_id": "7056119_4_Ent2", "role": "Effect", "text": "AVT with syncope", "start": 25, "end": 28}]}, {"id": "7056119_4_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "responded", "start": 30, "end": 31}, "arguments": [{"entity_id": "7056119_4_Ent8", "role": "Treatment_Disorder", "text": "AVT with syncope", "start": 25, "end": 28}, {"entity_id": "7056119_4_Ent7", "role": "Treatment", "text": "atropine", "start": 33, "end": 34}, {"entity_id": "7056119_4_Ent9", "role": "Treatment_Drug", "text": "atropine", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "7056119_4_Ent0", "text": "paroxysmal atrial fibrillation", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "7056119_4_Ent1", "text": "paroxysmal atrial fibrillation", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "7056119_4_Ent3", "text": "the dose of the drug was increased to 1.4 g / day", "entity_type": "Entity", "start": 9, "end": 21}, {"id": "7056119_4_Ent6", "text": "the drug", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "7056119_4_Ent5", "text": "1.4 g / day", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "7056119_4_Ent4", "text": "24 hours", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "7056119_4_Ent2", "text": "AVT with syncope", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "7056119_4_Ent8", "text": "AVT with syncope", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "7056119_4_Ent7", "text": "atropine", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "7056119_4_Ent9", "text": "atropine", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "7056119_5", "wnd_id": "7056119_5_1", "text": "Two years later , 24 hours following an increase in the dose of disopyramide from 300 to 600 mg / day , AVT with syncope occurred ; isoproterenol abolished the arrhythmia instantly .", "tokens": ["Two", "years", "later", ",", "24", "hours", "following", "an", "increase", "in", "the", "dose", "of", "disopyramide", "from", "300", "to", "600", "mg", "/", "day", ",", "AVT", "with", "syncope", "occurred", ";", "isoproterenol", "abolished", "the", "arrhythmia", "instantly", "."], "event_mentions": [{"id": "7056119_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 25, "end": 26}, "arguments": [{"entity_id": "7056119_5_Ent5", "role": "Treatment_Duration", "text": "Two years", "start": 0, "end": 2}, {"entity_id": "7056119_5_Ent1", "role": "Treatment", "text": "Two years later , 24 hours following an increase in the dose of disopyramide from 300 to 600 mg / day", "start": 0, "end": 21}, {"entity_id": "7056119_5_Ent2", "role": "Treatment_Time_elapsed", "text": "24 hours", "start": 4, "end": 6}, {"entity_id": "7056119_5_Ent4", "role": "Treatment_Drug", "text": "disopyramide", "start": 13, "end": 14}, {"entity_id": "7056119_5_Ent3", "role": "Treatment_Dosage", "text": "300 to 600 mg / day", "start": 15, "end": 21}, {"entity_id": "7056119_5_Ent0", "role": "Effect", "text": "AVT with syncope", "start": 22, "end": 25}]}, {"id": "7056119_5_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "abolished", "start": 28, "end": 29}, "arguments": [{"entity_id": "7056119_5_Ent6", "role": "Treatment", "text": "isoproterenol", "start": 27, "end": 28}, {"entity_id": "7056119_5_Ent8", "role": "Treatment_Drug", "text": "isoproterenol", "start": 27, "end": 28}, {"entity_id": "7056119_5_Ent7", "role": "Treatment_Disorder", "text": "arrhythmia", "start": 30, "end": 31}]}], "entity_mentions": [{"id": "7056119_5_Ent5", "text": "Two years", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7056119_5_Ent1", "text": "Two years later , 24 hours following an increase in the dose of disopyramide from 300 to 600 mg / day", "entity_type": "Entity", "start": 0, "end": 21}, {"id": "7056119_5_Ent2", "text": "24 hours", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "7056119_5_Ent4", "text": "disopyramide", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "7056119_5_Ent3", "text": "300 to 600 mg / day", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "7056119_5_Ent0", "text": "AVT with syncope", "entity_type": "Entity", "start": 22, "end": 25}, {"id": "7056119_5_Ent6", "text": "isoproterenol", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "7056119_5_Ent8", "text": "isoproterenol", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "7056119_5_Ent7", "text": "arrhythmia", "entity_type": "Entity", "start": 30, "end": 31}], "lang": "en"}
{"doc_id": "7056119_6", "wnd_id": "7056119_6_1", "text": "Amiodarone was the third drug to induce AVT in this patient ; she received 200 mg / day six days per week for six months .", "tokens": ["Amiodarone", "was", "the", "third", "drug", "to", "induce", "AVT", "in", "this", "patient", ";", "she", "received", "200", "mg", "/", "day", "six", "days", "per", "week", "for", "six", "months", "."], "event_mentions": [{"id": "7056119_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 6, "end": 7}, "arguments": [{"entity_id": "7056119_6_Ent4", "role": "Treatment", "text": "Amiodarone", "start": 0, "end": 1}, {"entity_id": "7056119_6_Ent6", "role": "Treatment_Drug", "text": "Amiodarone", "start": 0, "end": 1}, {"entity_id": "7056119_6_Ent3", "role": "Effect", "text": "AVT", "start": 7, "end": 8}, {"entity_id": "7056119_6_Ent0", "role": "Subject", "text": "patient", "start": 10, "end": 11}, {"entity_id": "7056119_6_Ent1", "role": "Subject", "text": "she", "start": 12, "end": 13}, {"entity_id": "7056119_6_Ent2", "role": "Subject_Gender", "text": "she", "start": 12, "end": 13}, {"entity_id": "7056119_6_Ent7", "role": "Treatment_Dosage", "text": "200 mg / day", "start": 14, "end": 18}, {"entity_id": "7056119_6_Ent5", "role": "Treatment", "text": "200 mg / day six days per week for six months", "start": 14, "end": 25}, {"entity_id": "7056119_6_Ent8", "role": "Treatment_Freq", "text": "six days per week", "start": 18, "end": 22}, {"entity_id": "7056119_6_Ent9", "role": "Treatment_Freq", "text": "six months", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "7056119_6_Ent4", "text": "Amiodarone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7056119_6_Ent6", "text": "Amiodarone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7056119_6_Ent3", "text": "AVT", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7056119_6_Ent0", "text": "patient", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7056119_6_Ent1", "text": "she", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "7056119_6_Ent2", "text": "she", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "7056119_6_Ent7", "text": "200 mg / day", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "7056119_6_Ent5", "text": "200 mg / day six days per week for six months", "entity_type": "Entity", "start": 14, "end": 25}, {"id": "7056119_6_Ent8", "text": "six days per week", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "7056119_6_Ent9", "text": "six months", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "7117795_1", "wnd_id": "7117795_1_1", "text": "Flucytosine - associated diarrhea has been previously described in 6% - 10 % of patients receiving the drug .", "tokens": ["Flucytosine", "-", "associated", "diarrhea", "has", "been", "previously", "described", "in", "6%", "-", "10", "%", "of", "patients", "receiving", "the", "drug", "."], "event_mentions": [{"id": "7117795_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "7117795_1_Ent3", "role": "Treatment", "text": "Flucytosine", "start": 0, "end": 1}, {"entity_id": "7117795_1_Ent4", "role": "Treatment_Drug", "text": "Flucytosine", "start": 0, "end": 1}, {"entity_id": "7117795_1_Ent2", "role": "Effect", "text": "diarrhea", "start": 3, "end": 4}, {"entity_id": "7117795_1_Ent1", "role": "Subject_Population", "text": "6% - 10 %", "start": 9, "end": 13}, {"entity_id": "7117795_1_Ent0", "role": "Subject", "text": "6% - 10 % of patients", "start": 9, "end": 15}]}], "entity_mentions": [{"id": "7117795_1_Ent3", "text": "Flucytosine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7117795_1_Ent4", "text": "Flucytosine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7117795_1_Ent2", "text": "diarrhea", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7117795_1_Ent1", "text": "6% - 10 %", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "7117795_1_Ent0", "text": "6% - 10 % of patients", "entity_type": "Entity", "start": 9, "end": 15}], "lang": "en"}
{"doc_id": "7139589_3", "wnd_id": "7139589_3_1", "text": "L - asparaginase - induced pancreatitis has been reported during or closely following administration of the drug .", "tokens": ["L", "-", "asparaginase", "-", "induced", "pancreatitis", "has", "been", "reported", "during", "or", "closely", "following", "administration", "of", "the", "drug", "."], "event_mentions": [{"id": "7139589_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "7139589_3_Ent1", "role": "Treatment", "text": "L - asparaginase", "start": 0, "end": 3}, {"entity_id": "7139589_3_Ent2", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 0, "end": 3}, {"entity_id": "7139589_3_Ent0", "role": "Effect", "text": "pancreatitis", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "7139589_3_Ent1", "text": "L - asparaginase", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "7139589_3_Ent2", "text": "L - asparaginase", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "7139589_3_Ent0", "text": "pancreatitis", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "7151655_1", "wnd_id": "7151655_1_1", "text": "In one patient , treatment with DCA was associated with a decrease in blood lactate levels from 11.2 mM before treatment to 0.8 mM 16 h later .", "tokens": ["In", "one", "patient", ",", "treatment", "with", "DCA", "was", "associated", "with", "a", "decrease", "in", "blood", "lactate", "levels", "from", "11.2", "mM", "before", "treatment", "to", "0.8", "mM", "16", "h", "later", "."], "event_mentions": [{"id": "7151655_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "7151655_1_Ent1", "role": "Subject_Population", "text": "one", "start": 1, "end": 2}, {"entity_id": "7151655_1_Ent0", "role": "Subject", "text": "one patient", "start": 1, "end": 3}, {"entity_id": "7151655_1_Ent3", "role": "Treatment", "text": "DCA", "start": 6, "end": 7}, {"entity_id": "7151655_1_Ent4", "role": "Treatment_Drug", "text": "DCA", "start": 6, "end": 7}, {"entity_id": "7151655_1_Ent2", "role": "Effect", "text": "decrease in blood lactate levels", "start": 11, "end": 16}, {"entity_id": "7151655_1_Ent5", "role": "Treatment_Time_elapsed", "text": "16 h later", "start": 24, "end": 27}]}], "entity_mentions": [{"id": "7151655_1_Ent1", "text": "one", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7151655_1_Ent0", "text": "one patient", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "7151655_1_Ent3", "text": "DCA", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7151655_1_Ent4", "text": "DCA", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7151655_1_Ent2", "text": "decrease in blood lactate levels", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "7151655_1_Ent5", "text": "16 h later", "entity_type": "Entity", "start": 24, "end": 27}], "lang": "en"}
{"doc_id": "7174620_2", "wnd_id": "7174620_2_1", "text": "The course of delirium due to lithium intoxication .", "tokens": ["The", "course", "of", "delirium", "due", "to", "lithium", "intoxication", "."], "event_mentions": [{"id": "7174620_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 4, "end": 5}, "arguments": [{"entity_id": "7174620_2_Ent0", "role": "Effect", "text": "delirium", "start": 3, "end": 4}, {"entity_id": "7174620_2_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 6, "end": 7}, {"entity_id": "7174620_2_Ent1", "role": "Treatment", "text": "lithium intoxication", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "7174620_2_Ent0", "text": "delirium", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7174620_2_Ent2", "text": "lithium", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7174620_2_Ent1", "text": "lithium intoxication", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "7212107_1", "wnd_id": "7212107_1_1", "text": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible .", "tokens": ["Secondary", "hyperparathyroidism", "in", "certain", "patients", "with", "lithium", "nephrotoxicity", "is", "also", "possible", "."], "event_mentions": [{"id": "7212107_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 2, "end": 3}, "arguments": [{"entity_id": "7212107_1_Ent2", "role": "Effect", "text": "Secondary hyperparathyroidism", "start": 0, "end": 2}, {"entity_id": "7212107_1_Ent0", "role": "Subject", "text": "certain patients", "start": 3, "end": 5}, {"entity_id": "7212107_1_Ent3", "role": "Treatment", "text": "lithium", "start": 6, "end": 7}, {"entity_id": "7212107_1_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 6, "end": 7}, {"entity_id": "7212107_1_Ent1", "role": "Effect", "text": "nephrotoxicity", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "7212107_1_Ent2", "text": "Secondary hyperparathyroidism", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7212107_1_Ent0", "text": "certain patients", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "7212107_1_Ent3", "text": "lithium", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7212107_1_Ent4", "text": "lithium", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7212107_1_Ent1", "text": "nephrotoxicity", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "7226916_1", "wnd_id": "7226916_1_1", "text": "A 57 - year - old woman with right bundle branch block + LPH and ventricular premature contractions developed complete heart block ( CHB ) following administration of disopyramide phosphate ( Norpace ) .", "tokens": ["A", "57", "-", "year", "-", "old", "woman", "with", "right", "bundle", "branch", "block", "+", "LPH", "and", "ventricular", "premature", "contractions", "developed", "complete", "heart", "block", "(", "CHB", ")", "following", "administration", "of", "disopyramide", "phosphate", "(", "Norpace", ")", "."], "event_mentions": [{"id": "7226916_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 18, "end": 19}, "arguments": [{"entity_id": "7226916_1_Ent0", "role": "Subject", "text": "A 57 - year - old woman with right bundle branch block + LPH and ventricular premature contractions", "start": 0, "end": 18}, {"entity_id": "7226916_1_Ent1", "role": "Subject_Age", "text": "57 - year - old", "start": 1, "end": 6}, {"entity_id": "7226916_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "7226916_1_Ent3", "role": "Subject_Disorder", "text": "right bundle branch block + LPH", "start": 8, "end": 14}, {"entity_id": "7226916_1_Ent4", "role": "Subject_Disorder", "text": "ventricular premature contractions", "start": 15, "end": 18}, {"entity_id": "7226916_1_Ent5", "role": "Effect", "text": "complete heart block ( CHB )", "start": 19, "end": 25}, {"entity_id": "7226916_1_Ent7", "role": "Treatment_Drug", "text": "disopyramide phosphate", "start": 28, "end": 30}, {"entity_id": "7226916_1_Ent6", "role": "Treatment", "text": "disopyramide phosphate ( Norpace )", "start": 28, "end": 33}]}], "entity_mentions": [{"id": "7226916_1_Ent0", "text": "A 57 - year - old woman with right bundle branch block + LPH and ventricular premature contractions", "entity_type": "Entity", "start": 0, "end": 18}, {"id": "7226916_1_Ent1", "text": "57 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "7226916_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7226916_1_Ent3", "text": "right bundle branch block + LPH", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "7226916_1_Ent4", "text": "ventricular premature contractions", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "7226916_1_Ent5", "text": "complete heart block ( CHB )", "entity_type": "Entity", "start": 19, "end": 25}, {"id": "7226916_1_Ent7", "text": "disopyramide phosphate", "entity_type": "Entity", "start": 28, "end": 30}, {"id": "7226916_1_Ent6", "text": "disopyramide phosphate ( Norpace )", "entity_type": "Entity", "start": 28, "end": 33}], "lang": "en"}
{"doc_id": "7235792_2", "wnd_id": "7235792_2_1", "text": "In the first patient , two episodes of ventricular tachycardia requiring cardioversion occurred in close temporal sequence with administering bretylium .", "tokens": ["In", "the", "first", "patient", ",", "two", "episodes", "of", "ventricular", "tachycardia", "requiring", "cardioversion", "occurred", "in", "close", "temporal", "sequence", "with", "administering", "bretylium", "."], "event_mentions": [{"id": "7235792_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 12, "end": 13}, "arguments": [{"entity_id": "7235792_2_Ent0", "role": "Subject", "text": "first patient", "start": 2, "end": 4}, {"entity_id": "7235792_2_Ent1", "role": "Effect", "text": "two episodes of ventricular tachycardia requiring cardioversion", "start": 5, "end": 12}, {"entity_id": "7235792_2_Ent3", "role": "Treatment_Time_elapsed", "text": "close temporal sequence", "start": 14, "end": 17}, {"entity_id": "7235792_2_Ent2", "role": "Treatment", "text": "close temporal sequence with administering bretylium", "start": 14, "end": 20}, {"entity_id": "7235792_2_Ent4", "role": "Treatment_Drug", "text": "bretylium", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "7235792_2_Ent0", "text": "first patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "7235792_2_Ent1", "text": "two episodes of ventricular tachycardia requiring cardioversion", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "7235792_2_Ent3", "text": "close temporal sequence", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "7235792_2_Ent2", "text": "close temporal sequence with administering bretylium", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "7235792_2_Ent4", "text": "bretylium", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "7235792_4", "wnd_id": "7235792_4_1", "text": "Paradoxical ventricular tachycardia and fibrillation after intravenous bretylium therapy .", "tokens": ["Paradoxical", "ventricular", "tachycardia", "and", "fibrillation", "after", "intravenous", "bretylium", "therapy", "."], "event_mentions": [{"id": "7235792_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 5, "end": 6}, "arguments": [{"entity_id": "7235792_4_Ent0", "role": "Effect", "text": "Paradoxical ventricular tachycardia and fibrillation", "start": 0, "end": 5}, {"entity_id": "7235792_4_Ent2", "role": "Treatment_Route", "text": "intravenous", "start": 6, "end": 7}, {"entity_id": "7235792_4_Ent1", "role": "Treatment", "text": "intravenous bretylium", "start": 6, "end": 8}, {"entity_id": "7235792_4_Ent3", "role": "Treatment_Drug", "text": "bretylium", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "7235792_4_Ent0", "text": "Paradoxical ventricular tachycardia and fibrillation", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "7235792_4_Ent2", "text": "intravenous", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7235792_4_Ent1", "text": "intravenous bretylium", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "7235792_4_Ent3", "text": "bretylium", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "7272895_2", "wnd_id": "7272895_2_1", "text": "Acute acoustic nerve palsy associated with vincristine therapy .", "tokens": ["Acute", "acoustic", "nerve", "palsy", "associated", "with", "vincristine", "therapy", "."], "event_mentions": [{"id": "7272895_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "7272895_2_Ent0", "role": "Effect", "text": "Acute acoustic nerve palsy", "start": 0, "end": 4}, {"entity_id": "7272895_2_Ent2", "role": "Treatment_Drug", "text": "vincristine", "start": 6, "end": 7}, {"entity_id": "7272895_2_Ent1", "role": "Treatment", "text": "vincristine therapy", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "7272895_2_Ent0", "text": "Acute acoustic nerve palsy", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "7272895_2_Ent2", "text": "vincristine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7272895_2_Ent1", "text": "vincristine therapy", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "7282702_3", "wnd_id": "7282702_3_1", "text": "On the second day of hospitalization , it was noted that the patient 's dyspnea and sinus bradycardia could be related to a recent increase in his timolol dosage .", "tokens": ["On", "the", "second", "day", "of", "hospitalization", ",", "it", "was", "noted", "that", "the", "patient", "'s", "dyspnea", "and", "sinus", "bradycardia", "could", "be", "related", "to", "a", "recent", "increase", "in", "his", "timolol", "dosage", "."], "event_mentions": [{"id": "7282702_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 20, "end": 21}, "arguments": [{"entity_id": "7282702_3_Ent0", "role": "Subject", "text": "patient", "start": 12, "end": 13}, {"entity_id": "7282702_3_Ent1", "role": "Effect", "text": "dyspnea and sinus bradycardia", "start": 14, "end": 18}, {"entity_id": "7282702_3_Ent2", "role": "Treatment", "text": "a recent increase in his timolol dosage", "start": 22, "end": 29}, {"entity_id": "7282702_3_Ent3", "role": "Treatment_Drug", "text": "timolol", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "7282702_3_Ent0", "text": "patient", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "7282702_3_Ent1", "text": "dyspnea and sinus bradycardia", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "7282702_3_Ent2", "text": "a recent increase in his timolol dosage", "entity_type": "Entity", "start": 22, "end": 29}, {"id": "7282702_3_Ent3", "text": "timolol", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "7321956_1", "wnd_id": "7321956_1_1", "text": "Liver disease induced by perhexiline maleate .", "tokens": ["Liver", "disease", "induced", "by", "perhexiline", "maleate", "."], "event_mentions": [{"id": "7321956_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced by", "start": 2, "end": 4}, "arguments": [{"entity_id": "7321956_1_Ent0", "role": "Effect", "text": "Liver disease", "start": 0, "end": 2}, {"entity_id": "7321956_1_Ent1", "role": "Treatment", "text": "perhexiline maleate", "start": 4, "end": 6}, {"entity_id": "7321956_1_Ent2", "role": "Treatment_Drug", "text": "perhexiline maleate", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "7321956_1_Ent0", "text": "Liver disease", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7321956_1_Ent1", "text": "perhexiline maleate", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "7321956_1_Ent2", "text": "perhexiline maleate", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "7351000_1", "wnd_id": "7351000_1_1", "text": "Acute non - lymphocytic leukemia in patients with ovarian carcinoma following long - term treatment with Treosulfan (= dihydroxybusulfan ) .", "tokens": ["Acute", "non", "-", "lymphocytic", "leukemia", "in", "patients", "with", "ovarian", "carcinoma", "following", "long", "-", "term", "treatment", "with", "Treosulfan", "(=", "dihydroxybusulfan", ")", "."], "event_mentions": [{"id": "7351000_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 10, "end": 11}, "arguments": [{"entity_id": "7351000_1_Ent1", "role": "Effect", "text": "Acute non - lymphocytic leukemia", "start": 0, "end": 5}, {"entity_id": "7351000_1_Ent0", "role": "Subject", "text": "patients with ovarian carcinoma", "start": 6, "end": 10}, {"entity_id": "7351000_1_Ent4", "role": "Treatment_Disorder", "text": "ovarian carcinoma", "start": 8, "end": 10}, {"entity_id": "7351000_1_Ent2", "role": "Treatment", "text": "long - term treatment with Treosulfan (= dihydroxybusulfan )", "start": 11, "end": 20}, {"entity_id": "7351000_1_Ent3", "role": "Treatment_Drug", "text": "Treosulfan", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "7351000_1_Ent1", "text": "Acute non - lymphocytic leukemia", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "7351000_1_Ent0", "text": "patients with ovarian carcinoma", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "7351000_1_Ent4", "text": "ovarian carcinoma", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "7351000_1_Ent2", "text": "long - term treatment with Treosulfan (= dihydroxybusulfan )", "entity_type": "Entity", "start": 11, "end": 20}, {"id": "7351000_1_Ent3", "text": "Treosulfan", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "7355327_3", "wnd_id": "7355327_3_1", "text": "Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy , the bronchospasm was believed to be caused by propranolol .", "tokens": ["Since", "the", "bronchospasm", "was", "relieved", "with", "discontinuation", "of", "propranolol", "and", "supportive", "bronchodilator", "therapy", ",", "the", "bronchospasm", "was", "believed", "to", "be", "caused", "by", "propranolol", "."], "event_mentions": [{"id": "7355327_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 20, "end": 21}, "arguments": [{"entity_id": "7355327_3_Ent2", "role": "Treatment_Drug", "text": "propranolol", "start": 8, "end": 9}, {"entity_id": "7355327_3_Ent0", "role": "Effect", "text": "bronchospasm", "start": 15, "end": 16}, {"entity_id": "7355327_3_Ent1", "role": "Treatment", "text": "propranolol", "start": 22, "end": 23}, {"entity_id": "7355327_3_Ent3", "role": "Treatment_Drug", "text": "propranolol", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "7355327_3_Ent2", "text": "propranolol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7355327_3_Ent0", "text": "bronchospasm", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "7355327_3_Ent1", "text": "propranolol", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "7355327_3_Ent3", "text": "propranolol", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "7387219_1", "wnd_id": "7387219_1_1", "text": "Hepatotoxicity associated with use of D - penicillamine in rheumatoid arthritis .", "tokens": ["Hepatotoxicity", "associated", "with", "use", "of", "D", "-", "penicillamine", "in", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "7387219_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "7387219_1_Ent0", "role": "Effect", "text": "Hepatotoxicity", "start": 0, "end": 1}, {"entity_id": "7387219_1_Ent1", "role": "Treatment", "text": "D - penicillamine", "start": 5, "end": 8}, {"entity_id": "7387219_1_Ent3", "role": "Treatment_Drug", "text": "D - penicillamine", "start": 5, "end": 8}, {"entity_id": "7387219_1_Ent2", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "7387219_1_Ent0", "text": "Hepatotoxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7387219_1_Ent1", "text": "D - penicillamine", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "7387219_1_Ent3", "text": "D - penicillamine", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "7387219_1_Ent2", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "7393795_1", "wnd_id": "7393795_1_1", "text": "A 62 - year - old Indian with diabetic nephropathy controlled with metformin , developed miliary tuberculosis for which he was treated with rifampicin , isoniazid and ethambutol .", "tokens": ["A", "62", "-", "year", "-", "old", "Indian", "with", "diabetic", "nephropathy", "controlled", "with", "metformin", ",", "developed", "miliary", "tuberculosis", "for", "which", "he", "was", "treated", "with", "rifampicin", ",", "isoniazid", "and", "ethambutol", "."], "event_mentions": [{"id": "7393795_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "7393795_1_Ent0", "role": "Subject", "text": "A 62 - year - old Indian with diabetic nephropathy", "start": 0, "end": 10}, {"entity_id": "7393795_1_Ent1", "role": "Subject_Age", "text": "62 - year - old", "start": 1, "end": 6}, {"entity_id": "7393795_1_Ent2", "role": "Subject_Race", "text": "Indian", "start": 6, "end": 7}, {"entity_id": "7393795_1_Ent5", "role": "Treatment_Disorder", "text": "diabetic nephropathy", "start": 8, "end": 10}, {"entity_id": "7393795_1_Ent4", "role": "Treatment", "text": "metformin", "start": 12, "end": 13}, {"entity_id": "7393795_1_Ent6", "role": "Treatment_Drug", "text": "metformin", "start": 12, "end": 13}, {"entity_id": "7393795_1_Ent3", "role": "Effect", "text": "miliary tuberculosis", "start": 15, "end": 17}]}, {"id": "7393795_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 21, "end": 22}, "arguments": [{"entity_id": "7393795_1_Ent8", "role": "Treatment_Disorder", "text": "miliary tuberculosis", "start": 15, "end": 17}, {"entity_id": "7393795_1_Ent10", "role": "Treatment_Drug", "text": "rifampicin", "start": 23, "end": 24}, {"entity_id": "7393795_1_Ent14", "role": "Combination_Drug", "text": "rifampicin", "start": 23, "end": 24}, {"entity_id": "7393795_1_Ent7", "role": "Treatment", "text": "rifampicin , isoniazid and ethambutol", "start": 23, "end": 28}, {"entity_id": "7393795_1_Ent11", "role": "Treatment_Drug", "text": "isoniazid", "start": 25, "end": 26}, {"entity_id": "7393795_1_Ent13", "role": "Combination_Drug", "text": "isoniazid", "start": 25, "end": 26}, {"entity_id": "7393795_1_Ent9", "role": "Treatment_Drug", "text": "ethambutol", "start": 27, "end": 28}, {"entity_id": "7393795_1_Ent12", "role": "Combination_Drug", "text": "ethambutol", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "7393795_1_Ent0", "text": "A 62 - year - old Indian with diabetic nephropathy", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "7393795_1_Ent1", "text": "62 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "7393795_1_Ent2", "text": "Indian", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7393795_1_Ent5", "text": "diabetic nephropathy", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "7393795_1_Ent4", "text": "metformin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "7393795_1_Ent6", "text": "metformin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "7393795_1_Ent3", "text": "miliary tuberculosis", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "7393795_1_Ent8", "text": "miliary tuberculosis", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "7393795_1_Ent10", "text": "rifampicin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "7393795_1_Ent14", "text": "rifampicin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "7393795_1_Ent7", "text": "rifampicin , isoniazid and ethambutol", "entity_type": "Entity", "start": 23, "end": 28}, {"id": "7393795_1_Ent11", "text": "isoniazid", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "7393795_1_Ent13", "text": "isoniazid", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "7393795_1_Ent9", "text": "ethambutol", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "7393795_1_Ent12", "text": "ethambutol", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "7428724_1", "wnd_id": "7428724_1_1", "text": "Four cases of oesophageal damage associated with ingestion of the urinary anti - spasmodic agent emepronium bromide are described .", "tokens": ["Four", "cases", "of", "oesophageal", "damage", "associated", "with", "ingestion", "of", "the", "urinary", "anti", "-", "spasmodic", "agent", "emepronium", "bromide", "are", "described", "."], "event_mentions": [{"id": "7428724_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "7428724_1_Ent1", "role": "Subject_Population", "text": "Four", "start": 0, "end": 1}, {"entity_id": "7428724_1_Ent0", "role": "Subject", "text": "Four cases", "start": 0, "end": 2}, {"entity_id": "7428724_1_Ent2", "role": "Effect", "text": "oesophageal damage", "start": 3, "end": 5}, {"entity_id": "7428724_1_Ent4", "role": "Treatment_Route", "text": "ingestion", "start": 7, "end": 8}, {"entity_id": "7428724_1_Ent3", "role": "Treatment", "text": "ingestion of the urinary anti - spasmodic agent emepronium bromide", "start": 7, "end": 17}, {"entity_id": "7428724_1_Ent5", "role": "Treatment_Drug", "text": "emepronium bromide", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "7428724_1_Ent1", "text": "Four", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7428724_1_Ent0", "text": "Four cases", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7428724_1_Ent2", "text": "oesophageal damage", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "7428724_1_Ent4", "text": "ingestion", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7428724_1_Ent3", "text": "ingestion of the urinary anti - spasmodic agent emepronium bromide", "entity_type": "Entity", "start": 7, "end": 17}, {"id": "7428724_1_Ent5", "text": "emepronium bromide", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "7459812_1", "wnd_id": "7459812_1_1", "text": "Fatal interstitial pneumonitis following high - dose intermittent chlorambucil therapy for chronic lymphocyte leukemia .", "tokens": ["Fatal", "interstitial", "pneumonitis", "following", "high", "-", "dose", "intermittent", "chlorambucil", "therapy", "for", "chronic", "lymphocyte", "leukemia", "."], "event_mentions": [{"id": "7459812_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "7459812_1_Ent0", "role": "Effect", "text": "Fatal interstitial pneumonitis", "start": 0, "end": 3}, {"entity_id": "7459812_1_Ent2", "role": "Treatment_Dosage", "text": "high - dose", "start": 4, "end": 7}, {"entity_id": "7459812_1_Ent1", "role": "Treatment", "text": "high - dose intermittent chlorambucil therapy", "start": 4, "end": 10}, {"entity_id": "7459812_1_Ent3", "role": "Treatment_Drug", "text": "chlorambucil", "start": 8, "end": 9}, {"entity_id": "7459812_1_Ent4", "role": "Treatment_Disorder", "text": "chronic lymphocyte leukemia", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "7459812_1_Ent0", "text": "Fatal interstitial pneumonitis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "7459812_1_Ent2", "text": "high - dose", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "7459812_1_Ent1", "text": "high - dose intermittent chlorambucil therapy", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "7459812_1_Ent3", "text": "chlorambucil", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7459812_1_Ent4", "text": "chronic lymphocyte leukemia", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "7485371_1", "wnd_id": "7485371_1_1", "text": "CONCLUSION : Atovaquone should be added to the list of agents causing vortex keratopathy involving the corneal epithelium .", "tokens": ["CONCLUSION", ":", "Atovaquone", "should", "be", "added", "to", "the", "list", "of", "agents", "causing", "vortex", "keratopathy", "involving", "the", "corneal", "epithelium", "."], "event_mentions": [{"id": "7485371_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causing", "start": 11, "end": 12}, "arguments": [{"entity_id": "7485371_1_Ent1", "role": "Treatment", "text": "Atovaquone", "start": 2, "end": 3}, {"entity_id": "7485371_1_Ent2", "role": "Treatment_Drug", "text": "Atovaquone", "start": 2, "end": 3}, {"entity_id": "7485371_1_Ent0", "role": "Effect", "text": "vortex keratopathy involving the corneal epithelium", "start": 12, "end": 18}]}], "entity_mentions": [{"id": "7485371_1_Ent1", "text": "Atovaquone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "7485371_1_Ent2", "text": "Atovaquone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "7485371_1_Ent0", "text": "vortex keratopathy involving the corneal epithelium", "entity_type": "Entity", "start": 12, "end": 18}], "lang": "en"}
{"doc_id": "7549443_1", "wnd_id": "7549443_1_1", "text": "The second had acute cystitis and was treated by sulphonamide and the third developed myopia coincident with metronidazole treatment for trichomonas vaginalis .", "tokens": ["The", "second", "had", "acute", "cystitis", "and", "was", "treated", "by", "sulphonamide", "and", "the", "third", "developed", "myopia", "coincident", "with", "metronidazole", "treatment", "for", "trichomonas", "vaginalis", "."], "event_mentions": [{"id": "7549443_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 7, "end": 8}, "arguments": [{"entity_id": "7549443_1_Ent6", "role": "Treatment_Disorder", "text": "acute cystitis", "start": 3, "end": 5}, {"entity_id": "7549443_1_Ent5", "role": "Treatment", "text": "sulphonamide", "start": 9, "end": 10}, {"entity_id": "7549443_1_Ent7", "role": "Treatment_Drug", "text": "sulphonamide", "start": 9, "end": 10}]}, {"id": "7549443_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "7549443_1_Ent0", "role": "Subject", "text": "the third", "start": 11, "end": 13}, {"entity_id": "7549443_1_Ent1", "role": "Effect", "text": "myopia", "start": 14, "end": 15}, {"entity_id": "7549443_1_Ent3", "role": "Treatment_Drug", "text": "metronidazole", "start": 17, "end": 18}, {"entity_id": "7549443_1_Ent2", "role": "Treatment", "text": "metronidazole treatment", "start": 17, "end": 19}, {"entity_id": "7549443_1_Ent4", "role": "Treatment_Disorder", "text": "trichomonas vaginalis", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "7549443_1_Ent6", "text": "acute cystitis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "7549443_1_Ent5", "text": "sulphonamide", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7549443_1_Ent7", "text": "sulphonamide", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7549443_1_Ent0", "text": "the third", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "7549443_1_Ent1", "text": "myopia", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "7549443_1_Ent3", "text": "metronidazole", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "7549443_1_Ent2", "text": "metronidazole treatment", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "7549443_1_Ent4", "text": "trichomonas vaginalis", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "7577414_3", "wnd_id": "7577414_3_1", "text": "We report a 16 - year - old male who developed nephrotic syndrome related to membranous glomerulopathy with clinical and serological evidence of systemic lupus erythematosus after treatment with griseofulvin .", "tokens": ["We", "report", "a", "16", "-", "year", "-", "old", "male", "who", "developed", "nephrotic", "syndrome", "related", "to", "membranous", "glomerulopathy", "with", "clinical", "and", "serological", "evidence", "of", "systemic", "lupus", "erythematosus", "after", "treatment", "with", "griseofulvin", "."], "event_mentions": [{"id": "7577414_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 26, "end": 27}, "arguments": [{"entity_id": "7577414_3_Ent0", "role": "Subject", "text": "a 16 - year - old male", "start": 2, "end": 9}, {"entity_id": "7577414_3_Ent1", "role": "Subject_Age", "text": "16 - year - old", "start": 3, "end": 8}, {"entity_id": "7577414_3_Ent2", "role": "Subject_Gender", "text": "male", "start": 8, "end": 9}, {"entity_id": "7577414_3_Ent3", "role": "Effect", "text": "nephrotic syndrome related to membranous glomerulopathy with clinical and serological evidence of systemic lupus erythematosus", "start": 11, "end": 26}, {"entity_id": "7577414_3_Ent4", "role": "Treatment", "text": "treatment with griseofulvin", "start": 27, "end": 30}, {"entity_id": "7577414_3_Ent5", "role": "Treatment_Drug", "text": "griseofulvin", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "7577414_3_Ent0", "text": "a 16 - year - old male", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "7577414_3_Ent1", "text": "16 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "7577414_3_Ent2", "text": "male", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7577414_3_Ent3", "text": "nephrotic syndrome related to membranous glomerulopathy with clinical and serological evidence of systemic lupus erythematosus", "entity_type": "Entity", "start": 11, "end": 26}, {"id": "7577414_3_Ent4", "text": "treatment with griseofulvin", "entity_type": "Entity", "start": 27, "end": 30}, {"id": "7577414_3_Ent5", "text": "griseofulvin", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "7606071_1", "wnd_id": "7606071_1_1", "text": "Anaphylactoid reactions with intraperitoneal cisplatin .", "tokens": ["Anaphylactoid", "reactions", "with", "intraperitoneal", "cisplatin", "."], "event_mentions": [{"id": "7606071_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 2, "end": 3}, "arguments": [{"entity_id": "7606071_1_Ent0", "role": "Effect", "text": "Anaphylactoid reactions", "start": 0, "end": 2}, {"entity_id": "7606071_1_Ent2", "role": "Treatment_Route", "text": "intraperitoneal", "start": 3, "end": 4}, {"entity_id": "7606071_1_Ent1", "role": "Treatment", "text": "intraperitoneal cisplatin", "start": 3, "end": 5}, {"entity_id": "7606071_1_Ent3", "role": "Treatment_Drug", "text": "cisplatin", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "7606071_1_Ent0", "text": "Anaphylactoid reactions", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7606071_1_Ent2", "text": "intraperitoneal", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7606071_1_Ent1", "text": "intraperitoneal cisplatin", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "7606071_1_Ent3", "text": "cisplatin", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "7606071_5", "wnd_id": "7606071_5_1", "text": "During her third cycle , she again received cisplatin 100 mg / m2 over 30 minutes and developed palmar pruritus , urticaria , and edema .", "tokens": ["During", "her", "third", "cycle", ",", "she", "again", "received", "cisplatin", "100", "mg", "/", "m2", "over", "30", "minutes", "and", "developed", "palmar", "pruritus", ",", "urticaria", ",", "and", "edema", "."], "event_mentions": [{"id": "7606071_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 17, "end": 18}, "arguments": [{"entity_id": "7606071_5_Ent0", "role": "Subject", "text": "she", "start": 5, "end": 6}, {"entity_id": "7606071_5_Ent1", "role": "Subject_Gender", "text": "she", "start": 5, "end": 6}, {"entity_id": "7606071_5_Ent6", "role": "Treatment_Drug", "text": "cisplatin", "start": 8, "end": 9}, {"entity_id": "7606071_5_Ent3", "role": "Treatment", "text": "cisplatin 100 mg / m2 over 30 minutes", "start": 8, "end": 16}, {"entity_id": "7606071_5_Ent5", "role": "Treatment_Dosage", "text": "100 mg / m2", "start": 9, "end": 13}, {"entity_id": "7606071_5_Ent4", "role": "Treatment_Time_elapsed", "text": "30 minutes", "start": 14, "end": 16}, {"entity_id": "7606071_5_Ent2", "role": "Effect", "text": "palmar pruritus , urticaria , and edema", "start": 18, "end": 25}]}], "entity_mentions": [{"id": "7606071_5_Ent0", "text": "she", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7606071_5_Ent1", "text": "she", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7606071_5_Ent6", "text": "cisplatin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7606071_5_Ent3", "text": "cisplatin 100 mg / m2 over 30 minutes", "entity_type": "Entity", "start": 8, "end": 16}, {"id": "7606071_5_Ent5", "text": "100 mg / m2", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "7606071_5_Ent4", "text": "30 minutes", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "7606071_5_Ent2", "text": "palmar pruritus , urticaria , and edema", "entity_type": "Entity", "start": 18, "end": 25}], "lang": "en"}
{"doc_id": "7632529_2", "wnd_id": "7632529_2_1", "text": "Acute renal failure in a child associated with acyclovir .", "tokens": ["Acute", "renal", "failure", "in", "a", "child", "associated", "with", "acyclovir", "."], "event_mentions": [{"id": "7632529_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "7632529_2_Ent2", "role": "Effect", "text": "Acute renal failure", "start": 0, "end": 3}, {"entity_id": "7632529_2_Ent0", "role": "Subject", "text": "a child", "start": 4, "end": 6}, {"entity_id": "7632529_2_Ent1", "role": "Subject_Age", "text": "child", "start": 5, "end": 6}, {"entity_id": "7632529_2_Ent3", "role": "Treatment", "text": "acyclovir", "start": 8, "end": 9}, {"entity_id": "7632529_2_Ent4", "role": "Treatment_Drug", "text": "acyclovir", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "7632529_2_Ent2", "text": "Acute renal failure", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "7632529_2_Ent0", "text": "a child", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "7632529_2_Ent1", "text": "child", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7632529_2_Ent3", "text": "acyclovir", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7632529_2_Ent4", "text": "acyclovir", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "7639655_3", "wnd_id": "7639655_3_1", "text": "OBJECTIVE : To report the occurrence of anterior ischemic optic neuropathy as a complication of treatment with interferon alfa and to consider the possible underlying mechanisms for this association .", "tokens": ["OBJECTIVE", ":", "To", "report", "the", "occurrence", "of", "anterior", "ischemic", "optic", "neuropathy", "as", "a", "complication", "of", "treatment", "with", "interferon", "alfa", "and", "to", "consider", "the", "possible", "underlying", "mechanisms", "for", "this", "association", "."], "event_mentions": [{"id": "7639655_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 13, "end": 14}, "arguments": [{"entity_id": "7639655_3_Ent0", "role": "Effect", "text": "anterior ischemic optic neuropathy", "start": 7, "end": 11}, {"entity_id": "7639655_3_Ent1", "role": "Treatment", "text": "interferon alfa", "start": 17, "end": 19}, {"entity_id": "7639655_3_Ent2", "role": "Treatment_Drug", "text": "interferon alfa", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "7639655_3_Ent0", "text": "anterior ischemic optic neuropathy", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "7639655_3_Ent1", "text": "interferon alfa", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "7639655_3_Ent2", "text": "interferon alfa", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "7661076_1", "wnd_id": "7661076_1_1", "text": "Evidence is shown in this report that adenosine was associated with dangerous worsening of arrhythmia in patients with atrial flutter .", "tokens": ["Evidence", "is", "shown", "in", "this", "report", "that", "adenosine", "was", "associated", "with", "dangerous", "worsening", "of", "arrhythmia", "in", "patients", "with", "atrial", "flutter", "."], "event_mentions": [{"id": "7661076_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "7661076_1_Ent2", "role": "Treatment", "text": "adenosine", "start": 7, "end": 8}, {"entity_id": "7661076_1_Ent4", "role": "Treatment_Drug", "text": "adenosine", "start": 7, "end": 8}, {"entity_id": "7661076_1_Ent1", "role": "Effect", "text": "dangerous worsening of arrhythmia", "start": 11, "end": 15}, {"entity_id": "7661076_1_Ent0", "role": "Subject", "text": "patients with atrial flutter", "start": 16, "end": 20}, {"entity_id": "7661076_1_Ent3", "role": "Treatment_Disorder", "text": "atrial flutter .", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "7661076_1_Ent2", "text": "adenosine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7661076_1_Ent4", "text": "adenosine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7661076_1_Ent1", "text": "dangerous worsening of arrhythmia", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "7661076_1_Ent0", "text": "patients with atrial flutter", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "7661076_1_Ent3", "text": "atrial flutter .", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "7661076_2", "wnd_id": "7661076_2_1", "text": "Life - threatening alterations in heart rate after the use of adenosine in atrial flutter .", "tokens": ["Life", "-", "threatening", "alterations", "in", "heart", "rate", "after", "the", "use", "of", "adenosine", "in", "atrial", "flutter", "."], "event_mentions": [{"id": "7661076_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "7661076_2_Ent0", "role": "Effect", "text": "Life - threatening alterations in heart rate", "start": 0, "end": 7}, {"entity_id": "7661076_2_Ent1", "role": "Treatment", "text": "adenosine", "start": 11, "end": 12}, {"entity_id": "7661076_2_Ent2", "role": "Treatment_Drug", "text": "adenosine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "7661076_2_Ent0", "text": "Life - threatening alterations in heart rate", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "7661076_2_Ent1", "text": "adenosine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7661076_2_Ent2", "text": "adenosine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "7663030_2", "wnd_id": "7663030_2_1", "text": "OBJECTIVE : To describe a probable case of transient global amnesia caused by propafenone .", "tokens": ["OBJECTIVE", ":", "To", "describe", "a", "probable", "case", "of", "transient", "global", "amnesia", "caused", "by", "propafenone", "."], "event_mentions": [{"id": "7663030_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 11, "end": 12}, "arguments": [{"entity_id": "7663030_2_Ent0", "role": "Effect", "text": "transient global amnesia", "start": 8, "end": 11}, {"entity_id": "7663030_2_Ent1", "role": "Treatment", "text": "propafenone", "start": 13, "end": 14}, {"entity_id": "7663030_2_Ent2", "role": "Treatment_Drug", "text": "propafenone", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "7663030_2_Ent0", "text": "transient global amnesia", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "7663030_2_Ent1", "text": "propafenone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "7663030_2_Ent2", "text": "propafenone", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "7696938_2", "wnd_id": "7696938_2_1", "text": "Correction of serum electrolyte imbalance prevents cardiac arrhythmia during amphotericin B administration .", "tokens": ["Correction", "of", "serum", "electrolyte", "imbalance", "prevents", "cardiac", "arrhythmia", "during", "amphotericin", "B", "administration", "."], "event_mentions": [{"id": "7696938_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 8, "end": 9}, "arguments": [{"entity_id": "7696938_2_Ent0", "role": "Effect", "text": "cardiac arrhythmia", "start": 6, "end": 8}, {"entity_id": "7696938_2_Ent2", "role": "Treatment_Drug", "text": "amphotericin B", "start": 9, "end": 11}, {"entity_id": "7696938_2_Ent1", "role": "Treatment", "text": "amphotericin B administration", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "7696938_2_Ent0", "text": "cardiac arrhythmia", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "7696938_2_Ent2", "text": "amphotericin B", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "7696938_2_Ent1", "text": "amphotericin B administration", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "7724306_1", "wnd_id": "7724306_1_1", "text": "Acute INH neurotoxicity was not suspected on the first admission ; however , when readmitted 4 weeks later with another seizure , the diagnosis of acute INH neurotoxicity was made .", "tokens": ["Acute", "INH", "neurotoxicity", "was", "not", "suspected", "on", "the", "first", "admission", ";", "however", ",", "when", "readmitted", "4", "weeks", "later", "with", "another", "seizure", ",", "the", "diagnosis", "of", "acute", "INH", "neurotoxicity", "was", "made", "."], "event_mentions": [{"id": "7724306_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "diagnosis", "start": 23, "end": 24}, "arguments": [{"entity_id": "7724306_1_Ent0", "role": "Effect", "text": "seizure", "start": 20, "end": 21}, {"entity_id": "7724306_1_Ent1", "role": "Effect", "text": "acute INH neurotoxicity", "start": 25, "end": 28}, {"entity_id": "7724306_1_Ent2", "role": "Treatment", "text": "INH", "start": 26, "end": 27}, {"entity_id": "7724306_1_Ent3", "role": "Treatment_Drug", "text": "INH", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "7724306_1_Ent0", "text": "seizure", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "7724306_1_Ent1", "text": "acute INH neurotoxicity", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "7724306_1_Ent2", "text": "INH", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "7724306_1_Ent3", "text": "INH", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "7724306_6", "wnd_id": "7724306_6_1", "text": "Parenteral pyridoxine , the specific antidote for INH - induced refractory seizures , should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB .", "tokens": ["Parenteral", "pyridoxine", ",", "the", "specific", "antidote", "for", "INH", "-", "induced", "refractory", "seizures", ",", "should", "be", "readily", "available", "in", "every", "emergency", "department", "in", "the", "areas", "similarly", "experiencing", "increasing", "trends", "of", "TB", "."], "event_mentions": [{"id": "7724306_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "7724306_6_Ent1", "role": "Treatment", "text": "INH", "start": 7, "end": 8}, {"entity_id": "7724306_6_Ent2", "role": "Treatment_Drug", "text": "INH", "start": 7, "end": 8}, {"entity_id": "7724306_6_Ent0", "role": "Effect", "text": "refractory seizures", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "7724306_6_Ent1", "text": "INH", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7724306_6_Ent2", "text": "INH", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7724306_6_Ent0", "text": "refractory seizures", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "7724306_7", "wnd_id": "7724306_7_1", "text": "RESULTS : At our institution , no children appeared with acute INH neurotoxicity in the period 1985 through 1990 , whereas seven patients were treated from 1991 through 1993 .", "tokens": ["RESULTS", ":", "At", "our", "institution", ",", "no", "children", "appeared", "with", "acute", "INH", "neurotoxicity", "in", "the", "period", "1985", "through", "1990", ",", "whereas", "seven", "patients", "were", "treated", "from", "1991", "through", "1993", "."], "event_mentions": [{"id": "7724306_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "appeared with", "start": 8, "end": 10}, "arguments": [{"entity_id": "7724306_7_Ent0", "role": "Subject", "text": "children", "start": 7, "end": 8}, {"entity_id": "7724306_7_Ent1", "role": "Subject_Age", "text": "children", "start": 7, "end": 8}, {"entity_id": "7724306_7_Ent3", "role": "Treatment", "text": "INH", "start": 11, "end": 12}, {"entity_id": "7724306_7_Ent4", "role": "Treatment_Drug", "text": "INH", "start": 11, "end": 12}, {"entity_id": "7724306_7_Ent2", "role": "Effect", "text": "neurotoxicity", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "7724306_7_Ent0", "text": "children", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7724306_7_Ent1", "text": "children", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7724306_7_Ent3", "text": "INH", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7724306_7_Ent4", "text": "INH", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7724306_7_Ent2", "text": "neurotoxicity", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "7761316_1", "wnd_id": "7761316_1_1", "text": "Musculoskeletal complaints were the presenting symptoms in four of 44 children ( 9 % ) treated for relapsed Wilms ' tumors with ifosfamide , a derivative of cyclophosphamide .", "tokens": ["Musculoskeletal", "complaints", "were", "the", "presenting", "symptoms", "in", "four", "of", "44", "children", "(", "9", "%", ")", "treated", "for", "relapsed", "Wilms", "'", "tumors", "with", "ifosfamide", ",", "a", "derivative", "of", "cyclophosphamide", "."], "event_mentions": [{"id": "7761316_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 21, "end": 22}, "arguments": [{"entity_id": "7761316_1_Ent3", "role": "Effect", "text": "Musculoskeletal complaints", "start": 0, "end": 2}, {"entity_id": "7761316_1_Ent1", "role": "Subject_Population", "text": "four of 44", "start": 7, "end": 10}, {"entity_id": "7761316_1_Ent0", "role": "Subject", "text": "four of 44 children ( 9 % )", "start": 7, "end": 15}, {"entity_id": "7761316_1_Ent2", "role": "Subject_Age", "text": "children", "start": 10, "end": 11}, {"entity_id": "7761316_1_Ent5", "role": "Treatment_Disorder", "text": "relapsed Wilms ' tumors", "start": 17, "end": 21}, {"entity_id": "7761316_1_Ent4", "role": "Treatment", "text": "ifosfamide", "start": 22, "end": 23}, {"entity_id": "7761316_1_Ent6", "role": "Treatment_Drug", "text": "ifosfamide", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "7761316_1_Ent3", "text": "Musculoskeletal complaints", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7761316_1_Ent1", "text": "four of 44", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "7761316_1_Ent0", "text": "four of 44 children ( 9 % )", "entity_type": "Entity", "start": 7, "end": 15}, {"id": "7761316_1_Ent2", "text": "children", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7761316_1_Ent5", "text": "relapsed Wilms ' tumors", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "7761316_1_Ent4", "text": "ifosfamide", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "7761316_1_Ent6", "text": "ifosfamide", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "7776854_3", "wnd_id": "7776854_3_1", "text": "We report three cases of severe hepatotoxicity related to benzarone , a benzofuran derivative .", "tokens": ["We", "report", "three", "cases", "of", "severe", "hepatotoxicity", "related", "to", "benzarone", ",", "a", "benzofuran", "derivative", "."], "event_mentions": [{"id": "7776854_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 7, "end": 8}, "arguments": [{"entity_id": "7776854_3_Ent1", "role": "Subject_Population", "text": "three", "start": 2, "end": 3}, {"entity_id": "7776854_3_Ent0", "role": "Subject", "text": "three cases", "start": 2, "end": 4}, {"entity_id": "7776854_3_Ent2", "role": "Effect", "text": "severe hepatotoxicity", "start": 5, "end": 7}, {"entity_id": "7776854_3_Ent3", "role": "Treatment", "text": "benzarone", "start": 9, "end": 10}, {"entity_id": "7776854_3_Ent4", "role": "Treatment_Drug", "text": "benzarone", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "7776854_3_Ent1", "text": "three", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "7776854_3_Ent0", "text": "three cases", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "7776854_3_Ent2", "text": "severe hepatotoxicity", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "7776854_3_Ent3", "text": "benzarone", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7776854_3_Ent4", "text": "benzarone", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "7781845_1", "wnd_id": "7781845_1_1", "text": "Mefloquine - associated hypoglycaemia in a cachectic AIDS patient .", "tokens": ["Mefloquine", "-", "associated", "hypoglycaemia", "in", "a", "cachectic", "AIDS", "patient", "."], "event_mentions": [{"id": "7781845_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "7781845_1_Ent3", "role": "Treatment", "text": "Mefloquine", "start": 0, "end": 1}, {"entity_id": "7781845_1_Ent4", "role": "Treatment_Drug", "text": "Mefloquine", "start": 0, "end": 1}, {"entity_id": "7781845_1_Ent2", "role": "Effect", "text": "hypoglycaemia", "start": 3, "end": 4}, {"entity_id": "7781845_1_Ent1", "role": "Subject_Disorder", "text": "cachectic AIDS", "start": 6, "end": 8}, {"entity_id": "7781845_1_Ent0", "role": "Subject", "text": "cachectic AIDS patient", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "7781845_1_Ent3", "text": "Mefloquine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7781845_1_Ent4", "text": "Mefloquine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7781845_1_Ent2", "text": "hypoglycaemia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7781845_1_Ent1", "text": "cachectic AIDS", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "7781845_1_Ent0", "text": "cachectic AIDS patient", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "7781845_4", "wnd_id": "7781845_4_1", "text": "In particular , this adverse effect has never been described with mefloquine ( Lariam ) .", "tokens": ["In", "particular", ",", "this", "adverse", "effect", "has", "never", "been", "described", "with", "mefloquine", "(", "Lariam", ")", "."], "event_mentions": [{"id": "7781845_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "described", "start": 9, "end": 10}, "arguments": [{"entity_id": "7781845_4_Ent0", "role": "Effect", "text": "adverse effect", "start": 4, "end": 6}, {"entity_id": "7781845_4_Ent2", "role": "Treatment_Drug", "text": "mefloquine", "start": 11, "end": 12}, {"entity_id": "7781845_4_Ent1", "role": "Treatment", "text": "mefloquine ( Lariam )", "start": 11, "end": 15}]}], "entity_mentions": [{"id": "7781845_4_Ent0", "text": "adverse effect", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "7781845_4_Ent2", "text": "mefloquine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7781845_4_Ent1", "text": "mefloquine ( Lariam )", "entity_type": "Entity", "start": 11, "end": 15}], "lang": "en"}
{"doc_id": "7783891_1", "wnd_id": "7783891_1_1", "text": "Because sumatriptan can cause coronary artery vasospasm , patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan .", "tokens": ["Because", "sumatriptan", "can", "cause", "coronary", "artery", "vasospasm", ",", "patients", "with", "significant", "risk", "factors", "for", "coronary", "artery", "disease", "should", "be", "carefully", "evaluated", "for", "cardiovascular", "disease", "prior", "to", "the", "use", "of", "sumatriptan", "."], "event_mentions": [{"id": "7783891_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 3, "end": 4}, "arguments": [{"entity_id": "7783891_1_Ent1", "role": "Treatment", "text": "sumatriptan", "start": 1, "end": 2}, {"entity_id": "7783891_1_Ent2", "role": "Treatment_Drug", "text": "sumatriptan", "start": 1, "end": 2}, {"entity_id": "7783891_1_Ent0", "role": "Effect", "text": "coronary artery vasospasm", "start": 4, "end": 7}]}], "entity_mentions": [{"id": "7783891_1_Ent1", "text": "sumatriptan", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7783891_1_Ent2", "text": "sumatriptan", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7783891_1_Ent0", "text": "coronary artery vasospasm", "entity_type": "Entity", "start": 4, "end": 7}], "lang": "en"}
{"doc_id": "7783891_3", "wnd_id": "7783891_3_1", "text": "I report a 35 - year - old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first - time dose of subcutaneous sumatriptan for migraine .", "tokens": ["I", "report", "a", "35", "-", "year", "-", "old", "woman", "with", "occult", "coronary", "artery", "disease", "who", "experienced", "cardiac", "arrest", "within", "minutes", "after", "receiving", "a", "first", "-", "time", "dose", "of", "subcutaneous", "sumatriptan", "for", "migraine", "."], "event_mentions": [{"id": "7783891_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 15, "end": 16}, "arguments": [{"entity_id": "7783891_3_Ent0", "role": "Subject", "text": "a 35 - year - old woman with occult coronary artery disease", "start": 2, "end": 14}, {"entity_id": "7783891_3_Ent1", "role": "Subject_Age", "text": "35 - year - old", "start": 3, "end": 8}, {"entity_id": "7783891_3_Ent2", "role": "Subject_Gender", "text": "woman", "start": 8, "end": 9}, {"entity_id": "7783891_3_Ent3", "role": "Subject_Disorder", "text": "occult coronary artery disease", "start": 10, "end": 14}, {"entity_id": "7783891_3_Ent4", "role": "Effect", "text": "cardiac arrest", "start": 16, "end": 18}, {"entity_id": "7783891_3_Ent9", "role": "Treatment_Time_elapsed", "text": "within minutes", "start": 18, "end": 20}, {"entity_id": "7783891_3_Ent5", "role": "Treatment", "text": "within minutes after receiving a first - time dose of subcutaneous sumatriptan", "start": 18, "end": 30}, {"entity_id": "7783891_3_Ent10", "role": "Treatment_Dosage", "text": "a first - time dose", "start": 22, "end": 27}, {"entity_id": "7783891_3_Ent8", "role": "Treatment_Route", "text": "subcutaneous", "start": 28, "end": 29}, {"entity_id": "7783891_3_Ent6", "role": "Treatment_Drug", "text": "sumatriptan", "start": 29, "end": 30}, {"entity_id": "7783891_3_Ent7", "role": "Treatment_Disorder", "text": "migraine", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "7783891_3_Ent0", "text": "a 35 - year - old woman with occult coronary artery disease", "entity_type": "Entity", "start": 2, "end": 14}, {"id": "7783891_3_Ent1", "text": "35 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "7783891_3_Ent2", "text": "woman", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7783891_3_Ent3", "text": "occult coronary artery disease", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "7783891_3_Ent4", "text": "cardiac arrest", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "7783891_3_Ent9", "text": "within minutes", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "7783891_3_Ent5", "text": "within minutes after receiving a first - time dose of subcutaneous sumatriptan", "entity_type": "Entity", "start": 18, "end": 30}, {"id": "7783891_3_Ent10", "text": "a first - time dose", "entity_type": "Entity", "start": 22, "end": 27}, {"id": "7783891_3_Ent8", "text": "subcutaneous", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "7783891_3_Ent6", "text": "sumatriptan", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "7783891_3_Ent7", "text": "migraine", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "7797283_2", "wnd_id": "7797283_2_1", "text": "Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy .", "tokens": ["Esophageal", "candidiasis", "was", "diagnosed", "at", "endoscopy", "in", "two", "patients", "receiving", "omeprazole", "therapy", "."], "event_mentions": [{"id": "7797283_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 9, "end": 10}, "arguments": [{"entity_id": "7797283_2_Ent2", "role": "Effect", "text": "Esophageal candidiasis", "start": 0, "end": 2}, {"entity_id": "7797283_2_Ent1", "role": "Subject_Population", "text": "two", "start": 7, "end": 8}, {"entity_id": "7797283_2_Ent0", "role": "Subject", "text": "two patients", "start": 7, "end": 9}, {"entity_id": "7797283_2_Ent4", "role": "Treatment_Drug", "text": "omeprazole", "start": 10, "end": 11}, {"entity_id": "7797283_2_Ent3", "role": "Treatment", "text": "omeprazole therapy", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "7797283_2_Ent2", "text": "Esophageal candidiasis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7797283_2_Ent1", "text": "two", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7797283_2_Ent0", "text": "two patients", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "7797283_2_Ent4", "text": "omeprazole", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7797283_2_Ent3", "text": "omeprazole therapy", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "7831179_2", "wnd_id": "7831179_2_1", "text": "There is a dose - effect relationship between doxorubicin and the incidence of symptomatic cardiac failure .", "tokens": ["There", "is", "a", "dose", "-", "effect", "relationship", "between", "doxorubicin", "and", "the", "incidence", "of", "symptomatic", "cardiac", "failure", "."], "event_mentions": [{"id": "7831179_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "relationship", "start": 6, "end": 7}, "arguments": [{"entity_id": "7831179_2_Ent1", "role": "Treatment", "text": "doxorubicin", "start": 8, "end": 9}, {"entity_id": "7831179_2_Ent2", "role": "Treatment_Drug", "text": "doxorubicin", "start": 8, "end": 9}, {"entity_id": "7831179_2_Ent0", "role": "Effect", "text": "symptomatic cardiac failure", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "7831179_2_Ent1", "text": "doxorubicin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7831179_2_Ent2", "text": "doxorubicin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7831179_2_Ent0", "text": "symptomatic cardiac failure", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "7865488_1", "wnd_id": "7865488_1_1", "text": "A case of noncardiogenic pulmonary edema by ethanolamine oleate .", "tokens": ["A", "case", "of", "noncardiogenic", "pulmonary", "edema", "by", "ethanolamine", "oleate", "."], "event_mentions": [{"id": "7865488_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "by", "start": 6, "end": 7}, "arguments": [{"entity_id": "7865488_1_Ent0", "role": "Subject", "text": "A case", "start": 0, "end": 2}, {"entity_id": "7865488_1_Ent1", "role": "Effect", "text": "noncardiogenic pulmonary edema", "start": 3, "end": 6}, {"entity_id": "7865488_1_Ent2", "role": "Treatment", "text": "ethanolamine oleate", "start": 7, "end": 9}, {"entity_id": "7865488_1_Ent3", "role": "Treatment_Drug", "text": "ethanolamine oleate", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "7865488_1_Ent0", "text": "A case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7865488_1_Ent1", "text": "noncardiogenic pulmonary edema", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "7865488_1_Ent2", "text": "ethanolamine oleate", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "7865488_1_Ent3", "text": "ethanolamine oleate", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "7865488_3", "wnd_id": "7865488_3_1", "text": "We report a case of noncardiogenic pulmonary edema developed after therapeutic trial of EO as sclerosing agent for esophageal varix .", "tokens": ["We", "report", "a", "case", "of", "noncardiogenic", "pulmonary", "edema", "developed", "after", "therapeutic", "trial", "of", "EO", "as", "sclerosing", "agent", "for", "esophageal", "varix", "."], "event_mentions": [{"id": "7865488_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "7865488_3_Ent0", "role": "Effect", "text": "noncardiogenic pulmonary edema", "start": 5, "end": 8}, {"entity_id": "7865488_3_Ent1", "role": "Treatment", "text": "EO", "start": 13, "end": 14}, {"entity_id": "7865488_3_Ent2", "role": "Treatment_Drug", "text": "EO", "start": 13, "end": 14}, {"entity_id": "7865488_3_Ent3", "role": "Treatment_Disorder", "text": "esophageal varix", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "7865488_3_Ent0", "text": "noncardiogenic pulmonary edema", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "7865488_3_Ent1", "text": "EO", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "7865488_3_Ent2", "text": "EO", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "7865488_3_Ent3", "text": "esophageal varix", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "788666_3", "wnd_id": "788666_3_1", "text": "Renal failure appeared 8 to 17 days after beginning gentamicin therapy and was characterized by creatinine clearances 4 to 10 ml / min , urine to plasma creatinine ratios less than 20 , urinary sodium concentrations 16 to 60 mEq / liter , proteinuria , and cylindruria .", "tokens": ["Renal", "failure", "appeared", "8", "to", "17", "days", "after", "beginning", "gentamicin", "therapy", "and", "was", "characterized", "by", "creatinine", "clearances", "4", "to", "10", "ml", "/", "min", ",", "urine", "to", "plasma", "creatinine", "ratios", "less", "than", "20", ",", "urinary", "sodium", "concentrations", "16", "to", "60", "mEq", "/", "liter", ",", "proteinuria", ",", "and", "cylindruria", "."], "event_mentions": [{"id": "788666_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "beginning", "start": 8, "end": 9}, "arguments": [{"entity_id": "788666_3_Ent0", "role": "Effect", "text": "Renal failure", "start": 0, "end": 2}, {"entity_id": "788666_3_Ent3", "role": "Treatment_Time_elapsed", "text": "8 to 17 days", "start": 3, "end": 7}, {"entity_id": "788666_3_Ent4", "role": "Treatment_Drug", "text": "gentamicin", "start": 9, "end": 10}, {"entity_id": "788666_3_Ent2", "role": "Treatment", "text": "gentamicin therapy", "start": 9, "end": 11}, {"entity_id": "788666_3_Ent1", "role": "Effect", "text": "creatinine clearances 4 to 10 ml / min , urine to plasma creatinine ratios less than 20 , urinary sodium concentrations 16 to 60 mEq / liter , proteinuria , and cylindruria", "start": 15, "end": 47}]}], "entity_mentions": [{"id": "788666_3_Ent0", "text": "Renal failure", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "788666_3_Ent3", "text": "8 to 17 days", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "788666_3_Ent4", "text": "gentamicin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "788666_3_Ent2", "text": "gentamicin therapy", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "788666_3_Ent1", "text": "creatinine clearances 4 to 10 ml / min , urine to plasma creatinine ratios less than 20 , urinary sodium concentrations 16 to 60 mEq / liter , proteinuria , and cylindruria", "entity_type": "Entity", "start": 15, "end": 47}], "lang": "en"}
{"doc_id": "7893301_2", "wnd_id": "7893301_2_1", "text": "Hypokalemia after normal doses of neubulized albuterol ( salbutamol ) .", "tokens": ["Hypokalemia", "after", "normal", "doses", "of", "neubulized", "albuterol", "(", "salbutamol", ")", "."], "event_mentions": [{"id": "7893301_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 1, "end": 2}, "arguments": [{"entity_id": "7893301_2_Ent0", "role": "Effect", "text": "Hypokalemia", "start": 0, "end": 1}, {"entity_id": "7893301_2_Ent4", "role": "Treatment_Dosage", "text": "normal doses", "start": 2, "end": 4}, {"entity_id": "7893301_2_Ent1", "role": "Treatment", "text": "normal doses of neubulized albuterol ( salbutamol )", "start": 2, "end": 10}, {"entity_id": "7893301_2_Ent2", "role": "Treatment_Drug", "text": "albuterol", "start": 6, "end": 7}, {"entity_id": "7893301_2_Ent3", "role": "Treatment_Drug", "text": "salbutamol", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "7893301_2_Ent0", "text": "Hypokalemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7893301_2_Ent4", "text": "normal doses", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "7893301_2_Ent1", "text": "normal doses of neubulized albuterol ( salbutamol )", "entity_type": "Entity", "start": 2, "end": 10}, {"id": "7893301_2_Ent2", "text": "albuterol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7893301_2_Ent3", "text": "salbutamol", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "7900744_1", "wnd_id": "7900744_1_1", "text": "Case report : mannitol nephrotoxicity syndrome : role of hemodialysis and postulate of mechanisms .", "tokens": ["Case", "report", ":", "mannitol", "nephrotoxicity", "syndrome", ":", "role", "of", "hemodialysis", "and", "postulate", "of", "mechanisms", "."], "event_mentions": [{"id": "7900744_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "syndrome", "start": 5, "end": 6}, "arguments": [{"entity_id": "7900744_1_Ent1", "role": "Treatment", "text": "mannitol", "start": 3, "end": 4}, {"entity_id": "7900744_1_Ent2", "role": "Treatment_Drug", "text": "mannitol", "start": 3, "end": 4}, {"entity_id": "7900744_1_Ent0", "role": "Effect", "text": "nephrotoxicity", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "7900744_1_Ent1", "text": "mannitol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7900744_1_Ent2", "text": "mannitol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7900744_1_Ent0", "text": "nephrotoxicity", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "7900744_2", "wnd_id": "7900744_2_1", "text": "Hemodialysis should be performed for rapid reversal of mannitol - induced ARF .", "tokens": ["Hemodialysis", "should", "be", "performed", "for", "rapid", "reversal", "of", "mannitol", "-", "induced", "ARF", "."], "event_mentions": [{"id": "7900744_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "performed", "start": 3, "end": 4}, "arguments": [{"entity_id": "7900744_2_Ent3", "role": "Treatment", "text": "Hemodialysis", "start": 0, "end": 1}, {"entity_id": "7900744_2_Ent4", "role": "Treatment_Drug", "text": "Hemodialysis", "start": 0, "end": 1}, {"entity_id": "7900744_2_Ent5", "role": "Treatment_Disorder", "text": "mannitol - induced ARF", "start": 8, "end": 12}]}, {"id": "7900744_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "7900744_2_Ent1", "role": "Treatment", "text": "mannitol", "start": 8, "end": 9}, {"entity_id": "7900744_2_Ent2", "role": "Treatment_Drug", "text": "mannitol", "start": 8, "end": 9}, {"entity_id": "7900744_2_Ent0", "role": "Effect", "text": "ARF", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "7900744_2_Ent3", "text": "Hemodialysis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7900744_2_Ent4", "text": "Hemodialysis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7900744_2_Ent1", "text": "mannitol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7900744_2_Ent2", "text": "mannitol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7900744_2_Ent5", "text": "mannitol - induced ARF", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "7900744_2_Ent0", "text": "ARF", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "7900744_5", "wnd_id": "7900744_5_1", "text": "The literature is also reviewed for ARF associated with mannitol infusion in patients who received dialysis and those who did not receive dialysis ; and the possible mechanism(s ) of mannitol nephrotoxicity are discussed .", "tokens": ["The", "literature", "is", "also", "reviewed", "for", "ARF", "associated", "with", "mannitol", "infusion", "in", "patients", "who", "received", "dialysis", "and", "those", "who", "did", "not", "receive", "dialysis", ";", "and", "the", "possible", "mechanism(s", ")", "of", "mannitol", "nephrotoxicity", "are", "discussed", "."], "event_mentions": [{"id": "7900744_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "7900744_5_Ent1", "role": "Effect", "text": "ARF", "start": 6, "end": 7}, {"entity_id": "7900744_5_Ent3", "role": "Treatment_Drug", "text": "mannitol", "start": 9, "end": 10}, {"entity_id": "7900744_5_Ent2", "role": "Treatment", "text": "mannitol infusion", "start": 9, "end": 11}, {"entity_id": "7900744_5_Ent4", "role": "Treatment_Route", "text": "infusion", "start": 10, "end": 11}, {"entity_id": "7900744_5_Ent0", "role": "Subject", "text": "patients", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "7900744_5_Ent1", "text": "ARF", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7900744_5_Ent3", "text": "mannitol", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7900744_5_Ent2", "text": "mannitol infusion", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "7900744_5_Ent4", "text": "infusion", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7900744_5_Ent0", "text": "patients", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "7907218_1", "wnd_id": "7907218_1_1", "text": "Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM - SPECT .", "tokens": ["Two", "patients", "with", "extrapyramidal", "side", "effects", "after", "the", "use", "of", "fluphenazine", "decanoate", "were", "evaluated", "by", "means", "of", "IBZM", "-", "SPECT", "."], "event_mentions": [{"id": "7907218_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 6, "end": 7}, "arguments": [{"entity_id": "7907218_1_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "7907218_1_Ent0", "role": "Subject", "text": "Two patients", "start": 0, "end": 2}, {"entity_id": "7907218_1_Ent2", "role": "Effect", "text": "extrapyramidal side effects", "start": 3, "end": 6}, {"entity_id": "7907218_1_Ent3", "role": "Treatment", "text": "fluphenazine decanoate", "start": 10, "end": 12}, {"entity_id": "7907218_1_Ent4", "role": "Treatment_Drug", "text": "fluphenazine decanoate", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "7907218_1_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7907218_1_Ent0", "text": "Two patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7907218_1_Ent2", "text": "extrapyramidal side effects", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "7907218_1_Ent3", "text": "fluphenazine decanoate", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "7907218_1_Ent4", "text": "fluphenazine decanoate", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "7919557_5", "wnd_id": "7919557_5_1", "text": "We report a case of cough following the administration of quinapril , with complete resolution after changing to the alternative ACE inhibitor fosinopril in a patient with essential hypertension .", "tokens": ["We", "report", "a", "case", "of", "cough", "following", "the", "administration", "of", "quinapril", ",", "with", "complete", "resolution", "after", "changing", "to", "the", "alternative", "ACE", "inhibitor", "fosinopril", "in", "a", "patient", "with", "essential", "hypertension", "."], "event_mentions": [{"id": "7919557_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 6, "end": 7}, "arguments": [{"entity_id": "7919557_5_Ent1", "role": "Effect", "text": "cough", "start": 5, "end": 6}, {"entity_id": "7919557_5_Ent2", "role": "Treatment", "text": "the administration of quinapril", "start": 7, "end": 11}, {"entity_id": "7919557_5_Ent3", "role": "Treatment_Drug", "text": "quinapril", "start": 10, "end": 11}, {"entity_id": "7919557_5_Ent0", "role": "Subject", "text": "patient with essential hypertension", "start": 25, "end": 29}, {"entity_id": "7919557_5_Ent4", "role": "Treatment_Disorder", "text": "hypertension", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "7919557_5_Ent1", "text": "cough", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7919557_5_Ent2", "text": "the administration of quinapril", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "7919557_5_Ent3", "text": "quinapril", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7919557_5_Ent0", "text": "patient with essential hypertension", "entity_type": "Entity", "start": 25, "end": 29}, {"id": "7919557_5_Ent4", "text": "hypertension", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "7937287_10", "wnd_id": "7937287_10_1", "text": "This is the first reported case of suspected DIAN due to cefuroxime .", "tokens": ["This", "is", "the", "first", "reported", "case", "of", "suspected", "DIAN", "due", "to", "cefuroxime", "."], "event_mentions": [{"id": "7937287_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 9, "end": 11}, "arguments": [{"entity_id": "7937287_10_Ent0", "role": "Subject", "text": "first reported case", "start": 3, "end": 6}, {"entity_id": "7937287_10_Ent1", "role": "Effect", "text": "DIAN", "start": 8, "end": 9}, {"entity_id": "7937287_10_Ent2", "role": "Treatment", "text": "cefuroxime", "start": 11, "end": 12}, {"entity_id": "7937287_10_Ent3", "role": "Treatment_Drug", "text": "cefuroxime", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "7937287_10_Ent0", "text": "first reported case", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "7937287_10_Ent1", "text": "DIAN", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7937287_10_Ent2", "text": "cefuroxime", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7937287_10_Ent3", "text": "cefuroxime", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "7946029_1", "wnd_id": "7946029_1_1", "text": "Basilar invagination and mid - line skeletal abnormalities due to in utero exposure to phenytoin .", "tokens": ["Basilar", "invagination", "and", "mid", "-", "line", "skeletal", "abnormalities", "due", "to", "in", "utero", "exposure", "to", "phenytoin", "."], "event_mentions": [{"id": "7946029_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 8, "end": 9}, "arguments": [{"entity_id": "7946029_1_Ent0", "role": "Effect", "text": "Basilar invagination and mid - line skeletal abnormalities", "start": 0, "end": 8}, {"entity_id": "7946029_1_Ent1", "role": "Treatment", "text": "utero exposure to phenytoin", "start": 11, "end": 15}, {"entity_id": "7946029_1_Ent2", "role": "Treatment_Drug", "text": "phenytoin", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "7946029_1_Ent0", "text": "Basilar invagination and mid - line skeletal abnormalities", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "7946029_1_Ent1", "text": "utero exposure to phenytoin", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "7946029_1_Ent2", "text": "phenytoin", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "7962394_1", "wnd_id": "7962394_1_1", "text": "Acute pancreatitis associated with danazol treatment for endometriosis .", "tokens": ["Acute", "pancreatitis", "associated", "with", "danazol", "treatment", "for", "endometriosis", "."], "event_mentions": [{"id": "7962394_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "7962394_1_Ent0", "role": "Effect", "text": "Acute pancreatitis", "start": 0, "end": 2}, {"entity_id": "7962394_1_Ent2", "role": "Treatment_Drug", "text": "danazol", "start": 4, "end": 5}, {"entity_id": "7962394_1_Ent1", "role": "Treatment", "text": "danazol treatment", "start": 4, "end": 6}, {"entity_id": "7962394_1_Ent3", "role": "Treatment_Disorder", "text": "endometriosis", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "7962394_1_Ent0", "text": "Acute pancreatitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7962394_1_Ent2", "text": "danazol", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "7962394_1_Ent1", "text": "danazol treatment", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "7962394_1_Ent3", "text": "endometriosis", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "7962394_2", "wnd_id": "7962394_2_1", "text": "Additionally , danazol produces hepatocellular damage in approximately 10 % of women .", "tokens": ["Additionally", ",", "danazol", "produces", "hepatocellular", "damage", "in", "approximately", "10", "%", "of", "women", "."], "event_mentions": [{"id": "7962394_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "produces", "start": 3, "end": 4}, "arguments": [{"entity_id": "7962394_2_Ent4", "role": "Treatment", "text": "danazol", "start": 2, "end": 3}, {"entity_id": "7962394_2_Ent5", "role": "Treatment_Drug", "text": "danazol", "start": 2, "end": 3}, {"entity_id": "7962394_2_Ent3", "role": "Effect", "text": "hepatocellular damage", "start": 4, "end": 6}, {"entity_id": "7962394_2_Ent1", "role": "Subject_Population", "text": "10 %", "start": 8, "end": 10}, {"entity_id": "7962394_2_Ent0", "role": "Subject", "text": "10 % of women", "start": 8, "end": 12}, {"entity_id": "7962394_2_Ent2", "role": "Subject_Gender", "text": "women", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "7962394_2_Ent4", "text": "danazol", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "7962394_2_Ent5", "text": "danazol", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "7962394_2_Ent3", "text": "hepatocellular damage", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "7962394_2_Ent1", "text": "10 %", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "7962394_2_Ent0", "text": "10 % of women", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "7962394_2_Ent2", "text": "women", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "7973922_3", "wnd_id": "7973922_3_1", "text": "Systemic disease , most commonly renal dysfunction , preceded all 30 reported cases of acyclovir neurotoxicity .", "tokens": ["Systemic", "disease", ",", "most", "commonly", "renal", "dysfunction", ",", "preceded", "all", "30", "reported", "cases", "of", "acyclovir", "neurotoxicity", "."], "event_mentions": [{"id": "7973922_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "preceded", "start": 8, "end": 9}, "arguments": [{"entity_id": "7973922_3_Ent2", "role": "Effect", "text": "Systemic disease , most commonly renal dysfunction", "start": 0, "end": 7}, {"entity_id": "7973922_3_Ent1", "role": "Subject_Population", "text": "30", "start": 10, "end": 11}, {"entity_id": "7973922_3_Ent0", "role": "Subject", "text": "30 reported cases", "start": 10, "end": 13}, {"entity_id": "7973922_3_Ent4", "role": "Treatment", "text": "acyclovir", "start": 14, "end": 15}, {"entity_id": "7973922_3_Ent5", "role": "Treatment_Drug", "text": "acyclovir", "start": 14, "end": 15}, {"entity_id": "7973922_3_Ent3", "role": "Effect", "text": "neurotoxicity", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "7973922_3_Ent2", "text": "Systemic disease , most commonly renal dysfunction", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "7973922_3_Ent1", "text": "30", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7973922_3_Ent0", "text": "30 reported cases", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "7973922_3_Ent4", "text": "acyclovir", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "7973922_3_Ent5", "text": "acyclovir", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "7973922_3_Ent3", "text": "neurotoxicity", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "7995508_1", "wnd_id": "7995508_1_1", "text": "Phenylpropanolamine - induced psychosis .", "tokens": ["Phenylpropanolamine", "-", "induced", "psychosis", "."], "event_mentions": [{"id": "7995508_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "7995508_1_Ent1", "role": "Treatment", "text": "Phenylpropanolamine", "start": 0, "end": 1}, {"entity_id": "7995508_1_Ent2", "role": "Treatment_Drug", "text": "Phenylpropanolamine", "start": 0, "end": 1}, {"entity_id": "7995508_1_Ent0", "role": "Effect", "text": "psychosis", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "7995508_1_Ent1", "text": "Phenylpropanolamine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7995508_1_Ent2", "text": "Phenylpropanolamine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7995508_1_Ent0", "text": "psychosis", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "8013261_4", "wnd_id": "8013261_4_1", "text": "We report a case of IDDM which occurred during interferon therapy for chronic hepatitis .", "tokens": ["We", "report", "a", "case", "of", "IDDM", "which", "occurred", "during", "interferon", "therapy", "for", "chronic", "hepatitis", "."], "event_mentions": [{"id": "8013261_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 7, "end": 8}, "arguments": [{"entity_id": "8013261_4_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "8013261_4_Ent1", "role": "Effect", "text": "IDDM", "start": 5, "end": 6}, {"entity_id": "8013261_4_Ent3", "role": "Treatment_Drug", "text": "interferon", "start": 9, "end": 10}, {"entity_id": "8013261_4_Ent2", "role": "Treatment", "text": "interferon therapy", "start": 9, "end": 11}, {"entity_id": "8013261_4_Ent4", "role": "Treatment_Disorder", "text": "chronic hepatitis .", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "8013261_4_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "8013261_4_Ent1", "text": "IDDM", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8013261_4_Ent3", "text": "interferon", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8013261_4_Ent2", "text": "interferon therapy", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "8013261_4_Ent4", "text": "chronic hepatitis .", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "8024670_1", "wnd_id": "8024670_1_1", "text": "Four patients who manifested symptoms of the antiepileptic drug ( AED ) hypersensitivity syndrome during therapy with carbamazepine are reported .", "tokens": ["Four", "patients", "who", "manifested", "symptoms", "of", "the", "antiepileptic", "drug", "(", "AED", ")", "hypersensitivity", "syndrome", "during", "therapy", "with", "carbamazepine", "are", "reported", "."], "event_mentions": [{"id": "8024670_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "symptoms of", "start": 4, "end": 6}, "arguments": [{"entity_id": "8024670_1_Ent1", "role": "Subject_Population", "text": "Four", "start": 0, "end": 1}, {"entity_id": "8024670_1_Ent0", "role": "Subject", "text": "Four patients", "start": 0, "end": 2}, {"entity_id": "8024670_1_Ent3", "role": "Treatment", "text": "antiepileptic drug ( AED )", "start": 7, "end": 12}, {"entity_id": "8024670_1_Ent5", "role": "Treatment_Drug", "text": "antiepileptic drug ( AED )", "start": 7, "end": 12}, {"entity_id": "8024670_1_Ent2", "role": "Effect", "text": "hypersensitivity syndrome", "start": 12, "end": 14}, {"entity_id": "8024670_1_Ent4", "role": "Treatment", "text": "during therapy with carbamazepine", "start": 14, "end": 18}, {"entity_id": "8024670_1_Ent6", "role": "Treatment_Drug", "text": "carbamazepine", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "8024670_1_Ent1", "text": "Four", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8024670_1_Ent0", "text": "Four patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8024670_1_Ent3", "text": "antiepileptic drug ( AED )", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "8024670_1_Ent5", "text": "antiepileptic drug ( AED )", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "8024670_1_Ent2", "text": "hypersensitivity syndrome", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "8024670_1_Ent4", "text": "during therapy with carbamazepine", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "8024670_1_Ent6", "text": "carbamazepine", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "8034807_1", "wnd_id": "8034807_1_1", "text": "The use of methotrexate ( MTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and accelerate HIV disease .", "tokens": ["The", "use", "of", "methotrexate", "(", "MTX", ")", "has", "been", "contraindicated", "for", "treatment", "of", "severe", "psoriasis", "in", "HIV", "infection", "on", "the", "basis", "of", "six", "previously", "reported", "cases", "in", "which", "MTX", "appeared", "to", "potentiate", "opportunistic", "infections", "and", "accelerate", "HIV", "disease", "."], "event_mentions": [{"id": "8034807_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "accelerate", "start": 35, "end": 36}, "arguments": [{"entity_id": "8034807_1_Ent2", "role": "Treatment_Drug", "text": "methotrexate ( MTX )", "start": 3, "end": 7}, {"entity_id": "8034807_1_Ent1", "role": "Treatment", "text": "MTX", "start": 28, "end": 29}, {"entity_id": "8034807_1_Ent3", "role": "Treatment_Drug", "text": "MTX", "start": 28, "end": 29}, {"entity_id": "8034807_1_Ent0", "role": "Effect", "text": "HIV disease", "start": 36, "end": 38}]}], "entity_mentions": [{"id": "8034807_1_Ent2", "text": "methotrexate ( MTX )", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "8034807_1_Ent1", "text": "MTX", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "8034807_1_Ent3", "text": "MTX", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "8034807_1_Ent0", "text": "HIV disease", "entity_type": "Entity", "start": 36, "end": 38}], "lang": "en"}
{"doc_id": "8053440_1", "wnd_id": "8053440_1_1", "text": "Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .", "tokens": ["Cholestatic", "liver", "disease", "with", "ductopenia", "(", "vanishing", "bile", "duct", "syndrome", ")", "after", "administration", "of", "clindamycin", "and", "trimethoprim", "-", "sulfamethoxazole", "."], "event_mentions": [{"id": "8053440_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 11, "end": 12}, "arguments": [{"entity_id": "8053440_1_Ent0", "role": "Effect", "text": "Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome )", "start": 0, "end": 11}, {"entity_id": "8053440_1_Ent2", "role": "Treatment_Drug", "text": "clindamycin", "start": 14, "end": 15}, {"entity_id": "8053440_1_Ent5", "role": "Combination_Drug", "text": "clindamycin", "start": 14, "end": 15}, {"entity_id": "8053440_1_Ent1", "role": "Treatment", "text": "clindamycin and trimethoprim - sulfamethoxazole", "start": 14, "end": 19}, {"entity_id": "8053440_1_Ent3", "role": "Treatment_Drug", "text": "trimethoprim", "start": 16, "end": 17}, {"entity_id": "8053440_1_Ent7", "role": "Combination_Drug", "text": "trimethoprim", "start": 16, "end": 17}, {"entity_id": "8053440_1_Ent4", "role": "Treatment_Drug", "text": "sulfamethoxazole", "start": 18, "end": 19}, {"entity_id": "8053440_1_Ent6", "role": "Combination_Drug", "text": "sulfamethoxazole", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "8053440_1_Ent0", "text": "Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome )", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "8053440_1_Ent2", "text": "clindamycin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8053440_1_Ent5", "text": "clindamycin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8053440_1_Ent1", "text": "clindamycin and trimethoprim - sulfamethoxazole", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "8053440_1_Ent3", "text": "trimethoprim", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "8053440_1_Ent7", "text": "trimethoprim", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "8053440_1_Ent4", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "8053440_1_Ent6", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "8098286_3", "wnd_id": "8098286_3_1", "text": "We report on a patient who developed hypersensitivity pneumonitis during treatment with the beta - blocker , celiprolol .", "tokens": ["We", "report", "on", "a", "patient", "who", "developed", "hypersensitivity", "pneumonitis", "during", "treatment", "with", "the", "beta", "-", "blocker", ",", "celiprolol", "."], "event_mentions": [{"id": "8098286_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "8098286_3_Ent0", "role": "Subject", "text": "a patient", "start": 3, "end": 5}, {"entity_id": "8098286_3_Ent1", "role": "Effect", "text": "hypersensitivity pneumonitis", "start": 7, "end": 9}, {"entity_id": "8098286_3_Ent2", "role": "Treatment", "text": "celiprolol", "start": 17, "end": 18}, {"entity_id": "8098286_3_Ent3", "role": "Treatment_Drug", "text": "celiprolol", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "8098286_3_Ent0", "text": "a patient", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "8098286_3_Ent1", "text": "hypersensitivity pneumonitis", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "8098286_3_Ent2", "text": "celiprolol", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "8098286_3_Ent3", "text": "celiprolol", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "812008_1", "wnd_id": "812008_1_1", "text": "Diphenylhydantoin apparently adversely affected both the clinical and biochemical parameters of the acute intermittent porphyria .", "tokens": ["Diphenylhydantoin", "apparently", "adversely", "affected", "both", "the", "clinical", "and", "biochemical", "parameters", "of", "the", "acute", "intermittent", "porphyria", "."], "event_mentions": [{"id": "812008_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "affected", "start": 3, "end": 4}, "arguments": [{"entity_id": "812008_1_Ent1", "role": "Treatment", "text": "Diphenylhydantoin", "start": 0, "end": 1}, {"entity_id": "812008_1_Ent2", "role": "Treatment_Drug", "text": "Diphenylhydantoin", "start": 0, "end": 1}, {"entity_id": "812008_1_Ent0", "role": "Effect", "text": "adversely affected both the clinical and biochemical parameters of the acute intermittent porphyria", "start": 2, "end": 15}]}], "entity_mentions": [{"id": "812008_1_Ent1", "text": "Diphenylhydantoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "812008_1_Ent2", "text": "Diphenylhydantoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "812008_1_Ent0", "text": "adversely affected both the clinical and biochemical parameters of the acute intermittent porphyria", "entity_type": "Entity", "start": 2, "end": 15}], "lang": "en"}
{"doc_id": "8140860_3", "wnd_id": "8140860_3_1", "text": "Seven days after the introduction of amoxycillin ( 500 mg/8 h ) for a probable respiratory infection , the patient developed spontaneous bruising , with an INR of 7.1 .", "tokens": ["Seven", "days", "after", "the", "introduction", "of", "amoxycillin", "(", "500", "mg/8", "h", ")", "for", "a", "probable", "respiratory", "infection", ",", "the", "patient", "developed", "spontaneous", "bruising", ",", "with", "an", "INR", "of", "7.1", "."], "event_mentions": [{"id": "8140860_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 20, "end": 21}, "arguments": [{"entity_id": "8140860_3_Ent4", "role": "Treatment_Time_elapsed", "text": "Seven days after", "start": 0, "end": 3}, {"entity_id": "8140860_3_Ent2", "role": "Treatment", "text": "Seven days after the introduction of amoxycillin ( 500 mg/8 h )", "start": 0, "end": 12}, {"entity_id": "8140860_3_Ent5", "role": "Treatment_Drug", "text": "amoxycillin", "start": 6, "end": 7}, {"entity_id": "8140860_3_Ent6", "role": "Treatment_Dosage", "text": "500 mg/8 h", "start": 8, "end": 11}, {"entity_id": "8140860_3_Ent3", "role": "Treatment_Disorder", "text": "a probable respiratory infection", "start": 13, "end": 17}, {"entity_id": "8140860_3_Ent0", "role": "Subject", "text": "the patient", "start": 18, "end": 20}, {"entity_id": "8140860_3_Ent1", "role": "Effect", "text": "spontaneous bruising , with an INR of 7.1", "start": 21, "end": 29}]}], "entity_mentions": [{"id": "8140860_3_Ent4", "text": "Seven days after", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8140860_3_Ent2", "text": "Seven days after the introduction of amoxycillin ( 500 mg/8 h )", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "8140860_3_Ent5", "text": "amoxycillin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8140860_3_Ent6", "text": "500 mg/8 h", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "8140860_3_Ent3", "text": "a probable respiratory infection", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "8140860_3_Ent0", "text": "the patient", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "8140860_3_Ent1", "text": "spontaneous bruising , with an INR of 7.1", "entity_type": "Entity", "start": 21, "end": 29}], "lang": "en"}
{"doc_id": "8140860_5", "wnd_id": "8140860_5_1", "text": "In this case , the increase in the INR value with associated bruising after the addition of amoxycillin suggests a drug interaction between acenocoumarol and amoxycillin , other possible causes having been eliminated .", "tokens": ["In", "this", "case", ",", "the", "increase", "in", "the", "INR", "value", "with", "associated", "bruising", "after", "the", "addition", "of", "amoxycillin", "suggests", "a", "drug", "interaction", "between", "acenocoumarol", "and", "amoxycillin", ",", "other", "possible", "causes", "having", "been", "eliminated", "."], "event_mentions": [{"id": "8140860_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 13, "end": 14}, "arguments": [{"entity_id": "8140860_5_Ent0", "role": "Effect", "text": "the increase in the INR value with associated bruising", "start": 4, "end": 13}, {"entity_id": "8140860_5_Ent1", "role": "Treatment", "text": "amoxycillin", "start": 17, "end": 18}, {"entity_id": "8140860_5_Ent2", "role": "Treatment_Drug", "text": "amoxycillin", "start": 17, "end": 18}, {"entity_id": "8140860_5_Ent3", "role": "Treatment_Drug", "text": "acenocoumarol", "start": 23, "end": 24}, {"entity_id": "8140860_5_Ent5", "role": "Combination_Drug", "text": "acenocoumarol", "start": 23, "end": 24}, {"entity_id": "8140860_5_Ent4", "role": "Treatment_Drug", "text": "amoxycillin", "start": 25, "end": 26}, {"entity_id": "8140860_5_Ent6", "role": "Combination_Drug", "text": "amoxycillin", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "8140860_5_Ent0", "text": "the increase in the INR value with associated bruising", "entity_type": "Entity", "start": 4, "end": 13}, {"id": "8140860_5_Ent1", "text": "amoxycillin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "8140860_5_Ent2", "text": "amoxycillin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "8140860_5_Ent3", "text": "acenocoumarol", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "8140860_5_Ent5", "text": "acenocoumarol", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "8140860_5_Ent4", "text": "amoxycillin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "8140860_5_Ent6", "text": "amoxycillin", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "8149366_2", "wnd_id": "8149366_2_1", "text": "We report on three observations of parkinsonian patients with levo - dopa - induced diphasic dyskinesias , who received subcutaneous apomorphine to reduce the duration of abnormal movements .", "tokens": ["We", "report", "on", "three", "observations", "of", "parkinsonian", "patients", "with", "levo", "-", "dopa", "-", "induced", "diphasic", "dyskinesias", ",", "who", "received", "subcutaneous", "apomorphine", "to", "reduce", "the", "duration", "of", "abnormal", "movements", "."], "event_mentions": [{"id": "8149366_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 13, "end": 14}, "arguments": [{"entity_id": "8149366_2_Ent1", "role": "Subject_Disorder", "text": "parkinsonian", "start": 6, "end": 7}, {"entity_id": "8149366_2_Ent0", "role": "Subject", "text": "parkinsonian patients", "start": 6, "end": 8}, {"entity_id": "8149366_2_Ent3", "role": "Treatment", "text": "levo - dopa", "start": 9, "end": 12}, {"entity_id": "8149366_2_Ent4", "role": "Treatment_Drug", "text": "levo - dopa", "start": 9, "end": 12}, {"entity_id": "8149366_2_Ent2", "role": "Effect", "text": "diphasic dyskinesias", "start": 14, "end": 16}]}, {"id": "8149366_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "reduce", "start": 22, "end": 23}, "arguments": [{"entity_id": "8149366_2_Ent6", "role": "Subject_Disorder", "text": "parkinsonian", "start": 6, "end": 7}, {"entity_id": "8149366_2_Ent5", "role": "Subject", "text": "parkinsonian patients", "start": 6, "end": 8}, {"entity_id": "8149366_2_Ent9", "role": "Treatment_Route", "text": "subcutaneous", "start": 19, "end": 20}, {"entity_id": "8149366_2_Ent7", "role": "Treatment", "text": "subcutaneous apomorphine", "start": 19, "end": 21}, {"entity_id": "8149366_2_Ent10", "role": "Treatment_Drug", "text": "apomorphine", "start": 20, "end": 21}, {"entity_id": "8149366_2_Ent8", "role": "Treatment_Disorder", "text": "abnormal movements", "start": 26, "end": 28}]}], "entity_mentions": [{"id": "8149366_2_Ent1", "text": "parkinsonian", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8149366_2_Ent6", "text": "parkinsonian", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8149366_2_Ent0", "text": "parkinsonian patients", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "8149366_2_Ent5", "text": "parkinsonian patients", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "8149366_2_Ent3", "text": "levo - dopa", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "8149366_2_Ent4", "text": "levo - dopa", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "8149366_2_Ent2", "text": "diphasic dyskinesias", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "8149366_2_Ent9", "text": "subcutaneous", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "8149366_2_Ent7", "text": "subcutaneous apomorphine", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "8149366_2_Ent10", "text": "apomorphine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8149366_2_Ent8", "text": "abnormal movements", "entity_type": "Entity", "start": 26, "end": 28}], "lang": "en"}
{"doc_id": "8151270_1", "wnd_id": "8151270_1_1", "text": "Fulminant hepatitis with severe lactate acidosis in HIV - infected patients on didanosine therapy .", "tokens": ["Fulminant", "hepatitis", "with", "severe", "lactate", "acidosis", "in", "HIV", "-", "infected", "patients", "on", "didanosine", "therapy", "."], "event_mentions": [{"id": "8151270_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "on", "start": 11, "end": 12}, "arguments": [{"entity_id": "8151270_1_Ent1", "role": "Effect", "text": "Fulminant hepatitis with severe lactate acidosis", "start": 0, "end": 6}, {"entity_id": "8151270_1_Ent3", "role": "Treatment_Disorder", "text": "HIV", "start": 7, "end": 8}, {"entity_id": "8151270_1_Ent0", "role": "Subject", "text": "HIV - infected patients", "start": 7, "end": 11}, {"entity_id": "8151270_1_Ent2", "role": "Treatment", "text": "didanosine", "start": 12, "end": 13}, {"entity_id": "8151270_1_Ent4", "role": "Treatment_Drug", "text": "didanosine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "8151270_1_Ent1", "text": "Fulminant hepatitis with severe lactate acidosis", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "8151270_1_Ent3", "text": "HIV", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8151270_1_Ent0", "text": "HIV - infected patients", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "8151270_1_Ent2", "text": "didanosine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8151270_1_Ent4", "text": "didanosine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "8192712_3", "wnd_id": "8192712_3_1", "text": "Hyperammonemia secondary to valproic acid as a cause of lethargy in a postictal patient .", "tokens": ["Hyperammonemia", "secondary", "to", "valproic", "acid", "as", "a", "cause", "of", "lethargy", "in", "a", "postictal", "patient", "."], "event_mentions": [{"id": "8192712_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 7, "end": 8}, "arguments": [{"entity_id": "8192712_3_Ent1", "role": "Effect", "text": "Hyperammonemia", "start": 0, "end": 1}, {"entity_id": "8192712_3_Ent2", "role": "Treatment", "text": "valproic acid", "start": 3, "end": 5}, {"entity_id": "8192712_3_Ent3", "role": "Treatment_Drug", "text": "valproic acid", "start": 3, "end": 5}, {"entity_id": "8192712_3_Ent0", "role": "Subject", "text": "a postictal patient", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "8192712_3_Ent1", "text": "Hyperammonemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8192712_3_Ent2", "text": "valproic acid", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "8192712_3_Ent3", "text": "valproic acid", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "8192712_3_Ent0", "text": "a postictal patient", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "8244201_3", "wnd_id": "8244201_3_1", "text": "Hyperkalaemia with renal tubular dysfunction by sulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy .", "tokens": ["Hyperkalaemia", "with", "renal", "tubular", "dysfunction", "by", "sulfamethoxazole", "-", "trimethoprim", "for", "Pneumocystis", "carinii", "pneumonia", "in", "patients", "with", "lymphoid", "malignancy", "."], "event_mentions": [{"id": "8244201_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "by", "start": 5, "end": 6}, "arguments": [{"entity_id": "8244201_3_Ent2", "role": "Effect", "text": "Hyperkalaemia with renal tubular dysfunction", "start": 0, "end": 5}, {"entity_id": "8244201_3_Ent5", "role": "Treatment_Drug", "text": "sulfamethoxazole - trimethoprim", "start": 6, "end": 9}, {"entity_id": "8244201_3_Ent3", "role": "Treatment", "text": "sulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia", "start": 6, "end": 13}, {"entity_id": "8244201_3_Ent4", "role": "Treatment_Disorder", "text": "Pneumocystis carinii pneumonia", "start": 10, "end": 13}, {"entity_id": "8244201_3_Ent0", "role": "Subject", "text": "patients with lymphoid malignancy", "start": 14, "end": 18}, {"entity_id": "8244201_3_Ent1", "role": "Subject_Disorder", "text": "lymphoid malignancy", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "8244201_3_Ent2", "text": "Hyperkalaemia with renal tubular dysfunction", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "8244201_3_Ent5", "text": "sulfamethoxazole - trimethoprim", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "8244201_3_Ent3", "text": "sulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "8244201_3_Ent4", "text": "Pneumocystis carinii pneumonia", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "8244201_3_Ent0", "text": "patients with lymphoid malignancy", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "8244201_3_Ent1", "text": "lymphoid malignancy", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "8250714_1", "wnd_id": "8250714_1_1", "text": "Five cases ( four from the literature and one new case ) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia .", "tokens": ["Five", "cases", "(", "four", "from", "the", "literature", "and", "one", "new", "case", ")", "are", "presented", "in", "which", "patients", "unsuspected", "of", "having", "vitamin", "B12", "deficiency", "developed", "subacute", "combined", "degeneration", "of", "the", "spinal", "cord", "following", "nitrous", "oxide", "anesthesia", "."], "event_mentions": [{"id": "8250714_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 23, "end": 24}, "arguments": [{"entity_id": "8250714_1_Ent1", "role": "Subject_Population", "text": "Five", "start": 0, "end": 1}, {"entity_id": "8250714_1_Ent0", "role": "Subject", "text": "Five cases ( four from the literature and one new case ) are presented in which patients unsuspected of having vitamin B12 deficiency", "start": 0, "end": 23}, {"entity_id": "8250714_1_Ent5", "role": "Treatment_Disorder", "text": "vitamin B12 deficiency", "start": 20, "end": 23}, {"entity_id": "8250714_1_Ent2", "role": "Effect", "text": "subacute combined degeneration of the spinal cord", "start": 24, "end": 31}, {"entity_id": "8250714_1_Ent4", "role": "Treatment_Drug", "text": "nitrous oxide", "start": 32, "end": 34}, {"entity_id": "8250714_1_Ent3", "role": "Treatment", "text": "nitrous oxide anesthesia", "start": 32, "end": 35}]}], "entity_mentions": [{"id": "8250714_1_Ent1", "text": "Five", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8250714_1_Ent0", "text": "Five cases ( four from the literature and one new case ) are presented in which patients unsuspected of having vitamin B12 deficiency", "entity_type": "Entity", "start": 0, "end": 23}, {"id": "8250714_1_Ent5", "text": "vitamin B12 deficiency", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "8250714_1_Ent2", "text": "subacute combined degeneration of the spinal cord", "entity_type": "Entity", "start": 24, "end": 31}, {"id": "8250714_1_Ent4", "text": "nitrous oxide", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "8250714_1_Ent3", "text": "nitrous oxide anesthesia", "entity_type": "Entity", "start": 32, "end": 35}], "lang": "en"}
{"doc_id": "8255797_2", "wnd_id": "8255797_2_1", "text": "Neutropenia is an infrequent complication following administration of the angiotensin - converting enzyme ( ACE ) inhibitor , captopril .", "tokens": ["Neutropenia", "is", "an", "infrequent", "complication", "following", "administration", "of", "the", "angiotensin", "-", "converting", "enzyme", "(", "ACE", ")", "inhibitor", ",", "captopril", "."], "event_mentions": [{"id": "8255797_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 5, "end": 6}, "arguments": [{"entity_id": "8255797_2_Ent0", "role": "Effect", "text": "Neutropenia", "start": 0, "end": 1}, {"entity_id": "8255797_2_Ent1", "role": "Treatment", "text": "the angiotensin - converting enzyme ( ACE ) inhibitor , captopril", "start": 8, "end": 19}, {"entity_id": "8255797_2_Ent2", "role": "Treatment_Drug", "text": "captopril", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "8255797_2_Ent0", "text": "Neutropenia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8255797_2_Ent1", "text": "the angiotensin - converting enzyme ( ACE ) inhibitor , captopril", "entity_type": "Entity", "start": 8, "end": 19}, {"id": "8255797_2_Ent2", "text": "captopril", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "8260059_2", "wnd_id": "8260059_2_1", "text": "No explanation for this delay was found , other than the possibility that magnesium sulfate treatment impeded lactogenesis .", "tokens": ["No", "explanation", "for", "this", "delay", "was", "found", ",", "other", "than", "the", "possibility", "that", "magnesium", "sulfate", "treatment", "impeded", "lactogenesis", "."], "event_mentions": [{"id": "8260059_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "impeded", "start": 16, "end": 17}, "arguments": [{"entity_id": "8260059_2_Ent1", "role": "Treatment", "text": "magnesium sulfate", "start": 13, "end": 15}, {"entity_id": "8260059_2_Ent2", "role": "Treatment_Drug", "text": "magnesium sulfate", "start": 13, "end": 15}, {"entity_id": "8260059_2_Ent0", "role": "Effect", "text": "lactogenesis", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "8260059_2_Ent1", "text": "magnesium sulfate", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "8260059_2_Ent2", "text": "magnesium sulfate", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "8260059_2_Ent0", "text": "lactogenesis", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "8276031_5", "wnd_id": "8276031_5_1", "text": "The symptomatology of 18 other paediatric cases of naphthylimidazoline exposure reported to the Belgian National Poison Centre , is also discussed .", "tokens": ["The", "symptomatology", "of", "18", "other", "paediatric", "cases", "of", "naphthylimidazoline", "exposure", "reported", "to", "the", "Belgian", "National", "Poison", "Centre", ",", "is", "also", "discussed", "."], "event_mentions": [{"id": "8276031_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "symptomatology", "start": 1, "end": 2}, "arguments": [{"entity_id": "8276031_5_Ent1", "role": "Subject_Population", "text": "18", "start": 3, "end": 4}, {"entity_id": "8276031_5_Ent0", "role": "Subject", "text": "18 other paediatric cases", "start": 3, "end": 7}, {"entity_id": "8276031_5_Ent2", "role": "Subject_Age", "text": "paediatric", "start": 5, "end": 6}, {"entity_id": "8276031_5_Ent4", "role": "Treatment", "text": "naphthylimidazoline", "start": 8, "end": 9}, {"entity_id": "8276031_5_Ent5", "role": "Treatment_Drug", "text": "naphthylimidazoline", "start": 8, "end": 9}, {"entity_id": "8276031_5_Ent3", "role": "Effect", "text": "naphthylimidazoline exposure", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "8276031_5_Ent1", "text": "18", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8276031_5_Ent0", "text": "18 other paediatric cases", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "8276031_5_Ent2", "text": "paediatric", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8276031_5_Ent4", "text": "naphthylimidazoline", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8276031_5_Ent5", "text": "naphthylimidazoline", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8276031_5_Ent3", "text": "naphthylimidazoline exposure", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "8276031_6", "wnd_id": "8276031_6_1", "text": "Imidazoline intoxication due to overdose or accidental ingestion but also after normal therapeutic usage is frequent in children .", "tokens": ["Imidazoline", "intoxication", "due", "to", "overdose", "or", "accidental", "ingestion", "but", "also", "after", "normal", "therapeutic", "usage", "is", "frequent", "in", "children", "."], "event_mentions": [{"id": "8276031_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 2, "end": 3}, "arguments": [{"entity_id": "8276031_6_Ent3", "role": "Treatment", "text": "Imidazoline", "start": 0, "end": 1}, {"entity_id": "8276031_6_Ent2", "role": "Effect", "text": "intoxication", "start": 1, "end": 2}, {"entity_id": "8276031_6_Ent6", "role": "Treatment_Dosage", "text": "overdose or accidental", "start": 4, "end": 7}, {"entity_id": "8276031_6_Ent4", "role": "Treatment", "text": "overdose or accidental ingestion but also after normal therapeutic usage", "start": 4, "end": 14}, {"entity_id": "8276031_6_Ent5", "role": "Treatment_Route", "text": "ingestion", "start": 7, "end": 8}, {"entity_id": "8276031_6_Ent7", "role": "Treatment_Dosage", "text": "but also after normal therapeutic usage", "start": 8, "end": 14}, {"entity_id": "8276031_6_Ent0", "role": "Subject", "text": "children", "start": 17, "end": 18}, {"entity_id": "8276031_6_Ent1", "role": "Subject_Age", "text": "children", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "8276031_6_Ent3", "text": "Imidazoline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8276031_6_Ent2", "text": "intoxication", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "8276031_6_Ent6", "text": "overdose or accidental", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "8276031_6_Ent4", "text": "overdose or accidental ingestion but also after normal therapeutic usage", "entity_type": "Entity", "start": 4, "end": 14}, {"id": "8276031_6_Ent5", "text": "ingestion", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8276031_6_Ent7", "text": "but also after normal therapeutic usage", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "8276031_6_Ent0", "text": "children", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "8276031_6_Ent1", "text": "children", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "8292513_2", "wnd_id": "8292513_2_1", "text": "Children with acute lymphoblastic leukemia ( ALL ) , treated with L - asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies .", "tokens": ["Children", "with", "acute", "lymphoblastic", "leukemia", "(", "ALL", ")", ",", "treated", "with", "L", "-", "asparaginase", "are", "at", "risk", "for", "cerebral", "thrombosis", "or", "hemorrhage", "because", "of", "coagulation", "protein", "deficiencies", "."], "event_mentions": [{"id": "8292513_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "risk", "start": 16, "end": 17}, "arguments": [{"entity_id": "8292513_2_Ent1", "role": "Subject_Age", "text": "Children", "start": 0, "end": 1}, {"entity_id": "8292513_2_Ent0", "role": "Subject", "text": "Children with acute lymphoblastic leukemia ( ALL )", "start": 0, "end": 8}, {"entity_id": "8292513_2_Ent6", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukemia ( ALL )", "start": 2, "end": 8}, {"entity_id": "8292513_2_Ent4", "role": "Treatment", "text": "L - asparaginase", "start": 11, "end": 14}, {"entity_id": "8292513_2_Ent5", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 11, "end": 14}, {"entity_id": "8292513_2_Ent2", "role": "Effect", "text": "cerebral thrombosis or hemorrhage", "start": 18, "end": 22}, {"entity_id": "8292513_2_Ent3", "role": "Effect", "text": "coagulation protein deficiencies", "start": 24, "end": 27}]}], "entity_mentions": [{"id": "8292513_2_Ent1", "text": "Children", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8292513_2_Ent0", "text": "Children with acute lymphoblastic leukemia ( ALL )", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "8292513_2_Ent6", "text": "acute lymphoblastic leukemia ( ALL )", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "8292513_2_Ent4", "text": "L - asparaginase", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "8292513_2_Ent5", "text": "L - asparaginase", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "8292513_2_Ent2", "text": "cerebral thrombosis or hemorrhage", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "8292513_2_Ent3", "text": "coagulation protein deficiencies", "entity_type": "Entity", "start": 24, "end": 27}], "lang": "en"}
{"doc_id": "8301877_2", "wnd_id": "8301877_2_1", "text": "Myoclonus and seizures in a patient with parkinsonism : induction by levodopa and its confirmation on SEPs .", "tokens": ["Myoclonus", "and", "seizures", "in", "a", "patient", "with", "parkinsonism", ":", "induction", "by", "levodopa", "and", "its", "confirmation", "on", "SEPs", "."], "event_mentions": [{"id": "8301877_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induction", "start": 9, "end": 10}, "arguments": [{"entity_id": "8301877_2_Ent1", "role": "Effect", "text": "Myoclonus and seizures", "start": 0, "end": 3}, {"entity_id": "8301877_2_Ent0", "role": "Subject", "text": "a patient with parkinsonism", "start": 4, "end": 8}, {"entity_id": "8301877_2_Ent3", "role": "Treatment_Disorder", "text": "parkinsonism", "start": 7, "end": 8}, {"entity_id": "8301877_2_Ent2", "role": "Treatment", "text": "levodopa", "start": 11, "end": 12}, {"entity_id": "8301877_2_Ent4", "role": "Treatment_Drug", "text": "levodopa", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "8301877_2_Ent1", "text": "Myoclonus and seizures", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8301877_2_Ent0", "text": "a patient with parkinsonism", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "8301877_2_Ent3", "text": "parkinsonism", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8301877_2_Ent2", "text": "levodopa", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8301877_2_Ent4", "text": "levodopa", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "8301877_3", "wnd_id": "8301877_3_1", "text": "Myoclonus was induced and enhanced by L - dopa , developing into generalized seizures .", "tokens": ["Myoclonus", "was", "induced", "and", "enhanced", "by", "L", "-", "dopa", ",", "developing", "into", "generalized", "seizures", "."], "event_mentions": [{"id": "8301877_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced and enhanced", "start": 2, "end": 5}, "arguments": [{"entity_id": "8301877_3_Ent1", "role": "Effect", "text": "Myoclonus", "start": 0, "end": 1}, {"entity_id": "8301877_3_Ent2", "role": "Treatment", "text": "L - dopa", "start": 6, "end": 9}, {"entity_id": "8301877_3_Ent3", "role": "Treatment_Drug", "text": "L - dopa", "start": 6, "end": 9}, {"entity_id": "8301877_3_Ent0", "role": "Effect", "text": "developing into generalized seizures", "start": 10, "end": 14}]}], "entity_mentions": [{"id": "8301877_3_Ent1", "text": "Myoclonus", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8301877_3_Ent2", "text": "L - dopa", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "8301877_3_Ent3", "text": "L - dopa", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "8301877_3_Ent0", "text": "developing into generalized seizures", "entity_type": "Entity", "start": 10, "end": 14}], "lang": "en"}
{"doc_id": "8329789_2", "wnd_id": "8329789_2_1", "text": "OBJECTIVE : To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population .", "tokens": ["OBJECTIVE", ":", "To", "report", "the", "first", "five", "cases", "of", "amphotericin", "B", "overdose", "with", "secondary", "cardiac", "complications", "in", "a", "pediatric", "population", "."], "event_mentions": [{"id": "8329789_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 13, "end": 14}, "arguments": [{"entity_id": "8329789_2_Ent0", "role": "Subject", "text": "first five cases of", "start": 5, "end": 9}, {"entity_id": "8329789_2_Ent3", "role": "Subject_Population", "text": "five", "start": 6, "end": 7}, {"entity_id": "8329789_2_Ent6", "role": "Treatment_Drug", "text": "amphotericin B", "start": 9, "end": 11}, {"entity_id": "8329789_2_Ent5", "role": "Treatment", "text": "amphotericin B overdose", "start": 9, "end": 12}, {"entity_id": "8329789_2_Ent7", "role": "Treatment_Dosage", "text": "overdose", "start": 11, "end": 12}, {"entity_id": "8329789_2_Ent4", "role": "Effect", "text": "cardiac complications", "start": 14, "end": 16}, {"entity_id": "8329789_2_Ent1", "role": "Subject", "text": "a pediatric population", "start": 17, "end": 20}, {"entity_id": "8329789_2_Ent2", "role": "Subject_Age", "text": "pediatric", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "8329789_2_Ent0", "text": "first five cases of", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "8329789_2_Ent3", "text": "five", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8329789_2_Ent6", "text": "amphotericin B", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "8329789_2_Ent5", "text": "amphotericin B overdose", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "8329789_2_Ent7", "text": "overdose", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8329789_2_Ent4", "text": "cardiac complications", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "8329789_2_Ent1", "text": "a pediatric population", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "8329789_2_Ent2", "text": "pediatric", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "8345435_2", "wnd_id": "8345435_2_1", "text": "L - Carnitine supplementation has been recommended to prevent the fatal hepatotoxic effects associated with valproic acid .", "tokens": ["L", "-", "Carnitine", "supplementation", "has", "been", "recommended", "to", "prevent", "the", "fatal", "hepatotoxic", "effects", "associated", "with", "valproic", "acid", "."], "event_mentions": [{"id": "8345435_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "recommended", "start": 6, "end": 7}, "arguments": [{"entity_id": "8345435_2_Ent3", "role": "Treatment", "text": "L - Carnitine", "start": 0, "end": 3}, {"entity_id": "8345435_2_Ent4", "role": "Treatment_Drug", "text": "L - Carnitine", "start": 0, "end": 3}, {"entity_id": "8345435_2_Ent5", "role": "Treatment_Disorder", "text": "fatal hepatotoxic effects", "start": 10, "end": 13}]}, {"id": "8345435_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 13, "end": 14}, "arguments": [{"entity_id": "8345435_2_Ent0", "role": "Effect", "text": "hepatotoxic effects", "start": 11, "end": 13}, {"entity_id": "8345435_2_Ent1", "role": "Treatment", "text": "valproic acid", "start": 15, "end": 17}, {"entity_id": "8345435_2_Ent2", "role": "Treatment_Drug", "text": "valproic acid", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "8345435_2_Ent3", "text": "L - Carnitine", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8345435_2_Ent4", "text": "L - Carnitine", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8345435_2_Ent5", "text": "fatal hepatotoxic effects", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "8345435_2_Ent0", "text": "hepatotoxic effects", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "8345435_2_Ent1", "text": "valproic acid", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "8345435_2_Ent2", "text": "valproic acid", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "8375752_1", "wnd_id": "8375752_1_1", "text": "Although retinoic acid is well tolerated by the majority of patients with this disease , a potentially fatal complication of this kind of treatment has been reported : \" the retinoic acid syndrome \" .", "tokens": ["Although", "retinoic", "acid", "is", "well", "tolerated", "by", "the", "majority", "of", "patients", "with", "this", "disease", ",", "a", "potentially", "fatal", "complication", "of", "this", "kind", "of", "treatment", "has", "been", "reported", ":", "\"", "the", "retinoic", "acid", "syndrome", "\"", "."], "event_mentions": [{"id": "8375752_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 18, "end": 19}, "arguments": [{"entity_id": "8375752_1_Ent1", "role": "Treatment", "text": "retinoic acid", "start": 1, "end": 3}, {"entity_id": "8375752_1_Ent2", "role": "Treatment_Drug", "text": "retinoic acid", "start": 1, "end": 3}, {"entity_id": "8375752_1_Ent0", "role": "Effect", "text": "fatal complication", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "8375752_1_Ent1", "text": "retinoic acid", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "8375752_1_Ent2", "text": "retinoic acid", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "8375752_1_Ent0", "text": "fatal complication", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "8384030_1", "wnd_id": "8384030_1_1", "text": "CONCLUSIONS : It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient .", "tokens": ["CONCLUSIONS", ":", "It", "is", "probable", "that", "foscarnet", "contributed", "to", "the", "electrolyte", "disorders", "and", "symptomatology", "in", "this", "patient", "."], "event_mentions": [{"id": "8384030_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "contributed", "start": 7, "end": 8}, "arguments": [{"entity_id": "8384030_1_Ent2", "role": "Treatment", "text": "foscarnet", "start": 6, "end": 7}, {"entity_id": "8384030_1_Ent3", "role": "Treatment_Drug", "text": "foscarnet", "start": 6, "end": 7}, {"entity_id": "8384030_1_Ent1", "role": "Effect", "text": "electrolyte disorders and symptomatology", "start": 10, "end": 14}, {"entity_id": "8384030_1_Ent0", "role": "Subject", "text": "this patient", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "8384030_1_Ent2", "text": "foscarnet", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8384030_1_Ent3", "text": "foscarnet", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8384030_1_Ent1", "text": "electrolyte disorders and symptomatology", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "8384030_1_Ent0", "text": "this patient", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "8404753_3", "wnd_id": "8404753_3_1", "text": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures .", "tokens": ["We", "report", "3", "children", "with", "epilepsy", "who", "developed", "facial", "motor", "tics", "after", "initiation", "of", "CBZ", "for", "complex", "partial", "seizures", "."], "event_mentions": [{"id": "8404753_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 11, "end": 12}, "arguments": [{"entity_id": "8404753_3_Ent1", "role": "Subject_Population", "text": "3", "start": 2, "end": 3}, {"entity_id": "8404753_3_Ent0", "role": "Subject", "text": "3 children with epilepsy", "start": 2, "end": 6}, {"entity_id": "8404753_3_Ent2", "role": "Subject_Age", "text": "children", "start": 3, "end": 4}, {"entity_id": "8404753_3_Ent5", "role": "Treatment_Disorder", "text": "epilepsy", "start": 5, "end": 6}, {"entity_id": "8404753_3_Ent3", "role": "Effect", "text": "facial motor tics", "start": 8, "end": 11}, {"entity_id": "8404753_3_Ent4", "role": "Treatment", "text": "CBZ", "start": 14, "end": 15}, {"entity_id": "8404753_3_Ent6", "role": "Treatment_Drug", "text": "CBZ", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "8404753_3_Ent1", "text": "3", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8404753_3_Ent0", "text": "3 children with epilepsy", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "8404753_3_Ent2", "text": "children", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8404753_3_Ent5", "text": "epilepsy", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8404753_3_Ent3", "text": "facial motor tics", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "8404753_3_Ent4", "text": "CBZ", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8404753_3_Ent6", "text": "CBZ", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "8430717_1", "wnd_id": "8430717_1_1", "text": "Acyclovir - induced neurotoxicity : concentration - side effect relationship in acyclovir overdose .", "tokens": ["Acyclovir", "-", "induced", "neurotoxicity", ":", "concentration", "-", "side", "effect", "relationship", "in", "acyclovir", "overdose", "."], "event_mentions": [{"id": "8430717_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "8430717_1_Ent1", "role": "Treatment", "text": "Acyclovir", "start": 0, "end": 1}, {"entity_id": "8430717_1_Ent2", "role": "Treatment_Drug", "text": "Acyclovir", "start": 0, "end": 1}, {"entity_id": "8430717_1_Ent0", "role": "Effect", "text": "neurotoxicity", "start": 3, "end": 4}, {"entity_id": "8430717_1_Ent3", "role": "Treatment_Dosage", "text": "overdose", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "8430717_1_Ent1", "text": "Acyclovir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8430717_1_Ent2", "text": "Acyclovir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8430717_1_Ent0", "text": "neurotoxicity", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8430717_1_Ent3", "text": "overdose", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "8467620_1", "wnd_id": "8467620_1_1", "text": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate .", "tokens": ["Lymphoma", "developing", "in", "a", "patient", "with", "rheumatoid", "arthritis", "taking", "methotrexate", "."], "event_mentions": [{"id": "8467620_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developing", "start": 1, "end": 2}, "arguments": [{"entity_id": "8467620_1_Ent1", "role": "Effect", "text": "Lymphoma", "start": 0, "end": 1}, {"entity_id": "8467620_1_Ent0", "role": "Subject", "text": "a patient with rheumatoid arthritis", "start": 3, "end": 8}, {"entity_id": "8467620_1_Ent4", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 6, "end": 8}, {"entity_id": "8467620_1_Ent2", "role": "Treatment", "text": "methotrexate", "start": 9, "end": 10}, {"entity_id": "8467620_1_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "8467620_1_Ent1", "text": "Lymphoma", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8467620_1_Ent0", "text": "a patient with rheumatoid arthritis", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "8467620_1_Ent4", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "8467620_1_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8467620_1_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "847572_2", "wnd_id": "847572_2_1", "text": "The biochemistry of paracetamol hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of paracetamol is remarked upon .", "tokens": ["The", "biochemistry", "of", "paracetamol", "hepatotoxicity", "is", "outlined", "and", "the", "increased", "susceptibility", "of", "alcoholic", "patients", "to", "the", "hepatotoxic", "effects", "of", "paracetamol", "is", "remarked", "upon", "."], "event_mentions": [{"id": "847572_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "remarked", "start": 21, "end": 22}, "arguments": [{"entity_id": "847572_2_Ent0", "role": "Subject", "text": "alcoholic patients", "start": 12, "end": 14}, {"entity_id": "847572_2_Ent1", "role": "Effect", "text": "hepatotoxic effects", "start": 16, "end": 18}, {"entity_id": "847572_2_Ent2", "role": "Treatment", "text": "paracetamol", "start": 19, "end": 20}, {"entity_id": "847572_2_Ent3", "role": "Treatment_Drug", "text": "paracetamol", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "847572_2_Ent0", "text": "alcoholic patients", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "847572_2_Ent1", "text": "hepatotoxic effects", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "847572_2_Ent2", "text": "paracetamol", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "847572_2_Ent3", "text": "paracetamol", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "8485005_3", "wnd_id": "8485005_3_1", "text": "We report a case of drug - induced Kaposi 's sarcoma ( KS ) on the sole of the right foot in a 71 - year - old man , treated for 6 months with corticosteroid therapy ( prednisolone 25 mg / day ) for pericardial effusion .", "tokens": ["We", "report", "a", "case", "of", "drug", "-", "induced", "Kaposi", "'s", "sarcoma", "(", "KS", ")", "on", "the", "sole", "of", "the", "right", "foot", "in", "a", "71", "-", "year", "-", "old", "man", ",", "treated", "for", "6", "months", "with", "corticosteroid", "therapy", "(", "prednisolone", "25", "mg", "/", "day", ")", "for", "pericardial", "effusion", "."], "event_mentions": [{"id": "8485005_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "8485005_3_Ent0", "role": "Subject", "text": "a case of", "start": 2, "end": 5}, {"entity_id": "8485005_3_Ent5", "role": "Effect", "text": "Kaposi 's sarcoma ( KS )", "start": 8, "end": 14}, {"entity_id": "8485005_3_Ent1", "role": "Subject", "text": "a 71 - year - old man", "start": 22, "end": 29}, {"entity_id": "8485005_3_Ent3", "role": "Subject_Age", "text": "71 - year - old", "start": 23, "end": 28}, {"entity_id": "8485005_3_Ent4", "role": "Subject_Gender", "text": "man", "start": 28, "end": 29}, {"entity_id": "8485005_3_Ent7", "role": "Treatment_Duration", "text": "6 months", "start": 32, "end": 34}, {"entity_id": "8485005_3_Ent6", "role": "Treatment", "text": "6 months with corticosteroid therapy ( prednisolone 25 mg / day )", "start": 32, "end": 44}, {"entity_id": "8485005_3_Ent9", "role": "Treatment_Drug", "text": "prednisolone", "start": 38, "end": 39}, {"entity_id": "8485005_3_Ent8", "role": "Treatment_Dosage", "text": "25 mg / day", "start": 39, "end": 43}, {"entity_id": "8485005_3_Ent2", "role": "Subject", "text": "for pericardial effusion", "start": 44, "end": 47}, {"entity_id": "8485005_3_Ent10", "role": "Treatment_Disorder", "text": "pericardial effusion", "start": 45, "end": 47}]}], "entity_mentions": [{"id": "8485005_3_Ent0", "text": "a case of", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "8485005_3_Ent5", "text": "Kaposi 's sarcoma ( KS )", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "8485005_3_Ent1", "text": "a 71 - year - old man", "entity_type": "Entity", "start": 22, "end": 29}, {"id": "8485005_3_Ent3", "text": "71 - year - old", "entity_type": "Entity", "start": 23, "end": 28}, {"id": "8485005_3_Ent4", "text": "man", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "8485005_3_Ent7", "text": "6 months", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "8485005_3_Ent6", "text": "6 months with corticosteroid therapy ( prednisolone 25 mg / day )", "entity_type": "Entity", "start": 32, "end": 44}, {"id": "8485005_3_Ent9", "text": "prednisolone", "entity_type": "Entity", "start": 38, "end": 39}, {"id": "8485005_3_Ent8", "text": "25 mg / day", "entity_type": "Entity", "start": 39, "end": 43}, {"id": "8485005_3_Ent2", "text": "for pericardial effusion", "entity_type": "Entity", "start": 44, "end": 47}, {"id": "8485005_3_Ent10", "text": "pericardial effusion", "entity_type": "Entity", "start": 45, "end": 47}], "lang": "en"}
{"doc_id": "8496127_2", "wnd_id": "8496127_2_1", "text": "This paper reports on a 6.9 - year - old autistic male who developed repeated episodes of acute dystonic reactions associated with pimozide administration at the doses of 0.096 mg / kg / day and 0.032 mg / kg / day and 32 hours following pimozide withdrawal , as well as during subsequent thioridazine administration .", "tokens": ["This", "paper", "reports", "on", "a", "6.9", "-", "year", "-", "old", "autistic", "male", "who", "developed", "repeated", "episodes", "of", "acute", "dystonic", "reactions", "associated", "with", "pimozide", "administration", "at", "the", "doses", "of", "0.096", "mg", "/", "kg", "/", "day", "and", "0.032", "mg", "/", "kg", "/", "day", "and", "32", "hours", "following", "pimozide", "withdrawal", ",", "as", "well", "as", "during", "subsequent", "thioridazine", "administration", "."], "event_mentions": [{"id": "8496127_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 20, "end": 21}, "arguments": [{"entity_id": "8496127_2_Ent1", "role": "Subject_Age", "text": "6.9 - year - old", "start": 5, "end": 10}, {"entity_id": "8496127_2_Ent0", "role": "Subject", "text": "6.9 - year - old autistic male", "start": 5, "end": 12}, {"entity_id": "8496127_2_Ent2", "role": "Subject_Disorder", "text": "autistic", "start": 10, "end": 11}, {"entity_id": "8496127_2_Ent3", "role": "Subject_Gender", "text": "male", "start": 11, "end": 12}, {"entity_id": "8496127_2_Ent4", "role": "Effect", "text": "repeated episodes of acute dystonic reactions", "start": 14, "end": 20}, {"entity_id": "8496127_2_Ent6", "role": "Treatment_Drug", "text": "pimozide", "start": 22, "end": 23}, {"entity_id": "8496127_2_Ent5", "role": "Treatment", "text": "pimozide administration at the doses of 0.096 mg / kg / day and 0.032 mg / kg / day and 32 hours following pimozide withdrawal , as well as during subsequent thioridazine administration", "start": 22, "end": 55}, {"entity_id": "8496127_2_Ent9", "role": "Treatment_Dosage", "text": "0.096 mg / kg", "start": 28, "end": 32}, {"entity_id": "8496127_2_Ent11", "role": "Treatment_Freq", "text": "day", "start": 33, "end": 34}, {"entity_id": "8496127_2_Ent10", "role": "Treatment_Dosage", "text": "0.032 mg / kg", "start": 35, "end": 39}, {"entity_id": "8496127_2_Ent12", "role": "Treatment_Freq", "text": "day", "start": 40, "end": 41}, {"entity_id": "8496127_2_Ent7", "role": "Treatment_Drug", "text": "pimozide", "start": 45, "end": 46}, {"entity_id": "8496127_2_Ent8", "role": "Treatment_Drug", "text": "thioridazine", "start": 53, "end": 54}]}], "entity_mentions": [{"id": "8496127_2_Ent1", "text": "6.9 - year - old", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "8496127_2_Ent0", "text": "6.9 - year - old autistic male", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "8496127_2_Ent2", "text": "autistic", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8496127_2_Ent3", "text": "male", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8496127_2_Ent4", "text": "repeated episodes of acute dystonic reactions", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "8496127_2_Ent6", "text": "pimozide", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "8496127_2_Ent5", "text": "pimozide administration at the doses of 0.096 mg / kg / day and 0.032 mg / kg / day and 32 hours following pimozide withdrawal , as well as during subsequent thioridazine administration", "entity_type": "Entity", "start": 22, "end": 55}, {"id": "8496127_2_Ent9", "text": "0.096 mg / kg", "entity_type": "Entity", "start": 28, "end": 32}, {"id": "8496127_2_Ent11", "text": "day", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "8496127_2_Ent10", "text": "0.032 mg / kg", "entity_type": "Entity", "start": 35, "end": 39}, {"id": "8496127_2_Ent12", "text": "day", "entity_type": "Entity", "start": 40, "end": 41}, {"id": "8496127_2_Ent7", "text": "pimozide", "entity_type": "Entity", "start": 45, "end": 46}, {"id": "8496127_2_Ent8", "text": "thioridazine", "entity_type": "Entity", "start": 53, "end": 54}], "lang": "en"}
{"doc_id": "8503421_3", "wnd_id": "8503421_3_1", "text": "We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .", "tokens": ["We", "report", "the", "occurrence", "of", "renal", "failure", "due", "to", "cholesterol", "crystal", "embolization", "following", "thrombolytic", "therapy", "with", "intravenous", "recombinant", "tissue", "-", "type", "plasminogen", "activator", "(", "t", "-", "PA", ")", "."], "event_mentions": [{"id": "8503421_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurrence", "start": 3, "end": 4}, "arguments": [{"entity_id": "8503421_3_Ent0", "role": "Effect", "text": "renal failure due to cholesterol crystal embolization", "start": 5, "end": 12}, {"entity_id": "8503421_3_Ent1", "role": "Treatment", "text": "thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA )", "start": 13, "end": 28}, {"entity_id": "8503421_3_Ent2", "role": "Treatment_Route", "text": "intravenous", "start": 16, "end": 17}, {"entity_id": "8503421_3_Ent3", "role": "Treatment_Drug", "text": "recombinant tissue - type plasminogen activator", "start": 17, "end": 23}]}], "entity_mentions": [{"id": "8503421_3_Ent0", "text": "renal failure due to cholesterol crystal embolization", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "8503421_3_Ent1", "text": "thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA )", "entity_type": "Entity", "start": 13, "end": 28}, {"id": "8503421_3_Ent2", "text": "intravenous", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "8503421_3_Ent3", "text": "recombinant tissue - type plasminogen activator", "entity_type": "Entity", "start": 17, "end": 23}], "lang": "en"}
{"doc_id": "85289_2", "wnd_id": "85289_2_1", "text": "We have seen a case of terminal malignant melanoma in which clinical manifestations , indicative of anterior spinal artery syndrome , developed following the injection of 0.3 ml of 10 % phenol - glycerine into the cervical subarachnoid space at the C4 - - C5 level for the control of severe right arm pain .", "tokens": ["We", "have", "seen", "a", "case", "of", "terminal", "malignant", "melanoma", "in", "which", "clinical", "manifestations", ",", "indicative", "of", "anterior", "spinal", "artery", "syndrome", ",", "developed", "following", "the", "injection", "of", "0.3", "ml", "of", "10", "%", "phenol", "-", "glycerine", "into", "the", "cervical", "subarachnoid", "space", "at", "the", "C4", "-", "-", "C5", "level", "for", "the", "control", "of", "severe", "right", "arm", "pain", "."], "event_mentions": [{"id": "85289_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 21, "end": 22}, "arguments": [{"entity_id": "85289_2_Ent0", "role": "Effect", "text": "terminal malignant melanoma in which clinical manifestations , indicative of anterior spinal artery syndrome", "start": 6, "end": 20}, {"entity_id": "85289_2_Ent1", "role": "Treatment", "text": "the injection of 0.3 ml of 10 % phenol - glycerine into the cervical subarachnoid space at the C4 - - C5 level", "start": 23, "end": 46}, {"entity_id": "85289_2_Ent4", "role": "Treatment_Route", "text": "injection", "start": 24, "end": 25}, {"entity_id": "85289_2_Ent6", "role": "Treatment_Dosage", "text": "0.3 ml", "start": 26, "end": 28}, {"entity_id": "85289_2_Ent2", "role": "Treatment_Drug", "text": "10 % phenol - glycerine", "start": 29, "end": 34}, {"entity_id": "85289_2_Ent5", "role": "Treatment_Route", "text": "cervical subarachnoid space at the C4 - - C5 level", "start": 36, "end": 46}, {"entity_id": "85289_2_Ent3", "role": "Treatment_Disorder", "text": "severe right arm pain", "start": 50, "end": 54}]}], "entity_mentions": [{"id": "85289_2_Ent0", "text": "terminal malignant melanoma in which clinical manifestations , indicative of anterior spinal artery syndrome", "entity_type": "Entity", "start": 6, "end": 20}, {"id": "85289_2_Ent1", "text": "the injection of 0.3 ml of 10 % phenol - glycerine into the cervical subarachnoid space at the C4 - - C5 level", "entity_type": "Entity", "start": 23, "end": 46}, {"id": "85289_2_Ent4", "text": "injection", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "85289_2_Ent6", "text": "0.3 ml", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "85289_2_Ent2", "text": "10 % phenol - glycerine", "entity_type": "Entity", "start": 29, "end": 34}, {"id": "85289_2_Ent5", "text": "cervical subarachnoid space at the C4 - - C5 level", "entity_type": "Entity", "start": 36, "end": 46}, {"id": "85289_2_Ent3", "text": "severe right arm pain", "entity_type": "Entity", "start": 50, "end": 54}], "lang": "en"}
{"doc_id": "8530331_1", "wnd_id": "8530331_1_1", "text": "Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson 's disease and other akinetic - rigid syndromes .", "tokens": ["Risperidone", "versus", "clozapine", "in", "the", "treatment", "of", "psychosis", "in", "six", "patients", "with", "Parkinson", "'s", "disease", "and", "other", "akinetic", "-", "rigid", "syndromes", "."], "event_mentions": [{"id": "8530331_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 5, "end": 6}, "arguments": [{"entity_id": "8530331_1_Ent5", "role": "Treatment_Drug", "text": "Risperidone", "start": 0, "end": 1}, {"entity_id": "8530331_1_Ent4", "role": "Treatment", "text": "Risperidone versus clozapine", "start": 0, "end": 3}, {"entity_id": "8530331_1_Ent6", "role": "Treatment_Drug", "text": "clozapine", "start": 2, "end": 3}, {"entity_id": "8530331_1_Ent7", "role": "Treatment_Disorder", "text": "psychosis", "start": 7, "end": 8}, {"entity_id": "8530331_1_Ent1", "role": "Subject_Population", "text": "six", "start": 9, "end": 10}, {"entity_id": "8530331_1_Ent0", "role": "Subject", "text": "six patients with Parkinson 's disease and other akinetic - rigid syndromes", "start": 9, "end": 21}, {"entity_id": "8530331_1_Ent2", "role": "Subject_Disorder", "text": "Parkinson 's disease", "start": 12, "end": 15}, {"entity_id": "8530331_1_Ent3", "role": "Subject_Disorder", "text": "akinetic - rigid syndromes", "start": 17, "end": 21}]}], "entity_mentions": [{"id": "8530331_1_Ent5", "text": "Risperidone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8530331_1_Ent4", "text": "Risperidone versus clozapine", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8530331_1_Ent6", "text": "clozapine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8530331_1_Ent7", "text": "psychosis", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8530331_1_Ent1", "text": "six", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8530331_1_Ent0", "text": "six patients with Parkinson 's disease and other akinetic - rigid syndromes", "entity_type": "Entity", "start": 9, "end": 21}, {"id": "8530331_1_Ent2", "text": "Parkinson 's disease", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "8530331_1_Ent3", "text": "akinetic - rigid syndromes", "entity_type": "Entity", "start": 17, "end": 21}], "lang": "en"}
{"doc_id": "8530331_8", "wnd_id": "8530331_8_1", "text": "CONCLUSION : We believe that risperidone is not a substitute for clozapine in treating psychosis in parkinsonian patients and should be used with caution .", "tokens": ["CONCLUSION", ":", "We", "believe", "that", "risperidone", "is", "not", "a", "substitute", "for", "clozapine", "in", "treating", "psychosis", "in", "parkinsonian", "patients", "and", "should", "be", "used", "with", "caution", "."], "event_mentions": [{"id": "8530331_8_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treating", "start": 13, "end": 14}, "arguments": [{"entity_id": "8530331_8_Ent2", "role": "Treatment", "text": "risperidone", "start": 5, "end": 6}, {"entity_id": "8530331_8_Ent4", "role": "Treatment_Drug", "text": "risperidone", "start": 5, "end": 6}, {"entity_id": "8530331_8_Ent3", "role": "Treatment_Disorder", "text": "psychosis", "start": 14, "end": 15}, {"entity_id": "8530331_8_Ent1", "role": "Subject_Disorder", "text": "parkinsonian", "start": 16, "end": 17}, {"entity_id": "8530331_8_Ent0", "role": "Subject", "text": "parkinsonian patients", "start": 16, "end": 18}]}, {"id": "8530331_8_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treating", "start": 13, "end": 14}, "arguments": [{"entity_id": "8530331_8_Ent7", "role": "Treatment", "text": "clozapine", "start": 11, "end": 12}, {"entity_id": "8530331_8_Ent8", "role": "Treatment_Drug", "text": "clozapine", "start": 11, "end": 12}, {"entity_id": "8530331_8_Ent6", "role": "Subject_Disorder", "text": "parkinsonian", "start": 16, "end": 17}, {"entity_id": "8530331_8_Ent5", "role": "Subject", "text": "parkinsonian patients", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "8530331_8_Ent2", "text": "risperidone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8530331_8_Ent4", "text": "risperidone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8530331_8_Ent7", "text": "clozapine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8530331_8_Ent8", "text": "clozapine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8530331_8_Ent3", "text": "psychosis", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8530331_8_Ent1", "text": "parkinsonian", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "8530331_8_Ent6", "text": "parkinsonian", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "8530331_8_Ent0", "text": "parkinsonian patients", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "8530331_8_Ent5", "text": "parkinsonian patients", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "8551001_3", "wnd_id": "8551001_3_1", "text": "The azathioprine dose was low ( 1 mg / kg ) and pancytopenia occurred after 56 days therapy .", "tokens": ["The", "azathioprine", "dose", "was", "low", "(", "1", "mg", "/", "kg", ")", "and", "pancytopenia", "occurred", "after", "56", "days", "therapy", "."], "event_mentions": [{"id": "8551001_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 13, "end": 14}, "arguments": [{"entity_id": "8551001_3_Ent2", "role": "Treatment", "text": "The azathioprine dose was low ( 1 mg / kg )", "start": 0, "end": 11}, {"entity_id": "8551001_3_Ent4", "role": "Treatment_Drug", "text": "azathioprine", "start": 1, "end": 2}, {"entity_id": "8551001_3_Ent5", "role": "Treatment_Dosage", "text": "1 mg / kg", "start": 6, "end": 10}, {"entity_id": "8551001_3_Ent0", "role": "Effect", "text": "pancytopenia", "start": 12, "end": 13}, {"entity_id": "8551001_3_Ent3", "role": "Treatment_Time_elapsed", "text": "56 days", "start": 15, "end": 17}, {"entity_id": "8551001_3_Ent1", "role": "Treatment", "text": "56 days therapy", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "8551001_3_Ent2", "text": "The azathioprine dose was low ( 1 mg / kg )", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "8551001_3_Ent4", "text": "azathioprine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "8551001_3_Ent5", "text": "1 mg / kg", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "8551001_3_Ent0", "text": "pancytopenia", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8551001_3_Ent3", "text": "56 days", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "8551001_3_Ent1", "text": "56 days therapy", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "8570441_1", "wnd_id": "8570441_1_1", "text": "Nabumetone - associated interstitial nephritis .", "tokens": ["Nabumetone", "-", "associated", "interstitial", "nephritis", "."], "event_mentions": [{"id": "8570441_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "8570441_1_Ent1", "role": "Treatment", "text": "Nabumetone", "start": 0, "end": 1}, {"entity_id": "8570441_1_Ent2", "role": "Treatment_Drug", "text": "Nabumetone", "start": 0, "end": 1}, {"entity_id": "8570441_1_Ent0", "role": "Effect", "text": "interstitial nephritis", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "8570441_1_Ent1", "text": "Nabumetone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8570441_1_Ent2", "text": "Nabumetone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8570441_1_Ent0", "text": "interstitial nephritis", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "8579054_3", "wnd_id": "8579054_3_1", "text": "Prolonged used of hydroxyurea in patients with ET may lead to therapy - associated acute leukemia .", "tokens": ["Prolonged", "used", "of", "hydroxyurea", "in", "patients", "with", "ET", "may", "lead", "to", "therapy", "-", "associated", "acute", "leukemia", "."], "event_mentions": [{"id": "8579054_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 13, "end": 14}, "arguments": [{"entity_id": "8579054_3_Ent5", "role": "Treatment_Freq", "text": "Prolonged used", "start": 0, "end": 2}, {"entity_id": "8579054_3_Ent2", "role": "Treatment", "text": "hydroxyurea", "start": 3, "end": 4}, {"entity_id": "8579054_3_Ent3", "role": "Treatment_Drug", "text": "hydroxyurea", "start": 3, "end": 4}, {"entity_id": "8579054_3_Ent0", "role": "Subject", "text": "patients with ET", "start": 5, "end": 8}, {"entity_id": "8579054_3_Ent4", "role": "Treatment_Disorder", "text": "ET", "start": 7, "end": 8}, {"entity_id": "8579054_3_Ent1", "role": "Effect", "text": "therapy - associated acute leukemia", "start": 11, "end": 16}]}], "entity_mentions": [{"id": "8579054_3_Ent5", "text": "Prolonged used", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8579054_3_Ent2", "text": "hydroxyurea", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8579054_3_Ent3", "text": "hydroxyurea", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8579054_3_Ent0", "text": "patients with ET", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "8579054_3_Ent4", "text": "ET", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8579054_3_Ent1", "text": "therapy - associated acute leukemia", "entity_type": "Entity", "start": 11, "end": 16}], "lang": "en"}
{"doc_id": "8586895_4", "wnd_id": "8586895_4_1", "text": "The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency .", "tokens": ["The", "pharmaceutical", "company", "producing", "Halfan", "has", "reported", "8", "cardiac", "arrests", ",", "leading", "to", "6", "deaths", ",", "when", "a", "higher", "dose", "than", "recommended", "was", "used", ",", "there", "was", "recent", "or", "concomitant", "treatment", "with", "mefloquine", ",", "there", "was", "pre", "-", "existing", "prolongation", "of", "the", "QT", "interval", "or", "the", "patient", "had", "a", "thiamine", "deficiency", "."], "event_mentions": [{"id": "8586895_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 6, "end": 7}, "arguments": [{"entity_id": "8586895_4_Ent2", "role": "Treatment", "text": "Halfan", "start": 4, "end": 5}, {"entity_id": "8586895_4_Ent4", "role": "Treatment_Drug", "text": "Halfan", "start": 4, "end": 5}, {"entity_id": "8586895_4_Ent0", "role": "Effect", "text": "8 cardiac arrests", "start": 7, "end": 10}, {"entity_id": "8586895_4_Ent1", "role": "Effect", "text": "6 deaths", "start": 13, "end": 15}, {"entity_id": "8586895_4_Ent3", "role": "Treatment", "text": "when a higher dose than recommended was used", "start": 16, "end": 24}, {"entity_id": "8586895_4_Ent6", "role": "Treatment_Dosage", "text": "a higher dose than recommended", "start": 17, "end": 22}, {"entity_id": "8586895_4_Ent5", "role": "Treatment_Drug", "text": "mefloquine", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "8586895_4_Ent2", "text": "Halfan", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8586895_4_Ent4", "text": "Halfan", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8586895_4_Ent0", "text": "8 cardiac arrests", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "8586895_4_Ent1", "text": "6 deaths", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "8586895_4_Ent3", "text": "when a higher dose than recommended was used", "entity_type": "Entity", "start": 16, "end": 24}, {"id": "8586895_4_Ent6", "text": "a higher dose than recommended", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "8586895_4_Ent5", "text": "mefloquine", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "8597009_4", "wnd_id": "8597009_4_1", "text": "The wide use of phenytoin during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to phenytoin toxicity .", "tokens": ["The", "wide", "use", "of", "phenytoin", "during", "the", "recent", "tuberculosis", "epidemic", "makes", "it", "imperative", "to", "suspect", "this", "drug", "interaction", "in", "patients", "exhibiting", "clinical", "features", "that", "might", "be", "related", "to", "phenytoin", "toxicity", "."], "event_mentions": [{"id": "8597009_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suspect", "start": 14, "end": 15}, "arguments": [{"entity_id": "8597009_4_Ent2", "role": "Treatment", "text": "phenytoin", "start": 4, "end": 5}, {"entity_id": "8597009_4_Ent4", "role": "Treatment_Drug", "text": "phenytoin", "start": 4, "end": 5}, {"entity_id": "8597009_4_Ent3", "role": "Treatment_Duration", "text": "tuberculosis", "start": 8, "end": 9}, {"entity_id": "8597009_4_Ent0", "role": "Subject", "text": "patients", "start": 19, "end": 20}, {"entity_id": "8597009_4_Ent1", "role": "Effect", "text": "phenytoin toxicity", "start": 28, "end": 30}]}], "entity_mentions": [{"id": "8597009_4_Ent2", "text": "phenytoin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8597009_4_Ent4", "text": "phenytoin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8597009_4_Ent3", "text": "tuberculosis", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8597009_4_Ent0", "text": "patients", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "8597009_4_Ent1", "text": "phenytoin toxicity", "entity_type": "Entity", "start": 28, "end": 30}], "lang": "en"}
{"doc_id": "8604715_4", "wnd_id": "8604715_4_1", "text": "We present a patient with human immunodeficiency virus infection under treatment with foscarnet for CMV retinitis who complained of thirst and polyuria .", "tokens": ["We", "present", "a", "patient", "with", "human", "immunodeficiency", "virus", "infection", "under", "treatment", "with", "foscarnet", "for", "CMV", "retinitis", "who", "complained", "of", "thirst", "and", "polyuria", "."], "event_mentions": [{"id": "8604715_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complained", "start": 17, "end": 18}, "arguments": [{"entity_id": "8604715_4_Ent0", "role": "Subject", "text": "a patient with human immunodeficiency virus infection", "start": 2, "end": 9}, {"entity_id": "8604715_4_Ent1", "role": "Subject_Disorder", "text": "human immunodeficiency virus infection", "start": 5, "end": 9}, {"entity_id": "8604715_4_Ent3", "role": "Treatment", "text": "foscarnet", "start": 12, "end": 13}, {"entity_id": "8604715_4_Ent5", "role": "Treatment_Drug", "text": "foscarnet", "start": 12, "end": 13}, {"entity_id": "8604715_4_Ent4", "role": "Treatment_Disorder", "text": "CMV retinitis", "start": 14, "end": 16}, {"entity_id": "8604715_4_Ent2", "role": "Effect", "text": "thirst and polyuria", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "8604715_4_Ent0", "text": "a patient with human immunodeficiency virus infection", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "8604715_4_Ent1", "text": "human immunodeficiency virus infection", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "8604715_4_Ent3", "text": "foscarnet", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8604715_4_Ent5", "text": "foscarnet", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8604715_4_Ent4", "text": "CMV retinitis", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "8604715_4_Ent2", "text": "thirst and polyuria", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "8610807_3", "wnd_id": "8610807_3_1", "text": "PURPOSE : To determine the cause of spontaneous choroidal hemorrhage in a 67 - year - old man after a myocardial infarction and administration of tissue plasminogen activator .", "tokens": ["PURPOSE", ":", "To", "determine", "the", "cause", "of", "spontaneous", "choroidal", "hemorrhage", "in", "a", "67", "-", "year", "-", "old", "man", "after", "a", "myocardial", "infarction", "and", "administration", "of", "tissue", "plasminogen", "activator", "."], "event_mentions": [{"id": "8610807_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 10, "end": 11}, "arguments": [{"entity_id": "8610807_3_Ent3", "role": "Effect", "text": "spontaneous choroidal hemorrhage", "start": 7, "end": 10}, {"entity_id": "8610807_3_Ent1", "role": "Subject_Age", "text": "67 - year - old", "start": 12, "end": 17}, {"entity_id": "8610807_3_Ent0", "role": "Subject", "text": "67 - year - old man after a myocardial infarction", "start": 12, "end": 22}, {"entity_id": "8610807_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 17, "end": 18}, {"entity_id": "8610807_3_Ent5", "role": "Treatment_Disorder", "text": "myocardial infarction", "start": 20, "end": 22}, {"entity_id": "8610807_3_Ent4", "role": "Treatment", "text": "tissue plasminogen activator", "start": 25, "end": 28}, {"entity_id": "8610807_3_Ent6", "role": "Treatment_Drug", "text": "tissue plasminogen activator", "start": 25, "end": 28}]}], "entity_mentions": [{"id": "8610807_3_Ent3", "text": "spontaneous choroidal hemorrhage", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "8610807_3_Ent1", "text": "67 - year - old", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "8610807_3_Ent0", "text": "67 - year - old man after a myocardial infarction", "entity_type": "Entity", "start": 12, "end": 22}, {"id": "8610807_3_Ent2", "text": "man", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "8610807_3_Ent5", "text": "myocardial infarction", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "8610807_3_Ent4", "text": "tissue plasminogen activator", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "8610807_3_Ent6", "text": "tissue plasminogen activator", "entity_type": "Entity", "start": 25, "end": 28}], "lang": "en"}
{"doc_id": "8636829_1", "wnd_id": "8636829_1_1", "text": "A macrophage activation syndrome , possibly related to methotrexate toxicity , developed in a boy with systemic juvenile rheumatoid arthritis .", "tokens": ["A", "macrophage", "activation", "syndrome", ",", "possibly", "related", "to", "methotrexate", "toxicity", ",", "developed", "in", "a", "boy", "with", "systemic", "juvenile", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "8636829_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 11, "end": 12}, "arguments": [{"entity_id": "8636829_1_Ent2", "role": "Effect", "text": "macrophage activation syndrome", "start": 1, "end": 4}, {"entity_id": "8636829_1_Ent4", "role": "Treatment_Drug", "text": "methotrexate", "start": 8, "end": 9}, {"entity_id": "8636829_1_Ent3", "role": "Treatment", "text": "methotrexate toxicity", "start": 8, "end": 10}, {"entity_id": "8636829_1_Ent0", "role": "Subject", "text": "a boy with systemic juvenile rheumatoid arthritis", "start": 13, "end": 20}, {"entity_id": "8636829_1_Ent1", "role": "Subject_Gender", "text": "boy", "start": 14, "end": 15}, {"entity_id": "8636829_1_Ent5", "role": "Treatment_Disorder", "text": "systemic juvenile rheumatoid arthritis", "start": 16, "end": 20}]}], "entity_mentions": [{"id": "8636829_1_Ent2", "text": "macrophage activation syndrome", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "8636829_1_Ent4", "text": "methotrexate", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8636829_1_Ent3", "text": "methotrexate toxicity", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "8636829_1_Ent0", "text": "a boy with systemic juvenile rheumatoid arthritis", "entity_type": "Entity", "start": 13, "end": 20}, {"id": "8636829_1_Ent1", "text": "boy", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8636829_1_Ent5", "text": "systemic juvenile rheumatoid arthritis", "entity_type": "Entity", "start": 16, "end": 20}], "lang": "en"}
{"doc_id": "8638872_1", "wnd_id": "8638872_1_1", "text": "Jaundice induced by streptokinase .", "tokens": ["Jaundice", "induced", "by", "streptokinase", "."], "event_mentions": [{"id": "8638872_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "8638872_1_Ent0", "role": "Effect", "text": "Jaundice", "start": 0, "end": 1}, {"entity_id": "8638872_1_Ent1", "role": "Treatment", "text": "streptokinase", "start": 3, "end": 4}, {"entity_id": "8638872_1_Ent2", "role": "Treatment_Drug", "text": "streptokinase", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "8638872_1_Ent0", "text": "Jaundice", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8638872_1_Ent1", "text": "streptokinase", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8638872_1_Ent2", "text": "streptokinase", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "8641617_5", "wnd_id": "8641617_5_1", "text": "Severe C. difficile colitis occurred in 2 patients ( 6.1 % ) after receiving cisplatin - based combination chemotherapy for ovarian malignancies .", "tokens": ["Severe", "C.", "difficile", "colitis", "occurred", "in", "2", "patients", "(", "6.1", "%", ")", "after", "receiving", "cisplatin", "-", "based", "combination", "chemotherapy", "for", "ovarian", "malignancies", "."], "event_mentions": [{"id": "8641617_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 4, "end": 5}, "arguments": [{"entity_id": "8641617_5_Ent3", "role": "Effect", "text": "Severe C. difficile colitis", "start": 0, "end": 4}, {"entity_id": "8641617_5_Ent1", "role": "Subject_Population", "text": "2", "start": 6, "end": 7}, {"entity_id": "8641617_5_Ent0", "role": "Subject", "text": "2 patients ( 6.1 % )", "start": 6, "end": 12}, {"entity_id": "8641617_5_Ent2", "role": "Subject_Population", "text": "( 6.1 % )", "start": 8, "end": 12}, {"entity_id": "8641617_5_Ent5", "role": "Treatment_Drug", "text": "cisplatin", "start": 14, "end": 15}, {"entity_id": "8641617_5_Ent4", "role": "Treatment", "text": "cisplatin - based combination chemotherapy", "start": 14, "end": 19}, {"entity_id": "8641617_5_Ent7", "role": "Treatment_Route", "text": "chemotherapy", "start": 18, "end": 19}, {"entity_id": "8641617_5_Ent6", "role": "Treatment_Disorder", "text": "ovarian malignancies", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "8641617_5_Ent3", "text": "Severe C. difficile colitis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "8641617_5_Ent1", "text": "2", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8641617_5_Ent0", "text": "2 patients ( 6.1 % )", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "8641617_5_Ent2", "text": "( 6.1 % )", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "8641617_5_Ent5", "text": "cisplatin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8641617_5_Ent4", "text": "cisplatin - based combination chemotherapy", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "8641617_5_Ent7", "text": "chemotherapy", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "8641617_5_Ent6", "text": "ovarian malignancies", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "8651254_3", "wnd_id": "8651254_3_1", "text": "The possibility can be raised that M - CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome .", "tokens": ["The", "possibility", "can", "be", "raised", "that", "M", "-", "CSF", "accelerated", "the", "underlying", "renal", "disease", "in", "this", "case", "through", "enhancing", "macrophage", "accumulation", "into", "the", "glomerulus", ",", "leading", "to", "the", "development", "of", "nephrotic", "syndrome", "."], "event_mentions": [{"id": "8651254_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "accelerated", "start": 9, "end": 10}, "arguments": [{"entity_id": "8651254_3_Ent1", "role": "Treatment", "text": "M - CSF", "start": 6, "end": 9}, {"entity_id": "8651254_3_Ent2", "role": "Treatment_Drug", "text": "M - CSF", "start": 6, "end": 9}, {"entity_id": "8651254_3_Ent0", "role": "Effect", "text": "underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome", "start": 11, "end": 32}]}], "entity_mentions": [{"id": "8651254_3_Ent1", "text": "M - CSF", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "8651254_3_Ent2", "text": "M - CSF", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "8651254_3_Ent0", "text": "underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome", "entity_type": "Entity", "start": 11, "end": 32}], "lang": "en"}
{"doc_id": "8672829_1", "wnd_id": "8672829_1_1", "text": "After receiving 3 doses of ifosfamide / mesna , she was found to be unresponsive .", "tokens": ["After", "receiving", "3", "doses", "of", "ifosfamide", "/", "mesna", ",", "she", "was", "found", "to", "be", "unresponsive", "."], "event_mentions": [{"id": "8672829_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "found", "start": 11, "end": 12}, "arguments": [{"entity_id": "8672829_1_Ent4", "role": "Treatment_Drug", "text": "ifosfamide", "start": 5, "end": 6}, {"entity_id": "8672829_1_Ent6", "role": "Combination_Drug", "text": "ifosfamide", "start": 5, "end": 6}, {"entity_id": "8672829_1_Ent3", "role": "Treatment", "text": "ifosfamide / mesna", "start": 5, "end": 8}, {"entity_id": "8672829_1_Ent5", "role": "Treatment_Drug", "text": "mesna", "start": 7, "end": 8}, {"entity_id": "8672829_1_Ent7", "role": "Combination_Drug", "text": "mesna", "start": 7, "end": 8}, {"entity_id": "8672829_1_Ent0", "role": "Subject", "text": "she", "start": 9, "end": 10}, {"entity_id": "8672829_1_Ent1", "role": "Subject_Gender", "text": "she", "start": 9, "end": 10}, {"entity_id": "8672829_1_Ent2", "role": "Effect", "text": "unresponsive", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "8672829_1_Ent4", "text": "ifosfamide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8672829_1_Ent6", "text": "ifosfamide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8672829_1_Ent3", "text": "ifosfamide / mesna", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "8672829_1_Ent5", "text": "mesna", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8672829_1_Ent7", "text": "mesna", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8672829_1_Ent0", "text": "she", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8672829_1_Ent1", "text": "she", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8672829_1_Ent2", "text": "unresponsive", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "8678015_3", "wnd_id": "8678015_3_1", "text": "While undergoing treatment with albendazole , he developed worsening diarrhea with abdominal pain and fever .", "tokens": ["While", "undergoing", "treatment", "with", "albendazole", ",", "he", "developed", "worsening", "diarrhea", "with", "abdominal", "pain", "and", "fever", "."], "event_mentions": [{"id": "8678015_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "8678015_3_Ent3", "role": "Treatment", "text": "albendazole", "start": 4, "end": 5}, {"entity_id": "8678015_3_Ent4", "role": "Treatment_Drug", "text": "albendazole", "start": 4, "end": 5}, {"entity_id": "8678015_3_Ent0", "role": "Subject", "text": "he", "start": 6, "end": 7}, {"entity_id": "8678015_3_Ent1", "role": "Subject_Gender", "text": "he", "start": 6, "end": 7}, {"entity_id": "8678015_3_Ent2", "role": "Effect", "text": "worsening diarrhea with abdominal pain and fever", "start": 8, "end": 15}]}], "entity_mentions": [{"id": "8678015_3_Ent3", "text": "albendazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8678015_3_Ent4", "text": "albendazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8678015_3_Ent0", "text": "he", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8678015_3_Ent1", "text": "he", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8678015_3_Ent2", "text": "worsening diarrhea with abdominal pain and fever", "entity_type": "Entity", "start": 8, "end": 15}], "lang": "en"}
{"doc_id": "8691927_5", "wnd_id": "8691927_5_1", "text": "METHODS : Growth retardation was observed in six severely asthmatic children after introduction of high - dose fluticasone propionate treatment ( dry powder ) .", "tokens": ["METHODS", ":", "Growth", "retardation", "was", "observed", "in", "six", "severely", "asthmatic", "children", "after", "introduction", "of", "high", "-", "dose", "fluticasone", "propionate", "treatment", "(", "dry", "powder", ")", "."], "event_mentions": [{"id": "8691927_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 11, "end": 12}, "arguments": [{"entity_id": "8691927_5_Ent3", "role": "Effect", "text": "Growth retardation", "start": 2, "end": 4}, {"entity_id": "8691927_5_Ent1", "role": "Subject_Population", "text": "six", "start": 7, "end": 8}, {"entity_id": "8691927_5_Ent0", "role": "Subject", "text": "six severely asthmatic children", "start": 7, "end": 11}, {"entity_id": "8691927_5_Ent5", "role": "Treatment_Disorder", "text": "severely asthmatic", "start": 8, "end": 10}, {"entity_id": "8691927_5_Ent2", "role": "Subject_Age", "text": "children", "start": 10, "end": 11}, {"entity_id": "8691927_5_Ent4", "role": "Treatment", "text": "introduction of high - dose fluticasone propionate treatment ( dry powder )", "start": 12, "end": 24}, {"entity_id": "8691927_5_Ent6", "role": "Treatment_Dosage", "text": "high - dose", "start": 14, "end": 17}, {"entity_id": "8691927_5_Ent7", "role": "Treatment_Drug", "text": "fluticasone propionate", "start": 17, "end": 19}, {"entity_id": "8691927_5_Ent8", "role": "Treatment_Route", "text": "dry powder", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "8691927_5_Ent3", "text": "Growth retardation", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "8691927_5_Ent1", "text": "six", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8691927_5_Ent0", "text": "six severely asthmatic children", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "8691927_5_Ent5", "text": "severely asthmatic", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "8691927_5_Ent2", "text": "children", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8691927_5_Ent4", "text": "introduction of high - dose fluticasone propionate treatment ( dry powder )", "entity_type": "Entity", "start": 12, "end": 24}, {"id": "8691927_5_Ent6", "text": "high - dose", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "8691927_5_Ent7", "text": "fluticasone propionate", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "8691927_5_Ent8", "text": "dry powder", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "8700794_1", "wnd_id": "8700794_1_1", "text": "A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia , all of whom experienced seizures or altered mental status .", "tokens": ["A", "review", "of", "the", "literature", "found", "11", "children", "and", "2", "adults", "in", "whom", "intranasal", "desmopressin", "was", "associated", "with", "hyponatremia", ",", "all", "of", "whom", "experienced", "seizures", "or", "altered", "mental", "status", "."], "event_mentions": [{"id": "8700794_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 16, "end": 17}, "arguments": [{"entity_id": "8700794_1_Ent1", "role": "Subject_Population", "text": "11", "start": 6, "end": 7}, {"entity_id": "8700794_1_Ent0", "role": "Subject", "text": "11 children and 2 adults", "start": 6, "end": 11}, {"entity_id": "8700794_1_Ent3", "role": "Subject_Age", "text": "children", "start": 7, "end": 8}, {"entity_id": "8700794_1_Ent2", "role": "Subject_Population", "text": "2", "start": 9, "end": 10}, {"entity_id": "8700794_1_Ent4", "role": "Subject_Age", "text": "adults", "start": 10, "end": 11}, {"entity_id": "8700794_1_Ent9", "role": "Treatment_Route", "text": "intranasal", "start": 13, "end": 14}, {"entity_id": "8700794_1_Ent7", "role": "Treatment", "text": "intranasal desmopressin", "start": 13, "end": 15}, {"entity_id": "8700794_1_Ent8", "role": "Treatment_Drug", "text": "desmopressin", "start": 14, "end": 15}, {"entity_id": "8700794_1_Ent5", "role": "Effect", "text": "hyponatremia", "start": 18, "end": 19}, {"entity_id": "8700794_1_Ent6", "role": "Effect", "text": "seizures or altered mental status", "start": 24, "end": 29}]}], "entity_mentions": [{"id": "8700794_1_Ent1", "text": "11", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8700794_1_Ent0", "text": "11 children and 2 adults", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "8700794_1_Ent3", "text": "children", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8700794_1_Ent2", "text": "2", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8700794_1_Ent4", "text": "adults", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8700794_1_Ent9", "text": "intranasal", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8700794_1_Ent7", "text": "intranasal desmopressin", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "8700794_1_Ent8", "text": "desmopressin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8700794_1_Ent5", "text": "hyponatremia", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "8700794_1_Ent6", "text": "seizures or altered mental status", "entity_type": "Entity", "start": 24, "end": 29}], "lang": "en"}
{"doc_id": "8726608_4", "wnd_id": "8726608_4_1", "text": "Until additional data are available , if intravenous acyclovir is administered concurrently with lithium , we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day .", "tokens": ["Until", "additional", "data", "are", "available", ",", "if", "intravenous", "acyclovir", "is", "administered", "concurrently", "with", "lithium", ",", "we", "recommend", "closely", "monitoring", "patients", "for", "signs", "of", "lithium", "toxicity", "and", "measuring", "serum", "lithium", "levels", "every", "second", "or", "third", "day", "."], "event_mentions": [{"id": "8726608_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "signs", "start": 21, "end": 22}, "arguments": [{"entity_id": "8726608_4_Ent4", "role": "Treatment_Route", "text": "intravenous", "start": 7, "end": 8}, {"entity_id": "8726608_4_Ent1", "role": "Treatment", "text": "intravenous acyclovir is administered concurrently with lithium", "start": 7, "end": 14}, {"entity_id": "8726608_4_Ent2", "role": "Treatment_Drug", "text": "acyclovir", "start": 8, "end": 9}, {"entity_id": "8726608_4_Ent6", "role": "Combination_Drug", "text": "acyclovir", "start": 8, "end": 9}, {"entity_id": "8726608_4_Ent3", "role": "Treatment_Drug", "text": "lithium", "start": 13, "end": 14}, {"entity_id": "8726608_4_Ent5", "role": "Combination_Drug", "text": "lithium", "start": 13, "end": 14}, {"entity_id": "8726608_4_Ent0", "role": "Effect", "text": "lithium toxicity", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "8726608_4_Ent4", "text": "intravenous", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8726608_4_Ent1", "text": "intravenous acyclovir is administered concurrently with lithium", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "8726608_4_Ent2", "text": "acyclovir", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8726608_4_Ent6", "text": "acyclovir", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8726608_4_Ent3", "text": "lithium", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8726608_4_Ent5", "text": "lithium", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8726608_4_Ent0", "text": "lithium toxicity", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "8726608_5", "wnd_id": "8726608_5_1", "text": "When measured , the serum lithium level had increased 4 - fold during acyclovir therapy .", "tokens": ["When", "measured", ",", "the", "serum", "lithium", "level", "had", "increased", "4", "-", "fold", "during", "acyclovir", "therapy", "."], "event_mentions": [{"id": "8726608_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 12, "end": 13}, "arguments": [{"entity_id": "8726608_5_Ent0", "role": "Effect", "text": "serum lithium level had increased 4 - fold", "start": 4, "end": 12}, {"entity_id": "8726608_5_Ent3", "role": "Treatment_Drug", "text": "lithium", "start": 5, "end": 6}, {"entity_id": "8726608_5_Ent4", "role": "Combination_Drug", "text": "lithium", "start": 5, "end": 6}, {"entity_id": "8726608_5_Ent1", "role": "Treatment", "text": "acyclovir", "start": 13, "end": 14}, {"entity_id": "8726608_5_Ent2", "role": "Treatment_Drug", "text": "acyclovir", "start": 13, "end": 14}, {"entity_id": "8726608_5_Ent5", "role": "Combination_Drug", "text": "acyclovir", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "8726608_5_Ent0", "text": "serum lithium level had increased 4 - fold", "entity_type": "Entity", "start": 4, "end": 12}, {"id": "8726608_5_Ent3", "text": "lithium", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8726608_5_Ent4", "text": "lithium", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8726608_5_Ent1", "text": "acyclovir", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8726608_5_Ent2", "text": "acyclovir", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8726608_5_Ent5", "text": "acyclovir", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "8733532_1", "wnd_id": "8733532_1_1", "text": "A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder .", "tokens": ["A", "case", "is", "presented", "which", "illustrates", "a", "probably", "fatal", "interaction", "between", "minoxidil", "and", "a", "coagulation", "disorder", "."], "event_mentions": [{"id": "8733532_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "between", "start": 10, "end": 11}, "arguments": [{"entity_id": "8733532_1_Ent0", "role": "Subject", "text": "A case", "start": 0, "end": 2}, {"entity_id": "8733532_1_Ent2", "role": "Effect", "text": "fatal interaction", "start": 8, "end": 10}, {"entity_id": "8733532_1_Ent3", "role": "Treatment", "text": "minoxidil", "start": 11, "end": 12}, {"entity_id": "8733532_1_Ent4", "role": "Treatment_Drug", "text": "minoxidil", "start": 11, "end": 12}, {"entity_id": "8733532_1_Ent1", "role": "Subject_Disorder", "text": "coagulation disorder", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "8733532_1_Ent0", "text": "A case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8733532_1_Ent2", "text": "fatal interaction", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "8733532_1_Ent3", "text": "minoxidil", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8733532_1_Ent4", "text": "minoxidil", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8733532_1_Ent1", "text": "coagulation disorder", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "8739289_4", "wnd_id": "8739289_4_1", "text": "We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI .", "tokens": ["We", "report", "a", "patient", "receiving", "chronic", "lithium", "therapy", "who", "presented", "with", "a", "transient", "CDI", "occurring", "in", "the", "setting", "of", "underlying", "chronic", "NDI", "."], "event_mentions": [{"id": "8739289_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 9, "end": 10}, "arguments": [{"entity_id": "8739289_4_Ent0", "role": "Subject", "text": "patient", "start": 3, "end": 4}, {"entity_id": "8739289_4_Ent5", "role": "Treatment_Duration", "text": "chronic", "start": 5, "end": 6}, {"entity_id": "8739289_4_Ent3", "role": "Treatment", "text": "chronic lithium therapy", "start": 5, "end": 8}, {"entity_id": "8739289_4_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 6, "end": 7}, {"entity_id": "8739289_4_Ent2", "role": "Effect", "text": "transient CDI", "start": 12, "end": 14}, {"entity_id": "8739289_4_Ent1", "role": "Subject_Disorder", "text": "underlying chronic NDI", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "8739289_4_Ent0", "text": "patient", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8739289_4_Ent5", "text": "chronic", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8739289_4_Ent3", "text": "chronic lithium therapy", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "8739289_4_Ent4", "text": "lithium", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8739289_4_Ent2", "text": "transient CDI", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "8739289_4_Ent1", "text": "underlying chronic NDI", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "8739289_7", "wnd_id": "8739289_7_1", "text": "This case emphasizes the importance of the evaluation of lithium - associated polyuria with a direct measurement of plasma vasopressin , interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management .", "tokens": ["This", "case", "emphasizes", "the", "importance", "of", "the", "evaluation", "of", "lithium", "-", "associated", "polyuria", "with", "a", "direct", "measurement", "of", "plasma", "vasopressin", ",", "interpreted", "with", "simultaneous", "plasma", "and", "urine", "osmolality", "to", "secure", "the", "correct", "diagnosis", "and", "ensure", "appropriate", "therapeutic", "management", "."], "event_mentions": [{"id": "8739289_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 11, "end": 12}, "arguments": [{"entity_id": "8739289_7_Ent0", "role": "Subject", "text": "This case", "start": 0, "end": 2}, {"entity_id": "8739289_7_Ent2", "role": "Treatment", "text": "lithium", "start": 9, "end": 10}, {"entity_id": "8739289_7_Ent3", "role": "Treatment_Drug", "text": "lithium", "start": 9, "end": 10}, {"entity_id": "8739289_7_Ent1", "role": "Effect", "text": "polyuria", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "8739289_7_Ent0", "text": "This case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8739289_7_Ent2", "text": "lithium", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8739289_7_Ent3", "text": "lithium", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8739289_7_Ent1", "text": "polyuria", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "8742573_2", "wnd_id": "8742573_2_1", "text": "CONCLUSIONS : Jet - injection devices might constitute a helpful method to treat those patients affected by severe human insulin - induced lipoatrophy .", "tokens": ["CONCLUSIONS", ":", "Jet", "-", "injection", "devices", "might", "constitute", "a", "helpful", "method", "to", "treat", "those", "patients", "affected", "by", "severe", "human", "insulin", "-", "induced", "lipoatrophy", "."], "event_mentions": [{"id": "8742573_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treat", "start": 12, "end": 13}, "arguments": [{"entity_id": "8742573_2_Ent3", "role": "Treatment_Route", "text": "Jet - injection", "start": 2, "end": 5}, {"entity_id": "8742573_2_Ent1", "role": "Treatment", "text": "Jet - injection devices", "start": 2, "end": 6}, {"entity_id": "8742573_2_Ent0", "role": "Subject", "text": "patients", "start": 14, "end": 15}, {"entity_id": "8742573_2_Ent2", "role": "Treatment_Disorder", "text": "insulin - induced lipoatrophy", "start": 19, "end": 23}]}, {"id": "8742573_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 21, "end": 22}, "arguments": [{"entity_id": "8742573_2_Ent5", "role": "Treatment", "text": "insulin", "start": 19, "end": 20}, {"entity_id": "8742573_2_Ent6", "role": "Treatment_Drug", "text": "insulin", "start": 19, "end": 20}, {"entity_id": "8742573_2_Ent4", "role": "Effect", "text": "lipoatrophy", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "8742573_2_Ent3", "text": "Jet - injection", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "8742573_2_Ent1", "text": "Jet - injection devices", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "8742573_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8742573_2_Ent5", "text": "insulin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "8742573_2_Ent6", "text": "insulin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "8742573_2_Ent2", "text": "insulin - induced lipoatrophy", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "8742573_2_Ent4", "text": "lipoatrophy", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "8742573_3", "wnd_id": "8742573_3_1", "text": "Human insulin - induced lipoatrophy .", "tokens": ["Human", "insulin", "-", "induced", "lipoatrophy", "."], "event_mentions": [{"id": "8742573_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "8742573_3_Ent1", "role": "Treatment", "text": "Human insulin", "start": 0, "end": 2}, {"entity_id": "8742573_3_Ent2", "role": "Treatment_Drug", "text": "Human insulin", "start": 0, "end": 2}, {"entity_id": "8742573_3_Ent0", "role": "Effect", "text": "lipoatrophy", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "8742573_3_Ent1", "text": "Human insulin", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8742573_3_Ent2", "text": "Human insulin", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8742573_3_Ent0", "text": "lipoatrophy", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "8742573_4", "wnd_id": "8742573_4_1", "text": "OBJECTIVE : To evaluate the efficacy of the administration of insulin by a jet - injector device in stopping and reversing severe human insulin - induced lipoatrophy .", "tokens": ["OBJECTIVE", ":", "To", "evaluate", "the", "efficacy", "of", "the", "administration", "of", "insulin", "by", "a", "jet", "-", "injector", "device", "in", "stopping", "and", "reversing", "severe", "human", "insulin", "-", "induced", "lipoatrophy", "."], "event_mentions": [{"id": "8742573_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 25, "end": 26}, "arguments": [{"entity_id": "8742573_4_Ent0", "role": "Effect", "text": "severe human", "start": 21, "end": 23}, {"entity_id": "8742573_4_Ent2", "role": "Treatment", "text": "insulin", "start": 23, "end": 24}, {"entity_id": "8742573_4_Ent3", "role": "Treatment_Drug", "text": "insulin", "start": 23, "end": 24}, {"entity_id": "8742573_4_Ent1", "role": "Effect", "text": "lipoatrophy", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "8742573_4_Ent0", "text": "severe human", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "8742573_4_Ent2", "text": "insulin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "8742573_4_Ent3", "text": "insulin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "8742573_4_Ent1", "text": "lipoatrophy", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "8771575_2", "wnd_id": "8771575_2_1", "text": "Acute pulmonary reactions to nitrofurantoin are an uncommon side effect of therapy and can cause minor or life - threatening pulmonary dysfunction .", "tokens": ["Acute", "pulmonary", "reactions", "to", "nitrofurantoin", "are", "an", "uncommon", "side", "effect", "of", "therapy", "and", "can", "cause", "minor", "or", "life", "-", "threatening", "pulmonary", "dysfunction", "."], "event_mentions": [{"id": "8771575_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "are", "start": 5, "end": 6}, "arguments": [{"entity_id": "8771575_2_Ent0", "role": "Effect", "text": "Acute pulmonary reactions", "start": 0, "end": 3}, {"entity_id": "8771575_2_Ent2", "role": "Treatment", "text": "nitrofurantoin", "start": 4, "end": 5}, {"entity_id": "8771575_2_Ent3", "role": "Treatment_Drug", "text": "nitrofurantoin", "start": 4, "end": 5}, {"entity_id": "8771575_2_Ent1", "role": "Effect", "text": "can cause minor or life - threatening pulmonary dysfunction", "start": 13, "end": 22}]}], "entity_mentions": [{"id": "8771575_2_Ent0", "text": "Acute pulmonary reactions", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8771575_2_Ent2", "text": "nitrofurantoin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8771575_2_Ent3", "text": "nitrofurantoin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8771575_2_Ent1", "text": "can cause minor or life - threatening pulmonary dysfunction", "entity_type": "Entity", "start": 13, "end": 22}], "lang": "en"}
{"doc_id": "8792511_2", "wnd_id": "8792511_2_1", "text": "Methemoglobinemia is another common finding among patients receiving dapsone therapy , but rarely does it result in prominent symptoms other than transient pallor .", "tokens": ["Methemoglobinemia", "is", "another", "common", "finding", "among", "patients", "receiving", "dapsone", "therapy", ",", "but", "rarely", "does", "it", "result", "in", "prominent", "symptoms", "other", "than", "transient", "pallor", "."], "event_mentions": [{"id": "8792511_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 7, "end": 8}, "arguments": [{"entity_id": "8792511_2_Ent1", "role": "Effect", "text": "Methemoglobinemia", "start": 0, "end": 1}, {"entity_id": "8792511_2_Ent0", "role": "Subject", "text": "patients", "start": 6, "end": 7}, {"entity_id": "8792511_2_Ent4", "role": "Treatment_Drug", "text": "dapsone", "start": 8, "end": 9}, {"entity_id": "8792511_2_Ent3", "role": "Treatment", "text": "dapsone therapy", "start": 8, "end": 10}, {"entity_id": "8792511_2_Ent2", "role": "Effect", "text": "transient pallor", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "8792511_2_Ent1", "text": "Methemoglobinemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8792511_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8792511_2_Ent4", "text": "dapsone", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8792511_2_Ent3", "text": "dapsone therapy", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "8792511_2_Ent2", "text": "transient pallor", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "8816294_2", "wnd_id": "8816294_2_1", "text": "We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by , in the first case intrathecally administered methotrexate and , in the second by intrathecally administered methotrexate and cranial irradiation .", "tokens": ["We", "report", "the", "case", "histories", "of", "identical", "twin", "brothers", "who", "developed", "concordant", "acute", "lymphoblastic", "leukemia", "at", "the", "age", "of", "4", "years", "and", "who", "later", "developed", "leukoencephalopathy", "and", "hydrocephalus", "related", "to", "central", "nervous", "system", "prophylaxis", "by", ",", "in", "the", "first", "case", "intrathecally", "administered", "methotrexate", "and", ",", "in", "the", "second", "by", "intrathecally", "administered", "methotrexate", "and", "cranial", "irradiation", "."], "event_mentions": [{"id": "8816294_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 24, "end": 25}, "arguments": [{"entity_id": "8816294_2_Ent0", "role": "Subject", "text": "identical twin brothers", "start": 6, "end": 9}, {"entity_id": "8816294_2_Ent1", "role": "Subject_Gender", "text": "brothers", "start": 8, "end": 9}, {"entity_id": "8816294_2_Ent2", "role": "Effect", "text": "leukoencephalopathy and hydrocephalus", "start": 25, "end": 28}, {"entity_id": "8816294_2_Ent7", "role": "Treatment_Route", "text": "intrathecally", "start": 40, "end": 41}, {"entity_id": "8816294_2_Ent3", "role": "Treatment", "text": "intrathecally administered methotrexate", "start": 40, "end": 43}, {"entity_id": "8816294_2_Ent5", "role": "Treatment_Drug", "text": "methotrexate", "start": 42, "end": 43}, {"entity_id": "8816294_2_Ent8", "role": "Treatment_Route", "text": "intrathecally", "start": 49, "end": 50}, {"entity_id": "8816294_2_Ent4", "role": "Treatment", "text": "intrathecally administered methotrexate and cranial irradiation", "start": 49, "end": 55}, {"entity_id": "8816294_2_Ent6", "role": "Treatment_Drug", "text": "methotrexate", "start": 51, "end": 52}]}], "entity_mentions": [{"id": "8816294_2_Ent0", "text": "identical twin brothers", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "8816294_2_Ent1", "text": "brothers", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8816294_2_Ent2", "text": "leukoencephalopathy and hydrocephalus", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "8816294_2_Ent7", "text": "intrathecally", "entity_type": "Entity", "start": 40, "end": 41}, {"id": "8816294_2_Ent3", "text": "intrathecally administered methotrexate", "entity_type": "Entity", "start": 40, "end": 43}, {"id": "8816294_2_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 42, "end": 43}, {"id": "8816294_2_Ent8", "text": "intrathecally", "entity_type": "Entity", "start": 49, "end": 50}, {"id": "8816294_2_Ent4", "text": "intrathecally administered methotrexate and cranial irradiation", "entity_type": "Entity", "start": 49, "end": 55}, {"id": "8816294_2_Ent6", "text": "methotrexate", "entity_type": "Entity", "start": 51, "end": 52}], "lang": "en"}
{"doc_id": "8828999_3", "wnd_id": "8828999_3_1", "text": "Lithium neurotoxicity should be considered in Creutzfeldt - Jakob disease differential diagnosis , serial electroencephalograms being the most valuable .", "tokens": ["Lithium", "neurotoxicity", "should", "be", "considered", "in", "Creutzfeldt", "-", "Jakob", "disease", "differential", "diagnosis", ",", "serial", "electroencephalograms", "being", "the", "most", "valuable", "."], "event_mentions": [{"id": "8828999_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "considered", "start": 4, "end": 5}, "arguments": [{"entity_id": "8828999_3_Ent1", "role": "Treatment", "text": "Lithium", "start": 0, "end": 1}, {"entity_id": "8828999_3_Ent3", "role": "Treatment_Drug", "text": "Lithium", "start": 0, "end": 1}, {"entity_id": "8828999_3_Ent0", "role": "Effect", "text": "Lithium neurotoxicity", "start": 0, "end": 2}, {"entity_id": "8828999_3_Ent2", "role": "Treatment_Disorder", "text": "Creutzfeldt - Jakob disease", "start": 6, "end": 10}]}], "entity_mentions": [{"id": "8828999_3_Ent1", "text": "Lithium", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8828999_3_Ent3", "text": "Lithium", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8828999_3_Ent0", "text": "Lithium neurotoxicity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8828999_3_Ent2", "text": "Creutzfeldt - Jakob disease", "entity_type": "Entity", "start": 6, "end": 10}], "lang": "en"}
{"doc_id": "8828999_4", "wnd_id": "8828999_4_1", "text": "Several cases of lithium - induced Creutzfeldt - Jakob syndrome have been reported to date ; all of them were elderly patients and a half had \" therapeutic \" lithium serum levels .", "tokens": ["Several", "cases", "of", "lithium", "-", "induced", "Creutzfeldt", "-", "Jakob", "syndrome", "have", "been", "reported", "to", "date", ";", "all", "of", "them", "were", "elderly", "patients", "and", "a", "half", "had", "\"", "therapeutic", "\"", "lithium", "serum", "levels", "."], "event_mentions": [{"id": "8828999_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "8828999_4_Ent3", "role": "Treatment", "text": "lithium", "start": 3, "end": 4}, {"entity_id": "8828999_4_Ent5", "role": "Treatment_Drug", "text": "lithium", "start": 3, "end": 4}, {"entity_id": "8828999_4_Ent2", "role": "Effect", "text": "Creutzfeldt - Jakob syndrome", "start": 6, "end": 10}, {"entity_id": "8828999_4_Ent1", "role": "Subject_Age", "text": "elderly", "start": 20, "end": 21}, {"entity_id": "8828999_4_Ent0", "role": "Subject", "text": "elderly patients", "start": 20, "end": 22}, {"entity_id": "8828999_4_Ent4", "role": "Treatment", "text": "\" therapeutic \" lithium serum levels", "start": 26, "end": 32}, {"entity_id": "8828999_4_Ent6", "role": "Treatment_Drug", "text": "lithium", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "8828999_4_Ent3", "text": "lithium", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8828999_4_Ent5", "text": "lithium", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8828999_4_Ent2", "text": "Creutzfeldt - Jakob syndrome", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "8828999_4_Ent1", "text": "elderly", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8828999_4_Ent0", "text": "elderly patients", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "8828999_4_Ent4", "text": "\" therapeutic \" lithium serum levels", "entity_type": "Entity", "start": 26, "end": 32}, {"id": "8828999_4_Ent6", "text": "lithium", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "8832451_3", "wnd_id": "8832451_3_1", "text": "We also describe a new , noninvasive method to assess magnesium - induced neuromuscular block when curariform muscle relaxant was given simultaneously .", "tokens": ["We", "also", "describe", "a", "new", ",", "noninvasive", "method", "to", "assess", "magnesium", "-", "induced", "neuromuscular", "block", "when", "curariform", "muscle", "relaxant", "was", "given", "simultaneously", "."], "event_mentions": [{"id": "8832451_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 12, "end": 13}, "arguments": [{"entity_id": "8832451_3_Ent2", "role": "Treatment_Drug", "text": "magnesium", "start": 10, "end": 11}, {"entity_id": "8832451_3_Ent4", "role": "Combination_Drug", "text": "magnesium", "start": 10, "end": 11}, {"entity_id": "8832451_3_Ent0", "role": "Effect", "text": "neuromuscular block", "start": 13, "end": 15}, {"entity_id": "8832451_3_Ent3", "role": "Treatment_Drug", "text": "curariform muscle relaxant", "start": 16, "end": 19}, {"entity_id": "8832451_3_Ent5", "role": "Combination_Drug", "text": "curariform muscle relaxant", "start": 16, "end": 19}, {"entity_id": "8832451_3_Ent1", "role": "Treatment", "text": "curariform muscle relaxant was given simultaneously", "start": 16, "end": 22}]}], "entity_mentions": [{"id": "8832451_3_Ent2", "text": "magnesium", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8832451_3_Ent4", "text": "magnesium", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8832451_3_Ent0", "text": "neuromuscular block", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "8832451_3_Ent3", "text": "curariform muscle relaxant", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "8832451_3_Ent5", "text": "curariform muscle relaxant", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "8832451_3_Ent1", "text": "curariform muscle relaxant was given simultaneously", "entity_type": "Entity", "start": 16, "end": 22}], "lang": "en"}
{"doc_id": "8835752_2", "wnd_id": "8835752_2_1", "text": "Terbinafine - induced cholestatic liver disease .", "tokens": ["Terbinafine", "-", "induced", "cholestatic", "liver", "disease", "."], "event_mentions": [{"id": "8835752_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "8835752_2_Ent1", "role": "Treatment", "text": "Terbinafine", "start": 0, "end": 1}, {"entity_id": "8835752_2_Ent2", "role": "Treatment_Drug", "text": "Terbinafine", "start": 0, "end": 1}, {"entity_id": "8835752_2_Ent0", "role": "Effect", "text": "cholestatic liver disease .", "start": 3, "end": 7}]}], "entity_mentions": [{"id": "8835752_2_Ent1", "text": "Terbinafine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8835752_2_Ent2", "text": "Terbinafine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8835752_2_Ent0", "text": "cholestatic liver disease .", "entity_type": "Entity", "start": 3, "end": 7}], "lang": "en"}
{"doc_id": "8840640_1", "wnd_id": "8840640_1_1", "text": "A patient with a large hydatid cyst of the left lobe of the liver developed metabolic acidosis following rather liberal use of cetrimide - chlorhexidine solution as a scolicidal agent .", "tokens": ["A", "patient", "with", "a", "large", "hydatid", "cyst", "of", "the", "left", "lobe", "of", "the", "liver", "developed", "metabolic", "acidosis", "following", "rather", "liberal", "use", "of", "cetrimide", "-", "chlorhexidine", "solution", "as", "a", "scolicidal", "agent", "."], "event_mentions": [{"id": "8840640_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "8840640_1_Ent0", "role": "Subject", "text": "A patient with a large hydatid cyst of the left lobe of the liver", "start": 0, "end": 14}, {"entity_id": "8840640_1_Ent1", "role": "Subject_Disorder", "text": "a large hydatid cyst of the left lobe of the liver", "start": 3, "end": 14}, {"entity_id": "8840640_1_Ent2", "role": "Effect", "text": "metabolic acidosis", "start": 15, "end": 17}, {"entity_id": "8840640_1_Ent5", "role": "Treatment_Dosage", "text": "rather liberal use", "start": 18, "end": 21}, {"entity_id": "8840640_1_Ent3", "role": "Treatment", "text": "rather liberal use of cetrimide - chlorhexidine solution as a scolicidal agent", "start": 18, "end": 30}, {"entity_id": "8840640_1_Ent4", "role": "Treatment_Drug", "text": "cetrimide - chlorhexidine", "start": 22, "end": 25}, {"entity_id": "8840640_1_Ent6", "role": "Treatment_Route", "text": "a scolicidal agent", "start": 27, "end": 30}]}], "entity_mentions": [{"id": "8840640_1_Ent0", "text": "A patient with a large hydatid cyst of the left lobe of the liver", "entity_type": "Entity", "start": 0, "end": 14}, {"id": "8840640_1_Ent1", "text": "a large hydatid cyst of the left lobe of the liver", "entity_type": "Entity", "start": 3, "end": 14}, {"id": "8840640_1_Ent2", "text": "metabolic acidosis", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "8840640_1_Ent5", "text": "rather liberal use", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "8840640_1_Ent3", "text": "rather liberal use of cetrimide - chlorhexidine solution as a scolicidal agent", "entity_type": "Entity", "start": 18, "end": 30}, {"id": "8840640_1_Ent4", "text": "cetrimide - chlorhexidine", "entity_type": "Entity", "start": 22, "end": 25}, {"id": "8840640_1_Ent6", "text": "a scolicidal agent", "entity_type": "Entity", "start": 27, "end": 30}], "lang": "en"}
{"doc_id": "8850251_4", "wnd_id": "8850251_4_1", "text": "Mequitazine seemed to play a part similar to chlorpromazine , and absence of mequitazine - induced photosensitivity may be due to a relatively low dosage of the drug .", "tokens": ["Mequitazine", "seemed", "to", "play", "a", "part", "similar", "to", "chlorpromazine", ",", "and", "absence", "of", "mequitazine", "-", "induced", "photosensitivity", "may", "be", "due", "to", "a", "relatively", "low", "dosage", "of", "the", "drug", "."], "event_mentions": [{"id": "8850251_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 15, "end": 16}, "arguments": [{"entity_id": "8850251_4_Ent1", "role": "Treatment", "text": "mequitazine", "start": 13, "end": 14}, {"entity_id": "8850251_4_Ent3", "role": "Treatment_Drug", "text": "mequitazine", "start": 13, "end": 14}, {"entity_id": "8850251_4_Ent0", "role": "Effect", "text": "photosensitivity", "start": 16, "end": 17}, {"entity_id": "8850251_4_Ent2", "role": "Treatment", "text": "due to a relatively low dosage of the drug", "start": 19, "end": 28}, {"entity_id": "8850251_4_Ent4", "role": "Treatment_Dosage", "text": "low dosage", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "8850251_4_Ent1", "text": "mequitazine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8850251_4_Ent3", "text": "mequitazine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8850251_4_Ent0", "text": "photosensitivity", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "8850251_4_Ent2", "text": "due to a relatively low dosage of the drug", "entity_type": "Entity", "start": 19, "end": 28}, {"id": "8850251_4_Ent4", "text": "low dosage", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "8862924_1", "wnd_id": "8862924_1_1", "text": "Keratitis in methamphetamine abusers .", "tokens": ["Keratitis", "in", "methamphetamine", "abusers", "."], "event_mentions": [{"id": "8862924_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 1, "end": 2}, "arguments": [{"entity_id": "8862924_1_Ent0", "role": "Effect", "text": "Keratitis", "start": 0, "end": 1}, {"entity_id": "8862924_1_Ent2", "role": "Treatment_Drug", "text": "methamphetamine", "start": 2, "end": 3}, {"entity_id": "8862924_1_Ent1", "role": "Treatment", "text": "methamphetamine abusers", "start": 2, "end": 4}]}], "entity_mentions": [{"id": "8862924_1_Ent0", "text": "Keratitis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8862924_1_Ent2", "text": "methamphetamine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8862924_1_Ent1", "text": "methamphetamine abusers", "entity_type": "Entity", "start": 2, "end": 4}], "lang": "en"}
{"doc_id": "8862924_2", "wnd_id": "8862924_2_1", "text": "Methamphetamine 's extensive physiologic effects , inconsistent street purity , and multiple routes of administration offer many possibilities for injury to the cornea .", "tokens": ["Methamphetamine", "'s", "extensive", "physiologic", "effects", ",", "inconsistent", "street", "purity", ",", "and", "multiple", "routes", "of", "administration", "offer", "many", "possibilities", "for", "injury", "to", "the", "cornea", "."], "event_mentions": [{"id": "8862924_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "offer", "start": 15, "end": 16}, "arguments": [{"entity_id": "8862924_2_Ent0", "role": "Treatment", "text": "Methamphetamine 's", "start": 0, "end": 2}, {"entity_id": "8862924_2_Ent2", "role": "Treatment_Drug", "text": "Methamphetamine 's", "start": 0, "end": 2}, {"entity_id": "8862924_2_Ent1", "role": "Treatment_Disorder", "text": "injury to the cornea", "start": 19, "end": 23}]}], "entity_mentions": [{"id": "8862924_2_Ent0", "text": "Methamphetamine 's", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8862924_2_Ent2", "text": "Methamphetamine 's", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8862924_2_Ent1", "text": "injury to the cornea", "entity_type": "Entity", "start": 19, "end": 23}], "lang": "en"}
{"doc_id": "8862924_3", "wnd_id": "8862924_3_1", "text": "Potential causes of methamphetamine - related keratitis can be divided into four categories resulting from ( a ) direct pharmacologic and physical effects of methamphetamine ; ( b ) the toxic effects of diluting or \" cutting \" agents such as lidocaine and quinine ; ( c ) effects related to the route of drug administration ( intravenous , inhalation , smoking ) ; and ( d ) manufacture - related effects of exposure to unintentional caustic contaminants in the final product .", "tokens": ["Potential", "causes", "of", "methamphetamine", "-", "related", "keratitis", "can", "be", "divided", "into", "four", "categories", "resulting", "from", "(", "a", ")", "direct", "pharmacologic", "and", "physical", "effects", "of", "methamphetamine", ";", "(", "b", ")", "the", "toxic", "effects", "of", "diluting", "or", "\"", "cutting", "\"", "agents", "such", "as", "lidocaine", "and", "quinine", ";", "(", "c", ")", "effects", "related", "to", "the", "route", "of", "drug", "administration", "(", "intravenous", ",", "inhalation", ",", "smoking", ")", ";", "and", "(", "d", ")", "manufacture", "-", "related", "effects", "of", "exposure", "to", "unintentional", "caustic", "contaminants", "in", "the", "final", "product", "."], "event_mentions": [{"id": "8862924_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 5, "end": 6}, "arguments": [{"entity_id": "8862924_3_Ent1", "role": "Treatment", "text": "methamphetamine", "start": 3, "end": 4}, {"entity_id": "8862924_3_Ent2", "role": "Treatment_Drug", "text": "methamphetamine", "start": 3, "end": 4}, {"entity_id": "8862924_3_Ent0", "role": "Effect", "text": "keratitis", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "8862924_3_Ent1", "text": "methamphetamine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8862924_3_Ent2", "text": "methamphetamine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8862924_3_Ent0", "text": "keratitis", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "8864370_1", "wnd_id": "8864370_1_1", "text": "BACKGROUND : Methotrexate ( MTX ) may induce liver damage , which in some psoriatics will lead to fibrosis or cirrhosis .", "tokens": ["BACKGROUND", ":", "Methotrexate", "(", "MTX", ")", "may", "induce", "liver", "damage", ",", "which", "in", "some", "psoriatics", "will", "lead", "to", "fibrosis", "or", "cirrhosis", "."], "event_mentions": [{"id": "8864370_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 7, "end": 8}, "arguments": [{"entity_id": "8864370_1_Ent2", "role": "Treatment_Drug", "text": "Methotrexate", "start": 2, "end": 3}, {"entity_id": "8864370_1_Ent1", "role": "Treatment", "text": "Methotrexate ( MTX )", "start": 2, "end": 6}, {"entity_id": "8864370_1_Ent0", "role": "Effect", "text": "liver damage , which in some psoriatics will lead to fibrosis or cirrhosis", "start": 8, "end": 21}, {"entity_id": "8864370_1_Ent3", "role": "Treatment_Disorder", "text": "psoriatics", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "8864370_1_Ent2", "text": "Methotrexate", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8864370_1_Ent1", "text": "Methotrexate ( MTX )", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "8864370_1_Ent0", "text": "liver damage , which in some psoriatics will lead to fibrosis or cirrhosis", "entity_type": "Entity", "start": 8, "end": 21}, {"id": "8864370_1_Ent3", "text": "psoriatics", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "889156_1", "wnd_id": "889156_1_1", "text": "The use of beclomethasone diproprionate inhaler complicated by the development of an eosinophilic pneumonia reaction .", "tokens": ["The", "use", "of", "beclomethasone", "diproprionate", "inhaler", "complicated", "by", "the", "development", "of", "an", "eosinophilic", "pneumonia", "reaction", "."], "event_mentions": [{"id": "889156_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 9, "end": 10}, "arguments": [{"entity_id": "889156_1_Ent3", "role": "Treatment_Drug", "text": "beclomethasone diproprionate", "start": 3, "end": 5}, {"entity_id": "889156_1_Ent1", "role": "Treatment", "text": "beclomethasone diproprionate inhaler", "start": 3, "end": 6}, {"entity_id": "889156_1_Ent2", "role": "Treatment_Route", "text": "inhaler", "start": 5, "end": 6}, {"entity_id": "889156_1_Ent0", "role": "Effect", "text": "eosinophilic pneumonia reaction", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "889156_1_Ent3", "text": "beclomethasone diproprionate", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "889156_1_Ent1", "text": "beclomethasone diproprionate inhaler", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "889156_1_Ent2", "text": "inhaler", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "889156_1_Ent0", "text": "eosinophilic pneumonia reaction", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "889156_4", "wnd_id": "889156_4_1", "text": "A more serious development of adrenal insufficiency may occur upon the improper replacement of systemic steroids .", "tokens": ["A", "more", "serious", "development", "of", "adrenal", "insufficiency", "may", "occur", "upon", "the", "improper", "replacement", "of", "systemic", "steroids", "."], "event_mentions": [{"id": "889156_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "replacement", "start": 12, "end": 13}, "arguments": [{"entity_id": "889156_4_Ent0", "role": "Effect", "text": "development of adrenal insufficiency", "start": 3, "end": 7}, {"entity_id": "889156_4_Ent1", "role": "Treatment", "text": "systemic steroids", "start": 14, "end": 16}, {"entity_id": "889156_4_Ent2", "role": "Treatment_Drug", "text": "steroids", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "889156_4_Ent0", "text": "development of adrenal insufficiency", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "889156_4_Ent1", "text": "systemic steroids", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "889156_4_Ent2", "text": "steroids", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "8891729_5", "wnd_id": "8891729_5_1", "text": "When the patient was treated again with fludarabine nine months later , the DAT became positive with anti - IgG and anti - C3d antiglobulins after the second course of treatment .", "tokens": ["When", "the", "patient", "was", "treated", "again", "with", "fludarabine", "nine", "months", "later", ",", "the", "DAT", "became", "positive", "with", "anti", "-", "IgG", "and", "anti", "-", "C3d", "antiglobulins", "after", "the", "second", "course", "of", "treatment", "."], "event_mentions": [{"id": "8891729_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 4, "end": 5}, "arguments": [{"entity_id": "8891729_5_Ent0", "role": "Subject", "text": "the patient", "start": 1, "end": 3}, {"entity_id": "8891729_5_Ent2", "role": "Treatment", "text": "fludarabine", "start": 7, "end": 8}, {"entity_id": "8891729_5_Ent4", "role": "Treatment_Drug", "text": "fludarabine", "start": 7, "end": 8}, {"entity_id": "8891729_5_Ent5", "role": "Treatment_Time_elapsed", "text": "nine months later", "start": 8, "end": 11}, {"entity_id": "8891729_5_Ent1", "role": "Effect", "text": "the DAT became positive with anti - IgG and anti - C3d antiglobulins", "start": 12, "end": 25}, {"entity_id": "8891729_5_Ent3", "role": "Treatment", "text": "second course of treatment", "start": 27, "end": 31}]}], "entity_mentions": [{"id": "8891729_5_Ent0", "text": "the patient", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "8891729_5_Ent2", "text": "fludarabine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8891729_5_Ent4", "text": "fludarabine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8891729_5_Ent5", "text": "nine months later", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "8891729_5_Ent1", "text": "the DAT became positive with anti - IgG and anti - C3d antiglobulins", "entity_type": "Entity", "start": 12, "end": 25}, {"id": "8891729_5_Ent3", "text": "second course of treatment", "entity_type": "Entity", "start": 27, "end": 31}], "lang": "en"}
{"doc_id": "8912599_2", "wnd_id": "8912599_2_1", "text": "Methotrexate is an effective but potentially toxic treatment for psoriasis .", "tokens": ["Methotrexate", "is", "an", "effective", "but", "potentially", "toxic", "treatment", "for", "psoriasis", "."], "event_mentions": [{"id": "8912599_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 7, "end": 8}, "arguments": [{"entity_id": "8912599_2_Ent0", "role": "Treatment", "text": "Methotrexate", "start": 0, "end": 1}, {"entity_id": "8912599_2_Ent1", "role": "Treatment_Drug", "text": "Methotrexate", "start": 0, "end": 1}, {"entity_id": "8912599_2_Ent2", "role": "Treatment_Disorder", "text": "psoriasis", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "8912599_2_Ent0", "text": "Methotrexate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8912599_2_Ent1", "text": "Methotrexate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8912599_2_Ent2", "text": "psoriasis", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "8912599_5", "wnd_id": "8912599_5_1", "text": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature , emphasizing the risk factors associated with this manifestation .", "tokens": ["We", "describe", "two", "patients", "in", "whom", "painful", "erosions", "of", "their", "psoriasis", "developed", "as", "the", "presenting", "sign", "of", "methotrexate", "toxicity", "and", "review", "the", "literature", ",", "emphasizing", "the", "risk", "factors", "associated", "with", "this", "manifestation", "."], "event_mentions": [{"id": "8912599_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 16, "end": 17}, "arguments": [{"entity_id": "8912599_5_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "8912599_5_Ent0", "role": "Subject", "text": "two patients", "start": 2, "end": 4}, {"entity_id": "8912599_5_Ent2", "role": "Effect", "text": "painful erosions of their psoriasis", "start": 6, "end": 11}, {"entity_id": "8912599_5_Ent4", "role": "Treatment_Disorder", "text": "psoriasis", "start": 10, "end": 11}, {"entity_id": "8912599_5_Ent3", "role": "Treatment", "text": "methotrexate", "start": 17, "end": 18}, {"entity_id": "8912599_5_Ent5", "role": "Treatment_Drug", "text": "methotrexate", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "8912599_5_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8912599_5_Ent0", "text": "two patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "8912599_5_Ent2", "text": "painful erosions of their psoriasis", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "8912599_5_Ent4", "text": "psoriasis", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8912599_5_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "8912599_5_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "8921647_1", "wnd_id": "8921647_1_1", "text": "After treatment with cimetidine , there was a rapid deterioration with decreased oxygen saturation and arterial PO2 values .", "tokens": ["After", "treatment", "with", "cimetidine", ",", "there", "was", "a", "rapid", "deterioration", "with", "decreased", "oxygen", "saturation", "and", "arterial", "PO2", "values", "."], "event_mentions": [{"id": "8921647_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "was", "start": 6, "end": 7}, "arguments": [{"entity_id": "8921647_1_Ent1", "role": "Treatment", "text": "cimetidine", "start": 3, "end": 4}, {"entity_id": "8921647_1_Ent2", "role": "Treatment_Drug", "text": "cimetidine", "start": 3, "end": 4}, {"entity_id": "8921647_1_Ent0", "role": "Effect", "text": "a rapid deterioration with decreased oxygen saturation and arterial PO2 values", "start": 7, "end": 18}]}], "entity_mentions": [{"id": "8921647_1_Ent1", "text": "cimetidine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8921647_1_Ent2", "text": "cimetidine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8921647_1_Ent0", "text": "a rapid deterioration with decreased oxygen saturation and arterial PO2 values", "entity_type": "Entity", "start": 7, "end": 18}], "lang": "en"}
{"doc_id": "8949576_2", "wnd_id": "8949576_2_1", "text": "Failure of plasmapheresis , corticosteroids and thionamides to ameliorate a case of protracted amiodarone - induced thyroiditis .", "tokens": ["Failure", "of", "plasmapheresis", ",", "corticosteroids", "and", "thionamides", "to", "ameliorate", "a", "case", "of", "protracted", "amiodarone", "-", "induced", "thyroiditis", "."], "event_mentions": [{"id": "8949576_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "ameliorate", "start": 8, "end": 9}, "arguments": [{"entity_id": "8949576_2_Ent3", "role": "Treatment", "text": "plasmapheresis , corticosteroids and thionamides", "start": 2, "end": 7}, {"entity_id": "8949576_2_Ent5", "role": "Treatment_Drug", "text": "corticosteroids", "start": 4, "end": 5}, {"entity_id": "8949576_2_Ent6", "role": "Treatment_Drug", "text": "thionamides", "start": 6, "end": 7}, {"entity_id": "8949576_2_Ent4", "role": "Treatment_Disorder", "text": "amiodarone - induced thyroiditis", "start": 13, "end": 17}]}, {"id": "8949576_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 15, "end": 16}, "arguments": [{"entity_id": "8949576_2_Ent1", "role": "Treatment", "text": "amiodarone", "start": 13, "end": 14}, {"entity_id": "8949576_2_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 13, "end": 14}, {"entity_id": "8949576_2_Ent0", "role": "Effect", "text": "thyroiditis", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "8949576_2_Ent3", "text": "plasmapheresis , corticosteroids and thionamides", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "8949576_2_Ent5", "text": "corticosteroids", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8949576_2_Ent6", "text": "thionamides", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8949576_2_Ent1", "text": "amiodarone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8949576_2_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8949576_2_Ent4", "text": "amiodarone - induced thyroiditis", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "8949576_2_Ent0", "text": "thyroiditis", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "8961730_1", "wnd_id": "8961730_1_1", "text": "Psychotic disorder associated with isoniazid .", "tokens": ["Psychotic", "disorder", "associated", "with", "isoniazid", "."], "event_mentions": [{"id": "8961730_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "8961730_1_Ent0", "role": "Effect", "text": "Psychotic disorder", "start": 0, "end": 2}, {"entity_id": "8961730_1_Ent1", "role": "Treatment", "text": "isoniazid", "start": 4, "end": 5}, {"entity_id": "8961730_1_Ent2", "role": "Treatment_Drug", "text": "isoniazid", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "8961730_1_Ent0", "text": "Psychotic disorder", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8961730_1_Ent1", "text": "isoniazid", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8961730_1_Ent2", "text": "isoniazid", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "8961730_2", "wnd_id": "8961730_2_1", "text": "We evaluated a patient who developed a psychotic disorder after 4 months of isoniazid prophylaxis for a positive tuberculosis tine test .", "tokens": ["We", "evaluated", "a", "patient", "who", "developed", "a", "psychotic", "disorder", "after", "4", "months", "of", "isoniazid", "prophylaxis", "for", "a", "positive", "tuberculosis", "tine", "test", "."], "event_mentions": [{"id": "8961730_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "8961730_2_Ent0", "role": "Subject", "text": "patient", "start": 3, "end": 4}, {"entity_id": "8961730_2_Ent1", "role": "Effect", "text": "psychotic disorder", "start": 7, "end": 9}, {"entity_id": "8961730_2_Ent4", "role": "Treatment_Time_elapsed", "text": "4 months", "start": 10, "end": 12}, {"entity_id": "8961730_2_Ent2", "role": "Treatment", "text": "4 months of isoniazid prophylaxis", "start": 10, "end": 15}, {"entity_id": "8961730_2_Ent3", "role": "Treatment_Drug", "text": "isoniazid", "start": 13, "end": 14}, {"entity_id": "8961730_2_Ent5", "role": "Treatment_Disorder", "text": "tuberculosis", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "8961730_2_Ent0", "text": "patient", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8961730_2_Ent1", "text": "psychotic disorder", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "8961730_2_Ent4", "text": "4 months", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "8961730_2_Ent2", "text": "4 months of isoniazid prophylaxis", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "8961730_2_Ent3", "text": "isoniazid", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8961730_2_Ent5", "text": "tuberculosis", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "897744_2", "wnd_id": "897744_2_1", "text": "A drug addict with staphylococcal endocarditis treated with methicillin , who developed massive proteinuria and acute nephritic syndrome is described .", "tokens": ["A", "drug", "addict", "with", "staphylococcal", "endocarditis", "treated", "with", "methicillin", ",", "who", "developed", "massive", "proteinuria", "and", "acute", "nephritic", "syndrome", "is", "described", "."], "event_mentions": [{"id": "897744_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 11, "end": 12}, "arguments": [{"entity_id": "897744_2_Ent0", "role": "Subject", "text": "A drug addict", "start": 0, "end": 3}, {"entity_id": "897744_2_Ent1", "role": "Subject_Disorder", "text": "drug addict", "start": 1, "end": 3}, {"entity_id": "897744_2_Ent4", "role": "Treatment_Disorder", "text": "staphylococcal endocarditis", "start": 4, "end": 6}, {"entity_id": "897744_2_Ent3", "role": "Treatment", "text": "methicillin", "start": 8, "end": 9}, {"entity_id": "897744_2_Ent5", "role": "Treatment_Drug", "text": "methicillin", "start": 8, "end": 9}, {"entity_id": "897744_2_Ent2", "role": "Effect", "text": "massive proteinuria and acute nephritic syndrome", "start": 12, "end": 18}]}], "entity_mentions": [{"id": "897744_2_Ent0", "text": "A drug addict", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "897744_2_Ent1", "text": "drug addict", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "897744_2_Ent4", "text": "staphylococcal endocarditis", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "897744_2_Ent3", "text": "methicillin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "897744_2_Ent5", "text": "methicillin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "897744_2_Ent2", "text": "massive proteinuria and acute nephritic syndrome", "entity_type": "Entity", "start": 12, "end": 18}], "lang": "en"}
{"doc_id": "9007910_2", "wnd_id": "9007910_2_1", "text": "PURPOSE / OBJECTIVES : To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase ( DPD ) deficiency , which predisposes patients with cancer to potentially lethal adverse reactions following 5 - fluorouracil ( 5 - FU) - based chemotherapy .", "tokens": ["PURPOSE", "/", "OBJECTIVES", ":", "To", "describe", "the", "pharmacogenetic", "syndrome", "of", "dihydropyrimidine", "dehydrogenase", "(", "DPD", ")", "deficiency", ",", "which", "predisposes", "patients", "with", "cancer", "to", "potentially", "lethal", "adverse", "reactions", "following", "5", "-", "fluorouracil", "(", "5", "-", "FU)", "-", "based", "chemotherapy", "."], "event_mentions": [{"id": "9007910_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "predisposes", "start": 18, "end": 19}, "arguments": [{"entity_id": "9007910_2_Ent0", "role": "Subject", "text": "dihydropyrimidine dehydrogenase ( DPD ) deficiency", "start": 10, "end": 16}, {"entity_id": "9007910_2_Ent1", "role": "Subject_Disorder", "text": "dihydropyrimidine dehydrogenase ( DPD ) deficiency", "start": 10, "end": 16}, {"entity_id": "9007910_2_Ent4", "role": "Treatment_Disorder", "text": "cancer", "start": 21, "end": 22}, {"entity_id": "9007910_2_Ent2", "role": "Effect", "text": "lethal adverse reactions", "start": 24, "end": 27}, {"entity_id": "9007910_2_Ent5", "role": "Treatment_Drug", "text": "5 - fluorouracil", "start": 28, "end": 31}, {"entity_id": "9007910_2_Ent3", "role": "Treatment", "text": "5 - fluorouracil ( 5 - FU) - based chemotherapy", "start": 28, "end": 38}, {"entity_id": "9007910_2_Ent6", "role": "Treatment_Route", "text": "chemotherapy", "start": 37, "end": 38}]}], "entity_mentions": [{"id": "9007910_2_Ent0", "text": "dihydropyrimidine dehydrogenase ( DPD ) deficiency", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "9007910_2_Ent1", "text": "dihydropyrimidine dehydrogenase ( DPD ) deficiency", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "9007910_2_Ent4", "text": "cancer", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "9007910_2_Ent2", "text": "lethal adverse reactions", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "9007910_2_Ent5", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 28, "end": 31}, {"id": "9007910_2_Ent3", "text": "5 - fluorouracil ( 5 - FU) - based chemotherapy", "entity_type": "Entity", "start": 28, "end": 38}, {"id": "9007910_2_Ent6", "text": "chemotherapy", "entity_type": "Entity", "start": 37, "end": 38}], "lang": "en"}
{"doc_id": "9007910_4", "wnd_id": "9007910_4_1", "text": "DATA SYNTHESIS : Genetic deficiencies in DPD , the rate - limiting enzyme responsible for 5 - FU catabolism , may occur in 3 % or more of patients with cancer putting them at increased risk for unusually severe adverse reactions ( e.g. , diarrhea , stomatitis , mucositis , myelosuppression , neurotoxicity ) to standard doses of 5 - FU .", "tokens": ["DATA", "SYNTHESIS", ":", "Genetic", "deficiencies", "in", "DPD", ",", "the", "rate", "-", "limiting", "enzyme", "responsible", "for", "5", "-", "FU", "catabolism", ",", "may", "occur", "in", "3", "%", "or", "more", "of", "patients", "with", "cancer", "putting", "them", "at", "increased", "risk", "for", "unusually", "severe", "adverse", "reactions", "(", "e.g.", ",", "diarrhea", ",", "stomatitis", ",", "mucositis", ",", "myelosuppression", ",", "neurotoxicity", ")", "to", "standard", "doses", "of", "5", "-", "FU", "."], "event_mentions": [{"id": "9007910_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "putting", "start": 31, "end": 32}, "arguments": [{"entity_id": "9007910_4_Ent2", "role": "Subject_Disorder", "text": "Genetic deficiencies in DPD", "start": 3, "end": 7}, {"entity_id": "9007910_4_Ent0", "role": "Subject", "text": "Genetic deficiencies in DPD , the rate - limiting enzyme responsible for 5 - FU catabolism , may occur in 3 % or more of patients with cancer", "start": 3, "end": 31}, {"entity_id": "9007910_4_Ent1", "role": "Subject_Population", "text": "3 % or more", "start": 23, "end": 27}, {"entity_id": "9007910_4_Ent7", "role": "Treatment_Disorder", "text": "cancer", "start": 30, "end": 31}, {"entity_id": "9007910_4_Ent3", "role": "Effect", "text": "increased risk for unusually severe adverse reactions ( e.g. , diarrhea , stomatitis , mucositis , myelosuppression , neurotoxicity )", "start": 34, "end": 54}, {"entity_id": "9007910_4_Ent6", "role": "Treatment_Dosage", "text": "standard doses", "start": 55, "end": 57}, {"entity_id": "9007910_4_Ent4", "role": "Treatment", "text": "standard doses of 5 - FU", "start": 55, "end": 61}, {"entity_id": "9007910_4_Ent5", "role": "Treatment_Drug", "text": "5 - FU", "start": 58, "end": 61}]}], "entity_mentions": [{"id": "9007910_4_Ent2", "text": "Genetic deficiencies in DPD", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "9007910_4_Ent0", "text": "Genetic deficiencies in DPD , the rate - limiting enzyme responsible for 5 - FU catabolism , may occur in 3 % or more of patients with cancer", "entity_type": "Entity", "start": 3, "end": 31}, {"id": "9007910_4_Ent1", "text": "3 % or more", "entity_type": "Entity", "start": 23, "end": 27}, {"id": "9007910_4_Ent7", "text": "cancer", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "9007910_4_Ent3", "text": "increased risk for unusually severe adverse reactions ( e.g. , diarrhea , stomatitis , mucositis , myelosuppression , neurotoxicity )", "entity_type": "Entity", "start": 34, "end": 54}, {"id": "9007910_4_Ent6", "text": "standard doses", "entity_type": "Entity", "start": 55, "end": 57}, {"id": "9007910_4_Ent4", "text": "standard doses of 5 - FU", "entity_type": "Entity", "start": 55, "end": 61}, {"id": "9007910_4_Ent5", "text": "5 - FU", "entity_type": "Entity", "start": 58, "end": 61}], "lang": "en"}
{"doc_id": "9013348_3", "wnd_id": "9013348_3_1", "text": "Mesalamine may cause hypersensitivity pneumonitis in patients with Crohn 's disease .", "tokens": ["Mesalamine", "may", "cause", "hypersensitivity", "pneumonitis", "in", "patients", "with", "Crohn", "'s", "disease", "."], "event_mentions": [{"id": "9013348_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 2, "end": 3}, "arguments": [{"entity_id": "9013348_3_Ent2", "role": "Treatment", "text": "Mesalamine", "start": 0, "end": 1}, {"entity_id": "9013348_3_Ent4", "role": "Treatment_Drug", "text": "Mesalamine", "start": 0, "end": 1}, {"entity_id": "9013348_3_Ent1", "role": "Effect", "text": "hypersensitivity pneumonitis", "start": 3, "end": 5}, {"entity_id": "9013348_3_Ent0", "role": "Subject", "text": "patients with Crohn 's disease", "start": 6, "end": 11}, {"entity_id": "9013348_3_Ent3", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "9013348_3_Ent2", "text": "Mesalamine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9013348_3_Ent4", "text": "Mesalamine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9013348_3_Ent1", "text": "hypersensitivity pneumonitis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "9013348_3_Ent0", "text": "patients with Crohn 's disease", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "9013348_3_Ent3", "text": "Crohn 's disease", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "9022114_4", "wnd_id": "9022114_4_1", "text": "The authors report on two patients with corneal ulcers refractory to conventional treatment while the patients were undergoing oral colchicine therapy .", "tokens": ["The", "authors", "report", "on", "two", "patients", "with", "corneal", "ulcers", "refractory", "to", "conventional", "treatment", "while", "the", "patients", "were", "undergoing", "oral", "colchicine", "therapy", "."], "event_mentions": [{"id": "9022114_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "undergoing", "start": 17, "end": 18}, "arguments": [{"entity_id": "9022114_4_Ent1", "role": "Subject_Population", "text": "two", "start": 4, "end": 5}, {"entity_id": "9022114_4_Ent0", "role": "Subject", "text": "two patients", "start": 4, "end": 6}, {"entity_id": "9022114_4_Ent2", "role": "Effect", "text": "corneal ulcers", "start": 7, "end": 9}, {"entity_id": "9022114_4_Ent5", "role": "Treatment_Route", "text": "oral", "start": 18, "end": 19}, {"entity_id": "9022114_4_Ent3", "role": "Treatment", "text": "oral colchicine therapy", "start": 18, "end": 21}, {"entity_id": "9022114_4_Ent4", "role": "Treatment_Drug", "text": "colchicine", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "9022114_4_Ent1", "text": "two", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9022114_4_Ent0", "text": "two patients", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9022114_4_Ent2", "text": "corneal ulcers", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "9022114_4_Ent5", "text": "oral", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9022114_4_Ent3", "text": "oral colchicine therapy", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "9022114_4_Ent4", "text": "colchicine", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "9022114_5", "wnd_id": "9022114_5_1", "text": "The authors suggest that in patients with corneal ulcers refractory to conventional treatment who are receiving colchicine , cessation of colchicine therapy should be considered .", "tokens": ["The", "authors", "suggest", "that", "in", "patients", "with", "corneal", "ulcers", "refractory", "to", "conventional", "treatment", "who", "are", "receiving", "colchicine", ",", "cessation", "of", "colchicine", "therapy", "should", "be", "considered", "."], "event_mentions": [{"id": "9022114_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "receiving", "start": 15, "end": 16}, "arguments": [{"entity_id": "9022114_5_Ent0", "role": "Subject", "text": "patients with corneal ulcers", "start": 5, "end": 9}, {"entity_id": "9022114_5_Ent3", "role": "Treatment_Disorder", "text": "corneal ulcers", "start": 7, "end": 9}, {"entity_id": "9022114_5_Ent1", "role": "Treatment", "text": "colchicine", "start": 16, "end": 17}, {"entity_id": "9022114_5_Ent2", "role": "Treatment_Drug", "text": "colchicine", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "9022114_5_Ent0", "text": "patients with corneal ulcers", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "9022114_5_Ent3", "text": "corneal ulcers", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "9022114_5_Ent1", "text": "colchicine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9022114_5_Ent2", "text": "colchicine", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "9039216_1", "wnd_id": "9039216_1_1", "text": "A 17 - year - old female patient who had been taking oral minocycline ( 50 mg twice daily ) for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis .", "tokens": ["A", "17", "-", "year", "-", "old", "female", "patient", "who", "had", "been", "taking", "oral", "minocycline", "(", "50", "mg", "twice", "daily", ")", "for", "3", "weeks", "for", "acne", "developed", "an", "eruption", "that", "progressed", "to", "an", "exfoliative", "dermatitis", "."], "event_mentions": [{"id": "9039216_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 25, "end": 26}, "arguments": [{"entity_id": "9039216_1_Ent0", "role": "Subject", "text": "A 17 - year - old female patient", "start": 0, "end": 8}, {"entity_id": "9039216_1_Ent1", "role": "Subject_Age", "text": "17 - year - old", "start": 1, "end": 6}, {"entity_id": "9039216_1_Ent2", "role": "Subject_Gender", "text": "female", "start": 6, "end": 7}, {"entity_id": "9039216_1_Ent11", "role": "Treatment_Route", "text": "oral", "start": 12, "end": 13}, {"entity_id": "9039216_1_Ent5", "role": "Treatment", "text": "oral minocycline ( 50 mg twice daily ) for 3 weeks", "start": 12, "end": 23}, {"entity_id": "9039216_1_Ent7", "role": "Treatment_Drug", "text": "minocycline", "start": 13, "end": 14}, {"entity_id": "9039216_1_Ent8", "role": "Treatment_Dosage", "text": "50 mg", "start": 15, "end": 17}, {"entity_id": "9039216_1_Ent9", "role": "Treatment_Freq", "text": "twice daily", "start": 17, "end": 19}, {"entity_id": "9039216_1_Ent10", "role": "Treatment_Duration", "text": "3 weeks", "start": 21, "end": 23}, {"entity_id": "9039216_1_Ent6", "role": "Treatment_Disorder", "text": "acne", "start": 24, "end": 25}, {"entity_id": "9039216_1_Ent3", "role": "Effect", "text": "eruption", "start": 27, "end": 28}, {"entity_id": "9039216_1_Ent4", "role": "Effect", "text": "an exfoliative dermatitis", "start": 31, "end": 34}]}], "entity_mentions": [{"id": "9039216_1_Ent0", "text": "A 17 - year - old female patient", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "9039216_1_Ent1", "text": "17 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "9039216_1_Ent2", "text": "female", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9039216_1_Ent11", "text": "oral", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9039216_1_Ent5", "text": "oral minocycline ( 50 mg twice daily ) for 3 weeks", "entity_type": "Entity", "start": 12, "end": 23}, {"id": "9039216_1_Ent7", "text": "minocycline", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9039216_1_Ent8", "text": "50 mg", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "9039216_1_Ent9", "text": "twice daily", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "9039216_1_Ent10", "text": "3 weeks", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "9039216_1_Ent6", "text": "acne", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "9039216_1_Ent3", "text": "eruption", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "9039216_1_Ent4", "text": "an exfoliative dermatitis", "entity_type": "Entity", "start": 31, "end": 34}], "lang": "en"}
{"doc_id": "9039216_2", "wnd_id": "9039216_2_1", "text": "Fever , lymphadenopathy , eosinophilia , lymphocytosis , hepatitis , and dermatitis : a severe adverse reaction to minocycline .", "tokens": ["Fever", ",", "lymphadenopathy", ",", "eosinophilia", ",", "lymphocytosis", ",", "hepatitis", ",", "and", "dermatitis", ":", "a", "severe", "adverse", "reaction", "to", "minocycline", "."], "event_mentions": [{"id": "9039216_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse reaction", "start": 15, "end": 17}, "arguments": [{"entity_id": "9039216_2_Ent0", "role": "Effect", "text": "Fever , lymphadenopathy , eosinophilia , lymphocytosis , hepatitis , and dermatitis", "start": 0, "end": 12}, {"entity_id": "9039216_2_Ent1", "role": "Treatment", "text": "minocycline", "start": 18, "end": 19}, {"entity_id": "9039216_2_Ent2", "role": "Treatment_Drug", "text": "minocycline", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "9039216_2_Ent0", "text": "Fever , lymphadenopathy , eosinophilia , lymphocytosis , hepatitis , and dermatitis", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "9039216_2_Ent1", "text": "minocycline", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9039216_2_Ent2", "text": "minocycline", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "9161656_3", "wnd_id": "9161656_3_1", "text": "CASE SUMMARY : A 66 - year - old white woman with a 10 - year history of hypertension and bronchial asthma was switched from immediate - release verapamil hydrocloride 40 mg tid to sustained - release verapamil 240 mg / d po for better hypertension control .", "tokens": ["CASE", "SUMMARY", ":", "A", "66", "-", "year", "-", "old", "white", "woman", "with", "a", "10", "-", "year", "history", "of", "hypertension", "and", "bronchial", "asthma", "was", "switched", "from", "immediate", "-", "release", "verapamil", "hydrocloride", "40", "mg", "tid", "to", "sustained", "-", "release", "verapamil", "240", "mg", "/", "d", "po", "for", "better", "hypertension", "control", "."], "event_mentions": [{"id": "9161656_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "control", "start": 46, "end": 47}, "arguments": [{"entity_id": "9161656_3_Ent0", "role": "Subject", "text": "A 66 - year - old white woman with a 10 - year history of hypertension and bronchial asthma", "start": 3, "end": 22}, {"entity_id": "9161656_3_Ent1", "role": "Subject_Age", "text": "66 - year - old", "start": 4, "end": 9}, {"entity_id": "9161656_3_Ent2", "role": "Subject_Race", "text": "white", "start": 9, "end": 10}, {"entity_id": "9161656_3_Ent3", "role": "Subject_Gender", "text": "woman", "start": 10, "end": 11}, {"entity_id": "9161656_3_Ent6", "role": "Treatment_Disorder", "text": "hypertension", "start": 18, "end": 19}, {"entity_id": "9161656_3_Ent4", "role": "Subject_Disorder", "text": "bronchial asthma", "start": 20, "end": 22}, {"entity_id": "9161656_3_Ent5", "role": "Treatment", "text": "switched from immediate - release verapamil hydrocloride 40 mg tid to sustained - release verapamil 240 mg / d po", "start": 23, "end": 43}, {"entity_id": "9161656_3_Ent8", "role": "Treatment_Drug", "text": "immediate - release verapamil hydrocloride", "start": 25, "end": 30}, {"entity_id": "9161656_3_Ent11", "role": "Treatment_Dosage", "text": "40 mg tid", "start": 30, "end": 33}, {"entity_id": "9161656_3_Ent9", "role": "Treatment_Drug", "text": "sustained - release verapamil", "start": 34, "end": 38}, {"entity_id": "9161656_3_Ent10", "role": "Treatment_Dosage", "text": "240 mg / d", "start": 38, "end": 42}, {"entity_id": "9161656_3_Ent12", "role": "Treatment_Route", "text": "po", "start": 42, "end": 43}, {"entity_id": "9161656_3_Ent7", "role": "Treatment_Disorder", "text": "hypertension", "start": 45, "end": 46}]}], "entity_mentions": [{"id": "9161656_3_Ent0", "text": "A 66 - year - old white woman with a 10 - year history of hypertension and bronchial asthma", "entity_type": "Entity", "start": 3, "end": 22}, {"id": "9161656_3_Ent1", "text": "66 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "9161656_3_Ent2", "text": "white", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9161656_3_Ent3", "text": "woman", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9161656_3_Ent6", "text": "hypertension", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9161656_3_Ent4", "text": "bronchial asthma", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "9161656_3_Ent5", "text": "switched from immediate - release verapamil hydrocloride 40 mg tid to sustained - release verapamil 240 mg / d po", "entity_type": "Entity", "start": 23, "end": 43}, {"id": "9161656_3_Ent8", "text": "immediate - release verapamil hydrocloride", "entity_type": "Entity", "start": 25, "end": 30}, {"id": "9161656_3_Ent11", "text": "40 mg tid", "entity_type": "Entity", "start": 30, "end": 33}, {"id": "9161656_3_Ent9", "text": "sustained - release verapamil", "entity_type": "Entity", "start": 34, "end": 38}, {"id": "9161656_3_Ent10", "text": "240 mg / d", "entity_type": "Entity", "start": 38, "end": 42}, {"id": "9161656_3_Ent12", "text": "po", "entity_type": "Entity", "start": 42, "end": 43}, {"id": "9161656_3_Ent7", "text": "hypertension", "entity_type": "Entity", "start": 45, "end": 46}], "lang": "en"}
{"doc_id": "9169264_1", "wnd_id": "9169264_1_1", "text": "Cephalexin rash in infectious mononucleosis .", "tokens": ["Cephalexin", "rash", "in", "infectious", "mononucleosis", "."], "event_mentions": [{"id": "9169264_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 2, "end": 3}, "arguments": [{"entity_id": "9169264_1_Ent1", "role": "Treatment", "text": "Cephalexin", "start": 0, "end": 1}, {"entity_id": "9169264_1_Ent2", "role": "Treatment_Drug", "text": "Cephalexin", "start": 0, "end": 1}, {"entity_id": "9169264_1_Ent0", "role": "Effect", "text": "Cephalexin rash", "start": 0, "end": 2}, {"entity_id": "9169264_1_Ent3", "role": "Treatment_Disorder", "text": "infectious mononucleosis", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "9169264_1_Ent1", "text": "Cephalexin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9169264_1_Ent2", "text": "Cephalexin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9169264_1_Ent0", "text": "Cephalexin rash", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9169264_1_Ent3", "text": "infectious mononucleosis", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "9184269_4", "wnd_id": "9184269_4_1", "text": "Our review of 194 RA patients and 38 PsA patients receiving MTX has identified four RA patients and one PsA patient with MTX - induced pneumonitis , giving a prevalence of 2.1 % and 0.03 % , respectively .", "tokens": ["Our", "review", "of", "194", "RA", "patients", "and", "38", "PsA", "patients", "receiving", "MTX", "has", "identified", "four", "RA", "patients", "and", "one", "PsA", "patient", "with", "MTX", "-", "induced", "pneumonitis", ",", "giving", "a", "prevalence", "of", "2.1", "%", "and", "0.03", "%", ",", "respectively", "."], "event_mentions": [{"id": "9184269_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 24, "end": 25}, "arguments": [{"entity_id": "9184269_4_Ent0", "role": "Subject", "text": "194 RA patients and 38 PsA patients receiving MTX has identified four RA patients and one PsA patient", "start": 3, "end": 21}, {"entity_id": "9184269_4_Ent1", "role": "Subject_Population", "text": "four", "start": 14, "end": 15}, {"entity_id": "9184269_4_Ent5", "role": "Treatment_Disorder", "text": "RA", "start": 15, "end": 16}, {"entity_id": "9184269_4_Ent2", "role": "Subject_Population", "text": "one", "start": 18, "end": 19}, {"entity_id": "9184269_4_Ent6", "role": "Treatment_Disorder", "text": "PsA", "start": 19, "end": 20}, {"entity_id": "9184269_4_Ent4", "role": "Treatment", "text": "MTX", "start": 22, "end": 23}, {"entity_id": "9184269_4_Ent7", "role": "Treatment_Drug", "text": "MTX", "start": 22, "end": 23}, {"entity_id": "9184269_4_Ent3", "role": "Effect", "text": "pneumonitis", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "9184269_4_Ent0", "text": "194 RA patients and 38 PsA patients receiving MTX has identified four RA patients and one PsA patient", "entity_type": "Entity", "start": 3, "end": 21}, {"id": "9184269_4_Ent1", "text": "four", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "9184269_4_Ent5", "text": "RA", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "9184269_4_Ent2", "text": "one", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9184269_4_Ent6", "text": "PsA", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "9184269_4_Ent4", "text": "MTX", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "9184269_4_Ent7", "text": "MTX", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "9184269_4_Ent3", "text": "pneumonitis", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "9195619_2", "wnd_id": "9195619_2_1", "text": "Mental nerve neuropathy as a result of hepatitis B vaccination .", "tokens": ["Mental", "nerve", "neuropathy", "as", "a", "result", "of", "hepatitis", "B", "vaccination", "."], "event_mentions": [{"id": "9195619_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "result", "start": 5, "end": 6}, "arguments": [{"entity_id": "9195619_2_Ent0", "role": "Effect", "text": "Mental nerve neuropathy", "start": 0, "end": 3}, {"entity_id": "9195619_2_Ent1", "role": "Treatment", "text": "hepatitis B vaccination", "start": 7, "end": 10}, {"entity_id": "9195619_2_Ent2", "role": "Treatment_Drug", "text": "hepatitis B vaccination .", "start": 7, "end": 11}]}], "entity_mentions": [{"id": "9195619_2_Ent0", "text": "Mental nerve neuropathy", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9195619_2_Ent1", "text": "hepatitis B vaccination", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "9195619_2_Ent2", "text": "hepatitis B vaccination .", "entity_type": "Entity", "start": 7, "end": 11}], "lang": "en"}
{"doc_id": "9220046_4", "wnd_id": "9220046_4_1", "text": "Erythromycin is a macrolide antibiotic that may increase the risk of lovastatin - induced rhabdomyolysis .", "tokens": ["Erythromycin", "is", "a", "macrolide", "antibiotic", "that", "may", "increase", "the", "risk", "of", "lovastatin", "-", "induced", "rhabdomyolysis", "."], "event_mentions": [{"id": "9220046_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 13, "end": 14}, "arguments": [{"entity_id": "9220046_4_Ent1", "role": "Treatment", "text": "Erythromycin", "start": 0, "end": 1}, {"entity_id": "9220046_4_Ent2", "role": "Treatment_Drug", "text": "Erythromycin", "start": 0, "end": 1}, {"entity_id": "9220046_4_Ent5", "role": "Combination_Drug", "text": "Erythromycin", "start": 0, "end": 1}, {"entity_id": "9220046_4_Ent0", "role": "Effect", "text": "increase the risk of lovastatin - induced rhabdomyolysis", "start": 7, "end": 15}, {"entity_id": "9220046_4_Ent3", "role": "Treatment_Drug", "text": "lovastatin", "start": 11, "end": 12}, {"entity_id": "9220046_4_Ent4", "role": "Combination_Drug", "text": "lovastatin", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "9220046_4_Ent1", "text": "Erythromycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9220046_4_Ent2", "text": "Erythromycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9220046_4_Ent5", "text": "Erythromycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9220046_4_Ent0", "text": "increase the risk of lovastatin - induced rhabdomyolysis", "entity_type": "Entity", "start": 7, "end": 15}, {"id": "9220046_4_Ent3", "text": "lovastatin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9220046_4_Ent4", "text": "lovastatin", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "9232614_2", "wnd_id": "9232614_2_1", "text": "Tamoxifen is suggested to be carcinogenic both through direct genotoxic and epigenetic mechanisms .", "tokens": ["Tamoxifen", "is", "suggested", "to", "be", "carcinogenic", "both", "through", "direct", "genotoxic", "and", "epigenetic", "mechanisms", "."], "event_mentions": [{"id": "9232614_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suggested", "start": 2, "end": 3}, "arguments": [{"entity_id": "9232614_2_Ent1", "role": "Treatment", "text": "Tamoxifen", "start": 0, "end": 1}, {"entity_id": "9232614_2_Ent2", "role": "Treatment_Drug", "text": "Tamoxifen", "start": 0, "end": 1}, {"entity_id": "9232614_2_Ent0", "role": "Effect", "text": "carcinogenic both through direct genotoxic and epigenetic mechanisms", "start": 5, "end": 13}]}], "entity_mentions": [{"id": "9232614_2_Ent1", "text": "Tamoxifen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9232614_2_Ent2", "text": "Tamoxifen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9232614_2_Ent0", "text": "carcinogenic both through direct genotoxic and epigenetic mechanisms", "entity_type": "Entity", "start": 5, "end": 13}], "lang": "en"}
{"doc_id": "9232614_3", "wnd_id": "9232614_3_1", "text": "We report two cases that developed acute myeloid leukaemia ( AML ) during tamoxifen therapy for breast cancer .", "tokens": ["We", "report", "two", "cases", "that", "developed", "acute", "myeloid", "leukaemia", "(", "AML", ")", "during", "tamoxifen", "therapy", "for", "breast", "cancer", "."], "event_mentions": [{"id": "9232614_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "9232614_3_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "9232614_3_Ent0", "role": "Subject", "text": "two cases", "start": 2, "end": 4}, {"entity_id": "9232614_3_Ent2", "role": "Effect", "text": "acute myeloid leukaemia ( AML )", "start": 6, "end": 12}, {"entity_id": "9232614_3_Ent5", "role": "Treatment_Drug", "text": "tamoxifen", "start": 13, "end": 14}, {"entity_id": "9232614_3_Ent3", "role": "Treatment", "text": "tamoxifen therapy for breast cancer", "start": 13, "end": 18}, {"entity_id": "9232614_3_Ent4", "role": "Treatment_Disorder", "text": "breast cancer", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "9232614_3_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9232614_3_Ent0", "text": "two cases", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "9232614_3_Ent2", "text": "acute myeloid leukaemia ( AML )", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "9232614_3_Ent5", "text": "tamoxifen", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9232614_3_Ent3", "text": "tamoxifen therapy for breast cancer", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "9232614_3_Ent4", "text": "breast cancer", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "9247841_1", "wnd_id": "9247841_1_1", "text": "Propylthiouracil - induced cutaneous vasculitis .", "tokens": ["Propylthiouracil", "-", "induced", "cutaneous", "vasculitis", "."], "event_mentions": [{"id": "9247841_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "9247841_1_Ent1", "role": "Treatment", "text": "Propylthiouracil", "start": 0, "end": 1}, {"entity_id": "9247841_1_Ent2", "role": "Treatment_Drug", "text": "Propylthiouracil", "start": 0, "end": 1}, {"entity_id": "9247841_1_Ent0", "role": "Effect", "text": "cutaneous vasculitis", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "9247841_1_Ent1", "text": "Propylthiouracil", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9247841_1_Ent2", "text": "Propylthiouracil", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9247841_1_Ent0", "text": "cutaneous vasculitis", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "9253492_1", "wnd_id": "9253492_1_1", "text": "A 2 - year - old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide .", "tokens": ["A", "2", "-", "year", "-", "old", "mentally", "retarded", "boy", "with", "frontal", "lobe", "epilepsy", "presented", "with", "an", "episode", "that", "resembled", "heat", "stroke", "during", "the", "administration", "of", "zonisamide", "."], "event_mentions": [{"id": "9253492_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 21, "end": 22}, "arguments": [{"entity_id": "9253492_1_Ent0", "role": "Subject", "text": "A 2 - year - old mentally retarded boy with frontal lobe epilepsy", "start": 0, "end": 13}, {"entity_id": "9253492_1_Ent1", "role": "Subject_Age", "text": "2 - year - old", "start": 1, "end": 6}, {"entity_id": "9253492_1_Ent2", "role": "Subject_Gender", "text": "boy", "start": 8, "end": 9}, {"entity_id": "9253492_1_Ent6", "role": "Treatment_Disorder", "text": "frontal lobe epilepsy", "start": 10, "end": 13}, {"entity_id": "9253492_1_Ent3", "role": "Effect", "text": "an episode that resembled heat stroke", "start": 15, "end": 21}, {"entity_id": "9253492_1_Ent4", "role": "Treatment", "text": "zonisamide", "start": 25, "end": 26}, {"entity_id": "9253492_1_Ent5", "role": "Treatment_Drug", "text": "zonisamide", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "9253492_1_Ent0", "text": "A 2 - year - old mentally retarded boy with frontal lobe epilepsy", "entity_type": "Entity", "start": 0, "end": 13}, {"id": "9253492_1_Ent1", "text": "2 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "9253492_1_Ent2", "text": "boy", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9253492_1_Ent6", "text": "frontal lobe epilepsy", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "9253492_1_Ent3", "text": "an episode that resembled heat stroke", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "9253492_1_Ent4", "text": "zonisamide", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "9253492_1_Ent5", "text": "zonisamide", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "9256906_1", "wnd_id": "9256906_1_1", "text": "Acute renal failure in a patient receiving treatment with suramin .", "tokens": ["Acute", "renal", "failure", "in", "a", "patient", "receiving", "treatment", "with", "suramin", "."], "event_mentions": [{"id": "9256906_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 3, "end": 4}, "arguments": [{"entity_id": "9256906_1_Ent1", "role": "Effect", "text": "Acute renal failure", "start": 0, "end": 3}, {"entity_id": "9256906_1_Ent0", "role": "Subject", "text": "a patient", "start": 4, "end": 6}, {"entity_id": "9256906_1_Ent2", "role": "Treatment", "text": "suramin", "start": 9, "end": 10}, {"entity_id": "9256906_1_Ent3", "role": "Treatment_Drug", "text": "suramin", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "9256906_1_Ent1", "text": "Acute renal failure", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9256906_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9256906_1_Ent2", "text": "suramin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9256906_1_Ent3", "text": "suramin", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "9337441_14", "wnd_id": "9337441_14_1", "text": "To our knowledge , this case report represents only the third description of laxative - induced TEN .", "tokens": ["To", "our", "knowledge", ",", "this", "case", "report", "represents", "only", "the", "third", "description", "of", "laxative", "-", "induced", "TEN", "."], "event_mentions": [{"id": "9337441_14_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 15, "end": 16}, "arguments": [{"entity_id": "9337441_14_Ent1", "role": "Treatment", "text": "laxative", "start": 13, "end": 14}, {"entity_id": "9337441_14_Ent2", "role": "Treatment_Drug", "text": "laxative", "start": 13, "end": 14}, {"entity_id": "9337441_14_Ent0", "role": "Effect", "text": "TEN", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "9337441_14_Ent1", "text": "laxative", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9337441_14_Ent2", "text": "laxative", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9337441_14_Ent0", "text": "TEN", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "9337441_2", "wnd_id": "9337441_2_1", "text": "OBJECTIVE : To report a case of phenolphthalein - induced toxic epidermal necrolysis ( TEN ) in a patient maintained on several other medications more commonly known to be associated with TEN .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "phenolphthalein", "-", "induced", "toxic", "epidermal", "necrolysis", "(", "TEN", ")", "in", "a", "patient", "maintained", "on", "several", "other", "medications", "more", "commonly", "known", "to", "be", "associated", "with", "TEN", "."], "event_mentions": [{"id": "9337441_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "9337441_2_Ent0", "role": "Subject", "text": "a case of", "start": 4, "end": 7}, {"entity_id": "9337441_2_Ent3", "role": "Treatment", "text": "phenolphthalein", "start": 7, "end": 8}, {"entity_id": "9337441_2_Ent5", "role": "Treatment_Drug", "text": "phenolphthalein", "start": 7, "end": 8}, {"entity_id": "9337441_2_Ent2", "role": "Effect", "text": "toxic epidermal necrolysis ( TEN )", "start": 10, "end": 16}, {"entity_id": "9337441_2_Ent1", "role": "Subject", "text": "a patient", "start": 17, "end": 19}, {"entity_id": "9337441_2_Ent4", "role": "Treatment", "text": "maintained on several other medications more commonly known to be associated with TEN", "start": 19, "end": 32}]}], "entity_mentions": [{"id": "9337441_2_Ent0", "text": "a case of", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "9337441_2_Ent3", "text": "phenolphthalein", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9337441_2_Ent5", "text": "phenolphthalein", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9337441_2_Ent2", "text": "toxic epidermal necrolysis ( TEN )", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "9337441_2_Ent1", "text": "a patient", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "9337441_2_Ent4", "text": "maintained on several other medications more commonly known to be associated with TEN", "entity_type": "Entity", "start": 19, "end": 32}], "lang": "en"}
{"doc_id": "9366852_1", "wnd_id": "9366852_1_1", "text": "Skin necrosis secondary to low - molecular weight heparin in a patient with antiphospholipid antibody syndrome .", "tokens": ["Skin", "necrosis", "secondary", "to", "low", "-", "molecular", "weight", "heparin", "in", "a", "patient", "with", "antiphospholipid", "antibody", "syndrome", "."], "event_mentions": [{"id": "9366852_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary to", "start": 2, "end": 4}, "arguments": [{"entity_id": "9366852_1_Ent1", "role": "Effect", "text": "Skin necrosis", "start": 0, "end": 2}, {"entity_id": "9366852_1_Ent2", "role": "Treatment", "text": "low - molecular weight heparin", "start": 4, "end": 9}, {"entity_id": "9366852_1_Ent4", "role": "Treatment_Drug", "text": "low - molecular weight heparin", "start": 4, "end": 9}, {"entity_id": "9366852_1_Ent0", "role": "Subject", "text": "a patient with antiphospholipid antibody syndrome", "start": 10, "end": 16}, {"entity_id": "9366852_1_Ent3", "role": "Treatment_Disorder", "text": "antiphospholipid antibody syndrome", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "9366852_1_Ent1", "text": "Skin necrosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9366852_1_Ent2", "text": "low - molecular weight heparin", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "9366852_1_Ent4", "text": "low - molecular weight heparin", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "9366852_1_Ent0", "text": "a patient with antiphospholipid antibody syndrome", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "9366852_1_Ent3", "text": "antiphospholipid antibody syndrome", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "937377_1", "wnd_id": "937377_1_1", "text": "Finally , reserpine toxicity , in particular central nervous system ( CNS ) disturbances , was reported more frequently in patients also receiving barbiturates , suggesting additive CNS effects .", "tokens": ["Finally", ",", "reserpine", "toxicity", ",", "in", "particular", "central", "nervous", "system", "(", "CNS", ")", "disturbances", ",", "was", "reported", "more", "frequently", "in", "patients", "also", "receiving", "barbiturates", ",", "suggesting", "additive", "CNS", "effects", "."], "event_mentions": [{"id": "937377_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 16, "end": 17}, "arguments": [{"entity_id": "937377_1_Ent2", "role": "Treatment", "text": "reserpine", "start": 2, "end": 3}, {"entity_id": "937377_1_Ent5", "role": "Treatment_Drug", "text": "reserpine", "start": 2, "end": 3}, {"entity_id": "937377_1_Ent7", "role": "Combination_Drug", "text": "reserpine", "start": 2, "end": 3}, {"entity_id": "937377_1_Ent0", "role": "Effect", "text": "reserpine toxicity , in particular central nervous system ( CNS ) disturbances", "start": 2, "end": 14}, {"entity_id": "937377_1_Ent3", "role": "Treatment", "text": "also receiving barbiturates ,", "start": 21, "end": 25}, {"entity_id": "937377_1_Ent4", "role": "Treatment_Drug", "text": "barbiturates", "start": 23, "end": 24}, {"entity_id": "937377_1_Ent6", "role": "Combination_Drug", "text": "barbiturates", "start": 23, "end": 24}, {"entity_id": "937377_1_Ent1", "role": "Effect", "text": "additive CNS effects", "start": 26, "end": 29}]}], "entity_mentions": [{"id": "937377_1_Ent2", "text": "reserpine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "937377_1_Ent5", "text": "reserpine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "937377_1_Ent7", "text": "reserpine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "937377_1_Ent0", "text": "reserpine toxicity , in particular central nervous system ( CNS ) disturbances", "entity_type": "Entity", "start": 2, "end": 14}, {"id": "937377_1_Ent3", "text": "also receiving barbiturates ,", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "937377_1_Ent4", "text": "barbiturates", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "937377_1_Ent6", "text": "barbiturates", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "937377_1_Ent1", "text": "additive CNS effects", "entity_type": "Entity", "start": 26, "end": 29}], "lang": "en"}
{"doc_id": "9375469_3", "wnd_id": "9375469_3_1", "text": "We report a case of contact dermatitis due to sodium bisulfite in Tathion eye drops .", "tokens": ["We", "report", "a", "case", "of", "contact", "dermatitis", "due", "to", "sodium", "bisulfite", "in", "Tathion", "eye", "drops", "."], "event_mentions": [{"id": "9375469_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 7, "end": 8}, "arguments": [{"entity_id": "9375469_3_Ent0", "role": "Effect", "text": "contact dermatitis", "start": 5, "end": 7}, {"entity_id": "9375469_3_Ent1", "role": "Treatment", "text": "sodium bisulfite", "start": 9, "end": 11}, {"entity_id": "9375469_3_Ent2", "role": "Treatment_Drug", "text": "sodium bisulfite", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "9375469_3_Ent0", "text": "contact dermatitis", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "9375469_3_Ent1", "text": "sodium bisulfite", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "9375469_3_Ent2", "text": "sodium bisulfite", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "9399776_3", "wnd_id": "9399776_3_1", "text": "A rechallenge , performed in both patients , confirmed the diagnosis of mesalamine - induced pancreatitis .", "tokens": ["A", "rechallenge", ",", "performed", "in", "both", "patients", ",", "confirmed", "the", "diagnosis", "of", "mesalamine", "-", "induced", "pancreatitis", "."], "event_mentions": [{"id": "9399776_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 14, "end": 15}, "arguments": [{"entity_id": "9399776_3_Ent0", "role": "Subject", "text": "both patients", "start": 5, "end": 7}, {"entity_id": "9399776_3_Ent2", "role": "Treatment", "text": "mesalamine", "start": 12, "end": 13}, {"entity_id": "9399776_3_Ent3", "role": "Treatment_Drug", "text": "mesalamine", "start": 12, "end": 13}, {"entity_id": "9399776_3_Ent1", "role": "Effect", "text": "pancreatitis", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "9399776_3_Ent0", "text": "both patients", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "9399776_3_Ent2", "text": "mesalamine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9399776_3_Ent3", "text": "mesalamine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9399776_3_Ent1", "text": "pancreatitis", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "9399776_4", "wnd_id": "9399776_4_1", "text": "These case reports provide evidence that 5 - aminosalicylic acid may induce acute pancreatitis after long term treatment .", "tokens": ["These", "case", "reports", "provide", "evidence", "that", "5", "-", "aminosalicylic", "acid", "may", "induce", "acute", "pancreatitis", "after", "long", "term", "treatment", "."], "event_mentions": [{"id": "9399776_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 11, "end": 12}, "arguments": [{"entity_id": "9399776_4_Ent1", "role": "Treatment", "text": "5 - aminosalicylic acid", "start": 6, "end": 10}, {"entity_id": "9399776_4_Ent2", "role": "Treatment_Drug", "text": "5 - aminosalicylic acid", "start": 6, "end": 10}, {"entity_id": "9399776_4_Ent0", "role": "Effect", "text": "acute pancreatitis", "start": 12, "end": 14}, {"entity_id": "9399776_4_Ent3", "role": "Treatment_Duration", "text": "long term", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "9399776_4_Ent1", "text": "5 - aminosalicylic acid", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "9399776_4_Ent2", "text": "5 - aminosalicylic acid", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "9399776_4_Ent0", "text": "acute pancreatitis", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "9399776_4_Ent3", "text": "long term", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "9426968_1", "wnd_id": "9426968_1_1", "text": "Vitiligo associated with alpha - interferon in a patient with chronic active hepatitis C.", "tokens": ["Vitiligo", "associated", "with", "alpha", "-", "interferon", "in", "a", "patient", "with", "chronic", "active", "hepatitis", "C."], "event_mentions": [{"id": "9426968_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "9426968_1_Ent1", "role": "Effect", "text": "Vitiligo", "start": 0, "end": 1}, {"entity_id": "9426968_1_Ent2", "role": "Treatment", "text": "alpha - interferon", "start": 3, "end": 6}, {"entity_id": "9426968_1_Ent3", "role": "Treatment_Drug", "text": "alpha - interferon", "start": 3, "end": 6}, {"entity_id": "9426968_1_Ent0", "role": "Subject", "text": "a patient with chronic active hepatitis C.", "start": 7, "end": 14}, {"entity_id": "9426968_1_Ent4", "role": "Treatment_Disorder", "text": "chronic active hepatitis C.", "start": 10, "end": 14}]}], "entity_mentions": [{"id": "9426968_1_Ent1", "text": "Vitiligo", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9426968_1_Ent2", "text": "alpha - interferon", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "9426968_1_Ent3", "text": "alpha - interferon", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "9426968_1_Ent0", "text": "a patient with chronic active hepatitis C.", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "9426968_1_Ent4", "text": "chronic active hepatitis C.", "entity_type": "Entity", "start": 10, "end": 14}], "lang": "en"}
{"doc_id": "9426968_2", "wnd_id": "9426968_2_1", "text": "We report a case of vitiligo that occurred during the second month of interferon alpha 2a therapy for chronic active hepatitis C.", "tokens": ["We", "report", "a", "case", "of", "vitiligo", "that", "occurred", "during", "the", "second", "month", "of", "interferon", "alpha", "2a", "therapy", "for", "chronic", "active", "hepatitis", "C."], "event_mentions": [{"id": "9426968_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 7, "end": 8}, "arguments": [{"entity_id": "9426968_2_Ent0", "role": "Effect", "text": "vitiligo", "start": 5, "end": 6}, {"entity_id": "9426968_2_Ent1", "role": "Treatment", "text": "during the second month of interferon alpha 2a therapy", "start": 8, "end": 17}, {"entity_id": "9426968_2_Ent3", "role": "Treatment_Duration", "text": "the second month", "start": 9, "end": 12}, {"entity_id": "9426968_2_Ent4", "role": "Treatment_Drug", "text": "interferon alpha 2a", "start": 13, "end": 16}, {"entity_id": "9426968_2_Ent2", "role": "Treatment_Disorder", "text": "chronic active hepatitis C.", "start": 18, "end": 22}]}], "entity_mentions": [{"id": "9426968_2_Ent0", "text": "vitiligo", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9426968_2_Ent1", "text": "during the second month of interferon alpha 2a therapy", "entity_type": "Entity", "start": 8, "end": 17}, {"id": "9426968_2_Ent3", "text": "the second month", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "9426968_2_Ent4", "text": "interferon alpha 2a", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "9426968_2_Ent2", "text": "chronic active hepatitis C.", "entity_type": "Entity", "start": 18, "end": 22}], "lang": "en"}
{"doc_id": "9476721_3", "wnd_id": "9476721_3_1", "text": "We reported 3 patients who developed acute generalized dystonia and akinetic rigid syndrome following an initial therapy with d - penicillamine 125 - 500 mg daily .", "tokens": ["We", "reported", "3", "patients", "who", "developed", "acute", "generalized", "dystonia", "and", "akinetic", "rigid", "syndrome", "following", "an", "initial", "therapy", "with", "d", "-", "penicillamine", "125", "-", "500", "mg", "daily", "."], "event_mentions": [{"id": "9476721_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 13, "end": 14}, "arguments": [{"entity_id": "9476721_3_Ent1", "role": "Subject_Population", "text": "3", "start": 2, "end": 3}, {"entity_id": "9476721_3_Ent0", "role": "Subject", "text": "3 patients", "start": 2, "end": 4}, {"entity_id": "9476721_3_Ent2", "role": "Effect", "text": "acute generalized dystonia and akinetic rigid syndrome", "start": 6, "end": 13}, {"entity_id": "9476721_3_Ent4", "role": "Treatment_Drug", "text": "d - penicillamine", "start": 18, "end": 21}, {"entity_id": "9476721_3_Ent3", "role": "Treatment", "text": "d - penicillamine 125 - 500 mg daily", "start": 18, "end": 26}, {"entity_id": "9476721_3_Ent5", "role": "Treatment_Dosage", "text": "125 - 500 mg daily", "start": 21, "end": 26}]}], "entity_mentions": [{"id": "9476721_3_Ent1", "text": "3", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9476721_3_Ent0", "text": "3 patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "9476721_3_Ent2", "text": "acute generalized dystonia and akinetic rigid syndrome", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "9476721_3_Ent4", "text": "d - penicillamine", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "9476721_3_Ent3", "text": "d - penicillamine 125 - 500 mg daily", "entity_type": "Entity", "start": 18, "end": 26}, {"id": "9476721_3_Ent5", "text": "125 - 500 mg daily", "entity_type": "Entity", "start": 21, "end": 26}], "lang": "en"}
{"doc_id": "9491301_2", "wnd_id": "9491301_2_1", "text": "Patient 1 presented bilateral ballism 1 week after intravenous heroin injection .", "tokens": ["Patient", "1", "presented", "bilateral", "ballism", "1", "week", "after", "intravenous", "heroin", "injection", "."], "event_mentions": [{"id": "9491301_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 2, "end": 3}, "arguments": [{"entity_id": "9491301_2_Ent0", "role": "Subject", "text": "Patient 1", "start": 0, "end": 2}, {"entity_id": "9491301_2_Ent1", "role": "Effect", "text": "bilateral ballism", "start": 3, "end": 5}, {"entity_id": "9491301_2_Ent3", "role": "Treatment_Route", "text": "intravenous", "start": 8, "end": 9}, {"entity_id": "9491301_2_Ent2", "role": "Treatment", "text": "intravenous heroin injection", "start": 8, "end": 11}, {"entity_id": "9491301_2_Ent5", "role": "Treatment_Drug", "text": "heroin", "start": 9, "end": 10}, {"entity_id": "9491301_2_Ent4", "role": "Treatment_Route", "text": "injection", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "9491301_2_Ent0", "text": "Patient 1", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9491301_2_Ent1", "text": "bilateral ballism", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "9491301_2_Ent3", "text": "intravenous", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9491301_2_Ent2", "text": "intravenous heroin injection", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "9491301_2_Ent5", "text": "heroin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9491301_2_Ent4", "text": "injection", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "9494448_5", "wnd_id": "9494448_5_1", "text": "Fortunately , a hypersensitivity reaction to one formulation of cyclosporine does not preclude use of a different formulation .", "tokens": ["Fortunately", ",", "a", "hypersensitivity", "reaction", "to", "one", "formulation", "of", "cyclosporine", "does", "not", "preclude", "use", "of", "a", "different", "formulation", "."], "event_mentions": [{"id": "9494448_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 5, "end": 6}, "arguments": [{"entity_id": "9494448_5_Ent0", "role": "Effect", "text": "hypersensitivity reaction", "start": 3, "end": 5}, {"entity_id": "9494448_5_Ent1", "role": "Treatment", "text": "one formulation of cyclosporine", "start": 6, "end": 10}, {"entity_id": "9494448_5_Ent2", "role": "Treatment_Drug", "text": "cyclosporine", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "9494448_5_Ent0", "text": "hypersensitivity reaction", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "9494448_5_Ent1", "text": "one formulation of cyclosporine", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "9494448_5_Ent2", "text": "cyclosporine", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "9494448_8", "wnd_id": "9494448_8_1", "text": "The literature search revealed 22 cases of hypersensitivity reaction to cyclosporine .", "tokens": ["The", "literature", "search", "revealed", "22", "cases", "of", "hypersensitivity", "reaction", "to", "cyclosporine", "."], "event_mentions": [{"id": "9494448_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 9, "end": 10}, "arguments": [{"entity_id": "9494448_8_Ent1", "role": "Subject_Population", "text": "22", "start": 4, "end": 5}, {"entity_id": "9494448_8_Ent0", "role": "Subject", "text": "22 cases", "start": 4, "end": 6}, {"entity_id": "9494448_8_Ent2", "role": "Effect", "text": "hypersensitivity reaction", "start": 7, "end": 9}, {"entity_id": "9494448_8_Ent3", "role": "Treatment", "text": "cyclosporine", "start": 10, "end": 11}, {"entity_id": "9494448_8_Ent4", "role": "Treatment_Drug", "text": "cyclosporine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "9494448_8_Ent1", "text": "22", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9494448_8_Ent0", "text": "22 cases", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9494448_8_Ent2", "text": "hypersensitivity reaction", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "9494448_8_Ent3", "text": "cyclosporine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9494448_8_Ent4", "text": "cyclosporine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "9497597_1", "wnd_id": "9497597_1_1", "text": "Prothipendylhydrochloride - induced priapism : case report .", "tokens": ["Prothipendylhydrochloride", "-", "induced", "priapism", ":", "case", "report", "."], "event_mentions": [{"id": "9497597_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "9497597_1_Ent1", "role": "Treatment", "text": "Prothipendylhydrochloride", "start": 0, "end": 1}, {"entity_id": "9497597_1_Ent2", "role": "Treatment_Drug", "text": "Prothipendylhydrochloride", "start": 0, "end": 1}, {"entity_id": "9497597_1_Ent0", "role": "Effect", "text": "priapism", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "9497597_1_Ent1", "text": "Prothipendylhydrochloride", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9497597_1_Ent2", "text": "Prothipendylhydrochloride", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9497597_1_Ent0", "text": "priapism", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "9509511_2", "wnd_id": "9509511_2_1", "text": "We conclude that vincristine and actinomycin D were the cause of this rare from of hepatotoxicity and that chemotherapy for the underlying malignant disease could be given safely after clinical recovery .", "tokens": ["We", "conclude", "that", "vincristine", "and", "actinomycin", "D", "were", "the", "cause", "of", "this", "rare", "from", "of", "hepatotoxicity", "and", "that", "chemotherapy", "for", "the", "underlying", "malignant", "disease", "could", "be", "given", "safely", "after", "clinical", "recovery", "."], "event_mentions": [{"id": "9509511_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 9, "end": 10}, "arguments": [{"entity_id": "9509511_2_Ent2", "role": "Treatment_Drug", "text": "vincristine", "start": 3, "end": 4}, {"entity_id": "9509511_2_Ent4", "role": "Combination_Drug", "text": "vincristine", "start": 3, "end": 4}, {"entity_id": "9509511_2_Ent1", "role": "Treatment", "text": "vincristine and actinomycin D", "start": 3, "end": 7}, {"entity_id": "9509511_2_Ent3", "role": "Treatment_Drug", "text": "actinomycin D", "start": 5, "end": 7}, {"entity_id": "9509511_2_Ent5", "role": "Combination_Drug", "text": "actinomycin D", "start": 5, "end": 7}, {"entity_id": "9509511_2_Ent0", "role": "Effect", "text": "hepatotoxicity", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "9509511_2_Ent2", "text": "vincristine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9509511_2_Ent4", "text": "vincristine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9509511_2_Ent1", "text": "vincristine and actinomycin D", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "9509511_2_Ent3", "text": "actinomycin D", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "9509511_2_Ent5", "text": "actinomycin D", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "9509511_2_Ent0", "text": "hepatotoxicity", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "9512187_2", "wnd_id": "9512187_2_1", "text": "In this report , one patient who developed gangrene after bleomycin and vincristine / vinblastine chemotherapy for AIDS - related Kaposi 's sarcoma and another HIV - infected patient who exhibited symptoms of severe Raynaud 's phenomenon related to the same regimen are presented .", "tokens": ["In", "this", "report", ",", "one", "patient", "who", "developed", "gangrene", "after", "bleomycin", "and", "vincristine", "/", "vinblastine", "chemotherapy", "for", "AIDS", "-", "related", "Kaposi", "'s", "sarcoma", "and", "another", "HIV", "-", "infected", "patient", "who", "exhibited", "symptoms", "of", "severe", "Raynaud", "'s", "phenomenon", "related", "to", "the", "same", "regimen", "are", "presented", "."], "event_mentions": [{"id": "9512187_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "9512187_2_Ent1", "role": "Subject_Population", "text": "one", "start": 4, "end": 5}, {"entity_id": "9512187_2_Ent0", "role": "Subject", "text": "one patient", "start": 4, "end": 6}, {"entity_id": "9512187_2_Ent2", "role": "Effect", "text": "gangrene", "start": 8, "end": 9}, {"entity_id": "9512187_2_Ent4", "role": "Treatment_Drug", "text": "bleomycin", "start": 10, "end": 11}, {"entity_id": "9512187_2_Ent7", "role": "Combination_Drug", "text": "bleomycin", "start": 10, "end": 11}, {"entity_id": "9512187_2_Ent3", "role": "Treatment", "text": "bleomycin and vincristine / vinblastine", "start": 10, "end": 15}, {"entity_id": "9512187_2_Ent5", "role": "Treatment_Drug", "text": "vincristine", "start": 12, "end": 13}, {"entity_id": "9512187_2_Ent8", "role": "Combination_Drug", "text": "vincristine", "start": 12, "end": 13}, {"entity_id": "9512187_2_Ent6", "role": "Treatment_Drug", "text": "vinblastine", "start": 14, "end": 15}, {"entity_id": "9512187_2_Ent9", "role": "Combination_Drug", "text": "vinblastine", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "9512187_2_Ent1", "text": "one", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9512187_2_Ent0", "text": "one patient", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9512187_2_Ent2", "text": "gangrene", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9512187_2_Ent4", "text": "bleomycin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9512187_2_Ent7", "text": "bleomycin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9512187_2_Ent3", "text": "bleomycin and vincristine / vinblastine", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "9512187_2_Ent5", "text": "vincristine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9512187_2_Ent8", "text": "vincristine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9512187_2_Ent6", "text": "vinblastine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "9512187_2_Ent9", "text": "vinblastine", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "9517515_1", "wnd_id": "9517515_1_1", "text": "Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia .", "tokens": ["Development", "of", "essential", "thrombocythemia", "in", "a", "patient", "treated", "with", "interferon", "alfa", "and", "pentostatin", "for", "hairy", "cell", "leukemia", "."], "event_mentions": [{"id": "9517515_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "Development", "start": 0, "end": 1}, "arguments": [{"entity_id": "9517515_1_Ent1", "role": "Effect", "text": "essential thrombocythemia", "start": 2, "end": 4}, {"entity_id": "9517515_1_Ent0", "role": "Subject", "text": "a patient", "start": 5, "end": 7}, {"entity_id": "9517515_1_Ent4", "role": "Treatment_Drug", "text": "interferon alfa", "start": 9, "end": 11}, {"entity_id": "9517515_1_Ent6", "role": "Combination_Drug", "text": "interferon alfa", "start": 9, "end": 11}, {"entity_id": "9517515_1_Ent2", "role": "Treatment", "text": "interferon alfa and pentostatin", "start": 9, "end": 13}, {"entity_id": "9517515_1_Ent5", "role": "Treatment_Drug", "text": "pentostatin", "start": 12, "end": 13}, {"entity_id": "9517515_1_Ent7", "role": "Combination_Drug", "text": "pentostatin", "start": 12, "end": 13}, {"entity_id": "9517515_1_Ent3", "role": "Treatment_Disorder", "text": "hairy cell leukemia", "start": 14, "end": 17}]}], "entity_mentions": [{"id": "9517515_1_Ent1", "text": "essential thrombocythemia", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "9517515_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "9517515_1_Ent4", "text": "interferon alfa", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "9517515_1_Ent6", "text": "interferon alfa", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "9517515_1_Ent2", "text": "interferon alfa and pentostatin", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "9517515_1_Ent5", "text": "pentostatin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9517515_1_Ent7", "text": "pentostatin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9517515_1_Ent3", "text": "hairy cell leukemia", "entity_type": "Entity", "start": 14, "end": 17}], "lang": "en"}
{"doc_id": "9527943_3", "wnd_id": "9527943_3_1", "text": "STUDY DESIGN : Case reports are presented of three premature infants ( mean gestational age 27 weeks ) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and left ventricular outflow tract obstruction developed during dexamethasone treatment for bronchopulmonary dysplasia .", "tokens": ["STUDY", "DESIGN", ":", "Case", "reports", "are", "presented", "of", "three", "premature", "infants", "(", "mean", "gestational", "age", "27", "weeks", ")", "cared", "for", "in", "the", "intensive", "care", "nursery", "in", "whom", "clinically", "significant", "septal", "hypertrophy", "and", "left", "ventricular", "outflow", "tract", "obstruction", "developed", "during", "dexamethasone", "treatment", "for", "bronchopulmonary", "dysplasia", "."], "event_mentions": [{"id": "9527943_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 37, "end": 38}, "arguments": [{"entity_id": "9527943_3_Ent1", "role": "Subject_Population", "text": "three", "start": 8, "end": 9}, {"entity_id": "9527943_3_Ent0", "role": "Subject", "text": "three premature infants ( mean gestational age 27 weeks ) cared for in the intensive care nursery", "start": 8, "end": 25}, {"entity_id": "9527943_3_Ent2", "role": "Subject_Age", "text": "premature infants ( mean gestational age 27 weeks )", "start": 9, "end": 18}, {"entity_id": "9527943_3_Ent3", "role": "Effect", "text": "clinically significant septal hypertrophy and left ventricular outflow tract obstruction", "start": 27, "end": 37}, {"entity_id": "9527943_3_Ent4", "role": "Treatment", "text": "during dexamethasone treatment for bronchopulmonary dysplasia", "start": 38, "end": 44}, {"entity_id": "9527943_3_Ent5", "role": "Treatment_Drug", "text": "dexamethasone", "start": 39, "end": 40}, {"entity_id": "9527943_3_Ent6", "role": "Treatment_Disorder", "text": "bronchopulmonary dysplasia .", "start": 42, "end": 45}]}], "entity_mentions": [{"id": "9527943_3_Ent1", "text": "three", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9527943_3_Ent0", "text": "three premature infants ( mean gestational age 27 weeks ) cared for in the intensive care nursery", "entity_type": "Entity", "start": 8, "end": 25}, {"id": "9527943_3_Ent2", "text": "premature infants ( mean gestational age 27 weeks )", "entity_type": "Entity", "start": 9, "end": 18}, {"id": "9527943_3_Ent3", "text": "clinically significant septal hypertrophy and left ventricular outflow tract obstruction", "entity_type": "Entity", "start": 27, "end": 37}, {"id": "9527943_3_Ent4", "text": "during dexamethasone treatment for bronchopulmonary dysplasia", "entity_type": "Entity", "start": 38, "end": 44}, {"id": "9527943_3_Ent5", "text": "dexamethasone", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "9527943_3_Ent6", "text": "bronchopulmonary dysplasia .", "entity_type": "Entity", "start": 42, "end": 45}], "lang": "en"}
{"doc_id": "9562211_2", "wnd_id": "9562211_2_1", "text": "Risperidone - induced tardive dyskinesia .", "tokens": ["Risperidone", "-", "induced", "tardive", "dyskinesia", "."], "event_mentions": [{"id": "9562211_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "9562211_2_Ent1", "role": "Treatment", "text": "Risperidone", "start": 0, "end": 1}, {"entity_id": "9562211_2_Ent2", "role": "Treatment_Drug", "text": "Risperidone", "start": 0, "end": 1}, {"entity_id": "9562211_2_Ent0", "role": "Effect", "text": "tardive dyskinesia", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "9562211_2_Ent1", "text": "Risperidone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9562211_2_Ent2", "text": "Risperidone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9562211_2_Ent0", "text": "tardive dyskinesia", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "9579301_1", "wnd_id": "9579301_1_1", "text": "Increased ocular pressure in two patients with narrow angle glaucoma treated with venlafaxine .", "tokens": ["Increased", "ocular", "pressure", "in", "two", "patients", "with", "narrow", "angle", "glaucoma", "treated", "with", "venlafaxine", "."], "event_mentions": [{"id": "9579301_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 3, "end": 4}, "arguments": [{"entity_id": "9579301_1_Ent3", "role": "Effect", "text": "Increased ocular pressure", "start": 0, "end": 3}, {"entity_id": "9579301_1_Ent2", "role": "Subject_Population", "text": "two", "start": 4, "end": 5}, {"entity_id": "9579301_1_Ent0", "role": "Subject", "text": "two patients with narrow angle glaucoma", "start": 4, "end": 10}, {"entity_id": "9579301_1_Ent1", "role": "Subject_Disorder", "text": "narrow angle glaucoma", "start": 7, "end": 10}, {"entity_id": "9579301_1_Ent4", "role": "Treatment", "text": "venlafaxine", "start": 12, "end": 13}, {"entity_id": "9579301_1_Ent5", "role": "Treatment_Drug", "text": "venlafaxine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "9579301_1_Ent3", "text": "Increased ocular pressure", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9579301_1_Ent2", "text": "two", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9579301_1_Ent0", "text": "two patients with narrow angle glaucoma", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "9579301_1_Ent1", "text": "narrow angle glaucoma", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "9579301_1_Ent4", "text": "venlafaxine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9579301_1_Ent5", "text": "venlafaxine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "95811_1", "wnd_id": "95811_1_1", "text": "A 61 - year - old man developed clinical lupus syndrome with positive antinuclear antibody , positive lupus erythematosus ( LE ) cell preparation , and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy .", "tokens": ["A", "61", "-", "year", "-", "old", "man", "developed", "clinical", "lupus", "syndrome", "with", "positive", "antinuclear", "antibody", ",", "positive", "lupus", "erythematosus", "(", "LE", ")", "cell", "preparation", ",", "and", "diffuse", "proliferative", "glomerulonephritis", "following", "26", "months", "of", "procainamide", "therapy", "."], "event_mentions": [{"id": "95811_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "95811_1_Ent1", "role": "Subject_Age", "text": "61 - year - old", "start": 1, "end": 6}, {"entity_id": "95811_1_Ent0", "role": "Subject", "text": "61 - year - old man", "start": 1, "end": 7}, {"entity_id": "95811_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "95811_1_Ent3", "role": "Effect", "text": "clinical lupus syndrome with positive antinuclear antibody , positive lupus erythematosus ( LE ) cell preparation , and diffuse proliferative glomerulonephritis", "start": 8, "end": 29}, {"entity_id": "95811_1_Ent6", "role": "Treatment_Duration", "text": "26 months", "start": 30, "end": 32}, {"entity_id": "95811_1_Ent4", "role": "Treatment", "text": "26 months of procainamide therapy", "start": 30, "end": 35}, {"entity_id": "95811_1_Ent5", "role": "Treatment_Drug", "text": "procainamide", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "95811_1_Ent1", "text": "61 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "95811_1_Ent0", "text": "61 - year - old man", "entity_type": "Entity", "start": 1, "end": 7}, {"id": "95811_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "95811_1_Ent3", "text": "clinical lupus syndrome with positive antinuclear antibody , positive lupus erythematosus ( LE ) cell preparation , and diffuse proliferative glomerulonephritis", "entity_type": "Entity", "start": 8, "end": 29}, {"id": "95811_1_Ent6", "text": "26 months", "entity_type": "Entity", "start": 30, "end": 32}, {"id": "95811_1_Ent4", "text": "26 months of procainamide therapy", "entity_type": "Entity", "start": 30, "end": 35}, {"id": "95811_1_Ent5", "text": "procainamide", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "961329_1", "wnd_id": "961329_1_1", "text": "A case of prolonged suxamethonium apnoea successfully terminated by the infusion of a commercial preparation of serumcholinesterase is reported .", "tokens": ["A", "case", "of", "prolonged", "suxamethonium", "apnoea", "successfully", "terminated", "by", "the", "infusion", "of", "a", "commercial", "preparation", "of", "serumcholinesterase", "is", "reported", "."], "event_mentions": [{"id": "961329_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "terminated", "start": 7, "end": 8}, "arguments": [{"entity_id": "961329_1_Ent0", "role": "Effect", "text": "prolonged suxamethonium apnoea", "start": 3, "end": 6}, {"entity_id": "961329_1_Ent2", "role": "Treatment_Drug", "text": "suxamethonium", "start": 4, "end": 5}, {"entity_id": "961329_1_Ent1", "role": "Treatment", "text": "the infusion of a commercial preparation of serumcholinesterase", "start": 9, "end": 17}, {"entity_id": "961329_1_Ent4", "role": "Treatment_Route", "text": "infusion", "start": 10, "end": 11}, {"entity_id": "961329_1_Ent3", "role": "Treatment_Drug", "text": "serumcholinesterase", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "961329_1_Ent0", "text": "prolonged suxamethonium apnoea", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "961329_1_Ent2", "text": "suxamethonium", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "961329_1_Ent1", "text": "the infusion of a commercial preparation of serumcholinesterase", "entity_type": "Entity", "start": 9, "end": 17}, {"id": "961329_1_Ent4", "text": "infusion", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "961329_1_Ent3", "text": "serumcholinesterase", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "9619226_1", "wnd_id": "9619226_1_1", "text": "Cardiac arrest associated with sulprostone use during caesarean section .", "tokens": ["Cardiac", "arrest", "associated", "with", "sulprostone", "use", "during", "caesarean", "section", "."], "event_mentions": [{"id": "9619226_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "9619226_1_Ent0", "role": "Effect", "text": "Cardiac arrest", "start": 0, "end": 2}, {"entity_id": "9619226_1_Ent1", "role": "Treatment", "text": "sulprostone", "start": 4, "end": 5}, {"entity_id": "9619226_1_Ent2", "role": "Treatment_Drug", "text": "sulprostone", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "9619226_1_Ent0", "text": "Cardiac arrest", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9619226_1_Ent1", "text": "sulprostone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9619226_1_Ent2", "text": "sulprostone", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "9651465_1", "wnd_id": "9651465_1_1", "text": "METHODS : Double - blind , placebo - controlled titrated oral challenges with pancreatic enzymes resulted in definite vomiting within 1 to 1.5 hours after challenges with Viokase and Pancrease MT 16 , but not with placebo .", "tokens": ["METHODS", ":", "Double", "-", "blind", ",", "placebo", "-", "controlled", "titrated", "oral", "challenges", "with", "pancreatic", "enzymes", "resulted", "in", "definite", "vomiting", "within", "1", "to", "1.5", "hours", "after", "challenges", "with", "Viokase", "and", "Pancrease", "MT", "16", ",", "but", "not", "with", "placebo", "."], "event_mentions": [{"id": "9651465_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted in", "start": 15, "end": 17}, "arguments": [{"entity_id": "9651465_1_Ent0", "role": "Effect", "text": "vomiting", "start": 18, "end": 19}, {"entity_id": "9651465_1_Ent2", "role": "Treatment_Drug", "text": "Viokase", "start": 27, "end": 28}, {"entity_id": "9651465_1_Ent4", "role": "Combination_Drug", "text": "Viokase", "start": 27, "end": 28}, {"entity_id": "9651465_1_Ent1", "role": "Treatment", "text": "Viokase and Pancrease MT 16", "start": 27, "end": 32}, {"entity_id": "9651465_1_Ent3", "role": "Treatment_Drug", "text": "Pancrease MT 16", "start": 29, "end": 32}, {"entity_id": "9651465_1_Ent5", "role": "Combination_Drug", "text": "Pancrease MT 16", "start": 29, "end": 32}]}], "entity_mentions": [{"id": "9651465_1_Ent0", "text": "vomiting", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9651465_1_Ent2", "text": "Viokase", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "9651465_1_Ent4", "text": "Viokase", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "9651465_1_Ent1", "text": "Viokase and Pancrease MT 16", "entity_type": "Entity", "start": 27, "end": 32}, {"id": "9651465_1_Ent3", "text": "Pancrease MT 16", "entity_type": "Entity", "start": 29, "end": 32}, {"id": "9651465_1_Ent5", "text": "Pancrease MT 16", "entity_type": "Entity", "start": 29, "end": 32}], "lang": "en"}
{"doc_id": "9651465_3", "wnd_id": "9651465_3_1", "text": "The vomiting occurred on switching to different pancreatic enzymes preparations , ie , Creon 10 , Viokase , and Pancrease MT 16 .", "tokens": ["The", "vomiting", "occurred", "on", "switching", "to", "different", "pancreatic", "enzymes", "preparations", ",", "ie", ",", "Creon", "10", ",", "Viokase", ",", "and", "Pancrease", "MT", "16", "."], "event_mentions": [{"id": "9651465_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "switching", "start": 4, "end": 5}, "arguments": [{"entity_id": "9651465_3_Ent0", "role": "Effect", "text": "vomiting", "start": 1, "end": 2}, {"entity_id": "9651465_3_Ent1", "role": "Treatment", "text": "different pancreatic enzymes preparations , ie , Creon 10 , Viokase , and Pancrease MT 16", "start": 6, "end": 22}, {"entity_id": "9651465_3_Ent2", "role": "Treatment_Drug", "text": "Creon 10", "start": 13, "end": 15}, {"entity_id": "9651465_3_Ent3", "role": "Treatment_Drug", "text": "Viokase", "start": 16, "end": 17}, {"entity_id": "9651465_3_Ent4", "role": "Treatment_Drug", "text": "Pancrease MT 16", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "9651465_3_Ent0", "text": "vomiting", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "9651465_3_Ent1", "text": "different pancreatic enzymes preparations , ie , Creon 10 , Viokase , and Pancrease MT 16", "entity_type": "Entity", "start": 6, "end": 22}, {"id": "9651465_3_Ent2", "text": "Creon 10", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "9651465_3_Ent3", "text": "Viokase", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9651465_3_Ent4", "text": "Pancrease MT 16", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "9660541_2", "wnd_id": "9660541_2_1", "text": "Mitomycin C - related hemolytic uremic syndrome in cancer patients .", "tokens": ["Mitomycin", "C", "-", "related", "hemolytic", "uremic", "syndrome", "in", "cancer", "patients", "."], "event_mentions": [{"id": "9660541_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 3, "end": 4}, "arguments": [{"entity_id": "9660541_2_Ent2", "role": "Treatment", "text": "Mitomycin C", "start": 0, "end": 2}, {"entity_id": "9660541_2_Ent3", "role": "Treatment_Drug", "text": "Mitomycin C", "start": 0, "end": 2}, {"entity_id": "9660541_2_Ent1", "role": "Effect", "text": "hemolytic uremic syndrome", "start": 4, "end": 7}, {"entity_id": "9660541_2_Ent4", "role": "Treatment_Disorder", "text": "cancer", "start": 8, "end": 9}, {"entity_id": "9660541_2_Ent0", "role": "Subject", "text": "cancer patients", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "9660541_2_Ent2", "text": "Mitomycin C", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9660541_2_Ent3", "text": "Mitomycin C", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9660541_2_Ent1", "text": "hemolytic uremic syndrome", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "9660541_2_Ent4", "text": "cancer", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9660541_2_Ent0", "text": "cancer patients", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "9681092_10", "wnd_id": "9681092_10_1", "text": "The combination of cyclobenzaprine and fluoxetine resulted in significant QT prolongation in our patient that progressed to torsade de pointes after preoperative droperidol administration .", "tokens": ["The", "combination", "of", "cyclobenzaprine", "and", "fluoxetine", "resulted", "in", "significant", "QT", "prolongation", "in", "our", "patient", "that", "progressed", "to", "torsade", "de", "pointes", "after", "preoperative", "droperidol", "administration", "."], "event_mentions": [{"id": "9681092_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 6, "end": 7}, "arguments": [{"entity_id": "9681092_10_Ent3", "role": "Treatment", "text": "The combination of cyclobenzaprine and fluoxetine", "start": 0, "end": 6}, {"entity_id": "9681092_10_Ent5", "role": "Treatment_Drug", "text": "cyclobenzaprine", "start": 3, "end": 4}, {"entity_id": "9681092_10_Ent9", "role": "Combination_Drug", "text": "cyclobenzaprine", "start": 3, "end": 4}, {"entity_id": "9681092_10_Ent6", "role": "Treatment_Drug", "text": "fluoxetine", "start": 5, "end": 6}, {"entity_id": "9681092_10_Ent10", "role": "Combination_Drug", "text": "fluoxetine", "start": 5, "end": 6}, {"entity_id": "9681092_10_Ent1", "role": "Effect", "text": "significant QT prolongation", "start": 8, "end": 11}, {"entity_id": "9681092_10_Ent0", "role": "Subject", "text": "our patient", "start": 12, "end": 14}, {"entity_id": "9681092_10_Ent2", "role": "Effect", "text": "progressed to torsade de pointes", "start": 15, "end": 20}, {"entity_id": "9681092_10_Ent8", "role": "Treatment_Time_elapsed", "text": "preoperative", "start": 21, "end": 22}, {"entity_id": "9681092_10_Ent4", "role": "Treatment", "text": "preoperative droperidol administration", "start": 21, "end": 24}, {"entity_id": "9681092_10_Ent7", "role": "Treatment_Drug", "text": "droperidol", "start": 22, "end": 23}, {"entity_id": "9681092_10_Ent11", "role": "Combination_Drug", "text": "droperidol", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "9681092_10_Ent3", "text": "The combination of cyclobenzaprine and fluoxetine", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "9681092_10_Ent5", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9681092_10_Ent9", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9681092_10_Ent6", "text": "fluoxetine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9681092_10_Ent10", "text": "fluoxetine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9681092_10_Ent1", "text": "significant QT prolongation", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "9681092_10_Ent0", "text": "our patient", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "9681092_10_Ent2", "text": "progressed to torsade de pointes", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "9681092_10_Ent8", "text": "preoperative", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "9681092_10_Ent4", "text": "preoperative droperidol administration", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "9681092_10_Ent7", "text": "droperidol", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "9681092_10_Ent11", "text": "droperidol", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "9681092_8", "wnd_id": "9681092_8_1", "text": "Cyclobenzaprine shares anticholinergic effects , tachycardia , and dysrhythmic potential with the tricyclic antidepressants ( TCAs ) .", "tokens": ["Cyclobenzaprine", "shares", "anticholinergic", "effects", ",", "tachycardia", ",", "and", "dysrhythmic", "potential", "with", "the", "tricyclic", "antidepressants", "(", "TCAs", ")", "."], "event_mentions": [{"id": "9681092_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "potential", "start": 9, "end": 10}, "arguments": [{"entity_id": "9681092_8_Ent1", "role": "Treatment", "text": "Cyclobenzaprine", "start": 0, "end": 1}, {"entity_id": "9681092_8_Ent3", "role": "Treatment_Drug", "text": "Cyclobenzaprine", "start": 0, "end": 1}, {"entity_id": "9681092_8_Ent0", "role": "Effect", "text": "anticholinergic effects , tachycardia , and dysrhythmic", "start": 2, "end": 9}, {"entity_id": "9681092_8_Ent2", "role": "Treatment", "text": "with the tricyclic antidepressants ( TCAs )", "start": 10, "end": 17}, {"entity_id": "9681092_8_Ent4", "role": "Treatment_Drug", "text": "tricyclic antidepressants", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "9681092_8_Ent1", "text": "Cyclobenzaprine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9681092_8_Ent3", "text": "Cyclobenzaprine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9681092_8_Ent0", "text": "anticholinergic effects , tachycardia , and dysrhythmic", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "9681092_8_Ent2", "text": "with the tricyclic antidepressants ( TCAs )", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "9681092_8_Ent4", "text": "tricyclic antidepressants", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "968449_2", "wnd_id": "968449_2_1", "text": "Bone marrow chromosomes were studied in 2 patients with polycythaemia vera ( PV ) at the time of diagnosis and several times subsequently during therapy with chlorambucil .", "tokens": ["Bone", "marrow", "chromosomes", "were", "studied", "in", "2", "patients", "with", "polycythaemia", "vera", "(", "PV", ")", "at", "the", "time", "of", "diagnosis", "and", "several", "times", "subsequently", "during", "therapy", "with", "chlorambucil", "."], "event_mentions": [{"id": "968449_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "therapy", "start": 24, "end": 25}, "arguments": [{"entity_id": "968449_2_Ent1", "role": "Subject_Population", "text": "2", "start": 6, "end": 7}, {"entity_id": "968449_2_Ent0", "role": "Subject", "text": "2 patients with polycythaemia vera ( PV )", "start": 6, "end": 14}, {"entity_id": "968449_2_Ent3", "role": "Treatment_Disorder", "text": "polycythaemia vera ( PV )", "start": 9, "end": 14}, {"entity_id": "968449_2_Ent2", "role": "Treatment", "text": "chlorambucil", "start": 26, "end": 27}, {"entity_id": "968449_2_Ent4", "role": "Treatment_Drug", "text": "chlorambucil", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "968449_2_Ent1", "text": "2", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "968449_2_Ent0", "text": "2 patients with polycythaemia vera ( PV )", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "968449_2_Ent3", "text": "polycythaemia vera ( PV )", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "968449_2_Ent2", "text": "chlorambucil", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "968449_2_Ent4", "text": "chlorambucil", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "9701106_1", "wnd_id": "9701106_1_1", "text": "A drug interaction between zafirlukast and theophylline .", "tokens": ["A", "drug", "interaction", "between", "zafirlukast", "and", "theophylline", "."], "event_mentions": [{"id": "9701106_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "between", "start": 3, "end": 4}, "arguments": [{"entity_id": "9701106_1_Ent0", "role": "Effect", "text": "drug interaction", "start": 1, "end": 3}, {"entity_id": "9701106_1_Ent2", "role": "Treatment_Drug", "text": "zafirlukast", "start": 4, "end": 5}, {"entity_id": "9701106_1_Ent4", "role": "Combination_Drug", "text": "zafirlukast", "start": 4, "end": 5}, {"entity_id": "9701106_1_Ent1", "role": "Treatment", "text": "zafirlukast and theophylline", "start": 4, "end": 7}, {"entity_id": "9701106_1_Ent3", "role": "Treatment_Drug", "text": "theophylline", "start": 6, "end": 7}, {"entity_id": "9701106_1_Ent5", "role": "Combination_Drug", "text": "theophylline", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "9701106_1_Ent0", "text": "drug interaction", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "9701106_1_Ent2", "text": "zafirlukast", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9701106_1_Ent4", "text": "zafirlukast", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9701106_1_Ent1", "text": "zafirlukast and theophylline", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "9701106_1_Ent3", "text": "theophylline", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9701106_1_Ent5", "text": "theophylline", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "9701106_2", "wnd_id": "9701106_2_1", "text": "Attempts were made to stop and then restart the theophylline therapy at progressively lower doses ; however , with each attempt , the patient 's reaction to the drug became more toxic , with serum theophylline levels ranging between 99.9 and 149.9 micromol / L ( 18 and 27 microg / mL ) .", "tokens": ["Attempts", "were", "made", "to", "stop", "and", "then", "restart", "the", "theophylline", "therapy", "at", "progressively", "lower", "doses", ";", "however", ",", "with", "each", "attempt", ",", "the", "patient", "'s", "reaction", "to", "the", "drug", "became", "more", "toxic", ",", "with", "serum", "theophylline", "levels", "ranging", "between", "99.9", "and", "149.9", "micromol", "/", "L", "(", "18", "and", "27", "microg", "/", "mL", ")", "."], "event_mentions": [{"id": "9701106_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "became", "start": 29, "end": 30}, "arguments": [{"entity_id": "9701106_2_Ent3", "role": "Treatment_Drug", "text": "theophylline", "start": 9, "end": 10}, {"entity_id": "9701106_2_Ent2", "role": "Treatment", "text": "theophylline therapy", "start": 9, "end": 11}, {"entity_id": "9701106_2_Ent0", "role": "Subject", "text": "patient", "start": 23, "end": 24}, {"entity_id": "9701106_2_Ent1", "role": "Effect", "text": "reaction to the drug became more toxic", "start": 25, "end": 32}, {"entity_id": "9701106_2_Ent4", "role": "Treatment_Dosage", "text": "99.9 and 149.9 micromol / L", "start": 39, "end": 45}, {"entity_id": "9701106_2_Ent5", "role": "Treatment_Dosage", "text": "18 and 27 microg / mL", "start": 46, "end": 52}]}], "entity_mentions": [{"id": "9701106_2_Ent3", "text": "theophylline", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9701106_2_Ent2", "text": "theophylline therapy", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "9701106_2_Ent0", "text": "patient", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "9701106_2_Ent1", "text": "reaction to the drug became more toxic", "entity_type": "Entity", "start": 25, "end": 32}, {"id": "9701106_2_Ent4", "text": "99.9 and 149.9 micromol / L", "entity_type": "Entity", "start": 39, "end": 45}, {"id": "9701106_2_Ent5", "text": "18 and 27 microg / mL", "entity_type": "Entity", "start": 46, "end": 52}], "lang": "en"}
{"doc_id": "9704170_3", "wnd_id": "9704170_3_1", "text": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium - dependent potassium permeability of cell membranes .", "tokens": ["Rhabdomyolysis", "associated", "with", "clozapine", "treatment", "in", "a", "patient", "with", "decreased", "calcium", "-", "dependent", "potassium", "permeability", "of", "cell", "membranes", "."], "event_mentions": [{"id": "9704170_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 2, "end": 3}, "arguments": [{"entity_id": "9704170_3_Ent2", "role": "Effect", "text": "Rhabdomyolysis", "start": 0, "end": 1}, {"entity_id": "9704170_3_Ent3", "role": "Treatment", "text": "clozapine", "start": 3, "end": 4}, {"entity_id": "9704170_3_Ent4", "role": "Treatment_Drug", "text": "clozapine", "start": 3, "end": 4}, {"entity_id": "9704170_3_Ent0", "role": "Subject", "text": "a patient with decreased calcium - dependent potassium permeability of cell membranes", "start": 6, "end": 18}, {"entity_id": "9704170_3_Ent1", "role": "Subject_Disorder", "text": "decreased calcium - dependent potassium permeability of cell membranes", "start": 9, "end": 18}]}], "entity_mentions": [{"id": "9704170_3_Ent2", "text": "Rhabdomyolysis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9704170_3_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9704170_3_Ent4", "text": "clozapine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9704170_3_Ent0", "text": "a patient with decreased calcium - dependent potassium permeability of cell membranes", "entity_type": "Entity", "start": 6, "end": 18}, {"id": "9704170_3_Ent1", "text": "decreased calcium - dependent potassium permeability of cell membranes", "entity_type": "Entity", "start": 9, "end": 18}], "lang": "en"}
{"doc_id": "9723127_3", "wnd_id": "9723127_3_1", "text": "Decreased plasma cortisol level during alprazolam treatment of panic disorder : a case report .", "tokens": ["Decreased", "plasma", "cortisol", "level", "during", "alprazolam", "treatment", "of", "panic", "disorder", ":", "a", "case", "report", "."], "event_mentions": [{"id": "9723127_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 4, "end": 5}, "arguments": [{"entity_id": "9723127_3_Ent0", "role": "Effect", "text": "Decreased plasma cortisol level", "start": 0, "end": 4}, {"entity_id": "9723127_3_Ent1", "role": "Treatment", "text": "alprazolam", "start": 5, "end": 6}, {"entity_id": "9723127_3_Ent2", "role": "Treatment_Drug", "text": "alprazolam", "start": 5, "end": 6}, {"entity_id": "9723127_3_Ent3", "role": "Treatment_Disorder", "text": "panic disorder", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "9723127_3_Ent0", "text": "Decreased plasma cortisol level", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "9723127_3_Ent1", "text": "alprazolam", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9723127_3_Ent2", "text": "alprazolam", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9723127_3_Ent3", "text": "panic disorder", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "9758325_1", "wnd_id": "9758325_1_1", "text": "Seizures occurred in two patients with probable Alzheimer 's disease who were receiving long - term treatment with metrifonate , an irreversible acetylcholinesterase inhibitor .", "tokens": ["Seizures", "occurred", "in", "two", "patients", "with", "probable", "Alzheimer", "'s", "disease", "who", "were", "receiving", "long", "-", "term", "treatment", "with", "metrifonate", ",", "an", "irreversible", "acetylcholinesterase", "inhibitor", "."], "event_mentions": [{"id": "9758325_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 1, "end": 2}, "arguments": [{"entity_id": "9758325_1_Ent2", "role": "Effect", "text": "Seizures", "start": 0, "end": 1}, {"entity_id": "9758325_1_Ent1", "role": "Subject_Population", "text": "two", "start": 3, "end": 4}, {"entity_id": "9758325_1_Ent0", "role": "Subject", "text": "two patients with probable Alzheimer 's disease", "start": 3, "end": 10}, {"entity_id": "9758325_1_Ent4", "role": "Treatment_Disorder", "text": "Alzheimer 's disease", "start": 7, "end": 10}, {"entity_id": "9758325_1_Ent3", "role": "Treatment", "text": "long - term treatment with metrifonate", "start": 13, "end": 19}, {"entity_id": "9758325_1_Ent5", "role": "Treatment_Drug", "text": "metrifonate", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "9758325_1_Ent2", "text": "Seizures", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9758325_1_Ent1", "text": "two", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9758325_1_Ent0", "text": "two patients with probable Alzheimer 's disease", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "9758325_1_Ent4", "text": "Alzheimer 's disease", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "9758325_1_Ent3", "text": "long - term treatment with metrifonate", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "9758325_1_Ent5", "text": "metrifonate", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "9777751_1", "wnd_id": "9777751_1_1", "text": "Methimazole - induced aplastic anemia in third exposure : successful treatment with recombinant human granulocyte colony - stimulating factor .", "tokens": ["Methimazole", "-", "induced", "aplastic", "anemia", "in", "third", "exposure", ":", "successful", "treatment", "with", "recombinant", "human", "granulocyte", "colony", "-", "stimulating", "factor", "."], "event_mentions": [{"id": "9777751_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "9777751_1_Ent1", "role": "Treatment", "text": "Methimazole", "start": 0, "end": 1}, {"entity_id": "9777751_1_Ent2", "role": "Treatment_Drug", "text": "Methimazole", "start": 0, "end": 1}, {"entity_id": "9777751_1_Ent0", "role": "Effect", "text": "aplastic anemia", "start": 3, "end": 5}, {"entity_id": "9777751_1_Ent3", "role": "Treatment_Drug", "text": "granulocyte colony - stimulating factor", "start": 14, "end": 19}]}], "entity_mentions": [{"id": "9777751_1_Ent1", "text": "Methimazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9777751_1_Ent2", "text": "Methimazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9777751_1_Ent0", "text": "aplastic anemia", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "9777751_1_Ent3", "text": "granulocyte colony - stimulating factor", "entity_type": "Entity", "start": 14, "end": 19}], "lang": "en"}
{"doc_id": "9792602_2", "wnd_id": "9792602_2_1", "text": "Tubulointerstitial nephritis induced by the leukotriene receptor antagonist pranlukast .", "tokens": ["Tubulointerstitial", "nephritis", "induced", "by", "the", "leukotriene", "receptor", "antagonist", "pranlukast", "."], "event_mentions": [{"id": "9792602_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "9792602_2_Ent0", "role": "Effect", "text": "Tubulointerstitial nephritis", "start": 0, "end": 2}, {"entity_id": "9792602_2_Ent1", "role": "Treatment", "text": "pranlukast", "start": 8, "end": 9}, {"entity_id": "9792602_2_Ent2", "role": "Treatment_Drug", "text": "pranlukast", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "9792602_2_Ent0", "text": "Tubulointerstitial nephritis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9792602_2_Ent1", "text": "pranlukast", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9792602_2_Ent2", "text": "pranlukast", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "9796135_1", "wnd_id": "9796135_1_1", "text": "A 65 - year - old woman with angina pectoris presented with syncope after sublingual ingestion of isosorbide dinitrate ( 5 mg ) .", "tokens": ["A", "65", "-", "year", "-", "old", "woman", "with", "angina", "pectoris", "presented", "with", "syncope", "after", "sublingual", "ingestion", "of", "isosorbide", "dinitrate", "(", "5", "mg", ")", "."], "event_mentions": [{"id": "9796135_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 10, "end": 11}, "arguments": [{"entity_id": "9796135_1_Ent0", "role": "Subject", "text": "A 65 - year - old woman with angina pectoris", "start": 0, "end": 10}, {"entity_id": "9796135_1_Ent1", "role": "Subject_Age", "text": "65 - year - old", "start": 1, "end": 6}, {"entity_id": "9796135_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "9796135_1_Ent5", "role": "Treatment_Disorder", "text": "angina pectoris", "start": 8, "end": 10}, {"entity_id": "9796135_1_Ent3", "role": "Effect", "text": "syncope", "start": 12, "end": 13}, {"entity_id": "9796135_1_Ent6", "role": "Treatment_Route", "text": "sublingual ingestion", "start": 14, "end": 16}, {"entity_id": "9796135_1_Ent4", "role": "Treatment", "text": "sublingual ingestion of isosorbide dinitrate ( 5 mg )", "start": 14, "end": 23}, {"entity_id": "9796135_1_Ent7", "role": "Treatment_Drug", "text": "isosorbide dinitrate", "start": 17, "end": 19}, {"entity_id": "9796135_1_Ent8", "role": "Treatment_Dosage", "text": "5 mg", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "9796135_1_Ent0", "text": "A 65 - year - old woman with angina pectoris", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "9796135_1_Ent1", "text": "65 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "9796135_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9796135_1_Ent5", "text": "angina pectoris", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "9796135_1_Ent3", "text": "syncope", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9796135_1_Ent6", "text": "sublingual ingestion", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "9796135_1_Ent4", "text": "sublingual ingestion of isosorbide dinitrate ( 5 mg )", "entity_type": "Entity", "start": 14, "end": 23}, {"id": "9796135_1_Ent7", "text": "isosorbide dinitrate", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "9796135_1_Ent8", "text": "5 mg", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "9796135_4", "wnd_id": "9796135_4_1", "text": "Syncope in a 65 - year - old woman after nitrate ingestion .", "tokens": ["Syncope", "in", "a", "65", "-", "year", "-", "old", "woman", "after", "nitrate", "ingestion", "."], "event_mentions": [{"id": "9796135_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 9, "end": 10}, "arguments": [{"entity_id": "9796135_4_Ent3", "role": "Effect", "text": "Syncope", "start": 0, "end": 1}, {"entity_id": "9796135_4_Ent0", "role": "Subject", "text": "a 65 - year - old woman", "start": 2, "end": 9}, {"entity_id": "9796135_4_Ent1", "role": "Subject_Age", "text": "65 - year - old", "start": 3, "end": 8}, {"entity_id": "9796135_4_Ent2", "role": "Subject_Gender", "text": "woman", "start": 8, "end": 9}, {"entity_id": "9796135_4_Ent5", "role": "Treatment_Drug", "text": "nitrate", "start": 10, "end": 11}, {"entity_id": "9796135_4_Ent4", "role": "Treatment", "text": "nitrate ingestion", "start": 10, "end": 12}, {"entity_id": "9796135_4_Ent6", "role": "Treatment_Route", "text": "ingestion", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "9796135_4_Ent3", "text": "Syncope", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9796135_4_Ent0", "text": "a 65 - year - old woman", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "9796135_4_Ent1", "text": "65 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "9796135_4_Ent2", "text": "woman", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9796135_4_Ent5", "text": "nitrate", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9796135_4_Ent4", "text": "nitrate ingestion", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "9796135_4_Ent6", "text": "ingestion", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "9831311_1", "wnd_id": "9831311_1_1", "text": "Although major hazards of treatment of hypophosphatemic osteomalacia with phosphate and calcitriol are secondary hyperparathyroidism and vitamin D intoxication , potassium loss also should be kept in mind .", "tokens": ["Although", "major", "hazards", "of", "treatment", "of", "hypophosphatemic", "osteomalacia", "with", "phosphate", "and", "calcitriol", "are", "secondary", "hyperparathyroidism", "and", "vitamin", "D", "intoxication", ",", "potassium", "loss", "also", "should", "be", "kept", "in", "mind", "."], "event_mentions": [{"id": "9831311_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "major hazards", "start": 1, "end": 3}, "arguments": [{"entity_id": "9831311_1_Ent4", "role": "Treatment_Disorder", "text": "hypophosphatemic osteomalacia", "start": 6, "end": 8}, {"entity_id": "9831311_1_Ent1", "role": "Treatment", "text": "hypophosphatemic osteomalacia with phosphate and calcitriol", "start": 6, "end": 12}, {"entity_id": "9831311_1_Ent2", "role": "Treatment_Drug", "text": "phosphate", "start": 9, "end": 10}, {"entity_id": "9831311_1_Ent5", "role": "Combination_Drug", "text": "phosphate", "start": 9, "end": 10}, {"entity_id": "9831311_1_Ent3", "role": "Treatment_Drug", "text": "calcitriol", "start": 11, "end": 12}, {"entity_id": "9831311_1_Ent6", "role": "Combination_Drug", "text": "calcitriol", "start": 11, "end": 12}, {"entity_id": "9831311_1_Ent0", "role": "Effect", "text": "secondary hyperparathyroidism and vitamin D intoxication , potassium loss", "start": 13, "end": 22}]}], "entity_mentions": [{"id": "9831311_1_Ent4", "text": "hypophosphatemic osteomalacia", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "9831311_1_Ent1", "text": "hypophosphatemic osteomalacia with phosphate and calcitriol", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "9831311_1_Ent2", "text": "phosphate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9831311_1_Ent5", "text": "phosphate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9831311_1_Ent3", "text": "calcitriol", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9831311_1_Ent6", "text": "calcitriol", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9831311_1_Ent0", "text": "secondary hyperparathyroidism and vitamin D intoxication , potassium loss", "entity_type": "Entity", "start": 13, "end": 22}], "lang": "en"}
{"doc_id": "9831311_4", "wnd_id": "9831311_4_1", "text": "Progressive hypokalemia developed during phosphate treatment .", "tokens": ["Progressive", "hypokalemia", "developed", "during", "phosphate", "treatment", "."], "event_mentions": [{"id": "9831311_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "9831311_4_Ent0", "role": "Effect", "text": "Progressive hypokalemia", "start": 0, "end": 2}, {"entity_id": "9831311_4_Ent1", "role": "Treatment", "text": "phosphate", "start": 4, "end": 5}, {"entity_id": "9831311_4_Ent2", "role": "Treatment_Drug", "text": "phosphate", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "9831311_4_Ent0", "text": "Progressive hypokalemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9831311_4_Ent1", "text": "phosphate", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9831311_4_Ent2", "text": "phosphate", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "984862_1", "wnd_id": "984862_1_1", "text": "A patient with psoriasis is described who had an abnormal response to the glucose tolerance test without other evidence of diabetes and then developed postprandial hyperglycemia and glycosuria during a period of topical administration of a corticosteroid cream , halcinonide cream 0.1 % , under occlusion .", "tokens": ["A", "patient", "with", "psoriasis", "is", "described", "who", "had", "an", "abnormal", "response", "to", "the", "glucose", "tolerance", "test", "without", "other", "evidence", "of", "diabetes", "and", "then", "developed", "postprandial", "hyperglycemia", "and", "glycosuria", "during", "a", "period", "of", "topical", "administration", "of", "a", "corticosteroid", "cream", ",", "halcinonide", "cream", "0.1", "%", ",", "under", "occlusion", "."], "event_mentions": [{"id": "984862_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 23, "end": 24}, "arguments": [{"entity_id": "984862_1_Ent0", "role": "Subject", "text": "A patient with psoriasis is described who had an abnormal response to the glucose tolerance test without other evidence of diabetes", "start": 0, "end": 21}, {"entity_id": "984862_1_Ent4", "role": "Treatment_Disorder", "text": "psoriasis", "start": 3, "end": 4}, {"entity_id": "984862_1_Ent1", "role": "Subject_Disorder", "text": "an abnormal response to the glucose tolerance test without other evidence of diabetes", "start": 8, "end": 21}, {"entity_id": "984862_1_Ent2", "role": "Effect", "text": "postprandial hyperglycemia and glycosuria", "start": 24, "end": 28}, {"entity_id": "984862_1_Ent3", "role": "Treatment", "text": "a period of topical administration of a corticosteroid cream , halcinonide cream 0.1 % , under occlusion", "start": 29, "end": 46}, {"entity_id": "984862_1_Ent5", "role": "Treatment_Drug", "text": "halcinonide", "start": 39, "end": 40}, {"entity_id": "984862_1_Ent6", "role": "Treatment_Route", "text": "cream", "start": 40, "end": 41}]}], "entity_mentions": [{"id": "984862_1_Ent0", "text": "A patient with psoriasis is described who had an abnormal response to the glucose tolerance test without other evidence of diabetes", "entity_type": "Entity", "start": 0, "end": 21}, {"id": "984862_1_Ent4", "text": "psoriasis", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "984862_1_Ent1", "text": "an abnormal response to the glucose tolerance test without other evidence of diabetes", "entity_type": "Entity", "start": 8, "end": 21}, {"id": "984862_1_Ent2", "text": "postprandial hyperglycemia and glycosuria", "entity_type": "Entity", "start": 24, "end": 28}, {"id": "984862_1_Ent3", "text": "a period of topical administration of a corticosteroid cream , halcinonide cream 0.1 % , under occlusion", "entity_type": "Entity", "start": 29, "end": 46}, {"id": "984862_1_Ent5", "text": "halcinonide", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "984862_1_Ent6", "text": "cream", "entity_type": "Entity", "start": 40, "end": 41}], "lang": "en"}
{"doc_id": "9855339_2", "wnd_id": "9855339_2_1", "text": "Coadministration of antidepressant agents such as nefazodone , or any other drug that inhibits the CYP3A4 isoenzyme subfamily , should be anticipated to interfere with tacrolimus metabolism .", "tokens": ["Coadministration", "of", "antidepressant", "agents", "such", "as", "nefazodone", ",", "or", "any", "other", "drug", "that", "inhibits", "the", "CYP3A4", "isoenzyme", "subfamily", ",", "should", "be", "anticipated", "to", "interfere", "with", "tacrolimus", "metabolism", "."], "event_mentions": [{"id": "9855339_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "interfere", "start": 23, "end": 24}, "arguments": [{"entity_id": "9855339_2_Ent2", "role": "Treatment", "text": "Coadministration of antidepressant agents such as nefazodone , or any other drug that inhibits the CYP3A4 isoenzyme subfamily", "start": 0, "end": 18}, {"entity_id": "9855339_2_Ent4", "role": "Treatment_Drug", "text": "nefazodone", "start": 6, "end": 7}, {"entity_id": "9855339_2_Ent5", "role": "Combination_Drug", "text": "nefazodone", "start": 6, "end": 7}, {"entity_id": "9855339_2_Ent1", "role": "Treatment", "text": "tacrolimus", "start": 25, "end": 26}, {"entity_id": "9855339_2_Ent3", "role": "Treatment_Drug", "text": "tacrolimus", "start": 25, "end": 26}, {"entity_id": "9855339_2_Ent6", "role": "Combination_Drug", "text": "tacrolimus", "start": 25, "end": 26}, {"entity_id": "9855339_2_Ent0", "role": "Effect", "text": "tacrolimus metabolism", "start": 25, "end": 27}]}], "entity_mentions": [{"id": "9855339_2_Ent2", "text": "Coadministration of antidepressant agents such as nefazodone , or any other drug that inhibits the CYP3A4 isoenzyme subfamily", "entity_type": "Entity", "start": 0, "end": 18}, {"id": "9855339_2_Ent4", "text": "nefazodone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9855339_2_Ent5", "text": "nefazodone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9855339_2_Ent1", "text": "tacrolimus", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "9855339_2_Ent3", "text": "tacrolimus", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "9855339_2_Ent6", "text": "tacrolimus", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "9855339_2_Ent0", "text": "tacrolimus metabolism", "entity_type": "Entity", "start": 25, "end": 27}], "lang": "en"}
{"doc_id": "9870779_3", "wnd_id": "9870779_3_1", "text": "MTX - induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia , gestational disease and during treatment of psoriasis and rheumatoid arthritis .", "tokens": ["MTX", "-", "induced", "hepatic", "injury", "and", "liver", "enzyme", "elevations", "have", "been", "demonstrated", "after", "treatment", "of", "leukemia", ",", "gestational", "disease", "and", "during", "treatment", "of", "psoriasis", "and", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "9870779_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "9870779_3_Ent1", "role": "Treatment", "text": "MTX", "start": 0, "end": 1}, {"entity_id": "9870779_3_Ent2", "role": "Treatment_Drug", "text": "MTX", "start": 0, "end": 1}, {"entity_id": "9870779_3_Ent0", "role": "Effect", "text": "hepatic injury and liver enzyme elevations", "start": 3, "end": 9}]}, {"id": "9870779_3_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "demonstrated", "start": 11, "end": 12}, "arguments": [{"entity_id": "9870779_3_Ent3", "role": "Treatment", "text": "treatment of leukemia , gestational disease and during treatment of psoriasis and rheumatoid arthritis", "start": 13, "end": 27}, {"entity_id": "9870779_3_Ent4", "role": "Treatment_Disorder", "text": "leukemia", "start": 15, "end": 16}, {"entity_id": "9870779_3_Ent5", "role": "Treatment_Disorder", "text": "gestational disease", "start": 17, "end": 19}, {"entity_id": "9870779_3_Ent6", "role": "Treatment_Disorder", "text": "psoriasis", "start": 23, "end": 24}, {"entity_id": "9870779_3_Ent7", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 25, "end": 27}]}], "entity_mentions": [{"id": "9870779_3_Ent1", "text": "MTX", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9870779_3_Ent2", "text": "MTX", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9870779_3_Ent0", "text": "hepatic injury and liver enzyme elevations", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "9870779_3_Ent3", "text": "treatment of leukemia , gestational disease and during treatment of psoriasis and rheumatoid arthritis", "entity_type": "Entity", "start": 13, "end": 27}, {"id": "9870779_3_Ent4", "text": "leukemia", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "9870779_3_Ent5", "text": "gestational disease", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "9870779_3_Ent6", "text": "psoriasis", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "9870779_3_Ent7", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 25, "end": 27}], "lang": "en"}
{"doc_id": "9892272_1", "wnd_id": "9892272_1_1", "text": "Massive subfascial hematoma after alteplase therapy for acute myocardial infarction .", "tokens": ["Massive", "subfascial", "hematoma", "after", "alteplase", "therapy", "for", "acute", "myocardial", "infarction", "."], "event_mentions": [{"id": "9892272_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "9892272_1_Ent0", "role": "Effect", "text": "Massive subfascial hematoma", "start": 0, "end": 3}, {"entity_id": "9892272_1_Ent2", "role": "Treatment_Drug", "text": "alteplase", "start": 4, "end": 5}, {"entity_id": "9892272_1_Ent1", "role": "Treatment", "text": "alteplase therapy", "start": 4, "end": 6}, {"entity_id": "9892272_1_Ent3", "role": "Treatment_Disorder", "text": "acute myocardial infarction", "start": 7, "end": 10}]}], "entity_mentions": [{"id": "9892272_1_Ent0", "text": "Massive subfascial hematoma", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9892272_1_Ent2", "text": "alteplase", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9892272_1_Ent1", "text": "alteplase therapy", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9892272_1_Ent3", "text": "acute myocardial infarction", "entity_type": "Entity", "start": 7, "end": 10}], "lang": "en"}
{"doc_id": "9925865_2", "wnd_id": "9925865_2_1", "text": "In patients with swallowing dysfunction and pneumonia , a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred .", "tokens": ["In", "patients", "with", "swallowing", "dysfunction", "and", "pneumonia", ",", "a", "history", "of", "mineral", "oil", "use", "should", "be", "obtained", "and", "a", "diagnosis", "of", "ELP", "should", "be", "considered", "in", "the", "differential", "diagnoses", "if", "mineral", "oil", "use", "has", "occurred", "."], "event_mentions": [{"id": "9925865_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "considered", "start": 24, "end": 25}, "arguments": [{"entity_id": "9925865_2_Ent0", "role": "Subject", "text": "In patients with swallowing dysfunction and pneumonia", "start": 0, "end": 7}, {"entity_id": "9925865_2_Ent2", "role": "Treatment", "text": "a history of mineral oil use", "start": 8, "end": 14}, {"entity_id": "9925865_2_Ent3", "role": "Treatment_Drug", "text": "mineral oil", "start": 11, "end": 13}, {"entity_id": "9925865_2_Ent1", "role": "Effect", "text": "ELP", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "9925865_2_Ent0", "text": "In patients with swallowing dysfunction and pneumonia", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "9925865_2_Ent2", "text": "a history of mineral oil use", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "9925865_2_Ent3", "text": "mineral oil", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "9925865_2_Ent1", "text": "ELP", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "9925865_6", "wnd_id": "9925865_6_1", "text": "Treatment of ELP in children is generally supportive , with the symptoms and roentgenographic abnormalities resolving within months after stopping the use of mineral oil .", "tokens": ["Treatment", "of", "ELP", "in", "children", "is", "generally", "supportive", ",", "with", "the", "symptoms", "and", "roentgenographic", "abnormalities", "resolving", "within", "months", "after", "stopping", "the", "use", "of", "mineral", "oil", "."], "event_mentions": [{"id": "9925865_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "after", "start": 18, "end": 19}, "arguments": [{"entity_id": "9925865_6_Ent3", "role": "Treatment_Disorder", "text": "ELP", "start": 2, "end": 3}, {"entity_id": "9925865_6_Ent0", "role": "Effect", "text": "symptoms and roentgenographic abnormalities resolving", "start": 11, "end": 16}, {"entity_id": "9925865_6_Ent1", "role": "Treatment", "text": "stopping the use of mineral oil", "start": 19, "end": 25}, {"entity_id": "9925865_6_Ent2", "role": "Treatment_Drug", "text": "mineral oil", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "9925865_6_Ent3", "text": "ELP", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9925865_6_Ent0", "text": "symptoms and roentgenographic abnormalities resolving", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "9925865_6_Ent1", "text": "stopping the use of mineral oil", "entity_type": "Entity", "start": 19, "end": 25}, {"id": "9925865_6_Ent2", "text": "mineral oil", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "9972383_2", "wnd_id": "9972383_2_1", "text": "OBJECTIVE : To report a case of reversible nonthrombocytopenic palpable purpura associated with metoclopramide .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "reversible", "nonthrombocytopenic", "palpable", "purpura", "associated", "with", "metoclopramide", "."], "event_mentions": [{"id": "9972383_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 11, "end": 12}, "arguments": [{"entity_id": "9972383_2_Ent0", "role": "Effect", "text": "reversible nonthrombocytopenic palpable purpura", "start": 7, "end": 11}, {"entity_id": "9972383_2_Ent1", "role": "Treatment", "text": "metoclopramide", "start": 13, "end": 14}, {"entity_id": "9972383_2_Ent2", "role": "Treatment_Drug", "text": "metoclopramide", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "9972383_2_Ent0", "text": "reversible nonthrombocytopenic palpable purpura", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "9972383_2_Ent1", "text": "metoclopramide", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9972383_2_Ent2", "text": "metoclopramide", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "9988365_2", "wnd_id": "9988365_2_1", "text": "Eosinophilia has been encountered from 0.2 to 61.7 % in clozapine - treated patients , mostly with a transient course and spontaneous remission .", "tokens": ["Eosinophilia", "has", "been", "encountered", "from", "0.2", "to", "61.7", "%", "in", "clozapine", "-", "treated", "patients", ",", "mostly", "with", "a", "transient", "course", "and", "spontaneous", "remission", "."], "event_mentions": [{"id": "9988365_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "encountered", "start": 3, "end": 4}, "arguments": [{"entity_id": "9988365_2_Ent1", "role": "Effect", "text": "Eosinophilia", "start": 0, "end": 1}, {"entity_id": "9988365_2_Ent2", "role": "Treatment", "text": "clozapine", "start": 10, "end": 11}, {"entity_id": "9988365_2_Ent3", "role": "Treatment_Drug", "text": "clozapine", "start": 10, "end": 11}, {"entity_id": "9988365_2_Ent0", "role": "Subject", "text": "patients", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "9988365_2_Ent1", "text": "Eosinophilia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9988365_2_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9988365_2_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9988365_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
